

GenCore version 5.1.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 4, 2004, 16:49:08 ; Search time 245 Seconds
(without alignments)
4.079 Million cell updates/sec

Title: US-10-017-084a-522

Perfect score: 1679

Sequence: 1 gttgttccttcagcaaac.....ataaaagagcaaaaaaa 1679

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 177 seqs, 297588 residues

Total number of hits satisfying chosen parameters: 354

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 177 summaries

Database : rng522.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1679	100.0	1679	1	ADBS38667 Novel human secret
2	1679	100.0	1679	1	ADBS78344 Novel human secret
3	1679	100.0	1679	1	ADBS38115 Novel human secret
4	1679	100.0	1679	1	ADBS65897 Novel human secret
5	1679	100.0	1679	1	ADBS48992 Human PRO polynucle
6	1679	100.0	1679	1	ADBS86667 Human PRO polynucle
7	1679	100.0	1679	1	ADBS90399 Human PRO polynucle
8	1679	100.0	1679	1	ADBS39500 Novel human secret
9	1679	100.0	1679	1	ADBS78098 Novel human secret
10	1679	100.0	1679	1	ADBS74028 Human PRO polynucle
11	1679	100.0	1679	1	ADBS87164 Human PRO polynucle
12	1679	100.0	1679	1	ADBS84746 Novel human secret
13	1679	100.0	1679	1	ADBS47123 Novel human secret
14	1679	100.0	1679	1	ADBS83861 Human PRO polynucle
15	1679	100.0	1679	1	ADBS86730 Novel human secret
16	1679	100.0	1679	1	ADBS73016 Human PRO polynucle
17	1679	100.0	1679	1	ADBS67644 Novel human secret
18	1679	100.0	1679	1	ADBS77335 Novel human secret
19	1679	100.0	1679	1	ADBS34492 Novel human secret
20	1679	100.0	1679	1	ADBS35596 Human PRO polynucle
21	1679	100.0	1679	1	ADBS33940 Human PRO polynucle
22	1679	100.0	1679	1	ADBS50444 Human PRO polynucle
23	1679	100.0	1679	1	ADBS36148 Human PRO polynucle
24	1679	100.0	1679	1	ADBS46543 Novel human secret
25	1679	100.0	1679	1	ADBS4170 Human CDNA encodin
26	1679	100.0	1679	1	ADBS61930 Human CDNA encodin
27	1679	100.0	1679	1	ADBS63894 Human CDNA encodin
28	1679	100.0	1679	1	ADBS66994 Human CDNA encodin
29	1679	100.0	1679	1	ADBS69118 Human CDNA encodin
30	1679	100.0	1679	1	ADBS63178 Human CDNA encodin
31	1679	100.0	1679	1	ADBS68243 Human CDNA encodin
32	1679	100.0	1679	1	ADBS41563 Human CDNA encodin
33	1679	100.0	1679	1	ADBS67618 Human CDNA encodin

34	1679	100.0	1679	1	ADBS2554 Human CDNA encodin
35	1679	100.0	1679	1	ADBS38854 Human PRO polynucle
36	1679	100.0	1679	1	ADBS42187 Human CDNA encodin
37	1679	100.0	1679	1	ADBS21844 Human PRO polynucle
38	1679	100.0	1679	1	ADBS0416 Novel human secret
39	1679	100.0	1679	1	ADBS71963 Novel human secret
40	1679	100.0	1679	1	ADBS9942 Novel human secret
41	1679	100.0	1679	1	ADBS9875 Novel human secret
42	1679	100.0	1679	1	ADBS9074 Novel human secret
43	1679	100.0	1679	1	ADBS49591 Novel human secret
44	1679	100.0	1679	1	ADBS7452 Novel human secret
45	1679	100.0	1679	1	ADBS2949 Novel human secret
46	1679	100.0	1679	1	ADBS7303 Novel human secret
47	1679	100.0	1679	1	ADBS60494 Novel human secret
48	1679	100.0	1679	1	ADBS0969 Human PRO polynucle
49	1679	100.0	1679	1	ADBS4596 Novel human secret
50	1679	100.0	1679	1	ADBS4594 Novel human secret
51	1679	100.0	1679	1	ADBS3555 Novel human secret
52	1679	100.0	1679	1	ADBS9078 Novel human secret
53	1679	100.0	1679	1	ADBS5956 Novel human secret
54	1679	100.0	1679	1	ADBS8526 Novel human secret
55	1679	100.0	1679	1	ADBS47197 Novel human secret
56	1679	100.0	1679	1	ADBS03200 Novel human secret
57	1679	100.0	1679	1	ADBS0192 Novel human secret
58	1679	100.0	1679	1	ADBS69611 CDNA encoding huma
59	1679	100.0	1679	1	ADBS48500 Human PRO polynucle
60	1679	100.0	1679	1	ADBS10029 Human PRO polynucle
61	1679	100.0	1679	1	ADBS78072 Novel human secret
62	1679	100.0	1679	1	ADBS04604 Novel human secret
63	1679	100.0	1679	1	ADBS06307 Novel human secret
64	1679	100.0	1679	1	ADBS0560 Novel human secret
65	1679	100.0	1679	1	ADBS11067 Human PRO polynucle
66	1679	100.0	1679	1	ADBS10344 Human secreted/tra
67	1679	100.0	1679	1	ADBS47948 Human PRO polynucle
68	1679	100.0	1679	1	ADBS7826 Novel human secret
69	1679	100.0	1679	1	ADBS00008 Novel human secret
70	1679	100.0	1679	1	ADBS11304 Human secreted/tra
71	1679	100.0	1679	1	ADBS09477 Human PRO polynucle
72	1679	100.0	1679	1	ADBS0789 Novel human secret
73	1679	100.0	1679	1	ADBS41190 Novel human secret
74	1679	100.0	1679	1	ADBS25329 CDNA encoding huma
75	1679	100.0	1679	1	ADBS1035 Novel human secret
76	1679	100.0	1679	1	ADBS3069 CDNA encoding huma
77	1679	100.0	1679	1	ADBS3821 Novel human secret
78	1679	100.0	1679	1	ADBS7097 Human secreted/tra
79	1679	100.0	1679	1	ADBS1777 CDNA encoding huma
80	1679	100.0	1679	1	ADBS02576 Human PRO polynucle
81	1679	100.0	1679	1	ADBS0516 Human PRO polynucle
82	1679	100.0	1679	1	ADBS02010 Human PRO polynucle
83	1679	100.0	1679	1	ADBS4192 Novel human secret
84	1679	100.0	1679	1	ADBS0270 Human CDNA encodin
85	1679	100.0	1679	1	ADBS1281 Human CDNA encodin
86	1679	100.0	1679	1	ADBS49556 Human PRO polynucle
87	1679	100.0	1679	1	ADBS2509 Human PRO polynucle
88	1679	100.0	1679	1	ADBS1405 Human PRO polynucle
89	1679	100.0	1679	1	ADBS04019 Novel human secret
90	1679	100.0	1679	1	ADBS2316 Human PRO polynucle
91	1679	100.0	1679	1	ADBS2248 CDNA encoding huma
92	1679	100.0	1679	1	ADBS79472 Human CDNA encodin
93	1679	100.0	1679	1	ADBS35610 Human CDNA encodin
94	1679	100.0	1679	1	ADBS16724 Human CDNA encodin
95	1679	100.0	1679	1	ADBS73339 Human PRO polynucle
96	1679	100.0	1679	1	ADBS42008 Human PRO polynucle
97	1679	100.0	1679	1	ADBS17825 Human PRO polynucle
98	1679	100.0	1679	1	ADBS1957 Novel human secret
99	1679	100.0	1679	1	ADBS33420 Novel human secret
100	1679	100.0	1679	1	ADBS3972 CDNA encoding huma
101	1679	100.0	1679	1	ADBS0024 Human PRO polynucle
102	1679	100.0	1679	1	ADBS3061 Human CDNA encodin
103	1679	100.0	1679	1	ADBS72697 Human PRO polynucle
104	1679	100.0	1679	1	ADBS19481 Human PRO polynucle
105	1679	100.0	1679	1	ADBS18929 Human PRO polynucle
106	1679	100.0	1679	1	ADBS43135 Human PRO polynucle

107	1679	100.0	1679	1	ADP95914	Human PRO polynucl
108	1679	100.0	1679	1	ADP22800	CDNA encoding huma
109	1679	100.0	1679	1	ADP78918	CDNA encoding huma
110	1679	100.0	1679	1	ADP32868	Novel human secret
111	1679	100.0	1679	1	ADP42560	Human PRO polynucl
112	1679	100.0	1679	1	ADP17348	Human CDNA encodin
113	1679	100.0	1679	1	ADP80576	CDNA encoding huma
114	1679	100.0	1679	1	ADP89604	Human PRO polynucl
115	1679	100.0	1679	1	ADP40888	Human PRO polynucl
116	1679	100.0	1679	1	ADP40887	Human PRO polynucl
117	1679	100.0	1679	1	ADP48828	Novel human secret
118	1679	100.0	1679	1	ADP81112	Novel human secret
119	1679	100.0	1679	1	ADP20999	Novel human secret
120	1679	100.0	1679	1	ADP5843	Human PRO polynucl
121	1679	100.0	1679	1	ADP76560	Human PRO polynucl
122	1679	100.0	1679	1	ADP75072	Human PRO polynucl
123	1679	100.0	1679	1	ADP75818	Novel human secret
124	1679	100.0	1679	1	ADP85050	Novel human secret
125	1679	100.0	1679	1	ADP86876	Novel human secret
126	1679	100.0	1679	1	ADP20753	Novel human secret
127	1679	100.0	1679	1	ADP39050	Novel human secret
128	1679	100.0	1679	1	ADP87924	Human PRO polynucl
129	1679	100.0	1679	1	ADP86328	Human PRO polynucl
130	1679	100.0	1679	1	ADP85597	Human PRO polynucl
131	1679	100.0	1679	1	ADP73582	Human PRO polynucl
132	1679	100.0	1679	1	ADP75776	Human CDNA encodin
133	1679	100.0	1679	1	ADP48856	Human PRO polynucl
134	1679	100.0	1679	1	ADP78422	Novel human secret
135	1679	100.0	1679	1	ADP41305	Human secreted/tra
136	1679	100.0	1679	1	ADP23352	CDNA encoding huma
137	1679	100.0	1679	1	ADP21245	Novel human secret
138	1679	100.0	1679	1	ADP7360	Novel human secret
139	1679	100.0	1679	1	ADP20507	Novel human secret
140	1679	100.0	1679	1	ADP75572	Human PRO polynucl
141	1679	100.0	1679	1	ADP74088	Human PRO polynucl
142	1679	100.0	1679	1	ADP74334	Human PRO polynucl
143	1679	100.0	1679	1	ADP76064	Novel human secret
144	1679	100.0	1679	1	ADP85556	Novel human secret
145	1679	100.0	1679	1	ADP23904	CDNA encoding huma
146	1679	100.0	1679	1	ADP4547	CDNA encoding huma
147	1679	100.0	1679	1	ADP87372	Human PRO polynucl
148	1679	100.0	1679	1	ADP05105	Human PRO polynucl
149	1679	100.0	1679	1	ADP75318	Human PRO polynucl
150	1679	100.0	1679	1	ADP76862	Novel human secret
151	1679	100.0	1679	1	ADP86630	Novel human secret
152	1679	100.0	1679	1	ADP89238	Human PRO polynucl
153	1679	100.0	1679	1	ADP41138	Human secreted/tra
154	1679	100.0	1679	1	ADP78098	Novel human secret
155	1679	100.0	1679	1	ADP18377	Human PRO polynucl
156	1679	100.0	1679	1	ADP88686	Human PRO polynucl
157	1679	100.0	1679	1	ADP89957	Human CDNA encodin
158	1679	100.0	1679	1	ADP77606	Novel human secret
159	1679	100.0	1679	1	ADP77852	Novel human secret
160	1679	100.0	1679	1	ADP85310	Novel human secret
161	1679	100.0	1679	1	ADP73842	Human PRO polynucl
162	1679	100.0	1679	1	ADP74580	Human PRO polynucl
163	1679	100.0	1679	1	ADP77108	Novel human secret
164	1679	100.0	1679	1	ADP85802	Novel human secret
165	1679	100.0	1679	1	ADP05351	Human PRO polynucl
166	1679	100.0	1679	1	ADP74826	Human PRO polynucl
167	1661.9	99.0	1693	1	AAZ47893	Human protein enco
168	1643.4	97.9	2012	1	AAA8791	Human SECX cDNA Cl
169	1643.4	97.9	2012	1	ADP18290	Human molecule (NO
170	1601.4	95.4	1603	1	AAA88790	Human SECX cDNA Cl
171	1601.4	95.4	1603	1	ADP18298	Human molecule (NO
172	1571.3	93.6	1873	1	ABK49272	Human Kruppel asso
173	1457	86.8	1678	1	AAI57869	Human protein enco
174	1442.8	85.9	1839	1	ABT17330	Human IG gene rela
175	1442.8	85.9	1839	1	ABX76448	Lung cancer-associ
176	1316.5	78.4	1690	1	AAI59655	Human polynucleoti
177	1032	61.5	1032	1	AAZ47892	Human protein enco

ALIGNMENTS

RESULT 1

ID	ADP38667	standard; cdna; 1679 BP.
XX	ADP38667	
AC	ADP38667	
XX		
DT	04-DEC-2003	(first entry)
XX		
DE	Novel human secreted and transmembrane protein PRO337 CDNA.	
XX		
KW	Human; secreted and transmembrane protein; PRO; gene; as;	
KW	Tumour necrosis factor alpha release; TNF-alpha release;	
KW	Glucose uptake modulator; FFA uptake modulator;	
KW	cell proliferation stimulator; cell differentiation stimulator;	
KW	cell differentiation inhibitor; cytokine release stimulator;	
KW	lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;	
KW	cervical tumour; liver tumour; chromosome mapping; gene mapping;	
XX	gene therapy; chromosome identification; chromosome marker.	
OS	Homo sapiens.	
XX		
PN	US2003082766-A1.	
XX		
PD	01-MAY-2003.	
XX		
PF	30-MAY-2002; 2002US-00158782.	
XX		
PR	31-MAR-1997; 97WO-US0005230.	
PR	12-JUN-1998; 98WO-US012456.	
PR	14-JUL-1998; 98WO-US014552.	
PR	28-AUG-1998; 98WO-US017888.	
PR	10-SEP-1998; 98WO-US018824.	
PR	14-SEP-1998; 98WO-US019093.	
PR	14-SEP-1998; 98WO-US019094.	
PR	14-SEP-1998; 98WO-US019177.	
PR	16-SEP-1998; 98WO-US019330.	
PR	17-SEP-1998; 98WO-US019437.	
PR	07-OCT-1998; 98WO-US021141.	
PR	29-OCT-1998; 98WO-US022991.	
PR	29-OCT-1998; 98WO-US022992.	
PR	20-NOV-1998; 98WO-US024855.	
PR	01-DEC-1998; 98WO-US025108.	
PR	05-JAN-1999; 99WO-US000106.	
PR	08-MAR-1999; 99WO-US005028.	
PR	10-MAR-1999; 99WO-US005190.	
PR	20-APR-1999; 99WO-US008615.	
PR	14-MAY-1999; 99WO-US010733.	
PR	02-JUN-1999; 99WO-US020111.	
PR	08-SEP-1999; 99WO-US020594.	
PR	13-SEP-1999; 99WO-US020594.	
PR	15-SEP-1999; 99WO-US021547.	
PR	05-OCT-1999; 99WO-US023089.	
PR	29-NOV-1999; 99WO-US028214.	
PR	30-NOV-1999; 99WO-US028313.	
PR	30-NOV-1999; 99WO-US028409.	
PR	01-DEC-1999; 99WO-US028301.	
PR	01-DEC-1999; 99WO-US028624.	
PR	02-DEC-1999; 99WO-US028551.	
PR	02-DEC-1999; 99WO-US028564.	
PR	16-DEC-1999; 99WO-US028565.	
PR	20-DEC-1999; 99WO-US030095.	
PR	20-DEC-1999; 99WO-US030911.	
PR	20-DEC-1999; 99WO-US030999.	
PR	22-DEC-1999; 99WO-US030720.	
PR	30-DEC-1999; 99WO-US031243.	
PR	05-JAN-2000; 2000WO-US000219.	
PR	06-JAN-2000; 2000WO-US000277.	

PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 10-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 04-AUG-2000; 2000WO-US023328.
 PR 28-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00854280.
 PR 25-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen WE, Goddard A, Godowski P, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-786921/74.
 DR P-PSDB; ADB38668.
 XX
 XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, detecting the presence of tumor in a mammal, or
 PT modulating the uptake of glucose or free fatty acid by skeletal muscle
 PT cells or adipocyte cells.
 XX
 PS Claim 2; Fig 375; 660pp; English.
 PS
 XX

CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PBMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 GTTGTGCTTCAGCAAAACAGTGGATTTAAATCTCTTGCACAAAGTTGAGAGCAAC 60
 Db 1 GTTGTGCTTCAGCAAAACAGTGGATTTAAATCTCTTGCACAAAGTTGAGAGCAAC 60
 Qy 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 Db 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 Qy 121 AAGAAAAAAATCATGAAAAACCATCCAGCCAAATGCAAAATTCATCTCTTTGGCAAT 180
 Db 121 AAGAAAAAAATCATGAAAAACCATCCAGCCAAATGCAAAATTCATCTCTTTGGCAAT 180
 Qy 181 CTTACGGGGCTGGCTCTCTGTCTCTTCCAGAGAGTCCCGTGGGAGCGGAGATGC 240
 Db 181 CTTACGGGGCTGGCTCTCTGTCTCTTCCAGAGAGTCCCGTGGGAGCGGAGATGC 240
 Qy 241 CACCTTCCCAAGCTATGACAAACGTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
 Db 241 CACCTTCCCAAGCTATGACAAACGTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
 Qy 301 GTGCATATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGGAGCAACCTCTCTA 360
 Db 301 GTGCATATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGGAGCAACCTCTCTA 360
 Qy 361 TGCTGGCAATGACAGAGTGGCTGGATCCTCGGTGGTCTCTTCTGAGCAACACCAAC 420
 Db 361 TGCTGGCAATGACAGAGTGGCTGGATCCTCGGTGGTCTCTTCTGAGCAACACCAAC 420
 Qy 421 GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
 Db 421 GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
 Qy 481 GGTCACAGACCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
 Db 481 GGTCACAGACCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
 Qy 541 CAAATATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAACAATATTAGCCTCAC 600
 Db 541 CAAATATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAACAATATTAGCCTCAC 600

541	Db	CAAAAATTGTAGAGATTTCCTCAGATATCTCCATTATTAAGAGGGAACAATATTAGCCTCAC	600
601	Qy	CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTGGAGACACATCTCTCCCAAAGC	660
601	Db	CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTGGAGACACATCTCTCCCAAAGC	660
661	Qy	GGTTGGCTTTGTGAGTGAAGACGAATACTTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720
661	Db	GGTTGGCTTTGTGAGTGAAGACGAATACTTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720
721	Qy	AGGGGACTACGATGCGAGTCCTCCAAATGACGTGGCGCGCCCGTGGTACGGAGAGTAAA	780
721	Db	AGGGGACTACGATGCGAGTCCTCCAAATGACGTGGCGCGCCCGTGGTACGGAGAGTAAA	780
781	Qy	GGTCACCGTGAACCTATCCACCATATCTTCAGAAAGCCAAAGGTACAGTCTCCCCGTGGG	840
781	Db	GGTCACCGTGAACCTATCCACCATATCTTCAGAAAGCCAAAGGTACAGTCTCCCCGTGGG	840
841	Qy	ACAAAAGGGGACACTGCACTGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
841	Db	ACAAAAGGGGACACTGCACTGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
901	Qy	CAAGGATGACAAAAGACTGATTTGAAGGAAAGAGGGTGAAAGTGGAAACACAGACCTTT	960
901	Db	CAAGGATGACAAAAGACTGATTTGAAGGAAAGAGGGTGAAAGTGGAAACACAGACCTTT	960
961	Qy	CCTCTCAAAACTCATCTTTTCAATGTCTCTGAACATGACTATGGGAACTACACTTTGCGT	1020
961	Db	CCTCTCAAAACTCATCTTTTCAATGTCTCTGAACATGACTATGGGAACTACACTTTGCGT	1020
1021	Qy	GGCTCCAAACAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGCGCGCGT	1080
1021	Db	GGCTCCAAACAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGCGCGCGT	1080
1081	Qy	CAGGAGGTGAGGAAACGGCAGCTGAGAGAGGGCAGGTGGCTGTGGCTGTGCTCTTCT	1140
1081	Db	CAGGAGGTGAGGAAACGGCAGCTGAGAGAGGGCAGGTGGCTGTGGCTGTGCTCTTCT	1140
1141	Qy	GGTCTTGCACTGCTTCTCAAAATTTTCATGTAGTGCACCTCCCAACCCGGGAAAGGCT	1200
1141	Db	GGTCTTGCACTGCTTCTCAAAATTTTCATGTAGTGCACCTCCCAACCCGGGAAAGGCT	1200
1201	Qy	GCGCCACCAACCACCAACACACAGCAATGGCACAACGGACAGCAACCAATCAGATA	1260
1201	Db	GCGCCACCAACCACCAACACACAGCAATGGCACAACGGACAGCAACCAATCAGATA	1260
1261	Qy	TATACAAATGAAATTAGAGAAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC	1320
1261	Db	TATACAAATGAAATTAGAGAAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC	1320
1321	Qy	AAAGAAATCTTTGGGGGAAAAGTTTAAAGAAATGAAATTTGCTTTGCAGATA	1380
1321	Db	AAAGAAATCTTTGGGGGAAAAGTTTAAAGAAATGAAATTTGCTTTGCAGATA	1380
1381	Qy	TTTAGGTACAAATGGAGTTTCTTTTCCAAAACGGGAAGAAACACAGCACACCCGGCTTGG	1440
1381	Db	TTTAGGTACAAATGGAGTTTCTTTTCCAAAACGGGAAGAAACACAGCACACCCGGCTTGG	1440
1441	Qy	CCCACTGCAGCTGCATCGTGCACCTCTTTGGTCCAGTGTGGCAGAGGGCTCAGCCTC	1500
1441	Db	CCCACTGCAGCTGCATCGTGCACCTCTTTGGTCCAGTGTGGCAGAGGGCTCAGCCTC	1500
1501	Qy	TCTGCCCAACAGAGTCCCCCAACGTGGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA	1560
1501	Db	TCTGCCCAACAGAGTCCCCCAACGTGGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA	1560
1561	Qy	GTCCATAGAGACGAACAGAAATGACACTTCGGGCCCAAGCGTGGCGCTCGGGCAGCTTTG	1620
1561	Db	GTCCATAGAGACGAACAGAAATGACACTTCGGGCCCAAGCGTGGCGCTCGGGCAGCTTTG	1620
1621	Qy	GTAGCTGTGCCACCAACGGCGTGTGTGTGAAACGTGAAATPAAAAAGACAAAAA	1679
1621	Db	GTAGCTGTGCCACCAACGGCGTGTGTGTGAAACGTGAAATPAAAAAGACAAAAA	1679

is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for chromosome and gene mapping or gene therapy. (II) is useful for generating transgenic animals or knock-out animals which are useful screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide is useful for treating bone and/or cartilage disorders (e.g., arthritis, CC sport injuries). This sequence encodes a human secreted and transmembrane CC PRO polypeptide.

XX SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6.7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCTTCGCAAAAGCTTTGAGAGCAAC	60
Db	1	GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCTTCGCAAAAGCTTTGAGAGCAAC	60
Qy	61	AATCTATCGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
Db	61	AATCTATCGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
Qy	121	AAGAAAAAAATCATGAAAAACCATCCAGCAAAATGCAAAATCTATCTTTGGGCAAT	180
Db	121	AAGAAAAAAATCATGAAAAACCATCCAGCAAAATGCAAAATCTATCTTTGGGCAAT	180
Qy	181	CTTACGGGGCTGGTGTCTGTGTCTCTTCAAGAGTGGCCCTGCGCAGCGAGATGC	240
Db	181	CTTACGGGGCTGGTGTCTGTGTCTCTTCAAGAGTGGCCCTGCGCAGCGAGATGC	240
Qy	241	CACCTTCCCAAGCTATGGAACAGTGAAGTGGTCCGCGAGGGGAGCGCCACCTCAG	300
Db	241	CACCTTCCCAAGCTATGGAACAGTGAAGTGGTCCGCGAGGGGAGCGCCACCTCAG	300
Qy	301	GTGCACTATTGACAAACGGGTCAACCGGGTGGCTGGTAAACCGCAGCACCATCTCTTA	360
Db	301	GTGCACTATTGACAAACGGGTCAACCGGGTGGCTGGTAAACCGCAGCACCATCTCTTA	360
Qy	361	TGCTGGGAATGACAGTGGTGGTGGTCTCTGCGTGGTCTCTGAGCAACACCCAAAC	420
Db	361	TGCTGGGAATGACAGTGGTGGTGGTCTCTGCGTGGTCTCTGAGCAACACCCAAAC	420
Qy	421	GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACGAGGGCCCTTACACCTGCTC	480
Db	421	GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACGAGGGCCCTTACACCTGCTC	480
Qy	481	GGTGCAGACAGCAACACCAAGACCTCTAGGGTCCACCTCATTTGTCAGATATCTCC	540
Db	481	GGTGCAGACAGCAACACCAAGACCTCTAGGGTCCACCTCATTTGTCAGATATCTCC	540
Qy	541	CAAAATTTGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCTCAC	600
Db	541	CAAAATTTGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCTCAC	600
Qy	601	CTGCATAGCAACTGTGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCAAAGC	660
Db	601	CTGCATAGCAACTGTGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCAAAGC	660
Qy	661	GGTTGGCTTTGTGAGTGAAGCAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720
Db	661	GGTTGGCTTTGTGAGTGAAGCAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720
Qy	721	AGGGGACTACAGTGTAGTCTCTCAATGACGTGGCCCGCGTGGTACGAGAGTAA	780
Db	721	AGGGGACTACAGTGTAGTCTCTCAATGACGTGGCCCGCGTGGTACGAGAGTAA	780
Qy	781	GGTCCGGTGAATTCACCATACATTTTCAGAAAGCAAGGGTACAGGGTGTCCCGTGGG	840
Db	781	GGTCCGGTGAATTCACCATACATTTTCAGAAAGCAAGGGTACAGGGTGTCCCGTGGG	840

Qy	841	ACAAAAGGGGACACTGAGTGTGAAGCTCAGAGTCCCTCAGAGAAATTCAGTGGTA	900
Db	841	ACAAAAGGGGACACTGAGTGTGAAGCTCAGAGTCCCTCAGAGAAATTCAGTGGTA	900
Qy	901	CAAGGATGACAAAGACTGATTGAAGAAAGAGGGGTGAAAGTGGAAAAACAGACTTT	960
Db	901	CAAGGATGACAAAGACTGATTGAAGAAAGAGGGGTGAAAGTGGAAAAACAGACTTT	960
Qy	961	CTCTCAAAACTCATCTTTCTCAATGTCTGAACATGACTATGGAACTTACACTTGCCT	1020
Db	961	CTCTCAAAACTCATCTTTCTCAATGTCTGAACATGACTATGGAACTTACACTTGCCT	1020
Qy	1021	GGCTCCCAACAGCTGGGCCACACCAATGCCAGCATCATCTATTTGGTCCAGCGCGCT	1080
Db	1021	GGCTCCCAACAGCTGGGCCACACCAATGCCAGCATCATCTATTTGGTCCAGCGCGCT	1080
Qy	1081	CAGCGAGTGTAGCAACCGGCACTGTGAGAGGGGAGGCTGCTGTGGTGTCTCTTCT	1140
Db	1081	CAGCGAGTGTAGCAACCGGCACTGTGAGAGGGGAGGCTGCTGTGGTGTCTCTTCT	1140
Qy	1141	GGTCTTCACCTGCTCTCAAAATTTTGAATGTGAGTGCCTTCCCAACCGGAAAGGCT	1200
Db	1141	GGTCTTCACCTGCTCTCAAAATTTTGAATGTGAGTGCCTTCCCAACCGGAAAGGCT	1200
Qy	1201	GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA	1260
Db	1201	GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA	1260
Qy	1261	TATACAAATGAAATTTAGAAAGAAACAGCTCATGGAGAGAAATTTGAGGGAGGGAAC	1320
Db	1261	TATACAAATGAAATTTAGAAAGAAACAGCTCATGGAGAGAAATTTGAGGGAGGGAAC	1320
Qy	1321	AAAGATACCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTTCAGATA	1380
Db	1321	AAAGATACCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTTCAGATA	1380
Qy	1381	TTTAGGTACAAATGAGTTTCTTTTCCCAACCGGAAAGAAACAGCACACCCCGCTTGG	1440
Db	1381	TTTAGGTACAAATGAGTTTCTTTTCCCAACCGGAAAGAAACAGCACACCCCGCTTGG	1440
Qy	1441	CCCACTGCAAGTGCATGCTGCAACCTTTTGGTGGCAGTGTGGGCAAGGCTCAGGCTC	1500
Db	1441	CCCACTGCAAGTGCATGCTGCAACCTTTTGGTGGCAGTGTGGGCAAGGCTCAGGCTC	1500
Qy	1501	TCTGCCACAGAGTGCCCCCAGTGGAACTTTTGGAGCTGGCCATCCCAAAATTCATCA	1560
Db	1501	TCTGCCACAGAGTGCCCCCAGTGGAACTTTTGGAGCTGGCCATCCCAAAATTCATCA	1560
Qy	1561	GTCCATAGAGACGAACAGATGAGACCTTCGGCCCAAGCGTGGCGCTGGGCACTTTG	1620
Db	1561	GTCCATAGAGACGAACAGATGAGACCTTCGGCCCAAGCGTGGCGCTGGGCACTTTG	1620
Qy	1621	GTAGACTGTGCCACCGGCTGTGTGTGAACGTGAATATAAGAGCAAAAAA	1679
Db	1621	GTAGACTGTGCCACCGGCTGTGTGTGAACGTGAATATAAGAGCAAAAAA	1679

RESULT 3

ADB38115

ID ADB38115 standard; cDNA; 1679 BP.

XX

AC ADB38115;

XX

DT 04-DEC-2003 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO337 cDNA.

XX

KW Human; secreted and transmembrane protein; PRO; gene; ss;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW Glucose uptake modulator; PFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;

KW cell differentiation inhibitor; cytokine release stimulator; tumour;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
OS Homo sapiens.
XX US2003087347-A1.
XX 08-MAY-2003.
XX 19-APR-2002; 2002US-00125921.
XX 17-AUG-1998; 98US-0096791P.
XX 02-JUN-1999; 99WO-US012252.
XX 25-AUG-1999; 99US-00380137.
XX 30-MAR-2000; 2000WO-US008439.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WJ, Zhang Z;
XX DR P-PSDB; ADB38116.
XX WPI; 2003-786938/74.
XX P-PSDB; ADB38116.
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX Claim 2; Fig 375; 637pp; English.
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PMBC cells, for inhibiting the binding of
CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCTTCCATGACAGCTTGAGCAACAC 60
DB 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCTTCCATGACAGCTTGAGCAACAC 60
QY 61 AATCTATCGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

61 AATCTATCGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAAATTCATCTCTTGGGCAAT 180
121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAAATTCATCTCTTGGGCAAT 180
QY 181 CTTACGGGGCTGGCTGCTCTCTTCCAGAGAGTCCCGTCCGACGCGGAGATGC 240
181 CTTACGGGGCTGGCTGCTCTCTTCCAGAGAGTCCCGTCCGACGCGGAGATGC 240
QY 241 CACCTTCCCAAAAGCTATGGAACAAGCTGACGGTCCGAGGGGAGAGCGCCACCTCAG 300
241 CACCTTCCCAAAAGCTATGGAACAAGCTGACGGTCCGAGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCACTATTGACAACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCATCTCTTA 360
301 GTGCACTATTGACAACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCATCTCTTA 360
QY 361 TGCTGGGAATGACAAAGTGGTGGTCTCTCTCGCTGGTCTCTCTGAGCAACACCCAAAC 420
361 TGCTGGGAATGACAAAGTGGTGGTCTCTCTCGCTGGTCTCTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACGTTGGATGTGATGACGAGGGCCCTTACACCTGTC 480
421 GCAGTACAGCATCGAGATCCAGAACGTTGGATGTGATGACGAGGGCCCTTACACCTGTC 480
QY 481 GGTGACAGACAGCAACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
481 GGTGACAGACAGCAACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCTAC 600
541 CAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCTAC 600
QY 601 CTGCATAGCAACTGGTACAGCAGAGCCCTACGTTACTTGGAGACACATCTCTCCAAAGC 660
601 CTGCATAGCAACTGGTACAGCAGAGCCCTACGTTACTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGACGAATATCTTGAAGATTCAGGGCATCAACCCGGAGCAGTC 720
661 GGTGGCTTTGTGAGTGAAGACGAATATCTTGAAGATTCAGGGCATCAACCCGGAGCAGTC 720
QY 721 AGGGGACTAGAGTGCAGTGCCTCAATGACGTGGCGCCGCGGTGACGAGAGTAAA 780
721 AGGGGACTAGAGTGCAGTGCCTCAATGACGTGGCGCCGCGGTGACGAGAGTAAA 780
QY 781 GGTCAACCGTGAACCTATCCACCATACATTTTCAAGCAAGGGTACAGGTGTCCCCGTGG 840
781 GGTCAACCGTGAACCTATCCACCATACATTTTCAAGCAAGGGTACAGGTGTCCCCGTGG 840
QY 841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
QY 901 CAAGGATGACAAAAGACTGATTGAAAGGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT 960
901 CAAGGATGACAAAAGACTGATTGAAAGGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT 960
QY 961 CCTCTCAAAACCTATCTTCTCAATGTCTCTGAAATGATGATGGAATCACTTGGCT 1020
961 CCTCTCAAAACCTATCTTCTCAATGTCTCTGAAATGATGATGGAATCACTTGGCT 1020
QY 1021 GGCTCCCAAGAGCTGGGCAACCAATGCCAGCATCATGCTATTGTCAGGGGCGCT 1080
1021 GGCTCCCAAGAGCTGGGCAACCAATGCCAGCATCATGCTATTGTCAGGGGCGCT 1080
QY 1081 CAGCGAGGTGAGCAACCGGACCGTCAAGGAGGCGAGGCTCGCTGCTGCTGCTCTTCT 1140
1081 CAGCGAGGTGAGCAACCGGACCGTCAAGGAGGCGAGGCTCGCTGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGCACTGCTCTCTCAAAATTTTGTGAGTGCCACTTCCCACCCCGGAAAGGCT 1200
1141 GGTCTTGCACTGCTCTCTCAAAATTTTGTGAGTGCCACTTCCCACCCCGGAAAGGCT 1200

QY	1201	GC	CGCCACCA	CACCA	CACCA	CAGCAAT	GGCAAC	CACCG	CAGCAACCAAT	CAGATA	1260
DB	1201	GC	CGCCACCA	CACCA	CACCA	CAGCAAT	GGCAAC	CACCG	CAGCAACCAAT	CAGATA	1260
QY	1261	TAT	ACAAATGA	AAATTA	AGAAAC	CACAG	CCTCAT	GGACAC	AGAAATTT	TGAGGAGGGGAAC	1320
DB	1261	TAT	ACAAATGA	AAATTA	AGAAAC	CACAG	CCTCAT	GGACAC	AGAAATTT	TGAGGAGGGGAAC	1320
QY	1321	AA	AGAAATCT	TTGGGGG	AAAGAG	TTTT	AAAAA	AGAAAT	TGAAAA	TTGCCTTGCAGATA	1380
DB	1321	AA	AGAAATCT	TTGGGGG	AAAGAG	TTTT	AAAAA	AGAAAT	TGAAAA	TTGCCTTGCAGATA	1380
QY	1381	TTT	TAGGTACA	ATGGAG	TTTT	CTTTT	CCCAA	CGGAGAA	CACAG	CACACCCCGCTTGGGA	1440
DB	1381	TTT	TAGGTACA	ATGGAG	TTTT	CTTTT	CCCAA	CGGAGAA	CACAG	CACACCCCGCTTGGGA	1440
QY	1441	CC	CACGTCAA	AGCTGC	ATCGT	GC	AACTCT	TTTGT	GCCAGTGT	GGGCAAGGCTCAGGCTC	1500
DB	1441	CC	CACGTCAA	AGCTGC	ATCGT	GC	AACTCT	TTTGT	GCCAGTGT	GGGCAAGGCTCAGGCTC	1500
QY	1501	TC	TGCCCC	CACAG	AGTGCC	CCCC	CAGTGG	AAACAT	TTCTG	GAGCTGGCCATCCCAAAATTCAAATCA	1560
DB	1501	TC	TGCCCC	CACAG	AGTGCC	CCCC	CAGTGG	AAACAT	TTCTG	GAGCTGGCCATCCCAAAATTCAAATCA	1560
QY	1561	GT	CCATAG	ACG	GAACGA	ATG	ACAC	CTTC	CGGCC	CCCAAGGTGGCGCTGGGGCACCTTTG	1620
DB	1561	GT	CCATAG	ACG	GAACGA	ATG	ACAC	CTTC	CGGCC	CCCAAGGTGGCGCTGGGGCACCTTTG	1620
QY	1621	GT	AGCTGT	GC	CCAC	CACCG	CGTG	TGTTG	TG	AAACGTTGAAATATAAAGAGCAAAAAAAA	1679
DB	1621	GT	AGCTGT	GC	CCAC	CACCG	CGTG	TGTTG	TG	AAACGTTGAAATATAAAGAGCAAAAAAAA	1679

```

PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S,
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786905/74.
DR P-PSDB; ADB66588.
XX
XX New PRO nucleic acid, useful for preparing a composition for treating
PT e.g. tumor or for tissue typing.
XX
XX Claim 2; Fig 375; 637pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear articular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PMBC cells, for inhibiting the binding of
CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping. In generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTCTGCAAGCTTGAGAGCAAC 60
DB 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTCTGCAAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAATGCAAAATCTCTCTGGGCAAT 180

```

```

DB 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAATGCAAAATCTCTCTGGGCAAT 180
QY 181 CTTACGGGGGCTGGCTGTCTGTCTCTTCCAAAGGAGTGCCTGGCGCAGCGAGATGC 240
DB 181 CTTACGGGGGCTGGCTGTCTGTCTCTTCCAAAGGAGTGCCTGGCGCAGCGAGATGC 240
QY 241 CACCTTCCCCAAAAGCTATGGAACAACGTCGCGGAGGGGAGAGCGCCACCTCTAG 300
DB 241 CACCTTCCCCAAAAGCTATGGAACAACGTCGCGGAGGGGAGAGCGCCACCTCTAG 300
QY 301 GTGCACACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCCTCTTA 360
DB 301 GTGCACACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCCTCTTA 360
QY 361 TGCTGGGAATGACAAAGTGGTCTGGATTCCTCGGGTGGTCTCTTGAGCAACACCCAAAC 420
DB 361 TGCTGGGAATGACAAAGTGGTCTGGATTCCTCGGGTGGTCTCTTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAGACGTGGATGTGTATGACGAGGGCCCTTACACTGTCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAGACGTGGATGTGTATGACGAGGGCCCTTACACTGTCTC 480
QY 481 GGTGAGAGACAGAACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 540
DB 481 GGTGAGAGACAGAACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 540
QY 541 CAARATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTTCC 600
DB 541 CAARATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTTCC 600
QY 601 CTGCATAGCAACTGGTAGACAGCCTTACCGTTTACTTTGGAGACACATCTCTCCAAAAGC 660
DB 601 CTGCATAGCAACTGGTAGACAGCCTTACCGTTTACTTTGGAGACACATCTCTCCAAAAGC 660
QY 661 GGTGGCTTTGTAGTGAAGCGATCTTGGAAATTCAGGGCATCCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTAGTGAAGCGATCTTGGAAATTCAGGGCATCCCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCCGCTGGTACGGAGAGTAAA 780
DB 721 AGGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCCGCTGGTACGGAGAGTAAA 780
QY 781 GGTCCCGTGAACATCCACCTATCTTCAGAGCCAAAGGTACAGGTGTCGGCGTGG 840
DB 781 GGTCCCGTGAACATCCACCTATCTTCAGAGCCAAAGGTACAGGTGTCGGCGTGG 840
QY 841 ACAAAGGGGACACTGCGAGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTA 900
DB 841 ACAAAGGGGACACTGCGAGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTA 900
QY 901 CAAGATGACAAAAGCTGATTGAAGGAAAGAAAGGGGTGAAGTGAAGGAAAGAAAGCTTT 960
DB 901 CAAGATGACAAAAGCTGATTGAAGGAAAGAAAGGGGTGAAGTGAAGGAAAGAAAGCTTT 960
QY 961 CTTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAACACTACACTTGGT 1020
DB 961 CTTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAACACTACACTTGGT 1020
QY 1021 GGCCTCCAAAGCTGGGCGCACCAATGCCAGCATCATCTATTGTTGGTCCAGGGCGCGT 1080
DB 1021 GGCCTCCAAAGCTGGGCGCACCAATGCCAGCATCATCTATTGTTGGTCCAGGGCGCGT 1080
QY 1081 CAGCGAGGTGACCAACGGCAGCTGCGAGGAGGCGGCTGCGTCTGGCTGCTGCTCTTCT 1140
DB 1081 CAGCGAGGTGACCAACGGCAGCTGCGAGGAGGCGGCTGCGTCTGGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGCACTGCTTCTCAAAATTTTGAATGTGAGTGCCACTTCCCGCAAGGCT 1200
DB 1141 GGTCTTGCACTGCTTCTCAAAATTTTGAATGTGAGTGCCACTTCCCGCAAGGCT 1200
QY 1201 GCGCGCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260

```


601 CTGATAGCACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
661 GGTGGCTTTGTAGTGAAGACGAATCTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
661 GGTGGCTTTGTAGTGAAGACGAATCTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
721 AGGGGACTACAGTGCAGTGCTCCCAATGACGTGGCGCGCCGTGTGTGAGAGAGTAAA 780
721 AGGGGACTACAGTGCAGTGCTCCCAATGACGTGGCGCGCCGTGTGTGAGAGAGTAAA 780
781 GGTCAACCGTGAATATCCACCATATTCAGAAAGCCAGGGTACAGGTTCCTCCCGTGGG 840
781 GGTCAACCGTGAATATCCACCATATTCAGAAAGCCAGGGTACAGGTTCCTCCCGTGGG 840
841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGCAGTCCCTCAGCGAATTCAGTGGTA 900
841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGCAGTCCCTCAGCGAATTCAGTGGTA 900
901 CAAGGATGACAAAAGACTGATTGAAGAAAGAGGGGTGAAAGTGGAACACAGACTTT 960
901 CAAGGATGACAAAAGACTGATTGAAGAAAGAGGGGTGAAAGTGGAACACAGACTTT 960
961 CCTCTCAAACTCATCTCTCTCAATGCTCTGACATGACTATGGGAACCTACACTTGGCT 1020
961 CCTCTCAAACTCATCTCTCTCAATGCTCTGACATGACTATGGGAACCTACACTTGGCT 1020
1021 GGCCTCCAAACAGCTGGGCCCAACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGCT 1080
1021 GGCCTCCAAACAGCTGGGCCCAACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGCT 1080
1081 CAGGAGGTGAGCAACCGCAGCTGAGAGGGGAGGCTGGTCTGGTCTGCTCTTCT 1140
1081 CAGGAGGTGAGCAACCGCAGCTGAGAGGGGAGGCTGGTCTGGTCTGCTCTTCT 1140
1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTAGTGCCACTTCCCAACCGGGAAGGCT 1200
1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTAGTGCCACTTCCCAACCGGGAAGGCT 1200
1201 GCGGCACACACACCAACCAACAGCAATGCGACACAGCAGCAACCAATTCAGATA 1260
1201 GCGGCACACACACCAACCAACAGCAATGCGACACAGCAGCAACCAATTCAGATA 1260
1261 TATCAAAATGAAATAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC 1320
1261 TATCAAAATGAAATAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC 1320
1321 AAAGATACTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCCATGATA 1380
1321 AAAGATACTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCCATGATA 1380
1381 TTTAGGTACATGAGTTTCTTTTCCCAACCGGAGAGACACAGCACACCCGGCTTGA 1440
1381 TTTAGGTACATGAGTTTCTTTTCCCAACCGGAGAGACACAGCACACCCGGCTTGA 1440
1441 CCCACTGCAAGCTGCATGTCACACTTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
1441 CCCACTGCAAGCTGCATGTCACACTTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
1501 TCTGCCACAGAGTCCCAACGTTGAACTTCTGGAGCTGGCCATCCCAATTCATCA 1560
1501 TCTGCCACAGAGTCCCAACGTTGAACTTCTGGAGCTGGCCATCCCAATTCATCA 1560
1561 GTCCATAGAGACGAACAGATGAGACTTCCGCGCCCAAGCGTGGCGTGGGCACTTTG 1620
1561 GTCCATAGAGACGAACAGATGAGACTTCCGCGCCCAAGCGTGGCGTGGGCACTTTG 1620
1621 GTAGACTGTGCCACAGCGGTGTGTGAAAGCTGAATTAAGAGAGCAAAAAA 1679
1621 GTAGACTGTGCCACAGCGGTGTGTGAAAGCTGAATTAAGAGAGCAAAAAA 1679

RESULT 6

ADB89667
ID ADB89667 standard; cDNA; 1679 BP.
XX
AC ADB89667;
XX
DT 04-DEC-2003 (first entry)
XX
KW Human PRO polynucleotide #188.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082698-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127850.
XX
PR 20-AUG-1998; 98US-0097218P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 98US-00380137.
PR 02-MAR-2000; 2000WO-US005841.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-743896/70.
XX
P-PSDB; ADB89668.
XX
PT New PRO nucleic acids and encoded polypeptides, useful in the treatment
of cancer.
XX
PS Claim 2; Fig 375; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCCTTGCAACAGCTTGAGAGCAAC	60
Db	1	GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCCTTGCAACAGCTTGAGAGCAAC	60
Qy	61	AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
Db	61	AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
Qy	121	AGAAAGAAATCATGAAACCATCCAGCCAAATGCAATCTCTCTTGGGCAAT	180
Db	121	AGAAAGAAATCATGAAACCATCCAGCCAAATGCAATCTCTCTTGGGCAAT	180
Qy	181	CTTCAGGGGCTGGCTGCTCTGTGTCTCTTCAAGAGTGGCCGTGCGCAGGGAGATGC	240
Db	181	CTTCAGGGGCTGGCTGCTGTGTCTCTTCAAGAGTGGCCGTGCGCAGGGAGATGC	240
Qy	241	CACCTTCCCAAGCTATGGACAGTGCAGCTCCGGCAGGGGAGAGCCACCTCAG	300
Db	241	CACCTTCCCAAGCTATGGACAGTGCAGCTCCGGCAGGGGAGAGCCACCTCAG	300
Qy	301	GTGCATATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCCTCTTA	360
Db	301	GTGCATATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCCTCTTA	360
Qy	361	TGCTGGGATGACAGTGTGCTGATCTCGCTGGTCTCTTGGAGCAACCCCAAC	420
Db	361	TGCTGGGATGACAGTGTGCTGATCTCGCTGGTCTCTTGGAGCAACCCCAAC	420
Qy	421	GCAGTACAGCATCGAGATCCAGAACCTGTATGATGACGAGGGCCCTTACACCTGCTC	480
Db	421	GCAGTACAGCATCGAGATCCAGAACCTGTATGATGACGAGGGCCCTTACACCTGCTC	480
Qy	481	GGTGACAGACAAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540
Db	481	GGTGACAGACAAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540
Qy	541	CAAAATGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCTCAC	600
Db	541	CAAAATGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCTCAC	600
Qy	601	CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC	660
Db	601	CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC	660
Qy	661	GGTTGGCTTTGTGAGTGAAGAGAAATCTTGGAAATTCAGGGCATCACCCTGGGAGTGC	720
Db	661	GGTTGGCTTTGTGAGTGAAGAGAAATCTTGGAAATTCAGGGCATCACCCTGGGAGTGC	720
Qy	721	AGGGGACTACAGTGCAGTGCCTCCCAATGACGTGGCCGCGCGTGGTACGGAGAGTAA	780
Db	721	AGGGGACTACAGTGCAGTGCCTCCCAATGACGTGGCCGCGCGTGGTACGGAGAGTAA	780
Qy	781	GGTACCGTGAAATATCCACATATTTACAGAGCCAGGGTACAGGGTCCCGTGGG	840
Db	781	GGTACCGTGAAATATCCACATATTTACAGAGCCAGGGTACAGGGTCCCGTGGG	840

Qy	841	ACAAAAGGGACACTGCAGTGTGAAGCCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA	900
Db	841	ACAAAAGGGACACTGCAGTGTGAAGCCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA	900
Qy	901	CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGTGAAGTGAAGAAACAGACCTTT	960
Db	901	CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGTGAAGTGAAGAAACAGACCTTT	960
Qy	961	CTCTCAAAACTCATTTCTTCAATCTCTCTGAACATGATGGAACATACACTTGGCT	1020
Db	961	CTCTCAAAACTCATTTCTTCAATCTCTCTGAACATGATGGAACATACACTTGGCT	1020
Qy	1021	GGCTCCCAACAGCTGGGCCACACCAATGCCAGCATCATGCTATTGTCACGGCCCGT	1080
Db	1021	GGCTCCCAACAGCTGGGCCACACCAATGCCAGCATCATGCTATTGTCACGGCCCGT	1080
Qy	1081	CAGCGAGGTGAGCAACCGGCACGTCGAGGAGGGCAGGCTGCTGCTGCTCTTCT	1140
Db	1081	CAGCGAGGTGAGCAACCGGCACGTCGAGGAGGGCAGGCTGCTGCTGCTCTTCT	1140
Qy	1141	GGTCTTGACCTCTCTCAAAATTTTGAATGTGATGCCACTTCCCAACCGGGAAGGCT	1200
Db	1141	GGTCTTGACCTCTCTCAAAATTTTGAATGTGATGCCACTTCCCAACCGGGAAGGCT	1200
Qy	1201	GGCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA	1260
Db	1201	GGCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA	1260
Qy	1261	TATACAAATGAATTTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGGAGGGAAC	1320
Db	1261	TATACAAATGAATTTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGGAGGGAAC	1320
Qy	1321	AAAGAAATCTTTGGGGGAAAAGAGTTTAAAAAAGAAATTTGAAATTTGCTTTGCAGATA	1380
Db	1321	AAAGAAATCTTTGGGGGAAAAGAGTTTAAAAAAGAAATTTGAAATTTGCTTTGCAGATA	1380
Qy	1381	TTTAGTACAAATGAGGTTTCTTTCCAAAACGGGAAGAACACAGCACACCCCGCTTGA	1440
Db	1381	TTTAGTACAAATGAGGTTTCTTTCCAAAACGGGAAGAACACAGCACACCCCGCTTGA	1440
Qy	1441	CCCACTCAAGCTGCATCGTGCAACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC	1500
Db	1441	CCCACTCAAGCTGCATCGTGCAACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC	1500
Qy	1501	TCTGCCACAGAGTGCCTCCCAACCTCTTGGAAACATTTCTGAGCTGGCCATCCCAATCA	1560
Db	1501	TCTGCCACAGAGTGCCTCCCAACCTCTTGGAAACATTTCTGAGCTGGCCATCCCAATCA	1560
Qy	1561	GTCCATAGACAGCAACAGAAATGAGACCTTCCGGCCCAAGCTGGCGTGGGGCACTTTG	1620
Db	1561	GTCCATAGACAGCAACAGAAATGAGACCTTCCGGCCCAAGCTGGCGTGGGGCACTTTG	1620
Qy	1621	GTAGACTGTGCCACCGGCTGTGTTGTAACCTGTAATATAAGAGCAAAAAA	1679
Db	1621	GTAGACTGTGCCACCGGCTGTGTTGTAACCTGTAATATAAGAGCAAAAAA	1679

RESULT 7

ADB90399 standard; cDNA; 1679 BP.

XX ADB90399;

XX 04-DEC-2003 (first entry)

XX Human PRO polynucleotide #188.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumor necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; RFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

OS Homo sapiens.

PN US2003082762-A1.

XX 01-MAY-2003.

PD 15-APR-2002; 2002US-00123335.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 01-DEC-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 30-NOV-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 05-JAN-2000; 99WO-US031274.

PR 06-JAN-2000; 2000WO-US000219.

PR 02-JUN-2000; 2000WO-US014941.
PR 28-JUL-2000; 2000WO-US015264.
PR 11-AUG-2000; 2000WO-US020710.
PR 23-AUG-2000; 2000WO-US022031.
PR 24-AUG-2000; 2000WO-US023522.
PR 08-NOV-2000; 2000WO-US023328.
PR 10-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US030873.
PR 20-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796496.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808699.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854288.
PR 10-MAY-2001; 2001US-00854280.
PR 19-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-743899/70.
DR P-PSDB; ADB90400.

XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, and in the detection and treatment of tumor in a mammal.
PS Claim 2; Fig 375; 649pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTCTTGCACAACTTGAGCAAAAC	60
DB	1	GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTCTTGCACAACTTGAGCAAAAC	60
QY	61	AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
DB	61	AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
QY	121	AAGAAAGAAATCATGAAGAAACCATCAGCCAAATGCAATTCCTCTTGGGCAAT	180
DB	121	AAGAAAGAAATCATGAAGAAACCATCAGCCAAATGCAATTCCTCTTGGGCAAT	180
QY	181	CTTCAGGGGCTGGTGTCTGTGTCTCTTCAAGGAGTCCCGTCCGAGCGGAGATGC	240
DB	181	CTTCAGGGGCTGGTGTCTGTGTCTCTTCAAGGAGTCCCGTCCGAGCGGAGATGC	240
QY	241	CACCTTCCCAAGCTATGACAACTGACGCTCGGTCGGGAGGAGCGCCACCTCAG	300
DB	241	CACCTTCCCAAGCTATGACAACTGACGCTCGGTCGGGAGGAGCGCCACCTCAG	300
QY	301	GTGCACATATTGACAAACCGGCTCACCGGGTGGCTGTCTTCAAGGAGTCCCGTCCG	360
DB	301	GTGCACATATTGACAAACCGGCTCACCGGGTGGCTGTCTTCAAGGAGTCCCGTCCG	360
QY	361	TGCTGGGAATGACAGTGGTGGTGGATCTCTCGGTCGGTCTTCTGAGCAACACCCAAAC	420
DB	361	TGCTGGGAATGACAGTGGTGGTGGATCTCTCGGTCGGTCTTCTGAGCAACACCCAAAC	420
QY	421	GCAGTACAGCATCGAGATCCAGAACTGGATGTGTATGAGCGGGCCCTTACACCTGCTC	480
DB	421	GCAGTACAGCATCGAGATCCAGAACTGGATGTGTATGAGCGGGCCCTTACACCTGCTC	480
QY	481	GGTGAGAGACAAACCCAAAGACCTTAGGGTCCACCTCATTTGTCAGATATCTCC	540
DB	481	GGTGAGAGACAAACCCAAAGACCTTAGGGTCCACCTCATTTGTCAGATATCTCC	540
QY	541	CAAAATTTGAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC	600
DB	541	CAAAATTTGAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC	600
QY	601	CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCAAAGC	660
DB	601	CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCAAAGC	660
QY	661	GGTTGGCTTTGTAGTGAAGCAAGTACTTTGAAATTCAGGGCATCACCGGGAGCAGTC	720
DB	661	GGTTGGCTTTGTAGTGAAGCAAGTACTTTGAAATTCAGGGCATCACCGGGAGCAGTC	720
QY	721	AGGGGACTACAGTGCAGTCCCTCAATGACGTGGCGGCCCGTGGTACGGAGATGAA	780
DB	721	AGGGGACTACAGTGCAGTCCCTCAATGACGTGGCGGCCCGTGGTACGGAGATGAA	780

QY	781	GGTCACCGTGAACCTATCCACCATACATTTTCAGAAAGCCAAAGGGTACAGGTGTCCCCCGTGGG	840
DB	781	GGTCACCGTGAACCTATCCACCATACATTTTCAGAAAGCCAAAGGGTACAGGTGTCCCCCGTGGG	840
QY	841	ACAAAAGGGGACACTGCAAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
DB	841	ACAAAAGGGGACACTGCAAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
QY	901	CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAAGTGGAAAACAGACCTTT	960
DB	901	CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAAGTGGAAAACAGACCTTT	960
QY	961	CCTCTCAAAACTCATCTTCTCTCAATGCTCTGAACATGACTATGAGGAACTACACTTCGCT	1020
DB	961	CCTCTCAAAACTCATCTTCTCTCAATGCTCTGAACATGACTATGAGGAACTACACTTCGCT	1020
QY	1021	GGCTCCCAAGCTGGGCGCACCAATGCCAGCATCATCTATTTGCTCCAGCGCGCT	1080
DB	1021	GGCTCCCAAGCTGGGCGCACCAATGCCAGCATCATCTATTTGCTCCAGCGCGCT	1080
QY	1081	CAGCGAGTGAAGCAACCGCACGCTCGAGAGGGGAGGCTGTGCTGTGCTCTCTCT	1140
DB	1081	CAGCGAGTGAAGCAACCGCACGCTCGAGAGGGGAGGCTGTGCTGTGCTCTCTCTCT	1140
QY	1141	GGTCTTGCACCTGCTCTCAAAATTTTTCATGAGTGCACCTTCCCGACCGGGAAGGCT	1200
DB	1141	GGTCTTGCACCTGCTCTCAAAATTTTTCATGAGTGCACCTTCCCGACCGGGAAGGCT	1200
QY	1201	GCCGCCACCCACCAACCAACAGCAATGSCAAACCCGACAGCAACCAATCAGATA	1260
DB	1201	GCCGCCACCCACCAACCAACAGCAATGSCAAACCCGACAGCAACCAATCAGATA	1260
QY	1261	TATACAAATGAAATAGAGAAACACAGAGCTCATGGGACAGAAATTTGAGGGAGGGAAC	1320
DB	1261	TATACAAATGAAATAGAGAAACACAGAGCTCATGGGACAGAAATTTGAGGGAGGGAAC	1320
QY	1321	AAAGAAATCTTTGGGGGAAAGAGTGTAAAAAAGAAATTTGAAAAATTTGCCCTTCAGATA	1380
DB	1321	AAAGAAATCTTTGGGGGAAAGAGTGTAAAAAAGAAATTTGAAAAATTTGCCCTTCAGATA	1380
QY	1381	TTTAGGTACAAATGAGATTTCTTTTCCAAACCGGGAAGAACACAGCACACCGGCTTGA	1440
DB	1381	TTTAGGTACAAATGAGATTTCTTTTCCAAACCGGGAAGAACACAGCACACCGGCTTGA	1440
QY	1441	CCCACTGCAAGCTGCATCGTGCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGGCTC	1500
DB	1441	CCCACTGCAAGCTGCATCGTGCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGGCTC	1500
QY	1501	TCTGCCACAGAGTGCCGCCACGCTGGAAACATTTCTGGAGCTGGCCATCCCAAAATCAATCA	1560
DB	1501	TCTGCCACAGAGTGCCGCCACGCTGGAAACATTTCTGGAGCTGGCCATCCCAAAATCAATCA	1560
QY	1561	GTCCATAGAGACGAAACAGATGAGACCTTCCGGCCCAAGCGTGGCTGCGGCACTTTG	1620
DB	1561	GTCCATAGAGACGAAACAGATGAGACCTTCCGGCCCAAGCGTGGCTGCGGCACTTTG	1620
QY	1621	GTAGACTGTGCCACACCGCGCTGTGTGTGAAAAGTGAATATAAGAGCAAAAAAAA	1679
DB	1621	GTAGACTGTGCCACACCGCGCTGTGTGTGAAAAGTGAATATAAGAGCAAAAAAAA	1679

RESULT 8

ADB39500
ID ADB39500 standard; cDNA; 1679 BP.
XX AC ADB39500;
XX DT 04-DEC-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;

CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.

XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCTTACGAAAAACAGTGGATTAAATCTCTTGGCAAGCTTGAGCAACAC 60
DB 1 GTTGTGCTCTTACGAAAAACAGTGGATTAAATCTCTTGGCAAGCTTGAGCAACAC 60
QY 61 AATCTATCAGAAAGAAAGAAAGAAAAACCGAACCTGACAAAAAAGAAAGAAAG 120
DB 61 AATCTATCAGAAAGAAAGAAAGAAAAACCGAACCTGACAAAAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAACCAATCAGCCAAAAATGCAAAATTCATCTCTTGGCAAT 180
DB 121 AAGAAAAAATCATGAAACCAATCAGCCAAAAATGCAAAATTCATCTCTTGGCAAT 180
QY 181 CTTTACGGGGTGGCTGCTGTGCTCTTCAAGAGGTGCCCTGCGCAGCGGAGATGC 240
DB 181 CTTTACGGGGTGGCTGCTGTGCTCTTCAAGAGGTGCCCTGCGCAGCGGAGATGC 240
QY 241 CACCTTCCCAAGCTPATGCAAAACGTGACGCTCGGCAAGGGGAGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAGCTPATGCAAAACGTGACGCTCGGCAAGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCACTATTGCAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCATCTCTA 360
DB 301 GTGCACTATTGCAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCATCTCTA 360
QY 361 TGTGGAATGCAAGTGTGCTGTGATCTCTCGCTGTGCTCTTCTGAGCAACACCCAAAC 420
DB 361 TGTGGAATGCAAGTGTGCTGTGATCTCTCGCTGTGCTCTTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGATCGAGATCCAGAAACGTGATGTATGACGAGGCGCTTACACCTGCTC 480
DB 421 GCAGTACAGATCGAGATCCAGAAACGTGATGTATGACGAGGCGCTTACACCTGCTC 480
QY 481 GGTGCAAGACAAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGCAAGACAAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAAATTGTAGATTTCTTCAATATCTCCATTAATGAAGGAAACATATTAGCTCAG 600
DB 541 CAAAATTGTAGATTTCTTCAATATCTCCATTAATGAAGGAAACATATTAGCTCAG 600
QY 601 CTGATAGCAACTGTGAGACAGAGCTACGGTTACTTGCAGACACATCTCTCCAAAGC 660
DB 601 CTGATAGCAACTGTGAGACAGAGCTACGGTTACTTGCAGACACATCTCTCCAAAGC 660
QY 661 GGTGCTTTGTGAGTGAAGAAATCTTGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGCTTTGTGAGTGAAGAAATCTTGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTCCCAATCACTGCGCGCGCGCGGTGACGAGAGTAA 780
DB 721 AGGGGACTACGAGTGCAGTCCCAATCACTGCGCGCGCGCGGTGACGAGAGTAA 780
QY 781 GGTCCCGTGAATATCCACCATACATTTTCAAGAGCAAGGGTACAGGTGTCCTCCGTGG 840
DB 781 GGTCCCGTGAATATCCACCATACATTTTCAAGAGCAAGGGTACAGGTGTCCTCCGTGG 840

DB 781 GGTCAACCGTGAATATCCACCATACATTTTCAAGAGCAAGGGTACAGGTGTCCTCCGTGG 840
QY 841 ACAAAGGGGACACTGCACTGAGTGTGAGCTCAGAGTCCCTCAGCAAAATTCAGTGGTA 900
DB 841 ACAAAGGGGACACTGCACTGAGTGTGAGCTCAGAGTCCCTCAGCAAAATTCAGTGGTA 900
QY 901 CAAGGATGACAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAACACAGACCTTT 960
DB 901 CAAGGATGACAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAACACAGACCTTT 960
QY 961 CCTCTCAAACTCATCTCTTCAATGTCTGAAACATGACTATGGAACATACACTTCCGT 1020
DB 961 CCTCTCAAACTCATCTCTTCAATGTCTGAAACATGACTATGGAACATACACTTCCGT 1020
QY 1021 GGCCTCCAAAGCTGGGCCACCAATGCCAGCATCATCTATTTGGTCCAGCGCGCT 1080
DB 1021 GGCCTCCAAAGCTGGGCCACCAATGCCAGCATCATCTATTTGGTCCAGCGCGCT 1080
QY 1081 CAGCGAGTGAGCAACCGGCACTGAGGAGGGCAGGCTGCTGTGGTGTGCTCTCTTCT 1140
DB 1081 CAGCGAGTGAGCAACCGGCACTGAGGAGGGCAGGCTGCTGTGGTGTGCTCTCTTCT 1140
QY 1141 GGTCTTGCACTGCTCTCAAAATTTTGTGAGTGCACCTTCCCAACCGGGAAGGCT 1200
DB 1141 GGTCTTGCACTGCTCTCAAAATTTTGTGAGTGCACCTTCCCAACCGGGAAGGCT 1200
QY 1201 GCCGCCACCAACCAACCAAGCAATGGCAACACCGCACAGCAACCAATCAGATA 1260
DB 1201 GCCGCCACCAACCAACCAAGCAATGGCAACACCGCACAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATTTAGAAGAAACACAGCCTCATGGACAGAAATTTGAGGGAGGGAAC 1320
DB 1261 TATACAAATGAATTTAGAAGAAACACAGCCTCATGGACAGAAATTTGAGGGAGGGAAC 1320
QY 1321 AAGAATACCTTTGGGGGAAAAAGAGTTTAAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB 1321 AAGAATACCTTTGGGGGAAAAAGAGTTTAAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGGTACAACTGGAGTTTCTTTCCCAACCGGAGAACACAGCACACCCCGCTTGG 1440
DB 1381 TTTAGGTACAACTGGAGTTTCTTTCCCAACCGGAGAACACAGCACACCCCGCTTGG 1440
QY 1441 CCCACTGCAAGCTGCACTGTCGCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGCACTGTCGCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTCCCGCCACAGTGGAAACATTTGAGAGTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTCCCGCCACAGTGGAAACATTTGAGAGTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACGAACAAAGATGAGACCTTCCGGCCCAAGCGTGGCGCTGCGGCACTTTG 1620
DB 1561 GTCCATAGAGACGAACAAAGATGAGACCTTCCGGCCCAAGCGTGGCGCTGCGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACAGCGGCTGTGTGTAACGTGTAATTAAGAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACAGCGGCTGTGTGTGTAACGTGTAATTAAGAGAGCAAAAAA 1679

RESULT 9

ADB78098

ID ADB78098 standard; cDNA; 1679 BP.

XX ADB78098;

XX 04-DEC-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO337 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;

KW vulnary; antithratic; pericyte cell proliferation;

KW pericyte cell differentiation; chondrocyte cell proliferation;

KW chondrocyte cell differentiation; tumour necrosis factor alpha release;

KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX
 OS Homo sapiens.
 XX
 XX US2003092886-A1.
 PN
 XX 15-MAY-2003.
 PD
 XX 09-AUG-2002; 2002US-00216165.
 PF
 XX 25-JUL-2000; 2000US-0220607P.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021086.
 PR 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.
 PA
 PI Baker KP, Deenoyers L, Gerritsen ME, Goddard A, Godowski PU;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX
 DR WPI; 2003-765494/72.
 DR P-PSDB; ADB78099.
 XX
 PT Novel isolated PRO polypeptide useful for tissue typing, gene therapy, as
 PT molecular weight markers in protein electrophoresis, for treating
 PT arthritis, tumor.
 PT
 PS Claim 2; Fig 125; 308pp; English.
 CC The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO351, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1285, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1397, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1328, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO1714, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 CC
 XX
 SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

	Matches 1679;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
QY	1	GTGTGTCTCTCAGCAAAACAGTGGATTAAATCTCTTGTGACAAAGCTTGAGACCAAC	60						
DB	1	GTGTGTCTCTCAGCAAAACAGTGGATTAAATCTCTTGTGACAAAGCTTGAGACCAAC	60						
QY	61	AATCTATCAGGAAACAGAAAGAAAGAAACCGACCTGACAAAGAAAGAAAGAAAG	120						
DB	61	AATCTATCAGGAAACAGAAAGAAAGAAACCGACCTGACAAAGAAAGAAAGAAAG	120						
QY	121	AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAAATTCATCTCTTGGCAAT	180						
DB	121	AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAAATTCATCTCTTGGCAAT	180						
QY	181	CTTCACGGGCTGGCTGCTCTGTGTCTCTTCCAGGAGTGCCTGCGCCGCGGAGATGC	240						
DB	181	CTTCACGGGCTGGCTGCTCTGTGTCTCTTCCAGGAGTGCCTGCGCCGCGGAGATGC	240						
QY	241	CACCTTCCCAAAAGCTATGGAACACGTCGCTCCGCGGAGAGCGCCACCTCAG	300						
DB	241	CACCTTCCCAAAAGCTATGGAACACGTCGCTCCGCGGAGAGCGCCACCTCAG	300						
QY	301	GTGCACTATTGACACCGGCTCACCCGGGTGCTGCTTAAACCGCAGCACCATTCTTA	360						
DB	301	GTGCACTATTGACACCGGCTCACCCGGGTGCTGCTTAAACCGCAGCACCATTCTTA	360						
QY	361	TGCTGGGAATGACAAAGTGTGCTTCCGCTGCTTCTTCTGAGCAACACCCAAAC	420						
DB	361	TGCTGGGAATGACAAAGTGTGCTTCCGCTGCTTCTTCTGAGCAACACCCAAAC	420						
QY	421	GCAGTACAGATCGAGATCCAGAACGTCGATGTGTATGACGAGGCCCTTACACCTGTC	480						
DB	421	GCAGTACAGATCGAGATCCAGAACGTCGATGTGTATGACGAGGCCCTTACACCTGTC	480						
QY	481	GGTGACAGACAGAACCAACCAACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540						
DB	481	GGTGACAGACAGAACCAACCAACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540						
QY	541	CAAAATTTAGAGATTTCTTCCAGATATCTCCATTAATGAGGAAACAATATTAGCTCAC	600						
DB	541	CAAAATTTAGAGATTTCTTCCAGATATCTCCATTAATGAGGAAACAATATTAGCTCAC	600						
QY	601	CTGCATAGCACTGTGTAGACAGACCTACGGTTACTTGGAGACACATCTCTCCCAAGC	660						
DB	601	CTGCATAGCACTGTGTAGACAGACCTACGGTTACTTGGAGACACATCTCTCCCAAGC	660						
QY	661	GGTTGGCTTTGTGAGTGAAGACGAAATATCTGGAATTCAGGGCATCACCCGGGAGCAGTC	720						
DB	661	GGTTGGCTTTGTGAGTGAAGACGAAATATCTGGAATTCAGGGCATCACCCGGGAGCAGTC	720						
QY	721	AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCGCGCCGCTGACGAGAGTAA	780						
DB	721	AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCGCGCCGCTGACGAGAGTAA	780						
QY	781	GGTACCGGTGAATATCCACCATATTCAGAACCCAAAGGGTACAGTGTCCCGTGG	840						
DB	781	GGTACCGGTGAATATTCACCATATTCAGAACCCAAAGGGTACAGTGTCCCGTGG	840						
QY	841	ACAAAGGGGACACTGCAGTGTGAGGCTCCAGCAGTCCCTCAGCAGAAATTCAGTGT	900						
DB	841	ACAAAGGGGACACTGCAGTGTGAGGCTCCAGCAGTCCCTCAGCAGAAATTCAGTGT	900						
QY	901	CAAGGATGACAAAGACGATTTGAAAGGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT	960						
DB	901	CAAGGATGACAAAGACGATTTGAAAGGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT	960						
QY	961	CCTCTCAAACTCATCTTCTTCAATGTCTCTGAAATGACTATGGAACTACACTTGGT	1020						
DB	961	CCTCTCAAACTCATCTTCTTCAATGTCTCTGAAATGACTATGGAACTACACTTGGT	1020						
QY	1021	GGCTCCCAACAGCTGGGCCACCAATGCCAGCATCATGCTATTGGTCCAGGGCCGT	1080						
DB	1021	GGCTCCCAACAGCTGGGCCACCAATGCCAGCATCATGCTATTGGTCCAGGGCCGT	1080						

Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;

98US-0077643P.
98US-0077791P.
98US-0078004P.
98US-00040220.
98US-0073886P.
98US-0078910P.
98US-0078933P.
98US-0078935P.
98US-0079294P.
98US-0079656P.
98US-0079663P.
98US-0079664P.
98US-0079689P.
98US-0079728P.
98US-0079786P.
98US-0079920P.
98US-0079932P.
98US-0080105P.
98US-0080107P.
98US-0080165P.
98US-0080194P.
98US-0080327P.
98US-0080328P.
98US-0080333P.
98US-0080334P.
98US-0081049P.
98US-0081071P.
98US-0081388P.
98US-0081552P.
98US-0081955P.
98US-0082568P.
98US-0082569P.
98US-0082700P.
98US-0082704P.
98US-0082797P.
98US-0082804P.
98US-0082966P.
98US-0083336P.
98US-0083332P.
98US-0083392P.
98US-0083495P.
98US-0083496P.
98US-0083499P.
98US-0083500P.
98US-0083545P.
98US-0083554P.
98US-0083558P.
98US-0083559P.
98US-0083742P.
98US-0084366P.
98US-0084414P.
98US-0084441P.
98US-0084443P.
98US-0084538P.
98US-0084600P.
98US-0084627P.
98US-0084637P.
98US-0084639P.
98US-0084640P.
98US-0084643P.
98US-0085233P.
98US-0085338P.
98US-0085359P.
98US-0085573P.
98US-0085579P.
98US-0085580P.
98US-0085582P.
98US-0085586P.

98US-00827566	PR	23-APR-1998
98US-0083336P	PR	27-APR-1998
98US-0083332P	PR	28-APR-1998
98US-0083392P	PR	29-APR-1998
98US-0083495P	PR	29-APR-1998
98US-0083496P	PR	29-APR-1998
98US-0083499P	PR	29-APR-1998
98US-0083500P	PR	29-APR-1998
98US-0083545P	PR	29-APR-1998
98US-0083554P	PR	29-APR-1998
98US-0083558P	PR	29-APR-1998
98US-0083559P	PR	29-APR-1998
98US-0083742P	PR	30-APR-1998
98US-0084366P	PR	05-MAY-1998
98US-0084414P	PR	06-MAY-1998
98US-0084441P	PR	06-MAY-1998
98US-0084598P	PR	07-MAY-1998
98US-0084600P	PR	07-MAY-1998
98US-0084627P	PR	07-MAY-1998
98US-0084637P	PR	07-MAY-1998
98US-0084639P	PR	07-MAY-1998
98US-0084640P	PR	07-MAY-1998
98US-0084643P	PR	07-MAY-1998
98US-0085232P	PR	13-MAY-1998
98US-0085388P	PR	13-MAY-1998
98US-0085339P	PR	13-MAY-1998
98US-0085573P	PR	15-MAY-1998
98US-0085579P	PR	15-MAY-1998
98US-0085600P	PR	15-MAY-1998
98US-0085582P	PR	15-MAY-1998
98US-0085659P	PR	15-MAY-1998

PR	24-AUG-2000;	2000WO-US023328.
PR	08-NOV-2000;	2000US-00709238.
PR	27-NOV-2000;	2000US-00723749.
PR	01-DEC-2000;	2000WO-US032678.
PR	20-DEC-2000;	2000US-00747259.
PR	20-DEC-2000;	2000WO-US034956.
PR	28-FEB-2001;	2001WO-US006520.
PR	22-MAR-2001;	2001US-00816744.
PR	22-MAR-2001;	2001US-00816920.
PR	22-MAR-2001;	2001WO-US009552.
PR	10-MAY-2001;	2001US-00854208.
PR	10-MAY-2001;	2001US-00854280.
PR	25-MAY-2001;	2001WO-US017092.
PR	01-JUN-2001;	2001US-00872035.
PR	01-JUN-2001;	2001WO-US017800.
PR	05-JUN-2001;	2001US-00874503.
PR	14-JUN-2001;	2001US-00882636.
PR	19-JUN-2001;	2001US-00886342.
PR	20-JUN-2001;	2001WO-US019692.
PR	29-JUN-2001;	2001WO-US021066.
PR	09-JUL-2001;	2001WO-US021735.
PR	30-JUL-2001;	2001US-00918585.
XX	(GETH) GENENTECH INC.	
PA		
XX		
Query Match 100.0%; Score 1679; DB 1; Length 1679;		
Best Local Similarity 100.0%; Pred. NO. 6.7e-05;		
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
QY	1	GTTGTGTCCTTTCAGCAAAACAGTGGAATTTAAATCTCCTTGACAAGCTTGAGACAACAC 60
DB	1	GTTGTGTCCTTTCAGCAAAACAGTGGAATTTAAATCTCCTTGACAAGCTTGAGACAACAC 60
QY	61	AATCTATCAGGAAGAAGAAAGAAAACCGPACTTCGACAAAAAGAAAAAAGAAAAAGAAAG 120
DB	61	AATCTATCAGGAAGAAGAAAGAAAACCGAACCTGCACAAAAACGAACTGCACAAAAAGAAAAGAG 120
QY	121	AAGAAAAAATCATGAAAACCATCAGCCAAAAATGCACAAATCTATCTCTGGGCAAT 180
DB	121	AAGAAAAAATCATGAAAACCATTACGCCAAAAATGCACAAATCTATCTCTGGGCAAT 180
QY	181	CTTCACGGGCTGGCTCTCTGTGTCTCTTCCAAGAGTGCCCGTGCCGACGCGAGATGC 240
DB	181	CTTCACGGGCTGGCTCTCTGTGTCTCTTCCAAGAGTGCCCGTGCCGACGCGAGATGC 240
QY	241	CACCTTCCCCAAAGCTATGGACAAACGTGACGCTCGCGCAGGGGGAGAGCGCACCCCTCAG 300
DB	241	CACCTTCCCCAAAGCTATGGACAAACGTGACGCTCGCGCAGGGGGAGAGCGCACCCCTCAG 300
QY	301	GTGCACACTATTGACAAACCGGCTCACCCGGTGCCCTGGCTTAAACCGCAGCACCATCTCTTA 360
DB	301	GTGCACACTATTGACAAACCGGCTCACCCGGTGCCCTGGCTTAAACCGCAGCACCATCTCTTA 360
QY	361	TGCTGGGAATGACAAGTGGTGCTGATCTCTCGGTGTCCTTCTTGAGCAAACACCCAAAC 420
DB	361	TGCTGGGAATGACAAGTGGTGCTGATCTCTCGGTGTCCTTCTTGAGCAAACACCCAAAC 420
QY	421	CGAGTACAGCATCGAGATCCAGAAACCTGGATGTGTATGACAGGGGCCCTTACACTGCTC 480
DB	421	CGAGTACAGCATCGAGATCCAGAAACCTGGATGTGTATGACAGGGGCCCTTACACTGCTC 480
QY	481	GGTGACAGACAAACCAACCAAGACCTCTAGGGTCCACCTCATNTGTGCAAGTATCTCCC 540
DB	481	GGTGACAGACAAACCAACCAAGACCTCTAGGGTCCACCTCATNTGTGCAAGTATCTCCC 540
QY	541	CAAAATTTGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
DB	541	CAAAATTTGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
QY	601	CTGCATAGCAACTCGGTAGACAGAGCCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
DB	601	CTGCATAGCAACTCGGTAGACAGAGCCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660

QY	661	GGTTGGCTTTGTGAGTGGAAGACGAAATACCTTGGAAAATTCAGGGCATCACCCGGGAGCAGTTC	720
DB	661	GGTTGGCTTTGTGAGTGGAAGACGAAATACCTTGGAAAATTCAGGGCATCACCCGGGAGCAGTTC	720
QY	721	AGGGGACTACGAGTCAGTGCCTCCAAATGACGTGGCGCGCCCGTGTGATCGAGAGATAAA	780
DB	721	AGGGGACTACGAGTCAGTGCCTCCAAATGACGTGGCGCGCCCGTGTGATCGAGAGATAAA	780
QY	781	GGTCACCGTGAACCTATCCACCATACATTTTCAGAAAGCAAAGGTGTACAGGTGTCCCCGTGGG	840
DB	781	GGTCACCGTGAACCTATCCACCATACATTTTCAGAAAGCAAAGGTGTACAGGTGTCCCCGTGGG	840
QY	841	ACAAAAGGGACACTCGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCACAGTGGTA	900
DB	841	ACAAAAGGGACACTCGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCACAGTGGTA	900
QY	901	CAAGGATGACAAAAGACTGATTCGAAGAAAAGAGGGGTGAAAGTGTGAAAACACAGACCTTT	960
DB	901	CAAGGATGACAAAAGACTGATTCGAAGAAAAGAGGGGTGAAAGTGTGAAAACACAGACCTTT	960
QY	961	CTCTCTAAAACCTGATCTTCTTCAATGTCTGTGAACATGACTATATGGAACTACACACTTGCCT	1020
DB	961	CTCTCTAAAACCTGATCTTCTTCAATGTCTGTGAACATGACTATATGGAACTACACACTTGCCT	1020
QY	1021	GGCTCTCAAACAAGCTGGGCCACACCAATGCCAGCATCATCTGATTTGGTCCAGCGCGCGT	1080
DB	1021	GGCTCTCAAACAAGCTGGGCCACACCAATGCCAGCATCATCTGATTTGGTCCAGCGCGCGT	1080
QY	1081	CAGCGAGTTCAGCAACCGCCACGTCGAGAGGGCAGGTGCGGTCTGGCTGTGCTCTTCTCT	1140
DB	1081	CAGCGAGTTCAGCAACCGCCACGTCGAGAGGGCAGGTGCGGTCTGGCTGTGCTCTTCTCT	1140
QY	1141	GGTCTTCGACCTGCTCTCCTCAAAATTTTCATGTGAGTGCACCTTCCCCACCCGGGAAAGGCT	1200
DB	1141	GGTCTTCGACCTGCTCTCCTCAAAATTTTCATGTGAGTGCACCTTCCCCACCCGGGAAAGGCT	1200
QY	1201	GCCGCCACCCACCAACCAACACAAAGCAATGGCAACACCGACAGCAACCAATTCAGATA	1260
DB	1201	GCCGCCACCCACCAACCAACACAAAGCAATGGCAACACCGACAGCAACCAATTCAGATA	1260
QY	1261	TATACAAATGAAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC	1320
DB	1261	TATACAAATGAAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC	1320
QY	1321	AAAGAAATCTTTGGGGGAAAAGAGTTTTTAAAAAAGAAATTTGAAAAATTCGCTTTCAGATA	1380
DB	1321	AAAGAAATCTTTGGGGGAAAAGAGTTTTTAAAAAAGAAATTTGAAAAATTCGCTTTCAGATA	1380
QY	1381	TTTAGGTACAAATGAGTTTTCTTTTCCAAAACGGGAAAGAACACAGCACACCCGGCTTGGGA	1440
DB	1381	TTTAGGTACAAATGAGTTTTCTTTTCCAAAACGGGAAAGAACACAGCACACCCGGCTTGGGA	1440
QY	1441	CCCACTGCAAGCTGCATCGTGCACCTCTTTTGGTGCCAGTGTGGGCAAGGCTCAGGCTC	1500
DB	1441	CCCACTGCAAGCTGCATCGTGCACCTCTTTTGGTGCCAGTGTGGGCAAGGCTCAGGCTC	1500
QY	1501	TCTGCCACACAGAGTGCCTCCACAGTGGAAATTCCTGGAGCTGGCCCATCCCAAAATTCATCA	1560
DB	1501	TCTGCCACACAGAGTGCCTCCACAGTGGAAATTCCTGGAGCTGGCCCATCCCAAAATTCATCA	1560
QY	1561	GTCCATAGACGACGACAGAAATGAGACCTTCGGGCCCAAGCGTGGCGCTGGGGCAGCTTGG	1620
DB	1561	GTCCATAGACGACGACAGAAATGAGACCTTCGGGCCCAAGCGTGGCGCTGGGGCAGCTTGG	1620
QY	1621	GTAGACTGTGCACCAACCGCGCTGTGTGTGTGAACCGTGAATATAAAGAGCAAAAAAAA	1679
DB	1621	GTAGACTGTGCACCAACCGCGCTGTGTGTGTGAACCGTGAATATAAAGAGCAAAAAAAA	1679

RESULT 11

ADB87164

ID ADB87164 standard; cDNA; 1679 BP.

RESULT 11
ADB87164
ID ADB8

XX	ADB87164;	
XX	AC	
XX	DT	04-DEC-2003 (first entry)
XX	DE	Human PRO polynucleotide #63.
XX	DE	
XX	DE	Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
XW		tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW		tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW		pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW		arthritis; sports injury; cytostatic; antiarthritic.
OS		Homo sapiens.
XX		
XX		US2003088067-A1.
XX	PD	08-MAY-2003.
XX	PD	
XX	PP	13-AUG-2002; 2002US-00219479.
XX	PP	
XX	PP	01-JUN-2001; 2001WO-US017800.
PR		29-JUN-2001; 2001WO-US021066.
PR		09-APR-2002; 2002US-00119480.
XX		(GETH) GENENTECH INC.
PA		
PI		Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI		Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX		WPI; 2003-657981/62.
DR		P-PSDB; ADB87165.
DR		
PT		One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT		useful in gene therapy, chromosome identification, tissue typing, or as
PT		hybridization probes in chromosome and gene mapping.
XX		
PS		Claim 2; Fig 125; 314pp; English.
XX		
CC		The invention relates to human PRO polypeptides (secreted and
CC		transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC		The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC		diagnostics, biosensors or bioeffectors. They are particularly useful for
CC		detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
CC		prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC		stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC		blood, for stimulating the proliferation or differentiation of
CC		chondrocyte cells, for stimulating the proliferation of or gene
CC		expression in pericyte cells or for stimulating the proliferation of
CC		normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC		hybridisation probes, in chromosome and gene mapping, in generating
CC		antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC		technology, in generating transgenic animals or knock-out animals which
CC		may be used in the development and screening of therapeutically useful
CC		reagents, in gene therapy, in chromosome identification, as anti-PRO
CC		markers and in generating probes. The PRO polypeptides, or anti-PRO
CC		antibodies, are useful for preparing a medicament for treating a
CC		condition which is responsive to the PRO polypeptides or anti-PRO
CC		antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC		disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC		differentiation of chondrocytes. The PRO polypeptides are useful as
CC		molecular markers for protein electrophoresis, and in tissue typing. This
CC		sequence represents a human PRO polynucleotide of the invention.
XX		
XX		Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
XX		
XX		Query Match 1679; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
XX		Best Local Similarity 100.0%; Score 1679; DB 1; Length 1679;
XX		Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY		1 GTTGTGTCCTTCAGCAAAACAGTCGATTTAAATCTCTTCGACAGCTTGAGCAACAC 60
DB		1 GTTGTGTCCTTCAGCAAAACAGTCGATTTAAATCTCTTCGACAGCTTGAGCAACAC 60

QY	61	AATCTATCAGGAAGAAAGAAAGAAAAAACCAGAACCTGACAAAAAAGAGAAAAAGAG	120
Db	61	AATCTATCAGGAAGAAAGAAAGAAAAAACCAGAACCTGACAAAAAAGAGAAAAAGAG	120
QY	121	AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAAATCTCTATCTCTTGGGCAAT	180
Db	121	AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAAATCTCTATCTCTTGGGCAAT	180
QY	181	CTTCA CGGGCTGGCTGCTCTGTGTCTCTTCCAAAGAGTGCCTGGTGGCGACGCGAGATGC	240
Db	181	CTTCA CGGGCTGGCTGCTCTGTGTCTCTTCCAAAGAGTGCCTGGTGGCGACGCGAGATGC	240
QY	241	CACCTTCCCAAGCATATGACAAACGTGACGGTCCGGCAGGGGAGAGGCCACCTCAG	300
Db	241	CACCTTCCCAAGCATATGACAAACGTGACGGTCCGGCAGGGGAGAGGCCACCTCAG	300
QY	301	GTGCACATATTGA CAA CCGGGTCACCCGGGTGGCTGTGCTTCCAAAGAGTGCCTGGTGGCGACGCGAGATGC	360
Db	301	GTGCACATATTGA CAA CCGGGTCACCCGGGTGGCTGTGCTTCCAAAGAGTGCCTGGTGGCGACGCGAGATGC	360
QY	361	TGCTGGGAATGACAAGTGGTGGCTTGGATCCTCGCGTGGTCTCTCTGAGCAACACCCAAAC	420
Db	361	TGCTGGGAATGACAAGTGGTGGCTTGGATCCTCGCGTGGTCTCTCTGAGCAACACCCAAAC	420
QY	421	GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACGAGGGCCCTTACACCTGGCTC	480
Db	421	GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACGAGGGCCCTTACACCTGGCTC	480
QY	481	GGTGCAGACAGAACCA CCA CCGAACGCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540
Db	481	GGTGCAGACAGAACCA CCA CCGAACGCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540
QY	541	CAAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGA CAAATATTAGCCTCAC	600
Db	541	CAAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGA CAAATATTAGCCTCAC	600
QY	601	CTGCATAGCAACTCGGTAGACAGAGCCTTAGGTTACTTTGGAGACACATCTCTCTCCCAAAGC	660
Db	601	CTGCATAGCAACTCGGTAGACAGAGCCTTAGGTTACTTTGGAGACACATCTCTCTCCCAAAGC	660
QY	661	GGTTGGCTTTGTGAGTGAAGACGAATACTTTGGAAATTCAGGGCATCACCGGAGCAGTC	720
Db	661	GGTTGGCTTTGTGAGTGAAGACGAATACTTTGGAAATTCAGGGCATCACCGGAGCAGTC	720
QY	721	AGGGGACTACGAGTGCAGTGCTCCAAATGACGTGGCGCGCCCGTGGTACGGAGAGTAAA	780
Db	721	AGGGGACTACGAGTGCAGTGCTCCAAATGACGTGGCGCGCCCGTGGTACGGAGAGTAAA	780
QY	781	GGTCA CCGTGAACCTATCCACATACATTTCAGAGCCAGGGTACAGGTCTCCCGTGG	840
Db	781	GGTCA CCGTGAACCTATCCACATACATTTCAGAGCCAGGGTACAGGTCTCCCGTGG	840
QY	841	ACAAAAGGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAA TTCAGTGGTA	900
Db	841	ACAAAAGGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAA TTCAGTGGTA	900
QY	901	CAAGGATGACAAAGACTGATTGAAGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT	960
Db	901	CAAGGATGACAAAGACTGATTGAAGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT	960
QY	961	CCTCTCAAACTCATCTTTCTTCAATGTCTGTGAACATGACTATGGGAACTACACTTGC	1020
Db	961	CCTCTCAAACTCATCTTTCTTCAATGTCTGTGAACATGACTATGGGAACTACACTTGC	1020
QY	1021	GGCTCCAAAGCTGGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT	1080
Db	1021	GGCTCCAAAGCTGGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT	1080
QY	1081	CAGCGAGGTGAGCAACCGCACGTCGAGGAGGCGAGGTGGCTGTGGCTGTGCTCTTCT	1140
Db	1081	CAGCGAGGTGAGCAACCGCACGTCGAGGAGGCGAGGTGGCTGTGGCTGTGCTCTTCT	1140

Qy	1141	GGTCTTGCACTGCTCTCTCAAAATTTGATGTAGTGCCCACTTCCCCACCCGGGAAAGGCT	1200
Db	1141	GGTCTTGCACTGCTCTCTCAAAATTTGATGTAGTGCCCACTTCCCCACCCGGGAAAGGCT	1200
Qy	1201	GGCGCCACACACACACACCAAGCAACAGCAATGGCAACACCGGACAGCAACCAATCAGATA	1260
Db	1201	GGCGCCACACACACACACCAAGCAACAGCAATGGCAACACCGGACAGCAACCAATCAGATA	1260
Qy	1261	TATACAAATGAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC	1320
Db	1261	TATACAAATGAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC	1320
Qy	1321	AAAGAATACATTTGGGGGGGAAAAGAGTTTTAAAAAAGAAATTTGAAAAATTCCTTTGCAGATA	1380
Db	1321	AAAGAATACATTTGGGGGGGAAAAGAGTTTTAAAAAAGAAATTTGAAAAATTCCTTTGCAGATA	1380
Qy	1381	TTTAGGTACAAATGGAGTTTCTTTTCCCAACCGGAGACACAGCACACCCGCGCTTGGGA	1440
Db	1381	TTTAGGTACAAATGGAGTTTCTTTTCCCAACCGGAGACACAGCACACCCGCGCTTGGGA	1440
Qy	1441	CCCACTGCAAGCTGCATCGTGCAACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC	1500
Db	1441	CCCACTGCAAGCTGCATCGTGCAACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC	1500
Qy	1501	TCGTGCCACAGAGTGCCTCCCAACGCTGGACATTTCTGGAGCTGGCCATCCCAAAATTCATCA	1560
Db	1501	TCGTGCCACAGAGTGCCTCCCAACGCTGGACATTTCTGGAGCTGGCCATCCCAAAATTCATCA	1560
Qy	1561	GTCCATAGACAGCAACAGAAATGAGACCTTCGGCCCAAGCGTGCAGCTGCGGCACCTTTG	1620
Db	1561	GTCCATAGACAGCAACAGAAATGAGACCTTCGGCCCAAGCGTGCAGCTGCGGCACCTTTG	1620
Qy	1621	GTAGACTGTCCCAACCGCGGCTGTGTGTCAAACGCTGAATTAATAAGAGCAAAAAA	1679
Db	1621	GTAGACTGTCCCAACCGCGGCTGTGTGTCAAACGCTGAATTAATAAGAGCAAAAAA	1679
RESULT 12			
ADB84746			
ID	ADB84746	standard; cDNA; 1679 BP.	
XX			
AC	ADB84746;		
XX			
DT	04-DEC-2003	(first entry)	
XX			
DE	Human PRO polynucleotide #63.		
XX			
KW	Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;		
KW	tumour; cancer; lung; colon; breast; prostate; rectum; liver;		
KW	tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;		
KW	pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;		
KW	arthritis; sports injury; cytostatic; antiarthritic.		
XX			
OS	Homo sapiens.		
XX			
PN	US2003092890-A1.		
XX			
PD	15-MAY-2003.		
XX			
PF	14-AUG-2002; 2002US-00219536.		
XX			
PR	28-JUL-1999; 99US-0146222P.		
PR	24-FEB-2000; 2000WO-US005004.		
PR	02-MAR-2000; 2000WO-US005841.		
PR	01-JUN-2001; 2001WO-US017800.		
PR	29-JUN-2001; 2001WO-US021066.		
PR	09-APR-2002; 2002US-00119480.		
XX			
PA	(GETH) GENENTECH INC.		
XX			
PI	Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PU;		
PI	Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;		
XX			

DR WPI: 2003-777259/73.
XX F-PSDB; ADB84747.
PT New isolated PRO polypeptides, useful for tissue typing, gene therapy, as
PT molecular weight markers in protein electrophoresis, and for treating
PT arthritis and tumors.
XX
PS Claim 2; Fig 125; 308pp; English.
XX
CC The invention relates to human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. They are particularly useful for
CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC blood, for stimulating the proliferation or differentiation of
CC chondrocyte cells, for stimulating the proliferation of or gene
CC expression in pericyte cells or for stimulating the proliferation of
CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTTCAGCAAAACAGTGGATTTAAATCTCTTGCACAACTTGAGAGCAAC 60
DB 1 GTTGTGCTTCAGCAAAACAGTGGATTTAAATCTCTTGCACAACTTGAGAGCAAC 60
QY 61 AATCTATCAGAAAGAAAGAAAGAAACCGAACCTGACAAAAGAAAGAAAGAG 120
DB 61 AATCTATCAGAAAGAAAGAAAGAAACCGAACCTGACAAAAGAAAGAAAGAG 120
QY 121 AAGAAAAAATCATGAAACCATCCAGCCAAAATGCAATTCCTTTGGSCAAT 180
DB 121 AAGAAAAAATCATGAAACCATCCAGCCAAAATGCAATTCCTTTGGSCAAT 180
QY 181 CTTTACGGGCTGGCTGCTGTGTCTCTTCCAAAGAGTGCCCGTCGCGAGGAGATGC 240
DB 181 CTTTACGGGCTGGCTGCTGTGTCTCTTCCAAAGAGTGCCCGTCGCGAGGAGATGC 240
QY 241 CACTTCCCAAGCTATGACAACCTGACGCTGCGGTCGGGGAGAGCGCCACTCAG 300
DB 241 CACTTCCCAAGCTATGACAACCTGACGCTGCGGTCGGGGAGAGCGCCACTCAG 300
QY 301 GTGCATATTGACAACCGGCTCACCGGGTGGCTGGCTAAACCGCAGCACCATTCTTA 360
DB 301 GTGCATATTGACAACCGGCTCACCGGGTGGCTGGCTAAACCGCAGCACCATTCTTA 360
QY 361 TGGTGGGAATGCAAGTGGTGCTGGATCTCGCGTGGTCTTCTGAGCAACCCCAAC 420
DB 361 TGGTGGGAATGCAAGTGGTGCTGGATCTCGCGTGGTCTTCTGAGCAACCCCAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTATGACGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTATGACGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGCGACAGACAAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540

DB 481 GGTGCGACAGACAAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAAATTTGATAGATTTCTTTTCCAGATATCTCCATTAATGAAGGAACAATATTAGCCTCAC 600
DB 541 CAAAATTTGATAGATTTCTTTTCCAGATATCTCCATTAATGAAGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGTTAGACACGAGCCTACGTTACTTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCAACTGTTAGACACGAGCCTACGTTACTTTGGAGACACATCTCTCCCAAGC 660
QY 661 GTTTGGCTTTGTGAGTGAAGACCAATACTTTGGAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GTTTGGCTTTGTGAGTGAAGACCAATACTTTGGAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGGCTCCATGAGTGGCGCCGCCCGTGTATCGGAGAGTAAA 780
DB 721 AGGGGACTACGAGTGCAGTGGCTCCATGAGTGGCGCCGCCCGTGTATCGGAGAGTAAA 780
QY 781 GGTCAACCGTGAACCTATCCACATACATTTTCAAGAACCAAGGTCACAGTGTCCCCGGTGG 840
DB 781 GGTCAACCGTGAACCTATCCACATACATTTTCAAGAACCAAGGTCACAGTGTCCCCGGTGG 840
QY 841 AAAAAAGGGGACACTGCAAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 AAAAAAGGGGACACTGCAAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGATGACAAAAAGACTGATTGAAGGAAGAAAGGGGTGAAGTGAAGAACAGACCTTT 960
DB 901 CAAGATGACAAAAAGACTGATTGAAGGAAGAAAGGGGTGAAGTGAAGAACAGACCTTT 960
QY 961 CCTCTCAAAACTCATCTCTTCAATGTCTGAAACATGACTATGGGAACATACACTTCGCT 1020
DB 961 CCTCTCAAAACTCATCTCTTCAATGTCTGAAACATGACTATGGGAACATACACTTCGCT 1020
QY 1021 GGCCTCCAAAGCTGGGCGCACCAATGCGCAGCATCATGCTATTTGGTCCAGCGCGCT 1080
DB 1021 GGCCTCCAAAGCTGGGCGCACCAATGCGCAGCATCATGCTATTTGGTCCAGCGCGCT 1080
QY 1081 CAGCGAGTGAAGCAACCGGACGTCGAGAGGGGAGGCTGCGTCTGGCTGCTCTTTCT 1140
DB 1081 CAGCGAGTGAAGCAACCGGACGTCGAGAGGGGAGGCTGCGTCTGGCTGCTCTTTCT 1140
QY 1141 GGTCTTGCACTGCTTCTTCAAAATTTTGTATGTAGTGCACCTTCCCAACCGGGAAGGCT 1200
DB 1141 GGTCTTGCACTGCTTCTTCAAAATTTTGTATGTAGTGCACCTTCCCAACCGGGAAGGCT 1200
QY 1201 GCCGCCCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
DB 1201 GCCGCCCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
QY 1261 TATACAAATGAATATGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320
DB 1261 TATACAAATGAATATGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320
QY 1321 AAAAATACTTTGGGGGGAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB 1321 AAAAATACTTTGGGGGGAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGGTACAAATGAGTTTCTTTTCCAAAACGGGAAAGAAACACAGCACAACCCGCTTGA 1440
DB 1381 TTTAGGTACAAATGAGTTTCTTTTCCAAAACGGGAAAGAAACACAGCACAACCCGCTTGA 1440
QY 1441 CCCACTGCAAGCTCATGTCGCAACCTTTTGGTGGCAGTGTGGGCAAGGGCTCAGGCTC 1500
DB 1441 CCCACTGCAAGCTCATGTCGCAACCTTTTGGTGGCAGTGTGGGCAAGGGCTCAGGCTC 1500
QY 1501 TCTGCCACAGAGTGCCCGCCACGTGGAAATTTTGGAGTGGCCATCTCCAAATTCATCA 1560
DB 1501 TCTGCCACAGAGTGCCCGCCACGTGGAAATTTTGGAGTGGCCATCTCCAAATTCATCA 1560
QY 1561 GTCCATAGAGCAGAAAGATGACCTTCGGGCGCCAGCGTGGCGCTGGGGCACTTTG 1620

Db	1561	GTCCATAGACAGCAAGATGAGACCTTCGGGCCCAAGCGTGGCGCTCGGGCACTTTC	1620
Qy	1621	GTAGACTGTCCACCACGGCGTGTGTGTGAAACGTGAATAAAGAGCAAAAAAAA	1679
Db	1621	GTAGACTGTGCACCAACGGCGTGTGTGTGAACCGTGAATAAAGAGCAAAAAAAA	1679

RESULT 13

ADB47123
ID ADB47123 standard; cDNA; 1679 BP.

AC AD347123;

XX
DT 04-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO337 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene; ss;
KW tumour necrosis factor alpha release; TNF; alpha release;
KW Glucose uptake modulator; TNF; alpha release;
KW Cell differentiation inducer; cell differentiation stimulator;
KW Cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker

AA
OS
OS
Homo sapiens.

XX PN US2003082687-A1:

XX PD 01-MAY-2003.

19-APR-2002: 2002US-00125930.

XX
PR 05-JUN-2000: 2000US-0209832P.

PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.

XX
PA (GETH) GENENTECH INC.

XX
PI Baker KP, Berasini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX
DR
WPI: 2003-786904/74.

DR P-PSDB; ADB47124.

XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PT
PT PR04978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.

XX
PS Claim 2: Fig 375: 627pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF- α from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or

841 ACATAAGGGGACACTGCAGTGTGAAGCCTCAGAGTCCCTCAGCAGAAATTCACGTGTA 900
901 CAAGGATGACAAAGACACTGATGAGGAAAGAGGGGTGAAGTGGAAACAGACCTTT 960
901 CAAGGATGACAAAGACACTGATGAGGAAAGAGGGGTGAAGTGGAAACAGACCTTT 960
961 CCTCTCAAAATCATCTCTCTCAATGTCTCTGAACATGACTATGGAACTACACTTGGT 1020
961 CCTCTCAAAATCATCTCTCTCAATGTCTCTGAACATGACTATGGAACTACACTTGGT 1020
1021 GGCCTCCAAAGCTGGGCGCACCAATGCGCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
1021 GGCCTCCAAAGCTGGGCGCACCAATGCGCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
1081 CAGCAGGTGACAAAGCAGCAGCTCGAGGAGGCGAGCTCTGCTGCTGCTCTCTCT 1140
1081 CAGCAGGTGACAAAGCAGCAGCTCGAGGAGGCGAGCTCTGCTGCTGCTCTCTCT 1140
1141 GGTCTTGCACTGCTCTCTCAATTTTGAATGAGTGCCTTCCCTCCCGGGAAGGCT 1200
1141 GGTCTTGCACTGCTCTCTCAATTTTGAATGAGTGCCTTCCCTCCCGGGAAGGCT 1200
1201 GCGGCGCACCAACACCAACACCAATGCGCAACACCAACCAACCAATCAGATA 1260
1201 GCGGCGCACCAACACCAACCAATGCGCAACACCAACCAACCAATCAGATA 1260
1261 TATACAAATGAATAGAAACACAGCCTCATCGGACAGAAATTTGAGGAGGGGAA 1320
1261 TATACAAATGAATAGAAACACAGCCTCATCGGACAGAAATTTGAGGAGGGGAA 1320
1321 AAAGATATCTTTGGGGGAAAGAGCTTTTAAAGAGAAATGAAATTTGCTTCAGATA 1380
1321 AAAGATATCTTTGGGGGAAAGAGCTTTTAAAGAGAAATGAAATTTGCTTCAGATA 1380
1381 TTTAGTACATAGGAGTCTTTCTTTTCCCAACCGGAGAAACACAGCACCCTGCTTGA 1440
1381 TTTAGTACATAGGAGTCTTTCTTTTCCCAACCGGAGAAACACAGCACCCTGCTTGA 1440
1441 CCCACTGCAAGCTGCTGCTGCACTCTTTGGTCCAGTGTGGCAGAGGCTCAGCTTC 1500
1441 CCCACTGCAAGCTGCTGCTGCACTCTTTGGTCCAGTGTGGCAGAGGCTCAGCTTC 1500
1501 TCTGCCCCACAGAGTGCCTCCAGTGAACATTTCTGGAGTGCCTCCCAATTCATCA 1560
1501 TCTGCCCCACAGAGTGCCTCCAGTGAACATTTCTGGAGTGCCTCCCAATTCATCA 1560
1561 GTCCATAGAGACGAAACAGATGAGACCTTCCGGCCCAAGCTGGCGCTCGGGCACTTTG 1620
1561 GTCCATAGAGACGAAACAGATGAGACCTTCCGGCCCAAGCTGGCGCTCGGGCACTTTG 1620
1621 GTAGACTGTGCCACCAACCGGCGTGTGTGTAACGCTGAATATAAGAGCAAAAAAAA 1679
1621 GTAGACTGTGCCACCAACCGGCGTGTGTGTAACGCTGAATATAAGAGCAAAAAAAA 1679

RESULT 14

ADB83861
ID ADB83861 standard; cDNA; 1679 BP.
XX AC ADB83861;
XX DT
XX 04-DEC-2003 (first entry)
XX Novel human secreted and transmembrane protein PRO337 cDNA.
XX human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;

gene therapy.
Homo sapiens.
US2003069397-A1.
10-APR-2003.
09-AUG-2002; 2002US-00216159.
25-JUL-2000; 2000US-0220607P.
01-JUN-2001; 2001WO-US017800.
29-JUN-2001; 2001WO-US021066.
09-APR-2002; 2002US-00119480.
(GETH) GENENTECH INC.
Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
Frimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
WPI; 2003-657584/62.
P-PSDB; ADB83862.
New isolated polypeptides designated PRO polypeptides including
polypeptides useful for stimulating the proliferation or differentiation
of specific cell types, and for diagnosing cancer.
Claim 2; Fig 125; 314pp; English.
The invention describes an isolated PRO (secreted and transmembrane)
polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
useful for stimulating the proliferation of or gene expression in
pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
for stimulating the proliferation or differentiation of chondrocyte
cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
are useful for stimulating the release of tumour necrosis factor (TNF)-
alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567,
PRO1887, PRO1928, PRO3431, PRO1801, PRO4333, PRO3543, PRO3444, PRO4332,
PRO9940, PRO6079, PRO3836 or PRO10096 polypeptide are useful for
stimulating the proliferation of normal human dermal fibroblasts cells.
PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
inhibiting the proliferation of normal human dermal fibroblast cells. PRO
polypeptides such as PRO6004, PRO4961, PRO7174, PRO5778, PRO4332, etc.,
are useful for detecting the presence of tumour in a mammal which
involves comparing the level of expression of the above PRO polypeptides
in a test sample of cells taken from the mammal, and a control sample of
normal cells of the same cell type, where a higher level of expression of
the PRO polypeptides in the test sample as compared to the control sample
is indicative of the presence of tumour in the mammal. The tumour is lung
tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
liver tumour. (I) is useful as molecular weight markers, for tissue
typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
useful for chromosome and gene mapping or gene therapy. (II) is useful
for generating transgenic animals or knock-out animals which are useful
for screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
is useful for treating bone and/or cartilage disorders (e.g., arthritis,
sport injuries). This sequence encodes a human secreted and transmembrane
PRO polypeptide.
Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 GTTGTGCTCTTCAGCAACAGTGGATTAAATCTCTTCACAGTTTGAGAGCAAC 60
|||||

Db 1 GTTGTGTCTTCAGCAAAACAGTGGATTTAAATCTCTCTGCAACGTTGAGAGCAAC 60
Qy 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAA 180
Db 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAA 180
Qy 181 CTTCAAGGGGCTGCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 240
Db 181 CTTCAAGGGGCTGCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 240
Qy 241 CAGCTTCCCAAGCTATGACAAAGTGAACGTCGTCGTCGTCGTCGTCGTCGTCGTC 300
Db 241 CAGCTTCCCAAGCTATGACAAAGTGAACGTCGTCGTCGTCGTCGTCGTCGTCGTC 300
Qy 301 GTGCACTATTGACAAAGCTGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTC 360
Db 301 GTGCACTATTGACAAAGCTGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTC 360
Qy 361 TGCTGGAAATGACAAAGCTGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTC 420
Db 361 TGCTGGAAATGACAAAGCTGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTC 420
Qy 421 GCAGTACAGATCGAGATCCAGAACGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTC 480
Db 421 GCAGTACAGATCGAGATCCAGAACGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTC 480
Qy 481 GGTGACAGACAAACCAACCAAGCTCTAGGCTCCACTCATTGTGCAAGTATCTCC 540
Db 481 GGTGACAGACAAACCAACCAAGCTCTAGGCTCCACTCATTGTGCAAGTATCTCC 540
Qy 541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAAATATTAGCTCC 600
Db 541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAAATATTAGCTCC 600
Qy 601 CTGCATAGCAACTGGTAGACAGAGCTCAGGTTACTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCATAGCAACTGGTAGACAGAGCTCAGGTTACTTGGAGACACATCTCTCCCAAGC 660
Qy 661 GGTGGCTTTGTAGTGAAGACGATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Db 661 GGTGGCTTTGTAGTGAAGACGATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Qy 721 AGGGGACTACAGTGCAGTCTCCATAGCTGCGCCGCGCTGCTGTAAGAGAGTAAA 780
Db 721 AGGGGACTACAGTGCAGTCTCCATAGCTGCGCCGCGCTGCTGTAAGAGAGTAAA 780
Qy 781 GGTCAAGTGAACATATCAACATATTCAGAACCAAGGTACAGGTGTCCCGGTGG 840
Db 781 GGTCAAGTGAACATATCAACATATTCAGAACCAAGGTACAGGTGTCCCGGTGG 840
Qy 841 ACAAAGGGGACACTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACAAAGGGGACACTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Qy 901 CAAGGATGACAAAGACTGATTGAAGAAAGAAAGGGGTGAAAGTGAAGAAACAGACTTT 960
Db 901 CAAGGATGACAAAGACTGATTGAAGAAAGAAAGGGGTGAAAGTGAAGAAACAGACTTT 960
Qy 961 CCTCTCAAAAGCTATCTTCTCAATGCTCTGACATGACTATGGGAATCAGCTTGGCT 1020
Db 961 CCTCTCAAAAGCTATCTTCTCAATGCTCTGACATGACTATGGGAATCAGCTTGGCT 1020
Qy 1021 GGCTTCAAGCTGGGCAACCAATGCGAGCATCATGCTATTTGGTCCAGGCGCGT 1080
Db 1021 GGCTTCAAGCTGGGCAACCAATGCGAGCATCATGCTATTTGGTCCAGGCGCGT 1080
Qy 1081 CAGCGAGTGAACCAAGCTGAGGAGGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTTCT 1140
Db 1081 CAGCGAGTGAACCAAGCTGAGGAGGAGGCTGCTGCTGCTGCTGCTGCTGCTTCT 1140

RESULT 15

ADB86730

ID ADB86730 standard; cDNA; 1679 BP.

XX AC ADB86730;

XX DT 04-DEC-2003 (first entry)

XX DE Human PRO polynucleotide #188.

XX KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003082697-A1.

XX PD 01-MAY-2003.

XX PF 22-APR-2002; 2002US-00127849.

XX PR 20-OCT-1998; 98US-0104987P.

XX PR 01-SEP-1999; 99WO-US020111.

XX PR 18-OCT-1999; 99US-00403297.

XX PR 18-FEB-2000; 2000WO-US004342.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

Db 541 CAAAATTGTAGATTTCTTCCAGATATCTCCATTATGAAGGGAACAATATTAGCCTCAC 600
Qy 601 CTGCTAGCAACTGGTGTAGACAGACCTACGTTACTTCTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCTAGCAACTGGTGTAGACAGACCTACGTTACTTCTGGAGACACATCTCTCCCAAGC 660
Qy 661 GGTGGCTTTGTGAGTGAAGAGCAATATCTTGAATAATTCAGGGCATCACCCGGGAGCAGTC 720
Db 661 GGTGGCTTTGTGAGTGAAGAGCAATATCTTGAATAATTCAGGGCATCACCCGGGAGCAGTC 720
Qy 721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGCGCGCGCGTGTACGGAGAGTAAA 780
Db 721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGCGCGCGCGTGTACGGAGAGTAAA 780
Qy 781 GGTCAACGTAACCTATCCACCATACATTTTCAAGCCAAAGGTACAGGTGTCCTCCGCTGG 840
Db 781 GGTCAACGTAACCTATCCACCATACATTTTCAAGCCAAAGGTACAGGTGTCCTCCGCTGG 840
Qy 841 ACAAGAGGGGACACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 900
Db 841 ACAAGAGGGGACACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 900
Qy 901 CAAGGATGACAAAGACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 960
Db 901 CAAGGATGACAAAGACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 960
Qy 961 CCTCTCAAACTCATCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1020
Db 961 CCTCTCAAACTCATCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1020
Qy 1021 GGCCTCCAAAGCTGGGCGACACCAATGCGCAGCATCATGCTATTTGGTCCAGGCGCGCT 1080
Db 1021 GGCCTCCAAAGCTGGGCGACACCAATGCGCAGCATCATGCTATTTGGTCCAGGCGCGCT 1080
Qy 1081 CAGCGAGTGAAGCAACGGGACGTCGAGGAGGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTTCT 1140
Db 1081 CAGCGAGTGAAGCAACGGGACGTCGAGGAGGCGGCTGCTGCTGCTGCTGCTGCTGCTTCT 1140
Qy 1141 GGTCTTGCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTTCT 1200
Db 1141 GGTCTTGCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTTCT 1200
Qy 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Db 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Qy 1261 TATACAAATGAATATGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGAGGAGAC 1320
Db 1261 TATACAAATGAATATGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGAGGAGAC 1320
Qy 1321 AAAGAATACCTTTGGGGGAAAAGAGTTTAAAAAAGAAATTTGAAATTCCTTGCAGATA 1380
Db 1321 AAAGAATACCTTTGGGGGAAAAGAGTTTAAAAAAGAAATTTGAAATTCCTTGCAGATA 1380
Qy 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACGGGAGAACACAGCACACCCGGCTTGA 1440
Db 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACGGGAGAACACAGCACACCCGGCTTGA 1440
Qy 1441 CCCACTGCAAGCTGATCGTGCACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGATCGTGCACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGCCTCCACAGTGTGAAACATTTCTGGAGCTGGGCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCACAGTGTGAAACATTTCTGGAGCTGGGCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGACCAACAGAAATGAGACCTTCCCGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
Db 1561 GTCCATAGAGACCAACAGAAATGAGACCTTCCCGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACACAGCGGTGTGTGTGAATATTAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACACAGCGGTGTGTGTGAATATTAAGAGCAAAAAA 1679

RESULT 17
ADB76744
ID ADB76744 standard; cDNA; 1679 BP.
XX
AC ADB76744;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide sequence #133.
XX
KW Human, PRO polypeptide; secreted protein; transmembrane protein;
cell death; neuropathy; neuropathy related disease;
KW Charcot-Marie-Tooth disorder; Refsum's disease; Krabbe's disease;
KW chromosome mapping; gene mapping; genetic disorder; septic shock;
KW antibacterial; immunosuppressive; neuroprotective; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003083248-A1.
XX
PD 01-MAY-2003.
XX
PF 16-OCT-2001; 2001US-00978757.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077731P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079684P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.

Page 28

Db 121 AAAAAAAAAATCATGAAAAAATCCATCCAGCCAAAAATGACAAATTCATCTCTTGGGCAAT 180
Qy 181 CTTTCAGGGGTGGTCTGTGTGTCTCTTCCAGAGAGTCCCGTGGCGACGAGATGC 240
Db 181 CTTTCAGGGGTGGTCTGTGTGTCTCTTCCAGAGAGTCCCGTGGCGACGAGATGC 240
Qy 241 CACCTTCCCAAGAGTATGGAACAACGTCAGCGTCCGGCAGGGGAGAGCGCACCTCAG 300
Db 241 CACCTTCCCAAGAGTATGGAACAACGTCAGCGTCCGGCAGGGGAGAGCGCACCTCAG 300
Qy 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCATCTCTTA 360
Db 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCATCTCTTA 360
Qy 361 TGTCTGGGAATGACAAAGTGTGCTGATCTCGCTGCTCTCTCTGAGCAACACCGCAAC 420
Db 361 TGTCTGGGAATGACAAAGTGTGCTGATCTCGCTGCTCTCTCTGAGCAACACCGCAAC 420
Qy 421 GCAGTACAGATCGAGATCCAGAAACGTCAGTGTATGACAGAGGCGCTTACACCTGTC 480
Db 421 GCAGTACAGATCGAGATCCAGAAACGTCAGTGTATGACAGAGGCGCTTACACCTGTC 480
Qy 481 GTGCGAGACAGAACCCAGCCAAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GTGCGAGACAGAACCCAGCCAAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Qy 541 CAAATTTGAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
Db 541 CAAATTTGAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
Qy 601 CTGCATAGCAACTGTGAGACGACCTCAATGACGTGCGCGCCCGTGGTACGAGAGTAAA 660
Db 601 CTGCATAGCAACTGTGAGACGACCTCAATGACGTGCGCGCCCGTGGTACGAGAGTAAA 660
Qy 661 GGTGGCTTTGTGAGTGAGAGAGATCTGGAATTCAGGGCATCACCGGAGCAGTC 720
Db 661 GGTGGCTTTGTGAGTGAGAGAGATCTGGAATTCAGGGCATCACCGGAGCAGTC 720
Qy 721 AGGGGACTACGAGTGCAGTCCCAATGACGTGCGCGCCCGTGGTACGAGAGTAAA 780
Db 721 AGGGGACTACGAGTGCAGTCCCAATGACGTGCGCGCCCGTGGTACGAGAGTAAA 780
Qy 781 GGTACCCGTGAACATCCACCATATCTTTCAGAGCCAGGTCAGAGTGTCCCGTGG 840
Db 781 GGTACCCGTGAACATCCACCATATCTTTCAGAGCCAGGTCAGAGTGTCCCGTGG 840
Qy 841 ACAAAGGGGACATCTGAGTGTGAAGCTTCAGAGTCCCTCAGCAGAAATCCAGTGGTA 900
Db 841 ACAAAGGGGACATCTGAGTGTGAAGCTTCAGAGTCCCTCAGCAGAAATCCAGTGGTA 900
Qy 901 CAAAGATGACAAAGCTGATTAAGGAAAGAAAGGGTGAAGTGAAGAACAGACCTTT 960
Db 901 CAAAGATGACAAAGCTGATTAAGGAAAGAAAGGGTGAAGTGAAGAACAGACCTTT 960
Qy 961 CTTCTCAAAATCATCTTCTCAATGTCTCTCAACATGACTATGGAACTACACTTGGT 1020
Db 961 CTTCTCAAAATCATCTTCTCAATGTCTCTCAACATGACTATGGAACTACACTTGGT 1020
Qy 1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATATGCTATTGTGTCAGGCGCGT 1080
Db 1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATATGCTATTGTGTCAGGCGCGT 1080
Qy 1081 CAGCGAGTGAACAACGACGTCGAGGAGGCGAGCTGCGTCTGCTGCTGCTCTTCT 1140
Db 1081 CAGCGAGTGAACAACGACGTCGAGGAGGCGAGCTGCGTCTGCTGCTGCTCTTCT 1140
Qy 1141 GGTCTTGCACTGCTTCTCAATTTTGTATGTGAGTGCCACTTCCCAACCGCGGAAGGCT 1200
Db 1141 GGTCTTGCACTGCTTCTCAATTTTGTATGTGAGTGCCACTTCCCAACCGCGGAAGGCT 1200
Qy 1201 GCGGCCACCAACGACCAACACAGCAATGAGCAACCGCAGCAGCAACCAATCAGATA 1260
Db 1201 GCGGCCACCAACGACCAACACAGCAATGAGCAACCGCAGCAGCAACCAATCAGATA 1260

Qy 1261 TATACAAATGAATTTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAC 1320
Db 1261 TATACAAATGAATTTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAC 1320
Qy 1321 AAAGAATACTTTGGGGGAAAAGAGTTTTAAAAAGAAATTTGAAAAATTCCTTTGCAGATA 1380
Db 1321 AAAGAATACTTTGGGGGAAAAGAGTTTTAAAAAGAAATTTGAAAAATTCCTTTGCAGATA 1380
Qy 1381 TTTAGGTACAAATGGAGTTTTTTTCCCAAAACGGGAGAACACAGCACACCGGCTTGA 1440
Db 1381 TTTAGGTACAAATGGAGTTTTTTTCCCAAAACGGGAGAACACAGCACACCGGCTTGA 1440
Qy 1441 CCCACTGCAAGCTGCATCGTCAACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGCATCGTCAACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGCCTCCACAGTGAACATTTCTGAGTGTGCCATTCCTCAATCAATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCACAGTGAACATTTCTGAGTGTGCCATTCCTCAATCAATCA 1560
Qy 1561 GTCCATAGACAGAAACAGATGAGACCTTCCGCGCCCAAGCGTGGCGCTCGGCGACTTTG 1620
Db 1561 GTCCATAGACAGAAACAGATGAGACCTTCCGCGCCCAAGCGTGGCGCTCGGCGACTTTG 1620
Qy 1621 GTAGACTGTGCCACCGCGCTGTGTGTGTAACAGTGAACATTAAGAGCAAAAAAAA 1679
Db 1621 GTAGACTGTGCCACCGCGCTGTGTGTGTAACAGTGAACATTAAGAGCAAAAAAAA 1679

RESULT 18

ADB77335
ID ADB77335 standard; cdna; 1679 BP.

XX ADB77335;

XX 04-DEC-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO337 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene; ss;

XX Tumour necrosis factor alpha release; TNF-alpha release;

XX Glucose uptake modulator; PFA uptake modulator;

XX cell proliferation stimulator; cell differentiation stimulator;

XX lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

XX cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

XX US2003082696-A1.

XX 01-MAY-2003.

XX 22-APR-2002; 2002US-00127848.

XX 03-NOV-1998; 98US-0106934P.

XX 26-JUL-1999; 99US-0145698P.

XX 01-SEP-1999; 99WO-US020111.

XX 18-OCT-1999; 99US-00403297.

XX 05-JAN-2000; 2000WO-US000219.

XX 18-FEB-2000; 2000WO-US004342.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755109/71.

DR P-PSDB; ADB77336.
 XX PRO nucleic acid, useful for preparing a composition for treating e.g.,
 PT tumor or for tissue typing.
 XS
 XX
 XX Claim 2; Fig 375; 637pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of n-lymphocyte cells, for stimulating
 CC the release of a cytokine from BMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 1 GTTGTGCTCTTTCAGCAAAACAGTGGATTAAATCTCTCTGTCACAACTTCTATCTCTTGGGCAAT 60
 1 GTTGTGCTCTTTCAGCAAAACAGTGGATTAAATCTCTCTGTCACAACTTCTATCTCTTGGGCAAC 60
 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
 181 CTTTCAAGGGGCTGGCT 240
 181 CTTTCAAGGGGCTGGCT 240
 241 CACCTTCCCAAGCTATGACAACTGACGCTGCGGTCGCGGTCGCGGTCGCGGTCGCGGTCGCGG 300
 241 CACCTTCCCAAGCTATGACAACTGACGCTGCGGTCGCGGTCGCGGTCGCGGTCGCGGTCGCGG 300
 301 GTGCATCTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGGACGACCACTCTCTCTA 360
 301 GTGCATCTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGGACGACCACTCTCTCTA 360
 361 TGCTGGGAATGACAAAGTGGTGGCTTAAACCGGGTGGCTTAAACCGGACGACCACTCTCTCTA 420
 361 TGCTGGGAATGACAAAGTGGTGGCTTAAACCGGGTGGCTTAAACCGGACGACCACTCTCTCTA 420
 421 GCAGTACAGCATCGAGATCCAGAAAGTGGATGTGTATGACAGAGGGCTTTACACCTGCTC 480
 421 GCAGTACAGCATCGAGATCCAGAAAGTGGATGTGTATGACAGAGGGCTTTACACCTGCTC 480

QY 481 GGTGCAGACAGACAAACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
 DB 481 GGTGCAGACAGACAAACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
 QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
 DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
 QY 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
 DB 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
 QY 661 GGTGGGCTTTGTAGTGAAGACGAATATCTTTGAAATTCAGGGCATCACCCGGGAGCAGTC 720
 DB 661 GGTGGGCTTTGTAGTGAAGACGAATATCTTTGAAATTCAGGGCATCACCCGGGAGCAGTC 720
 QY 721 AGGGGATACAGTGCAGTGCCTCCATGACGTGGCGCGCCGCTGTAGCGAGAGTAA 780
 DB 721 AGGGGATACAGTGCAGTGCCTCCATGACGTGGCGCGCCGCTGTAGCGAGAGTAA 780
 QY 781 GGTCAACCGTGAACCTATCCACATACATTTTCAAGGCAAGGGTACAGGTCTCCCGGTGG 840
 DB 781 GGTCAACCGTGAACCTATCCACATACATTTTCAAGGCAAGGGTACAGGTCTCCCGGTGG 840
 QY 841 ACAAAGGGGACACTGAGTGTGAGGCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900
 DB 841 ACAAAGGGGACACTGAGTGTGAGGCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900
 QY 901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAGGGGTGAAGTGGAAACAGACCTTT 960
 DB 901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAGGGGTGAAGTGGAAACAGACCTTT 960
 QY 961 CCTCTCAAACTCATCTTTCAATGTCTCTGAACATGATCTTGGGAACTACAGTTCGCT 1020
 DB 961 CCTCTCAAACTCATCTTTCAATGTCTCTGAACATGATCTTGGGAACTACAGTTCGCT 1020
 QY 1021 GGCCTCAAAAGCTGGGCGCACACCAATGCAGCATCATCTATTTGGTCCAGGCGCGT 1080
 DB 1021 GGCCTCAAAAGCTGGGCGCACACCAATGCAGCATCATCTATTTGGTCCAGGCGCGT 1080
 QY 1081 CAGCGAGTGAAGCAACCGGACGCTGAGGAGGCGGCTGGCTGGCTGGCTGGCTGGCT 1140
 DB 1081 CAGCGAGTGAAGCAACCGGACGCTGAGGAGGCGGCTGGCTGGCTGGCTGGCTGGCT 1140
 QY 1141 GGTCTTGACCTGCTCTCTCAATTTTGTATGTAGTGCCACTTCCCCACCGGGGAAAGGCT 1200
 DB 1141 GGTCTTGACCTGCTCTCTCAATTTTGTATGTAGTGCCACTTCCCCACCGGGGAAAGGCT 1200
 QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
 DB 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
 QY 1261 TATACAAATGAATTAGAAGAAACACAGCCTCTATGGGACAGAAATTTGAGGAGGGGAAAC 1320
 DB 1261 TATACAAATGAATTAGAAGAAACACAGCCTCTATGGGACAGAAATTTGAGGAGGGGAAAC 1320
 QY 1321 AAAGAATACTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
 DB 1321 AAAGAATACTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
 QY 1381 TTTAGGTACAAATGAGTTTCTTTTCCCAACCGGAGAAACACAGCAGCACCCGCTTGGGA 1440
 DB 1381 TTTAGGTACAAATGAGTTTCTTTTCCCAACCGGAGAAACACAGCAGCACCCGCTTGGGA 1440
 QY 1441 CCCACTGCAAGCTGCATCGTCAACCTCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
 DB 1441 CCCACTGCAAGCTGCATCGTCAACCTCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
 QY 1501 TCTGCCACAGAGTGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1560
 DB 1501 TCTGCCACAGAGTGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1560

QY 1561 GTCCATAGACGACAGACAGACTTCGGGCCCAAGCGTGGCGCTGGGGCACTTTG 1620
DB 1561 GTCCATAGACGACAGACAGACTTCGGGCCCAAGCGTGGCGCTGGGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCGCGCTGTGTGTGAAAGCTGAAATATAAAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACCGCGCTGTGTGTGAAAGCTGAAATATAAAGAGCAAAAAA 1679
RESULT 19
ADB34492
ID ADB34492 standard; cDNA; 1679 BP.
XX ADB34492;
AC ADB34492;
XX 04-DEC-2003 (first entry)
XX Human PRO polynucleotide SEQ ID NO 375.
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; PFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
XX immune system cell infiltration.
XX Homo sapiens.
XX OS
XX US2003077717-A1.
XX 24-APR-2003.
XX 24-APR-2002; 2002US-00131818.
XX 07-OCT-1998; 98US-0103328P.
XX 01-SEP-1999; 99WO-US020111.
XX 18-OCT-1999; 99US-00403297.
XX 30-NOV-1999; 99NO-US028313.
XX 18-FEB-2000; 2000WO-US004342.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755072/71.
XX P-PSDB; ADB34493.
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
XX acids, useful for the diagnosis, prevention and/or treatment of tumors,
XX such as lung, colon, breast, prostate, rectal, cervical and/or liver
XX tumors.
XX Claim 2; Fig 375; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAACTTGCAGAGCAACAC 60
DB 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAACTTGCAGAGCAACAC 60
QY 61 AATCTATCAGAAAGAAAGAAAGAAACCGAACCTGACAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGAAAGAAAGAAAGAAACCGAACCTGACAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAGAAATCATGAAGAACCATCCAGCCAAATGCAATCTATCTCTTGGGCAAT 180
DB 121 AAGAAAGAAATCATGAAGAACCATCCAGCCAAATGCAATCTATCTCTTGGGCAAT 180
QY 181 CTTTACCGGGCTGGCTGCTCTGTGTCTTCTTCCAAAGAGTGCCTGTCGACGAGATGC 240
DB 181 CTTTACCGGGCTGGCTGCTCTGTGTCTTCTTCCAAAGAGTGCCTGTCGACGAGATGC 240
QY 241 CACCTTCCCAAGCTATGCAACAGTACGCTCCGCGAGGGGAGAGGCCACCTTCAG 300
DB 241 CACCTTCCCAAGCTATGCAACAGTACGCTCCGCGAGGGGAGAGGCCACCTTCAG 300
QY 301 GTGCATATTGACAAACCGGGTCCACCCGGGTGGCTTAAACCGCAGCACCCTCTCTA 360
DB 301 GTGCATATTGACAAACCGGGTCCACCCGGGTGGCTTAAACCGCAGCACCCTCTCTA 360
QY 361 TGCTGGGAATGACAAAGTGGTCCCTGGATCTCTCGGTGGTCTTCTGTGACGACACCCAAAC 420
DB 361 TGCTGGGAATGACAAAGTGGTCCCTGGATCTCTCGGTGGTCTTCTGTGACGACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACGCTGGATGTGTATGACGAGGGCCCTTACACCTCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACGCTGGATGTGTATGACGAGGGCCCTTACACCTCTC 480
QY 481 GGTGCAGACAGACAAACCAACCAAGACCTCTAGGCTCCACTTCTGTGACGACACCCAAAC 540
DB 481 GGTGCAGACAGACAAACCAACCAAGACCTCTAGGCTCCACTTCTGTGACGACACCCAAAC 540
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACCAATATTAGCCTCAC 600
DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACCAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGGTGTAGACAGAGCCTACGGTTACTTGTGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCAACTGGTGTAGACAGAGCCTACGGTTACTTGTGAGACACATCTCTCCCAAGC 660

661 GGTGGCTTTGTGAGTGAAGACGAACTTGGAAATTCAGGGCATCACCCGGAGCAGTC 720
661 GGTGGCTTTGTGAGTGAAGACGAACTTGGAAATTCAGGGCATCACCCGGAGCAGTC 720
721 AGGGGACTAGAGTGCAGTGCCTCCCATGACGTGGCCGCGCGCTGGTACGGAGATAA 780
721 AGGGGACTAGAGTGCAGTGCCTCCCATGACGTGGCCGCGCGCTGGTACGGAGATAA 780
781 GGTCAACCGTGAATATCCACATACATATTCAGAAAGCCAGGGTACAGGTGTCCTCCGTTGG 840
781 GGTCAACCGTGAATATCCACATACATATTCAGAAAGCCAGGGTACAGGTGTCCTCCGTTGG 840
841 ACAAAGGGGACACTGCAGTGTGAAGCTCCAGAGTCCCTCAGCAGAGATTCAGAGTGA 900
841 ACAAAGGGGACACTGCAGTGTGAAGCTCCAGAGTCCCTCAGCAGAGATTCAGAGTGA 900
901 CAAGGATGACAAAAGACTGATTTGAAGAAAGAAAGGGGTGAAGTGAAGAAACAGACTTT 960
901 CAAGGATGACAAAAGACTGATTTGAAGAAAGAAAGGGGTGAAGTGAAGAAACAGACTTT 960
961 CCTCTCAAACTCATCTTCTCATGTCTCTGACATGACTATGGGAATCAGACTTGGT 1020
961 CCTCTCAAACTCATCTTCTCATGTCTCTGACATGACTATGGGAATCAGACTTGGT 1020
1021 GGCCTCCAAAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
1021 GGCCTCCAAAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
1081 CAGCGAGTGAACAAAGCGCTCGAGGAGGCGAGTGGTCTGGCTGGCTGCTCTTCT 1140
1081 CAGCGAGTGAACAAAGCGCTCGAGGAGGCGAGTGGTCTGGCTGGCTGCTCTTCT 1140
1141 GGTCTTGCACTGCTTCTCAATTTTATGTGAGTGCCATCTTCCACCCCGGAAAGGCT 1200
1141 GGTCTTGCACTGCTTCTCAATTTTATGTGAGTGCCATCTTCCACCCCGGAAAGGCT 1200
1201 GCCGCCACACACCAACACACACAGCATGCGACACCGACAGCAACCAATCAGATA 1260
1201 GCCGCCACACACCAACACACACAGCATGCGACACCGACAGCAACCAATCAGATA 1260
1261 TATACAAATGAAATAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
1261 TATACAAATGAAATAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
1321 AAAGTAATCTTTGGGGGAAAGAGTTTAAAGAAATGAAATTTGCTTGCAGATA 1380
1321 AAAGTAATCTTTGGGGGAAAGAGTTTAAAGAAATGAAATTTGCTTGCAGATA 1380
1381 TTTAGTCAATGAGTTTCTTTTCCAAACGGGAAAGAACACAGCACACCCGCTTGA 1440
1381 TTTAGTCAATGAGTTTCTTTTCCAAACGGGAAAGAACACAGCACACCCGCTTGA 1440
1441 CCCACTGAAGTGCATCGTCAACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
1441 CCCACTGAAGTGCATCGTCAACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
1501 TCTGCCACAGAGTSCCCACGCTGGAACATCTTGGAGCTGGCCATCCCAATTCATCA 1560
1501 TCTGCCACAGAGTSCCCACGCTGGAACATCTTGGAGCTGGCCATCCCAATTCATCA 1560
1561 GTCCATAGAGACGAACAGAAATGAGACTTCCGGGCCAAGCGTGGCTGGGGCAGCTTTG 1620
1561 GTCCATAGAGACGAACAGAAATGAGACTTCCGGGCCAAGCGTGGCTGGGGCAGCTTTG 1620
1621 GTAGACTGTGCCACCGCGTGTGCTGAAAGCTGAAATTAAGAGCAAAAAA 1679
1621 GTAGACTGTGCCACCGCGTGTGCTGAAAGCTGAAATTAAGAGCAAAAAA 1679

RESULT 20

ADB35596

ID ADB35596 standard; cDNA; 1679 BP.

XX

AC ADB35596;
XX 04-DEC-2003 (first entry)
XX Human PRO polynucleotide SEQ ID NO 375.
XX
XX Human; gene; ss; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
XX liver; microvascular endothelial cell; glioma; FFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX immune system cell infiltration.
XX Homo sapiens.
XX OS
XX US2003077719-A1.
XX PN
XX 24-APR-2003.
XX PD
XX 24-APR-2002; 2002US-00131824.
XX PF
XX 09-FEB-1999; 99WO-0119341P.
XX PR
XX 01-DEC-1999; 99WO-US028634.
XX PR
XX 01-DEC-2000; 2000WO-US032678.
XX PR
XX 19-DEC-2001; 2001US-00028072.
XX XX
XX (GENTH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2003-755074/71.
XX P-PSDB; ADB35597.
XX
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
XX acids, useful for the diagnosis, prevention and/or treatment of tumors,
XX such as lung, colon, breast, prostate, rectal, cervical and/or liver
XX tumors.
XX
XX Claim 2; Fig 375; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells and for treating
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems,
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

CC polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which CC may benefit from enhanced local immune system cell infiltration. This CC sequence represents a human PRO polynucleotide of the invention. Note: CC The sequence data for this patent is also available in electronic format CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTGTGCTCTCAGCAAAACAGTGAATTAATCTCTTGCAAGCTTGAGAGCAAC 60
DB 1 GTGTGCTCTCAGCAAAACAGTGAATTAATCTCTTGCAAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGCACAAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGCACAAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAACCATCCAGCCAAAATGACAAATTCATCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAACCATCCAGCCAAAATGACAAATTCATCTCTTGGGCAAT 180
QY 181 CTTACGGGGCTGGCTCTCTGTCTCTTCCAGAGAGTCCCGTCCGAGGGAGATGC 240
DB 181 CTTACGGGGCTGGCTCTCTGTCTCTTCCAGAGAGTCCCGTCCGAGGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGACAAAGTGAAGCTCCGGCAGGGGGAGAGCGCCCTCAG 300
DB 241 CACCTTCCCAAGCTATGACAAAGTGAAGCTCCGGCAGGGGGAGAGCGCCCTCAG 300
QY 301 GTGCATATTGACACCGGGTCAACGGGTGGCTTAAACCGCACCATCTCTCTA 360
DB 301 GTGCATATTGACACCGGGTCAACGGGTGGCTTAAACCGCACCATCTCTCTA 360
QY 361 TGTGGGAATGACAAGTGTGCTGTGATCTCCGCGTGTCTCTTCTGAGCAACACCCAAAC 420
DB 361 TGTGGGAATGACAAGTGTGCTGTGATCTCCGCGTGTCTCTTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGATCGAGATCCAGAAAGTGTGATGATGAGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGATCGAGATCCAGAAAGTGTGATGATGAGAGGGCCCTTACACCTGCTC 480
QY 481 GTGTCAGACAGAACACCCAAAGCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GTGTCAGACAGAACACCCAAAGCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAAACAATTTAGCCTCAC 600
DB 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAAACAATTTAGCCTCAC 600
QY 601 CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCCCAAAGC 660
DB 601 CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCCCAAAGC 660
QY 661 GGTGGCTTTGTAGTGAAGACGAATCTTGAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTAGTGAAGACGAATCTTGAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACAGTGCAGTCCCTCAATGACGTGGCCCGCGGTGATACGAGAGTAAA 780
DB 721 AGGGGACTACAGTGCAGTCCCTCAATGACGTGGCCCGCGGTGATACGAGAGTAAA 780
QY 781 GGTCCCGTGAATATCCACCATACATTTTCAAGAGCCAAAGGGTACAGGTGTCCCGTGGG 840
DB 781 GGTCCCGTGAATATCCACCATACATTTTCAAGAGCCAAAGGGTACAGGTGTCCCGTGGG 840
QY 841 ACAAAGGGGACACTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 ACAAAGGGGACACTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900

QY 901 CAAGGATGACAAAGACTGATTGAAGGAAAGAGGGTGAAAGTGGAAAAACAGACCTTT 960
DB 901 CAAGGATGACAAAGACTGATTGAAGGAAAGAGGGTGAAAGTGGAAAAACAGACCTTT 960
QY 961 CTTCTCAAACTCATCTTCTCAATGCTCTGCAATGACTATGGGAACTACACTTGGCT 1020
DB 961 CTTCTCAAACTCATCTTCTCAATGCTCTGCAATGACTATGGGAACTACACTTGGCT 1020
QY 1021 GGCTTCCAAAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCCGT 1080
DB 1021 GGCTTCCAAAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCCGT 1080
QY 1081 CAGGAGGTGAGCAACGGCAGCTGAGGAGGAGGAGCTGGCTGGCTGCTGCTCTTCT 1140
DB 1081 CAGGAGGTGAGCAACGGCAGCTGAGGAGGAGGAGCTGGCTGGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGCACCTCTCTCAAAATTTTGTGAGTGCCTCTCCCAACCCGGGAAAGGCT 1200
DB 1141 GGTCTTGCACCTCTCTCAAAATTTTGTGAGTGCCTCTCCCAACCCGGGAAAGGCT 1200
QY 1201 GCGCCACCAACCAACCAACCAACAGCAATGGCAACCGCAGCAACCAATCAGATA 1260
DB 1201 GCGCCACCAACCAACCAACCAACAGCAATGGCAACCGCAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAAATTAGAAGAAACACAGGCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320
DB 1261 TATACAAATGAAATTAGAAGAAACACAGGCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320
QY 1321 AAGAAATATCTTGGGGGAAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB 1321 AAGAAATATCTTGGGGGAAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAACCGGGAAGACACAGCACCCGGCTTGA 1440
DB 1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAACCGGGAAGACACAGCACCCGGCTTGA 1440
QY 1441 CCCACTGCAAGCTGCATCTGTCGCAACCTCTTTGGTGGCAGTGTGGGCAAGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGCATCTGTCGCAACCTCTTTGGTGGCAGTGTGGGCAAGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCACGTCGAAATCTTGGAGCTGGCCTCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTGCCTCCACGTCGAAATCTTGGAGCTGGCCTCCCAATTCATCA 1560
QY 1561 GTCCATAGACAGCAAGAAATGAGACTTCCGCCCAAGCGTGGCGTGGGCACTTTG 1620
DB 1561 GTCCATAGACAGCAAGAAATGAGACTTCCGCCCAAGCGTGGCGTGGGCACTTTG 1620
QY 1621 GTAGCTGTGCCACCGCGCTGTGTGTAACGTGAATTAAGAGCAAAAAA 1679
DB 1621 GTAGCTGTGCCACCGCGCTGTGTGTAACGTGAATTAAGAGCAAAAAA 1679

RESULT 21

ADB33940

ID ADB33940 standard; cDNA; 1679 BP.

XX ADB33940;

XX ADB33940;

XX 04-DEC-2003 (first entry)

XX Human PRO polynucleotide SEQ ID NO 375.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

XX tumor necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX liver; microvascular endothelial cell; glucose; FFA;

XX skeletal muscle cell; adipocyte cell; pericyte cell;

XX inner ear utricular supporting cell; T-lymphocyte cell;

XX endothelial cell tube formation; bone disorder; cartilage disorder;

XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX rheumatoid arthritis; haemoglobin-associated disorder thalassemia;

XX immune system cell infiltration.

XX OS Homo sapiens.
XX PN US2003077716-A1.
XX PD 24-APR-2003.
XX PF 24-APR-2002; 2002US-00131813.
XX PR 07-OCT-1998; 98US-0103315P.
XX PR 01-SEP-1999; 99WO-00420111.
XX PR 18-OCT-1999; 99US-00403297.
XX PR 18-FEB-2000; 2000WO-US004342.
XX PR 10-NOV-2000; 2000WO-US030873.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S,
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WIPI; 2003-755071/71.
XX DR P-ESDB; ADB33941.
XX PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
XX PT in gene therapy, in chromosome and gene mapping, as chromosome markers,
XX PT in tissue typing, and in identifying chromosomes.
XX PS Claim 2; Fig 375; 637pp; English.
XX CC The invention relates to isolated human PRO polypeptides (secreted and
XX CC transmembrane polypeptides) and the polynucleotides encoding them. The
XX CC invention also relates to an antibody which specifically binds to a PRO
XX CC polypeptide, a method for stimulating the release of tumour necrosis
XX CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX CC proliferation or differentiation of chondrocyte cells and a method for
XX CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX CC polynucleotides are useful in molecular biology, including uses as
XX CC hybridisation probes, in chromosome and gene mapping, in generating
XX CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX CC be used in preparing PRO polypeptides by recombinant techniques and in
XX CC generating either transgenic animals or knock-out animals which are
XX CC useful in the development and screening of therapeutically useful
XX CC reagents. The PRO polypeptides or antibodies are used in preparing a
XX CC medicament for treating a condition responsive to the polypeptides or
XX CC antibodies, such as tumours, for stimulating and inhibiting proliferation
XX CC of human microvascular endothelial cells, for modulating the uptake of
XX CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX CC stimulating differentiation of adipocyte cells, for stimulating
XX CC proliferation of or gene expression in pericyte cells, for stimulating
XX CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX CC cells, for inducing endothelial cell tube formation and for treating
XX CC various bone and/or cartilage disorders such as sports injuries and
XX CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX CC from cartilage are useful for treating sports-related joint problems,
XX CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX CC polypeptides are also useful for treating various mammalian haemoglobin-
XX CC associated disorders such as various thalassaemias and conditions which
XX CC may benefit from enhanced local immune system cell infiltration. This
XX CC sequence represents a human PRO polynucleotide of the invention. Note:
XX CC The sequence data for this patent is also available in electronic format
XX CC from USPTO at seqdata.uspto.gov/sequence.html.
XX SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGAGCAACAC 60

Db 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGAGCAACAC 60
Qy 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAARAAATCATGAARACCATCCAGCCCAAAATGCAAAATCTCTCTTTGGGCAAT 180
Db 121 AAGAAARAAATCATGAARACCATCCAGCCCAAAATGCAAAATCTCTCTTTGGGCAAT 180
Qy 181 CTTACGGGGGTGGCTGCTCTGTCTCTCTTTCCAAAGAGTGCCTGCGCAGCGAGATGC 240
Db 181 CTTACGGGGGTGGCTGCTCTGTCTCTCTTTCCAAAGAGTGCCTGCGCAGCGAGATGC 240
Qy 241 CACCTTCCCAAGCTATGACACGCTGACGGTCCGCGAGGGGAGAGCCGCCCTCAG 300
Db 241 CACCTTCCCAAGCTATGACACGCTGACGGTCCGCGAGGGGAGAGCCGCCCTCAG 300
Qy 301 GTGCACTATTGACAAACCGGGTCCACCCGGGTGGCTTAAACCGCAGCACCCTCTA 360
Db 301 GTGCACTATTGACAAACCGGGTCCACCCGGGTGGCTTAAACCGCAGCACCCTCTA 360
Qy 361 TGCTGGGAATGACAAAGTGGTGCCTGGATCTCTCGGTGGTCTTCTGAGCAACCCAAAC 420
Db 361 TGCTGGGAATGACAAAGTGGTGCCTGGATCTCTCGGTGGTCTTCTGAGCAACCCAAAC 420
Qy 421 CGAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACGAGGGGCCCTTACACCTCTC 480
Db 421 CGAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACGAGGGGCCCTTACACCTCTC 480
Qy 481 GGTGAGACAGACAAACCCCAAGACCTCTAGGGTCCACCTCATTTGCAAGTATCTCC 540
Db 481 GGTGAGACAGACAAACCCCAAGACCTCTAGGGTCCACCTCATTTGCAAGTATCTCC 540
Qy 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
Db 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
Qy 601 CTGCTAGCAACTGTGTAGACAGACCTTACGGTACTTTGAGAGACACATCTCTCCAAAGC 660
Db 601 CTGCTAGCAACTGTGTAGACAGACCTTACGGTACTTTGAGAGACACATCTCTCCAAAGC 660
Qy 661 GGTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATCCCGGGAGCAGTC 720
Db 661 GGTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATCCCGGGAGCAGTC 720
Qy 721 AGGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCCCGTGTGACGGAGAGTAA 780
Db 721 AGGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCCCGTGTGACGGAGAGTAA 780
Qy 781 GGTCAACCGTGAACATCCACCATATTTCAAGAGCCCAAGGGTACAGGTGCCCGTGGG 840
Db 781 GGTCAACCGTGAACATCCACCATATTTCAAGAGCCCAAGGGTACAGGTGCCCGTGGG 840
Qy 841 ACAAAAGGGGACACTGCAAGTGAAGGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACAAAAGGGGACACTGCAAGTGAAGGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Qy 901 CAAGGATGCAAAAGACACTGATTGAAGGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
Db 901 CAAGGATGCAAAAGACACTGATTGAAGGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
Qy 961 CCTCTCAAAACTCATCTTTCTTCAATGTCTCTGAACATGACTATGGAAGTACACTTGGCT 1020
Db 961 CCTCTCAAAACTCATCTTTCTTCAATGTCTCTGAACATGACTATGGAAGTACACTTGGCT 1020
Qy 1021 GGCCTCCACAGCTGGGGCCACCAATGCCAGCATCATGCTATTGCTGCAGGGCGCGT 1080
Db 1021 GGCCTCCACAGCTGGGGCCACCAATGCCAGCATCATGCTATTGCTGCAGGGCGCGT 1080
Qy 1081 CAGCGAGTGTAGCAACAGGCGACGTCGAGGAGGGCAGGCTCGCTGTGGCTGTGCTCTTCT 1140

Db 1081 CAGCGAGGTGACCAACGGCAGCTCGAGGAGGCGAGGCTGGCTGGCTGCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCAACCGGGAAAGGCT 1200
Db 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCAACCGGGAAAGGCT 1200
QY 1201 GCGGCCACACACACACACACACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
Db 1201 GCGGCCACACACACACACACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAAATTTAGAAAGAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAAC 1320
Db 1261 TATACAAATGAAATTTAGAAAGAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAAC 1320
QY 1321 AAAGATATCTTTGGGGGGAAGAGTTTAAAGAAAGAAATTCAGAAATTCAGATA 1380
Db 1321 AAAGATATCTTTGGGGGGAAGAGTTTAAAGAAAGAAATTCAGAAATTCAGATA 1380
QY 1381 TTTAGGTACAAATGGAAGTTTCTTTTCCCAACGGGAAGAACACAGCACACCCGGGCTTGA 1440
Db 1381 TTTAGGTACAAATGGAAGTTTCTTTTCCCAACGGGAAGAACACAGCACACCCGGGCTTGA 1440
QY 1441 CCACATGCAAGCTGCAATCGTGCACTCTTTGGTGCAGTGTGGGCAAGGCTCAGCCTC 1500
Db 1441 CCACATGCAAGCTGCAATCGTGCACTCTTTGGTGCAGTGTGGGCAAGGCTCAGCCTC 1500
QY 1501 TCTGCCACACAGTGTGCCCCACAGTGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
Db 1501 TCTGCCACACAGTGTGCCCCACAGTGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
QY 1561 GTCCATAGAGACGAAACAGAAATGAGACTTCCGGCCCCAAGCGTGCGCTCGGGGCACTTTG 1620
Db 1561 GTCCATAGAGACGAAACAGAAATGAGACTTCCGGCCCCAAGCGTGCGCTCGGGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCGCGCTGTGTGTAACGTAATTAAGAGACAAAAA 1679
Db 1621 GTAGACTGTGCCACCGCGCTGTGTGTAACGTAATTAAGAGACAAAAA 1679

RESULT 22
ADB35044
ID ADB35044 standard; cDNA; 1679 BP.
XX ADB35044;
XX ADB35044;
DT 04-DEC-2003 (first entry)
XX Human PRO polynucleotide SEQ ID NO 375.
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
XX US2003077718-A1.
XX 24-APR-2003.
PD 24-APR-2002; 2002US-00131823.
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.

PR	10-MAY-2001;	2001US-00854208.	
PR	10-MAY-2001;	2001US-00854280.	
PR	18-MAY-2001;	2001US-00860216.	
PR	25-MAY-2001;	2001US-00866028.	
PR	25-MAY-2001;	2001US-00866034.	
PR	01-JUN-2001;	2001WO-US017092.	
PR	01-JUN-2001;	2001US-00872035.	
PR	01-JUN-2001;	2001WO-US017800.	
PR	05-JUN-2001;	2001US-00874503.	
PR	14-JUN-2001;	2001US-00882636.	
PR	19-JUN-2001;	2001US-00886342.	
PR	20-JUN-2001;	2001WO-US019692.	
PR	21-JUN-2001;	2001US-00887879.	
PR	22-JUN-2001;	2001WO-US020116.	
PR	29-JUN-2001;	2001WO-US021066.	
PR	09-JUL-2001;	2001WO-US021735.	
PR	18-JUL-2001;	2001US-00908827.	
PR	06-AUG-2001;	2001US-00924419.	
PR	09-AUG-2001;	2001US-00927796.	
PR	16-AUG-2001;	2001US-00931836.	
PR	19-DEC-2001;	2001US-00028072.	
XX			
PA	(GETH)	GENENTECH INC.	
XX			
PI	Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;		
PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;		
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;		
XX			
DR	WPI; 2003-755073/71.		
DR	P-PSDB; ADB35045.		
XX			
DR	New isolated, secreted and transmembrane PRO polypeptides and nucleic		
PT	acids, useful for the diagnosis, prevention and/or treatment of tumors,		
PT	such as lung, colon, breast, prostate, rectal, cervical and/or liver		
PT	tumors.		
XX			
PS	Claim 2; Fig 375; 638pp; English.		
XX			
CC	The invention relates to isolated human PRO polypeptides (secreted and		
CC	transmembrane polypeptides) and the polynucleotides encoding them. The		
CC	invention also relates to an antibody which specifically binds to a PRO		
CC	polypeptide, a method for stimulating the release of tumour necrosis		
CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the		
CC	proliferation or differentiation of chondrocyte cells and a method for		
CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,		
CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The		
CC	polynucleotides are useful in molecular biology, including uses as		
CC	hybridisation probes, in chromosome and gene mapping, in generating		
CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also		
CC	be used in preparing PRO polypeptides by recombinant techniques and in		
CC	generating either transgenic animals or knock-out animals which are		
CC	useful in the development and screening of therapeutically useful		
CC	reagents. The PRO polypeptides or antibodies are used in preparing a		
CC	medicament for treating a condition responsive to the polypeptides or		
CC	antibodies, such as tumours, for stimulating and inhibiting proliferation		
CC	of human microvascular endothelial cells, for modulating the uptake of		
CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for		
CC	stimulating differentiation of adipocyte cells, for stimulating		
CC	the proliferation of or gene expression in pericyte cells, for stimulating		
CC	the proliferation of inner ear utricular supporting cells or T-lymphocyte		
CC	cells, for inducing endothelial cell tube formation and for treating		
CC	various bone and/or cartilage disorders such as sports injuries and		
CC	arthritis. PRO polypeptides which stimulate the release of proteoglycans		
CC	from cartilage are useful for treating sports-related joint problems,		
CC	articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO		
CC	polypeptides are also useful for treating various mammalian haemoglobin-		
CC	associated disorders such as various thalassemias and conditions which		
CC	may benefit from enhanced local immune system cell infiltration. This		
CC	sequence represents a human PRO polynucleotide of the invention. Note:		
CC	The sequence data for this patent is also available in electronic format		
CC	from USPTO at seqdata.uspto.gov/sequence.html .		
XX			
XX	Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;		

	Query Match	100.0%;	Score 1679;	DB 1;	Length 1679;
	Best Local Similarity	100.0%;	Pred. No. 6.7e-05;		
	Matches 1679;	Conservative	0;	Mismatches	0;
				Indels	0;
				Gaps	0;
QY	1	GTGTGTCTCTCAGCAAAACAGTGGAATTAATCTCTTGCACAAAGCTTGAGAGCAACAC	60		
DB	1	GTGTGTCTCTCAGCAAAACAGTGGAATTAATCTCTTGCACAAAGCTTGAGAGCAACAC	60		
QY	61	AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120		
DB	61	AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120		
QY	121	AAGAAAAAATCATGAAAAACATCCAGCCAAAAAATGCAATTTCTTCTTGGGCAAT	180		
DB	121	AAGAAAAAATCATGAAAAACATCCAGCCAAAAAATGCAATTTCTTCTTGGGCAAT	180		
QY	181	CTTCAAGGGCTGGCTCTCTCTCTTCCAAGAGTGGCCGTCGCGAGGAGATGC	240		
DB	181	CTTCAAGGGCTGGCTCTCTCTCTTCCAAGAGTGGCCGTCGCGAGGAGATGC	240		
QY	241	CACCTTCCCAAAAGCTATGGCAACAGTGAAGTCCGCGAGGGGAGAGGCCACCTCAG	300		
DB	241	CACCTTCCCAAAAGCTATGGCAACAGTGAAGTCCGCGAGGGGAGAGGCCACCTCAG	300		
QY	301	GTGCACTATTGACAAACCGGTCACCCGGTGGCTTCCGCTGGATCTCTTCTGAGCAAC	360		
DB	301	GTGCACTATTGACAAACCGGTCACCCGGTGGCTTCCGCTGGATCTCTTCTGAGCAAC	360		
QY	361	TGCTGGGAATGACAAAGTGGTGGTCTCTGCTGGATCTCTTCTGAGCAACACCCAAAC	420		
DB	361	TGCTGGGAATGACAAAGTGGTGGTCTCTGCTGGATCTCTTCTGAGCAACACCCAAAC	420		
QY	421	GCAGTACAGCANTCGAGATCCAGAAAGTGGATGTATGACGAGGGGCCCTTACCTGTC	480		
DB	421	GCAGTACAGCANTCGAGATCCAGAAAGTGGATGTATGACGAGGGGCCCTTACCTGTC	480		
QY	481	GGTGAGAGAGCAACACCCAAAGACCTCTAGGCTCCACCTCATTTGCAAGTATCTCC	540		
DB	481	GGTGAGAGAGCAACACCCAAAGACCTCTAGGCTCCACCTCATTTGCAAGTATCTCC	540		
QY	541	CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAGGAGACATATTAGCTCAC	600		
DB	541	CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAGGAGACATATTAGCTCAC	600		
QY	601	CTGCATAGCAACTGGTAGACACAGAGCTACGGTTACTTTGGAGACACATCTCTCCAAAGC	660		
DB	601	CTGCATAGCAACTGGTAGACACAGAGCTACGGTTACTTTGGAGACACATCTCTCCAAAGC	660		
QY	661	GGTTGGCTTTGTGAGTGAAGAGCAATATCTTGAATTCAGGSCATCACCAGGAGATC	720		
DB	661	GGTTGGCTTTGTGAGTGAAGAGCAATATCTTGAATTCAGGSCATCACCAGGAGATC	720		
QY	721	AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCGCCGCGTGGTACGGAGAGTAA	780		
DB	721	AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCGCCGCGTGGTACGGAGAGTAA	780		
QY	781	GGTACCGTGAATATTCACCATATATTTGAGAACCAAGGTCAGGTGTCCCGTGGG	840		
DB	781	GGTACCGTGAATATTCACCATATATTTGAGAACCAAGGTCAGGTGTCCCGTGGG	840		
QY	841	ACAAAAGGGGACACTGCTGCTGGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA	900		
DB	841	ACAAAAGGGGACACTGCTGCTGGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA	900		
QY	901	CAAGGATGACAAAGACTGATTTGAAGAAAGAAAGGGGTGAAGGTGGAAGAAAGACCTTT	960		
DB	901	CAAGGATGACAAAGACTGATTTGAAGAAAGAAAGGGGTGAAGGTGGAAGAAAGACCTTT	960		
QY	961	CTCTCAAAACTCATCTTCTCAATGTCTCTCAATGTCTCTGAACTATGGAACTACACTTGGT	1020		
DB	961	CTCTCAAAACTCATCTTCTCAATGTCTCTCAATGTCTCTGAACTATGGAACTACACTTGGT	1020		


```
QY 1021 GGCCTCCACAGCTGGGCCACCAATGCCAGCATCATGCTATTGCTCCAGCGCGT 1080
DB 1021 GGCCTCCACAGCTGGGCCACCAATGCCAGCATCATGCTATTGCTCCAGCGCGT 1080
QY 1081 CAGCGAGGTGACCAACGGCAGCTCGAGGAGGCGCTGCGTCTGGCTGCTGCTCTTCT 1140
DB 1081 CAGCGAGGTGACCAACGGCAGCTCGAGGAGGCGCTGCGTCTGGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTCTCAAAATTTTGTAGTGAGTGCCACTTCCACCCCGGGAAGGCT 1200
DB 1141 GGTCTTGACCTGCTCTCAAAATTTTGTAGTGAGTGCCACTTCCACCCCGGGAAGGCT 1200
QY 1201 GCGGCCACCAACACCAACCAACAGCAATGGCAACACCGACACCAACCAATCAGATA 1260
DB 1201 GCGGCCACCAACACCAACCAACAGCAATGGCAACACCGACACCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATTAGAAGAAACACAGCCTCATGGACAGAAATTTGAGGAGGGGAAC 1320
DB 1261 TATACAAATGAATTAGAAGAAACACAGCCTCATGGACAGAAATTTGAGGAGGGGAAC 1320
QY 1321 AAAGATATCTTTGGGGGGAAGAGTTTAAAGAAAGAAATTCAGAAATTCCTTGCAGATA 1380
DB 1321 AAAGATATCTTTGGGGGGAAGAGTTTAAAGAAAGAAATTCAGAAATTCCTTGCAGATA 1380
QY 1381 TTAGTACAATGAGAGTTTCTTTTCCCAACCGGAAGAACACAGACACCCGGCTTGA 1440
DB 1381 TTAGTACAATGAGAGTTTCTTTTCCCAACCGGAAGAACACAGACACCCGGCTTGA 1440
QY 1441 CCACCTGACAGCTGATCGTGCACTCTTTGTCAGTGCGGCAAGGGCTCAGCCTC 1500
DB 1441 CCACCTGACAGCTGATCGTGCACTCTTTGTCAGTGCGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCCCCAGTGAACATTTGGAGTGCCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTGCCCCCAGTGAACATTTGGAGTGCCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGACAGCAAGATGAGCTTCCGGCCCAAGCGTGCGGCTCGCGGCACTTGG 1620
DB 1561 GTCCATAGACAGCAAGATGAGCTTCCGGCCCAAGCGTGCGGCTCGCGGCACTTGG 1620
QY 1621 GTAGACTGTGCCACCAACCGCGCTGTGTGTGAACGTGAATTAAGAGCAAAAAAAA 1679
DB 1621 GTAGACTGTGCCACCAACCGCGCTGTGTGTGAACGTGAATTAAGAGCAAAAAAAA 1679
```

RESULT 23
ADB36148
ID ADB36148 standard; cDNA; 1679 BP.

AC ADB36148;

XX 04-DEC-2003 (first entry)

DE Human PRO polynucleotide SEQ ID NO 375.

XX Human; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; PFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003077720-A1.

XX 24-APR-2003.

XX 24-APR-2002; 2002US-00131930.

XX 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755075/71.
DR P-PSDB; ADB36149.

XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.

XX Claim 2; Fig 375; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or PFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems, PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polynucleotide of the invention. Note:
XX The sequence data for this patent is also available in electronic format
XX from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

XX Query Match 100.0%; Score 1679; DB 1; Length 1679;
XX Best Local Similarity 100.0%; Pred. No. 6.7e-05;
XX Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTCGACAAAGCTTGAGACACAC 60

DB 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTCGACAAAGCTTGAGACACAC 60

QY 61 AATCTATCAGGAAAGAAAGAAAAAACCAGAACCTGCACAAAAAGAGAAAAAGAG 120

DB 61 AATCTATCAGGAAAGAAAGAAAAAACCAGAACCTGCACAAAAAGAGAAAAAGAG 120

QY 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAGAAATCTATCTCTTGGCAAT 180

DB 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAGAAATCTATCTCTTGGCAAT 180

CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PMBC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (III) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.

xx
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCTCGAAAAACAGTGGATTTAAATCTCTTGGCAAGCTTGAGAGCAAC 60
DB 1 GTTGTGCTCTCAGCAAAAACAGTGGATTTAAATCTCTTGGCAAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAAACCGAACTGACAAAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAAACCGAACTGACAAAAAGAAAGAAAG 120
QY 121 AAAAAAATCATGAAACCATCAGCCAAAAATGCAAAATTCATCTCTTGGGCAAT 180
DB 121 AAAAAAATCATGAAACCATCAGCCAAAAATGCAAAATTCATCTCTTGGGCAAT 180
QY 181 CTTTCAGGGGCTGGCTGTCTGTCTCTTCCAAAGAGTGCCTGCGCAGCGGAGATGC 240
DB 181 CTTTCAGGGGCTGGCTGTCTGTCTCTTCCAAAGAGTGCCTGCGCAGCGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGACAAACGTGACGCTCGGCGAGGGGAGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAGCTATGACAAACGTGACGCTCGGCGAGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCATATGCAACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCATCTCTTA 360
DB 301 GTGCATATGCAACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCATCTCTTA 360
QY 361 TGTCTGGGAATGCAAGTGTGCTGGATCCTCGCGTGGTCTTCTTGAGCAACACCAAC 420
DB 361 TGTCTGGGAATGCAAGTGTGCTGGATCCTCGCGTGGTCTTCTTGAGCAACACCAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACGGGCGCTTACACCTGTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACGGGCGCTTACACCTGTC 480
QY 481 GGTGACAGACAGCAACACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGACAGACAGCAACACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAAATGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
DB 541 CAAAATGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600

DB 541 CAAAATGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
QY 601 CTCATAGCAACTGGTAGACAGAGAGCTACGGTTACTTGGAGACACATCTCTCCAAAGC 660
DB 601 CTCATAGCAACTGGTAGACAGAGAGCTACGGTTACTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTGAGTGAGAGCAATACCTTGGAAATTCAGGGCATCACCGGAGCAGTC 720
DB 661 GGTGGCTTTGTGAGTGAGAGCAATACCTTGGAAATTCAGGGCATCACCGGAGCAGTC 720
QY 721 AGGGGACTACAGTGCAGTCCCTCAATGACGTGGCGCCCGCTGATCGGAGAGTAAA 780
DB 721 AGGGGACTACAGTGCAGTCCCTCAATGACGTGGCGCCCGCTGATCGGAGAGTAAA 780
QY 781 GGTTCAGGTGAATATCCACCATATCTTTCAGAGCAAGGGTACAGGTGTCCCGCTGG 840
DB 781 GGTTCAGGTGAATATCCACCATATCTTTCAGAGCAAGGGTACAGGTGTCCCGCTGG 840
QY 841 AAAAAAGGACACTGCAAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGGTGTA 900
DB 841 AAAAAAGGACACTGCAAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGGTGTA 900
QY 901 CAAGGATGACAAAAGACTGATTCGAAGAAAGAAAGGGTGAAGAGTGAAGAAACAGACCTTT 960
DB 901 CAAGGATGACAAAAGACTGATTCGAAGAAAGAAAGGGTGAAGAGTGAAGAAACAGACCTTT 960
QY 961 CCTCTAAAACTCATCTTCTTCAATGTCTGAAACATGACTATGGAACTTACACTTGCCT 1020
DB 961 CCTCTAAAACTCATCTTCTTCAATGTCTGAAACATGACTATGGAACTTACACTTGCCT 1020
QY 1021 GGCCTCAACAGCTGGGCGCACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGCT 1080
DB 1021 GGCCTCAACAGCTGGGCGCACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGCT 1080
QY 1081 CAGCGAGTGAAGCAAGCGCACGTCGAGGAGGCGAGGCTGCTGCTGCTGCTCTTCT 1140
DB 1081 CAGCGAGTGAAGCAAGCGCACGTCGAGGAGGCGAGGCTGCTGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGCACCTGCTTCTCAAAATTTTGAATGAGTGCACCTTCCCAACCGGAAAGGCT 1200
DB 1141 GGTCTTGCACCTGCTTCTCAAAATTTTGAATGAGTGCACCTTCCCAACCGGAAAGGCT 1200
QY 1201 GCGCCACACCCACCCACCAACAGCAATGCGCAACCGCAGCAACCAATCAGATA 1260
DB 1201 GCGCCACACCCACCCACCAACAGCAATGCGCAACCGCAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGAGCAAAATTTGAGGAGGGGAAC 1320
DB 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGAGCAAAATTTGAGGAGGGGAAC 1320
QY 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTTGCAGATA 1380
DB 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTTGCAGATA 1380
QY 1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAACCGGAGAAACACAGCACACCCGGCTTGA 1440
DB 1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAACCGGAGAAACACAGCACACCCGGCTTGA 1440
QY 1441 CCCATGCAAGCTGCATCGTGCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCATGCAAGCTGCATCGTGCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCACCGTGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTGCCTCCACCGTGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGCAAGAAATGAGACCTTCCGGCCCAAGCGGTGGCGTGGGGCACTTTG 1620
DB 1561 GTCCATAGAGCAAGAAATGAGACCTTCCGGCCCAAGCGGTGGCGTGGGGCACTTTG 1620
QY 1621 GTAGCTGTGCCACCGCGGTGTGTGAAACGTGAAATATAAGAGCAAAAAA 1679
DB 1621 GTAGCTGTGCCACCGCGGTGTGTGAAACGTGAAATATAAGAGCAAAAAA 1679

PR	22-APR-1998;	98US-0082797P;
PR	23-APR-1998;	98US-0082804P;
PR	23-APR-1998;	98US-0083796P;
PR	27-APR-1998;	98US-0083336P;
PR	28-APR-1998;	98US-0083322P;
PR	28-APR-1998;	98US-0083392P;
PR	29-APR-1998;	98US-0083495P;
PR	29-APR-1998;	98US-0083496P;
PR	29-APR-1998;	98US-0083499P;
PR	29-APR-1998;	98US-0083500P;
PR	29-APR-1998;	98US-0083545P;
PR	29-APR-1998;	98US-0083554P;
PR	29-APR-1998;	98US-0083558P;
PR	30-APR-1998;	98US-0083559P;
PR	30-APR-1998;	98US-0083742P;
PR	06-MAY-1998;	98US-0084366P;
PR	06-MAY-1998;	98US-0084413P;
PR	07-MAY-1998;	98US-0084441P;
PR	07-MAY-1998;	98US-0084598P;
PR	07-MAY-1998;	98US-0084600P;
PR	07-MAY-1998;	98US-0084627P;
PR	07-MAY-1998;	98US-0084633P;
PR	07-MAY-1998;	98US-0084637P;
PR	07-MAY-1998;	98US-0084639P;
PR	07-MAY-1998;	98US-0084640P;
PR	07-MAY-1998;	98US-0084643P;
PR	13-MAY-1998;	98US-0085323P;
PR	13-MAY-1998;	98US-0085336P;
PR	13-MAY-1998;	98US-0085339P;
PR	15-MAY-1998;	98US-0085573P;
PR	15-MAY-1998;	98US-0085579P;
PR	15-MAY-1998;	98US-0085580P;
PR	15-MAY-1998;	98US-0085582P;
PR	15-MAY-1998;	98US-0085689P;
PR	15-MAY-1998;	98US-0085697P;
PR	15-MAY-1998;	98US-0085700P;
PR	15-MAY-1998;	98US-0085704P;
PR	18-MAY-1998;	98US-0086023P;
PR	22-MAY-1998;	98US-0086392P;
PR	22-MAY-1998;	98US-0086414P;
PR	22-MAY-1998;	98US-0086430P;
PR	22-MAY-1998;	98US-0086486P;
PR	28-MAY-1998;	98US-0087098P;
PR	28-MAY-1998;	98US-0087106P;
PR	28-MAY-1998;	98US-0087208P;
PR	26-JUN-1998;	98US-00105413;
PR	26-JUN-1998;	98US-0090863P;
PR	01-JUL-1998;	98US-0091105P;
PR	01-JUL-1998;	98US-0091359P;
PR	11-SEP-1998;	98US-0094651P;
PR	07-OCT-1998;	98US-0100038P;
PR	07-OCT-1998;	98US-0116897P;
PR	02-NOV-1998;	98US-0201141;
PR	06-NOV-1998;	98US-00184216;
PR	20-NOV-1998;	98US-00187368P;
PR	20-NOV-1998;	98US-0103904P;
PR	27-DEC-1998;	98NO-US0234855;
PR	27-DEC-1998;	98US-020202054;
PR	22-DEC-1998;	98US-00218517;
PR	23-DEC-1998;	98US-0113296P;
PR	05-JAN-1999;	98US-0113621P;
PR	05-MAR-1999;	98NO-US0000106;
PR	10-MAR-1999;	98US-00254465;
PR	10-MAR-1999;	98NO-US0050528;
PR	12-MAR-1999;	98NO-US005190;
PR	12-MAR-1999;	98US-00267213;
PR	12-MAR-1999;	98US-0123957P;
PR	12-MAR-1999;	98US-0126773P;
PR	12-APR-1999;	98US-00284291;
PR	26-APR-1999;	98US-0130232P;
PR	14-MAY-1999;	98US-0131445P;
PR	14-MAY-1999;	98US-00118832;

PR	14-MAY-1999;	99US-0134287P.	Db	121	AAGAAAAAATCATGA	180
PR	14-MAY-1999;	99MO-US010733.	Qy	181	CTTCA	240
PR	02-JUN-1999;	99MO-US012252.	Db	181	CTTCA	240
PR	16-JUN-1999;	99US-0139557P.	Qy	241	CACCTT	300
PR	23-JUN-1999;	99US-0141037P.	Db	241	CACCTT	300
PR	07-JUL-1999;	99US-0142680P.	Qy	301	GTG	360
PR	26-JUL-1999;	99US-0145698P.	Db	301	GTG	360
PR	28-JUL-1999;	99US-0146222P.	Qy	361	TGCTGG	420
PR	25-AUG-1999;	99US-00380137.	Db	361	TGCTGG	420
PR	25-AUG-1999;	99US-00380138.	Qy	421	GCAGT	480
PR	25-AUG-1999;	99US-00380142.	Db	421	GCAGT	480
PR	29-OCT-1999;	99US-0162506P.	Qy	481	GGT	540
PR	30-NOV-1999;	99MO-US028313.	Db	481	GGT	540
PR	02-DEC-1999;	99MO-US028551.	Qy	541	CAAAAT	600
PR	02-DEC-1999;	99MO-US028565.	Db	541	CAAAAT	600
PR	16-DEC-1999;	99MO-US030095.	Qy	601	CTGCAT	660
PR	30-DEC-1999;	99MO-US031243.	Db	601	CTGCAT	660
PR	30-DEC-1999;	99MO-US031274.	Qy	661	GGTTGG	720
PR	05-JAN-2000;	2000MO-US000219.	Db	661	GGTTGG	720
PR	06-JAN-2000;	2000MO-US000277.	Qy	721	AGGGG	780
PR	06-JAN-2000;	2000MO-US000376.	Db	721	AGGGG	780
PR	11-FEB-2000;	2000MO-US0003565.	Qy	781	GGT	840
PR	18-FEB-2000;	2000MO-US004341.	Db	781	GGT	840
PR	24-FEB-2000;	2000MO-US005004.	Qy	841	ACAAA	900
PR	02-MAR-2000;	2000MO-US005841.	Db	841	ACAAA	900
PR	10-MAR-2000;	2000MO-US006319.	Qy	901	CAAGG	960
PR	21-MAR-2000;	2000MO-US007532.	Db	901	CAAGG	960
PR	30-MAR-2000;	2000MO-US008439.	Qy	961	CCTCT	1020
PR	17-MAY-2000;	2000MO-US013705.	Db	961	CCTCT	1020
PR	22-MAY-2000;	2000MO-US014042.	Qy	1021	GGCTT	1080
PR	30-MAY-2000;	2000MO-US014941.	Db	1021	GGCTT	1080
PR	02-JUN-2000;	2000MO-US015264.	Qy	1081	CAGCG	1140
PR	28-JUL-2000;	2000MO-US020710.	Db	1081	CAGCG	1140
PR	24-AUG-2000;	2000MO-US023328.	Qy	1141	GGT	1200
PR	08-NOV-2000;	2000US-00709238.	Db	1141	GGT	1200
PR	27-NOV-2000;	2000US-00723749.	Qy	1201	GGCGC	1260
PR	01-DEC-2000;	2000MO-US032678.	Db	1201	GGCGC	1260
PR	20-DEC-2000;	2000US-00747259.	Qy			
PR	20-DEC-2000;	2000MO-US034956.	Db			
PR	28-FEB-2001;	2001MO-US006520.	Qy			
PR	22-MAR-2001;	2001US-00816744.	Db			
PR	22-MAR-2001;	2001US-00816920.	Qy			
PR	22-MAR-2001;	2001MO-US009552.	Db			
PR	10-MAY-2001;	2001US-00854208.	Qy			
PR	10-MAY-2001;	2001MO-US017092.	Db			
PR	01-JUN-2001;	2001US-00872035.	Qy			
PR	01-JUN-2001;	2001MO-US017800.	Db			
PR	05-JUN-2001;	2001US-00874503.	Qy			
PR	14-JUN-2001;	2001US-00882636.	Db			
PR	19-JUN-2001;	2001US-00886342.	Qy			
PR	20-JUN-2001;	2001MO-US019692.	Db			
PR	29-JUN-2001;	2001MO-US021066.	Qy			
PR	09-JUL-2001;	2001MO-US021735.	Db			
PR	30-JUL-2001;	2001US-00918585.	Qy			
XX						
PA						
XX						

(GETH) GENENTECH INC.

Query Match	100.0%;	Score 1679;	DB 1;	Length 1679;
Best Local Similarity	100.0%;	Pred. No. 6.7e-05;		
Matches 1679;	Conservative	0;	Mismatches	0;
			Indels	0;
			Gaps	0;
Qy	1	GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCCTTCGACAAAGCTTGAGAGCAACAC	60	
Db	1	GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCCTTCGACAAAGCTTGAGAGCAACAC	60	
Qy	61	AATCTATCAGGAAGAAGAAAGAAAAAACCAGACCTTGACAAAGAAAGAAAGAAAG	120	
Db	61	AATCTATCAGGAAGAAGAAAGAAAAAACCAGACCTTGACAAAGAAAGAAAGAAAG	120	
Qy	121	AAGAAAAAATCATGA	180	

QY 1261 TATACAAATGAAATAGAGAAACACACAGCCTCATGGACAGAAATTTGAGGGAGGGGAAAC 1320
DB 1261 TATACAAATGAAATAGAGAAACACACAGCCTCATGGACAGAAATTTGAGGGAGGGGAAAC 1320
QY 1321 AAGAAATACCTTTGGGGGAAAAGAGTTTTTAAAAAAGAAATTTGAAATTCCTTTCAGATA 1380
DB 1321 AAGAAATACCTTTGGGGGAAAAGAGTTTTTAAAAAAGAAATTTGAAATTCCTTTCAGATA 1380
QY 1381 TTTAGGTACAAATGAGTTTTCTTTTCCCAACGGGAGACACAGCACACCCCGCTTGA 1440
DB 1381 TTTAGGTACAAATGAGTTTTCTTTTCCCAACGGGAGACACAGCACACCCCGCTTGA 1440
QY 1441 CCCACTGCAAGCTGCATCGTGCACACCTCTTTGGTCCAGTGTGGCAAGGGCTTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGCATCGTGCACACCTCTTTGGTCCAGTGTGGCAAGGGCTTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCACGCTGGGAACATTTGGAGCTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTGCCTCCACGCTGGGAACATTTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCGGGCCCAAGCGTGGCGTGGGGCACTTTG 1620
DB 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCGGGCCCAAGCGTGGCGTGGGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACACAGCGCGTGTGTGTGAACGTGAATATAAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACACAGCGCGTGTGTGTGAACGTGAATATAAGAGCAAAAAA 1679

RESULT 26
ADC61930
ID AD661930 standard; cDNA; 1679 BP.
XX AC ADC61930;
XX DT 18-DEC-2003 (first entry)
XX DE Human cDNA encoding secreted/transmembrane protein, PRO337.
XX KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
OS Homo sapiens.
XX US2003049684-A1.
XX PD 13-MAR-2003.
XX PF 24-OCT-2001; 2001US-00017081.
XX PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-0004022O.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 30-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083332P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084411P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085330P.
PR 15-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085571P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 28-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.


```
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0103040P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 98WO-US000106.
PR 05-MAR-1999; 98US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 12-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 28-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.

PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 03-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX (GETH ) GENENTECH INC.
PA Ashkenazi AJ, Baker KP, Botstein D, Deenoyers L, Eaton DL;
PI Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTCTTGACAAAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTCTTGACAAAGCTTGAGAGCAAC 60
Qy 61 AATCTATCAGGAAGAAAGAAAGAAACCCGAACTGTACAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAGAAATCATGAAACCATCCAGCCAAAGATGCAAAATCTATCTCTTGGGCAAT 180
Db 121 AAGAAAGAAATCATGAAACCATCCAGCCAAAGATGCAAAATCTATCTCTTGGGCAAT 180
Qy 181 CTTACGGGGCTGGCTCTCTGTCTCTTCCAGGAGTGCCTGCGGAGCGGATGC 240
Db 181 CTTACGGGGCTGGCTCTCTGTCTCTTCCAGGAGTGCCTGCGGAGCGGATGC 240
Qy 241 CACCTTCCCAAGCTATGGACAAACGTGACGGTCCGGAGGGGAGAGGCCACCTCAG 300
Db 241 CACCTTCCCAAGCTATGGACAAACGTGACGGTCCGGAGGGGAGAGGCCACCTCAG 300
Qy 301 GTGCACCTATTGACAAACGGGTCAACGGGTGGCTGTGCTAAACCGGAGCAACCTCTCTA 360
Db 301 GTGCACCTATTGACAAACGGGTCAACGGGTGGCTGTGCTAAACCGGAGCAACCTCTCTA 360
Qy 361 TGTCTGGGAATGACAAAGTGTGCTCTGATCTCTCGGTGGTCTCTGTGAGCAACCCAAAC 420
Db 361 TGTCTGGGAATGACAAAGTGTGCTCTGATCTCTCGGTGGTCTCTGTGAGCAACCCAAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGAACCGTGGATCTCTAGAGGGGCTTACACCTCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACCGTGGATCTCTAGAGGGGCTTACACCTCTC 480
Qy 481 GGTGCAGACAGCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGCAGACAGCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Qy 541 CAAATTTGTAGAGATTTCTCAGATATCTCATTAAAGAGGGAACAAATATTAGCCTCAC 600
Db 541 CAAATTTGTAGAGATTTCTCAGATATCTCATTAAAGAGGGAACAAATATTAGCCTCAC 600
Qy 601 CTGCATAGCAACTCGTAGACCCAGAGCCTACGGTTACTTTGAGAGACACATCTCTCCAAAGC 660
Db 601 CTGCATAGCAACTCGTAGACCCAGAGCCTACGGTTACTTTGAGAGACACATCTCTCCAAAGC 660
Qy 661 GGTGGCTTTGTAGTGAAGACGAATCTTGGAAATTCAGGGCATACCCGGGAGAGATC 720
Db 661 GGTGGCTTTGTAGTGAAGACGAATCTTGGAAATTCAGGGCATACCCGGGAGAGATC 720
Qy 721 AGGGGACTACGAGTGCAGTGCCTCCAATGAGTGGCGCGCCCGTGTGTAGGAGTAAA 780
Db 721 AGGGGACTACGAGTGCAGTGCCTCCAATGAGTGGCGCGCCCGTGTGTAGGAGTAAA 780
Qy 781 GGTCAACCGTGAACCTATCCACCATACATTTTCAAGAGCCAGGGTACAGGTGTCCCGTGGG 840
Db 781 GGTCAACCGTGAACCTATCCACCATACATTTTCAAGAGCCAGGGTACAGGTGTCCCGTGGG 840
```

QY 841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db |
QY 841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db |
QY 901 CAAGGATGACAAAAGACTGATGTTGAAGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
Db |
QY 901 CAAGGATGACAAAAGACTGATGTTGAAGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
Db |
QY 961 CCTCTCAAACTCATCTTCTCAATGCTCTGACATGACTATGGGAATTCACACTTGGCT 1020
Db |
QY 961 CCTCTCAAACTCATCTTCTCAATGCTCTGACATGACTATGGGAATTCACACTTGGCT 1020
Db |
QY 1021 GGCTTCCAAAGCTGGGCCACCAATGCCAGCATCATGCTATTGTTGGTCCAGGCGCGCT 1080
Db |
QY 1021 GGCTTCCAAAGCTGGGCCACCAATGCCAGCATCATGCTATTGTTGGTCCAGGCGCGCT 1080
Db |
QY 1081 CAGCGAGTGAACAAAGCGCAGTGCAGGAGGCGAGGCTGGCTGGCTGGCTGGCTCTTCT 1140
Db |
QY 1081 CAGCGAGTGAACAAAGCGCAGTGCAGGAGGCGAGGCTGGCTGGCTGGCTGGCTCTTCT 1140
Db |
QY 1141 GGCTTGCACCTGCTTCTCAAAATTTGATGTGAGTGCCTTCCCAACCGGGAAGGCT 1200
Db |
QY 1141 GGCTTGCACCTGCTTCTCAAAATTTGATGTGAGTGCCTTCCCAACCGGGAAGGCT 1200
Db |
QY 1201 GCCGCCACCAACCAACACACAGCAATGGCAACCGGAGCAAGCAATCCAGATCAGATA 1260
Db |
QY 1201 GCCGCCACCAACCAACACACAGCAATGGCAACCGGAGCAAGCAATCCAGATCAGATA 1260
Db |
QY 1261 TATCAAAATGAATTTAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
Db |
QY 1261 TATCAAAATGAATTTAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
Db |
QY 1321 AAAGAATACTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db |
QY 1321 AAAGAATACTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db |
QY 1381 TTTAGGTACAAATGAGTGTCTTTTCCAAACCGGGAAGAAACACAGCACACCGGCTTGA 1440
Db |
QY 1381 TTTAGGTACAAATGAGTGTCTTTTCCAAACCGGGAAGAAACACAGCACACCGGCTTGA 1440
Db |
QY 1441 CCCACTGACAGCTGATGTCGACCTCTTTGGTGGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db |
QY 1441 CCCACTGACAGCTGATGTCGACCTCTTTGGTGGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db |
QY 1501 TCTGCCACAGAGTCCCAACGCTGGCAACATCTGGAGCTGGCCATCCCAAAATTCATCA 1560
Db |
QY 1501 TCTGCCACAGAGTCCCAACGCTGGCAACATCTGGAGCTGGCCATCCCAAAATTCATCA 1560
Db |
QY 1561 GTCCATGAGACGAACAGAAATGAGACCTTCCGCCCAAGCGTGGCGTGGCGGCACTTTG 1620
Db |
QY 1561 GTCCATGAGACGAACAGAAATGAGACCTTCCGCCCAAGCGTGGCGTGGCGGCACTTTG 1620
Db |
QY 1621 GTAGACTGTGCCACACGCGGTGTGTTGAAAGCTGAATTAAGAGCAAAAAA 1679
Db |
QY 1621 GTAGACTGTGCCACACGCGGTGTGTTGAAAGCTGAATTAAGAGCAAAAAA 1679
Db |

RESULT 27

ADC63894

ID ADC63894 standard; cDNA; 1679 BP.

AC ADC63894;

XX

XX

DT 18-DEC-2003 (first entry)

XX

DE Human cDNA encoding secreted/transmembrane protein, PRO337.

XX

KW Human; ss; gene; secreted protein; transmembrane protein; PRO;

KW cytosolic; ophthalmological; antiarthritis; osteopathic; antirheumatic;

KW vulnary; auditory; tumour growth; retinal disorder;

KW sports-related joint problem; articular cartilage defects;

KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.

XX Homo sapiens.
OS US2003054405-A1.
PN
XX
PD 20-MAR-2003.
PF
XX
XX 24-OCT-2001; 2001US-00999833.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083332P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083455P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.

PR	06-MAY-1998;	98US-0084441P.	PR	30-DEC-1999;	99WO-US031274.
PR	07-MAY-1998;	98US-0084598P.	PR	05-JAN-2000;	2000WO-US000219.
PR	07-MAY-1998;	98US-0084600P.	PR	06-JAN-2000;	2000WO-US000217.
PR	07-MAY-1998;	98US-0084627P.	PR	06-JAN-2000;	2000WO-US000376.
PR	07-MAY-1998;	98US-0084637P.	PR	11-FEB-2000;	2000WO-US000356.
PR	07-MAY-1998;	98US-0084639P.	PR	18-FEB-2000;	2000WO-US004341.
PR	07-MAY-1998;	98US-0084640P.	PR	24-FEB-2000;	2000WO-US005004.
PR	07-MAY-1998;	98US-0084643P.	PR	02-MAR-2000;	2000WO-US005841.
PR	13-MAY-1998;	98US-0085323P.	PR	10-MAR-2000;	2000WO-US006319.
PR	13-MAY-1998;	98US-0085338P.	PR	21-MAR-2000;	2000WO-US007532.
PR	13-MAY-1998;	98US-0085339P.	PR	30-MAR-2000;	2000WO-US008439.
PR	15-MAY-1998;	98US-0085573P.	PR	17-MAY-2000;	2000WO-US013705.
PR	15-MAY-1998;	98US-0085579P.	PR	22-MAY-2000;	2000WO-US014042.
PR	15-MAY-1998;	98US-0085580P.	PR	30-MAY-2000;	2000WO-US014941.
PR	15-MAY-1998;	98US-0085582P.	PR	02-JUN-2000;	2000WO-US015264.
PR	15-MAY-1998;	98US-0085689P.	PR	28-JUL-2000;	2000WO-US020710.
PR	15-MAY-1998;	98US-0085697P.	PR	24-AUG-2000;	2000WO-US023328.
PR	15-MAY-1998;	98US-0085700P.	PR	08-NOV-2000;	2000US-00709238.
PR	15-MAY-1998;	98US-0085704P.	PR	27-NOV-2000;	2000US-00723749.
PR	18-MAY-1998;	98US-0086023P.	PR	01-DEC-2000;	2000WO-US032678.
PR	22-MAY-1998;	98US-0086114P.	PR	20-DEC-2000;	2000US-00747259.
PR	22-MAY-1998;	98US-0086430P.	PR	20-DEC-2000;	2000WO-US034956.
PR	22-MAY-1998;	98US-0086489P.	PR	28-FEB-2001;	2001WO-US006520.
PR	22-MAY-1998;	98US-0087098P.	PR	22-MAR-2001;	2001US-00816744.
PR	28-MAY-1998;	98US-0087106P.	PR	22-MAR-2001;	2001US-00816920.
PR	28-MAY-1998;	98US-0087208P.	PR	22-MAR-2001;	2001WO-US009552.
PR	26-JUN-1998;	98US-00105413.	PR	10-MAY-2001;	2001US-00854208.
PR	26-JUN-1998;	98US-0090863P.	PR	10-MAY-2001;	2001US-00854280.
PR	26-JUN-1998;	98US-0091010P.	PR	01-JUN-2001;	2001WO-US017092.
PR	01-JUL-1998;	98US-0091359P.	PR	01-JUN-2001;	2001US-00872035.
PR	01-JUL-1998;	98US-0094651P.	PR	05-JUN-2001;	2001WO-US017800.
PR	11-SEP-1998;	98US-0100039P.	PR	14-JUN-2001;	2001US-00874503.
PR	07-OCT-1998;	98US-0016897P.	PR	19-JUN-2001;	2001US-00882636.
PR	07-OCT-1998;	98WO-US021141.	PR	20-JUN-2001;	2001US-00886342.
PR	06-NOV-1998;	98US-00184216.	PR	29-JUN-2001;	2001WO-US019692.
PR	06-NOV-1998;	98US-00187368.	PR	30-JUL-2001;	2001WO-US021066.
PR	20-NOV-1998;	98US-0102304P.	PR	30-JUL-2001;	2001WO-US021735.
PR	20-NOV-1998;	98WO-US024885.	XX		
PR	27-DEC-1998;	98US-00202054.	PA	(GETH) GENENTECH INC.	
PR	22-DEC-1998;	98US-00218517.	XX		
PR	23-DEC-1998;	98US-0113296P.			
PR	05-JAN-1999;	98WO-US000106.			
PR	05-MAR-1999;	98US-00254465.			
PR	08-MAR-1999;	99WO-US005028.			
PR	10-MAR-1999;	99US-00265686.			
PR	10-MAR-1999;	99WO-US005190.			
PR	12-MAR-1999;	99US-00267213.			
PR	12-MAR-1999;	99US-0123957P.			
PR	29-MAR-1999;	99US-0126773P.			
PR	12-APR-1999;	99US-00284291.			
PR	26-APR-1999;	99US-0130232P.			
PR	28-APR-1999;	99US-0131022P.			
PR	14-MAY-1999;	99US-00311832.			
PR	14-MAY-1999;	99US-0134287P.			
PR	14-MAY-1999;	99WO-US010733.			
PR	02-JUN-1999;	99WO-US012252.			
PR	16-JUN-1999;	99US-0139557P.			
PR	23-JUN-1999;	99US-0141037P.			
PR	07-JUL-1999;	99US-0142680P.			
PR	26-JUL-1999;	99US-0145698P.			
PR	28-JUL-1999;	99US-0146222P.			
PR	25-AUG-1999;	99US-00380137.			
PR	25-AUG-1999;	99US-00380138.			
PR	25-AUG-1999;	99US-00380142.			
PR	29-OCT-1999;	99US-0162506P.			
PR	30-NOV-1999;	99WO-US028313.			
PR	02-DEC-1999;	99WO-US028551.			
PR	16-DEC-1999;	99WO-US030095.			
PR	30-DEC-1999;	99WO-US031243.			
			Query Match 100.0%; Score 1679; DB 1; Length 1679;		
			Best Local Similarity 100.0%; Pred. No. 6.7e-05;		
			Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
Qy	1	GTGTGTCCTTCAGCAAAACAGTGGATTTAAATCTCCTTGCAACAGCTTGAGAGCAAC 60			
Db	1	GTGTGTCCTTCAGCAAAACAGTGGATTTAAATCTCCTTGCAACAGCTTGAGAGCAAC 60			
Qy	61	AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120			
Db	61	AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120			
Qy	121	AGAAAAAATCATGAAACCATCCAGCCAAATTCACAAATTCATCTCTTGGGCAAT 180			
Db	121	AGAAAAAATCATGAAACCATCCAGCCAAATTCACAAATTCATCTCTTGGGCAAT 180			
Qy	181	CTTCACGGGCTGGCTGCTGTCTCTTCCAGGAGTGCCGCGCGAGAGATGC 240			
Db	181	CTTCACGGGCTGGCTGCTGTCTCTTCCAGGAGTGCCGCGCGAGAGATGC 240			
Qy	241	CACCTTCCCAAGCTATGGACAAACGCGGTCCGCGAGGGGAGCGCCACCTTCAG 300			
Db	241	CACCTTCCCAAGCTATGGACAAACGCGGTCCGCGAGGGGAGCGCCACCTTCAG 300			
Qy	301	GTGCACCTATTGACAAACCGGCTCACCCTGGGCTGGCTAAACCGCAGCAACCATCTCTTA 360			
Db	301	GTGCACCTATTGACAAACCGGCTCACCCTGGGCTGGCTAAACCGCAGCAACCATCTCTTA 360			
Qy	361	TGCTGGGAATGACAAAGTGGTGGCTGCTGATCTCTCGGTGGTCTTCTTGAGCAACCCCAAC 420			
Db	361	TGCTGGGAATGACAAAGTGGTGGCTGCTGATCTCTCGGTGGTCTTCTTGAGCAACCCCAAC 420			

QY 421 GCAGTACAGCATCGAGATCCAGAACCGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACCGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGCGACGACGACACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGCGACGACGACACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
Db 541 CAAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCACTGGTAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
Db 601 CTGCATAGCACTGGTAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGACGAAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Db 661 GGTGGCTTTGTGAGTGAAGACGAAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACAGTGCAGTGCCTCCATGAGTGGCGCGCCCGGTGTAGCGAGGTAAA 780
Db 721 AGGGGACTACAGTGCAGTGCCTCCATGAGTGGCGCGCCCGGTGTAGCGAGGTAAA 780
QY 781 GGTCACTCCGTGAATTCACCATACATTTAGAAAGCCAAAGGTACAGGTGTCCCGCTGGG 840
Db 781 GGTCACTCCGTGAATTCACCATACATTTAGAAAGCCAAAGGTACAGGTGTCCCGCTGGG 840
QY 841 ACAAAGGGGACATGCGAGTGTGAAGCTCAGAGTGCCTCCAGCAGATTCAGAGTTA 900
Db 841 ACAAAGGGGACATGCGAGTGTGAAGCTCAGAGTGCCTCCAGCAGATTCAGAGTTA 900
QY 901 CAAGGATGACAAAGACATGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAGCAACAGACCTTT 960
Db 901 CAAGGATGACAAAGACATGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAGCAACAGACCTTT 960
QY 961 CCTCTCAAAACTCATCTTCTCAATGTCTTGAACATGATGAGTGGAACTACACTTCGCT 1020
Db 961 CCTCTCAAAACTCATCTTCTCAATGTCTTGAACATGATGAGTGGAACTACACTTCGCT 1020
QY 1021 GSCCTCCAAAGCTGGGCGCACCAATGCGCAGCATCATGCTATTGGTCCAGGCGCGCT 1080
Db 1021 GSCCTCCAAAGCTGGGCGCACCAATGCGCAGCATCATGCTATTGGTCCAGGCGCGCT 1080
QY 1081 CAGCAGGTGAGCAACGGCAGCTGAGAGGGGCGGTGGCTCTGGCTGTGCTCTCTCT 1140
Db 1081 CAGCAGGTGAGCAACGGCAGCTGAGAGGGGCGGTGGCTCTGGCTGTGCTCTCTCTCT 1140
QY 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTAGTGGCCACTTCCCAACCGGGGAAAGGCT 1200
Db 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTAGTGGCCACTTCCCAACCGGGGAAAGGCT 1200
QY 1201 GCGGCCACCCACCCACCAACCAACAGCAATGGCAACACCGCAGCAACCAATCAGATA 1260
Db 1201 GCGGCCACCCACCCACCAACCAACAGCAATGGCAACACCGCAGCAACCAATCAGATA 1260
QY 1261 TATACATATGAATTAGAAGAAACACGCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
Db 1261 TATACATATGAATTAGAAGAAACACGCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
QY 1321 AAAGAATACCTTTGGGGGAAAGAGTTTTTAAAGAAAGAAATTTGAAATTTGCTTTCAGATA 1380
Db 1321 AAAGAATACCTTTGGGGGAAAGAGTTTTTAAAGAAAGAAATTTGAAATTTGCTTTCAGATA 1380
QY 1381 TTTAGGTACATGGAGTTTCTTTTCCAAAGGGAAGAAACACAGCACACCCGGCTTGA 1440
Db 1381 TTTAGGTACATGGAGTTTCTTTTCCAAAGGGAAGAAACACAGCACACCCGGCTTGA 1440
QY 1441 CCCACTGCAAGTGCATCGTCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGTGCATCGTCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500

QY 1501 TCTGCCACAGAGTGGCCCGCCAGCTGGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGGCCCGCCAGCTGGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACGAAACAGCAATGAGACCTTCCGGGCCCAAGCGTGGCGTGGCGGCACTTTG 1620
Db 1561 GTCCATAGAGACGAAACAGCAATGAGACCTTCCGGGCCCAAGCGTGGCGTGGCGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCAACCGCGCTGTGTTGTGAAACGTGAATATAAGAGCAAAAGAAA 1679
Db 1621 GTAGACTGTGCCACCAACCGCGCTGTGTTGTGAAACGTGAATATAAGAGCAAAAGAAA 1679

RESULT 28
ADC66994
ID ADC66994 standard; cDNA; 1679 BP.
XX
AC ADC66994;
XX
XX
DT 18-DEC-2003 (first entry)
XX
XX Human cDNA encoding secreted/transmembrane protein, PRO337.
XX
XX vulnary; virucide; neuroprotective; cytostatic; gene therapy;
KW tumour cell proliferation inhibitor;
KW secreted and transmembrane protein; PRO; viral infection; wound healing;
KW tissue growth; muscle generation; muscle regeneration;
KW amyotrophic lateral sclerosis; neuropathy; AIDS-associated neuropathy;
KW diabetic peripheral neuropathy; chromosome identification; antagonist;
KW tissue typing; immunohistochemical staining; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003060406-A1.
XX
XX 27-MAR-2003.
XX
XX 30-JUL-2001; 2001US-00918585.
XX
XX 17-OCT-1997; 97US-0062250P.
XX 03-NOV-1997; 97US-0064249P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066364P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077641P.
XX 11-MAR-1998; 98US-0077649P.
XX 12-MAR-1998; 98US-0077791P.
XX 13-MAR-1998; 98US-0078004P.
XX 17-MAR-1998; 98US-00040220.
XX 20-MAR-1998; 98US-0078886P.
XX 20-MAR-1998; 98US-0078910P.
XX 20-MAR-1998; 98US-0078938P.
XX 20-MAR-1998; 98US-0078939P.
XX 25-MAR-1998; 98US-0079294P.
XX 26-MAR-1998; 98US-0079656P.
XX 27-MAR-1998; 98US-0079663P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079689P.
XX 27-MAR-1998; 98US-0079728P.
XX 27-MAR-1998; 98US-0079786P.
XX 30-MAR-1998; 98US-0079920P.
XX 30-MAR-1998; 98US-0079923P.
XX 31-MAR-1998; 98US-0080105P.
XX 26-JUN-1998; 98US-00105413.
XX 07-OCT-1998; 98US-00168978.
XX 07-OCT-1998; 98US-0021141.
XX 02-NOV-1998; 98US-00184216.
XX 06-NOV-1998; 98US-00187368.
XX 20-NOV-1998; 98US-00202485.
XX 07-DEC-1998; 98US-00202054.
XX 22-DEC-1998; 98US-00218517.
XX 05-JAN-1999; 99US-0000106.

PR 05-MAR-1999;	99US-00254465.	CC	CC	The invention describes an isolated secreted and transmembrane PRO
PR 08-MAR-1999;	99WO-US0005028.	CC	CC	polypeptide (I). PRO polypeptide such as PRO13, PRO700, PRO320 or PRO615
PR 09-MAR-1999;	99US-00265686.	CC	CC	is useful in biotechnological and medical research, as well as in various
PR 10-MAR-1999;	99WO-US0005190.	CC	CC	industrial applications. PRO polypeptide such as PRO300, PRO866, PRO703,
PR 12-MAR-1999;	99US-00267213.	CC	CC	PRO708, PRO320, PRO351, PRO381, PRO615, PRO310, PRO866, PRO703,
PR 12-APR-1999;	99US-00284291.	CC	CC	PRO860 or PRO846 is useful for therapeutic purposes. PRO363 is useful
PR 14-MAY-1999;	99WO-US0110733.	CC	CC	therapeutically in vivo for lessening the effects of viral infection.
PR 14-MAY-1999;	99WO-US010733.	CC	CC	PRO200 is useful for the treatment of wound healing, tissue growth and
PR 02-JUN-1999;	99WO-US012252.	CC	CC	muscle generation and regeneration. PRO337 is useful for treating
PR 25-AUG-1999;	99US-00380137.	CC	CC	amyotrophic lateral sclerosis, neuropathy, AIDS-associated neuropathy or
PR 25-AUG-1999;	99US-00380138.	CC	CC	diabetic peripheral neuropathy. A polynucleotide (II) encoding (I) is
PR 25-AUG-1999;	99US-00380142.	CC	CC	useful for generating transgenic animals or knockout animals which are
PR 30-NOV-1999;	99WO-US028313.	CC	CC	useful in the development and screening of therapeutically useful
PR 06-JAN-2000;	2000WO-US000219.	CC	CC	reagents, as probes for generating a pool of sequences for identifying
PR 06-JAN-2000;	2000WO-US000277.	CC	CC	related PRO coding sequences, and to construct hybridisation probes for
PR 18-FEB-2000;	2000WO-US000376.	CC	CC	mapping the gene which encodes the PRO and for the genetic analysis of
PR 18-FEB-2000;	2000WO-US003565.	CC	CC	individuals with genetic disorders, for recombinantly expressing (I) and
PR 18-FEB-2000;	2000WO-US0004341.	CC	CC	for chromosome identification. (I) is useful as molecular marker for
PR 02-MAR-2000;	2000WO-US005004.	CC	CC	protein electrophoresis purposes, and as therapeutic agents. (I) is also
PR 02-MAR-2000;	2000WO-US005841.	CC	CC	useful for screening compounds to identify those that mimic the PRO
PR 10-MAR-2000;	2000WO-US006319.	CC	CC	polypeptide (agonists) or prevent the effect of the PRO polypeptide
PR 21-MAR-2000;	2000WO-US007532.	CC	CC	(antagonists). (I) and (II) are useful for tissue typing. PRO antibodies
PR 30-MAR-2000;	2000WO-US008439.	CC	CC	are useful for immunohistochemical staining and/or assay of sample
PR 17-MAY-2000;	2000WO-US013705.	CC	CC	fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g.
PR 22-MAY-2000;	2000WO-US014042.	CC	CC	detecting its expression in specific cells, tissues or serum, and for
PR 30-MAY-2000;	2000WO-US014941.	CC	CC	affinity purification of PRO from recombinant cell culture or natural
PR 02-JUN-2000;	2000WO-US015264.	CC	CC	sources. This sequence encodes a human secreted and transmembrane PRO
PR 28-JUN-2000;	2000WO-US020710.	CC	CC	protein.
PR 24-AUG-2000;	2000WO-US023328.	CC	CC	
PR 08-NOV-2000;	2000US-00709238.	CC	CC	
PR 27-NOV-2000;	2000US-00723749.	CC	CC	
PR 01-DEC-2000;	2000WO-US032678.	CC	CC	
PR 20-DEC-2000;	2000US-00747259.	CC	CC	
PR 20-DEC-2000;	2000WO-US034556.	CC	CC	
PR 28-FEB-2001;	2001WO-US006520.	CC	CC	
PR 22-MAR-2001;	2001US-00816744.	CC	CC	
PR 22-MAR-2001;	2001US-00816920.	CC	CC	
PR 22-MAR-2001;	2001WO-US009552.	CC	CC	
PR 10-MAY-2001;	2001US-00854208.	CC	CC	
PR 25-MAY-2001;	2001WO-US017092.	CC	CC	
PR 01-JUN-2001;	2001US-00872035.	CC	CC	
PR 01-JUN-2001;	2001WO-US017800.	CC	CC	
PR 05-JUN-2001;	2001US-00874503.	CC	CC	
PR 14-JUN-2001;	2001US-00882636.	CC	CC	
PR 19-JUN-2001;	2001US-00886342.	CC	CC	
PR 20-JUN-2001;	2001WO-US019592.	CC	CC	
PR 29-JUN-2001;	2001WO-US021066.	CC	CC	
PR 09-JUL-2001;	2001WO-US021735.	CC	CC	
XX		XX	XX	(GETH) GENENTECH INC.
XX		XX	XX	Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
XX		XX	XX	Ferrara N, Filvaroff EJ, Fong S, Gao W, Gerber H, Gerritsen ME;
PI		PI	PI	Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI		PI	PI	Kijavini IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI		PI	PI	Stewart TA, Tamas D, Williams PM, Wood WI;
XX		XX	XX	WPI; 2003-596568/56.
DR		DR	DR	P-PSDB; ADC66995.
XX		XX	XX	Novel secreted and transmembrane polypeptides and polynucleotides
XX		XX	XX	encoding them, useful for treating wound healing, tissue growth and
PT		PT	PT	muscle generation and regeneration, amyotrophic lateral sclerosis or
PT		PT	PT	neuropathy.
XX		XX	XX	Claim 2; SEQ ID NO 522; 472pp; English.
PS		PS	PS	
XX		XX	XX	

541 CAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAGGGAACAATATTAGCCTCAC 600
601 CTGATAGCACTGGTAGACAGAGGCTTACGTTACTTTGAGACACATCTCTCCAAAGC 660
601 CTGATAGCACTGGTAGACAGAGGCTTACGTTACTTTGAGACACATCTCTCCAAAGC 660
661 GTTTGGCTTTGTAGTGAAGACCAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
661 GTTTGGCTTTGTAGTGAAGACCAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
721 AGGGACTACAGTGCAGTGGCTCCATAGAGTGGCGCGCGCTGTGTACGGAGAGTAAA 780
721 AGGGACTACAGTGCAGTGGCTCCATAGAGTGGCGCGCGCTGTGTACGGAGAGTAAA 780
781 GGTCAAGTGAATCATCATCATATCTTCAAGAGCAAGGTACAGTGTCCCGGTGGG 840
781 GGTCAAGTGAATCATCATCATATCTTCAAGAGCAAGGTACAGTGTCCCGGTGGG 840
841 ACAAAGGGGACATGCGAGTGTGAAGCTCAGAGTGCCTCAGCAGATTCAGTGGTA 900
841 ACAAAGGGGACATGCGAGTGTGAAGCTCAGAGTGCCTCAGCAGATTCAGTGGTA 900
901 CAAGATCACAAGAGACTGATTTGAAGGAAAGAGGGGTGAAGTGAAGACAGACCTTT 960
901 CAAGATCACAAGAGACTGATTTGAAGGAAAGAGGGGTGAAGTGAAGACAGACCTTT 960
961 CCTCTCAAAACTCATCTTCTTCAATGTCTTGAATGATGATGAGGAACTACATTCGGT 1020
961 CCTCTCAAAACTCATCTTCTTCAATGTCTTGAATGATGATGAGGAACTACATTCGGT 1020
1021 GGCCTTCAACAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGTCCAGCGCGCT 1080
1021 GGCCTTCAACAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGTCCAGCGCGCT 1080
1081 CAGCAGGTGAGCAACGGCAGCTCGAGGAGGCGAGGTGCTTGGCTGTGCTCTTCT 1140
1081 CAGCAGGTGAGCAACGGCAGCTCGAGGAGGCGAGGTGCTTGGCTGTGCTCTTCT 1140
1141 GGTCTTGCACCTGCTTCTTCAATTTTGAATGAGTGGCCACTTCCCGCGGAAAGCT 1200
1141 GGTCTTGCACCTGCTTCTTCAATTTTGAATGAGTGGCCACTTCCCGCGGAAAGCT 1200
1201 GCCGCCACACACACCAACCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
1201 GCCGCCACACACACCAACCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
1261 TATACAAATGAATTAGAAGAAACACAGCTCATGGGACAGAAATTTGAGGGGGGGAAC 1320
1261 TATACAAATGAATTAGAAGAAACACAGCTCATGGGACAGAAATTTGAGGGGGGGAAC 1320
1321 AAAGATATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCCTTGCAGATA 1380
1321 AAAGATATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCCTTGCAGATA 1380
1381 TTTAGGTACATGGAGTTTCTTTTCCCAACGGGAAAGAACACAGCACACCGGCTTGA 1440
1381 TTTAGGTACATGGAGTTTCTTTTCCCAACGGGAAAGAACACAGCACACCGGCTTGA 1440
1441 CCCATGCAAGCTGATCGTGCAACCTCTTTGGTGCAGTGTGGCAGAGGCTCAGCCTC 1500
1441 CCCATGCAAGCTGATCGTGCAACCTCTTTGGTGCAGTGTGGCAGAGGCTCAGCCTC 1500
1501 TCTGCCCAACAGAGTGCCTCCCACTGTGGACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
1501 TCTGCCCAACAGAGTGCCTCCCACTGTGGACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
1561 GTCCATAGAGACGAAACAGATCAGACCTTCCCGGCCCAAGCGTGGGCTCGCGGACCTTTG 1620
1561 GTCCATAGAGACGAAACAGATCAGACCTTCCCGGCCCAAGCGTGGGCTCGCGGACCTTTG 1620
1621 GTAGACTGTGCCACCAACCGCGTGTGTGTGAAACCTGTGAAATTAAGAGCAAAAAAAA 1679
1621 GTAGACTGTGCCACCAACCGCGTGTGTGTGAAACCTGTGAAATTAAGAGCAAAAAAAA 1679

RESULT 29

ADC69118
ID ADC69118 standard; cDNA; 1679 BP.
XX
AC ADC69118;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO337.
XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
PN US2003064407-A1.
XX
PD 03-APR-2003.
XX
PF 24-OCT-2001; 2001US-00999834.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064245P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-0004022O.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079820P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.


```
PR 22-APR-1998; 98US-0083797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0083742P.
PR 06-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085336P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98US-00204855.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 03-JAN-1999; 98US-00200106.
PR 05-MAR-1999; 98US-00254465.
PR 08-MAR-1999; 98US-00255028.
PR 10-MAR-1999; 98US-00265686.
PR 10-MAR-1999; 98US-00265190.
PR 12-MAR-1999; 98US-00267213.
PR 12-MAR-1999; 98US-0123957P.
PR 29-MAR-1999; 98US-0126773P.
PR 12-APR-1999; 98US-00284291.
PR 21-APR-1999; 98US-0130232P.
PR 26-APR-1999; 98US-0131022P.
PR 28-APR-1999; 98US-0131445P.
PR 14-MAY-1999; 98US-00311832.

PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99US-0134287P.
PR 02-JUN-1999; 99US-0134287P.
PR 16-JUN-1999; 99US-0134287P.
PR 23-JUN-1999; 99US-0140307P.
PR 26-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380142.
PR 25-AUG-1999; 99US-0162506P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99US-0162506P.
PR 02-DEC-1999; 99US-0162506P.
PR 02-DEC-1999; 99US-0162506P.
PR 16-DEC-1999; 99US-0162506P.
PR 30-DEC-1999; 99US-0162506P.
PR 30-DEC-1999; 99US-0162506P.
PR 05-JAN-2000; 2000US-0000219.
PR 06-JAN-2000; 2000US-0000219.
PR 06-JAN-2000; 2000US-0000376.
PR 11-FEB-2000; 2000US-0003565.
PR 18-FEB-2000; 2000US-0004341.
PR 24-FEB-2000; 2000US-0005004.
PR 02-MAR-2000; 2000US-0005841.
PR 10-MAR-2000; 2000US-0006319.
PR 21-MAR-2000; 2000US-0007532.
PR 30-MAR-2000; 2000US-0008439.
PR 17-MAY-2000; 2000US-0013705.
PR 22-MAY-2000; 2000US-0014042.
PR 30-MAY-2000; 2000US-0014941.
PR 02-JUN-2000; 2000US-0015264.
PR 28-JUL-2000; 2000US-0020710.
PR 24-AUG-2000; 2000US-0023328.
PR 08-NOV-2000; 2000US-00705238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000US-00732678.
PR 20-DEC-2000; 2000US-0074259.
PR 28-FEB-2001; 2000US-0074259.
PR 22-MAR-2001; 2000US-00818744.
PR 22-MAR-2001; 2000US-00818744.
PR 22-MAR-2001; 2000US-00818744.
PR 22-MAR-2001; 2000US-00818744.
PR 10-MAY-2001; 2000US-00854208.
PR 25-MAY-2001; 2000US-00854208.
PR 01-JUN-2001; 2000US-00872035.
PR 01-JUN-2001; 2000US-00872035.
PR 05-JUN-2001; 2000US-00874503.
PR 14-JUN-2001; 2000US-00882636.
PR 19-JUN-2001; 2000US-00886342.
PR 20-JUN-2001; 2000US-00886342.
PR 29-JUN-2001; 2000US-00886342.
PR 09-JUL-2001; 2000US-00886342.
PR 30-JUL-2001; 2000US-00886342.
XX 1 GETH ) GENENTECH INC.
FA Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Eaton DL;
PI Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGCTTCAGCAAAACAGTGGATTTAAATCTCTTCCACAAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTTCAGCAAAACAGTGGATTTAAATCTCTTCCACAAGCTTGAGAGCAAC 60
Qy 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAAAATCATGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
```

Db 121 AAGAAAAAATCATGAAACCATCCAGCCAAATGCACAATCTCTCTTGGGCAAT 180
Qy 181 CTTTCAAGGGGCTGCTGCTCTGCTCTCTCTTCCAGGAGTCCCGTGCAGCGGAGATGC 240
Db 181 CTTTCAAGGGGCTGCTGCTCTGCTCTCTCTTCCAGGAGTCCCGTGCAGCGGAGATGC 240
Qy 241 CACCTTCCCAAGCTATGACAACTGACGAGTCCCGTGCAGCGGAGGAGCCACCTCAG 300
Db 241 CACCTTCCCAAGCTATGACAACTGACGAGTCCCGTGCAGCGGAGGAGCCACCTCAG 300
Qy 301 GTGCACATATTGACAAACCGGCTCACCCGGGTGGCTGTAAACCGGAGCACCATCTCTA 360
Db 301 GTGCACATATTGACAAACCGGCTCACCCGGGTGGCTGTAAACCGGAGCACCATCTCTA 360
Qy 361 TGCTGGGAATGACAAAGTGGTCCCTGGATCTCGCGTGGTCTCTTGTGAGCAACACCCAAAC 420
Db 361 TGCTGGGAATGACAAAGTGGTCCCTGGATCTCGCGTGGTCTCTTGTGAGCAACACCCAAAC 420
Qy 421 GCAGTACAGCATCCAGATCCAGACGAGTGGATGTATGACGAGGCGCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCCAGATCCAGACGAGTGGATGTATGACGAGGCGCTTACACCTGCTC 480
Qy 481 GGTGCAGACAGCAACACCAACAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGCAGACAGCAACACCAACAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Qy 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAGGGGACAAATATTAGCCTCAC 600
Db 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAGGGGACAAATATTAGCCTCAC 600
Qy 601 CTGCATAGCAACTGGTACAGACAGCCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCATAGCAACTGGTACAGACAGCCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
Qy 661 GGTGGGCTTGTGAGTGAAGACGATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Db 661 GGTGGGCTTGTGAGTGAAGACGATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Qy 721 AGGGGACTACAGTGCAGTGCCTCCATGAGCTGGCGCGCCCTGTGATCGGAGAGTAA 780
Db 721 AGGGGACTACAGTGCAGTGCCTCCATGAGCTGGCGCGCCCTGTGATCGGAGAGTAA 780
Qy 781 GGTCAAGTGAACATATCCACATACATTTGAGCCAGGATACAGGTGTCCCGTGGG 840
Db 781 GGTCAAGTGAACATATCCACATACATTTGAGCCAGGATACAGGTGTCCCGTGGG 840
Qy 841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATCCAGTGGTA 900
Db 841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATCCAGTGGTA 900
Qy 901 CAAGATGACAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
Db 901 CAAGATGACAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
Qy 961 CCTCTCAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAACTACACTTGCCT 1020
Db 961 CCTCTCAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAACTACACTTGCCT 1020
Qy 1021 GGCTTCAAAAGCTTGGGCCACCAACATGCGAGCATCATGTATTTGGTCCAGGCGCGCT 1080
Db 1021 GGCTTCAAAAGCTTGGGCCACCAACATGCGAGCATCATGTATTTGGTCCAGGCGCGCT 1080
Qy 1081 CAGCGAGTGAACACGCGCTGCGAGGAGGAGGCTGCTGCTGCTGCTCTTCT 1140
Db 1081 CAGCGAGTGAACACGCGCTGCGAGGAGGAGGCTGCTGCTGCTGCTCTTCT 1140
Qy 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTAGTGCCACTTCCCAACCGGAAAGGCT 1200
Db 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTAGTGCCACTTCCCAACCGGAAAGGCT 1200
Qy 1201 GCCGCCACCCACCAACACAGCAATGCGACACCGACAGCAACCAATTCAGATA 1260
Db 1201 GCCGCCACCCACCAACACAGCAATGCGACACCGACAGCAACCAATTCAGATA 1260

Qy 1261 TATACAAATGAAATTAGAAAGAAACACAGCCCTCATGGGACAGAAATTTGAGGGGGAAC 1320
Db 1261 TATACAAATGAAATTAGAAAGAAACACAGCCCTCATGGGACAGAAATTTGAGGGGGAAC 1320
Qy 1321 AAAGAAATCTTTGGGGGAAAGAGATTTTAAAGAAATTTGAAATTTGCCCTTCAGATA 1380
Db 1321 AAAGAAATCTTTGGGGGAAAGAGATTTTAAAGAAATTTGAAATTTGCCCTTCAGATA 1380
Qy 1381 TTTAGGTACAATGAGATTTTCTTTCCCAACAGGGAAGAACACAGCACACCCGCTTGGGA 1440
Db 1381 TTTAGGTACAATGAGATTTTCTTTCCCAACAGGGAAGAACACAGCACACCCGCTTGGGA 1440
Qy 1441 CCCACTGCAAGCTGATCGTCAACCTCTTTGGTGCAGATGTGGGCAAGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGATCGTCAACCTCTTTGGTGCAGATGTGGGCAAGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGGCCCCCAGCTGGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGGCCCCCAGCTGGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCCGGGCCCAAGCGTGGCGTGGCGCACTTTG 1620
Db 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCCGGGCCCAAGCGTGGCGTGGCGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACCCAGCGCTGTGTGTGAAACGTGAAATATAAGAGCAAAAAAAA 1679
Db 1621 GTAGACTGTGCCACCCAGCGCTGTGTGTGAAACGTGAAATATAAGAGCAAAAAAAA 1679

RESULT 30

ADC63178

ID ADC63178 standard; cDNA; 1679 BP.

XX AC ADC63178;

XX DT 18-DEC-2003 (first entry)

XX DE Human cDNA encoding secreted/transmembrane protein, PRO337.

XX KW Human; ss; gene; secreted protein; transmembrane protein; PRO;

XX KW cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;

XX KW vulnary; auditory; tumor growth; retinal disorder;

XX KW sports-related joint problem; articular cartilage defects;

XX KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.

XX OS Homo sapiens.

XX PN US2003068648-A1.

XX PD 10-APR-2003.

XX PF 25-OCT-2001; 2001US-00013921.

XX PR 17-OCT-1997; 97US-0062250P.

XX PR 03-NOV-1997; 97US-0064249P.

XX PR 13-NOV-1997; 97US-0065311P.

XX PR 21-NOV-1997; 97US-0068364P.

XX PR 10-MAR-1998; 98US-0077450P.

XX PR 11-MAR-1998; 98US-0077632P.

XX PR 11-MAR-1998; 98US-0077641P.

XX PR 12-MAR-1998; 98US-0077791P.

XX PR 13-MAR-1998; 98US-0078004P.

XX PR 20-MAR-1998; 98US-0078888P.

XX PR 20-MAR-1998; 98US-0078910P.

XX PR 20-MAR-1998; 98US-0078939P.

XX PR 25-MAR-1998; 98US-0079294P.

XX PR 26-MAR-1998; 98US-0079656P.

XX PR 27-MAR-1998; 98US-0079663P.

XX PR 27-MAR-1998; 98US-0079664P.

XX PR 27-MAR-1998; 98US-0079689P.

PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079788P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 22-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 28-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 05-MAY-1998; 98US-0084414P.
PR 05-MAY-1998; 98US-0084412P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085877P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 22-DEC-1998; 98WO-US024855.
PR 23-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX (GETH) GENENTECH INC.
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Garber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kijavini IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX WPI, 2003-695924/66.
DR P-PSDB; ADC63179.
XX
PT New isolated secreted and transmembrane PRO polypeptides, useful in the
PT preparation of a medicament for treating a condition responsive to the
PT polypeptide, and as therapeutic agents e.g. vaccines.
XX
PS Claim 2; SEQ ID NO 522; 467pp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal

peptide, a PRO extracellular domain with or without its associated signal peptide). Also included are nucleic acids encoding the PRO proteins mentioned above, a vector comprising a PRO nucleic acid, a host cell comprising the vector and producing PRO, a chimeric molecule comprising PRO fused to a heterologous amino acid sequence, and an anti-PRO antibody. PRO337 polypeptide is useful for detecting a PRO4993 polypeptide in a sample suspected of containing PRO4993 polypeptide. Similarly, PRO4993 polypeptide is useful for detecting PRO337 polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive molecule is the toxin, radiolabel, or an antibody. The bioactive molecule

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCCACAACTCTTCAGAGCAACAC 60
DB 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCCACAACTCTTCAGAGCAACAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAACATCCAGCCCAAAATGCAAAATCTATCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAACATCCAGCCCAAAATGCAAAATCTATCTCTTGGGCAAT 180
QY 181 CTTTCAAGGGGCTGGTGTCTGTGTCTCTTCAAGAGAGTGCCTGCGCAGCGAGATGC 240
DB 181 CTTTCAAGGGGCTGGTGTCTGTGTCTCTTCAAGAGAGTGCCTGCGCAGCGAGATGC 240
QY 241 CACCTTCCCAAGTATGGAACAGTGCAGCGTCCGCGAGGGGAGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAGTATGGAACAGTGCAGCGTCCGCGAGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCATATTGCAACACCGGCTCACCGGGTGGCTGCTAAACCGCAGCACCATTCTCTA 360
DB 301 GTGCATATTGCAACACCGGCTCACCGGGTGGCTGCTAAACCGCAGCACCATTCTCTA 360
QY 361 TGCTGGGAATGCAAGTGGTGGTGGATCTCTCGGTGGTCTCTTGAGCAACACCGAAC 420
DB 361 TGCTGGGAATGCAAGTGGTGGTGGATCTCTCGGTGGTCTCTTGAGCAACACCGAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGAGACAGAACACCAAGACCTCTAGGGTCCACCTATTGTGCAAGTATCTCC 540
DB 481 GGTGAGACAGAACACCAAGACCTCTAGGGTCCACCTATTGTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAGGGAAACAATATTAGCCTCAC 600
DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAGGGAAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTAGTGAAGACGATCTCTGGAATTCAGGGCATCACCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTAGTGAAGACGATCTCTGGAATTCAGGGCATCACCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTSCAGTCTCCATGATGCTGGCCCGCCCTGGTGTGACGAGAGTAAA 780
DB 721 AGGGGACTACGAGTSCAGTCTCCATGATGCTGGCCCGCCCTGGTGTGACGAGAGTAAA 780
QY 781 GGTACCGGTGACATTCACCATATCTTCAGAGCCCAAGGGTACAGGTGTCCTCCGCTGG 840
DB 781 GGTACCGGTGACATTCACCATATCTTCAGAGCCCAAGGGTACAGGTGTCCTCCGCTGG 840
```

```
QY 841 ACAAAAGGGGACACTGACGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
DB 841 ACAAAAGGGGACACTGACGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
QY 901 CAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGGAAACACACCTTT 960
DB 901 CAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGGAAACACACACCTTT 960
QY 961 CTTCTCAAAACCTCATCTTCTTCAATGTCTCTGAACATGACTATGGAACACTACACTTGG 1020
DB 961 CTTCTCAAAACCTCATCTTCTTCAATGTCTCTGAACATGACTATGGAACACTACACTTGG 1020
QY 1021 GGCCTCCCAACAGCTGGGGCCACCAATGCCAGCATGCTGCTATTTGTCAGGGCCGCT 1080
DB 1021 GGCCTCCCAACAGCTGGGGCCACCAATGCCAGCATGCTGCTATTTGTCAGGGCCGCT 1080
QY 1081 CAGCAGAGTGAGCAACCGCACGTCGAGGAGGCGCAGGCTGCGCTCTGCTCTTCTCT 1140
DB 1081 CAGCAGAGTGAGCAACCGCACGTCGAGGAGGCGCAGGCTGCGCTCTGCTCTTCTCT 1140
QY 1141 GGTCTTGCACTGCTTCTCAAAATTTTGTATGTGAGTGCCACTTCCCCACCCCGGAAAGCT 1200
DB 1141 GGTCTTGCACTGCTTCTCAAAATTTTGTATGTGAGTGCCACTTCCCCACCCCGGAAAGCT 1200
QY 1201 GCGGCCACCAACCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
DB 1201 GCGGCCACCAACCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
QY 1261 TATACAAATGAAATTTAGAAAGAAACACAGCCTCATGGAAGCAAGAAATTTGAGGGAGG 1320
DB 1261 TATACAAATGAAATTTAGAAAGAAACACAGCCTCATGGAAGCAAGAAATTTGAGGGAGG 1320
QY 1321 AAAGAAATCTTTGGGGGAAAGAGTGTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB 1321 AAAGAAATCTTTGGGGGAAAGAGTGTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTATAGTACAAATGGAAGTGTCTTTTCCAAACCGGAGAAACACAGCAACCCCGGCTTGA 1440
DB 1381 TTATAGTACAAATGGAAGTGTCTTTTCCAAACCGGAGAAACACAGCAACCCCGGCTTGA 1440
QY 1441 CCACCTGCAAGCTGCATCTGTGCAACCTCTTGTGSCCAGTGTGGCAAGGCTCAGCCTC 1500
DB 1441 CCACCTGCAAGCTGCATCTGTGCAACCTCTTGTGSCCAGTGTGGCAAGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTCCCCCAGCTGGAAATTTGAGAGCTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTCCCCCAGCTGGAAATTTGAGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACAGACAGATGAGACCTTCCGGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
DB 1561 GTCCATAGAGACAGACAGATGAGACCTTCCGGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCAACCGCGTGTGTGTGAAACCTGTAATAAAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACCAACCGCGTGTGTGTGAAACCTGTAATAAAGAGCAAAAAA 1679
```

RESULT 31

ADC68243

ID ADC68243 standard; cDNA; 1679 BP.

XX ADC68243;

XX 18-DEC-2003 (first entry)

XX Human cDNA encoding secreted/transmembrane protein, PRO337.

Human; ss; gene; secreted protein; transmembrane protein; PRO;
cytostatic; ophthalmologic; antiarthritic; osteopathic; antirheumatic;
vulnary; auditory; tumour growth; retinal disorder;
sports-related joint problem; articular cartilage defects;
osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.

XX OS Homo sapiens.
XX PN US2003069178-A1.
XX XX
PD 10-APR-2003.
XX XX
PF 16-OCT-2001; 2001US-00978423.
XX XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0065364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079556P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079669P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081952P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083322P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0083742P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087088P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-01002141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98US-0109304P.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99US-0130232P.
PR 08-MAR-1999; 99US-0130232P.
PR 10-MAR-1999; 99US-0130232P.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0131022P.
PR 26-APR-1999; 99US-0131445P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99US-0134287P.
PR 02-JUN-1999; 99US-014037P.
PR 16-JUN-1999; 99US-014037P.
PR 23-JUN-1999; 99US-014037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99US-0162506P.
PR 02-DEC-1999; 99US-0162506P.
PR 02-DEC-1999; 99US-0162506P.
PR 16-DEC-1999; 99US-0162506P.
PR 16-DEC-1999; 99US-0162506P.
PR 30-DEC-1999; 99US-0162506P.
PR 30-DEC-1999; 99US-0162506P.
PR 05-JAN-2000; 2000US-0000219.
PR 06-JAN-2000; 2000US-0000277.
PR 06-JAN-2000; 2000US-0000376.
PR 11-FEB-2000; 2000US-0003565.
PR 18-FEB-2000; 2000US-0004341.
PR 24-FEB-2000; 2000US-0005004.
PR 02-MAR-2000; 2000US-0005841.
PR 10-MAR-2000; 2000US-0006319.
PR 21-MAR-2000; 2000US-0007532.
PR 30-MAR-2000; 2000US-0008439.
PR 17-MAY-2000; 2000US-013705.
PR 22-MAY-2000; 2000US-014042.
PR 02-JUN-2000; 2000US-014941.
PR 02-JUN-2000; 2000US-015264.
PR 28-JUL-2000; 2000US-020710.
PR 24-AUG-2000; 2000US-023328.

PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US009520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX (GETH) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrazi N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier WA, Pan J, Paoni NP, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX WPI; 2003-657582/62.
DR P-PSDB; ADC68244.
XX
XX Novel secreted and transmembrane polypeptides, designated PRO
PI polypeptides, and polynucleotides encoding them useful for treating
PI kidney diseases, bone, cartilage and retinal disorders.
XX
XX Claim 2; SEQ ID NO 522; 469pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTCTGACAAAGCTTGAGCAACAC 60
DB 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTCTGACAAAGCTTGAGCAACAC 60
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
DB 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
QY 181 CTTTCAGGGGCTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 240
DB 181 CTTTCAGGGGCTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 240
QY 241 CACCTTCCCAAGCTATGGACAAAGTGAAGTGGGAGGAGGAGGAGGAGGAGGAGGAG 300
DB 241 CACCTTCCCAAGCTATGGACAAAGTGAAGTGGGAGGAGGAGGAGGAGGAGGAGGAG 300
QY 301 GTGCACTATTGACAAACCGGCTCACCCTGGTGGCTGGCTGGCTGGCTGGCTGGCTG 360
DB 301 GTGCACTATTGACAAACCGGCTCACCCTGGTGGCTGGCTGGCTGGCTGGCTGGCTG 360
QY 361 TCGTGGGAATGACAAAGTGGTGGCTGGATCTCTGGATCTCTGGATCTCTGGATCTCTG 420
DB 361 TCGTGGGAATGACAAAGTGGTGGCTGGATCTCTGGATCTCTGGATCTCTGGATCTCTG 420

QY 421 GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGAGACAGCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 540
DB 481 GGTGAGACAGCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 540
QY 541 CAAATATGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTTAC 600
DB 541 CAAATATGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTTAC 600
QY 601 CTGCTATAGCAATGTAGACAGACCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
DB 601 CTGCTATAGCAATGTAGACAGACCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTTCGCTTTGTAGTGAAGACGATATCTTGGAAATTCAGGSCATCACCCGGGAGCAGTC 720
DB 661 GGTTCGCTTTGTAGTGAAGACGATATCTTGGAAATTCAGGSCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACAGTGCAGTGCCTCCCAATGACGTGGCCCGCCCGTGTACCGAGAGTAAA 780
DB 721 AGGGGACTACAGTGCAGTGCCTCCCAATGACGTGGCCCGCCCGTGTACCGAGAGTAAA 780
QY 781 GGTTCACCTGAACTATCCACCATACATTTCAAGAGCCAGGGGTACAGGTGTCCTCCGCTGG 840
DB 781 GGTTCACCTGAACTATCCACCATACATTTCAAGAGCCAGGGGTACAGGTGTCCTCCGCTGG 840
QY 841 ACAGAGAGGAGCACTGCAGTGTGAAGCCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 ACAGAGAGGAGCACTGCAGTGTGAAGCCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGATGACAAAGAACTGATTAAGAAAGAAAGAGGGGTGAAGTGAAGAAAGAAAGAAAG 960
DB 901 CAAGATGACAAAGAACTGATTAAGAAAGAAAGAGGGGTGAAGTGAAGAAAGAAAGAAAG 960
QY 961 CTTCTCAAAACTCATCTCTTCAATGTCTCTGAAATGAACTATGAGAACTACACTTGGCT 1020
DB 961 CTTCTCAAAACTCATCTCTTCAATGTCTCTGAAATGAACTATGAGAACTACACTTGGCT 1020
QY 1021 GGCCTCCAAAGCTGTGGCCACCAATGCCAGCATGCTATTTGGTCCAGGGCCGCT 1080
DB 1021 GGCCTCCAAAGCTGTGGCCACCAATGCCAGCATGCTATTTGGTCCAGGGCCGCT 1080
QY 1081 CAGCAGAGGTGAGCAACCGGACCGTCCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1140
DB 1081 CAGCAGAGGTGAGCAACCGGACCGTCCGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1140
QY 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTGATGAGTGCCACTTCCCCAGCCCGGAGAGGCT 1200
DB 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTGATGAGTGCCACTTCCCCAGCCCGGAGAGGCT 1200
QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
DB 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
QY 1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGAGGAG 1320
DB 1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGAGGAG 1320
QY 1321 AAGAAATATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGAAATTTGAAATTTG 1380
DB 1321 AAGAAATATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGAAATTTGAAATTTG 1380
QY 1381 TTTAGTACAAATGGAGTTTCTTTTCCCAACCGGAGAAACACAGCACCACCCGGCTTGA 1440
DB 1381 TTTAGTACAAATGGAGTTTCTTTTCCCAACCGGAGAAACACAGCACCACCCGGCTTGA 1440
QY 1441 CCCACTGCAAGCTGATCGTGGAACTCTTCTTGGTCCAGTGGGCAAGGGCTCAGCCCTC 1500
DB 1441 CCCACTGCAAGCTGATCGTGGAACTCTTCTTGGTCCAGTGGGCAAGGGCTCAGCCCTC 1500


```
QY 1501 TCTGCCACAGAGTGGCCCAACGTTGGAAACATTTCTGGAGTGGCCATCCCAAAATTCATCA 1560
    |||||
Db 1501 TCTGCCACAGAGTGGCCCAACGTTGGAAACATTTCTGGAGTGGCCATCCCAAAATTCATCA 1560
    |||||
QY 1561 GTCCATAGAGACCAACAGATGAGACTTCCGGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
    |||||
Db 1561 GTCCATAGAGACCAACAGATGAGACTTCCGGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
    |||||
QY 1621 GTAGACTGTGCCACCAACCGCGGTGTGTGAAACGTGAAATAAAAGACAAAAAAA 1679
    |||||
Db 1621 GTAGACTGTGCCACCAACCGCGGTGTGTGAAACGTGAAATAAAAGACAAAAAAA 1679
    |||||

RESULT 32
ADC41563
ID ADC41563 standard; cdna; 1679 BP.
XX AC ADC41563;
XX XX
DT 18-DEC-2003 (first entry)
XX XX
DE Human cDNA encoding secreted/transmembrane protein, PRO337.
XX XX
KW Human; sb; gene; secreted protein; transmembrane protein; PRO;
KW cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX XX
OS Homo sapiens.
XX XX
PN US2003072745-A1.
XX XX
PD 17-APR-2003.
XX XX
PF 25-OCT-2001; 2001US-00013929.
XX XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 12-MAR-1998; 98US-0077649P.
PR 13-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078866P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080155P.
PR 31-MAR-1998; 98US-0080156P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082737P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083332P.
PR 29-APR-1998; 98US-0083352P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083588P.
PR 29-APR-1998; 98US-0083599P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98WO-US02304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 98US-0123957P.
PR 29-MAR-1999; 98US-0126773P.
PR 21-APR-1999; 98US-0130232P.
PR 26-APR-1999; 98US-0131032P.
PR 28-APR-1999; 98US-0131445P.
PR 14-MAY-1999; 98US-0134287P.
```

PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028555.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX PA (GETH) GENENTECH INC.
XX PI Ashkenazi A, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kijavini IJ, Kho SS, Napier WA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PW, Wood WI;
XX WPI; 2003-743806/70.
XX P-PSDB; ADC41564.
XX PT Novel isolated secreted and transmembrane PRO polypeptides, useful in the
XX preparation of a medicament for treating a condition responsive to the
XX polypeptide, and as therapeutic agents e.g. vaccines.
XX PS Claim 2; SEQ ID NO 522; 466pp; English.
XX CC The invention relates to an isolated PRO polypeptide (secreted or
XX transmembrane protein) having at least 80% amino acid sequence identity
XX to an amino acid sequence chosen from 94 fully defined sequences as given
XX in the specification (including PRO lacking its associated signal
XX peptide, a PRO extracellular domain with or without its associated signal
XX peptide). Also included are nucleic acids encoding the PRO proteins
XX mentioned above, a vector comprising a PRO nucleic acid, a host cell
XX comprising the vector and producing PRO, a chimaeric molecule comprising
XX PRO fused to a heterologous amino acid sequence, and an anti-PRO
XX antibody. PRO337 polypeptide is useful for detecting a PRO4993
XX polypeptide in a sample suspected of containing PRO4993 polypeptide.
XX Query Match 100.0%; Score 1679; DB 1; Length 1679;
XX Best Local Similarity 100.0%; Pred. No. 6.7e-05;
XX Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCCTTCAGCAACACAGTGGATTAATCTCTTGGACAAGCTTGAGAGCAACAC 60
DB 1 GTTGTGCTCCTTCAGCAACACAGTGGATTAATCTCTTGGACAAGCTTGAGAGCAACAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
DB 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
QY 181 CTTACGGGGCTGGCTGCT 240
DB 181 CTTACGGGGCTGGCTGCT 240
QY 241 CACCTTCCCCAAAGCTATGGACAAAGTACGGTCCGGAGGGGAGAGGGCCACCTCAG 300
DB 241 CACCTTCCCCAAAGCTATGGACAAAGTACGGTCCGGAGGGGAGAGGGCCACCTCAG 300
QY 301 GTGCACCTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCCGAGCACCACCTCTCTA 360
DB 301 GTGCACCTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCCGAGCACCACCTCTCTA 360
QY 361 TGTGGAATGACAAAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 420
DB 361 TGTGGAATGACAAAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 420
QY 421 GCAGTACAGCATCGAGATCCAGAAAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 480
DB 421 GCAGTACAGCATCGAGATCCAGAAAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 480
QY 481 GGTGAGACAGACAAACCCGAGCCTTAGAGTCCACCTCATTTGCAAGTATCTCC 540
DB 481 GGTGAGACAGACAAACCCGAGCCTTAGAGTCCACCTCATTTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTTCATTAATGAAGGGAACAATATTAGCCTCAC 600
DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTTCATTAATGAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGCTAGCAACTGTTAGACAGCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
DB 601 CTGCTAGCAACTGTTAGACAGCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGACGATATCTTGAAGATTCAGGGCATCCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTGAGTGAAGACGATATCTTGAAGATTCAGGGCATCCCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCGCGCGCGCGCGCGCGCGCG 780
DB 721 AGGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCGCGCGCGCGCGCGCGCGCG 780
QY 781 GGTACCGGTGAAGTATCCACCATATCTTGAAGGGAAGGGAAGGGAAGGGAAGGGAAGG 840
DB 781 GGTACCGGTGAAGTATCCACCATATCTTGAAGGGAAGGGAAGGGAAGGGAAGGGAAGG 840
QY 841 ACAAAGGGGACACTGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 ACAAAGGGGACACTGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAAGTGAAGAAAGACTGATTGAAGGGAAGAAAGGGAAGGGAAGGGAAGGGAAGGGAAG 960
DB 901 CAAAGTGAAGAAAGACTGATTGAAGGGAAGAAAGGGAAGGGAAGGGAAGGGAAGGGAAG 960
QY 961 CTTCTCAAAACCTCATCTTCTTCAATGTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1020
DB 961 CTTCTCAAAACCTCATCTTCTTCAATGTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1020
QY 1021 GGCCTCAACAGCTGGGCGCACCAATGCCAGCATCATCTATTGGTTCAGGGCGCGCT 1080
DB 1021 GGCCTCAACAGCTGGGCGCACCAATGCCAGCATCATCTATTGGTTCAGGGCGCGCT 1080

```
QY 1081 CAGCGAGGTGAGCAACGGCAGCGTCGAGGAGGCGAGGCTGCGTCTGCTGCTGCTCTTCT 1140
DB 1081 CAGCGAGGTGAGCAACGGCAGCGTCGAGGAGGCGAGGCTGCGTCTGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTGAGTGGCACTTCCCAACCGGGAAGGCT 1200
DB 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTGAGTGGCACTTCCCAACCGGGAAGGCT 1200
QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
DB 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
QY 1261 TATACAAATGAATTAAGAAAGAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
DB 1261 TATACAAATGAATTAAGAAAGAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
QY 1321 AAGAGATACCTTTGGGGGGAAGAGATTTTAAAGAAAGAAATTTGAAATTTGCCCTTGCA 1380
DB 1321 AAGAGATACCTTTGGGGGGAAGAGATTTTAAAGAAAGAAATTTGAAATTTGCCCTTGCA 1380
QY 1381 TTATAGTACAATGAGATTTCTTTTCCCAACCGGGAAGAACACAGCACACCCGGGCTTGA 1440
DB 1381 TTATAGTACAATGAGATTTCTTTTCCCAACCGGGAAGAACACAGCACACCCGGGCTTGA 1440
QY 1441 CCACATGCAAGCTGATCGTGCAACCTCTTTGTGCGCAGTGTGGGCAAGGGCTCAGCCCTC 1500
DB 1441 CCACATGCAAGCTGATCGTGCAACCTCTTTGTGCGCAGTGTGGGCAAGGGCTCAGCCCTC 1500
QY 1501 TCTGCCACACAGAGTGGCCCCACGTCGGAACATTTGAGAGTGGCCATCCCAAAATCAATCA 1560
DB 1501 TCTGCCACACAGAGTGGCCCCACGTCGGAACATTTGAGAGTGGCCATCCCAAAATCAATCA 1560
QY 1561 GTCCATAGAGACCAACAGATGAGACTTCCCGCCCAAGCGTGGCGCTGGGGCACTTTG 1620
DB 1561 GTCCATAGAGACCAACAGATGAGACTTCCCGCCCAAGCGTGGCGCTGGGGCACTTTG 1620
QY 1621 GTAGACTGTCCCAACCGCGGCTGTGTGTGAACGTCGAAATTAAGACAAAAA 1679
DB 1621 GTAGACTGTCCCAACCGCGGCTGTGTGTGAACGTCGAAATTAAGACAAAAA 1679

RESULT 33
ADCS67618
ID ADC67618 standard; cDNA; 1679 BP.
AC
AC ADC67618;
XX
XX 18-DEC-2003 (first entry)
DT Human cDNA encoding secreted/transmembrane protein, PRO337.
XX
XX vulnary; virucide; neuroprotective; cytostatic; gene therapy;
XX tumour cell proliferation inhibitor;
XX secreted and transmembrane protein; PRO; viral infection; wound healing;
XX tissue growth; muscle generation; muscle regeneration;
XX anyotrophic lateral sclerosis; neuropathy; AIDS-associated neuropathy;
XX diabetic peripheral neuropathy; chromosome identification; antagonist;
XX tissue typing; immunohistochemical staining; gene; ss.
XX
XX Homo sapiens.
XX
XX US2003073131-A1.
XX
XX 17-APR-2003.
XX
XX 25-OCT-2001; 2001US-00016177.
XX
XX 17-OCT-1997; 97US-0062250P.
XX 03-NOV-1997; 97US-0084249P.
XX 13-NOV-1997; 97US-0085311P.
XX 21-NOV-1997; 97US-0086364P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX
```

```
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080155P.
PR 31-MAR-1998; 98US-0080159P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084444P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
```


QY	661	GGTTGGCTTTGTGAGTGAAGACGAATACTATTGGAAATTCAGGGCATACCCGGGAGCAGTC	720
Db	661	GGTTGGCTTTGTGAGTGAAGACGAATACTATTGGAAATTCAGGGCATACCCGGGAGCAGTC	720
QY	721	AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCGCGCGCGTGGTACGAGAGTAAA	780
Db	721	AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCGCGCGCGTGGTACGAGAGTAAA	780
QY	781	GGTCAACGGTGAACCTATCCACCATACATTTTCAGAAAGCCAAAGGTACAGGTGTCCCGTGGG	840
Db	781	GGTCAACGGTGAACCTATCCACCATACATTTTCAGAAAGCCAAAGGTACAGGTGTCCCGTGGG	840
QY	841	ACAAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
Db	841	ACAAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
QY	901	CAAGGATGACAAAAGACTGATTGAAGGAAGAAAGGGGTGAAGTGGAAAAACAGACCTTT	960
Db	901	CAAGGATGACAAAAGACTGATTGAAGGAAGAAAGGGGTGAAGTGGAAAAACAGACCTTT	960
QY	961	CCTCTCAAAACTCAATCTTCTTCAATGTCCTGAACATGACTATGGGAACTACACTTGGCT	1020
Db	961	CCTCTCAAAACTCAATCTTCTTCAATGTCCTGAACATGACTATGGGAACTACACTTGGCT	1020
QY	1021	GGCCTCCAAACAGCTGGGGCACACCAATGCCAGGATCATGCTATTTGGTCCAGGCGCCGT	1080
Db	1021	GGCCTCCAAACAGCTGGGGCACACCAATGCCAGGATCATGCTATTTGGTCCAGGCGCCGT	1080
QY	1081	CAGCGAGTGAACAAACGGCAGCTCGAGGAGGCGAGGCTGGCTCTGGCTGTGGCTCTTCT	1140
Db	1081	CAGCGAGTGAACAAACGGCAGCTCGAGGAGGCGAGGCTGGCTCTGGCTGTGGCTCTTCT	1140
QY	1141	GGTCTTGACCTGCTTCTAAAATTTTGAATGTGAGTGCACCTTCCCAACCCGGGAAAGGCT	1200
Db	1141	GGTCTTGACCTGCTTCTAAAATTTTGAATGTGAGTGCACCTTCCCAACCCGGGAAAGGCT	1200
QY	1201	GCCGCCACCAACCAACAAACAGCAATGGCAACACCGCACAGCAACCAATCAGATA	1260
Db	1201	GCCGCCACCAACCAACAAACAGCAATGGCAACACCGCACAGCAACCAATCAGATA	1260
QY	1261	TATACAAATGAAATTTAGAAGAAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC	1320
Db	1261	TATACAAATGAAATTTAGAAGAAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC	1320
QY	1321	AAAGAAATACTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCCTTGCAGATA	1380
Db	1321	AAAGAAATACTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCCTTGCAGATA	1380
QY	1381	TTTAGGTACAATGAGTTTCTTTTCCAAAACGGGAAAGAACACAGCAACCCCGCTTGGGA	1440
Db	1381	TTTAGGTACAATGAGTTTCTTTTCCAAAACGGGAAAGAACACAGCAACCCCGCTTGGGA	1440
QY	1441	CCCACTGCAGCTGCATCGTGCACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCCTC	1500
Db	1441	CCCACTGCAGCTGCATCGTGCACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCCTC	1500
QY	1501	TCTGCCACACAGAGTCCGCCACATCTTGGAGAGTGGCCATCCCAAAATTCATCA	1560
Db	1501	TCTGCCACACAGAGTCCGCCACATCTTGGAGAGTGGCCATCCCAAAATTCATCA	1560
QY	1561	GTCCTATAGAGACGAACAGATGAGACCTTCGGGCCCAAGCGTGGCGCTCGGGCAGCTTTG	1620
Db	1561	GTCCTATAGAGACGAACAGATGAGACCTTCGGGCCCAAGCGTGGCGCTCGGGCAGCTTTG	1620
QY	1621	GTAGACTGTGCCACACGGCGTGTGTGTAACCTGTAACCTGTAACCTGTAACCTGTAACCTG	1679
Db	1621	GTAGACTGTGCCACACGGCGTGTGTGTAACCTGTAACCTGTAACCTGTAACCTGTAACCTG	1679

SECRET

RESULT 34
ADCECEA

ADC62554
ID ADC62554 standard: CDNA: 1679 BP.

XXII

AC	ADC62554;
XX	
DT	18-DEC-2003 (first entry)
XX	
DE	Human cDNA encoding secreted/
XX	
KW	Human; ss; gene; secreted pro-
KW	cytostatic; ophthalmological;
KW	vulnerary; auditory; tumour g-
KW	sports-related joint problem;
KW	osteoarthritis; rheumatoid ar
XX	
OS	Homo sapiens.
XX	
PV	US2003073624-A1.
XX	
PD	17-APR-2003.
XX	
PF	15-OCT-2001; 2001US-00978193.
XX	
PR	17-OCT-1997; 97US-00632520P.
PR	03-NOV-1997; 97US-0064249P.
PR	11-NOV-1997; 97US-0065311P.
PR	21-NOV-1997; 97US-0066364P.
PR	10-MAR-1998; 98US-0077450P.
PR	11-MAR-1998; 98US-0077632P.
PR	11-MAR-1998; 98US-0077641P.
PR	11-MAR-1998; 98US-0077649P.
PR	12-MAR-1998; 98US-0077791P.
PR	13-MAR-1998; 98US-0078002P.
PR	17-MAR-1998; 98US-0004024P.
PR	20-MAR-1998; 98US-0078886P.
PR	20-MAR-1998; 98US-0078910P.
PR	20-MAR-1998; 98US-0078936P.
PR	20-MAR-1998; 98US-0078939P.
PR	23-MAR-1998; 98US-0079294P.
PR	26-MAR-1998; 98US-0079656P.
PR	27-MAR-1998; 98US-0079663P.
PR	27-MAR-1998; 98US-0079664P.
PR	27-MAR-1998; 98US-0079689P.
PR	27-MAR-1998; 98US-0079728P.
PR	27-MAR-1998; 98US-0079786P.
PR	30-MAR-1998; 98US-0079920P.
PR	30-MAR-1998; 98US-0079923P.
PR	31-MAR-1998; 98US-0080105P.
PR	31-MAR-1998; 98US-0080107P.
PR	31-MAR-1998; 98US-0080194P.
PR	01-APR-1998; 98US-0080327P.
PR	01-APR-1998; 98US-0080328P.
PR	01-APR-1998; 98US-0080333P.
PR	01-APR-1998; 98US-0080334P.
PR	08-APR-1998; 98US-0081049P.
PR	08-APR-1998; 98US-0081070P.
PR	08-APR-1998; 98US-0081071P.
PR	09-APR-1998; 98US-0081195P.
PR	09-APR-1998; 98US-0081203P.
PR	09-APR-1998; 98US-0081229P.
PR	15-APR-1998; 98US-0081817P.
PR	15-APR-1998; 98US-0081819P.
PR	15-APR-1998; 98US-0081838P.
PR	15-APR-1998; 98US-0081952P.
PR	15-APR-1998; 98US-0081955P.
PR	21-APR-1998; 98US-0082568P.
PR	21-APR-1998; 98US-0082569P.
PR	22-APR-1998; 98US-0082700P.
PR	22-APR-1998; 98US-0082704P.
PR	22-APR-1998; 98US-0082797P.
PR	22-APR-1998; 98US-0082804P.
PR	23-APR-1998; 98US-0082796P.
PR	28-APR-1998; 98US-0083322P.
PR	28-APR-1998; 98US-0083392P.
PR	29-APR-1998; 98US-0083495P.
PR	

PR	29-APR-1998;	98US-0083496P.	PR	28-JUL-1999;	99US-0146222P.	PR	28-JUL-1999;	99US-0146222P.
PR	29-APR-1998;	98US-0083496P.	PR	25-AUG-1999;	99US-00380137.	PR	25-AUG-1999;	99US-00380137.
PR	29-APR-1998;	98US-0083500P.	PR	25-AUG-1999;	99US-00380138.	PR	25-AUG-1999;	99US-00380138.
PR	29-APR-1998;	98US-0083545P.	PR	25-AUG-1999;	99US-00380142.	PR	25-AUG-1999;	99US-00380142.
PR	29-APR-1998;	98US-0083554P.	PR	29-OCT-1999;	99US-0162506P.	PR	29-OCT-1999;	99US-0162506P.
PR	29-APR-1998;	98US-0083558P.	PR	30-NOV-1999;	99WO-US028313.	PR	30-NOV-1999;	99WO-US028313.
PR	29-APR-1998;	98US-0083559P.	PR	02-DEC-1999;	99WO-US028551.	PR	02-DEC-1999;	99WO-US028551.
PR	30-APR-1998;	98US-0083742P.	PR	02-DEC-1999;	99WO-US028565.	PR	02-DEC-1999;	99WO-US028565.
PR	05-MAY-1998;	98US-0084366P.	PR	16-DEC-1999;	99WO-US030095.	PR	16-DEC-1999;	99WO-US030095.
PR	06-MAY-1998;	98US-0084414P.	PR	30-DEC-1999;	99WO-US031243.	PR	30-DEC-1999;	99WO-US031243.
PR	06-MAY-1998;	98US-0084441P.	PR	30-DEC-1999;	99WO-US031274.	PR	30-DEC-1999;	99WO-US031274.
PR	07-MAY-1998;	98US-0084598P.	PR	05-JAN-2000;	2000WO-US000219.	PR	05-JAN-2000;	2000WO-US000219.
PR	07-MAY-1998;	98US-0084600P.	PR	06-JAN-2000;	2000WO-US000277.	PR	06-JAN-2000;	2000WO-US000277.
PR	07-MAY-1998;	98US-0084627P.	PR	06-JAN-2000;	2000WO-US000376.	PR	06-JAN-2000;	2000WO-US000376.
PR	07-MAY-1998;	98US-0084637P.	PR	04-FEB-2000;	2000US-0180165P.	PR	04-FEB-2000;	2000US-0180165P.
PR	07-MAY-1998;	98US-0084639P.	PR	11-FEB-2000;	2000WO-US003565.	PR	11-FEB-2000;	2000WO-US003565.
PR	07-MAY-1998;	98US-0084640P.	PR	18-FEB-2000;	2000WO-US004341.	PR	18-FEB-2000;	2000WO-US004341.
PR	13-MAY-1998;	98US-0084643P.	PR	24-FEB-2000;	2000WO-US005004.	PR	24-FEB-2000;	2000WO-US005004.
PR	13-MAY-1998;	98US-0085233P.	PR	02-MAR-2000;	2000WO-US005841.	PR	02-MAR-2000;	2000WO-US005841.
PR	13-MAY-1998;	98US-0085338P.	PR	10-MAR-2000;	2000WO-US006319.	PR	10-MAR-2000;	2000WO-US006319.
PR	13-MAY-1998;	98US-0085339P.	PR	21-MAR-2000;	2000WO-US007532.	PR	21-MAR-2000;	2000WO-US007532.
PR	15-MAY-1998;	98US-0085573P.	PR	30-MAR-2000;	2000WO-US008439.	PR	30-MAR-2000;	2000WO-US008439.
PR	15-MAY-1998;	98US-0085579P.	PR	17-MAY-2000;	2000WO-US013705.	PR	17-MAY-2000;	2000WO-US013705.
PR	15-MAY-1998;	98US-0085580P.	PR	22-MAY-2000;	2000WO-US014042.	PR	22-MAY-2000;	2000WO-US014042.
PR	15-MAY-1998;	98US-0085582P.	PR	30-MAY-2000;	2000WO-US014941.	PR	30-MAY-2000;	2000WO-US014941.
PR	15-MAY-1998;	98US-0085689P.	PR	02-JUN-2000;	2000WO-US015264.	PR	02-JUN-2000;	2000WO-US015264.
PR	15-MAY-1998;	98US-0085697P.	PR	28-JUL-2000;	2000WO-US020710.	PR	28-JUL-2000;	2000WO-US020710.
PR	15-MAY-1998;	98US-0085700P.	PR	24-AUG-2000;	2000WO-US023328.	PR	24-AUG-2000;	2000WO-US023328.
PR	15-MAY-1998;	98US-0085704P.	PR	08-NOV-2000;	2000US-00709238.	PR	08-NOV-2000;	2000US-00709238.
PR	15-MAY-1998;	98US-0086023P.	PR	27-NOV-2000;	2000US-00723749.	PR	27-NOV-2000;	2000US-00723749.
PR	22-MAY-1998;	98US-0086392P.	PR	01-DEC-2000;	2000WO-US032678.	PR	01-DEC-2000;	2000WO-US032678.
PR	22-MAY-1998;	98US-0086414P.	PR	20-DEC-2000;	2000US-00747259.	PR	20-DEC-2000;	2000US-00747259.
PR	22-MAY-1998;	98US-0086430P.	PR	20-DEC-2000;	2000WO-US034956.	PR	20-DEC-2000;	2000WO-US034956.
PR	22-MAY-1998;	98US-0086486P.	PR	28-FEB-2001;	2001WO-US006520.	PR	28-FEB-2001;	2001WO-US006520.
PR	28-MAY-1998;	98US-0087098P.	PR	22-MAR-2001;	2001US-00816744.	PR	22-MAR-2001;	2001US-00816744.
PR	28-MAY-1998;	98US-0087106P.	PR	22-MAR-2001;				

Qy	241	CACCTTCCCAAGCTTATGGACAACTGACGGTCCGGCAGGGGAGAGCGCCACCTCTCAG	300
Db	241	CACCTTCCCAAGCTTATGGACAACTGACGGTCCGGCAGGGGAGAGCGCCACCTCTCAG	300
Qy	301	GTGCATAATTGACAAACCGGGTCACCCGGGTGGCGCTGGCTAAACCGCAGCACCATCTCTCTA	360
Db	301	GTGCATAATTGACAAACCGGGTCACCCGGGTGGCGCTGGCTAAACCGCAGCACCATCTCTCTA	360
Qy	361	TGCTGGGAATGACAAAGTGTCCTGTGANTCTCCGTGGTCTCTTCTGAGCAACACCCAAAC	420
Db	361	TGCTGGGAATGACAAAGTGTCCTGTGANTCTCCGTGGTCTCTTCTGAGCAACACCCAAAC	420
Qy	421	GCAGTAGCATCGAGATCCAGAACTGGATGTGATGACAGGGGCCCTTACACCTGCTC	480
Db	421	GCAGTAGCATCGAGATCCAGAACTGGATGTGATGACAGGGGCCCTTACACCTGCTC	480
Qy	481	GGTGACAGACAAACCAACCAAGACCTCTAGGGTCCACCTCAATTTAGCGATATCTCC	540
Db	481	GGTGACAGACAAACCAACCAAGACCTCTAGGGTCCACCTCAATTTAGCGATATCTCC	540
Qy	541	CAAAATGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAAATATTAGCTCTAC	600
Db	541	CAAAATGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAAATATTAGCTCTAC	600
Qy	601	CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGAGACACATCTCTCCCAAAGC	660
Db	601	CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGAGACACATCTCTCCCAAAGC	660
Qy	661	GGTTGGCTTTTGAGTGAAGACGAATACTTTGGAAATTCAGGGCATCACCGGAGCAGTCT	720
Db	661	GGTTGGCTTTTGAGTGAAGACGAATACTTTGGAAATTCAGGGCATCACCGGAGCAGTCT	720
Qy	721	AGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCGCGCCGTGGTACGGAGAGTAAA	780
Db	721	AGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCGCGCCGTGGTACGGAGAGTAAA	780
Qy	781	GGTCACCGTGAACTATCCACATACATTTGAGAAACCAAGGGTACAGGTGTCCCCGGG	840
Db	781	GGTCACCGTGAACTATCCACATACATTTGAGAAACCAAGGGTACAGGTGTCCCCGGG	840
Qy	841	ACAAAAGGGACACTGCAGGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGATGGTA	900
Db	841	ACAAAAGGGACACTGCAGGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGATGGTA	900
Qy	901	CAAGGATGACAAAGACTGTATTGAAGAAAGAAAGGGTGAAAGTGGAAAACAGACCTTT	960
Db	901	CAAGGATGACAAAGACTGTATTGAAGAAAGAAAGGGTGAAAGTGGAAAACAGACCTTT	960
Qy	961	CCTCTCAAACTCATCTTTCTCAATGTCTGTGACATGACTATGGGACTTACACTTGCCT	1020
Db	961	CCTCTCAAACTCATCTTTCTCAATGTCTGTGACATGACTATGGGACTTACACTTGCCT	1020
Qy	1021	GGCTCCAAACAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGCT	1080
Db	1021	GGCTCCAAACAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGCT	1080
Qy	1081	CAGCGAGGTGAGCAACGGCAGTCTGAGAGGGCGAGGCTGGGTCTGGGTGTGCTCTTCT	1140
Db	1081	CAGCGAGGTGAGCAACGGCAGTCTGAGAGGGCGAGGCTGGGTCTGGGTGTGCTCTTCT	1140
Qy	1141	GGTCTTGCACTGTCTCTCAATTTTGAATGTAGTGGCACTTCCCAACCGGAAAGGCT	1200
Db	1141	GGTCTTGCACTGTCTCTCAATTTTGAATGTAGTGGCACTTCCCAACCGGAAAGGCT	1200
Qy	1201	GGCGCCACCAACCAACCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA	1260
Db	1201	GGCGCCACCAACCAACCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA	1260
Qy	1261	TATACAATGAATTTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAC	1320
Db	1261	TATACAATGAATTTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAC	1320
Qy	1321	AAAGAACTACTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA	1380

RESULT 35

ADC36854

ID ADC36854 standard; cDNA; 1679 BP.

AC ADC36854;

DT 18-DEC-2003 (first entry)

Human PRO polynucleotide #63.

Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide; tumour; cancer; lung; breast; prostate; rectum; liver; tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell; pericyte cell; dermal fibroblast; bone disorder; cartilage disorder; arthritis; sports injury; cytostatic; antiarthritic.

Homo sapiens.

PN US2003088065-A1.

08-MAY-2003.

14-AUG-2002: 2002US-00219464.

AA
PR : 01-JUN-2001: 2001WO-US017800.

PR 29-JUN-2001; 2001WQ-US021066.
PR 09-APR-2002; 2002US-00119480.

XX PA (GETH) GENENTECH INC.

PI Baker KP. Desnovers L

FI GRIMMARDI JC, GURNEY AM, SMITH V, STEPHAN OF, NATANADE CN, NOOD NI,
XX

DR WPI; 2003-65/9/9/62.
D-NAME. 2003-68EE

X

PT useful in gene th

100

XXV

transmembrane polypeptides) and t

CC diagnostics, biosensors or bioarea

CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC stimulating the release of tumour necrosis factor (TNF)-alpha from human

blood, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells or for stimulating the proliferation of normal human dermal fibroblasts. The PRO nucleic acids are useful as hybridisation probes, in chromosomes and gene mapping, in generating antisense RNA and DNA, in preparing PRO polypeptides by recombinant technology, in generating transgenic animals or knock-out animals which may be used in the development and screening of therapeutically useful reagents, in gene therapy, in chromosome identification, as chromosome markers and in generating probes. The PRO polypeptides, or anti-PRO antibodies, are useful for preparing a medicament for treating a condition which is responsive to the PRO polypeptides or anti-PRO antibodies, such as pericyte-associated tumours and bone and/or cartilage disorders (e.g. arthritis, sports injuries), involving inducing the re-differentiation of chondrocytes. The PRO polypeptides are useful as molecular markers for protein electrophoresis, and in tissue typing. This sequence represents a human PRO polynucleotide of the invention.

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGGCACAAGCTTGAGAGCAAC 60
Db 1 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGGCACAAGCTTGAGAGCAAC 60

Qy 61 AATCTATCAGCAAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGCAAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

Qy 121 AAGAAAAAATATGAAAAATCTCAGCAAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
Db 121 AAGAAAAAATATGAAAAATCTCAGCAAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180

Qy 181 CTTACCGGGTGGCTGCTGCTGCTCTCTTCAAGAGAGTGGCTGCGCAGCGAGATGC 240
Db 181 CTTACCGGGTGGCTGCTGCTGCTCTCTTCAAGAGAGTGGCTGCGCAGCGAGATGC 240

Qy 241 CACCTTCCCAAGCTATGGAACAAGTGAACGCTGCGCAGGGGAGAGCGCCACCTCAG 300
Db 241 CACCTTCCCAAGCTATGGAACAAGTGAACGCTGCGCAGGGGAGAGCGCCACCTCAG 300

Qy 301 GTGCACTATTGCAACCGGTCACCGGGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 360
Db 301 GTGCACTATTGCAACCGGTCACCGGGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 360

Qy 361 TGCTGGGAATGCAAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 420
Db 361 TGCTGGGAATGCAAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 420

Qy 421 GCAGTAGCAATCGAGATCCAGAGCTGGATGTTATGAGAGGGGCTTTACACCTGCTC 480
Db 421 GCAGTAGCAATCGAGATCCAGAGCTGGATGTTATGAGAGGGGCTTTACACCTGCTC 480

Qy 481 GGTGAGACAGCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGAGACAGCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540

Qy 541 CAAATTTGTAGAGATTTCTCAGATATCTCCATTAAGAGGGAAACAATATTAGCTTCAC 600
Db 541 CAAATTTGTAGAGATTTCTCAGATATCTCCATTAAGAGGGAAACAATATTAGCTTCAC 600

Qy 601 CTGCATAGCAATGGTAGACAGCTTACGGTTTACTTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCATAGCAATGGTAGACAGCTTACGGTTTACTTTGGAGACACATCTCTCCCAAGC 660

Qy 661 GGTGGCTTTGTAGTGAAGACGAATATCTTGGAAATTCAGGGCATACCCGGAGGAGTGC 720
Db 661 GGTGGCTTTGTAGTGAAGACGAATATCTTGGAAATTCAGGGCATACCCGGAGGAGTGC 720

Qy 721 AGGGGACTACGAGTGCAGTCTCCATGAGCTGGCGCGCCCGTGGTACGAGAGTAAA 780

Db 721 AGGGGACTACGAGTGCAGTGTCTCAATGACGTGGCGCGCCGCTGGTACGAGAGTAAA 780

Qy 781 GGTCACTGTGAAGTACTTCCACCATATTCAGAAAGCCAAAGGGTACAGGTGTCCCGTGG 840

Db 781 GGTCACTGTGAAGTACTTCCACCATATTCAGAAAGCCAAAGGGTACAGGTGTCCCGTGG 840

Qy 841 ACARAAGGGGACACTGCAAGTGTGAGCCCTCAGAGTGTCCCTCAGCAGAAATTCAGTGTGA 900

Db 841 ACARAAGGGGACACTGCAAGTGTGAGCCCTCAGAGTGTCCCTCAGCAGAAATTCAGTGTGA 900

Qy 901 CAAGGATGACAAAAGACTGATTGAAAGAAAGAAAGGGGTGAAAGTGGAAACACAGACCTTT 960

Db 901 CAAGGATGACAAAAGACTGATTGAAAGAAAGAAAGGGGTGAAAGTGGAAACACAGACCTTT 960

Qy 961 CTTCTCAAAACTCATCTTCTCAATGTCTCTGAAACATGACTATGGGAACACTACACTTGGT 1020

Db 961 CTTCTCAAAACTCATCTTCTCAATGTCTCTGAAACATGACTATGGGAACACTACACTTGGT 1020

Qy 1021 GGCCTCCCAAGCTGGGCGCACCAATGCCAGCATCATGTATTGTCAGGCGCGCGT 1080

Db 1021 GGCCTCCCAAGCTGGGCGCACCAATGCCAGCATCATGTATTGTCAGGCGCGCGT 1080

Qy 1081 CAGCGAGTGTGAGCAACGGCAGCGTCGAGAGGGCAGGCTGCGTCTGGCTGCTCTTCT 1140

Db 1081 CAGCGAGTGTGAGCAACGGCAGCGTCGAGAGGGCAGGCTGCGTCTGGCTGCTCTTCT 1140

Qy 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCGACCCCGGAAAGGCT 1200

Db 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCGACCCCGGAAAGGCT 1200

Qy 1201 GCGCGCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA 1260

Db 1201 GCGCGCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA 1260

Qy 1261 TATACAAATGAAATTTAGAAAGAAACACAGCTCATGGGACAGAAATTTGAGGGAGGGGAAC 1320

Db 1261 TATACAAATGAAATTTAGAAAGAAACACAGCTCATGGGACAGAAATTTGAGGGAGGGGAAC 1320

Qy 1321 AAAGAATATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380

Db 1321 AAAGAATATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380

Qy 1381 TTTAGTACAAATGAGTGTCTTTTCCCAAGGGGAAAGACACAGCACACCGCGCTTGA 1440

Db 1381 TTTAGTACAAATGAGTGTCTTTTCCCAAGGGGAAAGACACAGCACACCGCGCTTGA 1440

Qy 1441 CCCACTGCAAGTGCATCGTCAACCTCTTTGGTSCCAAGTGTGGGCAAGGGCTCAGCCTC 1500

Db 1441 CCCACTGCAAGTGCATCGTCAACCTCTTTGGTSCCAAGTGTGGGCAAGGGCTCAGCCTC 1500

Qy 1501 TCTGCCACAGAGTGGCGGCAACATCTGGAGCTGGCCATCCCAATTCATCA 1560

Db 1501 TCTGCCACAGAGTGGCGGCAACATCTGGAGCTGGCCATCCCAATTCATCA 1560

Qy 1561 GTCCATAGAGAGCAACAGAAATGAGACCTTCCCGGCCCAAGCGTGGCGCTGCGGCACTTTG 1620

Db 1561 GTCCATAGAGAGCAACAGAAATGAGACCTTCCCGGCCCAAGCGTGGCGCTGCGGCACTTTG 1620

Qy 1621 GTAGACTGTGCCACACCGCGCTGTTGTTGAAACGTGAAATTAAGAGAGCAAAAAA 1679

Db 1621 GTAGACTGTGCCACACCGCGCTGTTGTTGAAACGTGAAATTAAGAGAGCAAAAAA 1679

RESULT 36
ADC42187
ID ADC42187 standard; cDNA; 1679 BP.
XX
AC ADC42187;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO337.

XX Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumor growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
XX US2003104998-A1.
XX
XX 05-JUN-2003.
XX
XX 16-OCT-2001; 2001US-00978643.
XX
XX 17-OCT-1997; 97US-0062250P.
XX 03-NOV-1997; 97US-0064249P.
XX 13-NOV-1997; 97US-0065311P.
XX 13-NOV-1997; 97US-0066364P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077641P.
XX 11-MAR-1998; 98US-0077649P.
XX 12-MAR-1998; 98US-0077791P.
XX 13-MAR-1998; 98US-0078004P.
XX 17-MAR-1998; 98US-00040220.
XX 20-MAR-1998; 98US-0078866P.
XX 20-MAR-1998; 98US-0078910P.
XX 20-MAR-1998; 98US-0078936P.
XX 20-MAR-1998; 98US-0078939P.
XX 25-MAR-1998; 98US-0079294P.
XX 26-MAR-1998; 98US-0079656P.
XX 27-MAR-1998; 98US-0079663P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079668P.
XX 27-MAR-1998; 98US-0079728P.
XX 30-MAR-1998; 98US-0079786P.
XX 30-MAR-1998; 98US-0079920P.
XX 31-MAR-1998; 98US-0079923P.
XX 31-MAR-1998; 98US-0080105P.
XX 31-MAR-1998; 98US-0080107P.
XX 31-MAR-1998; 98US-0080165P.
XX 31-MAR-1998; 98US-0080194P.
XX 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080328P.
XX 01-APR-1998; 98US-0080333P.
XX 01-APR-1998; 98US-0080334P.
XX 08-APR-1998; 98US-0081049P.
XX 08-APR-1998; 98US-0081070P.
XX 08-APR-1998; 98US-0081071P.
XX 09-APR-1998; 98US-0081195P.
XX 09-APR-1998; 98US-0081203P.
XX 09-APR-1998; 98US-0081229P.
XX 15-APR-1998; 98US-0081817P.
XX 15-APR-1998; 98US-0081819P.
XX 15-APR-1998; 98US-0081838P.
XX 15-APR-1998; 98US-0081952P.
XX 15-APR-1998; 98US-0081955P.
XX 21-APR-1998; 98US-0081955P.
XX 21-APR-1998; 98US-0082568P.
XX 21-APR-1998; 98US-0082569P.
XX 22-APR-1998; 98US-0082700P.
XX 22-APR-1998; 98US-0082704P.
XX 22-APR-1998; 98US-0082797P.
XX 22-APR-1998; 98US-0082804P.
XX 23-APR-1998; 98US-0082796P.
XX 27-APR-1998; 98US-0083322P.
XX 28-APR-1998; 98US-0083322P.
XX 29-APR-1998; 98US-0083392P.
XX 29-APR-1998; 98US-0083495P.
XX 29-APR-1998; 98US-0083496P.
XX 29-APR-1998; 98US-0083499P.
XX 29-APR-1998; 98US-0083500P.
XX 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0083742P.
PR 06-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 15-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-USO21141.
PR 07-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-USO24855.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-USO00106.
PR 08-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-USO05028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-USO005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-USO10733.
PR 02-JUN-1999; 99WO-USO12252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.

Db 1381 TTATGTTACATGAGTTTCTTTTCCCAACGGGAAGAACACACAGCACACCCGGCTTGA 1440
QY 1441 CCACATGCAAGTGCATGTCGAACCTTTTGGTCCAGTGTGGCAGGGCTCAGCTC 1500
Db 1441 CCACATGCAAGTGCATGTCGAACCTTTTGGTCCAGTGTGGCAGGGCTCAGCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCACGTCGGAACATTTCTGGAGCTGGCCATCCCAAAATCAATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCACGTCGGAACATTTCTGGAGCTGGCCATCCCAAAATCAATCA 1560
QY 1561 GTCCATAGAGACGACAGATGAGACCTTCCGGCCCAAGCGTGGCGCTGGCGCACTTTG 1620
Db 1561 GTCCATAGAGACGACAGATGAGACCTTCCGGCCCAAGCGTGGCGCTGGCGCACTTTG 1620
QY 1621 GTAGACTGTGCCACACGCGCTGTGTGTGGAACCTGAAATGAAAGACCAAAAAA 1679
Db 1621 GTAGACTGTGCCACACGCGCTGTGTGTGGAACCTGAAATGAAAGACCAAAAAA 1679

RESULT 37
ADC21844
ID ADC21844 standard; cDNA; 1679 BP.
XX AC ADC21844;
XX DT
XX 18-DEC-2003 (first entry)
XX Human PRO polynucleotide #63.
XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW arthritis; sports injury; cytostatic; antiarthritic.
XX
OS Homo sapiens.
XX
XX US2003096969-A1.
XX 22-MAY-2003.
XX
XX 29-AUG-2002; 2002US-00232225.
XX 02-JUN-2000; 2000WO-US015264.
XX 05-JUN-2000; 2000US-0209832P.
XX 20-JUN-2000; 2000US-0212901P.
XX 22-JUN-2000; 2000US-0213807P.
XX 20-JUL-2000; 2000US-0219556P.
XX 25-JUL-2000; 2000US-0220585P.
XX 25-JUL-2000; 2000US-0220605P.
XX 25-JUL-2000; 2000US-0220624P.
XX 25-JUL-2000; 2000US-0220638P.
XX 25-JUL-2000; 2000US-0220664P.
XX 25-JUL-2000; 2000US-0220666P.
XX 26-JUL-2000; 2000US-0220893P.
XX 01-AUG-2000; 2000US-0222425P.
XX 22-AUG-2000; 2000US-0227133P.
XX 23-AUG-2000; 2000WO-US023522.
XX 24-AUG-2000; 2000WO-US023328.
XX 10-NOV-2000; 2000WO-US030873.
XX 28-NOV-2000; 2000US-0253646P.
XX 01-DEC-2000; 2000WO-US032678.
XX 20-DEC-2000; 2000US-00747259.
XX 20-DEC-2000; 2000WO-US034956.
XX 28-FEB-2001; 2001WO-US006520.
XX 25-MAY-2001; 2001WO-US017092.
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.

PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
XX Grimaldi JC, Gurney AL, Smith V, Stephan JP, Watanabe CK, Wood WI;
DR WPI: 2003-765526/72.
XX P-PSDB; ADC21845.
PT Novel isolated PRO polypeptide useful for tissue typing, as molecular
XX weight markers in protein electrophoresis, for treating arthritis, tumor.
PS Claim 2; Fig 125; 308pp; English.
XX The invention relates to human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. They are particularly useful for
CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC blood, for stimulating the proliferation or differentiation of
CC chondrocyte cells, for stimulating the proliferation of or gene
CC expression in pericyte cells or for stimulating the proliferation of
CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTCACACAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTCACACAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAGAAGAAAGAAAAACCGAACCTGACAAAAAGAGAAAAAGAG 120
Db 61 AATCTATCAGGAAGAAGAAAGAAAAACCGAACCTGACAAAAAGAGAAAAAGAG 120
QY 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAATGCAAAATCTATCTTTGGGCAAT 180
Db 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAATGCAAAATCTATCTTTGGGCAAT 180
QY 181 CTTACGGGGCTGGCTCTGTGTCTCTTCCAGGAGTCCCGTGGCGAGCGAGATGC 240
Db 181 CTTACGGGGCTGGCTCTGTGTCTCTTCCAGGAGTCCCGTGGCGAGCGAGATGC 240
QY 241 CACCTTCCCAAAAGCTATGGACAAACGTGACGGTCCGCGAGGGGAGAGCGCACCTCAG 300
Db 241 CACCTTCCCAAAAGCTATGGACAAACGTGACGGTCCGCGAGGGGAGAGCGCACCTCAG 300
QY 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGAGCACCATTCTCTA 360
Db 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGAGCACCATTCTCTA 360
QY 361 TGCTGGGAATGACAAAGTGGTCCCTGGGATCTCTCGGTGGTCTCTTGAGCAACACCCAAAC 420
Db 361 TGCTGGGAATGACAAAGTGGTCCCTGGGATCTCTCGGTGGTCTCTTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACGTTGGATGTGTATGACAGAGGGCCCTTACCTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACGTTGGATGTGTATGACAGAGGGCCCTTACCTGCTC 480

QY 481 GGTGCAGACAGCAACCAACCCCAAGACCTCTAGGTCACCTCATTTGTGCAAGTATCTCC 540
Db |||||
QY 481 GGTGCAGACAGCAACCAACCCCAAGACCTCTAGGTCACCTCATTTGTGCAAGTATCTCC 540
Db |||||
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCTAC 600
Db |||||
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCTAC 600
Db |||||
QY 601 CTCATAGCAACTGTGTAGACAGAGCTAGCGTTACTTGGAGACACATCTCTCCCAAGC 660
Db |||||
QY 601 CTCATAGCAACTGTGTAGACAGAGCTAGCGTTACTTGGAGACACATCTCTCCCAAGC 660
Db |||||
QY 661 GGTGGCTTTGTGAGTGAAGCAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Db |||||
QY 661 GGTGGCTTTGTGAGTGAAGCAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Db |||||
QY 721 AGGGGACTAGCTGAGTGCCTTCCATGACGTGGCGCGCGCTGTACGAGAGTAA 780
Db |||||
QY 721 AGGGGACTAGCTGAGTGCCTTCCATGACGTGGCGCGCGCTGTACGAGAGTAA 780
Db |||||
QY 781 GGTCAACGCTGAACTATCCACATACATTTTCAGAAAGCAAGGTTACAGGTGTCCCGTGG 840
Db |||||
QY 781 GGTCAACGCTGAACTATCCACATACATTTTCAGAAAGCAAGGTTACAGGTGTCCCGTGG 840
Db |||||
QY 841 ACAAAGGGAACACTGAGTGTGAGCTCAGAGTCCCTCAGCAGAAATTCAGTGTA 900
Db |||||
QY 841 ACAAAGGGAACACTGAGTGTGAGCTCAGAGTCCCTCAGCAGAAATTCAGTGTA 900
Db |||||
QY 901 CAAGGATGACAAAGACTGATTTGAAGGAAAGAGGGGTGAAAGTGGAAACAGACCTTT 960
Db |||||
QY 901 CAAGGATGACAAAGACTGATTTGAAGGAAAGAGGGGTGAAAGTGGAAACAGACCTTT 960
Db |||||
QY 961 CCTCTCAAACTCATCTTCTCAATGTCTGACATGACTATGGGAACTACACTTGGCT 1020
Db |||||
QY 961 CCTCTCAAACTCATCTTCTCAATGTCTGACATGACTATGGGAACTACACTTGGCT 1020
Db |||||
QY 1021 GGCCTCAAAAGCTGGGCAACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCCGT 1080
Db |||||
QY 1021 GGCCTCAAAAGCTGGGCAACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCCGT 1080
Db |||||
QY 1081 CAGGAGGTGAGCAACCGCAGCTGAGAGGGGAGGCTGTGCTGTGCTGCTCTTCT 1140
Db |||||
QY 1081 CAGGAGGTGAGCAACCGCAGCTGAGAGGGGAGGCTGTGCTGTGCTGCTCTTCT 1140
Db |||||
QY 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTAGTGCCTTCCCAACCGGGAAGGCT 1200
Db |||||
QY 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTAGTGCCTTCCCAACCGGGAAGGCT 1200
Db |||||
QY 1201 GCCGCCACCAACCAACCAACCAAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
Db |||||
QY 1201 GCCGCCACCAACCAACCAACCAAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
Db |||||
QY 1261 TATCAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
Db |||||
QY 1261 TATCAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
Db |||||
QY 1321 AAAGAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db |||||
QY 1321 AAAGAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db |||||
QY 1381 TTTAGGTACATGGAGTTTCTTTTCCCAACGGGAAGAACACAGCACACCCGCTTGA 1440
Db |||||
QY 1381 TTTAGGTACATGGAGTTTCTTTTCCCAACGGGAAGAACACAGCACACCCGCTTGA 1440
Db |||||
QY 1441 CCCACTGCAAGCTGATCGTCAACCTTTTGGTGCCAGTGTGGGCAAGGCTCAGCCTC 1500
Db |||||
QY 1441 CCCACTGCAAGCTGATCGTCAACCTTTTGGTGCCAGTGTGGGCAAGGCTCAGCCTC 1500
Db |||||
QY 1501 TCTGCCACAGAGTGCCTCCCAAGTGGACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Db |||||
QY 1501 TCTGCCACAGAGTGCCTCCCAAGTGGACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Db |||||

QY 1561 GTCCATAGACGAAACAGAAATGAGACTTCCGGCCCAAGCGTGGCGCTGCGGCACCTTG 1620
Db |||||
QY 1561 GTCCATAGACGAAACAGAAATGAGACTTCCGGCCCAAGCGTGGCGCTGCGGCACCTTG 1620
Db |||||
QY 1621 GTAGACTGTCCACCCAGCGGTGTGTGTAACGTGAAATTAAGAGAGCAAAAAA 1679
Db |||||
QY 1621 GTAGACTGTCCACCCAGCGGTGTGTGTAACGTGAAATTAAGAGAGCAAAAAA 1679
Db |||||

RESULT 38

ADCS0416
ID ADCS0416 standard; cDNA; 1679 BP.
XX
AC ADCS0416;
XX
DT 18-DEC-2003 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO337 cDNA.
XX
XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;
transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
rectum; kidney; cervix; liver; microvascular endothelial cell;
glucose uptake modulator; FFA uptake modulator; cell proliferation;
cell differentiation; skeletal muscle cell; adipocyte cell;
pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
immune system cell infiltration; chromosome mapping; gene mapping;
gene therapy; chromosome identification; chromosome marker; Gene; ss.
XX Homo sapiens.
XX US2003092106-A1.
XX
XX 15-MAY-2003.
XX
XX 24-APR-2002; 2002US-00131822.
XX
XX 19-AUG-1998; 98US-0097141P.
XX 02-JUN-1999; 99WO-US012252.
XX 25-AUG-1999; 99US-00380137.
XX 30-MAR-2000; 2000WO-US008439.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX
XX WPI; 2003-801171/75.
XX P-PSDB; ADCS0417.
XX
XX New secreted and transmembrane nucleic acid useful for treating
inflammation, organ failure, atherosclerosis, cardiac injury,
infertility, birth defects, premature aging, acquired immunodeficiency
syndrome or cancer.
XX
XX Claim 2; Fig 375; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating

antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells, for T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6.7e-05; Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	GTTGTGTCCTTCAGCAAAACAGTGGATTTAAATCTCTTTGCAAAAGCTTGAGAGCAACAC	60
DB	1	GTTGTGTCCTTCAGCAAAACAGTGGATTTAAATCTCTTTGCAAAAGCTTGAGAGCAACAC	60
QY	61	AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
DB	61	AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
QY	121	AAGAAAAAATCATGAAACCATCCAGCCAAAAATGCACAAATTCATCTCTTGGGCAAT	180
DB	121	AAGAAAAAATCATGAAACCATCCAGCCAAAAATGCACAAATTCATCTCTTGGGCAAT	180
QY	181	CTTCAAGGGCTGGTCTGTCTGTCTTCCAGGAGTCCCGTGGCGAGGAGATGC	240
DB	181	CTTCAAGGGCTGGTCTGTCTGTCTTCCAGGAGTCCCGTGGCGAGGAGATGC	240
QY	241	CACCTTCCCAAGCTATGACAAAGTGCAGTCCGCGAGGGGAGGCGGCGCACCCCTCAG	300
DB	241	CACCTTCCCAAGCTATGACAAAGTGCAGTCCGCGAGGGGAGGCGGCGCACCCCTCAG	300
QY	301	GTGCATATTGACAAACCGGTCAACCGGGTGGCTGGCTTAAACCGCAGCAACATCTCTTA	360
DB	301	GTGCATATTGACAAACCGGTCAACCGGGTGGCTGGCTTAAACCGCAGCAACATCTCTTA	360
QY	361	TGCTGGGAATGACAGTGGTGGCTGGATCTCCGCTGGTCTTCTCAGCAACACCCAAAC	420
DB	361	TGCTGGGAATGACAGTGGTGGCTGGATCTCCGCTGGTCTTCTCAGCAACACCCAAAC	420
QY	421	GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACAGGGCCCTTACACCTGCTC	480
DB	421	GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACAGGGCCCTTACACCTGCTC	480
QY	481	GTTGTCAGACAGCAACCAACCAAGACCTCTAGGTCCTCCTCATTTGTCAGATCTCC	540
DB	481	GTTGTCAGACAGCAACCAACCAAGACCTCTAGGTCCTCCTCATTTGTCAGATCTCC	540
QY	541	CAAAATTTGTAGATTTCTTTTCAGATATCTCATTAAATGAAGGGAACAATATTAGCCTAC	600
DB	541	CAAAATTTGTAGATTTCTTTTCAGATATCTCATTAAATGAAGGGAACAATATTAGCCTAC	600
QY	601	CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTTGGAGACATCTCTCCCAAGC	660
DB	601	CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTTGGAGACATCTCTCCCAAGC	660

RESULT 39
ADC71963
ID ADC71963

standard; cDNA; 1679 BP.

Db 781 GGTCACTGAACTATCCACCATACATTTTCAAGAACCAAGGTACAGGTGTCCCGTGGG 840
Qy 841 ACAAAGGGGACATGAGTGTGAGCTCAGCAGTCCCTCAGCAGATTCAGTGGTA 900
Db 841 ACAAAGGGGACATGAGTGTGAGCTCAGCAGTCCCTCAGCAGATTCAGTGGTA 900
Qy 901 CAAGGATGACAAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
Db 901 CAAGGATGACAAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
Qy 961 CTTCTCAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAACATACCTTGGT 1020
Db 961 CTTCTCAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAACATACCTTGGT 1020
Qy 1021 GGCCTTCAAAAGCTGGGCGCACCAATGCGCAGATCATGCTATTTGGTCCAGCGCGGT 1080
Db 1021 GGCCTTCAAAAGCTGGGCGCACCAATGCGCAGATCATGCTATTTGGTCCAGCGCGGT 1080
Qy 1081 CAGCAGGTGAGCAACGGCAGCGTGCAGGAGGGCAGGCTGGCTGTCTTCTTCTTCT 1140
Db 1081 CAGCAGGTGAGCAACGGCAGCGTGCAGGAGGGCAGGCTGGCTGTCTTCTTCTTCT 1140
Qy 1141 GGTCTTGCACCTTCTTCTTCAATTTTGAATGAGTGGCAGTATTTGGTCCAGCGCGGT 1200
Db 1141 GGTCTTGCACCTTCTTCTTCAATTTTGAATGAGTGGCAGTATTTGGTCCAGCGCGGT 1200
Qy 1201 GCGGCGCACCCACCAACCAACAGCAATGCGCAACACCGACAGCAACCAATCAGATA 1260
Db 1201 GCGGCGCACCCACCAACCAACAGCAATGCGCAACACCGACAGCAACCAATCAGATA 1260
Qy 1261 TATACAAATGAAATTTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAA 1320
Db 1261 TATACAAATGAAATTTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAA 1320
Qy 1321 AAAGAATACTTTGGGGGGAAGAGTTTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAAGAATACTTTGGGGGGAAGAGTTTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Qy 1381 TTTAGTCAATTTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAG 1440
Db 1381 TTTAGTCAATTTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAG 1440
Qy 1441 CCCTGCAAGTGCATCTGCAACCTCTTTGGTCCAGTGTGGCAGAGGGCTCAGCCTC 1500
Db 1441 CCCTGCAAGTGCATCTGCAACCTCTTTGGTCCAGTGTGGCAGAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGCCTCCACAGTGCATCTTGGAGTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCACAGTGCATCTTGGAGTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGAGCAACAGAAATGAGACTTCCGGGCGGAGCGTGGCGGCACTTTG 1620
Db 1561 GTCCATAGAGAGCAACAGAAATGAGACTTCCGGGCGGAGCGTGGCGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACCGCGGTGTGTGTAAGAAAGTGAATTAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACCGCGGTGTGTGTAAGAAAGTGAATTAAGAGCAAAAAA 1679

RESULT 40
ADC59942
ID ADC59942 standard; cDNA; 1679 BP.

XX AC ADC59942;
XX AC ADC59942;
DT 18-DEC-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO337 cDNA.

XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;
XX transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;

KW Glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
OS Homo sapiens.
XX US2003092105-A1.
DN 15-MAY-2003.
XX 24-APR-2002; 2002US-00131821.
XX 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000NO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX WPI; 2003-801170/75.
DR P-PSDB; ADC59943.
XX New secreted and transmembrane nucleic acids and polypeptides, designated
as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX Claim 2; Fig 375; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, or stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match				100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity				100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative				0; Mismatches 0; Indels 0; Gaps 0;
QY	1	GTGTGTCTTTCAGCAAAACAGTGGATTAAATCTCTTGCAAGCTTGAGAGCAAC	60	
DB	1	GTGTGTCTTTCAGCAAAACAGTGGATTAAATCTCTTGCAAGCTTGAGAGCAAC	60	
QY	61	AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120	
DB	61	AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120	
QY	121	AAGAAAAAATCATGAAAAATCCAGCCAAATGCAAAATCTCTTTGGGCAAT	180	
DB	121	AAGAAAAAATCATGAAAAATCCAGCCAAATGCAAAATCTCTTTGGGCAAT	180	
QY	181	CTTACGGGGTGGCTGTCTGTCTCTTCCAGAGAGTGCCCTGCGCAGCGAGATGC	240	
DB	181	CTTACGGGGTGGCTGTCTGTCTCTTCCAGAGAGTGCCCTGCGCAGCGAGATGC	240	
QY	241	CACCTTCCCAAAAGCTATGGAACAAGTGCAGCGTCCGGCAGGGGAGAGCGCCACCTCAG	300	
DB	241	CACCTTCCCAAAAGCTATGGAACAAGTGCAGCGTCCGGCAGGGGAGAGCGCCACCTCAG	300	
QY	301	GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTCTGAGCAACACCCAAAC	360	
DB	301	GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTCTGAGCAACACCCAAAC	360	
QY	361	TGCTGGGAATGCAAGTGGTGGCTGGATCTCTGGGTGGTCTCTGAGCAACACCCAAAC	420	
DB	361	TGCTGGGAATGCAAGTGGTGGCTGGATCTCTGGGTGGTCTCTGAGCAACACCCAAAC	420	
QY	421	GCAGTACAGATCGAGATCCAGAGCGTGGATGTGTATGAAGAGGGCCCTTACCTGCTC	480	
DB	421	GCAGTACAGATCGAGATCCAGAGCGTGGATGTGTATGAAGAGGGCCCTTACCTGCTC	480	
QY	481	GCTGACAGACAAACCAACCGCTTACGGTCCACCTCATTTGCAAGTATCTCC	540	
DB	481	GCTGACAGACAAACCAACCGCTTACGGTCCACCTCATTTGCAAGTATCTCC	540	
QY	541	CAAAATTTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAAATTTAGCTTAC	600	
DB	541	CAAAATTTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAAATTTAGCTTAC	600	
QY	601	CTGCATAGCAACTGGTAGACAGAGCTTACGGTTACTTTGGAGACACATCTCTCCCAAGC	660	
DB	601	CTGCATAGCAACTGGTAGACAGAGCTTACGGTTACTTTGGAGACACATCTCTCCCAAGC	660	
QY	661	GTTGGCTTTGTGAGTGAAGACGAATACCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720	
DB	661	GTTGGCTTTGTGAGTGAAGACGAATACCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720	
QY	721	AGGGGACTACGAGTGCAGTGCCTCCATGAGCTGGCGCGCCGTGGTAGAGAGTAAA	780	
DB	721	AGGGGACTACGAGTGCAGTGCCTCCATGAGCTGGCGCGCCGTGGTAGAGAGTAAA	780	
QY	781	GGTCAACCGTGAATATCACCATATCTTCAAGAACCAAGGTTACAGGTGTCCTCCGTTGG	840	
DB	781	GGTCAACCGTGAATATCACCATATCTTCAAGAACCAAGGTTACAGGTGTCCTCCGTTGG	840	
QY	841	ACAAAGGGGACCTGCGAGTGTGAGCTTCCAGAGTCCCTCAGCAGAAATTCAGTGGTA	900	
DB	841	ACAAAGGGGACCTGCGAGTGTGAGCTTCCAGAGTCCCTCAGCAGAAATTCAGTGGTA	900	
QY	901	CAAGGATCAAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT	960	
DB	901	CAAGGATCAAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT	960	
QY	961	CCTCTCAAACTCATCTTCTTCAATGTCTTGACATGATCTATGGAACTACACTTCGGT	1020	
DB	961	CCTCTCAAACTCATCTTCTTCAATGTCTTGACATGATCTATGGAACTACACTTCGGT	1020	
QY	1021	GGCTCTCAAAAGTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGCGCGCT	1080	

DB	1021	GGCTCTCAAAAGTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGCGCGCT	1080	
QY	1081	CAGCAGGTGAGCAACGGCAAGTGCAGAGGGCAGGCTGCGTCTGGCTCTTCT	1140	
DB	1081	CAGCAGGTGAGCAACGGCAAGTGCAGAGGGCAGGCTGCGTCTGGCTCTTCT	1140	
QY	1141	GCTCTTGACACCTGCTTCTCAAAATTTGATGTGAGTGCACCTTCCCGCCGGGAAGGCT	1200	
DB	1141	GCTCTTGACACCTGCTTCTCAAAATTTGATGTGAGTGCACCTTCCCGCCGGGAAGGCT	1200	
QY	1201	GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA	1260	
DB	1201	GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA	1260	
QY	1261	TATACAAATGAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAAC	1320	
DB	1261	TATACAAATGAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAAC	1320	
QY	1321	AAAGAATATCTTTGGGGGAAAGAGTGTAAAAAAGAAATTTGAAATTTGCCTTGCAGATA	1380	
DB	1321	AAAGAATATCTTTGGGGGAAAGAGTGTAAAAAAGAAATTTGAAATTTGCCTTGCAGATA	1380	
QY	1381	TTTAGGTACAAATGGAGTTTCTTTTCCCAAGGGGAAACACAGCACACCGCGCTTGA	1440	
DB	1381	TTTAGGTACAAATGGAGTTTCTTTTCCCAAGGGGAAACACAGCACACCGCGCTTGA	1440	
QY	1441	CCCACTGCAAGTGCATGTCACACCTCTTTGGTSCCAAGTGTGGCAAGGCTCAGCCTC	1500	
DB	1441	CCCACTGCAAGTGCATGTCACACCTCTTTGGTSCCAAGTGTGGCAAGGCTCAGCCTC	1500	
QY	1501	TCCTGCCACAGAGTGCCTCCACAGTGTGGAGACATCTGGAGCTGGCCATCCCAATTCATCA	1560	
DB	1501	TCCTGCCACAGAGTGCCTCCACAGTGTGGAGACATCTGGAGCTGGCCATCCCAATTCATCA	1560	
QY	1561	GTCCATAGAGACGAACAGATGAGACCTTCGGGCCCAAGCGTGGCGCTGCGGCACTTTG	1620	
DB	1561	GTCCATAGAGACGAACAGATGAGACCTTCGGGCCCAAGCGTGGCGCTGCGGCACTTTG	1620	
QY	1621	GTAGACTGTGCCACCAAGCGCTGTGTGTAACCTGTAATTAATAAGAGCAAAAAA	1679	
DB	1621	GTAGACTGTGCCACCAAGCGCTGTGTGTAACCTGTAATTAATAAGAGCAAAAAA	1679	

RESULT 41
ADC49875
ID ADC49875 standard; cDNA; 1679 BP.
XX
AC ADC49875;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
XX
OS Homo sapiens.
XX
PN US2003088064-A1.
XX
PD 08-MAY-2003.
XX
PF 14-AUG-2002; 2002US-00219075.
XX
PR 25-JUL-2000; 2000US-0220605P.

PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WL;
XX WPI; 2003-801154/75.
DR P-PSDB; ADC49876.
XX
XX New secreted and transmembrane PRO polypeptide useful for preparing a
PT medicament for treating a condition that is responsive to the PRO
PT polypeptide or anti-PRO antibody, e.g. cancer.
XX
XX Claim 2; SEQ ID NO 125; 314pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (i). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblast cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTGTGCTCTTCAGCAAAACAGTGGATTTAAATCTCTTGGCAAGCTTGAGAGCAAC 60
DB 1 GTGTGCTCTTCAGCAAAACAGTGGATTTAAATCTCTTGGCAAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAGAAACCATCGCCAAATATGCAATTTCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAGAAACCATCGCCAAATATGCAATTTCTCTTGGGCAAT 180
QY 181 CTTACGGGGCTGGCTGCTGCTGCTCTCTTCCAAGAGAGTCCCGTGGCAGCGGAGATGC 240

DB 181 CTTACGGGGCTGGCTGCTGCTGCTCTCTTCCAAGAGAGTCCCGTGGCAGCGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGAACAAAGTACGGTCCGGAGGGGAGAGCGCCACCTCTAG 300
DB 241 CACCTTCCCAAGCTATGGAACAAAGTACGGTCCGGAGGGGAGAGCGCCACCTCTAG 300
QY 301 GTGCACATATTGACAAACCGGGTCCACCGGGTGGCTGGCTAAACCGGAGACCATCTCTA 360
DB 301 GTGCACATATTGACAAACCGGGTCCACCGGGTGGCTGGCTAAACCGGAGACCATCTCTA 360
QY 361 TGTGGGAATGACAAAGTGGTCTGATCTCCGGTGGTCTCTTCTGAGCAACACCAAAAC 420
DB 361 TGTGGGAATGACAAAGTGGTCTGATCTCCGGTGGTCTCTTCTGAGCAACACCAAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAAACGTGGATGATGACGAGCGGCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAAACGTGGATGATGACGAGCGGCTTACACCTGCTC 480
QY 481 GGTGCAGACAGCAACACCAAGAGCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGCAGACAGCAACACCAAGAGCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTC 600
DB 541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTC 600
QY 601 CTGCATAGCAACCTGGTAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCCAAAGC 660
DB 601 CTGCATAGCAACCTGGTAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCCAAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCGGAGAGTGC 720
DB 661 GGTGGCTTTGTGAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCGGAGAGTGC 720
QY 721 AGGGGACTAGCAGTGCAGTGCCTCCATGACGTGGCGCGCGCGCGCGCGCGCGCGTAAA 780
DB 721 AGGGGACTAGCAGTGCAGTGCCTCCATGACGTGGCGCGCGCGCGCGCGCGCGTAAA 780
QY 781 GGTCCAGTGAATTCACCATACATATTCAGAAAGCAAGGGTACAGGTGTCCTCCGTGGG 840
DB 781 GGTCCAGTGAATTCACCATACATATTCAGAAAGCAAGGGTACAGGTGTCCTCCGTGGG 840
QY 841 ACAAAGGGGACACTGCAAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGGTGTA 900
DB 841 ACAAAGGGGACACTGCAAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGGTGTA 900
QY 901 CAAGGATGACAAAGACTGATTGAAGAAAGAGAGGGGTGAAGTGGAAGAAAGACCTTT 960
DB 901 CAAGGATGACAAAGACTGATTGAAGAAAGAGAGGGGTGAAGTGGAAGAAAGACCTTT 960
QY 961 CTTCTAAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGAACTACACTTGGCT 1020
DB 961 CTTCTAAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGAACTACACTTGGCT 1020
QY 1021 GGCTTCAACAAAGCTGGGCCACCAATGCGAGCATCATGCTATTTGGTCCAGGCGCGCT 1080
DB 1021 GGCTTCAACAAAGCTGGGCCACCAATGCGAGCATCATGCTATTTGGTCCAGGCGCGCT 1080
QY 1081 CAGGAGGTGAGCAACGGGACGCTCGAGGGGAGGGTGGCTGGCTGGCTGGCTGGCTTCT 1140
DB 1081 CAGGAGGTGAGCAACGGGACGCTCGAGGGGAGGGTGGCTGGCTGGCTGGCTGGCTTCT 1140
QY 1141 GGTCTTGCACCTCTTCTCAAAATTTTGTGATGAGTGAGTGCCACTTCCCAACCGGAAAGGCT 1200
DB 1141 GGTCTTGCACCTCTTCTCAAAATTTTGTGATGAGTGAGTGCCACTTCCCAACCGGAAAGGCT 1200
QY 1201 GCGGCCACACCAACCAACCAACAGCAAGCAATGGCAACCGGAGCAACCAATCAGATA 1260
DB 1201 GCGGCCACACCAACCAACCAACAGCAAGCAATGGCAACCGGAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATTGGGACAGAAATTTGAGGGAGGGAAC 1320

Db 1261 TATCAATGAAATTAGAGAAACACACAGCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320
Qy 1321 AAAGAAATACCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCTTTGCAGATA 1380
Db 1321 AAAGAAATACCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCTTTGCAGATA 1380
Qy 1381 TTTAGGTACAAATGAGTTTCTTTCCCAACGGGAAGACACAGCACACCCGGCTTGA 1440
Db 1381 TTTAGGTACAAATGAGTTTCTTTCCCAACGGGAAGACACAGCACACCCGGCTTGA 1440
Qy 1441 CCCACTGCAAGCTGCATCGTCCAACTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGCATCGTCCAACTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGCCTCCCAAGTGGGAAACATCTTGGAGCTGSCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCCAAGTGGGAAACATCTTGGAGCTGSCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGACGAAACAGATGAGACCTTCGGGCCCAAGCGTGGCGCTGGGGCACTTTG 1620
Db 1561 GTCCATAGAGACGAAACAGATGAGACCTTCGGGCCCAAGCGTGGCGCTGGGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACACAGCGCTGTGTGTGTAACCTGAAATATAAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACACAGCGCTGTGTGTGTAACCTGAAATATAAAGAGCAAAAAA 1679

RESULT 42

ADC49074 ID ADC49074 standard; cDNA; 1679 BP.
AC ADC49074;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW chondrocyte cell differentiation; chondrocyte cell proliferation;
KW pericyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
PN US2003088070-A1.
XX
PD 08-MAY-2003.
XX
PF 28-AUG-2002; 2002US-00230260.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
DR WPI; 2003-801155/75.
DR P-FSDB; ADC49075.
XX
PT New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT in gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX
PS Claim 2; SEQ ID NO 125; 315pp; English.

CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF).
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO347, PRO337, PRO326, PRO363, PRO331, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1285, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1379, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1328, PRO3431, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO3940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO5725, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO229, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTGTGTCTCTTCAGCAACAGTGGATTTAAATCTCTTGCACAAAGCTTTGAGACCAAC 60
Db 1 GTGTGTCTCTTCAGCAACAGTGGATTTAAATCTCTTGCACAAAGCTTTGAGACCAAC 60
Qy 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAAAATCATGAAACCATCCAGCCAAATATGCAATTCATCTCTTTGGGCAAT 180
Db 121 AAGAAAAAATCATGAAACCATCCAGCCAAATATGCAATTCATCTCTTTGGGCAAT 180
Qy 181 CTTTCAGGGGCTGGCTGTCTGTGTCTCTTCCAAAGAGTGGCCGTCGACGAGATGC 240
Db 181 CTTTCAGGGGCTGGCTGTCTGTGTCTCTTCCAAAGAGTGGCCGTCGACGAGATGC 240
Qy 241 CACCTTCCCAAGCTATGGAACAGCTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
Db 241 CACCTTCCCAAGCTATGGAACAGCTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
Qy 301 GTGCACTATTGCAACACCGGGTCAACCCGGTGGCTGTGCTTAAACCGCAGCACCCTCTA 360
Db 301 GTGCACTATTGCAACACCGGGTCAACCCGGTGGCTGTGCTTAAACCGCAGCACCCTCTA 360
Qy 361 TCTCGGAATGCAAGTGTGCTGGATCTCTCGGTGTCTCTTGTGAGCAACCCCAAC 420
Db 361 TCTCGGAATGCAAGTGTGCTGGATCTCTCGGTGTCTCTTGTGAGCAACCCCAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGAAAGCTGGATGTGTATCAGAGGGCCCTTACACTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAAAGCTGGATGTGTATCAGAGGGCCCTTACACTGCTC 480

QY 481 GGTGACAGACAGCAACCAACCAAGACCTCTAGGCTCCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGACAGACAGCAACCAACCAAGACCTCTAGGCTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
Db 541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGCATACCACTGCTGACAGACGCTTACGTTTACTTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCATACCACTGCTGACAGACGCTTACGTTTACTTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Db 661 GGTGGCTTTGTGAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTCTCCATGAGTGGCGCGCTGTGAGGAGGAGTAA 780
Db 721 AGGGGACTACGAGTGCAGTCTCCATGAGTGGCGCGCTGTGAGGAGGAGTAA 780
QY 781 GGTCACTGCACTATCCACCATATATTCAGAAATTCAGGGCATCACCCGGGAGCAGTC 840
Db 781 GGTCACTGCACTATCCACCATATATTCAGAAATTCAGGGCATCACCCGGGAGCAGTC 840
QY 841 ACAAAGGGGACACTGCACTGAGTGAAGCTTACGAGTCCCTCAGCAGATTCAGTGGTA 900
Db 841 ACAAAGGGGACACTGCACTGAGTGAAGCTTACGAGTCCCTCAGCAGATTCAGTGGTA 900
QY 901 CAAAGATGCAAAAGACTGATTGAAGGAAAGAGGGGTGAAGTGGAAACACAGACCTTT 960
Db 901 CAAAGATGCAAAAGACTGATTGAAGGAAAGAGGGGTGAAGTGGAAACACAGACCTTT 960
QY 961 CCTCTCAAACTCATCTTCTTCAATGTCTGTAACATGACTATGGGAACACTACCTTGGT 1020
Db 961 CCTCTCAAACTCATCTTCTTCAATGTCTGTAACATGACTATGGGAACACTACCTTGGT 1020
QY 1021 GGCCTCCAAAGCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1080
Db 1021 GGCCTCCAAAGCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1080
QY 1081 CAGCAGGTGAGCAACGAGCAGTGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1140
Db 1081 CAGCAGGTGAGCAACGAGCAGTGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1140
QY 1141 GGTCTTGACCTGCTTCTCAATTTTGTGAGTGGCCACTTCCACCCGGGGAAGGCT 1200
Db 1141 GGTCTTGACCTGCTTCTCAATTTTGTGAGTGGCCACTTCCACCCGGGGAAGGCT 1200
QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Db 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
QY 1261 TATACAAATGAATTTAGAGAAACACAGGCTCATGGGACAGAAATTTGAGGAGGGGAGC 1320
Db 1261 TATACAAATGAATTTAGAGAAACACAGGCTCATGGGACAGAAATTTGAGGAGGGGAGC 1320
QY 1321 AAAAGATATCTTTGGGGGAAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTTCAGATA 1380
Db 1321 AAAAGATATCTTTGGGGGAAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTTCAGATA 1380
QY 1381 TTTAGGTAATTTGAGGATTTTCTTTTCCAAACCGGGAAGAACACAGCAGACCCGGTGGG 1440
Db 1381 TTTAGGTAATTTGAGGATTTTCTTTTCCAAACCGGGAAGAACACAGCAGACCCGGTGGG 1440
QY 1441 CCCACTGCAAGTGCATCTGCAACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGTGCATCTGCAACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCCAAGTGGAAATTTCTGAGTGTGCCATTCCTCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCCAAGTGGAAATTTCTGAGTGTGCCATTCCTCAATTCATCA 1560

QY 1561 GTCCATAGACAGCAAGTGAAGTGGCGCTTCCGGCCCAACGCTGGCGCTTGGCGCACTTTG 1620
Db 1561 GTCCATAGACAGCAAGTGAAGTGGCGCTTCCGGCCCAACGCTGGCGCTTGGCGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCAACGCGCTGTGTTGTGAAACCTGAAATTAAGAGGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACCAACGCGCTGTGTTGTGAAACCTGAAATTAAGAGGCAAAAAA 1679

RESULT 43
ADC49591
ID ADC49591 standard; cDNA; 1679 BP.
XX
AC ADC49591;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;
vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
(TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
gene therapy.
XX
OS Homo sapiens.
XX
PN US2003088071-A1.
XX
PD 08-MAY-2003.
XX
PF 29-AUG-2002; 2002US-00232231.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
XX WPI: 2003-801156/75.
DR P-PSDB; ADC49592.
XX
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
in gene therapy, chromosome identification, tissue typing, or as
hybridization probes in chromosome and gene mapping.
PS Claim 2; SEQ ID NO 125; 315pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
useful for stimulating the proliferation of or gene expression in
pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
for stimulating the proliferation or differentiation of chondrocyte
cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
are useful for stimulating the release of tumour necrosis factor (TNF)-
alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1367,
PRO1897, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
stimulating the proliferation of normal human dermal fibroblasts cells.
XX PRO181, PRO329, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
XX PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
84

DE Nove

DE Novel human secreted and transmembrane protein PRO337 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation; lung tumour;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX US2003088072-A1.
XX
XX 08-MAY-2003.
XX
XX 29-AUG-2002; 2002US-00232233.
XX
XX 25-JUL-2000; 2000US-0220603P.
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX P-PSDB; ADC47453.
XX
XX WPI; 2003-801157/75.
XX
XX New PRO polypeptide for use as molecular weight markers for protein
PT electrophoresis purposes and for detecting the presence of tumor in a
PT mammal.
XX
XX Claim 2; Fig 125; 314pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO382, PRO1140, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO331, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO382, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1387, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO3431, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (ii) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (ii) encoding (i) is
CC useful for chromosome and gene mapping or gene therapy. (ii) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.

XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTCTCTTTCAGCAAAACAGTGGATTTAAATCTCTTTCGCAAGCTTGTAGAGCAAC 60
DB 1 GTTGTCTCTTTCAGCAAAACAGTGGATTTAAATCTCTTTCGCAAGCTTGTAGAGCAAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATATCATGAAAAACCAATCCAGCAAAATGCAAAATCTATCTCTTGGGCAAT 180
DB 121 AAGAAAAAATATCATGAAAAACCAATCCAGCAAAATGCAAAATCTATCTCTTGGGCAAT 180
QY 181 CTTTCAGGGGCTGGCTCTGTCTCTTCCAGGAGTGCCTGCGGAGGAGATGC 240
DB 181 CTTTCAGGGGCTGGCTCTGTCTCTTCCAGGAGTGCCTGCGGAGGAGATGC 240
QY 241 CACCTTCCCCAAAGCTATGAGCAAACTGACGGTCCGGCAGGGGAGAGGCCACCTCAG 300
DB 241 CACCTTCCCCAAAGCTATGAGCAAACTGACGGTCCGGCAGGGGAGAGGCCACCTCAG 300
QY 301 GTGCACTATTGCAACCCGGTCAACCCGGTGGCTTAAACCCGAGCAACCTCTCTA 360
DB 301 GTGCACTATTGCAACCCGGTCAACCCGGTGGCTTAAACCCGAGCAACCTCTCTA 360
QY 361 TGTGGGAATGACAAAGTGTGGTCTCTGATCCTCGCTGGTCTCTTCTGAGCAACACCAAC 420
DB 361 TGTGGGAATGACAAAGTGTGGTCTCTGATCCTCGCTGGTCTCTTCTGAGCAACACCAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACCGTGGATGTGTATGACGAGGGGCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACCGTGGATGTGTATGACGAGGGGCTTACACCTGCTC 480
QY 481 GGTGCAGACAGACACCAACCAAGACCTCTAGGCTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGCAGACAGACACCAACCAAGACCTCTAGGCTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCTCAC 600
DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCTCAC 600
QY 601 CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTTGTAGTGAAGACGAATACTTTGGAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTTGTAGTGAAGACGAATACTTTGGAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTAGGTGAGTGCCTCCATGACGTGGCGCGCGCTGCTGCGGAGAGTAAA 780
DB 721 AGGGGACTAGGTGAGTGCCTCCATGACGTGGCGCGCGCTGCTGCGGAGAGTAAA 780
QY 781 GGTCAACGCTGAATCTATCCACATACATTTTCCAGAAAGCAAGGTTACAGGTGTCCCGTGG 840
DB 781 GGTCAACGCTGAATCTATCCACATACATTTTCCAGAAAGCAAGGTTACAGGTGTCCCGTGG 840
QY 841 ACAAAAGGACACTGAGTGTGAGCTTCAAGCTTCAGAGTCCCTCAGCAAAATCCAGTGTGA 900
DB 841 ACAAAAGGACACTGAGTGTGAGCTTCAAGCTTCAGAGTCCCTCAGCAAAATCCAGTGTGA 900
QY 901 CAAGGATGACAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
DB 901 CAAGGATGACAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
QY 961 CCTCTCAAACTCATCTTCTTCAATGCTGTAACATGATATGGGACTACACTTGGCT 1020
DB 961 CCTCTCAAACTCATCTTCTTCAATGCTGTAACATGATATGGGACTACACTTGGCT

Db 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGACATGACTATGGAACATACACTTGGCT 1020
Qy 1021 GGCCTCCAAAGCTGGCCACACCAATGCCAGCATCATCTATTTGGTCCAGGCGCCGT 1080
Db 1021 GGCCTCCAAAGCTGGCCACACCAATGCCAGCATCATCTATTTGGTCCAGGCGCCGT 1080
Qy 1081 CAGCGAGGTGAGCAACGGCGAGTGGAGAGGGGAGGCTGGCTGGCTGGCTGGCTTTCT 1140
Db 1081 CAGCGAGGTGAGCAACGGCGAGTGGAGAGGGGAGGCTGGCTGGCTGGCTGGCTTTCT 1140
Qy 1141 GGTCTTGACCTGCTTCTTCAAAATTTGATGTAGTGCACCTTCCCAACCCGGGAGGAGCT 1200
Db 1141 GGTCTTGACCTGCTTCTTCAAAATTTGATGTAGTGCACCTTCCCAACCCGGGAGGAGCT 1200
Qy 1201 GCCGCGCACACACACACACACAAAGCAATGGCAACAGCAGCAGCAACCAATCAGATA 1260
Db 1201 GCCGCGCACACACACACACACAAAGCAATGGCAACAGCAGCAGCAACCAATCAGATA 1260
Qy 1261 TATCAAAATGAAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGGAAC 1320
Db 1261 TATCAAAATGAAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGGAAC 1320
Qy 1321 AAAGAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAAGAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Qy 1381 TTTAGGTACAAATGAGTTTCTTTTCCCAACGGGAGAAACACAGCAGCAGCAGCAGTGG 1440
Db 1381 TTTAGGTACAAATGAGTTTCTTTTCCCAACGGGAGAAACACAGCAGCAGCAGCAGTGG 1440
Qy 1441 CCCACTGCAAGCTGCATCGTGCACCTTTTGGTGGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGCATCGTGCACCTTTTGGTGGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGGCCACGCTGGACATCTTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGGCCACGCTGGACATCTTGGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGACGAAACAGATGAGACCTTCCGCGCCAGCGTGGCGTGGCGGCACTTTG 1620
Db 1561 GTCCATAGAGACGAAACAGATGAGACCTTCCGCGCCAGCGTGGCGTGGCGGCACTTTG 1620
Qy 1621 GTAGCTGTGCACACCGCTGTGTGTGAACGTGAATATAAAGAGCAAAAAA 1679
Db 1621 GTAGCTGTGCACACCGCTGTGTGTGAACGTGAATATAAAGAGCAAAAAA 1679

RESULT 45
ADC52949
ID ADC52949 standard; cDNA; 1679 BP.
AC ADC52949;
XX
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein cDNA Seq ID375.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuroptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
XX Homo sapiens.
XX
PN US2003087365-A1.
XX
XX 08-MAY-2003.
PD
PF 23-APR-2002; 2002US-00128689.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1999; 98WO-US012456.

PR 14-JUL-1998; 99WO-US014552.
PR 28-AUG-1998; 99WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004344.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006620.
PR 09-MAR-2001; 2001US-00802706.

Db	601	CTGCATAGCAACTGGTATAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCCAAAGC	660
Qy	661	GGTTGGCTTTGTGAGTGAAGACGAATACTTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720
Db	661	GGTTGGCTTTGTGAGTGAAGACGAATACTTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720
Qy	721	AGGGGACTACGAGTGCAGTGCCTCCATGAGCTGGCGCGCCCGTGGTATGGAGAGTAAA	780
Db	721	AGGGGACTACGAGTGCAGTGCCTCCATGAGCTGGCGCGCCCGTGGTATGGAGAGTAAA	780
Qy	781	GGTCACCGTGAACCTATCCACATACATTTTCTGAGAGCCAAAGGTATCAGGTGTCCCCGTGGG	840
Db	781	GGTCACCGTGAACCTATCCACATACATTTTCTGAGAGCCAAAGGTATCAGGTGTCCCCGTGGG	840
Qy	841	ACAAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
Db	841	ACAAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
Qy	901	CAAGGATGACAAAAAGACTGATTGAAGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT	960
Db	901	CAAGGATGACAAAAGACTGATTGAAGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT	960
Qy	961	CCTCTCAAACTCATCTTTCTTCAATGTCTGTGAACATGACTATGGAACTACACTTCGCT	1020
Db	961	CCTCTCAAACTCATCTTTCTTCAATGTCTGTGAACATGACTATGGAACTACACTTCGCT	1020
Qy	1021	GGCCTCCAAAGCTGGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGCGCCGT	1080
Db	1021	GGCCTCCAAAGCTGGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGCGCCGT	1080
Qy	1081	CAGCGAGTGAACCAACCGCACGCTCGAGGAGGGCAGGTGCGTGTGGCTGTGCTCTTCT	1140
Db	1081	CAGCGAGTGAACCAACCGCACGCTCGAGGAGGGCAGGTGCGTGTGGCTGTGCTCTTCT	1140
Qy	1141	GGTCTTGCACTGCTTCTCAAATTTTCATGTGAGTGCACCTTCCACACCCGGGAAAGGCT	1200
Db	1141	GGTCTTGCACTGCTTCTCAAATTTTCATGTGAGTGCACCTTCCACACCCGGGAAAGGCT	1200
Qy	1201	GCCGCCACCAACCAACCAACAGCAATGSCAACACCGACAGCAACCAATCAGATA	1260
Db	1201	GCCGCCACCAACCAACCAACAGCAATGSCAACACCGACAGCAACCAATCAGATA	1260
Qy	1261	TATCAAAATGAAATTTGAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAAC	1320
Db	1261	TATCAAAATGAAATTTGAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAAC	1320
Qy	1321	AAAGAAATCTTTGGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCTTTCAGATA	1380
Db	1321	AAAGAAATCTTTGGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCTTTCAGATA	1380
Qy	1381	TTTAGGTACAAATGAGTTTCTTTTTTCCAAACGGGAGAAACACAGCACCCCGCTTGGAA	1440
Db	1381	TTTAGGTACAAATGAGTTTCTTTTTTCCAAACGGGAGAAACACAGCACCCCGCTTGGAA	1440
Qy	1441	CCCACTGCAAGCTGCATCGTGCAACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC	1500
Db	1441	CCCACTGCAAGCTGCATCGTGCAACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC	1500
Qy	1501	TCTGCCACAGAGTGCCTCCACGTGGAACATTTCTGGAGCTGGCCATCCCAAAATCAATCA	1560
Db	1501	TCTGCCACAGAGTGCCTCCACGTGGAACATTTCTGGAGCTGGCCATCCCAAAATCAATCA	1560
Qy	1561	GTCCATAGAGACGAACAGAAATGACACTTCCGGGCCCAAGCGTGGCGCTGGGGCAGCTTGT	1620
Db	1561	GTCCATAGAGACGAACAGAAATGACACTTCCGGGCCCAAGCGTGGCGCTGGGGCAGCTTGT	1620
Qy	1621	GTAGACTGTGCCACCAACGGCGTGTGTTGTGAACAGTGAATTAATAAGAGCAAAAAAAA	1679
Db	1621	GTAGACTGTGCCACCAACGGCGTGTGTTGTGAACAGTGAATTAATAAGAGCAAAAAAAA	1679

RESULT 47

AD	C60494	
ID	ADC60494 standard; cDNA; 1679 BP.	
XX		
AC	ADC60494;	
XX		
DT	18-DEC-2003 (first entry)	
XX		
DE	Novel human secreted and transmembrane protein PRO337 cDNA.	
XX		
KW	Human; secreted and transmembrane protein; PRO; secreted polypeptide;	
KW	transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;	
KW	chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;	
KW	rectum; kidney; cervix; liver; microvascular endothelial cell;	
KW	glucose uptake modulator; FFA uptake modulator; cell proliferation;	
KW	cell differentiation; skeletal muscle cell; adipocyte cell;	
KW	pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell	
KW	endothelial cell tube formation; bone disorder; cartilage disorder;	
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis	
KW	rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;	
KW	immune system cell infiltration; chromosome mapping; gene mapping;	
KW	gene therapy; chromosome identification; chromosome marker; gene; ss.	
XX		
OS	Homo sapiens.	

ADC60494

```
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US0003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUN-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030358.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00736498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-801152/75.
XX P-PSDB; ADC60495.
XX
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
XX and for manufacturing a medicament for diagnosing or treating tumor.
XX
XX Claim 2; Fig 375; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
```

```
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
```

```
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTCGACAAAGCTTGAGAGCAAC 60
DB 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTCGACAAAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAAACCGAACCTTGACAAAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAAACCGAACCTTGACAAAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAACCATCCAGCAAAAAATGCACAAATTCATCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAACCATCCAGCAAAAAATGCACAAATTCATCTCTTGGGCAAT 180
QY 181 CTTACGGGGCTGGCTGCTCTGTGTCTTTCAGAGAGTGCCCGTCGCGAGAGATGC 240
DB 181 CTTACGGGGCTGGCTGCTCTGTGTCTTTCAGAGAGTGCCCGTCGCGAGAGATGC 240
QY 241 CACCTTCCCAAAGCTATGGACAACGTCACGTCGCGAGGGGAGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAAGCTATGGACAACGTCACGTCGCGAGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCATATTGACAAACCGGGTCACCCGGGTGGCTGCTAAACCGCAGACCAATCCTCTA 360
DB 301 GTGCATATTGACAAACCGGGTCACCCGGGTGGCTGCTAAACCGCAGACCAATCCTCTA 360
QY 361 TCGTGGGAATGACAAAGTGGTGGCTGGATCCCTCGGTGGTCTTCTTGAGCAACACCCCAAC 420
DB 361 TCGTGGGAATGACAAAGTGGTGGCTGGATCCCTCGGTGGTCTTCTTGAGCAACACCCCAAC 420
QY 421 GCAGTACAGATCGAGATCCAGAACGTCGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGATCGAGATCCAGAACGTCGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGACAGACAGAACACCCCAAGACCTCTAGGGTCCACCTCATTTGCGAGTATCTCC 540
DB 481 GGTGACAGACAGAACACCCCAAGACCTCTAGGGTCCACCTCATTTGCGAGTATCTCC 540
```

541 CAAAATTGTAGAGATTCTTTCAGATATCTCCATTATTAAGGGACAAATATTAGCTCAC 600
Db CAAAATTGTAGAGATTCTTTCAGATATCTCCATTATTAAGGGACAAATATTAGCTCAC 600
601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTGGAGACACATCTCTCCAAAGC 660
Db CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTGGAGACACATCTCTCCAAAGC 660
661 GGTGGCTTTGTAGTAGAGAGAGATACCTTGAATTCAGGGCCTACCGGAGCAGTC 720
Db GGTGGCTTTGTAGTAGAGAGAGATACCTTGAATTCAGGGCCTACCGGAGCAGTC 720
721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCGCGCTGGTAGAGAGAGTAAA 780
Db AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCGCGCTGGTAGAGAGAGTAAA 780
781 GGTCAAGGTGAACTATCCACCATACATTTCAAGAGCAGAGGTACAGGTGTCCCGTGG 840
Db GGTCAAGGTGAACTATCCACCATACATTTCAAGAGCAGAGGTACAGGTGTCCCGTGG 840
841 ACAAAGGGGACACTCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGATTCAGGTGTA 900
Db ACAAAGGGGACACTCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGATTCAGGTGTA 900
901 CAAGGATGACAAAGACTGATTAAGAGAAAGAGGGGTGAAGTGGAAAAACAGACCTTT 960
Db CAAGGATGACAAAGACTGATTAAGAGAAAGAGGGGTGAAGTGGAAAAACAGACCTTT 960
961 CCTCTCAAACTCATCTTCTCAATCTCTCAATGATGATGAGTGCCTATCCACCGGAAAGGCT 1020
Db CCTCTCAAACTCATCTTCTCAATGATGATGAGTGCCTATCCACCGGAAAGGCT 1020
1021 GGCCTCCAAAGCTGGGACACCAATGCGAGCATCTGTTGTTGTCAGGCGCGCT 1080
Db GGCCTCCAAAGCTGGGACACCAATGCGAGCATCTGTTGTTGTCAGGCGCGCT 1080
1081 CAGCAGGTGAGCAACGGCAGCTGAGGAGGAGGAGGCTGGCTGCTGCTCTCTCTCT 1140
Db CAGCAGGTGAGCAACGGCAGCTGAGGAGGAGGAGGCTGGCTGCTGCTCTCTCTCT 1140
1141 GGTCTTGACCTGCTCTCTCAAAATTTGATGATGAGTGCCTATCCACCGGAAAGGCT 1200
Db GGTCTTGACCTGCTCTCTCAAAATTTGATGATGAGTGCCTATCCACCGGAAAGGCT 1200
1201 GCGCCAC 1260
Db GCGCCAC 1260
1261 TATACAAATGAAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGAGAC 1320
Db TATACAAATGAAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGAGAC 1320
1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTCGCTTGCAGATA 1380
Db AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTCGCTTGCAGATA 1380
1381 TTTAGGTACAAATGAGTTTCTTTTCCAAACGGGAAAGAACACAGACACACCGGCTTGA 1440
Db TTTAGGTACAAATGAGTTTCTTTTCCAAACGGGAAAGAACACAGACACACCGGCTTGA 1440
1441 CCACCTGCAAGTGCATCGTGAACCTCTTTGGTGCAGTGTGGGCAAGGCTCAGCCTC 1500
Db CCACCTGCAAGTGCATCGTGAACCTCTTTGGTGCAGTGTGGGCAAGGCTCAGCCTC 1500
1501 TCTGCCACACAGAGTGGCCACCTGGAACATCTTGGAGCTGGGCATCCCAATTCATCA 1560
Db TCTGCCACACAGAGTGGCCACCTGGAACATCTTGGAGCTGGGCATCCCAATTCATCA 1560
1561 GTCCATAGACGACGAAATGAGACCTTCCGCGCCACAGCGTGGCGCTGCGGCACTTTG 1620
Db GTCCATAGACGACGAAATGAGACCTTCCGCGCCACAGCGTGGCGCTGCGGCACTTTG 1620

Qy 1621 GTAGACTGTGCCACACGCGGTGTGTGTAACGTAATAAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACACGCGGTGTGTGTAACGTAATAAAGAGCAAAAAA 1679
RESULT 48
ADC50969
ID ADC50969 standard; cDNA; 1679 BP.
XX AC ADC50969;
XX DT 18-DEC-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
rectum; kidney; cervix; liver; microvascular endothelial cell;
glucose uptake modulator; FFA uptake modulator; cell proliferation;
cell differentiation; skeletal muscle cell; adipocyte cell;
pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage defect; osteoarthritis;
sports injury; proteoglycan; articular cartilage disorder; thalassaemia;
rheumatoid arthritis; haemoglobin-associated disorder; gene mapping;
immune system cell infiltration; chromosome mapping; gene mapping; ss.
gene therapy; chromosome identification; chromosome marker; gene; ss.
OS Homo sapiens.
XX US2003087361-A1.
XX PN 08-MAY-2003.
XX PD 22-APR-2002; 2002US-00127841.
XX PF 09-SEP-1998; 98US-0099536P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US02878.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX PA Baker KP, Baresini M, Deforge L, Desnovers L, Filvaroff E, Gao W;
Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-801146/75.
XX P-PSDB; ADC50970.
XX PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
and for manufacturing a medicament for diagnosing or treating tumor.
XX PS Claim 2; Fig 375; 637pp; English.
XX CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCCTTGCCACAAAGCTTGAGAGCAAC 60
DB 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCCTTGCCACAAAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
DB 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
QY 181 CTTTCAAGGGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 240
DB 181 CTTTCAAGGGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 240
QY 241 CACCTTCCCAAGCTATGGAACAAGTGAACGCTGCTGCTGCTGCTGCTGCTGCTGCTG 300
DB 241 CACCTTCCCAAGCTATGGAACAAGTGAACGCTGCTGCTGCTGCTGCTGCTGCTGCTG 300
QY 301 GTGCACTATTACAAACCGGGTCAACCGGGTGGCTGGCTGCTGCTGCTGCTGCTGCTG 360
DB 301 GTGCACTATTGCAACCGGGTCAACCGGGTGGCTGGCTGCTGCTGCTGCTGCTGCTGCT 360
QY 361 TGCTGGGAATGACAAAGTGGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 420
DB 361 TGCTGGGAATGACAAAGTGGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 420
QY 421 GCAGTACAGCATCGAGATCCAGACGCTGGATGCTGATGAGAGGGGCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGACGCTGGATGCTGATGAGAGGGGCTTACACCTGCTC 480
QY 481 GGTGAGACAGCAACCAACCAAGACCTCTAGGGTCCACTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGAGACAGCAACCAACCAAGACCTCTAGGGTCCACTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAGGGAACAAATATTAGCTTCC 600
DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAGGGAACAAATATTAGCTTCC 600
QY 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTTACTTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTTACTTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGCGAATCTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTGAGTGAAGCGAATCTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCTCTCAATGACGTGGCGCGCCCGTGGTACGAGAGTAAA 780

DB 721 AGGGGACTACGAGTGCAGTGCTCTCAATGACGTGGCGCGCCCGTGGTACGAGAGTAAA 780
QY 781 GGTACCGTGAATATCCACATATCCACATATCCACATATCCACATATCCACATATCCAC 840
DB 781 GGTACCGTGAATATCCACATATCCACATATCCACATATCCACATATCCACATATCCAC 840
QY 841 ACAAAGGGGACACTGCTGAGTGTGAAGCTCCAGAGTCCCTCAGCAGAAATTCAGAGTGA 900
DB 841 ACAAAGGGGACACTGCTGAGTGTGAAGCTCCAGAGTCCCTCAGCAGAAATTCAGAGTGA 900
QY 901 CAAGGATGACAAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
DB 901 CAAGGATGACAAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
QY 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAAACATGACTATGGAAGAACTACACTTCGCT 1020
DB 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAAACATGACTATGGAAGAACTACACTTCGCT 1020
QY 1021 GGCTTCCAAAGCTGGGCGCACACCAATGCGAGCATCATGCTATTTGGTTCAGGCGCGCT 1080
DB 1021 GGCTTCCAAAGCTGGGCGCACACCAATGCGAGCATCATGCTATTTGGTTCAGGCGCGCT 1080
QY 1081 CAGCGAGTGAAGCAACGCGACGTCGAGAGGGGAGGCTGCTGCTGCTGCTGCTGCTGCTGCT 1140
DB 1081 CAGCGAGTGAAGCAACGCGACGTCGAGAGGGGAGGCTGCTGCTGCTGCTGCTGCTGCTGCT 1140
QY 1141 GGTCTTGACCTGCTTCTTCAATTTTGTGAGTGCCACTTCCACCCCGGGGAAAGGCT 1200
DB 1141 GGTCTTGACCTGCTTCTTCAATTTTGTGAGTGCCACTTCCACCCCGGGGAAAGGCT 1200
QY 1201 GCCGCCACCCACCCACCAACACACAGCAGATGCGACACCGACAGCAACCAATCAGATA 1260
DB 1201 GCCGCCACCCACCCACCAACACACAGCAGATGCGACACCGACAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATTTAGAGAAACACACGCTCATGGGACAGAAATTTAGGGAGGGGAAAC 1320
DB 1261 TATACAAATGAATTTAGAGAAACACACGCTCATGGGACAGAAATTTAGGGAGGGGAAAC 1320
QY 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACCGGGGAAAGACACAGCAGACACCCGGCTTGA 1440
DB 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACCGGGGAAAGACACAGCAGACACCCGGCTTGA 1440
QY 1441 CCACCTGCAAGTGCATCGTCAACCTTTTGGTCCAGTGTGGGCAAGGGCTCAGGCTC 1500
DB 1441 CCACCTGCAAGTGCATCGTCAACCTTTTGGTCCAGTGTGGGCAAGGGCTCAGGCTC 1500
QY 1501 TCTGCCACAGAGTCCCCCAGCTGGAACTTCTGGAGCTGCCATCCCAATTTCAATCA 1560
DB 1501 TCTGCCACAGAGTCCCCCAGCTGGAACTTCTGGAGCTGCCATCCCAATTTCAATCA 1560
QY 1561 GTCCATAGAGAGCAAGCAAGTGAAGCTTCCGCCCAAGCGGTGGCGCTGCGGGCAGCTTTG 1620
DB 1561 GTCCATAGAGAGCAAGCAAGTGAAGCTTCCGCCCAAGCGGTGGCGCTGCGGGCAGCTTTG 1620
QY 1621 GTAGACTGTGCCACCAACCGCGCTGTGTGTAAGAGTGAATATAAGAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACCAACCGCGCTGTGTGTAAGAGTGAATATAAGAGAGCAAAAAA 1679

RESULT 49

ADC65496

ID ADC65496 standard; cDNA; 1679 BP.

XX

AC ADC65496;

XX

DT 18-DEC-2003 (first entry)

XX

DE Human PRO polynucleotide #188.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; Glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
 KW immune system cell infiltration.

XX Homo sapiens.

XX US2003087362-A1.

XX 08-MAY-2003.

XX 22-APR-2002; 2002US-00127844.

XX 05-JUN-2000; 2000US-0209832P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Deenoysers L, Filvaroff E, Gao W;
 PI Gerritsen MB, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;

XX WPI; 2003-801147/75.

XX P-PSDB; ADC55497.

XX New PRO nucleic acid, useful for manufacturing a medicament for

XX diagnosing or treating tumor.

XX Claim 2; Fig 375; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells and for treating
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match	100.0%	Score 1679;	DB 1;	Length 1679;
Best Local Similarity	100.0%	Pred. No. 6.7e-05;		
Matches 1679;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy 1	GTGTGTCCTTACGCAAAACAGTGGATTTAAATCTCTCTGTCACAAAGCTTGAGAGCAAC	60		
Db 1	GTGTGTCCTTACGCAAAACAGTGGATTTAAATCTCTCTGTCACAAAGCTTGAGAGCAAC	60		
Qy 61	AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120		
Db 61	AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120		
Qy 121	AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAAATTCATCTCTTTGGGCAAT	180		
Db 121	AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAAATTCATCTCTTTGGGCAAT	180		
Qy 181	CTTCAACGGGCTGGCTCTCTGTCTCTTCCAAAGAGTCCCGTCCGAGCGAGAGATGC	240		
Db 181	CTTCAACGGGCTGGCTCTCTGTCTCTTCCAAAGAGTCCCGTCCGAGCGAGAGATGC	240		
Qy 241	CACCTTCCCAAGCTATGGACAAACGTCAGCGTCCGAGCGGAGAGAGAGAGAGAGAG	300		
Db 241	CACCTTCCCAAGCTATGGACAAACGTCAGCGTCCGAGCGGAGAGAGAGAGAGAGAG	300		
Qy 301	GTGCACATTTGACAAACCGGCTCACCGGCTGCTGCTAAACCGGAGACCATCTCTTA	360		
Db 301	GTGCACATTTGACAAACCGGCTCACCGGCTGCTGCTAAACCGGAGACCATCTCTTA	360		
Qy 361	TGCTGGGAATGACAAAGTGGTGGCTTGGATCTCTCGTGGTCTCTCTGAGCAACACCAAC	420		
Db 361	TGCTGGGAATGACAAAGTGGTGGCTTGGATCTCTCGTGGTCTCTCTGAGCAACACCAAC	420		
Qy 421	GCAGTACAGATCGAGATCCAGAACGTCGATGTCATGACAGAGGCGCTTACACCTGCTC	480		
Db 421	GCAGTACAGATCGAGATCCAGAACGTCGATGTCATGACAGAGGCGCTTACACCTGCTC	480		
Qy 481	GGTCCAGACAGACAAACCAACCAAGACCTCTAGGCTCCACCTCATTTGTGCAAGTATCTCC	540		
Db 481	GGTCCAGACAGACAAACCAACCAAGACCTCTAGGCTCCACCTCATTTGTGCAAGTATCTCC	540		
Qy 541	CAAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAC	600		
Db 541	CAAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAC	600		
Qy 601	CTGCATAGCAACTGTGTAGACAGAGCGCTACGGTTACTTGGAGACACATCTCTCCAAAGC	660		
Db 601	CTGCATAGCAACTGTGTAGACAGAGCGCTACGGTTACTTGGAGACACATCTCTCCAAAGC	660		
Qy 661	GGTTGGCTTTGTGTAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720		
Db 661	GGTTGGCTTTGTGTAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720		
Qy 721	AGGGGACTACGAGTGCAGTGCCTCCATGACGTGGCGCGCGCTGTCAGGAGAGTAAA	780		
Db 721	AGGGGACTACGAGTGCAGTGCCTCCATGACGTGGCGCGCGCTGTCAGGAGAGTAAA	780		
Qy 781	GGTCACCGTGAACATPACCAACATACATTTCCAGAAAGCAAGGGTACAGGTGTCCCGTGGG	840		
Db 781	GGTCACCGTGAACATPACCAACATACATTTCCAGAAAGCAAGGGTACAGGTGTCCCGTGGG	840		
Qy 841	ACAAAAGGACATGACGTGTGAGGCTCAGCAGTCCCTCAGCAGCAATTCAGAGTGGTA	900		
Db 841	ACAAAAGGACATGACGTGTGAGGCTCAGCAGTCCCTCAGCAGCAATTCAGAGTGGTA	900		
Qy 901	CAAGGATGACAAAAGACATGATTGAAGGAAAGAGGGGTGAAAGTGGAAGCAACAGACCTTT	960		
Db 901	CAAGGATGACAAAAGACATGATTGAAGGAAAGAGGGGTGAAAGTGGAAGCAACAGACCTTT	960		
Qy 961	CTCTCAAAACTCATCTCTTCAATGTCTGACATGACTATGAGGAACTACACTTGGCT	1020		
Db 961	CTCTCAAAACTCATCTCTTCAATGTCTGACATGACTATGAGGAACTACACTTGGCT	1020		

1021	QY	GGCCTCCACAAAGCTTGGGCCACACCAANTGCCAGCATCATGCTATTGGTCCAGGCGCGGT	1080
1021	DB	GGCCTCAAACAAGCTGGGCCACACCAANTGCCAGCATCATGCTATTGGTCCAGGCGCGGT	1080
1081	QY	CAGCGAGGTGAGCAACCGCCACGTCGAGGAGGGCAGGCTGGGTCTGGGCTGCTGCTCTTCT	1140
1081	DB	CAGCGAGGTGAGCAACCGCCACGTCGAGGAGGGCAGGCTGGGTCTGGGCTGCTGCTCTTCT	1140
1141	QY	GGTCTTTCGACCTGCTCTCAAAATTTGATGTAGTGCCACTTCCCACCCGGGAAAGGCT	1200
1141	DB	GGTCTTTCGACCTGCTCTCAAAATTTGATGTAGTGCCACTTCCCACCCGGGAAAGGCT	1200
1201	QY	GCGCCACCAACCACCAACACACAGCAATGSCAACACCCGACAGCAACCAATCAGATA	1260
1201	DB	GCGCCACCAACCACCAACACACAGCAATGSCAACACCCGACAGCAACCAATCAGATA	1260
1261	QY	TATACAAATCAAAATTAGAACGAACACACAGCTCATGGGACAGAAATTTGAGGAGGGGAAC	1320
1261	DB	TATACAAATCAAAATTAGAACGAACACACAGCTCATGGGACAGAAATTTGAGGAGGGGAAC	1320
1321	QY	AAAGAAATACCTTTGGGGGAAAAGAGTTTTAAAAGAAAATGAAAAATGCTTGCAGATA	1380
1321	DB	AAAGAAATACCTTTGGGGGAAAAGAGTTTTAAAAGAAAATGAAAAATGCTTGCAGATA	1380
1381	QY	TTTAGGTACAAATGGAGTTTTCTTTTCCCAAACGGGAGAAACACAGCACACCCGGCTTGA	1440
1381	DB	TTTAGGTACAAATGGAGTTTTCTTTTCCCAAACGGGAGAAACACAGCACACCCGGCTTGA	1440
1441	QY	CCCACTGCAAGCTGCATGTGCAACCTCTTTGTGCCAGTGTGGGCAAGGGCTCAGGCTC	1500
1441	DB	CCCACTGCAAGCTGCATGTGCAACCTCTTTGTGCCAGTGTGGGCAAGGGCTCAGGCTC	1500
1501	QY	TCTGCCCAACAGAGTGCCCCCAACGTGGAAACATTTGAGAGCTGGGCATCCCAAAATTCATCA	1560
1501	DB	TCTGCCCAACAGAGTGCCCCCAACGTGGAAACATTTGAGAGCTGGGCATCCCAAAATTCATCA	1560
1561	QY	GTCCATAGACAGCAAGAAATGACCTTCGGGCCCAAGCGTGGCGCTCGGGCACTTTG	1620
1561	DB	GTCCATAGACAGCAAGAAATGACCTTCGGGCCCAAGCGTGGCGCTCGGGCACTTTG	1620
1621	QY	GTAGACTGTGCCACACCGGGTGTGTTGTGAAACGTGAAATAAAAAAGAGCAAAAAAAA	1679
1621	DB	GTAGACTGTGCCACACCGGGTGTGTTGTGAAACGTGAAATAAAAAAGAGCAAAAAAAA	1679

RESULT 50
ADC54594
ID ADC54594 standard; cDNA: 1679 BP.

01-DEC-2000; 2000WO-US032678.
19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Baresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-801148/75.
P-PSDB: ADC54595.

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

QY 421 GCAGTACAGCATCGATCCAGAACTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCGATCCAGAACTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGCAGACAGCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTCAGTATCTCC 540
Db 481 GGTGCAGACAGCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTCAGTATCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTTATGAAGGGAACAATATTAGCCTCAC 600
Db 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTTATGAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
Db 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGAGCAATCTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
Db 661 GGTGGCTTTGTGAGTGAAGAGCAATCTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTCCCAATGACGTGGCGCGCCCGTGGTACGGAGAGTAA 780
Db 721 AGGGGACTACGAGTGCAGTGCCTCCCAATGACGTGGCGCGCCCGTGGTACGGAGAGTAA 780
QY 781 GGTACGGTGAATCTCCACCATACATTTTCAGAGCCAAAGGTACAGGTGTCCCGTGGG 840
Db 781 GGTACGGTGAATCTCCACCATACATTTTCAGAGCCAAAGGTACAGGTGTCCCGTGGG 840
QY 841 ACAAAGGGGACACTGCGAGTGTCAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACAAAGGGGACACTGCGAGTGTCAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGGATGACAAAGACTGATGAAGAAAGGGGTGAAGTGGAAAAAGACCTTTT 960
Db 901 CAAGGATGACAAAGACTGATGAAGAAAGGGGTGAAGTGGAAAAAGACCTTTT 960
QY 961 CCTCTCAAACTCATCTTCTCAATGTCTGAACATGACTATGGAACTACACTTGGT 1020
Db 961 CCTCTCAAACTCATCTTCTCAATGTCTGAACATGACTATGGAACTACACTTGGT 1020
QY 1021 GGCTTCCAAAGCTGGGCGACCAACCAATGCCAGCATCATGCTATTTGGTCCAGGGCGCT 1080
Db 1021 GGCTTCCAAAGCTGGGCGACCAACCAATGCCAGCATCATGCTATTTGGTCCAGGGCGCT 1080
QY 1081 CAGGAGGTGACAAAGGCGACGTCGAGGAGGCGAGGCTGGCTCTGCTCTCTCTCT 1140
Db 1081 CAGGAGGTGACAAAGGCGACGTCGAGGAGGCGAGGCTGGCTCTGCTCTCTCTCTCT 1140
QY 1141 GGTCTTGCACTGCTTCTCAATTTTGTATGTGAGTGCCTTCCCAACCGGGAAAGCT 1200
Db 1141 GGTCTTGCACTGCTTCTCAATTTTGTATGTGAGTGCCTTCCCAACCGGGAAAGCT 1200
QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
Db 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
QY 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTAGGAGGGGAAAC 1320
Db 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTAGGAGGGGAAAC 1320
QY 1321 AAGAATACCTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCCCTTGCAGATA 1380
Db 1321 AAGAATACCTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCCCTTGCAGATA 1380
QY 1381 TTTAGGTACAAAGTGGTCTTTTCTTCCAAACGGGAAAGAACACAGACACCCCGCTTGA 1440
Db 1381 TTTAGGTACAAAGTGGTCTTTTCTTCCAAACGGGAAAGAACACAGACACCCCGCTTGA 1440
QY 1441 CCACCTGCAAGCTGCATCGTGCACCTCTTTTGTGTCAGGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCACCTGCAAGCTGCATCGTGCACCTCTTTTGTGTCAGGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGGCCCCACAGTGGACATCTTGGAGCTGGCCATCCCAAAATTCATCA 1560

Db 1501 TCTGCCACAGAGTGGCCCCACAGTGGACATCTTGGAGCTGGCCATCCCAAAATTCATCA 1560
QY 1561 GTCCATAGACAGCAACGAATGAGACCTTCCGCCCAAGCGTGGCGTGGCGCACTTTG 1620
Db 1561 GTCCATAGACAGCAACGAATGAGACCTTCCGCCCAAGCGTGGCGTGGCGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCGCGTGTGTGTAACGTGAAATATAAAAGAGCAAAAAAAA 1679
Db 1621 GTAGACTGTGCCACCGCGTGTGTGTAACGTGAAATATAAAAGAGCAAAAAAAA 1679
RESULT 51
ADCS3555
ID ADCS3555 standard; cDNA; 1679 BP.
XX
AC ADCS3555;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein cDNA Seq ID375.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neurotrophin; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
OS Homo sapiens.
XX
PN US2003087364-A1.
XX
PD 08-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128688.
XX
PR 09-FEB-1999; 99US-0119341P.
PR 01-DEC-1999; 99WO-US028634.
PR 01-DEC-2000; 2000WO-US032878.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerisken ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
DR WPI; 2003-801149/75.
DR P-PSDB; ADCS3555.
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 2; SEQ ID NO 375; 637pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neurotrophins or hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or

CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 GTTGTGCTCTTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAACAC 60
DB 1 GTTGTGCTCTTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAACAC 60
QY 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAAAATCCAGCCAAATGCAAAATGCAAAATGCAAAATGCAAAAT 180
DB 121 AAGAAAAAATCATGAAAAATCCAGCCAAATGCAAAATGCAAAATGCAAAATGCAAAAT 180
QY 181 CTTACGGGGTGGTGTCTGTCTCTTCCAAAGAGTGCCGTGCGGAGCGGAGATGC 240
DB 181 CTTACGGGGTGGTGTCTGTCTCTTCCAAAGAGTGCCGTGCGGAGCGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGACAAACGTGACGGTCCGGCAGGGGAGAGGCCACCTCAG 300
DB 241 CACCTTCCCAAGCTATGGACAAACGTGACGGTCCGGCAGGGGAGAGGCCACCTCAG 300
QY 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGGAGCCATCTCTCTA 360
DB 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGGAGCCATCTCTCTA 360
QY 361 TGCTGGGAATGACAAAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 420
DB 361 TGCTGGGAATGACAAAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 420
QY 421 GCAGTACAGATCGAGATCCAGAAAGTGGATGTGTATGACAGAGGGCCCTTACACCTGTC 480
DB 421 GCAGTACAGATCGAGATCCAGAAAGTGGATGTGTATGACAGAGGGCCCTTACACCTGTC 480
QY 481 GGTGACAGACAGACACCAACCAAGACCTTAGAGTCCACCTCATTGTGCAAGTATCTCC 540
DB 481 GGTGACAGACAGACACCAACCAAGACCTTAGAGTCCACCTCATTGTGCAAGTATCTCC 540
QY 541 CAAAAATTGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAAATATTAGCCTCAC 600
DB 541 CAAAAATTGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAAATATTAGCCTCAC 600
QY 601 CTGCATAGCACTGGTAGACAGGCTTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCACTGGTAGACAGGCTTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
QY 721 AGGGACTACAGTGCAGTCTCCATGAGTGGCGCCCGCTGGTAGGAGAGTAAA 780
DB 721 AGGGACTACAGTGCAGTCTCCATGAGTGGCGCCCGCTGGTAGGAGAGTAAA 780
QY 781 GGTCAACCGTGAATATCACCATACATTTCAAGAACCAAGGTACAGGTGTCCCGTGGG 840
DB 781 GGTCAACCGTGAATATCACCATACATTTCAAGAACCAAGGTACAGGTGTCCCGTGGG 840
QY 841 ACAAAGGGGACATGAGTGTGAGGCTCAGAGTCCCTCAGCAGAAATCCAGTGGA 900
DB 841 ACAAAGGGGACATGAGTGTGAGGCTCAGAGTCCCTCAGCAGAAATCCAGTGGA 900
QY 901 CAAGGATGACAAAGACATGATTGAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
DB 901 CAAGGATGACAAAGACATGATTGAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
```

RESULT 52

ADC59078

ID ADC59078 standard; cDNA; 1679 BP.

XX

AC

AC

XX

DT

18-DEC-2003 (first entry)

XX

DE

Novel human secreted and transmembrane protein cDNA Seq ID375.

XX

KW

human; PRO; membrane bound protein; membrane bound receptor;

KW

cell proliferation; cell migration; cell differentiation;

KW

mitogenic factor; survival factor; cytotoxic factor;

KW

differentiation factor; neurotrophin; hormone; cell receptor;

KW

receptor-ligand interaction; cytoskeletal; tumour; ss; gene.

XX

OS

Homo sapiens.

XX

XX

US2003087359-A1.

XX

PD

08-MAY-2003.

XX

PF

22-APR-2002; 2002US-00127834.

```

XX 17-SEP-1998; 98US-0100710P.
PR 01-SEP-1999; 99NO-US020111.
PR 18-OCT-1998; 99US-00403297.
PR 30-NOV-1999; 99NO-US028313.
PR 01-DEC-2000; 2000NO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,
PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S,
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-801144/75.
DR P-PSDB; ADC59079.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 2; SEQ ID NO 375; 637pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides or hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGTGCAAAAGCTTGAGAGCAAC 60
DB 1 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGTGCAAAAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAAAACCATCAGCCAAAAATGCACAAATCTATCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAAAACCATCAGCCAAAAATGCACAAATCTATCTCTTGGGCAAT 180
QY 181 CTTTCAGGGGCTGGTGTCTGTCTGTCTCTTCAAGAGTGCCCGTGCAGCGAGATGC 240
DB 181 CTTTCAGGGGCTGGTGTCTGTCTGTCTCTTCAAGAGTGCCCGTGCAGCGAGATGC 240
QY 241 CACCTTCCCAAGCTATGACAAAGTACGGTCCGGCAGGGGGAGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAGCTATGACAAAGTACGGTCCGGCAGGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCATATTGACAAACCGGGTCCCGGGTGGCTGGCTAAACCCGACGACCATCTCTTA 360
DB 301 GTGCATATTGACAAACCGGGTCCCGGGTGGCTGGCTAAACCCGACGACCATCTCTTA 360

```

```

QY 361 TGCTGGGAATGACAAGTGGTGCTCGATCCTCGCTGGTCTCTTCTGAGCAACACCCAAAC 420
DB 361 TGCTGGGAATGACAAGTGGTGCTCGATCCTCGCTGGTCTCTTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGCGACAGACAACCCCAAGACCTCTAGGTTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGCGACAGACAACCCCAAGACCTCTAGGTTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGTGTAGACAGAGCTTACGTTACTTTGGAGACACATCTCTCCAAAGC 660
DB 601 CTGCATAGCAACTGTGTAGACAGAGCTTACGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGTGGCTTTGTGAGTGAAGACCAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGTGGCTTTGTGAGTGAAGACCAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTTCAATGACGTGGCGCGCGCGTGTACGGAGAGTAAA 780
DB 721 AGGGGACTACGAGTGCAGTGCCTTCAATGACGTGGCGCGCGCGTGTACGGAGAGTAAA 780
QY 781 GGTTCACCGTGAACCTATCCACCATACATTTTCAAGAGCCAGGGTACAGGTGTCCCGTGG 840
DB 781 GGTTCACCGTGAACCTATCCACCATACATTTTCAAGAGCCAGGGTACAGGTGTCCCGTGG 840
QY 841 ACAAAAGGGAACACTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 ACAAAAGGGAACACTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGGATGACAAAGACTGATTCAAGGAAAGAAAGGAGTGAAGTGAAGAAAGAAAGCTTT 960
DB 901 CAAGGATGACAAAGACTGATTCAAGGAAAGAAAGGAGTGAAGTGAAGAAAGAAAGCTTT 960
QY 961 CTTCTCAAACTCATCTTCTTCAATGTCTGTAACATGACTATGGAACATACACTTTCGCT 1020
DB 961 CTTCTCAAACTCATCTTCTTCAATGTCTGTAACATGACTATGGAACATACACTTTCGCT 1020
QY 1021 GGCTCCCAACAGCTGGGCCACACCAATGCCAGCATCTGCTATTTGGTCCAGGCCCGT 1080
DB 1021 GGCTCCCAACAGCTGGGCCACACCAATGCCAGCATCTGCTATTTGGTCCAGGCCCGT 1080
QY 1081 CAGCGAGGTGAGCAACGGCAACGCGTCCGAGGAGGCGAGGCTGCTGCTGCTGCTCTTCT 1140
DB 1081 CAGCGAGGTGAGCAACGGCAACGCGTCCGAGGAGGCGAGGCTGCTGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTGAGTGGCCTCCCAACCCCGGAAAGGCT 1200
DB 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTGAGTGGCCTCCCAACCCCGGAAAGGCT 1200
QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
DB 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
QY 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGCGGACAGAAATTTGAGGAGGGGAAC 1320
DB 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGCGGACAGAAATTTGAGGAGGGGAAC 1320
QY 1321 AAGAAATACCTTTGGGGGAAAGAGTTTTTAAAGAAATTTGAAATTTGCTTTGCAGATA 1380
DB 1321 AAGAAATACCTTTGGGGGAAAGAGTTTTTAAAGAAATTTGAAATTTGCTTTGCAGATA 1380
QY 1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAAACCGGGAAGAACACAGCACACCCCGCTTGA 1440
DB 1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAAACCGGGAAGAACACAGCACACCCCGCTTGA 1440

```

Qy 1441 CCCACTGACGTCATGTCGTCACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGACGTCATGTCGTCACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACACAGAGTGCCTCCACGCTGGGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
Db 1501 TCTGCCACACAGAGTGCCTCCACGCTGGGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
Qy 1561 GTCCATAGACGACGACAGATGAGACCTTCGGGCCAAGCTGGCGTGGGCACTTTTG 1620
Db 1561 GTCCATAGACGACGACAGATGAGACCTTCGGGCCAAGCTGGCGTGGGCACTTTTG 1620
Qy 1621 GTAGACTGTGCCACACGCGGTGTGTGTAACGCTGAAATATAAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACACGCGGTGTGTGTAACGCTGAAATATAAAGAGCAAAAAA 1679

RESULT 53
ID ADC55956 standard; cDNA; 1679 BP.
AC ADC55956;
XX
DT 18-DEC-2003 (first entry)
DE Novel human secreted and transmembrane protein cDNA Seq ID375.
DE
XX human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
OS Homo sapiens.
XX
PN US2003087360-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127836.
XX
PR 17-NOV-1998; 98US-0108802P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801145/75.
DR P-PSDB; ADC55957.
XX
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 2; SEQ ID NO 375; 637pp; English.
XX
XX This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse

CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.

XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6.7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAACAC 60

Db 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAACAC 60

Qy 61 AATCTATCAGGAAGAAGAAAGAAAAAACCAGAACCTGCACAAAAAGAGAAAAAGAG 120

Db 61 AATCTATCAGGAAGAAGAAAGAAAAAACCAGAACCTGCACAAAAAGAGAAAAAGAG 120

Qy 121 AAGAAAAAATCATGAAACCATCCAGCCAAAAATGCACAAATTCATCTCTTGGGCAAT 180

Db 121 AAGAAAAAATCATGAAACCATCCAGCCAAAAATGCACAAATTCATCTCTTGGGCAAT 180

Qy 181 CTTACGGGGTGGTGTCTGTGTCTTCCAAAGAGTGGCCCTGCGCAGCGGAGATGC 240

Db 181 CTTACGGGGTGGTGTCTGTGTCTTCCAAAGAGTGGCCCTGCGCAGCGGAGATGC 240

Qy 241 CACCTTCCCCAAAGCTATGGAACAGTGCAGCGTCCGGCAGGGGAGAGCGCACCCCTCAG 300

Db 241 CACCTTCCCCAAAGCTATGGAACAGTGCAGCGTCCGGCAGGGGAGAGCGCACCCCTCAG 300

Qy 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGACCATCTCTTA 360

Db 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGACCATCTCTTA 360

Qy 361 TGCTGGGAATGACAAGTGGTGGTCTCGCGTGGTCTCTCTGAGCAACACCCAAAC 420

Db 361 TGCTGGGAATGACAAGTGGTGGTCTCGCGTGGTCTCTCTGAGCAACACCCAAAC 420

Qy 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACTGCTC 480

Db 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACTGCTC 480

Qy 481 GGTGACAGACACACACACCCCAAGACCTCTAGGTCACCCCTCATTTGTGCAAGTATCTCC 540

Db 481 GGTGACAGACACACACACCCCAAGACCTCTAGGTCACCCCTCATTTGTGCAAGTATCTCC 540

Qy 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600

Db 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600

Qy 601 CTGCATAGCACTGCTAGACCGACCTACCGTTACTTGGAGACACATCTCTCCCAAGC 660

Db 601 CTGCATAGCACTGCTAGACCGACCTACCGTTACTTGGAGACACATCTCTCCCAAGC 660

Qy 661 GGTGGCTTTGTGAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720

Db 661 GGTGGCTTTGTGAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720

Qy 721 AGGGACCTACGAGTGCAGTGCCTCCATGACGTGGCCGCCCGCTGGTACGGAGAGTAA 780

Db 721 AGGGACCTACGAGTGCAGTGCCTCCATGACGTGGCCGCCCGCTGGTACGGAGAGTAA 780

Qy 781 GGTCACCGTGAACATATCCACCATATTTCAAGAGCCAAAGGTACAGGTGTCCCGCTGGG 840

Db 781 GGTCACCGTGAACATATCCACCATATTTCAAGAGCCAAAGGTACAGGTGTCCCGCTGGG 840

Db 781 GGTACCGTGAACATATCCACCATATATTTCAGAAAGCCAGGGTACAGGTGTCCCGTGGG 840
Qy 841 ACAAAGGGGACACTGACAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACAAAGGGGACACTGACAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Qy 901 CAAGGATGACAAAGACATGATTGAGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
Db 901 CAAGGATGACAAAGACATGATTGAGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
Qy 961 CCTCTCAAAACTCATCTCTTCAATGCTCTGAACATGACTATGGAACATACACTTGCCT 1020
Db 961 CCTCTCAAAACTCATCTCTTCAATGCTCTGAACATGACTATGGAACATACACTTGCCT 1020
Qy 1021 GGCCTCCAAAGCTGGGCGACCAACCAATGCGCAGCATCATGCTATTGGTCCAGCGCGCT 1080
Db 1021 GGCCTCCAAAGCTGGGCGACCAACCAATGCGCAGCATCATGCTATTGGTCCAGCGCGCT 1080
Qy 1081 CAGCGAGTGAACAGCGCAGCTCGAGAGGGCAGGCTGCGTCTGGCTGCTGCTCTTCT 1140
Db 1081 CAGCGAGTGAACAGCGCAGCTCGAGAGGGCAGGCTGCGTCTGGCTGCTGCTCTTCT 1140
Qy 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGAGTGCACCTTCCCAACCGGGAAGGCT 1200
Db 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGAGTGCACCTTCCCAACCGGGAAGGCT 1200
Qy 1201 GCCGCCACACACACACACACAGCAGTGCACACAGCAGCAACCAATCAGATA 1260
Db 1201 GCCGCCACACACACACACAGCAGTGCACACAGCAGCAACCAATCAGATA 1260
Qy 1261 TATACAAATGAAATTTAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320
Db 1261 TATACAAATGAAATTTAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320
Qy 1321 AAGGATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCACATA 1380
Db 1321 AAGGATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCACATA 1380
Qy 1381 TTTAGGTCAATGGAGTTTCTTTTCCAAACGGGAAGAACACAGCACACCCGCTTGGG 1440
Db 1381 TTTAGGTCAATGGAGTTTCTTTTCCAAACGGGAAGAACACAGCACACCCGCTTGGG 1440
Qy 1441 CCCACTGCAAGTGCATGTCGCACTTTTGGTCCAGTGTGGCAGGCTCAGGCTC 1500
Db 1441 CCCACTGCAAGTGCATGTCGCACTTTTGGTCCAGTGTGGCAGGCTCAGGCTC 1500
Qy 1501 TCTGCCACAGAGTCCGCCACGTCGCACTTTTGGTCCAGTGTGGCAGGCTCAGGCTC 1560
Db 1501 TCTGCCACAGAGTCCGCCACGTCGCACTTTTGGTCCAGTGTGGCAGGCTCAGGCTC 1560
Qy 1561 GTCATAGAGACGAAACAGATGAGACCTTCCGCGCCAAAGCGTGGCGTGGCGCACTTTG 1620
Db 1561 GTCATAGAGACGAAACAGATGAGACCTTCCGCGCCAAAGCGTGGCGTGGCGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACACGCGGTGTGTGTGAACGTGAAATATAAAGAGCAAAAAAAA 1679
Db 1621 GTAGACTGTGCCACACGCGGTGTGTGTGAACGTGAAATATAAAGAGCAAAAAAAA 1679

RESULT 54
ID ADC58526 standard; cDNA; 1679 BP.
XX AC ADC58526;
XX AC ADC58526;
XX 18-DEC-2003 (first entry)
DE Novel human secreted and transmembrane protein cDNA Seq ID375.
XX human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neurotrophin; hormone; cell receptor;

KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX Homo sapiens.
XX US2003087346-A1.
XX 08-MAY-2003.
XX 17-APR-2002; 2002US-00124815.
XX 09-DEC-1999; 99US-0170262P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski P, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-801137/75.
XX P-PSDB; ADC58527.
XX Isolated nucleic acid for use in industrial applications has at least 80
XX percent nucleic acid sequence identity to nucleotide sequence that
XX encodes amino acid sequence selected from amino acid sequence group.
XX Claim 2; SEQ ID NO 375; 637pp; English.
XX This invention relates to novel nucleic acids encoding human PRO secreted
XX and transmembrane proteins. Extracellular proteins play important roles
XX in the formation, differentiation and maintenance of multicellular
XX organisms. The fate of many individual cells (for example proliferation,
XX migration or differentiation) is typically governed by information
XX received from other cells and the immediate environment. The information
XX is often transmitted by secreted polypeptides (for example mitogenic
XX factors, survival factors, cytotoxic factors, differentiation factors,
XX neuropeptides or hormones) which are received and interpreted by diverse
XX cell receptors or membrane bound proteins. These membrane bound proteins
XX and receptors may be of use as pharmaceutical and diagnostic agents, such
XX as in the blocking of receptor-ligand interactions. The current invention
XX provides the amino acid sequences of novel human membrane bound receptors
XX and proteins, along with the cDNA sequences encoding them. The novel
XX proteins of the invention may have cytostatic activities through the
XX stimulation of chondrocytes. The nucleic acids of the invention may be
XX useful for the manufacture of a medicament for diagnosing or treating a
XX tumour in a mammal. In addition, they may be useful for measuring or
XX detecting the expression of a tumour associated gene. The present
XX sequence is a cDNA sequence which encodes a human PRO protein of the
XX invention.

XX SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAAC 60
Db 1 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAAC 60
Qy 61 AATCTATCAGGAAGAAAGAAAGAAACCAACCTCACAACAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAACCAACCTCACAACAAAGAAAGAAAG 120
Qy 121 AAAAAAATATCATGAACACCATCCAGCCAAATTCACAAATTCATCTCTTGGGCAAT 180
Db 121 AAAAAAATATCATGAACACCATCCAGCCAAATTCACAAATTCATCTCTTGGGCAAT 180
Qy 181 CTTTCAGGGGCTGGCTGCTCTGTGTCTTCTTCAAGAGGTGCCCGTGCAGCGAGATGC 240
Db 181 CTTTCAGGGGCTGGCTGCTCTGTGTCTTCTTCAAGAGGTGCCCGTGCAGCGAGATGC 240

QY 241 CACCTTCCCAAGCTATGAGCAACGTGACGGTCCGGCAGGGGGAGAGCGCCACCTCTAG 300
Db 241 CACCTTCCCAAGCTATGAGCAACGTGACGGTCCGGCAGGGGGAGAGCGCCACCTCTAG 300
QY 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCAGCACCATCTCTA 360
Db 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCAGCACCATCTCTA 360
QY 361 TGCTGGGAATGACAAAGTGGTCCCTGATCTCCGCTGGTCTCTCTGAGCAACACCCAAAC 420
Db 361 TGCTGGGAATGACAAAGTGGTCCCTGATCTCCGCTGGTCTCTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAAACGGTGGATGTGTATGACAGGGGCCCTTACACCTGTCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAAACGGTGGATGTGTATGACAGGGGCCCTTACACCTGTCTC 480
QY 481 GGTGCAGACAGCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGCAGACAGCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAAAATTTGAGAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
Db 541 CAAAAATTTGAGAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTTCGGCTTTGTGAGTGAAGACGATATCTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
Db 661 GGTTCGGCTTTGTGAGTGAAGACGATATCTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTCCCTCAATGACGTGGCGCGCCCGTGGTAGCGGAGATAA 780
Db 721 AGGGGACTACGAGTGCAGTCCCTCAATGACGTGGCGCGCCCGTGGTAGCGGAGATAA 780
QY 781 GGTCAACGCTGACATCCACATACATTTTCAAGCCAGGGTACAGGTGTCCCGCTGG 840
Db 781 GGTCAACGCTGACATCCACATACATTTTCAAGCCAGGGTACAGGTGTCCCGCTGG 840
QY 841 ACAAAGGGGACACTGACAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACAAAGGGGACACTGACAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGGATGACAAAGCTGATTGAGGAAAGAGGGTGAAGTGGAAACAGACCTTT 960
Db 901 CAAGGATGACAAAGCTGATTGAGGAAAGAGGGTGAAGTGGAAACAGACCTTT 960
QY 961 CCTCTCAAAACTCATCTTTCTCAATGCTCTGAACATGACTATGGGAACTACACTTGGCT 1020
Db 961 CCTCTCAAAACTCATCTTTCTCAATGCTCTGAACATGACTATGGGAACTACACTTGGCT 1020
QY 1021 GGCCTCCAAAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
Db 1021 GGCCTCCAAAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
QY 1081 CAGCGAGTGAACAAAGGACCTGAGGAGGAGGCTGGCTGGCTGGCTGCTCTTCT 1140
Db 1081 CAGCGAGTGAACAAAGGACCTGAGGAGGAGGCTGGCTGGCTGGCTGCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTAGTGCATCTTCCCAACCGGGAAGGCT 1200
Db 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTAGTGCATCTTCCCAACCGGGAAGGCT 1200
QY 1201 GCGGCCACCAACCAACCAACAGCAATGSCAACCGCAGCAACCAATCAGATA 1260
Db 1201 GCGGCCACCAACCAACCAACAGCAATGSCAACCGCAGCAACCAATCAGATA 1260
QY 1261 TATCAAAATGAATTAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC 1320
Db 1261 TATCAAAATGAATTAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC 1320
QY 1321 AAGAATACTTTGGGGGAAAGAGTTTTTAAAGAAATTTGAAATTTGCCCTTGCAGATA 1380

RESULT 55
ADC47197

ID ADC47197 standard; cDNA; 1679 BP.

XX AC ADC47197;

XX DT 18-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO337 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;

XX KW vulnary; antiarthritic; pericyte cell proliferation;

XX KW pericyte cell differentiation; chondrocyte cell proliferation;

XX KW chondrocyte cell differentiation; tumour necrosis factor alpha release;

XX KW (TNF)-alpha release; dermal fibroblast cell proliferation; lung tumour;

XX KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;

XX KW colon tumour; breast tumour; prostate tumour; rectal tumour;

XX KW liver tumour; tissue typing; chromosome mapping; gene mapping;

XX KW gene therapy.

XX OS Homo sapiens.

XX XX US2003105288-A1.

XX XX 05-JUN-2003.

XX XX 13-AUG-2002; 2002US-00219070.

XX XX 25-JUL-2000; 2000US-0220666P.

XX XX 01-JUN-2001; 2001WO-US017800.

XX XX 29-JUN-2001; 2001WO-US021066.

XX XX 09-APR-2002; 2002US-00119480.

XX XX (GETH) GENENTECH INC.

XX XX Baker KP, Desnoyers L, Gerritsen WE, Goddard A, Godowski PJ;

XX XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WT;

XX XX WPI; 2003-801246/75.

XX XX DR P-PSDB; ADC47198.

XX XX New isolated nucleic acid encoding a secreted and transmembrane

XX XX polypeptide (PRO), for use in recombinantly producing a PRO polypeptide,

XX XX as a hybridization probe, and in gene therapy.

XX XX Claim 2; Fig 125; 308pp; English.

XX XX The invention describes an isolated PRO (secreted and transmembrane)

XX XX polypeptide (1). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are

useful for stimulating the proliferation of or gene expression in pericyte cells. PRO357, PRO329, PRO1272 or PRO4405 polypeptide are useful for stimulating the proliferation or differentiation of chondrocyte cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide are useful for stimulating the release of tumour necrosis factor (TNF)-alpha from human blood. PRO392, PRO357, PRO725, PRO1306, PRO1419, PRO214, PRO247, PRO337, PRO526, PRO363, PRO533, PRO1083, PRO840, PRO1080, PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309, PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412, PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338, PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567, PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO1543, PRO3444, PRO4322, PRO9840, PRO6079, PRO9836 or PRO10096 polypeptide are useful for stimulating the proliferation of normal human dermal fibroblasts cells. PRO181, PRO329, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408, PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for inhibiting the proliferation of normal human dermal fibroblast cells. PRO polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc., are useful for detecting the presence of tumour in a mammal which involves comparing the level of expression of the above PRO polypeptides in a test sample of cells taken from the mammal, and a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptides in the test sample as compared to the control sample is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for chromosome and gene mapping or gene therapy. (II) is useful for generating transgenic animals or knock-out animals which are useful screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide is useful for treating bone and/or cartilage disorders (e.g., arthritis, sport injuries). This sequence encodes a human secreted and transmembrane PRO polypeptide.

XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTCTCTTACGAAACAGTGGATTAAATCTCTTCTGCAACAGCTTGAGGCAACAC 60
DB |||||
QY 1 GTTGTCTCTTACGAAACAGTGGATTAAATCTCTTCTGCAACAGCTTGAGGCAACAC 60
DB |||||
QY 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB |||||
QY 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB |||||
QY 121 AAGAAAGAAATCATGAAACATCCAGCCAAATGCAATTTCTCTCTTGGCCAT 180
DB |||||
QY 121 AAGAAAGAAATCATGAAACATCCAGCCAAATGCAATTTCTCTCTTGGCCAT 180
DB |||||
QY 181 CTTTCAGGGGCTGGCTGCTGTGTCTCTTCCAAAGAGTGCCCGTGGCAGGGGAGATGC 240
DB |||||
QY 181 CTTTCAGGGGCTGGCTGCTGTGTCTCTTCCAAAGAGTGCCCGTGGCAGGGGAGATGC 240
DB |||||
QY 241 CACCTTCCCAAGCTATGACAAAGCTGACGGTCCGGCAGGGGAGAGCGCCACCTCTAG 300
DB |||||
QY 241 CACCTTCCCAAGCTATGACAAAGCTGACGGTCCGGCAGGGGAGAGCGCCACCTCTAG 300
DB |||||
QY 301 GTGCACATTTGACAAACCGGCTCACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360
DB |||||
QY 301 GTGCACATTTGACAAACCGGCTCACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360
DB |||||
QY 361 TGTGTGGAATGACAAAGTGTGTGATCTCTGCGGTGCTTCTGAGCAACACCAAC 420
DB |||||
QY 361 TGTGTGGAATGACAAAGTGTGTGATCTCTGCGGTGCTTCTGAGCAACACCAAC 420
DB |||||
QY 421 GCAGTACAGCATCGAGATCCAGAACTGGATGTGTATGACGGGGCCCTTACACCTGCTC 480
DB |||||
QY 421 GCAGTACAGCATCGAGATCCAGAACTGGATGTGTATGACGGGGCCCTTACACCTGCTC 480
DB |||||
QY 481 GGTGCGAGACAGACACCAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB |||||

DB |||||
QY 481 GGTGCGAGACAGACACCAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB |||||
QY 541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
DB |||||
QY 541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
DB |||||
QY 601 CTGATAGCAACTGCTGTAGACAGAGCCTTACGTTTACTTTGGAGACACATCTCTCCAAAGC 660
DB |||||
QY 601 CTGATAGCAACTGCTGTAGACAGAGCCTTACGTTTACTTTGGAGACACATCTCTCCAAAGC 660
DB |||||
QY 661 GTTTGGCTTTGTGAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
DB |||||
QY 661 GTTTGGCTTTGTGAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
DB |||||
QY 721 AGGGGACTAGAGTGAAGTGCCTCAATAGCTGGCGCGCCCGTGTGTCAGGAGTAA 780
DB |||||
QY 721 AGGGGACTAGAGTGAAGTGCCTCAATAGCTGGCGCGCCCGTGTGTCAGGAGTAA 780
DB |||||
QY 781 GGTCAACGCTGAACCTATCCACATATCTTTCAGAGCCAGGTCACAGTGTCCCGTGG 840
DB |||||
QY 781 GGTCAACGCTGAACCTATCCACATATCTTTCAGAGCCAGGTCACAGTGTCCCGTGG 840
DB |||||
QY 841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB |||||
QY 841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB |||||
QY 901 CAAGATGACAAAACACTGATTGAAGAAAGAGGGTGAAGTGGAAACACAGACCTTT 960
DB |||||
QY 901 CAAGATGACAAAACACTGATTGAAGAAAGAGGGTGAAGTGGAAACACAGACCTTT 960
DB |||||
QY 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGGAACATACACTTCG 1020
DB |||||
QY 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGGAACATACACTTCG 1020
DB |||||
QY 1021 GGCCTCGAAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTTCAGGCGCGCT 1080
DB |||||
QY 1021 GGCCTCGAAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTTCAGGCGCGCT 1080
DB |||||
QY 1081 CAGCGAGTGAAGCAACCGCAGCTCGAGAGGGGAGGCTGCTTGGCTGCTCTCTCTCT 1140
DB |||||
QY 1081 CAGCGAGTGAAGCAACCGCAGCTCGAGAGGGGAGGCTGCTTGGCTGCTCTCTCTCT 1140
DB |||||
QY 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTAGTGCACCTTCCCAACCGGGAAAGGCT 1200
DB |||||
QY 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTAGTGCACCTTCCCAACCGGGAAAGGCT 1200
DB |||||
QY 1201 GCCGCCACCCACCCACCAACAGCAATGSCAACACGACAGCAACCAATCAGATA 1260
DB |||||
QY 1201 GCCGCCACCCACCCACCAACAGCAATGSCAACACGACAGCAACCAATCAGATA 1260
DB |||||
QY 1261 TATCAAAATGAATTAGAAGAAACACAGCCTCATGGACAGAAATTTGAGGGAGGGAAC 1320
DB |||||
QY 1261 TATCAAAATGAATTAGAAGAAACACAGCCTCATGGACAGAAATTTGAGGGAGGGAAC 1320
DB |||||
QY 1321 AAGAAATACCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB |||||
QY 1321 AAGAAATACCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB |||||
QY 1381 TTTAGGTACAAATGGAGTTTCTTTCCAAACCGGAAAGAAACACAGCAGCACCCCGCTTGA 1440
DB |||||
QY 1381 TTTAGGTACAAATGGAGTTTCTTTCCAAACCGGAAAGAAACACAGCAGCACCCCGCTTGA 1440
DB |||||
QY 1441 CCCACTGCAAGCTGCATCGTGCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
DB |||||
QY 1441 CCCACTGCAAGCTGCATCGTGCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
DB |||||
QY 1501 TCTGCCACACAGAGTGCCTCCACAGTGGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
DB |||||
QY 1501 TCTGCCACACAGAGTGCCTCCACAGTGGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
DB |||||
QY 1561 GTCCATAGAGACGAAACAGATGAGACCTTCCGGCCAAAGGTGGCGCTGGGGCAGCTTG 1620
DB |||||

Db 1561 GTCCATAGAGACGACAGATGAGACCTTCGGGCCAAGCGTGCGCTGGCGGCACTTTG 1620
Qy 1621 GTAGACTGTCCACACCGCGTGTGTGTGAACGTGAATATATAAAGACGCAAAAAA 1679
Db 1621 GTAGACTGTCCACACCGCGTGTGTGTGAACGTGAATATATAAAGACGCAAAAAA 1679

RESULT 56
ADD03200
ID ADD03200 standard; cDNA; 1679 BP.
XX
AC ADD03200;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
XX
XX
PN US2003092104-A1.
XX
PD 15-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131817.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 01-DEC-1998; 98WO-US024855.
PR 05-JAN-1999; 98WO-US025108.
PR 08-FEB-1999; 98WO-US025028.
PR 10-MAR-1999; 98WO-US025190.
PR 20-APR-1999; 98WO-US0250615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 01-DEC-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028554.
PR 02-DEC-1999; 98WO-US028565.

PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 22-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 13-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-801169/75.
DR P-PSDB; ADD03201.
DR

XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; Fig 375; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human macrovascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTTCACAAAGCTTGAGAGCAAC 60
DB 1 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTTCACAAAGCTTGAGAGCAAC 60

QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

QY 121 AAGAAAAAAATCATGAAACCATCAGGCAAAATGCAATCTCTCTTGGGCAAT 180
DB 121 AAGAAAAAAATCATGAAACCATCAGGCAAAATGCAATCTCTCTTGGGCAAT 180

QY 181 CTTTACGGGGCTGGTGTCTCTGTCTCTTCAAGAGTGCCTGCGAGCGGAGATGC 240
DB 181 CTTTACGGGGCTGGTGTCTCTGTCTCTTCAAGAGTGCCTGCGAGCGGAGATGC 240

QY 241 CACCTTCCCAAGCTATGAGCAAGCTGACGTGCGGAGGGGAGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAGCTATGAGCAAGCTGACGTGCGGAGGGGAGAGCGCCACCTCAG 300

QY 301 GTGCACTATTGACAAACCGGCTCACCGGGTGGCTGGCTTAACCGCAGACCATCTCTA 360
DB 301 GTGCACTATTGACAAACCGGCTCACCGGGTGGCTGGCTTAACCGCAGACCATCTCTA 360

QY 361 TCGTGGGATGCAAGTGTGCTGTGATCCTCGCTGGTCTCTTCTGAGCAACCCCAAC 420
DB 361 TCGTGGGATGCAAGTGTGCTGTGATCCTCGCTGGTCTCTTCTGAGCAACCCCAAC 420

DB 361 TCGTGGGATGCAAGTGTGCTGTGATCCTCGCTGGTCTCTTCTGAGCAACCCCAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACTGGATGTGTATGACAGGGCCCTTACACCTGTCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACTGGATGTGTATGACAGGGCCCTTACACCTGTCTC 480
QY 481 GGTGCAGACAGCAACACCCCAAGACCTCTAGGTCACACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGCAGACAGCAACACCCCAAGACCTCTAGGTCACACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAAATTTGATAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
DB 541 CAAAATTTGATAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
QY 601 CTCATATAGCACTGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTCATATAGCACTGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGTGGCTTTGTGAGTGAAGACGAATPACTTGGAAATTCAGGGCATCACCGGAGCAGTC 720
DB 661 GGTGTGGCTTTGTGAGTGAAGACGAATPACTTGGAAATTCAGGGCATCACCGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCGCGCTGGTACGGAGAGTAA 780
DB 721 AGGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCGCGCTGGTACGGAGAGTAA 780
QY 781 GGTCCACGTGAATCTCCACCATACATTTTCAGAAAGCAAGGGTACAGGTGTCCCGTGGG 840
DB 781 GGTCCACGTGAATCTCCACCATACATTTTCAGAAAGCAAGGGTACAGGTGTCCCGTGGG 840
QY 841 ACAAAGGGGACACTGAGTGTGAAGCCTCAGCAGTCCCTCCATGAGAAATTCAGTGTGTA 900
DB 841 ACAAAGGGGACACTGAGTGTGAAGCCTCAGCAGTCCCTCCATGAGAAATTCAGTGTGTA 900
QY 901 CAAGGATGACAAAGACTGATTCAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
DB 901 CAAGGATGACAAAGACTGATTCAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
QY 961 CTTCTCAAAACTCATTTCTTCAATGTCTCTGAACATGACTATGGGAACTACACTTGGCT 1020
DB 961 CTTCTCAAAACTCATTTCTTCAATGTCTCTGAACATGACTATGGGAACTACACTTGGCT 1020
QY 1021 GGCTCCCAACAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGGCCCGT 1080
DB 1021 GGCTCCCAACAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGGCCCGT 1080
QY 1081 CAGCGAGGTGAGCAACGGGACGTCGAGGAGGGCAGGCTGCTGCTGCTGCTCTTCT 1140
DB 1081 CAGCGAGGTGAGCAACGGGACGTCGAGGAGGGCAGGCTGCTGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGCACTGCTCTCAAAATTTTGTGATGAGTGCCACTTCCCAACCGGGAAGGCT 1200
DB 1141 GGTCTTGCACTGCTCTCAAAATTTTGTGATGAGTGCCACTTCCCAACCGGGAAGGCT 1200
QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
DB 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
QY 1261 TATACAAATGAATATGAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
DB 1261 TATACAAATGAATATGAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
QY 1321 AAAGAATACTTTGGGGGAAAGAGTGTAAAAAAGAAATTTGAAATTTGCTTTGCAGATA 1380
DB 1321 AAAGAATACTTTGGGGGAAAGAGTGTAAAAAAGAAATTTGAAATTTGCTTTGCAGATA 1380
QY 1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAAACGGGAGAAACACAGCACACCCCGCTTGA 1440
DB 1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAAACGGGAGAAACACAGCACACCCCGCTTGA 1440
QY 1441 CCCACTGCAAGCTGCAATCGTGCAACCTCTTTGTGTCAGTGTGGGCAAGGGCTCACGCTC 1500
DB 1441 CCCACTGCAAGCTGCAATCGTGCAACCTCTTTGTGTCAGTGTGGGCAAGGGCTCACGCTC 1500

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTTTGACAAACAGTGGATTAAATCTCTTGCAAGCTTGAGAGCAAC 60
DB 1 GTTGTGCTTTGACAAACAGTGGATTAAATCTCTTGCAAGCTTGAGAGCAAC 60

QY 61 AATCTATCAGAAAGAAAGAAAGAAACCGACCTGACAAAGAAAGAAAGAG 120
DB 61 AATCTATCAGAAAGAAAGAAAGAAACCGACCTGACAAAGAAAGAAAGAG 120

QY 121 AAGAAAAAATCATGAAAAATCATCCAGCCAAATATCTATCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAAAATCATCCAGCCAAATATCTATCTCTTGGGCAAT 180

QY 181 CTTTCAAGGGGTGCTGCTGCTGCTCTCTTCCAGAGAGTGCCGTCAGCGAGATGC 240
DB 181 CTTTCAAGGGGTGCTGCTGCTGCTCTCTTCCAGAGAGTGCCGTCAGCGAGATGC 240

QY 241 CACCTTCCCAAGCTATGGACAACAGTGAACGCTCCGCGAGGGGAGAGCGCCCTCAG 300
DB 241 CACCTTCCCAAGCTATGGACAACAGTGAACGCTCCGCGAGGGGAGAGCGCCCTCAG 300

QY 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTGGCTAAACCGCAGCACTCTCTTA 360
DB 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCACTCTCTTA 360

QY 361 TGCTGGGAATGACAAGTGGTGGCTTGGATCTCTGCGGTGCTCTCTGAGCAACACCCAAAC 420
DB 361 TGCTGGGAATGACAAGTGGTGGCTTGGATCTCTGCGGTGCTCTCTGAGCAACACCCAAAC 420

QY 421 GCAGTACAGCATCGAGATCCAGAAAGTGGATGTGTATGAAGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAAAGTGGATGTGTATGAAGAGGGCCCTTACACCTGCTC 480

QY 481 GGTGACAGACAGACACCAACCTGAGCTTACAGCTTACCTATTGTGCAAGTATCTCC 540
DB 481 GGTGACAGACAGACACCAACCTGAGCTTACAGCTTACCTATTGTGCAAGTATCTCC 540

QY 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAAACAAATATTAGCTTAC 600
DB 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAAACAAATATTAGCTTAC 600

QY 601 CTGCTATGCACTGCTAGACAGAGCTTACGTTACTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCTATGCACTGCTAGACAGAGCTTACGTTACTTGGAGACACATCTCTCCCAAGC 660

QY 661 GGTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720

QY 721 AGGGACTACGAGTGCAGTCTCCATGAGCTGGCGCGCCGCTGTGAGAGATGATAA 780
DB 721 AGGGACTACGAGTGCAGTCTCCATGAGCTGGCGCGCCGCTGTGAGAGATGATAA 780

QY 781 GGTCAACCGTGAATATCCACCATATCTTCAAGAAATTCAGAGGTACAGGTGTCCTCCGTTGG 840
DB 781 GGTCAACCGTGAATATCCACCATATCTTCAAGAAATTCAGAGGTACAGGTGTCCTCCGTTGG 840

QY 841 ACAAAGGGGACATGCAAGTGAAGCTTCAAGTCCCTCAGCAGAAATTCAGAGTGA 900
DB 841 ACAAAGGGGACATGCAAGTGAAGCTTCAAGTCCCTCAGCAGAAATTCAGAGTGA 900

QY 901 CAAGGATGCAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGAAGAAACAGACCTTT 960
DB 901 CAAGGATGCAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGAAGAAACAGACCTTT 960

QY 961 CCTCTCAAAAATCTATCTTCTCAATGTCTCTGAAACATGATATGAGGAACTACCTTCGCT 1020
DB 961 CCTCTCAAAAATCTATCTTCTCAATGTCTCTGAAACATGATATGAGGAACTACCTTCGCT 1020

QY 1021 GGCCTCCAAACAGCTGGGCCACACAATGCCAGCATCATGCTATTGCTCCAGGCGCGT 1080
DB 1021 GGCCTCCAAACAGCTGGGCCACACAATGCCAGCATCATGCTATTGCTCCAGGCGCGT 1080

QY 1081 CAGCAGGTGAGCAACCGCACGTCGAGAGGCGAGGTGCTGCTGCTGCTCTTCT 1140
DB 1081 CAGCAGGTGAGCAACCGCACGTCGAGAGGCGAGGTGCTGCTGCTGCTCTTCT 1140

QY 1141 GGTCTTGCACCTGCTCTCAAAATTTGATGTGAGTGCCACTTCCCCACCGGGGAAAGCT 1200
DB 1141 GGTCTTGCACCTGCTCTCAAAATTTGATGTGAGTGCCACTTCCCCACCGGGGAAAGCT 1200

QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA 1260
DB 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA 1260

QY 1261 TATACAAATGAATTTAGAGAAACACACGCTCATGGGACAGAAATTTGAGGAGGGGAAAC 1320
DB 1261 TATACAAATGAATTTAGAGAAACACACGCTCATGGGACAGAAATTTGAGGAGGGGAAAC 1320

QY 1321 AAGAAATATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCCCTTGCAGATA 1380
DB 1321 AAGAAATATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCCCTTGCAGATA 1380

QY 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACGGGAGAAACACAGCACACCCGCTTGGGA 1440
DB 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACGGGAGAAACACAGCACACCCGCTTGGGA 1440

QY 1441 CCACTGCAAGCTGATCGTCAACCTCTTTTGGTCCAGTGTGGGCAAGGCTCAGGCTC 1500
DB 1441 CCACTGCAAGCTGATCGTCAACCTCTTTTGGTCCAGTGTGGGCAAGGCTCAGGCTC 1500

QY 1501 TCTGCCACAGAGTCCCCCAGTGGAACTTCTGGAGTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTCCCCCAGTGGAACTTCTGGAGTGGCCATCCCAATTCATCA 1560

QY 1561 GTCCATAGAGACGAACAGATGAGACCTTCCGGGCCAAGCGTGGCGTCCGGGACATTTG 1620
DB 1561 GTCCATAGAGACGAACAGATGAGACCTTCCGGGCCAAGCGTGGCGTCCGGGACATTTG 1620

QY 1621 GTAGACTGTGCCACACCGGCTGTGTGAAACGTGAAATTTGAAAGGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACACCGGCTGTGTGAAACGTGAAATTTGAAAGGCAAAAAA 1679

RESULT 59

ADC48500

ID ADC48500 standard; cDNA; 1679 BP.

XX

AC ADC48500;

XX

DT 01-JAN-2004 (first entry)

XX

DE Human PRO polynucleotide #188.

XX

Human; gens; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; PFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

OS Homo sapiens.

XX

XX US2003194773-A1.

XX

XX 16-OCT-2003.

XX

XX 21-MAY-2002; 2002US-00152391.

PF

XX 09-DEC-1999; 99US-0170262P.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Carritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-844455/78.
DR P-PSDB; ADC48501.
XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the release of tumor necrosis factor
PT alpha and stimulating the proliferation of endothelial cells.
XX Claim 2; Fig 375; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis.
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTTTCAGCAAAAACAGTGGATTAAATCTCTCTCCACAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTTTCAGCAAAAACAGTGGATTAAATCTCTCTCCACAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAGAAGAAAGAAAAACCGAACCTGCAAAAAAGAAAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAGAAAGAAAAACCGAACCTGCAAAAAAGAAAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAAAACCATCCAGCGCAAAAAATTCGCAATTCCTCTTGGGCAAT 180
Db 121 AAGAAAAAATCATGAAAAACCATCCAGCGCAAAAAATTCGCAATTCCTCTTGGGCAAT 180

QY 181 CTTTACGGGGCTGGCTGCTCTGTGTCTCTTCTTCAAGAGAGTCCCGTCCGAGCGAGATGC 240
Db 181 CTTTACGGGGCTGGCTGCTCTGTGTCTCTTCTTCAAGAGAGTCCCGTCCGAGCGAGATGC 240
QY 241 CACCTTCCCCAAAGCTATGAGCAAACTGAGCGTCCGCGAGGGGAGAGCGCCACCTCTCAG 300
Db 241 CACCTTCCCCAAAGCTATGAGCAAACTGAGCGTCCGCGAGGGGAGAGCGCCACCTCTCAG 300
QY 301 GTGCACATATTGACAAACCCGGGTCAACCCGGGTGGCTTAAACCCGAGCAACCAATCTCTTA 360
Db 301 GTGCACATATTGACAAACCCGGGTCAACCCGGGTGGCTTAAACCCGAGCAACCAATCTCTTA 360
QY 361 TGTGGAATGACAAAGTGGTGGCTTGTGATCTCTCGGTGGTCTTCTTGTGAGCAACCAAAAC 420
Db 361 TGTGGAATGACAAAGTGGTGGCTTGTGATCTCTCGGTGGTCTTCTTGTGAGCAACCAAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACAGAGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACAGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGACAGACAGCAACCAACCCAAAGACCTCTAGGTCCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGACAGACAGCAACCAACCCAAAGACCTCTAGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTTAC 600
Db 541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTTAC 600
QY 601 CTGCATAGCAACTGGTGAAGACAGAGCTACCGTTACTTGGAGACACATCTCTTCCAAAGC 660
Db 601 CTGCATAGCAACTGGTGAAGACAGAGCTACCGTTACTTGGAGACACATCTCTTCCAAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGCAAGTAATCTTGGAAATTCAGGGCATCACCCGGGAGAGTGC 720
Db 661 GGTGGCTTTGTGAGTGAAGCAAGTAATCTTGGAAATTCAGGGCATCACCCGGGAGAGTGC 720
QY 721 AGGGGACTTACAGTGCAGTGCCTCCAAATGAGTGGCGCCCGCTGTGTCGAGAGAGTAAA 780
Db 721 AGGGGACTTACAGTGCAGTGCCTCCAAATGAGTGGCGCCCGCTGTGTCGAGAGAGTAAA 780
QY 781 GGTACCGTGAACCTATCCACATACATTCAGAGCCCAAGGTCACAGTGTCCCGTGGG 840
Db 781 GGTACCGTGAACCTATCCACATACATTCAGAGCCCAAGGTCACAGTGTCCCGTGGG 840
QY 841 ACAAAGGGGACACTGCGAGTGTGAAGCTCAGACAGTCCCTCAGCAGAAATCCAGTGGTA 900
Db 841 ACAAAGGGGACACTGCGAGTGTGAAGCTCAGACAGTCCCTCAGCAGAAATCCAGTGGTA 900
QY 901 CAAAGATGACAAAGACTGATTGAAGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
Db 901 CAAAGATGACAAAGACTGATTGAAGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
QY 961 CTTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAACTACACTTGGT 1020
Db 961 CTTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAACTACACTTGGT 1020
QY 1021 GGCCTTCAAAAGCTGGGCGCACCAATGCCAGCATCATGTCTATTTGTCAGGGCGCGT 1080
Db 1021 GGCCTTCAAAAGCTGGGCGCACCAATGCCAGCATCATGTCTATTTGTCAGGGCGCGT 1080
QY 1081 CAGCGAGTGAAGCAACGCGACGTGAGGAGGCGAGGCTGCGCTCTGGCTGCTCTTCT 1140
Db 1081 CAGCGAGTGAAGCAACGCGACGTGAGGAGGCGAGGCTGCGCTCTGGCTGCTCTTCT 1140
QY 1141 GGTCTTGAACCTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCAACCCGGGAAAGCT 1200
Db 1141 GGTCTTGAACCTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCAACCCGGGAAAGCT 1200
QY 1201 GCCCGCACCCACCCACCAACAGCAATGGGCAACACCGAGCAACCAATCAGATA 1260
Db 1201 GCCCGCACCCACCCACCAACAGCAATGGGCAACACCGAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATTTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320

Db 1261 TATACAAATGAATATAGAGAAACACAGCTCATGGACAGAAATTTGAGGAGGGGAC 1320
Qy 1321 AAAGAATACTTTGGGGGAAAGAGTTTAAATAAGAAATGAAATTTGCTTGCAGATA 1380
Db 1321 AAAGAATACTTTGGGGGAAAGAGTTTAAATAAGAAATGAAATTTGCTTGCAGATA 1380
Qy 1381 TTTAGGTACATGAGTTTCTTTTCCCAACCGGAGAACACAGCACACCCGGCTTGGG 1440
Db 1381 TTTAGGTACATGAGTTTCTTTTCCCAACCGGAGAACACAGCACACCCGGCTTGGG 1440
Qy 1441 CCCACTGCAAGCTCATGTCGCAACCTTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTCATGTCGCAACCTTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTCCCGCCAGCTGGACATCTTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTCCCGCCAGCTGGACATCTTGGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGTGGCGCACTTTG 1620
Db 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGTGGCGCACTTTG 1620
Qy 1621 GTAGACTGTCACACACGCGCTGTGTGTAAGCTGAAATGAAATGAAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTCACACACGCGTGTGTGTAAGCTGAAATGAAATGAAAGAGCAAAAAA 1679

RESULT 60
ADD10029
ID ADD10029 standard; cDNA; 1679 BP.
XX
AC ADD10029;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194776-A1.
XX
PD 16-OCT-2003.
XX
PF 29-MAY-2002; 2002US-00157785.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerlitsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-852596/79.
DR P-PSDB; ADD10030.
XX
PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the release of proteoglycans from
PT cartilage and inhibiting the differentiation of adipocyte cells.

XX Claim 2; Fig 375; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells and for treating
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-08;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTTGTGTCCTTCAGCAAAACAGTGATTTAAATCTCTTGCACAACTTGAGAGCAACAC 60
Db 1 GTTGTGTCCTTCAGCAAAACAGTGATTTAAATCTCTTGCACAACTTGAGAGCAACAC 60
Qy 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAAAAATCATGAAAAACCATCCAGCAAAATGCACAATTCATCTCTTGGGCAAT 180
Db 121 AAGAAAAAAATCATGAAAAACCATCCAGCAAAATGCACAATTCATCTCTTGGGCAAT 180
Qy 181 CTTACGGGGCTGGTGTCTGTGTCTCTTCCAGAGTGGCCGTCGCGAGGAGATGC 240
Db 181 CTTACGGGGCTGGTGTCTGTGTCTCTTCCAGAGTGGCCGTCGCGAGGAGATGC 240
Qy 241 CACCTTCCCAAGCTATGCAACAGTGACGCTCGGCGAGGGGAGAGCCACCCCTCAG 300
Db 241 CACCTTCCCAAGCTATGCAACAGTGACGCTCGGCGAGGGGAGAGCCACCCCTCAG 300
Qy 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCAGCACCCTCTTA 360
Db 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCAGCACCCTCTTA 360
Qy 361 TCGTGGGAATGACAAAGTGTGCTGATCTCTCGCTGTGCTTCTTGAGCAACCCCAAC 420
Db 361 TCGTGGGAATGACAAAGTGTGCTGATCTCTCGCTGTGCTTCTTGAGCAACCCCAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGACGTGGATGTATGACGAGGCCCTTACACCTGTCTC 480

421 GCAGTACAGCATCGAGATCCAGAACGTTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
481 GTGTGAGACAGCAACACCAAGACCTCTTGGGTGTCACCTCATTTGTGCAAGTATCTCC 540
481 GTGTGAGACAGCAACACCAAGACCTCTTGGGTGTCACCTCATTTGTGCAAGTATCTCC 540
541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
601 CTGCATAGCAACTGTGTAGACAGAGCCTACGTTTACTTTGGAGACACATCTCTCCCAAGC 660
601 CTGCATAGCAACTGTGTAGACAGAGCCTACGTTTACTTTGGAGACACATCTCTCCCAAGC 660
661 GTTGGCTTTGTGAGTGAGAGAGCAATCTTGAATTTAGGGCATCACCGGAGCAGTC 720
661 GTTGGCTTTGTGAGTGAGAGAGCAATCTTGAATTTAGGGCATCACCGGAGCAGTC 720
721 AGGGGACTACGAGTGCAGTCCCTCCATGACGTGGCGCGCCGCTGGTACGAGAGTAAA 780
721 AGGGGACTACGAGTGCAGTCCCTCCATGACGTGGCGCGCCGCTGGTACGAGAGTAAA 780
781 GGTCAACGTGAACTATCCACCATACATTTTCAGAGCCAGGTTACAGTGTCCCGTGGG 840
781 GGTCAACGTGAACTATCCACCATACATTTTCAGAGCCAGGTTACAGTGTCCCGTGGG 840
841 ACAAAGGGGACACTGCTGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
841 ACAAAGGGGACACTGCTGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
901 CAAGGATGACAAAGACTGATTTAGAGGAAGAAAGGGGTGAAAGTGGAAACACAGACCTTT 960
901 CAAGGATGACAAAGACTGATTTAGAGGAAGAAAGGGGTGAAAGTGGAAACACAGACCTTT 960
961 CCTCTCAAACTCATCTTCTCAATGTCTCTGAACATGACTATGGAACTACACTTGGT 1020
961 CCTCTCAAACTCATCTTCTCAATGTCTCTGAACATGACTATGGAACTACACTTGGT 1020
1021 GGCCTCCAAAGCTGGGACACCAATATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
1021 GGCCTCCAAAGCTGGGACACCAATATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
1081 CAGCAGGTTGAGCAACGCGACGTCGAGGAGGCGGCTCGCTGCTGCTCCCTCTCT 1140
1081 CAGCAGGTTGAGCAACGCGACGTCGAGGAGGCGGCTCGCTGCTGCTCCCTCTCT 1140
1141 GGTCTTGACCTGCTCTCTCAAAATTTTGAATGTGAGTGCACCTTCCCAACCGGGAAGCT 1200
1141 GGTCTTGACCTGCTCTCTCAAAATTTTGAATGTGAGTGCACCTTCCCAACCGGGAAGCT 1200
1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAATTTGAAATTTGAAATTTGAA 1380
1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAATTTGAAATTTGAAATTTGAA 1380
1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACGGGAAGAACACAGACACCCCGGCTTGA 1440
1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACGGGAAGAACACAGACACCCCGGCTTGA 1440
1441 CCACCTGCAAGCTGATGTGCAACCTCTTTGGTGCAGTGTGGGCAAGGCTCAGCCTC 1500
1441 CCACCTGCAAGCTGATGTGCAACCTCTTTGGTGCAGTGTGGGCAAGGCTCAGCCTC 1500
1501 TCTGCCACACAGAGTGGCCCCACCTGCGAAATCTTGGAGCTGGGCAATCCCAAAATTAATCA 1560
1501 TCTGCCACACAGAGTGGCCCCACCTGCGAAATCTTGGAGCTGGGCAATCCCAAAATTAATCA 1560

Qy 1561 GTCCATAGACAGCAACAGATGAGACTTCCGCGCCCAAGGTTGGCGCTGGGCACTTTG 1620
Db 1561 GTCCATAGACAGCAACAGATGAGACTTCCGCGCCCAAGGTTGGCGCTGGGCACTTTG 1620
Qy 1621 GTAGACTGTCCCAACCAAGCGGCTGTGTTGTAACCGTGAATTAATAAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTCCCAACCAAGCGGCTGTGTTGTAACCGTGAATTAATAAAGAGCAAAAAA 1679

RESULT 61

ADCT78072
ID ADC78072 standard; cDNA; 1679 BP.

XX ADC78072;

XX AC ADC78072;

XX 01-JAN-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO337 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
XX vulnary; antiarthritic; pericyte cell proliferation;
XX pericyte cell differentiation; chondrocyte cell proliferation;
XX chondrocyte cell differentiation; tumour necrosis factor alpha release;
XX (TNF)-alpha release; dermal fibroblast cell proliferation;
XX dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
XX colon tumour; breast tumour; prostate tumour; rectal tumour;
XX liver tumour; tissue typing; chromosome mapping; gene mapping;
XX gene therapy.

XX Homo sapiens.

XX US2003096972-A1.

XX 22-MAY-2003.

XX 29-AUG-2002; 2002US-00232234.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2003-765523/72.

XX P-PSDB; ADC78073.

XX Novel isolated PRO polypeptide useful for tissue typing, gene therapy, as

XX molecular weight markers, for treating arthritis and tumor.

XX Claim 2; Fig 125; 308pp; English.

XX The invention describes an isolated PRO (secreted and transmembrane)
XX polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
XX useful for stimulating the proliferation of or gene expression in
XX pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
XX for stimulating the proliferation or differentiation of chondrocyte
XX cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO419 polypeptide
XX are useful for stimulating the release of tumour necrosis factor (TNF)-
XX alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
XX PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
XX PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
XX PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
XX PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
XX PRO1343, PRO1376, PRO1387, PRO1409, PRO1274, PRO1317, PRO1360, PRO1567,
XX PRO1887, PRO1928, PRO3431, PRO1801, PRO4333, PRO3543, PRO4344, PRO4322,
XX PRO3940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
XX stimulating the proliferation of normal human dermal fibroblasts cells.
XX PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
XX PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for

inhibiting the proliferation of normal human dermal fibroblast cells. PRO polypeptides such as PRO6004, PRO4981, PRO174, PRO5778, PRO4332, etc., are useful for detecting the presence of tumour in a mammal which involves comparing the level of expression of the above PRO polypeptides in a test sample of cells taken from the mammal, and a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptides in the test sample as compared to the control sample is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for chromosome and gene mapping or gene therapy. (II) is useful for generating transgenic animals or knock-out animals which are useful screening useful reagents. PRO357, PRO223, PRO1272 or PRO4405 polypeptide is useful for treating bone and/or cartilage disorders (e.g., arthritis, sport injuries). This sequence encodes a human secreted and transmembrane PRO polypeptide.

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Query Match 100.0%; Score 1073; DB 1
Best Local Similarity 100.0%; Pred. No. 6.7e-05;

Best local similarity 100.0%, freq. NO: 0.7e-05;
Matches 1679; Conservative 0; Mismatches 0;
Indels 0; Gaps 0;

Qy	1	GTTGTGTCCTTCAGC	AAAACAGTGA	TTAAATCTCCTTGC	ACAAGCTT	GAGCAACAC	60
Db	1	GTTGTGTCCTTCAGC	AAAACAGTGA	TTAAATCTCCTTGC	ACAAGCTT	GAGCAACAC	60
Qy	61	AATCTATCAGGAAAGAA	AGAAAGAA	AAAAACCGCAACCTG	CAAAAAGAGAA	AAAAAGAG	120
Db	61	AATCTATCAGGAAAGAA	AGAAAGAA	AAAAACCGCAACCTG	CAAAAAGAGAA	AAAAAGAG	120
Qy	121	AAGAAAAAAATCAT	TGAAAAACATCCAGC	CAAAAATATGCA	CAATTCCTCTTGGGCAAT	180	
Db	121	AAGAAAAAAATCAT	TGAAAAACATCCAGC	CAAAAATATGCA	CAATTCCTCTTGGGCAAT	180	
Qy	181	CTTCAGCGGCGCTGCT	GTGTCTCTTCCAAAGAGTGC	CCGTGCGCAGCGGAGATGC	240		
Db	181	CTTCAGCGGCGCTGCT	GTGTCTCTTCCAAAGAGTGC	CCGTGCGCAGCGGAGATGC	240		
Qy	241	CACCTTCCC	CAAGCTATGGAACAACGTGA	CCGGTCCGGAGGGGAGAGGCCAC	ACCCTCAG	300	
Db	241	CACCTTCCC	CAAGCTATGGAACAACGTGA	CCGGTCCGGAGGGGAGAGGCCAC	ACCCTCAG	300	
Qy	301	GTGCAC	TATTGTGAACAACCGGGTC	CACCCGGTGGCTTGGCTAAACCGCAGC	ACCATCTCTTA	360	
Db	301	GTGCAC	TATTGTGAACAACCGGGTC	CACCCGGTGGCTTGGCTAAACCGCAGC	ACCATCTCTTA	360	
Qy	361	TGCTGGGAATGA	CAAGTGGTGCTGGATCTCTCGGTGGT	CTCTTCTGAGCAACACCCAAAC	420		
Db	361	TGCTGGGAATGA	CAAGTGGTGCTGGATCTCTCGGTGGT	CTCTTCTGAGCAACACCCAAAC	420		
Qy	421	GCAGTACAGCATCG	AGATCCAGAACGTGGATGTGTATGACG	AGGGCCCTTACACCTGCTC	480		
Db	421	GCAGTACAGCATCG	AGATCCAGAACGTGGATGTGTATGACG	AGGGCCCTTACACCTGCTC	480		
Qy	481	GGTG	CAGACAGACAACCCAAAGACCTCTAGGGTCCA	CTCATTTGTGCAAGTATCTCC	540		
Db	481	GGTG	CAGACAGACAACCCAAAGACCTCTAGGGTCCA	CTCATTTGTGCAAGTATCTCC	540		
Qy	541	CAAAA	TTGTAGAGATTTCTTCAGATATCTCCATTAATG	CAAGGGAACAATATTAGCCTCAC	600		
Db	541	CAAAA	TTGTAGAGATTTCTTCAGATATCTCCATTAATG	CAAGGGAACAATATTAGCCTCAC	600		
Qy	601	CTGC	CATAGCAA	CTGGTAGACAGACCTACGGTTACTTGGAGACA	CATCTCTCCCCAAGC	660	
Db	601	CTGC	CATAGCAA	CTGGTAGACAGACCTACGGTTACTTGGAGACA	CATCTCTCCCCAAGC	660	
Qy	661	GGTGGC	TTGTGTGAGACG	AAATCTTGGMAATTCAGGCATCAC	CCGGGAGCAGTC	720	
Db	661	GGTGGC	TTGTGTGAGACG	AAATCTTGGMAATTCAGGCATCAC	CCGGGAGCAGTC	720	
Qy	721	AGGGG	ACTACGAGTGCAGTGCCTCCAAATGCACTGGC	CGCCCGCTGGTACGGAGAGTAA	780		

XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.

OS Homo sapiens.

XX US2003087354-A1.

XX 08-MAY-2003.

XX 22-APR-2002; 2002US-00127827.

XX 17-AUG-1998; 98US-0096991P.

XX 02-JUN-1999; 99WO-US012252.

XX 25-AUG-1999; 99US-0380137.

XX 30-MAR-2000; 2000WO-US008439.

XX 01-MAY-2000; 2000WO-US014941.

XX 31-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Deenoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-801139/75.

XX P-PSDB; ADD04605.

XX New PRO nucleic acid, useful for manufacturing a medicament for

XX diagnosing or treating tumor.

XX Claim 2; Fig 375; 637pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassemias

CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGCTTTCAGCAAAACAGTGGATTTAAATCTCTTGCACAAAGTTTGGAGCAAC 60

Db 1 GTTGTGCTTTCAGCAAAACAGTGGATTTAAATCTCTTGCACAAAGTTTGGAGCAAC 60

Qy 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGACAAAGAAAGAAAGAAAGAAAG 120

Db 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGACAAAGAAAGAAAGAAAGAAAG 120

Qy 121 AAGAAAAAATATGAAAAACCATCCAGCCAAATAATGCAAAATCTATCTTTGGGCAAT 180

Db 121 AAGAAAAAATATGAAAAACCATCCAGCCAAATAATGCAAAATCTATCTTTGGGCAAT 180

Qy 181 CTTTACCGGGCTGCTGCTGCTCTTCCAGGAGTCCCGTGGCGAGCGGAGATGC 240

Db 181 CTTTACCGGGCTGCTGCTGCTCTTCCAGGAGTCCCGTGGCGAGCGGAGATGC 240

Qy 241 CACCTTCCCAAGCTATGGACAACTGACGGTCCCGCAGGGGAGAGCGCACCTCAG 300

Db 241 CACCTTCCCAAGCTATGGACAACTGACGGTCCCGCAGGGGAGAGCGCACCTCAG 300

Qy 301 GTGCACTATTGACAAACCGGCTCACCGGTGGCTGCTTAAACCGAGCACCCTCTTA 360

Db 301 GTGCACTATTGACAAACCGGCTCACCGGTGGCTGCTTAAACCGAGCACCCTCTTA 360

Qy 361 TGCTGGGAATGACAAAGTGGTGCCTGGATCTCTCGCGTGTCTTCTGAGCAACACCCAAAC 420

Db 361 TGCTGGGAATGACAAAGTGGTGCCTGGATCTCTCGCGTGTCTTCTGAGCAACACCCAAAC 420

Qy 421 GCAGTACAGATCGAGATCCAGAACCTGAGTGTGTATGACAGGGCCCTTACCTGCTC 480

Db 421 GCAGTACAGATCGAGATCCAGAACCTGAGTGTGTATGACAGGGCCCTTACCTGCTC 480

Qy 481 GGTGCAGACAGCAACACCCAAAGACCTCTAGGGTCCACCTATTGTGCAAGTATCTCC 540

Db 481 GGTGCAGACAGCAACACCCAAAGACCTCTAGGGTCCACCTATTGTGCAAGTATCTCC 540

Qy 541 CAAAATTGTAGAGATTTCTTTCAGATATCTCCATTAAATGAAGGGAACAATATTAGCCTCAC 600

Db 541 CAAAATTGTAGAGATTTCTTTCAGATATCTCCATTAAATGAAGGGAACAATATTAGCCTCAC 600

Qy 601 CTGCATAGCACTGGTAGACAGAGCCCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660

Db 601 CTGCATAGCACTGGTAGACAGAGCCCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660

Qy 661 GGTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720

Db 661 GGTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720

Qy 721 AGGGGACTTACAGTGCAGTGCCTCCATGACGTGGCCGCCCGCTGGTACCGAGAGTAAA 780

Db 721 AGGGGACTTACAGTGCAGTGCCTCCATGACGTGGCCGCCCGCTGGTACCGAGAGTAAA 780

Qy 781 GGTCAACCGTGAACCTATCCACCATACATTTTCAAGAACCAAGGGTACAGGTGTCCCGTGGG 840

Db 781 GGTCAACCGTGAACCTATCCACCATACATTTTCAAGAACCAAGGGTACAGGTGTCCCGTGGG 840

Qy 841 ACAAAGGGGACATGCGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900

Db 841 ACAAAGGGGACATGCGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900

Qy 901 CAAGGATCAGAAAAAGATGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT 960

Db 901 CAAGGATCAGAAAAAGATGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT 960

121 AAGAAAAAATCATCAAAACCATCCAGCCAAAAATGCACAAATTCATCTCTTGGGCAAT 180
121 AAGAAAAAATCATCAAAACCATCCAGCCAAAAATGCACAAATTCATCTCTTGGGCAAT 180
181 CTTCAAGGGGCTGGCTGCTCTGTCTCTTCAAGAGTGGCGGTGCGCAGCGAGATGC 240
181 CTTCAAGGGGCTGGCTGCTCTGTCTCTTCAAGAGTGGCGGTGCGCAGCGAGATGC 240
241 CACCTTCCCAAGCTATGGACAACGTCAGCGTCCGGCAGGGGAGAGCGCCACCTCAG 300
241 CACCTTCCCAAGCTATGGACAACGTCAGCGTCCGGCAGGGGAGAGCGCCACCTCAG 300
301 GTGCATATGTGAACAACCGGCTCACCGGGTGGCTTGGCTAAACCGCAGCAATCTCTTA 360
301 GTGCATATGTGAACAACCGGCTCACCGGGTGGCTTGGCTAAACCGCAGCAATCTCTTA 360
361 TCGTGGGAATCAAGTGGTGGCTCGCTCGCTCGCTCGCTCGCTCGCTCGCTCGCTCG 420
361 TCGTGGGAATCAAGTGGTGGCTCGCTCGCTCGCTCGCTCGCTCGCTCGCTCGCTCG 420
421 GCAGTACAGCTCGAGATCCAGAACGTCGATGTGATCAACGAGGCGCTTACCTGCTC 480
421 GCAGTACAGCTCGAGATCCAGAACGTCGATGTGATCAACGAGGCGCTTACCTGCTC 480
481 GGTGACAGACACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 540
481 GGTGACAGACACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 540
541 CAAAATTGTAGAGATTTCTTTCAGATATCTCCATTAAATGAAGGGAACAATATTAGCCTCAC 600
541 CAAAATTGTAGAGATTTCTTTCAGATATCTCCATTAAATGAAGGGAACAATATTAGCCTCAC 600
601 CTGCATAGCACTGTGACAGACAGCTACGTTACTTGGAGACACATCTCTCCCAAGC 660
601 CTGCATAGCACTGTGACAGACAGCTACGTTACTTGGAGACACATCTCTCCCAAGC 660
661 GGTGGCTTTGTGAGTGAAGACGAATACCTTGAAATTCAGGCGATCACCGGAGCAGTC 720
661 GGTGGCTTTGTGAGTGAAGACGAATACCTTGAAATTCAGGCGATCACCGGAGCAGTC 720
721 AGGGACTACGATGAGTGCCTCCATGACGTGGCGCGCGCGCGCGCGCGCGCGCGCG 780
721 AGGGACTACGATGAGTGCCTCCATGACGTGGCGCGCGCGCGCGCGCGCGCGCGCG 780
781 GGTCAACCGTGAATATCCACCATATCTTCAAGCCCAAGGTACAGTGTCCCGTGGG 840
781 GGTCAACCGTGAATATCCACCATATCTTCAAGCCCAAGGTACAGTGTCCCGTGGG 840
841 ACAAAGGGGACACTGCAAGTGAAGCCTCAGCAGTCCCTCAGCAGAAATCCAGTGGA 900
841 ACAAAGGGGACACTGCAAGTGAAGCCTCAGCAGTCCCTCAGCAGAAATCCAGTGGA 900
901 CAGGATGACAAAGACTGATTTGAAGGAAGAAAGGGGTGAAGTGAAGGAACAGACCTTT 960
901 CAGGATGACAAAGACTGATTTGAAGGAAGAAAGGGGTGAAGTGAAGGAACAGACCTTT 960
961 CTTCTCAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAATCACTTGGT 1020
961 CTTCTCAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAATCACTTGGT 1020
1021 GGCCTCCACAGCTGGGCGACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
1021 GGCCTCCACAGCTGGGCGACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
1081 CAGCGAGTGAACAACCGCAGCTCGAGGAGGCGAGGCTGCGTCTGGCTGCTCTTCT 1140
1081 CAGCGAGTGAACAACCGCAGCTCGAGGAGGCGAGGCTGCGTCTGGCTGCTCTTCT 1140
1141 GGTCTTGACCTGCTTCTCAAAATTTTGTAGTGGCACTTCCCGCCCGGGAAGGCT 1200
1141 GGTCTTGACCTGCTTCTCAAAATTTTGTAGTGGCACTTCCCGCCCGGGAAGGCT 1200

1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAT 1260
1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAT 1260
1261 TATACAAATGAAATTTAGAAAGAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320
1261 TATACAAATGAAATTTAGAAAGAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320
1321 AAGAATACTTTTGGGGGAAAAGAGTTTTAAAAAGAAAATTTGAAAATTCCTTTGCAGATA 1380
1321 AAGAATACTTTTGGGGGAAAAGAGTTTTAAAAAGAAAATTTGAAAATTCCTTTGCAGATA 1380
1381 TTTAGTACAAATGGAGTTTTTCTTCCCAACGGGAGAACACACACACCCCGCTTGA 1440
1381 TTTAGTACAAATGGAGTTTTTCTTCCCAACGGGAGAACACACACACCCCGCTTGA 1440
1441 CCCACTGCAAGCTGATCGTGAACCTCTTTGGTGCAGTGTGGGCAAGGGTTCAGCCTC 1500
1441 CCCACTGCAAGCTGATCGTGAACCTCTTTGGTGCAGTGTGGGCAAGGGTTCAGCCTC 1500
1501 TCTGCCCAACAGAGTGCCCAACGTGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
1501 TCTGCCCAACAGAGTGCCCAACGTGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
1561 GTCCATAGAGACAAACAGAAATGAGACCTTCCGCCCAACGCTGGCGCTCGGCGACTTTG 1620
1561 GTCCATAGAGACAAACAGAAATGAGACCTTCCGCCCAACGCTGGCGCTCGGCGACTTTG 1620
1621 GTAGACTGTGCCACCAACGCGGTGTGTGTGAAACGTGAAATTAAGAGACAAAAAAA 1679
1621 GTAGACTGTGCCACCAACGCGGTGTGTGTGAAACGTGAAATTAAGAGACAAAAAAA 1679

RESULT 64

ADC80560
ID ADC80560 standard; cdna; 1679 BP.

XX AC ADC80560;

XX DT 01-JAN-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO337 cdna.

XX KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
rectum; kidney; cervix; liver; microvascular endothelial cell;
glucose uptake modulator; FFA uptake modulator; cell proliferation;
cell differentiation; skeletal muscle cell; adipocyte cell;
pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage defect; osteoarthritis;
sports injury; proteoglycan; articular cartilage defect; thalassaemia;
rheumatoid arthritis; haemoglobin-associated disorder; gene mapping;
immune system cell infiltration; chromosome mapping; gene mapping; ss.
gene therapy; chromosome identification; chromosome marker; gene; ss.

XX OS Homo sapiens.

XX XX US2003092103-A1.

XX XX 15-MAY-2003.

XX XX 24-APR-2002; 2002US-00131815.

XX XX 22-DEC-1998; 98US-0113511P.

XX XX 01-DEC-1999; 99WO-US028634.

XX XX 22-FEB-2000; 2000WO-US004414.

XX XX 01-DEC-2000; 2000WO-US032678.

XX XX 19-DEC-2001; 2001US-00028072.

XX XX (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
FI Smith V, Stewart RA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX P-PSDB; ADC80561.
DR WPI; 2003-801168/75.
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX Claim 2; Fig 375; 637pp; English.
PS The invention relates to isolated human PRO polypeptides (secreted and
PS transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting the proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
SQ Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTCTGACAAAGCTTGAGAGCAACAC 60
DB 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTCTGACAAAGCTTGAGAGCAACAC 60
QY 61 AATCTATCAGGAAG 120
DB 61 AATCTATCAGGAAG 120
QY 121 AAGAAAAAATATGAAAAATATGAAAAATATGAAAAATATGAAAAATATGAAAAAT 180
DB 121 AAGAAAAAATATGAAAAATATGAAAAATATGAAAAATATGAAAAATATGAAAAAT 180
QY 181 CTTACGGGGGTGGGTGCTGTGTCTCTTCAAGGAGTGGCCCGTGGCAGCGAGATGC 240
DB 181 CTTACGGGGGTGGGTGCTGTGTCTCTTCAAGGAGTGGCCCGTGGCAGCGAGATGC 240
QY 241 CACCTTCCCAAGAGTATGAGCAACGTGACGGTCCGGCAGGGGAGAGCGCACCTTCAG 300
DB 241 CACCTTCCCAAGAGTATGAGCAACGTGACGGTCCGGCAGGGGAGAGCGCACCTTCAG 300
QY 301 GTGCACATTATGACAAACCGGGTCAACCGGGTGGCTGCTAAACCGCAGCACCATCTCTA 360

DB 301 GTGCACATTATGACAAACCGGGTCAACCGGGTGGCTGCTAAACCGCAGCACCATCTCTA 360
QY 361 TCTCGGGAATGACAAAGTGGTCTCGATCTCTCGGTGGTCTCTCTGAGCAACACCCAAAC 420
DB 361 TCTCGGGAATGACAAAGTGGTCTCGATCTCTCGGTGGTCTCTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAGCTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAGCTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGCAGACAGACAAACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGCAGACAGACAAACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTGAGAGATTTCTTCCAGATATCTCCATTAATGAAGGAGCAATATAGCTCAGC 600
DB 541 CAAATTTGAGAGATTTCTTCCAGATATCTCCATTAATGAAGGAGCAATATATAGCTCAGC 600
QY 601 CTGTCATAGCAACTGCTAGACACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGTCATAGCAACTGCTAGACACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGAGTGAAGAGCAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGAGTGAAGAGCAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCCCGCCGCTGGTACCGAGAGTAAA 780
DB 721 AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCCCGCCGCTGGTACCGAGAGTAAA 780
QY 781 GGTACCGTGAACACTATCCACCATACATTTAGAGCCCAAGGGTACAGGTGTCCTCCGTTGG 840
DB 781 GGTACCGTGAACACTATCCACCATACATTTAGAGCCCAAGGGTACAGGTGTCCTCCGTTGG 840
QY 841 ACAAAGGGGACACTGTCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCCTCAGTGTA 900
DB 841 ACAAAGGGGACACTGTCAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCCTCAGTGTA 900
QY 901 CAAGATGACAAAAGACTGATTGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 960
DB 901 CAAGATGACAAAAGACTGATTGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 960
QY 961 CTTCTCAAAACCTCATCTTCTTCAATGTCTCTGAAATGATGATGATGATGATGATGATG 1020
DB 961 CTTCTCAAAACCTCATCTTCTTCAATGTCTCTGAAATGATGATGATGATGATGATGATG 1020
QY 1021 GGCCTCCAAAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGGT 1080
DB 1021 GGCCTCCAAAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGGT 1080
QY 1081 CAGCGAGGTGACCAACGGCAGCTGAGGAGGCGGCTGGCTGCTGGCTGCTGCTGCTTCT 1140
DB 1081 CAGCGAGGTGACCAACGGCAGCTGAGGAGGCGGCTGGCTGCTGGCTGCTGCTGCTTCT 1140
QY 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTGAGTGCCACTTTCCCGCCAGGAGAGGCT 1200
DB 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTGAGTGCCACTTTCCCGCCAGGAGAGGCT 1200
QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
DB 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
QY 1261 TATACAAATGAAATTTAG 1320
DB 1261 TATACAAATGAAATTTAG 1320
QY 1321 AAGAAATATCTTTGGGGGAG 1380
DB 1321 AAGAAATATCTTTGGGGGAG 1380
QY 1381 TTTAGTACAAATGAGAGTCTTTCTTTTCCCAAAACCGGAAGAACACAGCACACCGCGGCTTGA 1440

Db 1381 TTTAGGTACATGGAGTTTCTTTTCCCAACGGGAAGAACACACAGCACACCCGGCTTGG 1440
Qy 1441 CCCACTGCAAGCTGCATCGTCAACCTCTTTGGTGCCAGTGTGGCAAGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGCATCGTCAACCTCTTTGGTGCCAGTGTGGCAAGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTCCGCCACGCTGGAAACATCTTGGAGCTGGCAATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTCCGCCACGCTGGAAACATCTTGGAGCTGGCAATCCCAATTCATCA 1560
Qy 1561 GTCCTAGAGAGACAGATGAGACCTTCCGGCCCAAGCTGGCGCTGGCGGCACTTTG 1620
Db 1561 GTCCTAGAGAGACAGATGAGACCTTCCGGCCCAAGCTGGCGCTGGCGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACCAACGCGCTGTGTGTGAAACGTGAAATAAAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACCAACGCGCTGTGTGTGAAACGTGAAATAAAAGAGCAAAAAA 1679
RESULT 65
ADD11067
ID ADD11067 standard; cDNA; 1679 BP.
AC ADD11067;
XX
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
XX
XX Human; gene; ss; PRO; secreted TNF-alpha; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
XX
XX US2003194774-A1.
XX
XX 16-OCT-2003.
XX
XX 21-MAY-2002; 2002US-00152399.
XX
XX 03-MAR-2000; 2000US-0187202P.
XX
XX 01-DEC-2000; 2000WO-US032678.
XX
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Pilvaroff E, Gao W;
PI Gerritsen MB, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI: 2003-852594/79.
XX
XX P-PSDB; ADD11068.
XX
XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the proliferation or differentiation
PT of chondrocyte cells and stimulating the release of tumor necrosis factor
PT alpha.
XX
XX Claim 2; SEQ ID NO 375; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTTGTGCTTCAGCAAAACAGTGGATTTAAATCTCTTCGACAACTTGAGAGCAAC 60
Db 1 GTTGTGCTTCAGCAAAACAGTGGATTTAAATCTCTTCGACAACTTGAGAGCAAC 60
Qy 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAAATTCATCTCTTGGGCAAT 180
Db 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAAATTCATCTCTTGGGCAAT 180
Qy 181 CTTTCACGGGGCTGGCTCTCTGTGTCTTCTTCCAGGAGTGCCCGTGGCAGCGAGATGC 240
Db 181 CTTTCACGGGGCTGGCTCTCTGTGTCTTCTTCCAGGAGTGCCCGTGGCAGCGAGATGC 240
Qy 241 CACTTCCCAAGCTATGACAAACGTCGCTCCGCGAGGGGGAGAGCGCCACCTCTAG 300
Db 241 CACTTCCCAAGCTATGACAAACGTCGCTCCGCGAGGGGGAGAGCGCCACCTCTAG 300
Qy 301 GTGCACATTTGACAAACCGGCTCAACCGGGTGGCTGCTAAACCGCAGCACCCTCTCTA 360
Db 301 GTGCACATTTGACAAACCGGCTCAACCGGGTGGCTGCTAAACCGCAGCACCCTCTCTA 360
Qy 361 TGCTGGGAATGACAAGTGGTGGCTTGGATCTCTCGCTGGTCTCTTGTGAGCAACCCCAAC 420
Db 361 TGCTGGGAATGACAAGTGGTGGCTTGGATCTCTCGCTGGTCTCTTGTGAGCAACCCCAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGAACGTCGATGTGTATGAGAGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACGTCGATGTGTATGAGAGGGCCCTTACACCTGCTC 480
Qy 481 GGTGCAGACAGCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGCAGACAGCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Qy 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAGACAAATATTAGCTTAC 600
Db 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAGACAAATATTAGCTTAC 600

541 CAAAATTGTAGAGATTCTTCCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAC 600
601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
661 GGTGGCTTTGTGAGTGAAGCAAGCAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
661 GGTGGCTTTGTGAGTGAAGCAAGCAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
721 AGGGGACTACGAGTGCAGTGCCTCCATGACGTGGCGCGCCCGTGTACGGAGAGTAAA 780
721 AGGGGACTACGAGTGCAGTGCCTCCATGACGTGGCGCGCCCGTGTACGGAGAGTAAA 780
781 GGTCAACGCTGAATCTATCCACATACATTTTCAAGAGCAAGGGTACAGGTGTCCTCCG 840
781 GGTCAACGCTGAATCTATCCACATACATTTTCAAGAGCAAGGGTACAGGTGTCCTCCG 840
841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
901 CAAGGATGACAAAGACTGATGAAGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
901 CAAGGATGACAAAGACTGATGAAGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
961 CCTCTCAAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGGAATACACTTGCCT 1020
961 CCTCTCAAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGGAATACACTTGCCT 1020
1021 GGCCTCCAAAGCTGGGCGCACCAATGCGAGATCATGCTATTTGGTCCAGGCCCGT 1080
1021 GGCCTCCAAAGCTGGGCGCACCAATGCGAGATCATGCTATTTGGTCCAGGCCCGT 1080
1081 CAGCGAGTGAACAAAGCAGCTCGAGAGGGGAGGCTGCTGCTGGCTGCTCTTCT 1140
1081 CAGCGAGTGAACAAAGCAGCTCGAGAGGGGAGGCTGCTGCTGGCTGCTCTTCT 1140
1141 GGTCTTGACCTGCTTCTCAAAATTTTGAATGTGAGTGCCTATCCCAACCGGGAAGGCT 1200
1141 GGTCTTGACCTGCTTCTCAAAATTTTGAATGTGAGTGCCTATCCCAACCGGGAAGGCT 1200
1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1261 TATCAAAATGAATTAAGAAACACAGCTCTATGGGACAGAAATTTGAGGGAGGGGAAAC 1320
1261 TATCAAAATGAATTAAGAAACACAGCTCTATGGGACAGAAATTTGAGGGAGGGGAAAC 1320
1321 AAGAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
1321 AAGAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
1381 TTTAGGTACAAATGAGTTTCTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGA 1440
1381 TTTAGGTACAAATGAGTTTCTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGA 1440
1441 CCCACTGCAAGCTCATCGTGCACCTCTTTGGTCCAGTGGGCAAGGGCTCAGCCTC 1500
1441 CCCACTGCAAGCTCATCGTGCACCTCTTTGGTCCAGTGGGCAAGGGCTCAGCCTC 1500
1501 TCTGCCACAGAGTGCCTCCCAACGCTGGAACATTTGAGAGTGGCCATCCCAAAATCAATCA 1560
1501 TCTGCCACAGAGTGCCTCCCAACGCTGGAACATTTGAGAGTGGCCATCCCAAAATCAATCA 1560
1561 GTCCATGAGACGAAAGATGAGACTTCCGCCCAAGCTGGCGCTGGGCACTTTG 1620
1561 GTCCATGAGACGAAAGATGAGACTTCCGCCCAAGCTGGCGCTGGGCACTTTG 1620
1621 GTAGACTGTGCCACCGGGCTGTGTGTGTAAGAGCTGTAATATAAAGAGCAAAAAA 1679
1621 GTAGACTGTGCCACCGGGCTGTGTGTGTAAGAGCTGTAATATAAAGAGCAAAAAA 1679

RESULT 66

ADD10344

ID ADD10344 standard; cDNA; 1679 BP.

XX AC ADD10344;

XX DT 01-JAN-2004 (first entry)

XX DE Human secreted/transmembrane PRO polypeptide cDNA #28.

XX ss; gene; human; secreted protein; transmembrane protein;
XX cardiovascular disorder; endothelial disorder; angiogenic disorder;
XX myocardial infarction; cardiac hypertrophy; trauma; cancer;
XX age-related macular degeneration; angiogenesis;
XX endothelial cell apoptosis; smooth muscle cell growth;
XX endothelial cell tube formation.

XX OS Homo sapiens.

XX PN US2003105011-A1.

XX PD 05-JUN-2003.

XX PF 16-AUG-2002; 2002US-00223084.

XX PR 15-SEP-2000; 2000US-0232887P.

XX PR 20-JUN-2001; 2001WO-US019692.

XX PR 09-JUL-2001; 2001WO-US021735.

XX PR 20-FEB-2002; 2002US-00081056.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;
PI Watanabe CK, Williams PM, Wood WI, Ye W;

XX WPI; 2003-810831/76.

XX DR P-PSDB; ADD10345.

XX PT New isolated nucleic acid encoding a secreted and transmembrane
XX polypeptide for treating a cardiovascular, endothelial, or angiogenic
XX disorder in a mammal, such as cancer or age-related macular degeneration.

XX PS Claim 2; SEQ ID NO 55; 493pp; English.

XX CC The invention relates to an isolated nucleic acid encoding a secreted and
XX transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded
XX by the nucleic acid, or an agonist or antagonist, is used to treat a
XX cardiovascular, endothelial, or angiogenic disorder in a mammal,
XX preferably a human. The human may have suffered a myocardial infarction
XX or has cardiac hypertrophy, trauma, a cancer, or age-related macular
XX degeneration. The cardiac hypertrophy is characterized by the presence of
XX an elevated level of pR-2 alpha. A PRO polypeptide, given in the
XX specification, or an agonist is used to inhibit or stimulate endothelial
XX cell growth in a mammal. PRO21 or an agonist is used to induce cardiac
XX hypertrophy. PRO1376 or PRO1449 is used to stimulate angiogenesis.
XX PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO
XX polypeptide, given in the specification, or an agonist is used to
XX stimulate or inhibit smooth muscle cell growth, or to induce endothelial
XX cell tube formation. The present sequence represents a cDNA encoding a
XX PRO polypeptide of the invention.

XX SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6.7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCTTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGCAACAC 60

DB 1 GTTGTGCTCTTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGCAACAC 60

QY	61	AATCTTATCAGGAAGAAAGAAAGAAAAA	CGAACTTCA	CAAAAAAGAAAAAGAAAG	120
DB	61	AATCTTATCAGGAAGAAAGAAAGAAAAA	CGAACTTCA	CAAAAAAGAAAAAGAAAGAAAG	120
QY	121	AAGAAAAAATCATGAAACCATCCAGCC	CAAAATGCA	CAATTCCTCTTTGGGCAAT	180
DB	121	AAGAAAAAATCATGAAACCATCCAGCC	CAAAATGCA	CAATTCCTCTTTGGGCAAT	180
QY	181	CTTTCAGGGGCTGGCTGCTCTGTGTCT	TTCTTCC	AAGGAGTGC	240
DB	181	CTTTCAGGGGCTGGCTGCTCTGTGTCT	TTCTTCC	AAGGAGTGC	240
QY	241	CACCTTCCCAAGCTATGCAACAGTGAC	GGTCCG	CAGGGGAGAGCCACCTCAG	300
DB	241	CACCTTCCCAAGCTATGCAACAGTGAC	GGTCCG	CAGGGGAGAGCCACCTCAG	300
QY	301	GTGCACATATTGCAACCGGGTCA	CCCGGGTGGCT	TAAACCGCAGCACCATCTCTTA	360
DB	301	GTGCACATATTGCAACCGGGTCA	CCCGGGTGGCT	TAAACCGCAGCACCATCTCTTA	360
QY	361	TGCTGGGAATGCAAGTGAGTGGTCC	TGGATCCT	CGGTGGTCTTCTGAGCAACACCAAC	420
DB	361	TGCTGGGAATGCAAGTGAGTGGTCC	TGGATCCT	CGGTGGTCTTCTGAGCAACACCAAC	420
QY	421	GCAGTACAGCATCGAGATCCAGAAC	GTGGATGT	TATGACGAGGGCCCTTACCTGTCTC	480
DB	421	GCAGTACAGCATCGAGATCCAGAAC	GTGGATGT	TATGACGAGGGCCCTTACCTGTCTC	480
QY	481	GGTGCAGACAGCAACCAACCAAGAC	CTCTAG	GGTCCACTCATTTGTCAGATCTCTCC	540
DB	481	GGTGCAGACAGCAACCAACCAAGAC	CTCTAG	GGTCCACTCATTTGTCAGATCTCTCC	540
QY	541	CAAAATTTGTAGAGATTTCTTCAGAT	ATCTCCA	TATTAAGGGAAACAATATTAGCCTCAC	600
DB	541	CAAAATTTGTAGAGATTTCTTCAGAT	ATCTCCA	TATTAAGGGAAACAATATTAGCCTCAC	600
QY	601	CTGCATAGCAACTGGTAGACAGAGC	CTACGG	TACTTTGGAGACACATCTCTCCCAAGC	660
DB	601	CTGCATAGCAACTGGTAGACAGAGC	CTACGG	TACTTTGGAGACACATCTCTCCCAAGC	660
QY	661	GTTTGGCTTTGTAGTGAAGACGAAT	ACTTTG	GAATTCAGGGCATCACCGGAGCAGTCT	720
DB	661	GTTTGGCTTTGTAGTGAAGACGAAT	ACTTTG	GAATTCAGGGCATCACCGGAGCAGTCT	720
QY	721	AGGGGACTACGAGTGACAGTCCAT	GTGCG	CGCCGTCGTACGGAGAGTAAA	780
DB	721	AGGGGACTACGAGTGACAGTCCAT	GTGCG	CGCCGTCGTACGGAGAGTAAA	780
QY	781	GGTCAACCTGAACTATCACCATA	CAATTC	TAGAACGCAAGGGTACAGGTGTCCCCGTGG	840
DB	781	GGTCAACCTGAACTATCACCATA	CAATTC	TAGAACGCAAGGGTACAGGTGTCCCCGTGG	840
QY	841	ACAAAGGGGACATGCAAGTGTGAGC	CTCAG	AGTCCCTCAGCAAAATTCAGGTGTA	900
DB	841	ACAAAGGGGACATGCAAGTGTGAGC	CTCAG	AGTCCCTCAGCAAAATTCAGGTGTA	900
QY	901	CAAGGATCACAAAAGACTGATGAAG	AAAAA	GAAGGGGTGAAAGTGAAGAACAGACCTTT	960
DB	901	CAAGGATCACAAAAGACTGATGAAG	AAAAA	GAAGGGGTGAAAGTGAAGAACAGACCTTT	960
QY	961	CCTCTCAAAATCATCTTCTTCAAT	GTCTT	GAACATGACTATGGGAACATCACTTGCCT	1020
DB	961	CCTCTCAAAATCATCTTCTTCAAT	GTCTT	GAACATGACTATGGGAACATCACTTGCCT	1020
QY	1021	GSCCTCCAAAGCTGGGCCCA	CAACAT	TGCCAGATCATGCTATTTTGGTCCAGGCGCGT	1080
DB	1021	GSCCTCCAAAGCTGGGCCCA	CAACAT	TGCCAGATCATGCTATTTTGGTCCAGGCGCGT	1080
QY	1081	CAGCAGGTGACAAACGGCAGCT	CGAGAGG	CGCAGGTCTGCTGCTGCTGCTCTCTCT	1140
DB	1081	CAGCAGGTGACAAACGGCAGCT	CGAGAGG	CGCAGGTCTGCTGCTGCTGCTCTCTCT	1140

Qy	1141	GGTCTTGCACTGCTCTCTCAAAATTTGATGTGAGTGCCTACTTCCCCACCCGGGAAAGGCT	1200
Db	1141	GGTCTTTGCACTGCTCTCTCAAAATTTGATGTGAGTGCCTACTTCCCCACCCGGGAAAGGCT	1200
Qy	1201	GGCGCCACACACACACACCAACCAACAGCAATGGCCACACCGACAGCAACCAATCAGATA	1260
Db	1201	GGCGCCACACACACACACCAACCAACAGCAATGGCCACACCGACAGCAACCAATCAGATA	1260
Qy	1261	TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC	1320
Db	1261	TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC	1320
Qy	1321	AAAGAAATACCTTTGGGGGAAAAGAGTTTAAAAAAGAAATTTGAAAATTTGCTTTGCAGATA	1380
Db	1321	AAAGAAATACCTTTGGGGGAAAAGAGTTTAAAAAAGAAATTTGAAAATTTGCTTTGCAGATA	1380
Qy	1381	TTTAGGTACAAATGGAGTTTCTTTTCCAAAACGGGAAGAACACAGCACACCCCGCTTGGGA	1440
Db	1381	TTTAGGTACAAATGGAGTTTCTTTTCCAAAACGGGAAGAACACAGCACACCCCGCTTGGGA	1440
Qy	1441	CCCACTGCAGCTGCATCGTGCAACCTCTTTGTGTCCAGTGTGGGCAAGGGCTCAGCCTC	1500
Db	1441	CCCACTGCAGCTGCATCGTGCAACCTCTTTGTGTCCAGTGTGGGCAAGGGCTCAGCCTC	1500
Qy	1501	TCGTGCCACAGAGTGCCCCACGCTGGGAACATTTGGAGTGGCCATCCCAAAATCAATCA	1560
Db	1501	TCGTGCCACAGAGTGCCCCACGCTGGGAACATTTGGAGTGGCCATCCCAAAATCAATCA	1560
Qy	1561	GTCCATAGACAGCAACAGATGAGACCTTCCTCCGCCCAAGCGTGGCGCTGGGCGACCTTGG	1620
Db	1561	GTCCATAGACAGCAACAGATGAGACCTTCCTCCGCCCAAGCGTGGCGCTGGGCGACCTTGG	1620
Qy	1621	GTAGACTGTGCCACCCACGGCGTGTGTGTGAAACGTGAAATAAAAAGAGCAAAAAAAA	1679
Db	1621	GTAGACTGTGCCACCCACGGCGTGTGTGTGAAACGTGAAATAAAAAGAGCAAAAAAAA	1679
RESULT 67			
ADCA7948			
ID	ADCA7948	standard; cDNA; 1679 BP.	
XX	AC	ADCA7948;	
XX	AC	ADCA7948;	
DT	01-JAN-2004	(first entry)	
DE	Human PRO polynucleotide #188.		
XX	Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;		
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		
KW	liver; microvascular endothelial cell; glucose; rFA;		
KW	skeletal muscle cell; adipocyte cell; pericyte cell;		
KW	inner ear utricular supporting cell; T-lymphocyte cell;		
KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;		
KW	immune system cell infiltration.		
OS	Homo sapiens.		
XX	OS	Homo sapiens.	
PN	US2003194771-A1.		
XX	PN	US2003194771-A1.	
PD	16-OCT-2003.		
XX	PD	16-OCT-2003.	
PF	21-MAY-2002; 2002US-00152377.		
XX	PF	21-MAY-2002; 2002US-00152377.	
PR	09-DEC-1999; 99US-0170262P.		
PR	01-DEC-2000; 2000WO-US032678.		
PR	19-DEC-2001; 2001US-00028072.		
XX	PR	19-DEC-2001; 2001US-00028072.	
PA	(GETH) GENENTECH INC.		
PI	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;		

(GETH) GENENTECH INC.
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Gurney SL, Smith V;
PI Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-844454/78.
DR P-PSDB; ADC47949.

XX New secreted and transmembrane PRO polypeptides and nucleic acids useful
PT for detecting a tumor, stimulating the release of proteoglycans from
PT cartilage and stimulating the proliferation of endothelial cells.

XX Claim 2; Fig 375; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	GTGTGCTCTTCAGCAACAGTGGATTAAATCTCCTTGACACAGCTTGAGAGCAAC	60
DB	1	GTGTGCTCTTCAGCAACAGTGGATTAAATCTCCTTGACACAGCTTGAGAGCAAC	60
QY	61	AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGACAAAGAAAGAAAGAAAG	120
DB	61	AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGACAAAGAAAGAAAGAAAG	120
QY	121	AGAAAGAAATCATGAAACATCCAGCCAAATGCAATGCAATGCAATGCAATGCAAT	180
DB	121	AGAAAGAAATCATGAAAGAAATCATCCAGCCAAATGCAATGCAATGCAATGCAAT	180
QY	181	CTTACCGGGGTGGTGTCTGTGTCTCTTCCAGGAGTGCCTGGGCGAGCGAGATGC	240
DB	181	CTTACCGGGGTGGTGTCTGTGTCTCTTCCAGGAGTGCCTGGGCGAGCGAGATGC	240
QY	241	CACCTTCCCAAGATATGGAACAGTGAACGGTCCGCGAGGGGAGAGCGCCACCTCAG	300
DB	241	CACCTTCCCAAGATATGGAACAGTGAACGGTCCGCGAGGGGAGAGCGCCACCTCAG	300
QY	301	GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGCTAAACCGGAGCACCATCTCTA	360

DB	301	GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGCTGCTAAACCGGAGCACCATCTCTA	360
QY	361	TGCTGGGAATGACAAGTGGTGCCTCGGATCTCTCGGTGGTCTCTTGAGAGCAACCCAAAC	420
DB	361	TGCTGGGAATGACAAGTGGTGCCTCGGATCTCTCGGTGGTCTCTTGAGAGCAACCCAAAC	420
QY	421	CGAGTACAGCATCAGATCCAGAACGTTGGATGTATGACGAGGGCCCTTACACCTGCTC	480
DB	421	CGAGTACAGCATCAGATCCAGAACGTTGGATGTATGACGAGGGCCCTTACACCTGCTC	480
QY	481	GGTGAG	540
DB	481	GGTGAG	540
QY	541	CAAAATCTAGAGATCTTCTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTTAC	600
DB	541	CAAAATCTAGAGATCTTCTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTTAC	600
QY	601	CTGCATAGCAATCTGTAG	660
DB	601	CTGCATAGCAATCTGTAG	660
QY	661	GGTTCGCTTTGTAGTGAAGAGAGATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720
DB	661	GGTTCGCTTTGTAGTGAAGAGAGATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720
QY	721	AGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCGCGCGCGCGCGCGCGCGCG	780
DB	721	AGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCGCGCGCGCGCGCGCGCGCG	780
QY	781	GGTTCACCTGACATCTCCATCATCTTCAATGACGTGGCGCGCGCGCGCGCGCGCGCG	840
DB	781	GGTTCACCTGACATCTCCATCATCTTCAATGACGTGGCGCGCGCGCGCGCGCGCGCG	840
QY	841	ACAAAGGGGACACTGAGTGTGAAGCTCAGAGTCCCTCAGCAGATTCAGAGTGTGA	900
DB	841	ACAAAGGGGACACTGAGTGTGAAGCTCAGAGTCCCTCAGCAGATTCAGAGTGTGA	900
QY	901	CAAGATGACAAAGACTGATGAGGAAAGAAAGGGGTGAAGTGGAAAGCAACACCTTT	960
DB	901	CAAGATGACAAAGACTGATGAGGAAAGAAAGGGGTGAAGTGGAAAGCAACACCTTT	960
QY	961	CCTCTCAAACTCATCTTCTTCAATGCTCTGAAACATGACTATGGAACTACACTTGGT	1020
DB	961	CCTCTCAAACTCATCTTCTTCAATGCTCTGAAACATGACTATGGAACTACACTTGGT	1020
QY	1021	GGCTCCCAAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGGGCGCGT	1080
DB	1021	GGCTCCCAAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGGGCGCGT	1080
QY	1081	CAGCAGGTGAGCAACCGGACGTCGAGGAGGCGGCTGCGCTCTGGCTGTGCTCTTCT	1140
DB	1081	CAGCAGGTGAGCAACCGGACGTCGAGGAGGCGGCTGCGCTCTGGCTGTGCTCTTCT	1140
QY	1141	GGTCTTGACCTGCTTCTCAAAATTTTGAATGAGTGCCACTTCCCGCCGGGAAAGGT	1200
DB	1141	GGTCTTGACCTGCTTCTCAAAATTTTGAATGAGTGCCACTTCCCGCCGGGAAAGGT	1200
QY	1201	GGCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC	1260
DB	1201	GGCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC	1260
QY	1261	TATACAAATGAAATTAGAAGAAACACAGCTCATCGGACAGAAATTTGAGGGAGGGAAAC	1320
DB	1261	TATACAAATGAAATTAGAAGAAACACAGCTCATCGGACAGAAATTTGAGGGAGGGAAAC	1320
QY	1321	AAAGAAATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCCCTTGCAGATA	1380
DB	1321	AAAGAAATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCCCTTGCAGATA	1380
QY	1381	TTAGTACAAATGGAGTTTCTTTTCCCAACCGGGAAGAACACAGCACACCGCGCTTGA	1440

Db 1381 TTTAGGTACAATGGAGTTTCTTTTCCCAACGGGAAGAACACACAGCACACCCGGCTTGGGA 1440
Qy 1441 CCCACTGCAAGCTGCATCGTGCACCTCTTTGGTCCAGTGTGGCGAAGGCTCAGGCTC 1500
Db 1441 CCCACTGCAAGCTGCATCGTGCACCTCTTTGGTCCAGTGTGGCGAAGGCTCAGGCTC 1500
Qy 1501 TCTGCCACAGAGTGGCCCCCAGCTGGAACATCTTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGGCCCCCAGCTGGAACATCTTGGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGCGAACAGAAATGAGACCTTCCGGGCCAAGCGTGGCGCTGGCGGCACTTTG 1620
Db 1561 GTCCATAGAGCGAACAGAAATGAGACCTTCCGGGCCAAGCGTGGCGCTGGCGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACCAAGCGGTGTGTGTGAAACGTGAAATAAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACCAAGCGGTGTGTGTGAAACGTGAAATAAAGAGCAAAAAA 1679

RESULT 68
ADCT7826
ID ADC77826 standard; cDNA; 1679 BP.
XX
AC ADC77826;
DT
XX 01-JAN-2004 (first entry)
DE Novel human secreted and transmembrane protein PRO337 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.

XX Homo sapiens.
XX
XX US2003088066-A1.
XX
XX 08-MAY-2003.
XX
XX 13-AUG-2002; 2002US-00219466.
XX
XX 01-JUN-2001; 2001WO-US017800.
XX
XX 29-JUN-2001; 2001WO-US021066.
XX
XX 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-657980/62.
XX
XX P-PSDB; ADC77827.
XX
XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
XX useful in gene therapy, or for preparing a medicament for treating a
XX condition that is responsive to the PRO polypeptide or anti-PRO antibody,
XX e.g. cancer.
XX
XX Claim 2; Fig 125; 314pp; English.

XX The invention describes an isolated PRO (secreted and transmembrane)
XX polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
XX useful for stimulating the proliferation of or gene expression in
XX pericyte cells. PRO337, PRO229, PRO1272 or PRO4405 polypeptide are useful
XX for stimulating the proliferation or differentiation of chondrocyte
XX cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
XX are useful for stimulating the release of tumour necrosis factor (TNF) -

CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO1083, PRO840, PRO1080.
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.

XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGCTCTTCAGCAACAGTGGATTAAATCTCTTGCACAACTTGTGAGAGCAACAC 60
Db 1 GTTGTGCTCTTCAGCAACAGTGGATTAAATCTCTTGCACAACTTGTGAGAGCAACAC 60

Qy 61 AATCTATCAGGAAGAAAGAAAGAAAAACCGAACTGTACAAAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAAAACCGAACTGTACAAAAAGAAAGAAAGAAAG 120

Qy 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAATGCAAAATCTATCTCTTGGGCAAT 180
Db 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAATGCAAAATCTATCTCTTGGGCAAT 180

Qy 181 CTTTCAAGGGCTGGCTCTGTCTCTTCTTCCAGAGAGTCCCGTGGCAGCGAGATGC 240
Db 181 CTTTCAAGGGCTGGCTCTGTCTCTTCTTCCAGAGAGTCCCGTGGCAGCGAGATGC 240

Qy 241 CACTTTCCTCCAAAGCTATGGACAACTGTCGGTCCCGCAGGGGAGAGCCGCCCTCAG 300
Db 241 CACTTTCCTCCAAAGCTATGGACAACTGTCGGTCCCGCAGGGGAGAGCCGCCCTCAG 300

Qy 301 GTGCACATTATGACAAACCGGGTCCACCGGGTGGCTTAAACCGCAGCACCCTCTCTA 360
Db 301 GTGCACATTATGACAAACCGGGTCCACCGGGTGGCTTAAACCGCAGCACCCTCTCTA 360

Qy 361 TCGTGGGAATGACAAAGTGGTCCCTGGATCTCTGGGTGGTCTTCTGAGCAACACCCAAAC 420
Db 361 TCGTGGGAATGACAAAGTGGTCCCTGGATCTCTGGGTGGTCTTCTGAGCAACACCCAAAC 420

Qy 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACGAGGGCCCTTACACTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACGAGGGCCCTTACACTGCTC 480

Qy 481 GGTGCAGACAGAACCAACCCAAAGACCTTGGGTCCACTTATGAGCAACACCCAAAC 540
Db 481 GGTGCAGACAGAACCAACCCAAAGACCTTGGGTCCACTTATGAGCAACACCCAAAC 540

Qy 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTACCTCAC 600

Db 541 CAAAATTGTAGAGATTCTTTCAGATATCTCCATTAAATGAGGGAACAATATTAGCCTCAC 600
Qy 601 CTGATAGCAACTGCTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
Db 601 CTGATAGCAACTGCTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
Qy 661 GGTTCGGCTTTGTAGTGAAGACGAATACTTTGGAATTCAGGGCATCCCGGAGCAGTC 720
Db 661 GGTTCGGCTTTGTAGTGAAGACGAATACTTTGGAATTCAGGGCATCCCGGAGCAGTC 720
Qy 721 AGGGGACTACAGTGCAGTCTCCATAGAGTGGCGCGCGCTGTGTACGGAGAGTAA 780
Db 721 AGGGGACTACAGTGCAGTCTCCATAGAGTGGCGCGCGCTGTGTACGGAGAGTAA 780
Qy 781 GGTCAACGTTGAACATTCACCATATCTTCAAGACCAAGGTACAGTCTCCCGTGGG 840
Db 781 GGTCAACGTTGAACATTCACCATATCTTCAAGACCAAGGTACAGTCTCCCGTGGG 840
Qy 841 ACAAAGGGGACACTGAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGTGTGA 900
Db 841 ACAAAGGGGACACTGAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGTGTGA 900
Qy 901 CAGGATGACAAAGAGCTGATTGAAGGAAAGAGAGGGGTGAAGTGAAGACAGACTTT 960
Db 901 CAGGATGACAAAGAGCTGATTGAAGGAAAGAGAGGGGTGAAGTGAAGACAGACTTT 960
Qy 961 CCTCTCAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAATTCACCTTGGT 1020
Db 961 CCTCTCAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAATTCACCTTGGT 1020
Qy 1021 GGCCTCCAAAGCTGGGACCAACCAATGCCAGATCATGCTATTTGGTCCAGGCGCGT 1080
Db 1021 GGCCTCCAAAGCTGGGACCAACCAATGCCAGATCATGCTATTTGGTCCAGGCGCGT 1080
Qy 1081 CAGCGAGTGAACAAACGCGCTCGAGAGGCGAGGCTGCGTCTGGCTGCTCTTCT 1140
Db 1081 CAGCGAGTGAACAAACGCGCTCGAGAGGCGAGGCTGCGTCTGGCTGCTCTTCT 1140
Qy 1141 GGTCTTGACCTGCTTCTCAATTTTGAATGAGTGCACCTTCCACCGGGAAGGCT 1200
Db 1141 GGTCTTGACCTGCTTCTCAATTTTGAATGAGTGCACCTTCCACCGGGAAGGCT 1200
Qy 1201 CCGCGCACACACACCAACCAACAGCAATGGCAACCGCAGCAGCAACCAATCAGATA 1260
Db 1201 CCGCGCACACACACCAACCAACAGCAATGGCAACCGCAGCAGCAACCAATCAGATA 1260
Qy 1261 TATACAAATGAATTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGGAGGGGAAC 1320
Db 1261 TATACAAATGAATTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGGAGGGGAAC 1320
Qy 1321 AAAGAACTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAAGAACTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Qy 1381 TTTAGGTACAAATGAGTTTCTTTTCCAAACCGGGAAGAACAGCAGCACACCCGGCTTGA 1440
Db 1381 TTTAGGTACAAATGAGTTTCTTTTCCAAACCGGGAAGAACAGCAGCACACCCGGCTTGA 1440
Qy 1441 CCCACTGAAGCTCATGTCGAACCTTCTTTGGTCCAGTGTGGGCAAGGCTCAGCCTC 1500
Db 1441 CCCACTGAAGCTCATGTCGAACCTTCTTTGGTCCAGTGTGGGCAAGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGCCGCCACCTTCGCGCCCAAGCGTGGCGCTGGGCACTTTG 1560
Db 1501 TCTGCCACAGAGTGCCGCCACCTTCGCGCCCAAGCGTGGCGCTGGGCACTTTG 1560
Qy 1561 GTCCATAGACGAAACAGATGAGACCTTCGCGCCCAAGCGTGGCGCTGGGCACTTTG 1620
Db 1561 GTCCATAGACGAAACAGATGAGACCTTCGCGCCCAAGCGTGGCGCTGGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACCGGGGTGTGTGTGAAGCTGAATATAAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACCGGGGTGTGTGTGAAGCTGAATATAAAGAGCAAAAAA 1679

RESULT 69

ADC80008
ID ADC80008 standard; cDNA; 1679 BP.
XX
AC ADC80008;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
rectum; kidney; cervix; liver; microvascular endothelial cell;
glucose uptake modulator; PFA uptake modulator; cell proliferation;
cell differentiation; skeletal muscle cell; adipocyte cell;
pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
immune system cell infiltration; chromosome mapping; gene mapping;
gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003087358-A1.
XX
PD 06-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127833.
XX
PR 01-SEP-1999; 98US-0098750P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
(GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801143/75.
DR P-PSDB; ADC80009.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
diagnosing or treating tumor.
XX
PS Claim 2; Fig 375; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of

CC glucose or PFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX
 SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0

QY	1	GTGTGTCTTT	CAGCAAAA	CAGTGGATTT	TAATCTCTT	GCACAG	AGCTT	CAGAGCTT	CAGAGCAAC	60
DB	1	GTGTGTCTTT	CAGCAAAA	CAGTGGATTT	TAATCTCTT	TGCA	CAAGT	TTGAGAGCAAC	60	
QY	61	AATCTAT	CAGAAAGAA	GAAGAAAA	CCGAAC	CTTGA	CAAAAA	AAGAAAAA	GAAG	120
DB	61	AATCTAT	CAGAAAGAA	GAAGAAAA	CCGAAC	CTTGA	CAAAAA	AAGAAAAA	GAAG	120
QY	121	AGAAAAA	AAATCAT	GA AAAACCAT	CCAGCC	AAAAATG	CAATTC	TATCTCTT	GGGCAAT	180
DB	121	AGAAAAA	AAATCAT	GA AAAACCAT	CCAGCC	AAAAATG	CAATTC	TATCTCTT	GGGCAAT	180
QY	181	CTTCAC	GGGGCT	GGCTCTCT	TGTGTCTT	TCCAA	GGAGTGC	CGTGG	CAGCGAGATGC	240
DB	181	CTTCAC	GGGGCT	GGCTCTCT	TGTGTCTT	TCCAA	GGAGTGC	CGTGG	CAGCGAGATGC	240
QY	241	CACCTT	CCCCA	AGACTT	TGGA	CAACGT	GCATCG	GGGAGAG	CGCCACCT	300
DB	241	CACCTT	CCCCA	AGACTT	TGGA	CAACGT	GCATCG	GGGAGAG	CGCCACCT	300
QY	301	GTGCAC	TATTGA	CAACA	CGGGGT	CACCC	GGGTGG	CGCTTAA	ACCGCAG	360
DB	301	GTGCAC	TATTGA	CAACA	CGGGGT	CACCC	GGGTGG	CGCTTAA	ACCGCAG	360
QY	361	TGCTGG	GAATGA	CAAGT	GTGTCT	CGCTGT	CTCTT	CTGAG	CAACACCC	420
DB	361	TGCTGG	GAATGA	CAAGT	GTGTCT	CGCTGT	CTCTT	CTGAG	CAACACCC	420
QY	421	GCAGT	CAGCAT	CGAGAT	CCAGAA	CGTGG	ATGTAT	CACAG	GGGGCCCTT	480
DB	421	GCAGT	CAGCAT	CGAGAT	CCAGAA	CGTGG	ATGTAT	CACAG	GGGGCCCTT	480
QY	481	GGTCAG	CAGAC	AGAAC	CTT	AGGTT	CCACCT	CAATTGT	GCAAGTATCTCC	540
DB	481	GGTCAG	CAGAC	AGAAC	CTT	AGGTT	CCACCT	CAATTGT	GCAAGTATCTCC	540
QY	541	CAAAAT	TGTAGAG	ATTTCTT	CAGATAT	CTCC	CAATTAAT	GAAGG	AACAATATTAG	600
DB	541	CAAAAT	TGTAGAG	ATTTCTT	CAGATAT	CTCC	CAATTAAT	GAAGG	AACAATATTAG	600
QY	601	CTGCAT	AGCAAC	CTGGT	AGAC	CGAG	CTC	AGGTT	AGCA	660
DB	601	CTGCAT	AGCAAC	CTGGT	AGAC	CGAG	CTC	AGGTT	AGCA	660
QY	661	GGTTGG	CTTTGT	AGTGA	CAAGCA	AAATCTT	GGAAAT	TTCAGG	GCATCAC	720
DB	661	GGTTGG	CTTTGT	AGTGA	CAAGCA	AAATCTT	GGAAAT	TTCAGG	GCATCAC	720
QY	721	AGGGG	ACTAC	AGTGC	AGTCC	CTT	CAATGA	CTGTGC	CGCGCC	780
DB	721	AGGGG	ACTAC	AGTGC	AGTCC	CTT	CAATGA	CTGTGC	CGCGCC	780

QY	781	G	G	T	C	A	C	G	T	G	A	A	C	T	A	T	C	A	C	A	T	T	T	C	A	G	A	G	C	C	A	G	G	T	A	C	A	G	T	G	T	C	C	C	T	G	G		840			
DB	781	G	G	T	C	A	C	G	T	G	A	A	C	T	A	T	C	A	C	A	T	T	T	C	A	G	A	G	C	C	A	G	G	T	A	C	A	G	T	G	T	C	C	C	T	G	G		840			
QY	841	A	C	A	A	A	G	G	G	G	A	C	A	C	T	G	C	A	G	T	G	A	A	C	C	T	C	A	G	A	G	C	C	C	T	C	A	G	A	A	T	T	C	A	G	T	G	G		900		
DB	841	A	C	A	A	A	G	G	G	A	C	A	C	T	G	C	A	G	T	G	A	A	C	C	T	C	A	G	A	G	C	C	C	T	C	A	G	A	A	T	T	C	A	G	T	G	G		900			
QY	901	C	A	G	G	T	G	A	C	A	A	G	A	C	T	G	A	A	C	A	A	G	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A		960			
DB	901	C	A	G	G	T	G	A	C	A	A	G	A	C	T	G	A	A	C	A	A	G	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A		960			
QY	961	C	C	T	C	T	C	A	A	A	A	C	T	C	A	T	T	C	A	A	T	G	T	C	T	G	T	G	A	A	C	A	T	A	T	G	G	A	A	C	T	A	C	A	C	T	T	G	C	G		1020
DB	961	C	C	T	C	A	A	A	A	C	T	C	A	T	T	C	A	A	T	G	T	C	T	G	T	G	A	A	C	A	T	A	T	G	G	A	A	C	T	A	C	A	C	T	T	G	C	G		1020		
QY	1021	G	G	C	T	C	C	A	A	C	A	A	G	T	G	G	C	A	C	A	C	A	A	T	G	C	A	T	C	A	T	G	C	A	T	C	A	T	G	T	G	T	G	T	G	T	G	C	G		1080	
DB	1021	G	G	C	T	C	C	A	A	C	A	A	G	T	G	G	C	A	C	A	C	A	A	T	G	C	A	T	C	A	T	G	C	A	T	G	T	G	T	G	T	G	T	G	T	G	C	G		1080		
QY	1081	C	A	G	C	A	G	G	T	G	A	C	A	A	C	C	A	C	A	C	A	C	A	A	C	A	C	A	C	A	C	A	C	A	C	A	C	A	C	A	C	A	C	A	C	A	C		1140			
DB	1081	C	A	G	C	A	G	G	T	G	A	C	A	A	C	C	A	C	A	C	A	C	A	A	C	A	C	A	C	A	C	A	C	A	C	A	C	A	C	A	C	A	C	A	C	A	C		1140			
QY	1141	G	G	T	C	T	G	C	A	C	T	G	T	C	T	C	A	A	A	T	T	T	G	A	T	G	A	T	G	C	A	C	A	T	T	C	C	C	A	C	C	C	G	G	A	A	A	G	C	T		1200
DB	1141	G	G	T	C	T	G	C	A	C	T	G	T	C	T	C	A	A	A	T	T	T	G	A	T	G	A	T	G	C	A	C	A	T	T	C	C	C	A	C	C	C	G	G	A	A	A	G	C	T		1200
QY	1201	G	C	C	G	C	C	A	C	C	A	C	A	C	A	C	A	A	C	A	A	T	G	G	C	A	A	C	A	C	C	A	C	C	A	C	C	A	C	C	A	C	C	A	C	A	C		1260			
DB	1201	G	C	C	G	C	C	A	C	C	A	C	A	C	A	C	A	A</																																		

RESULT 70
ADD11304
ID ADD11304 standard; cDNA; 1679 BP.
XX
XX
AC ADD11304;
XX
XX
DT 01-JAN-2004 (first entry)
DE
DE 'Human secreted/transmembrane PRO polypeptide cDNA #28.
XX
XX ss: gene: human; secreted protein; transmembrane protein;

KW cardiovascular disorder; endothelial disorder; angiogenic disorder;
KW myocardial infarction; cardiac hypertrophy; trauma; cancer;
KW age-related macular degeneration; angiogenesis;
KW endothelial cell apoptosis; smooth muscle cell growth;
KW endothelial cell tube formation.

OS Homo sapiens.

XX US2003105013-A1.

XX 05-JUN-2003.

XX 16-AUG-2002; 2002US-00223090.

XX 20-JUN-2001; 2001WO-US019692.

PR 09-JUL-2001; 2001WO-US021735.

PR 20-FEB-2002; 2002US-00081056.

XX (GETH) GENENTECH INC.

XX Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;

PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;

PI Watanabe CK, Williams FM, Wood WI, Ye W;

XX WPI; 2003-801242/75.

DR P-PSDB; ADD11305.

XX New isolated nucleic acid encoding a secreted and transmembrane

PT polypeptide, useful for treating a cardiovascular, endothelial, or

PT angiogenic disorder in a mammal, such as cancer or age-related macular

PT degeneration.

XX Claim 2; SEQ ID NO 55; 493pp; English.

XX The invention relates to an isolated nucleic acid encoding a secreted and
XX transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded
XX by the nucleic acid, or an agonist or antagonist, is used to treat a
XX cardiovascular, endothelial, or angiogenic disorder in a mammal,
XX preferably a human. The human may have suffered a myocardial infarction
XX or has cardiac hypertrophy, trauma, a cancer, or age-related macular
XX degeneration. The cardiac hypertrophy is characterized by the presence of
XX an elevated level of pGF-2 alpha. A PRO polypeptide, given in the
XX specification, or an agonist is used to inhibit or stimulate endothelial
XX cell growth in a mammal. PRO21 or an agonist is used to induce cardiac
XX hypertrophy. PRO1376 or PRO1449 is used to stimulate angiogenesis.
XX PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO
XX polypeptide, given in the specification, or an agonist is used to
XX stimulate or inhibit smooth muscle cell growth, or to induce endothelial
XX cell tube formation. The present sequence represents a cDNA encoding a
XX PRO polypeptide of the invention.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

XX Query Match 100.0%; Score 1679; DB 1; Length 1679;

XX Best Local Similarity 100.0%; Pred. No. 6.7e-05;

XX Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAACAC 60

DB 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAACAC 60

QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

QY 121 AAGAAAAAATCATGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180

DB 121 AAGAAAAAATCATGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180

QY 181 CTTACGGGGTGGTGTCTGTGTCTCTTCCAAAGAGTGCCTCGCGCAGCGAGATGC 240

DB 181 CTTACGGGGTGGTGTCTGTGTCTCTTCCAAAGAGTGCCTCGCGCAGCGAGATGC 240

QY 241 CACCTTCCCAAGACTATGACAAACGTGACGGTCCGSCAGGGGGAGAGCGCCACCTTCAG 300

DB 241 CACCTTCCCAAGACTATGACAAACGTGACGGTCCGSCAGGGGGAGAGCGCCACCTTCAG 300

QY 301 GTGCATTATTGACAAACCGGTCACCGGGTGGCTGGCTTAAACCGCAGCAACCAATCTCTA 360

DB 301 GTGCATTATTGACAAACCGGTCACCGGGTGGCTGGCTTAAACCGCAGCAACCAATCTCTA 360

QY 361 TGCTGGGAATGACAAAGTGGTCCCTGGATCCCTCGGTGGTCTCTTCTGAGCAACCAAC 420

DB 361 TGCTGGGAATGACAAAGTGGTGGCTGGATCCCTCGGTGGTCTCTTCTGAGCAACCAAC 420

QY 421 GCAGTACAGCATCGAGATCCAGAAACGTGGATGTATGACGAGGGCCCTTACAGCTGCTC 480

DB 421 GCAGTACAGCATCGAGATCCAGAAACGTGGATGTATGACGAGGGCCCTTACAGCTGCTC 480

QY 481 GGTGAGACGACAAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 540

DB 481 GGTGAGACGACAAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 540

QY 541 CAAAATTGTAGAGATTTCTTTCAGATATCTCATTAAATGAAGGGAAACAATATTAGCTTCAC 600

DB 541 CAAAATTGTAGAGATTTCTTTCAGATATCTCATTAAATGAAGGGAAACAATATTAGCTTCAC 600

QY 601 CTGCATAGCACTGGTAGACGAGGCTACGGTACTTGGAGACACATCTCTCCCAAGC 660

DB 601 CTGCATAGCACTGGTAGACGAGGCTACGGTACTTGGAGACACATCTCTCTCCCAAGC 660

QY 661 GGTGGCTTTTGTAGTGAAGACGAATATCTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720

DB 661 GGTGGCTTTTGTAGTGAAGACGAATATCTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720

QY 721 AGGGGACTACAGTGCAGTGCCTCAATGACGTGGCGCGCGCGCGCGTGTACGGAGAGTAAA 780

DB 721 AGGGGACTACAGTGCAGTGCCTCAATGACGTGGCGCGCGCGCGTGTGTACGGAGAGTAAA 780

QY 781 GGTCACTGTAACATATCCACCATACATTTCAAGAGCAAGGGTACAGGTGTCTCCCGTGGG 840

DB 781 GGTCACTGTAACATATCCACCATACATTTCAAGAGCAAGGGTACAGGTGTCTCCCGTGGG 840

QY 841 ACAAAGGGGACACTGCACTGCACTGCACTGCACTGCACTGCACTGCACTGCACTGCACTG 900

DB 841 ACAAAGGGGACACTGCACTGCACTGCACTGCACTGCACTGCACTGCACTGCACTGCACTG 900

QY 901 CAAGGATGACAAAGACTGATTTGAAGAAAGAAAGGGGTGAAGTGGAAACACACCTTT 960

DB 901 CAAGGATGACAAAGACTGATTTGAAGAAAGAAAGGGGTGAAGTGGAAACACACCTTT 960

QY 961 CCTCTCAAAACCTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAACCTACCTTGGCT 1020

DB 961 CCTCTCAAAACCTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAACCTACCTTGGCT 1020

QY 1021 GGCCTCCACAGCTGGGCGCACCAATGCCAGATCATGTATTTGGTCCAGGCGCGCT 1080

DB 1021 GGCCTCCACAGCTGGGCGCACCAATGCCAGATCATGTATTTGGTCCAGGCGCGCT 1080

QY 1081 CAGCGAGGTGAGCAACCGGCACTGCGAGGGGCGAGGTGCGTCTGGCTGCTCTTCT 1140

DB 1081 CAGCGAGGTGAGCAACCGGCACTGCGAGGGGCGAGGTGCGTCTGGCTGCTCTTCT 1140

QY 1141 GGTCTGACCTGCTTCTCAAAATTTTGAATGAGTGGCACTTCCCGCCCGGGAAGGCT 1200

DB 1141 GGTCTGACCTGCTTCTCAAAATTTTGAATGAGTGGCACTTCCCGCCCGGGAAGGCT 1200

QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260

DB 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260

QY 1261 TATACAAATGAATTTAGAGAAACACGCTTATCGGACAGAAATTTGAGGGAGGGGAGC 1320

DB 1261 TATACAAATGAATTTAGAGAAACACGCTTATCGGACAGAAATTTGAGGGAGGGGAGC 1320

QY 1321 AAGAAATACCTTTGGGGGAAAGAGATTTTAAAAAAGAAATTTGAAATTTGCCTTGCAGATA 1380

Db 1321 AAGAAATACCTTTGGGGGAAAAGATTTTAAAAGAAATTTAAATTCCTTGCAGATA 1380
Qy 1381 TTTAGGTACAAATGAGTTTCTTTTCCCAACCGGAAGAACACAGACACACCGGCTTGA 1440
Db 1381 TTTAGGTACAAATGAGTTTCTTTTCCCAACCGGAAGAACACAGACACACCGGCTTGA 1440
Qy 1441 CCACCTGACAGCTGATCGTGCACCTCTTTGGTGCAGTGTGGGCAAGGCTCAGCCCTC 1500
Db 1441 CCACCTGACAGCTGATCGTGCACCTCTTTGGTGCAGTGTGGGCAAGGCTCAGCCCTC 1500
Qy 1501 TCTGCCCCACAGAGTGGCCCCACCTGGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
Db 1501 TCTGCCCCACAGAGTGGCCCCACCTGGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
Qy 1561 GTCCATAGACGACGACGATGAGACTTCCGGCCCAAGCGTGGCGCTGGGGCACTTTG 1620
Db 1561 GTCCATAGACGACGACGATGAGACTTCCGGCCCAAGCGTGGCGCTGGGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACCGCGTGTGTGTAACGTTGAAATATAAAGAGACAAAAA 1679
Db 1621 GTAGACTGTGCCACCGCGTGTGTGTAACGTTGTAACGTTGAAATATAAAGAGACAAAAA 1679

RESULT 71
ADD09477
ID ADD09477 standard; cDNA; 1679 BP.
XX
AC ADD09477;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumor necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003194775-A1.
XX
PD 16-OCT-2003.
XX
PF 28-MAY-2002; 2002US-00156848.
XX
XX 03-MAR-2000; 2000US-0187202P.
XX
PR 01-DEC-2000; 2000WO-US032678.
XX
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-852595/79.
XX
DR P-FSDS; ADD09478.
XX
XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful
XX for detecting a tumor, stimulating the release of tumor necrosis factor
XX alpha from blood and stimulating the release of proteoglycans from
XX cartilage.
XX
PS Claim 2; Fig 375; 637pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTGTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGACAAAGCTTGAGAGCAAC 60
Db 1 GTGTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGACAAAGCTTGAGAGCAAC 60
Qy 61 ATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAAAAATCATGAAAAACCATCCAGCCAAAAATGCACAAATTTCTTCTTGGGCAAT 180
Db 121 AAGAAAAAAATCATGAAAAACCATCCAGCCAAAAATGCACAAATTTCTTCTTGGGCAAT 180
Qy 181 CTTTCAGGGGCTGGCTGCTCTGTCTCTTCAGAGAGTCCCGTGGCAGCGAGATGC 240
Db 181 CTTTCAGGGGCTGGCTGCTCTGTCTCTTCAGAGAGTCCCGTGGCAGCGAGATGC 240
Qy 241 CACCTTCCCAAGCTATGGACAACTGACGGTCCGGCAGGGGAGAGCGCCCTCAG 300
Db 241 CACCTTCCCAAGCTATGGACAACTGACGGTCCGGCAGGGGAGAGCGCCCTCAG 300
Qy 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGACCACTCTTA 360
Db 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGACCACTCTTA 360
Qy 361 TGCTGGGAATGACAGTGGTGGCTGGATCTCGCTGGCTCTCTGTGAGCAACACCCAAAC 420
Db 361 TGCTGGGAATGACAGTGGTGGCTGGATCTCGCTGGCTCTCTGTGAGCAACACCCAAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGAACGTCGATGTGATGACGAGGGCCCTTACCTGTCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACGTCGATGTGATGACGAGGGCCCTTACCTGTCTC 480
Qy 481 GGTGCAGACAGACACACCACCTCTAGGGTCCACCTCAFTGTGTGCAAGTATCTCC 540

Db	481		GGTGCAGACAGACAACCCAAAGACCTCTAGGCTCCACTCATTTGTGCAAGTATCTCC	540
Qy	541	CAAAATTTGTAGAGATTTCTTCAGATATCTCCATTAAATGAAGGGAAACAATATTAGCCTCAC		600
Db	541	CAAAATTTGTAGAGATTTCTTCAGATATCTCCATTAAATGAAGGGAAACAATATTAGCCTCAC		600
Qy	601	CTGCATAGCAACTGGTATAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAAGC		660
Db	601	CTGCATAGCAACTGGTATAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAAGC		660
Qy	661	GGTTGGCTTTGTGTAGTCAAGACGAATACTTTGGAATTCAGGGCATCACCGGAGAGCAGTC		720
Db	661	GGTTGGCTTTGTGTAGTCAAGACGAATACTTTGGAATTCAGGGCATCACCGGAGAGCAGTC		720
Qy	721	AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCCGCGCCCGTGTACGGAGAGTAAA		780
Db	721	AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCCGCGCCCGTGTACGGAGAGTAAA		780
Qy	781	GGTCACCGTGAACCTATCCACCATACATTTCCAGAGCCAAAGGTACAGGTGTCCCGTGGG		840
Db	781	GGTCACCGTGAACCTATCCACCATACATTTCCAGAGCCAAAGGTACAGGTGTCCCGTGGG		840
Qy	841	ACAAAAGGGGACACTGCAAGTGTGAAGCCTCAGCAGTCCCTTCAGCAAAATTCAGTGGTA		900
Db	841	ACAAAAGGGGACACTGCAAGTGTGAAGCCTCAGCAGTCCCTTCAGCAAAATTCAGTGGTA		900
Qy	901	CAAGGATGACAAAAGACTGATTGAAGAAAGAAAGGGTGAAAGTGAAACACAGACCTTT		960
Db	901	CAAGGATGACAAAAGACTGATTGAAGAAAGAAAGGGTGAAAGTGAAACACAGACCTTT		960
Qy	961	CCTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAACTACACTTCGGT		1020
Db	961	CCTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAACTACACTTCGGT		1020
Qy	1021	GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGGT		1080
Db	1021	GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGGT		1080
Qy	1081	CAGCGAGTGAGCAACCGCACCTCGAGAGGGCAGGCTGGGTCTGGCTGTGCCTCTTCT		1140
Db	1081	CAGCGAGTGAGCAACCGCACCTCGAGAGGGCAGGCTGGGTCTGGCTGTGCCTCTTCT		1140
Qy	1141	GGTCTTGCACTGTCTCTAAAATTTTGAATGTAGTGCACCTTCCCAACCCGGGAAAGGCT		1200
Db	1141	GGTCTTGCACTGTCTCTAAAATTTTGAATGTAGTGCACCTTCCCAACCCGGGAAAGGCT		1200
Qy	1201	GGCGCCACCAACCCACACACACAGCAATGCCACACCGACAGCAACCAATCAGATA		1260
Db	1201	GGCGCCACCAACCCACACACACAGCAATGCCACACCGACAGCAACCAATCAGATA		1260
Qy	1261	TATACAAATGAAATTTAGAAGAAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC		1320
Db	1261	TATACAAATGAAATTTAGAAGAAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC		1320
Qy	1321	AAAGAAATCTTTGGGGGAAAAGATTTTAAAAGAAAATGAAAATTTGCCTTGCAGATA		1380
Db	1321	AAAGAAATCTTTGGGGGAAAAGATTTTAAAAGAAAATGAAAATTTGCCTTGCAGATA		1380
Qy	1381	TTTAGGTACAAATGGAGTTTTCTTTTCCAAACCGGGAAGAAACACAGCACACCCGGCTTGGGA		1440
Db	1381	TTTAGGTACAAATGGAGTTTTCTTTTCCAAACCGGGAAGAAACACAGCACACCCGGCTTGGGA		1440
Qy	1441	CCCACTGCAGCTGCATCGTGCAACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC		1500
Db	1441	CCCACTGCAGCTGCATCGTGCAACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC		1500
Qy	1501	TCTGCCCAACAGAGTGCCCCACGTGGAAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA		1560
Db	1501	TCTGCCCAACAGAGTGCCCCACGTGGAAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA		1560
Qy	1561	GTCCATAGACGAAACGAATGACCTTCGGGCCCAAGCGTGGCGTCCGGGCACTTTG		1620

Db	1561	GTCCATAGAGACGAAACAGAAATGAGACCTTCCGGCCCAACGCGTGGCGCTCGGGCACTTTG	1622
Qy	1621	GTAGACTGTGCCACCAACGCGGTGTGTTGTGAACGTGAATAAAAGACGCAAAAAA	1679
Db	1621	GTAGACTGTGCCACCAACGCGGTGTGTTGTGAACGTGAATAAAAGACGCAAAAAA	1679
RESULT 72			
AD	ADD50789		
ID	ADD50789	standard; cDNA; 1679 BP.	
XX	AC	ADD50789;	
XX	DT	15-JAN-2004 (first entry)	
XX	DE	Novel human secreted and transmembrane protein PRO337 cDNA.	
XX	KW	Human; secreted and transmembrane protein; PRO; Gene; ss; cytostatic;	
XX	KW	vulnary; antiarthritis; pericyte cell proliferation;	
XX	KW	pericyte cell differentiation; chondrocyte cell proliferation;	
XX	KW	chondrocyte cell differentiation; tumour necrosis factor alpha release;	
XX	KW	(TNF)-alpha release; dermal fibroblast cell proliferation;	
XX	KW	dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;	
XX	KW	colon tumour; breast tumour; prostate tumour; rectal tumour;	
XX	KW	liver tumour; tissue typing; chromosome mapping; gene mapping;	
XX	OS	gene therapy.	
XX	OS	Homo sapiens.	
XX	FN	US2003105291-A1.	
XX	XX	05-JUN-2003.	
XX	PD		
XX	XX	26-AUG-2002; 2002US-00227877.	
XX	PF		
XX	XX	29-JUN-2001; 2001WO-US021066.	
XX	PR		
XX	PR	09-APR-2002; 2002US-00119480.	
XX	XX		
XX	PA	(GETH) GENENTECH INC.	
XX	XX		
XX	PI	Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;	
XX	PI	Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;	
XX	XX	WFI; 2003-829361/77.	
XX	DR	P-PSDB; ADD50790.	
XX	DR		
XX	XX		
XX	PT	New isolated nucleic acid encoding a secreted and transmembrane	
XX	PT	polypeptide (PRO), for use in recombinantly producing a PRO polypeptide,	
XX	PT	as a hybridization probe, and in gene therapy.	
XX	PS	Claim 2; Fig 125; 308pp; English.	
XX	XX		
XX	CC	The invention describes an isolated PRO (secreted and transmembrane)	
XX	CC	polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are	
XX	CC	useful for stimulating the proliferation of or gene expression in	
XX	CC	pericyte cells. PRO357, PRO229, PRO1272 or PRO4305 polypeptide are useful	
XX	CC	for stimulating the proliferation or differentiation of chondrocyte	
XX	CC	cells. PRO211, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide	
XX	CC	are useful for stimulating the release of tumour necrosis factor (TNF)-	
XX	CC	alpha from human blood. PRO357, PRO725, PRO1306, PRO1419, PRO214,	
XX	CC	PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080.	
XX	CC	PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,	
XX	CC	PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,	
XX	CC	PRO1286, PRO1330, PRO1340, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,	
XX	CC	PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,	
XX	CC	PRO1887, PRO1938, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,	
XX	CC	PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for	
XX	CC	stimulating the proliferation of normal human dermal fibroblasts cells.	
XX	CC	PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,	
XX	CC	PRO5723, PRO5745, PRO154, or PRO7425 polypeptide are useful for	
XX	CC	inhibiting the proliferation of normal human dermal fibroblast cells. PRO	
XX	CC	polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,	
XX	CC	are useful for detecting the presence of tumour in a mammal which	

CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (III) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO259, PRO1372 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.

XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	GTGTGTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGCAACAC	60
Db	1	GTGTGTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGCAACAC	60
Qy	61	AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
Db	61	AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
Qy	121	AAGAAAGAAATCATGAAGAACCATCCAGCCCAAAATGCATTCCTCTTGGGCAAT	180
Db	121	AAGAAAGAAATCATGAAGAACCATCCAGCCCAAAATGCATTCCTCTTGGGCAAT	180
Qy	181	CTTCACGGGCTGGCTCTGTCTCTTCCAAAGAGTCCCGTCCGAGCGGAGATGC	240
Db	181	CTTCACGGGCTGGCTCTGTCTCTTCCAAAGAGTCCCGTCCGAGCGGAGATGC	240
Qy	241	CACCTTCCCAAGCTATGACAACTGACAGTCCCGGCGAGGAGCGCCACCTCAG	300
Db	241	CACCTTCCCAAGCTATGACAACTGACAGTCCCGGCGAGGAGCGCCACCTCAG	300
Qy	301	GTGCACATTAATGACAACTGACAGTCCCGGCGAGGAGCGCCACCTCCTTA	360
Db	301	GTGCACATTAATGACAACTGACAGTCCCGGCGAGGAGCGCCACCTCCTTA	360
Qy	361	TGCTGGGAATGACAACTGACAGTCCCGGCGAGGAGCGCCACCTCCTTA	420
Db	361	TGCTGGGAATGACAACTGACAGTCCCGGCGAGGAGCGCCACCTCCTTA	420
Qy	421	GCAGTACAGATCGAGATCCAGAACTGATGATGACGAGGCGCTTACACCTGCTC	480
Db	421	GCAGTACAGATCGAGATCCAGAACTGATGATGACGAGGCGCTTACACCTGCTC	480
Qy	481	GGTGCAGACAGAACCAACCAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540
Db	481	GGTGCAGACAGAACCAACCAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540
Qy	541	CAAAATGTAGAGATTTCTTCAGATATCTCCATTAATGAGGAAACAAATATTAGCTCAC	600
Db	541	CAAAATGTAGAGATTTCTTCAGATATCTCCATTAATGAGGAAACAAATATTAGCTCAC	600
Qy	601	CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTGTGAGACATCTCTCCCAAGC	660
Db	601	CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTGTGAGACATCTCTCCCAAGC	660
Qy	661	GGTTGGCTTTGTAGTGAAGACGAATCTTGGAAATTCAGGGATCACCGGGAGCAGTC	720
Db	661	GGTTGGCTTTGTAGTGAAGACGAATCTTGGAAATTCAGGGATCACCGGGAGCAGTC	720
Qy	721	AGGGGACTACAGTGCAGTGCCTCCATATGAGTGGCGCGCCCGTGTACGGAGTAA	780
Db	721	AGGGGACTACAGTGCAGTGCCTCCATATGAGTGGCGCGCCCGTGTACGGAGTAA	780

Qy	781	GGTCACCGTGAACCTATCCACATACATTTTCAGAAAGCAAGGTTACAGGTGTCCCGTGGG	840
Db	781	GGTCACCGTGAACCTATCCACATACATTTTCAGAAAGCAAGGTTACAGGTGTCCCGTGGG	840
Qy	841	ACAAAAGGGGACACTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
Db	841	ACAAAAGGGGACACTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
Qy	901	CAAGGATGACAAAGACTGATTGAAGGAAAGAGGGGTGAAAGTGGAAACAGACCTTT	960
Db	901	CAAGGATGACAAAGACTGATTGAAGGAAAGAGGGGTGAAAGTGGAAACAGACCTTT	960
Qy	961	CCTCTCAAAACTCATCTTCTTCAATGCTCTGAACATGACTATGCGGAACATACACTTC	1020
Db	961	CCTCTCAAAACTCATCTTCTTCAATGCTCTGAACATGACTATGCGGAACATACACTTC	1020
Qy	1021	GGCTCTCAACAAAGCTGGGCGCACCAATGCGCAGCATCATCTTTTCCAGCGCGCT	1080
Db	1021	GGCTCTCAACAAAGCTGGGCGCACCAATGCGCAGCATCATCTTTTCCAGCGCGCT	1080
Qy	1081	CAGCGAGGTGAGCAACCGCACGCTCGAGGAGGGCAGGCTGCGTCTGGCTGTCTCTTCT	1140
Db	1081	CAGCGAGGTGAGCAACCGCACGCTCGAGGAGGGCAGGCTGCGTCTGGCTGTCTCTTCT	1140
Qy	1141	GGTCTTGCACCTGCTCTCAAAATTTTTCATGTGAGTGCACCTTCCCGGAGGAGGCT	1200
Db	1141	GGTCTTGCACCTGCTCTCAAAATTTTTCATGTGAGTGCACCTTCCCGGAGGAGGCT	1200
Qy	1201	CCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC	1260
Db	1201	CCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC	1260
Qy	1261	TATACAAATGAATTAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAAC	1320
Db	1261	TATACAAATGAATTAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAAC	1320
Qy	1321	AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA	1380
Db	1321	AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA	1380
Qy	1381	TTTAGGTACAAATGAGATTTTCTTTCCAAACCGGAAAGAACACAGCACACCCGGCTTGG	1440
Db	1381	TTTAGGTACAAATGAGATTTTCTTTCCAAACCGGAAAGAACACAGCACACCCGGCTTGG	1440
Qy	1441	CCCACTGCAAGCTGATCGTGCACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC	1500
Db	1441	CCCACTGCAAGCTGATCGTGCACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC	1500
Qy	1501	TCTGCCACAGAGTCCCGCCACGTTGGAAACATTTGGAGCTGGCCATCCCAAAATTCATCA	1560
Db	1501	TCTGCCACAGAGTCCCGCCACGTTGGAAACATTTGGAGCTGGCCATCCCAAAATTCATCA	1560
Qy	1561	GTCCATAGAGACGACAGAAATGAGACCTTCCCGGCCCAAGCGTGGCGCTCGCGGCACTTTG	1620
Db	1561	GTCCATAGAGACGACAGAAATGAGACCTTCCCGGCCCAAGCGTGGCGCTCGCGGCACTTTG	1620
Qy	1621	GTAGACTGTGCCACCAACCGCGCTGTGTGTGAAACGTGAAATTAAGAGCAAAAAAAA	1679
Db	1621	GTAGACTGTGCCACCAACCGCGCTGTGTGTGAAACGTGAAATTAAGAGCAAAAAAAA	1679

RESULT 73

ADD41190
ID ADD41190 standard; cDNA; 1679 BP.

XX
AC ADD41190;
XX
DT 15-JAN-2004 (first entry)

XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
XX US2003203438-A1.
XX
XX 30-OCT-2003.
XX
XX 15-MAY-2002; 2002US-00146786.
XX
XX 24-NOV-1997; 97US-0066511P.
XX PR 16-SEP-1998; 98WO-US019330.
XX PR 25-AUG-1999; 99US-00380139.
XX PR 22-FEB-2000; 2000WO-US004414.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-875645/81.
XX DR P-P8DB; ADD41191.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
XX PRO4978, useful in molecular biology, chromosome and gene mapping, in
XX generating antisense RNA and DNA, and in gene therapy.
XX
XX Claim 2; SEQ ID NO 375; 637pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,
XX for stimulating the proliferation of or gene expression in pericyte
XX cells, for stimulating the release of proteoglycans from cartilage, for
XX stimulating the proliferation of inner ear utricular supporting cells,
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX the release of a cytokine from PMBC cells, for inhibiting the binding of
XX A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
XX cells, for stimulating proliferation of endothelial cells, for detecting
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,
XX prostate, rectal, cervical or liver. The oligonucleotide probes
XX are useful for isolating genomic and cDNA nucleotide sequences or
XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful
XX in assays to identify other proteins or molecules involved in binding
XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome
XX and gene mapping, in generation of antisense RNA and DNA, in the
XX preparation of PRO polypeptide, for generating transgenic animals or
XX knockout animals which in turn are useful in the development and
XX screening of therapeutically useful reagents, in gene therapy, for
XX chromosome identification, as chromosome marker, and for generating
XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
XX detecting its expression in specific cells, tissues or serum, and for
XX affinity purification of PRO from recombinant cell culture or natural
XX sources. (I) and (II) are useful for tissue typing. This sequence encodes
XX a novel human secreted and transmembrane PRO polypeptide.
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
XX
XX Query Match 100.0%; Score 1679; DB 1; Length 1679;
XX Best Local Similarity 100.0%; Pred. No. 6.7e-05;
XX Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCAACAGCTTGAGAGCAAC 60
61 AATCTATCAGGAAGAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
61 AATCTATCAGGAAGAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAATTCATCTCTTGGGCAAT 180
121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAATTCATCTCTTGGGCAAT 180
181 CTTTCAGGGGCTGGCTGCTCTCTCTTCCAGAGAGTGCCTGCGCAGCGAGAGATGC 240
181 CTTTCAGGGGCTGGCTGCTCTCTCTTCCAGAGAGTGCCTGCGCAGCGAGAGATGC 240
241 CACCTTCCCAAGCTATGGAACAAAGTGCAGGTCGGGAGGGGAGAGCGCCACCTCAG 300
241 CACCTTCCCAAGCTATGGAACAAAGTGCAGGTCGGGAGGGGAGAGCGCCACCTCAG 300
301 GTGCACCTATTGACACCGGGTCAACCGGGTGGCTTAAACCCGAGCAGCACCCTCTTA 360
301 GTGCACCTATTGACACCGGGTCAACCGGGTGGCTTAAACCCGAGCAGCACCCTCTTA 360
361 TGTGGAATGACAAAGTGGTGGTCTCGATCCTCGCGTGGTCTTCTGAGCAACACCAAAAC 420
361 TGTGGAATGACAAAGTGGTGGTCTCGATCCTCGCGTGGTCTTCTGAGCAACACCAAAAC 420
421 GCAGTACACATCGAGATCCAGAACGAGTGGTATGATGACGAGGGCCCTTACACCTGCTC 480
421 GCAGTACACATCGAGATCCAGAACGAGTGGTATGATGACGAGGGCCCTTACACCTGCTC 480
481 GTGTCAGACAGAACCAACCCCAAGACCTCTAGGTCACCTCATTTGCAAGTATCTCC 540
481 GTGTCAGACAGAACCAACCCCAAGACCTCTAGGTCACCTCATTTGCAAGTATCTCC 540
541 CAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAGGGGAAACATATTAGCTCAC 600
541 CAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAGGGGAAACATATTAGCTCAC 600
601 CTGCATAGCAACTGGTAGACACGAGCTACGGTTACTTGGAGACACATCTCTCCAAAGC 660
601 CTGCATAGCAACTGGTAGACACGAGCTACGGTTACTTGGAGACACATCTCTCCAAAGC 660
661 GGTGCTTTGTGAGTGAAGACGATCTTGAATTCAGGTCATCCCGGGGAGCAGTC 720
661 GGTGCTTTGTGAGTGAAGACGATCTTGAATTCAGGTCATCCCGGGGAGCAGTC 720
721 AGGGGACTACGAGTGCAGTCCCTCAATGACGTGGCGCGCGCGCTGAGAGAGTAAA 780
721 AGGGGACTACGAGTGCAGTCCCTCAATGACGTGGCGCGCGCGCTGAGAGAGTAAA 780
781 GGTACCGTGAATCTACCATATACATTTTCAAGCAAGGTTACAGGTGTCCTCCGTTGG 840
781 GGTACCGTGAATCTACCATATACATTTTCAAGCAAGGTTACAGGTGTCCTCCGTTGG 840
841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
901 CAAGGATGACAAAGACTGATTGAAGAAAGAAAGGGGTGAAGTGAAGAAACAGACTTT 960
901 CAAGGATGACAAAGACTGATTGAAGAAAGAAAGGGGTGAAGTGAAGAAACAGACTTT 960
961 CTTCTCAAAACTCATCTTCTTCAATCTCTTCAATGACTATGGAATCTTACACTTGGCT 1020
961 CTTCTCAAAACTCATCTTCTTCAATCTCTTCAATGACTATGGAATCTTACACTTGGCT 1020
1021 GGCTCTCAACAGCTGGGCAACCAATGCGAGCATCTATTTGGTCCAGGCGCGGT 1080
1021 GGCTCTCAACAGCTGGGCAACCAATGCGAGCATCTATTTGGTCCAGGCGCGGT 1080
1081 CAGCGAGTTCAGCAACCGGACGTCGAGGGGGGAGCTGCTGCTGCTGCTGCTCTTCT 1140

QY 1 GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCAACAGCTTGAGAGCAAC 60

Db 1081 CAGCGAGGTGAGCAACGCGACGTCGAGGAGGCGAGCTCGCTGCTGCTCTTCT 1140
Qy 1141 GGTCTTGCACCTGCTTCTCTCAATTTTGTAGTGAGTGCCACTTCCCCACCCGCGGAAGGCT 1200
Db 1141 GGTCTTGCACCTGCTTCTCTCAATTTTGTAGTGAGTGCCACTTCCCCACCCGCGGAAGGCT 1200
Qy 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA 1260
Db 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA 1260
Qy 1261 TATACAAATGAATTTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGAGGGAAC 1320
Db 1261 TATACAAATGAATTTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGAGGGAAC 1320
Qy 1321 AAAGAATACCTTTGGGGGGAAGAGAGTTTAAAGAAAGAAATTTGAAATTCCTTTCAGATA 1380
Db 1321 AAAGAATACCTTTGGGGGGAAGAGAGTTTAAAGAAAGAAATTTGAAATTCCTTTCAGATA 1380
Qy 1381 TTTAGGTACATGAGTTTCTTTTCCCAACGGGAGAGACACAGACACACCGGCTTGA 1440
Db 1381 TTTAGGTACATGAGTTTCTTTTCCCAACGGGAGAGACACAGACACACCGGCTTGA 1440
Qy 1441 CCCACTGCAAGCTGCATCGTGCACCTCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGCATCGTGCACCTCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGCCTCCCACTGAGAACTTTCTGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCCACTGAGAACTTTCTGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGACGACAGATGAGACCTTCCGGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
Db 1561 GTCCATAGAGACGACAGATGAGACCTTCCGGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACCGGCTGTGTGTGAACGTTGAATTAATAAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACCGGCTGTGTGTGAACGTTGAATTAATAAAGAGCAAAAAA 1679

RESULT 74

ADD52329
ID ADD52329 standard; cDNA; 1679 BP.

AC ADD52329;

15-JAN-2004 (first entry)

cDNA encoding human PRO polypeptide #188.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

Homo sapiens.

US2003194769-A1.

16-OCT-2003.

21-MAY-2002; 2002US-00152374.

09-DEC-1999; 99US-0170262P.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
DR WPI: 2003-852593/79.
XX P-FSDB; ADD52330.

New isolated, secreted and transmembrane PRO polypeptides and nucleic
acids, useful for detection of tumors, modulating the uptake of glucose
or free fatty acids and stimulating the release of proteoglycans from
cartilage.

Claim 2; Fig 375; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung, the
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems,
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassaemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence encodes a human PRO polypeptide of the invention. Note: the
sequence data for this patent is also available in electronic format from
the USPTO website at seqdata.uspto.gov.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGACCAAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGACCAAGCTTGAGAGCAAC 60
Qy 61 AATCTATCAGGAAGAAAGAAAGAAAAAACCAGACCTGCACAAAAAGAAAAAGAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAAAAACCAGACCTGCACAAAAAGAAAAAGAG 120
Qy 121 AAGAAAAAATCATGAAAAACATCCAGCAAAATGCACAAATTCATCTTTGGGCAAT 180
Db 121 AAGAAAAAATCATGAAAAACATCCAGCAAAATGCACAAATTCATCTTTGGGCAAT 180
Qy 181 CTTACGGGGCTGGCTGCTCTGTGTCTTTCCAGAGTGCCCGCGCAGCGAGATGC 240
Db 181 CTTACGGGGCTGGCTGCTCTGTGTCTTTCCAGAGTGCCCGCGCAGCGAGATGC 240
Qy 241 CACCTTCCCCAAGCTATGGACAGCTCCGCGAGGGGAGAGCGCCACCTCAG 300

DB 1621 GTAGACTGTGCACCCAGCGGTGTGTTGTGTAACGTGAATATATAGAGCAAAAAA 1679
|||||
RESULT 76
ADD53069
ID ADD53069 standard; cDNA; 1679 BP.
AC
XX
AC ADD53069;
XX
DT 15-JAN-2004 (first entry)
XX
DE cDNA encoding human PRO polypeptide #188.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003194792-A1.
XX
XX 16-OCT-2003.
XX
XX 15-APR-2002; 2002US-00123156.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 29-OCT-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025109.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-MAR-1999; 2000WO-US006319.
PR 10-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US020203.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2000US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-00878792.
PR 21-JUN-2001; 2001US-00878799.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX

WPI: 2003-852599/79.
P-PSDB; ADD53070.

XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
XX PRO4978, useful in chromosome and gene mapping, in generating antisense
XX RNA and DNA, and in the treatment of cancer.

XX

Claim 2; Fig 375; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- α (TNF- α) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTCACAGCTTGAGAGCAAC	60
Db	1	GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTCACAGCTTGAGAGCAAC	60
Qy	61	AATCTATCAGGAAGAAGAAAGAAACCCGCTGACCAAAAGAGAAAGAGAG	120
Db	61	AATCTATCAGGAAGAAGAAAGAAACCCGCTGACCAAAAGAGAAAGAGAG	120
Qy	121	AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCACAAATCTCTTTGGGCAAT	180
Db	121	AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCACAAATCTCTTTGGGCAAT	180
Qy	181	CTTCACGGGGTGCTGCTCTGTCTCTTCACAGAGTGCCCGTGGCGAGCGGATGC	240
Db	181	CTTCACGGGGTGCTGCTCTGTCTCTTCACAGAGTGCCCGTGGCGAGCGGATGC	240
Qy	241	CACCTTCCCAAGCTATGACAACTGACGGTCCGGCAGGGGGAGAGCGCCACCTCAG	300
Db	241	CACCTTCCCAAGCTATGACAACTGACGGTCCGGCAGGGGGAGAGCGCCACCTCAG	300
Qy	301	GTGCACATATTGACAAACCGGGTACCCGGGTGGCTGGCTAAACCGCAGACACATCTCTA	360
Db	301	GTGCACATATTGACAAACCGGGTACCCGGGTGGCTGGCTAAACCGCAGACACATCTCTA	360
Qy	361	TGCTGGGAATGACAAAGTGGTGGCTGGATCTCGGGTGGTCTCTTCAGCAACCCAAAC	420
Db	361	TGCTGGGAATGACAAAGTGGTGGCTGGATCTCGGGTGGTCTCTTCAGCAACCCAAAC	420
Qy	421	GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACAGGGGCCCTTACACCTGCTC	480
Db	421	GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACAGGGGCCCTTACACCTGCTC	480

Qy	481	GGTGACAGACAGCAACACCACCAAGAGCCTCTAGGGTCCACCTCATTGTGCAAGTATCTCC	540
Db	481	GGTGACAGACAGCAACACCACCAAGAGCCTCTAGGGTCCACCTCATTGTGCAAGTATCTCC	540
Qy	541	CAAAATTTAGAGATTTCTTCAGATATCTCCATTAAAGAGGGAACAATATTAGCCTCAC	600
Db	541	CAAAATTTAGAGATTTCTTCAGATATCTCCATTAAAGAGGGAACAATATTAGCCTCAC	600
Qy	601	CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC	660
Db	601	CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC	660
Qy	661	GTTTGGCTTTGTGAGTGAAGACGAATATTCTGGAATTCAGGGCATCACCCGGAGCAGTC	720
Db	661	GTTTGGCTTTGTGAGTGAAGACGAATATTCTGGAATTCAGGGCATCACCCGGAGCAGTC	720
Qy	721	AGGGGACTACGAGTGCAGTGCTCCATGACGTGGCGCCGCGCTGGTACCGAGAGTAA	780
Db	721	AGGGGACTACGAGTGCAGTGCTCCATGACGTGGCGCCGCGCTGGTACCGAGAGTAA	780
Qy	781	GGTCAACCGTGAACATATCCACCATACATTTAGAAAGCCAAAGGGTACAGGTGTCCCGTGG	840
Db	781	GGTCAACCGTGAACATATCCACCATACATTTAGAAAGCCAAAGGGTACAGGTGTCCCGTGG	840
Qy	841	ACAAAGGGGACACTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
Db	841	ACAAAGGGGACACTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
Qy	901	CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAACACAGACCTTT	960
Db	901	CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAACACAGACCTTT	960
Qy	961	CTCTCAAACTCATCTTCTCAATGTCTCTGAACATGACTATGGGAACACTACCTTGGT	1020
Db	961	CTCTCAAACTCATCTTCTCAATGTCTCTGAACATGACTATGGGAACACTACCTTGGT	1020
Qy	1021	GGCTTCCAAAGCTGGGCCACACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGGT	1080
Db	1021	GGCTTCCAAAGCTGGGCCACACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGGT	1080
Qy	1081	CAGCAGGTGAGCAACCGGCACTGAGAGGGCAGGTGCGCTCTGGCTGCTCTTCTTCT	1140
Db	1081	CAGCAGGTGAGCAACCGGCACTGAGAGGGCAGGTGCGCTCTGGCTGCTCTTCTTCT	1140
Qy	1141	GGTCTTGCACCTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCCACCCGGGAAAGGCT	1200
Db	1141	GGTCTTGCACCTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCCACCCGGGAAAGGCT	1200
Qy	1201	GGCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA	1260
Db	1201	GGCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA	1260
Qy	1261	TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAC	1320
Db	1261	TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAC	1320
Qy	1321	AAAGAAATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCCCTTCAGATA	1380
Db	1321	AAAGAAATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCCCTTCAGATA	1380
Qy	1381	TTTAGGTACATGGAGTTTCTTTTCCAAACGGGAGAAACACAGCAGACACCCGGCTTGA	1440
Db	1381	TTTAGGTACATGGAGTTTCTTTTCCAAACGGGAGAAACACAGCAGACACCCGGCTTGA	1440
Qy	1441	CCCACTGCAAGCTGATCGTCAACCTCTTTGGTGGCAGTGTGGGCAAGGGCTCAGCCTC	1500
Db	1441	CCCACTGCAAGCTGATCGTCAACCTCTTTGGTGGCAGTGTGGGCAAGGGCTCAGCCTC	1500
Qy	1501	TCTGCCACAGAGTGCCCGCCAGGTGGAACATCTGGAGCTGGCCATCCCAATTCATCA	1560
Db	1501	TCTGCCACAGAGTGCCCGCCAGGTGGAACATCTGGAGCTGGCCATCCCAATTCATCA	1560

781	Db	GTCTACCGTGAACACTATCCACCANATATTTCAGAACCAAGGATACAGGTGTCCCCGTGGG	840
841	Qy	ACAAAGGGGGACACTGCACTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
841	Db	ACAAAGGGGGACACTGCACTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
901	Qy	CAAGGATGACAAAGACTGATTCAGAGGAAGAAAGGGTGAAAGTGGAAACAGACCTTT	960
901	Db	CAAGGATGACAAAGACTGATTCAGAGGAAGAAAGGGTGAAAGTGGAAACAGACCTTT	960
961	Qy	CTCTCTCAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGGAATCACTTTGGT	1020
961	Db	CTCTCTCAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGGAATCACTTTGGT	1020
1021	Qy	GGCTCCCAACAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT	1080
1021	Db	GGCTCCCAACAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT	1080
1081	Qy	CAGCGAGTGAGCAACGGCACTGTCGAGAGGGCAGGCTGCGTCTGCTGCTGCTCTTCT	1140
1081	Db	CAGCGAGTGAGCAACGGCACTGTCGAGAGGGCAGGCTGCGTCTGCTGCTGCTCTTCT	1140
1141	Qy	GGTCTTGCACTGCTTCTCAAAATTTTGAATGATGCTGCTGCTTCCCAACCGCGGAAAGCT	1200
1141	Db	GGTCTTGCACTGCTTCTCAAAATTTTGAATGATGCTGCTTCCCAACCGCGGAAAGCT	1200
1201	Qy	GGCGCCACCAACCAACCAACACACAGCAATGGGAAACACCGACAGCAACCAATCAGATA	1260
1201	Db	GGCGCCACCAACCAACCAACACACAGCAATGGGAAACACCGACAGCAACCAATCAGATA	1260
1261	Qy	TATACAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGGAAC	1320
1261	Db	TATACAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGGAAC	1320
1321	Qy	AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAATTTAAAGAAATTTGCTTGCAGATA	1380
1321	Db	AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAATTTAAAGAAATTTGCTTGCAGATA	1380
1381	Qy	TTTAGGTACAATGGAGTTTCTTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGA	1440
1381	Db	TTTAGGTACAATGGAGTTTCTTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGA	1440
1441	Qy	CCCACTGCAAGCTGCATGCTGCAACCTTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC	1500
1441	Db	CCCACTGCAAGCTGCATGCTGCAACCTTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC	1500
1501	Qy	TCTGCCACACAGAGTGCCCCCAACGTCGGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA	1560
1501	Db	TCTGCCACACAGAGTGCCCCCAACGTCGGAACATTTCTGGAGCTGGCCATCCCAAAATTCATCA	1560
1561	Qy	GTCCATAGAGACGAACAGATGAGACCTTCGCGCCCAAGCGTGGCGTGGGCGACCTTTG	1620
1561	Db	GTCCATAGAGACGAACAGATGAGACCTTCGCGCCCAAGCGTGGCGTGGGCGACCTTTG	1620
1621	Qy	GTAGACTGTGCCACCAACGGCGTGTGTTGTGAACCGTGAATATAAAGAGCAAAAAAAA	1679
1621	Db	GTAGACTGTGCCACCAACGGCGTGTGTTGTGAACCGTGAATATAAAGAGCAAAAAAAA	1679

ADD37097

XX



100

Year	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100											

ss; gene; human; secreted protein; transmembrane protein;
 KW cardiovascular disorder; endothelial disorder; angiogenic disorder;
 KW myocardial infarction; cardiac hypertrophy; trauma; cancer;
 KW age-related macular degeneration; angiogenesis;

XX	endothelial cell apoptosis; smooth muscle cell growth;
XX	endothelial cell tube formation.
XX	
XX	Homo sapiens.
XX	US2003105012-A1.
XX	
XX	05-JUN-2003.
XX	
XX	16-AUG-2002; 2002US-00223088.
XX	
XX	15-SEP-2000; 2000US-0232887P.
XX	20-JUN-2001; 2001WO-US019692.
XX	09-JUL-2001; 2001WO-US021735.
XX	20-FEB-2002; 2002US-00081056.
XX	
XX	(GETH) GENENTECH INC.
XX	
XX	Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI	Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J,
PI	Watanabe CK, Williams PM, Wood WI, Ye W;
XX	
XX	WPI; 2003-829354/77.
DR	P-PSDB; ADD37098.
DR	
XX	
XX	New isolated nucleic acids encoding a secreted and transmembrane
PT	polypeptide for treating a cardiovascular, endothelial, or angiogenic
PT	disorder in a mammal, such as cancer or age-related macular degeneration.
XX	
XX	PS Claim 2; SEQ ID NO 55; 492pp; English.

The invention relates to an isolated nucleic acid encoding a secreted and transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded by the nucleic acid, or an agonist or antagonist, is used to treat a cardiovascular, endothelial, or angiogenic disorder in a mammal, preferably a human. The human may have suffered a myocardial infarction or has cardiac hypertrophy, trauma, a cancer, or age-related macular degeneration. The cardiac hypertrophy is characterised by the presence of an elevated level of PGF-2 alpha. A PRO polypeptide, given in the specification, or an agonist is used to inhibit or stimulate endothelial cell growth in a mammal. PRO1 or an agonist is used to induce cardiac hypertrophy. PRO1376 or PRO1449 is used to stimulate angiogenesis. PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO polypeptide, given in the specification, or an agonist is used to stimulate or inhibit smooth muscle cell growth, or to induce endothelial cell tube formation. The present sequence represents a cDNA encoding a PRO polypeptide of the invention.

100

Best Local Similarity 100.0%; Pred. No. 6.7e-05;

F

1 GTTGTGTCCTTTCAGCAAAAACGTGGATTTTAAATCTCTTTGACCAAGCTTGAGAGCAACAC 60

Qy

1 GTTGTGTCCTTTCAGCAAAAACGTGGATTTTAAATCTCTTTGACCAAGCTTGAGAGCAACAC 60

Db

QY 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGACATAAAAGAAAGAAAGAAAG 120

D8 AAATCTATCAGGAAAGAATAAATCGAACCTGGACCTTGACCAATTATTAAGAGAGTATTTATTTATTT
D9

QY 121 AAGAAAAATCAIGATAACCAICAGCCAAAAAGCAGAAATCTATCTCTTGGGCAAT 130

181 CTTCA CCGGGCTCGCTGCTCTGTGTCTCTTCCA AGGAGTGCCCGTGCGCAGCGGAGATGC 240

181 CTTCAAGGGCTGGCTGCTCTGTGTCTCTCTCAAGGAGTGCCTGCGCAGCGGAGAAGC 240

241 CACCTTCCCAAAAGCTATGGACAACTGACGGTCCGGCAGGGGAGAGCGCCACCCCTCAG 300
QY
QY

QY 1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAACGGGAAGAACACACAGCACACCCGCTTGA 1440
 Db TTTAGGTACAAATGGAGTTTCTTTTCCAAACGGGAAGAACACACAGCACACCCGCTTGA 1440
 QY 1441 CCACATGCAAGTGCATCGTGCACCTCTTTGGTCCAGTGTGGCAGAGGCTCAGCCTC 1500
 Db 1441 CCACATGCAAGTGCATCGTGCACCTCTTTGGTCCAGTGTGGCAGAGGCTCAGCCTC 1500
 QY 1501 TCTGCCACAGAGTCCCCCAGCTGGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
 Db 1501 TCTGCCACAGAGTCCCCCAGCTGGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
 QY 1561 GTCCATAGAGAGACAGATGAGACCTTCGGCCCAAGCGTGGCGCTGCGGCACTTTG 1620
 Db 1561 GTCCATAGAGAGACAGATGAGACCTTCGGCCCAAGCGTGGCGCTGCGGCACTTTG 1620
 QY 1621 GTAGACTGTGCCACACCGCGCTGTGTGTGAAACCTGAAATATAAAAGAGCAAAAAAAA 1679
 Db 1621 GTAGACTGTGCCACACCGCGCTGTGTGTGAAACCTGAAATATAAAAGAGCAAAAAAAA 1679

RESULT 79
 ADDS1777
 ID ADDS1777 standard; cDNA; 1679 BP.
 XX
 AC ADDS1777;
 DT 15-JAN-2004 (first entry)
 XX
 DE cDNA encoding human PRO polypeptide #188.
 XX
 KW Human; gene; 88; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 FN US2003194779-A1.
 PD 16-OCT-2003.
 PF 30-MAY-2002; 2002US-00160500.
 XX
 PR 05-JUN-2000; 2000US-0209832P.
 PR 01-DEC-2000; 2000MO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
 XX
 DR WPI; 2003-852597/79.
 DR P-PSDB; ADDS1778.
 XX
 PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful
 PT for detecting the presence of a tumor, stimulating the release of tumor
 PT necrosis factor alpha from human blood and treating, e.g. organ failure.
 XX
 PS Claim 2; Fig 375; 637pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis

QY 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGCTAAACCGCAGCACCCTCTCTA 360
 Db 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGCTAAACCGCAGCACCCTCTCTA 360
 QY 361 TGCTGGGAATGACAAAGTGGTCCCTGGATCTCCGGTGGTCTCTGAGCAACCCCAAC 420
 Db 361 TGCTGGGAATGACAAAGTGGTCCCTGGATCTCCGGTGGTCTCTGAGCAACCCCAAC 420
 QY 421 GCAGTACAGCATCGAGATCCAGAAACGCTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
 Db 421 GCAGTACAGCATCGAGATCCAGAAACGCTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
 QY 481 GGTGAGAGCAGACAAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
 Db 481 GGTGAGAGCAGACAAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
 QY 541 CAAATTTGTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGAAACAAATATTAGCCTCAC 600
 Db 541 CAAATTTGTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGAAACAAATATTAGCCTCAC 600
 QY 601 CTGCATAGCAACTGTGTAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
 Db 601 CTGCATAGCAACTGTGTAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
 QY 661 GGTTCGGCTTTGTAGTGAAGACGAACTACTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
 Db 661 GGTTCGGCTTTGTAGTGAAGACGAACTACTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
 QY 721 AGGGCACTACGAGTCCAGTCCCAATGACGTGGCCGCCCTGTGTGAGAGAGTAA 780
 Db 721 AGGGCACTACGAGTCCAGTCCCAATGACGTGGCCGCCCTGTGTGAGAGAGTAA 780
 QY 781 GGTCAACGCTGAACTATCCACATATATTTCAGAGCCCAAGGTACAGTGTCCCGTGG 840
 Db 781 GGTCAACGCTGAACTATCCACATATATTTCAGAGCCCAAGGTACAGTGTCCCGTGG 840
 QY 841 ACAAAGGGGACATCGCAGTGTGAAGCCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900
 Db 841 ACAAAGGGGACATCGCAGTGTGAAGCCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900
 QY 901 CAAGATGACAAAGACTGTTGAGGAAAGAGGGGTGAAGTGGAAACAGACCTTT 960
 Db 901 CAAGATGACAAAGACTGTTGAGGAAAGAGGGGTGAAGTGGAAACAGACCTTT 960
 QY 961 CCTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAATACACTTGGT 1020
 Db 961 CCTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAATACACTTGGT 1020
 QY 1021 GGCCTCCACAGCTGGGGCCACACCAATGCCAGCATGATGCTATTTGGTCCAGGGCGGT 1080
 Db 1021 GGCCTCCACAGCTGGGGCCACACCAATGCCAGCATGATGCTATTTGGTCCAGGGCGGT 1080
 QY 1081 CAGCGAGGTGACAAACGGCAGCTCGAGGAGGCGAGGCTGCGTCTGGCTGTGCTCTTCT 1140
 Db 1081 CAGCGAGGTGACAAACGGCAGCTCGAGGAGGCGAGGCTGCGTCTGGCTGTGCTCTTCT 1140
 QY 1141 GGTCTTGACCTGCTTCTCAATTTGTATGTGAGTGGCCATCTCCACCCCGGGAAGGCT 1200
 Db 1141 GGTCTTGACCTGCTTCTCAATTTGTATGTGAGTGGCCATCTCCACCCCGGGAAGGCT 1200
 QY 1201 GCGGCCACCCACCCACCAACACACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
 Db 1201 GCGGCCACCCACCCACCAACACACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
 QY 1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAA 1320
 Db 1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAA 1320
 QY 1321 AAGAAATCTTTGGGGGAAAGAGTGTATAAAGAAATTTGAAATTTGAAATTTGAAATTTG 1380
 Db 1321 AAGAAATCTTTGGGGGAAAGAGTGTATAAAGAAATTTGAAATTTGAAATTTGAAATTTG 1380

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 5,7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGCTTTCAGCAAAACAGTGGATTAAATCTCTTCCACAAAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTTTCAGCAAAACAGTGGATTAAATCTCTTCCACAAAGCTTGAGAGCAAC 60

Qy 61 AATCTATCAGAAAGAAAGAAAGAAACCGACCTGACAAAGAGAAAGAAAGAG 120
Db 61 AATCTATCAGAAAGAAAGAAAGAAACCGACCTGACAAAGAGAAAGAAAGAG 120

Qy 121 AAGAAAAAATCATGAAACCATCCAGCCAAAAATGCACAAATTCATCTTTGGCAAT 180
Db 121 AAGAAAAAATCATGAAACCATCCAGCCAAAAATGCACAAATTCATCTTTGGCAAT 180

Qy 181 CTTTACGGGGCTGGCTCTGTGTCTCTTCCAGAGTGCCGTCGCGAGCGGAGATGC 240
Db 181 CTTTACGGGGCTGGCTCTGTGTCTCTTCCAGAGTGCCGTCGCGAGCGGAGATGC 240

Qy 241 CACCTTCCCAAGCTATGACAACTGACGGTCCGGCAGGGGGAGAGCGCCCTCAG 300
Db 241 CACCTTCCCAAGCTATGACAACTGACGGTCCGGCAGGGGGAGAGCGCCCTCAG 300

Qy 301 GTGCACATATTGACAAACCGGGTACCCGGGTGGCTTAAACCGGAGCACTCTCTTA 360
Db 301 GTGCACATATTGACAAACCGGGTACCCGGGTGGCTTAAACCGGAGCACTCTCTTA 360

Qy 361 TGCTGGGAATGACAAGTGGTGGCTGGATCTCGGTGGTCTCTTCTGAGCAACCCAAAC 420
Db 361 TGCTGGGAATGACAAGTGGTGGCTGGATCTCGGTGGTCTCTTCTGAGCAACCCAAAC 420

Qy 421 GCAGTACAGCATCAGATCCAGAACTGATGATGATGAGAGGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCAGATCCAGAACTGATGATGATGAGAGGGGCCCTTACACCTGCTC 480

Qy 481 GGTGCAGACAGAACCAACCAAGACCTCTAGGGTCCACTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGCAGACAGAACCAACCAAGACCTCTAGGGTCCACTCATTTGTGCAAGTATCTCC 540

Qy 541 CAAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAC 600

Db 541 CAAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAC 600
Qy 601 CTGCATAGCAACTGTGTAGACAGAGCCTTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
Db 601 CTGCATAGCAACTGTGTAGACAGAGCCTTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
Qy 661 GTTGGCTTTTGTAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Db 661 GTTGGCTTTTGTAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Qy 721 AGGGGACTACGAGTGCACTGCTCCAAAGCTGGCCGCCGCCCTGGTGTACGAGAGTAAA 780
Db 721 AGGGGACTACGAGTGCACTGCTCCAAAGCTGGCCGCCGCCCTGGTGTACGAGAGTAAA 780
Qy 781 GGTCACTGAACTATCCACCATACATTTTCAAGAACCAAGGTTACAGGTGTCCTCCGCGG 840
Db 781 GGTCACTGAACTATCCACCATACATTTTCAAGAACCAAGGTTACAGGTGTCCTCCGCGG 840
Qy 841 ACAAAGGGGACACTGCACTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGAGTGTA 900
Db 841 ACAAAGGGGACACTGCACTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGAGTGTA 900
Qy 901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT 960
Db 901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT 960
Qy 961 CCTCTCAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGAACTACACTTGGT 1020
Db 961 CCTCTCAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGAACTACACTTGGT 1020
Qy 1021 GSCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTTGGTCCAGGCGCGT 1080
Db 1021 GSCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTTGGTCCAGGCGCGT 1080
Qy 1081 CAGCAGGTGAGCAACCGCACTGTGAGAGGGAGGCTGCGCTCTGGCTGCTGCTCTTCT 1140
Db 1081 CAGCAGGTGAGCAACCGCACTGTGAGAGGGAGGCTGCGCTCTGGCTGCTGCTCTTCT 1140
Qy 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTGAGTGCCACTTCCCAACCCGGGAAAGGCT 1200
Db 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTGAGTGCCACTTCCCAACCCGGGAAAGGCT 1200
Qy 1201 GCGGCCACACCAACCAACAGCAATGGAACACCGACAGCAACCAATCAGATA 1260
Db 1201 GCGGCCACACCAACCAACAGCAATGGAACACCGACAGCAACCAATCAGATA 1260
Qy 1261 TATACAAATGAAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAC 1320
Db 1261 TATACAAATGAAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAC 1320
Qy 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAAAATTTGCTTGCAGATA 1380
Db 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAAAATTTGCTTGCAGATA 1380
Qy 1381 TTTAGTACAATGGAGTTTCTTTTCCAAACGGGAGAAACACAGCACCACCGGCTTGA 1440
Db 1381 TTTAGTACAATGGAGTTTCTTTTCCAAACGGGAGAAACACAGCACCACCGGCTTGA 1440
Qy 1441 CCCACTGCAAGCTGATCGTCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGATCGTCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTCCCGCCAGCTGGAACTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTCCCGCCAGCTGGAACTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTTCCATAGAGACGAACAGAAATGAGACCTTCCGGGCCAAAGCGTGGCGCTCGCGGCACTTTG 1620
Db 1561 GTTCCATAGAGACGAACAGAAATGAGACCTTCCGGGCCAAAGCGTGGCGCTCGCGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACACCGCGCTGTGTGTGAAAAGTGAATTAAGAGCAAAAAAAA 1679

Db 1621 GTAGACTGTGCCACCGCGTGTGTGTGAACCTGAATAAAGAGCAAAAAA 1679

RESULT 80
ADD02576
ID ADD02576 standard; cDNA; 1679 BP.
XX
AC ADD02576;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003203431-A1.
XX
PD 30-OCT-2003.
XX
PF 24-APR-2002; 2002US-00131820.
XX
PR 28-OCT-1998; 98US-0106030P.
XX
PR 01-SEP-1999; 99WO-US020111.
XX
PR 18-OCT-1999; 99US-00403297.
XX
PR 18-FEB-2000; 2000WO-US004342.
XX
PR 24-AUG-2000; 2000WO-US023328.
XX
PR 01-DEC-2000; 2000WO-US032678.
XX
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-875638/81.
XX
DR P-PSDB; ADD02577.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; Fig 375; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1 GTTGTGCTCTTCAGCAAAACAGTGGATTTAAATCTCTTCGACACAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTCTTCAGCAAAACAGTGGATTTAAATCTCTTCGACACAGCTTGAGAGCAAC 60
Oy 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Oy 121 AAGAAAAAATCATGAAACCATCCAGCCAAATAATGCAATTTCTATCTCTTGGCAAT 180
Db 121 AAGAAAAAATCATGAAACCATCCAGCCAAATAATGCAATTTCTATCTCTTGGCAAT 180
Oy 181 CTTACAGGGGCTGGCTGCTCTGTCTCTTCCAGGAGTGCCTGCGCAGCGGAGATGC 240
Db 181 CTTACAGGGGCTGGCTGCTCTGTCTCTTCCAGGAGTGCCTGCGCAGCGGAGATGC 240
Oy 241 CACCTTCCCCAAAGCTATGACAAACCTGACGCTCCGGGAGGGGAGAGCCACCTCAG 300
Db 241 CACCTTCCCCAAAGCTATGACAAACCTGACGCTCCGGGAGGGGAGAGCCACCTCAG 300
Oy 301 GTGCACATTATGACAAACCGGTTCACCCGGTGGCTGCTGCTAAACCGCAGACCATCTCTA 360
Db 301 GTGCACATTATGACAAACCGGTTCACCCGGTGGCTGCTGCTAAACCGCAGACCATCTCTA 360
Oy 361 TGTGGGAATGACAAAGTGGTGCCTGGATCTCCGCTGGTCTTCTGAGCAACACCCAAAC 420
Db 361 TGTGGGAATGACAAAGTGGTGCCTGGATCTCCGCTGGTCTTCTGAGCAACACCCAAAC 420
Oy 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTTATGACGAGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTTATGACGAGGGCCCTTACACCTGCTC 480
Oy 481 GGTGCAGACAGCAACACCCAGACCTCTAGGGTCCACCTCATTTGTCAAGTATCTCC 540
Db 481 GGTGCAGACAGCAACACCCAGACCTCTAGGGTCCACCTCATTTGTCAAGTATCTCC 540
Oy 541 CAAAATTTGAGATTTCTTCAGATATCTCCATTAATGAGGGAACAATATTAGCCTCAC 600
Db 541 CAAAATTTGAGATTTCTTCAGATATCTCCATTAATGAGGGAACAATATTAGCCTCAC 600
Oy 601 CTGCATAGCAACTGGTAGACACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
Db 601 CTGCATAGCAACTGGTAGACACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
Oy 661 GGTGGGCTTTGTGAGTGAAGCAACCAATCTTGGAAATTCAGGGCATCACCCGGGAGGATC 720
Db 661 GGTGGGCTTTGTGAGTGAAGCAACCAATCTTGGAAATTCAGGGCATCACCCGGGAGGATC 720
Oy 721 AGGGGACTACAGTGCAGTGCCTCCAAATGACGTGGCGCGCCCGCTGGTACGGAGAGTAA 780
Db 721 AGGGGACTACAGTGCAGTGCCTCCAAATGACGTGGCGCGCCCGCTGGTACGGAGAGTAA 780

QY 781 GGTCAACGTCATATCCACATACATTTTTCAGAGCAAGGGTACAGGTGTCCCGTGGG 840
Db 781 GGTCAACGTCATATCCACATACATTTTTCAGAGCAAGGGTACAGGTGTCCCGTGGG 840
QY 841 ACAAAGGGGACACTGAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACAAAGGGGACACTGAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGGATGACAAAAGACTGATTGAAAGGAAAGGGGTGAAGTGGAAAAACAGACCTTT 960
Db 901 CAAGGATGACAAAAGACTGATTGAAAGGAAAGGGGTGAAGTGGAAAAACAGACCTTT 960
QY 961 CCTCTCAAACTONCTTCTTCAATGTCTTGAACATGACTATGGAACACTACACTTGGCT 1020
Db 961 CCTCTCAAACTONCTTCTTCAATGTCTTGAACATGACTATGGAACACTACACTTGGCT 1020
QY 1021 GGCTCCAAAGCTGGGCGACACCAATGCGAGCATCATCTATTGGTCCAGGCGCGCT 1080
Db 1021 GGCTCCAAAGCTGGGCGACACCAATGCGAGCATCATCTATTGGTCCAGGCGCGCT 1080
QY 1081 CAGCGAGTGAGCAACGGGCGCTGAGGAGGGCAGGCTGGCTGGCTGGCTGGCTGGCT 1140
Db 1081 CAGCGAGTGAGCAACGGGCGCTGAGGAGGGCAGGCTGGCTGGCTGGCTGGCTGGCT 1140
QY 1141 GGTCTGCACTGCTTCTCAAAATTTTCAATGTGAGTGCCACTTCCACCGCGGAAAGGCT 1200
Db 1141 GGTCTGCACTGCTTCTCAAAATTTTCAATGTGAGTGCCACTTCCACCGCGGAAAGGCT 1200
QY 1201 GCCGCCACCCACCCACCAACACACGCAATGCGAACACCGCAGCAGCAACCAATCAGATA 1260
Db 1201 GCCGCCACCCACCCACCAACACACGCAATGCGAACACCGCAGCAGCAACCAATCAGATA 1260
QY 1261 TATCAAAATGAATAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAAC 1320
Db 1261 TATCAAAATGAATAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAAC 1320
QY 1321 AAAGATACCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAAGATACCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGTACATGAGATTTCTTTTCCAAACGGGAAAGACACAGCAGCAGCCGCTTGA 1440
Db 1381 TTTAGTACATGAGATTTCTTTTCCAAACGGGAAAGACACAGCAGCAGCCGCTTGA 1440
QY 1441 CCCACTGCAAGCTGATGTCGCACTCTTTGGTGGCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGATGTCGCACTCTTTGGTGGCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGGCCCAACGTCGGAACATTTGAGAGTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGGCCCAACGTCGGAACATTTGAGAGTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACGACGAAATGAGACCTTCCGCGCCCAAGCGTGGCGTGGCGGACCTTG 1620
Db 1561 GTCCATAGAGACGACGAAATGAGACCTTCCGCGCCCAAGCGTGGCGTGGCGGACCTTG 1620
QY 1621 GTAGACTGTGCACACAGCGCTGTGTGTGAACCTGTAATTAAGAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCACACAGCGCTGTGTGTGAACCTGTAATTAAGAGAGCAAAAAA 1679

RESULT 81

ID ADD50516 standard; cDNA; 1679 BP.

XX AC ADD50516;

XX AC ADD50516;

DT 15-JAN-2004 (first entry)

XX Human PRO polynucleotide #63.

XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;

KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW arthritis; sports injury; cytostatic; antiarthritic.
OS Homo sapiens.
XX US2003096971-A1.
XX 22-MAY-2003.
XX 29-AUG-2002; 2002US-00232229.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
PI Baker KP, Desnoyers L, Gerritsen MB, Goddard A, Godowski PJ,
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WL;
XX WPI; 2003-765528/72.
XX P-PSDB; ADD50517.
PT Novel isolated PRO polypeptide useful for tissue typing, as molecular
XX weight markers in protein electrophoresis, for treating arthritis, tumor.
XX Claim 2; Fig 125; 308pp; English.
XX The invention relates to human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the PRO polynucleotides encoding them.
XX The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
XX diagnostics, biosensors or bioreactors. They are particularly useful for
XX detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
XX prostate tumour, rectal tumour or liver tumour) in a mammal, for
XX stimulating the release of tumour necrosis factor (TNF)-alpha from human
XX blood, for stimulating the proliferation or differentiation of
XX chondrocyte cells, for stimulating the proliferation of or gene
XX expression in pericyte cells or for stimulating the proliferation of
XX normal human dermal fibroblasts. The PRO nucleic acids are useful as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA, in preparing PRO polypeptides by recombinant
XX technology, in generating transgenic animals or knock-out animals which
XX may be used in the development and screening of therapeutically useful
XX reagents, in gene therapy, in chromosome identification, as chromosome
XX markers and in generating probes. The PRO polypeptides, or anti-PRO
XX antibodies, are useful for preparing a medicament for treating a
XX condition which is responsive to the PRO polypeptides or anti-PRO
XX antibodies, such as pericyte-associated tumours and bone and/or cartilage
XX disorders (e.g. arthritis, sports injuries), involving inducing the re-
XX differentiation of chondrocytes. The PRO polypeptides are useful as
XX molecular markers for protein electrophoresis, and in tissue typing. This
XX sequence represents a human PRO polynucleotide of the invention.

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Fred. No. 6.7e-05; Indels 0; Gaps 0;
Matches 1679; Conservative 0; Mismatches 0;

QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTCGACAAAGCTTGAGCAACAC 60
Db 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTCGACAAAGCTTGAGCAACAC 60
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAAATCATGAAACCATCCAGCAAAATTCGCAAAATTCATCTCTTGGGCAAT 180
Db 121 AAGAAAAAAATCATGAAACCATCCAGCAAAATTCGCAAAATTCATCTCTTGGGCAAT 180

PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.

PS Claim 2; Fig 375; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- α (TNF- α) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other; 0 A

Query Match	100.0%	Score 1679	DB 1	Length 1679
Best Local Similarity	100.0%	Pred. No. 6.7e-05		
Matches 1679	Conservative 0	Mismatches 0	Indels 0	Gaps 0

Qy	1	GTTGTGTCCTTCAGCNAACACAGTGAATTAATCTCCTTGACACAGCTTGAGAGCAACAC	60
Db	1	GTTGTGTCCTTCAGCNAACACAGTGAATTAATCTCCTTGACACAGCTTGAGAGCAACAC	60
Qy	61	AATCTATCAGGAAGAAAGAAAGAAAAAACCAGACCTGCACAAAAAGAAAGAAAGAAAG	120
Db	61	AATCTATCAGGAAGAAAGAAAGAAAAAACCAGAACCTGCACAAAAAGAAAGAAAGAAAG	120
Qy	121	AAGAAAAAAATCATGAAAACCATCCAGCCAAAAATGCACAAATTCATCTCTTTGGGCAAT	180
Db	121	AAGAAAAAAATCATGNAACCATCCAGCCAAAAATGCACAAATTCATCTCTTTGGGCAAT	180
Qy	181	CTTCA CGGGCTGGCTGCTCTGTGTCTTCCAGAGAGTCCCGTGGCGACGGAGATGC	240
Db	181	CTTCACGGGCTGGCTGCTCTGTGTCTCTTCCAGAGAGTCCCGTGGCGACGGAGATGC	240
Qy	241	CACCTTCCCAAGCTATATGACAAAGTGAACGTCGGCAGGGGAGAGCGCCACCCCTCAG	300
Db	241	CACCTTCCCAAGCTATATGACAAAGTGAACGTCGGCAGGGGAGAGCGCCACCCCTCAG	300
Qy	301	GTGCACATTATGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCATCTCTTA	360
Db	301	GTGCACATTATGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCATCTCTTA	360
Qy	361	TGCTGGGAATGACAAAGTGTGCTGTGATCCTCGCTGGTCTCTTCTTGAGACACACCCAAAC	420
Db	361	TGCTGGGAATGACAAAGTGTGCTGTGATCCTCGCTGGTCTCTTCTTGAGACACACCCAAAC	420

QY 1501 TCTGCCACAGAGTCCGCCAGCTGGACATCTCTGGAGCTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTCCGCCAGCTGGACATCTCTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGAGCAACAGAAATCAGACCTTCCGGCCCAAGCGTGGCGTCCGGCAGCTTTG 1620
DB 1561 GTCCATAGAGAGCAACAGAAATCAGACCTTCCGGCCCAAGCGTGGCGTCCGGCAGCTTTG 1620
QY 1621 GTAGACTGTGCCACACAGCGCTGTCTGTGAACGTGAATATAAAGAGCAAAAAAAA 1679
DB 1621 GTAGACTGTGCCACACAGCGCTGTCTGTGAACGTGAATATAAAGAGCAAAAAAAA 1679

RESULT 83

ADD54192
ID ADD54192 standard; cDNA; 1679 BP.

XX AC ADD54192;
XX DT 15-JAN-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX OS Homo sapiens.
XX US2003203432-A1.
XX PD 30-OCT-2003.
XX PF 10-MAY-2002; 2002US-00142886.
XX PR 05-JUN-2000; 2000US-0209832P.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski EJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2003-875639/81.
XX P-PSDB; ADD54193.

XX PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
XX PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
XX PT generating antisense RNA and DNA, and in gene therapy.

XX PS Claim 2; SEQ ID NO 375; 637pp; English.

XX CC The invention describes 305 nucleic acids encoding PRO (secreted and
XX CC transmembrane) polypeptides (I). (I) is useful for stimulating the
XX CC release of TNF-alpha from human blood, for modulating the uptake of
XX CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX CC stimulating the proliferation or differentiation of chondrocyte cells,
XX CC for stimulating the proliferation of or gene expression in pericyte
XX CC cells, for stimulating the release of proteoglycans from cartilage, for
XX CC stimulating the proliferation of inner ear utricular supporting cells,
XX CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX CC the release of a cytokine from PBMC cells, for inhibiting the binding of
XX CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
XX CC cells, for stimulating proliferation of endothelial cells, for detecting
XX CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
XX CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes

CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
XX a novel human secreted and transmembrane PRO polypeptide.
XX SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTCTGCAACAGCTTGAGAGCAAC 60
DB 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTCTGCAACAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAAAACCAGAACTTGACAAAAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAAAACCAGAACTTGACAAAAAAGAAAGAAAG 120
QY 121 AGAAAAAATAATCATGAAACCATCCAGCCAAATATGCAATTTCTCTCTTGGGCAAT 180
DB 121 AGAAAAAATAATCATGAAACCATCCAGCCAAATATGCAATTTCTCTCTTGGGCAAT 180
QY 181 CTTACGGGGTGGTGTCTCTGTGTCTTCAAGAGGTGCCGTGCGCAGCGGAGATGC 240
DB 181 CTTACGGGGTGGTGTCTCTGTGTCTTCAAGAGGTGCCGTGCGCAGCGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGAACAGTGCAGCTCCGGAGGGGAGAGCCGCCCTCAG 300
DB 241 CACCTTCCCAAGCTATGGAACAGTGCAGCTCCGGAGGGGAGAGCCGCCCTCAG 300
QY 301 GTGCACCTATTGCAACCCGGGTCAACCCGGTGGCTGGCTTAAACCCGAGCACCATTCTCTA 360
DB 301 GTGCACCTATTGCAACCCGGGTCAACCCGGTGGCTGGCTTAAACCCGAGCACCATTCTCTA 360
QY 361 TGTCTGGGAATGACAGTGGTGGCTGGATCCTCGGTGGTCTTCTGTAGCAACACCCCAAC 420
DB 361 TGTCTGGGAATGACAGTGGTGGCTGGATCCTCGGTGGTCTTCTGTAGCAACACCCCAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACCGTGGATGTGTATGACAGGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACCGTGGATGTGTATGACAGGGGCCCTTACACCTGCTC 480
QY 481 GGTGCAAGACAGCAACCCCAAGACCTTAGGGTCCACCTCATTTGTGCAAGATATCTCC 540
DB 481 GGTGCAAGACAGCAACCCCAAGACCTTAGGGTCCACCTCATTTGTGCAAGATATCTCC 540
QY 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
DB 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
QY 601 CTGCAATAGCAACTGGTAGACAGAGCTTAGGTACTCTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCAATAGCAACTGGTAGACAGAGCTTAGGTACTCTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTTCCAAATGAGTGGCGCGCCCGTGGTACGGAGATATA 780
DB 721 AGGGGACTACGAGTGCAGTGCCTTCCAAATGAGTGGCGCGCCCGTGGTACGGAGATATA 780

QY 181 CTTTACCGGGCTGGCTGCTCTGTGTCTCTTCCAAAGAGTGGCCGTGGCGAGCGGAGATGC 240
DB 181 CTTTACCGGGCTGGCTGCTCTGTGTCTCTTCCAAAGAGTGGCCGTGGCGAGCGGAGATGC 240
QY 241 CACCTTCCCCAAAGCTATGGAACAGCTGACGGTCCGCGAGGGGAGAGCGCCACCTTCAG 300
DB 241 CACCTTCCCCAAAGCTATGGAACAGCTGACGGTCCGCGAGGGGAGAGCGCCACCTTCAG 300
QY 301 GTGCACTATTGACAAACCGGCTCACCCGGGTGGCTTAAACCGCAGCACCATCTCTCTA 360
DB 301 GTGCACTATTGACAAACCGGCTCACCCGGGTGGCTTAAACCGCAGCACCATCTCTCTA 360
QY 361 TGCTGGGAATGACAAAGTGGTGGCTGGATCTCGCGTGGTCTCTTCTGAGCAACACCCAAAC 420
DB 361 TGCTGGGAATGACAAAGTGGTGGCTGGATCTCGCGTGGTCTCTTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACGTTGGATGTATCACGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACGTTGGATGTATCACGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGAGAGCAGAACACCCAAAGCCTCTAGGTTCCACCTCATTTGTGGAAGTATCTCC 540
DB 481 GGTGAGAGCAGAACACCCAAAGCCTCTAGGTTCCACCTCATTTGTGGAAGTATCTCC 540
QY 541 CAAAATTGTAGAGATTTCTTTCAGATATCTCCATTATGAAGGGAACATATTAGCCTCAC 600
DB 541 CAAAATTGTAGAGATTTCTTTCAGATATCTCCATTATGAAGGGAACATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGTGTAGACAGACCTAAGGTTACTTGGAGACACATCTCTCCCAAAGC 660
DB 601 CTGCATAGCAACTGTGTAGACAGACCTAAGGTTACTTGGAGACACATCTCTCCCAAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGAGCAATCTTGGAAATTCAGGGCATCACCCGGGAGCATGC 720
DB 661 GGTGGCTTTGTGAGTGAAGAGCAATCTTGGAAATTCAGGGCATCACCCGGGAGCATGC 720
QY 721 AGGGGACTACGAGTGCAGTCCCAATGACGTGCGCGCCGCGGTGTACGGAGAGTAAA 780
DB 721 AGGGGACTACGAGTGCAGTCCCAATGACGTGCGCGCCGCGGTGTACGGAGAGTAAA 780
QY 781 GGTACCGTGAATCTACCACTATCAATTCAGAGCCAGGGTACAGGTGCCCGTGGG 840
DB 781 GGTACCGTGAATCTACCACTATCAATTCAGAGCCAGGGTACAGGTGCCCGTGGG 840
QY 841 ACAAAGGGGACACTGCACTGTGAAGCCTTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 ACAAAGGGGACACTGCACTGTGAAGCCTTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAAGTGAACAAAGCTGATTAAGGAAGAGGGGTGAAGTGAAGACAGACCTTT 960
DB 901 CAAAGTGAACAAAGCTGATTAAGGAAGAGGGGTGAAGTGAAGACAGACCTTT 960
QY 961 CTTCTCAAACTCATCTTCTCAATGCTCTGAAACATGACTATGGGAACATACCTTGGT 1020
DB 961 CTTCTCAAACTCATCTTCTCAATGCTCTGAAACATGACTATGGGAACATACCTTGGT 1020
QY 1021 GGCCTTCAACAGAGTGGGACACCAATGCGAGCATCATGCTATTTGTTCAGGGCCGT 1080
DB 1021 GGCCTTCAACAGAGTGGGACACCAATGCGAGCATCATGCTATTTGTTCAGGGCCGT 1080
QY 1081 CAGCGAGGTGAGCAACCGGACCTGCGAGGAGGCGAGCTGCGTCTGGCTGCTGCTTCT 1140
DB 1081 CAGCGAGGTGAGCAACCGGACCTGCGAGGAGGCGAGCTGCGTCTGGCTGCTGCTTCT 1140
QY 1141 GGTCTTGAACCTGCTTCTCAATTTTGTATGTGAGTGGCACTTCCCGACCCGGGAAAGGCT 1200
DB 1141 GGTCTTGAACCTGCTTCTCAATTTTGTATGTGAGTGGCACTTCCCGACCCGGGAAAGGCT 1200
QY 1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
DB 1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260

QY 1261 TATACAAATGAATTAGAAGAAACACAGCTCATGGGACAGAAATTTGAGGGAGGGAAAC 1320
DB 1261 TATACAAATGAATTAGAAGAAACACAGCTCATGGGACAGAAATTTGAGGGAGGGAAAC 1320
QY 1321 AAAGAATACCTTTGGGGGAAAAGAGCTTTTAAAAAAGAAATTTGAAATTTGCCCTTGCA 1380
DB 1321 AAAGAATACCTTTGGGGGAAAAGAGCTTTTAAAAAAGAAATTTGAAATTTGCCCTTGCA 1380
QY 1381 TTTAGTACAATGGAGTTTCTTTTCCAAAACGGGAAGAACACAGCACACCCGGCTTGA 1440
DB 1381 TTTAGTACAATGGAGTTTCTTTTCCAAAACGGGAAGAACACAGCACACCCGGCTTGA 1440
QY 1441 CCACCTGCAAGCTGATCGTCAACCTTTTGGTCCAGTGGGCAAGGGCTCAGCCTC 1500
DB 1441 CCACCTGCAAGCTGATCGTCAACCTTTTGGTCCAGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCACCTGGAACATTTCTGGAGTGGCCATCCAAATTCATCA 1560
DB 1501 TCTGCCACAGAGTGCCTCCACCTGGAACATTTCTGGAGTGGCCATCCAAATTCATCA 1560
QY 1561 GTCCATAGAGAGCAAGCAATGAGACCTTCCGCGCCAGCGTGGCGCTCGGCGACTTTG 1620
DB 1561 GTCCATAGAGAGCAAGCAATGAGACCTTCCGCGCCAGCGTGGCGCTCGGCGACTTTG 1620
QY 1621 GTAGACTGTGCCACCAACCGCGCTGTGTGTGAAACGTGAAATTTAAAAAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACCAACCGCGCTGTGTGTGAAACGTGAAATTTAAAAAGAGCAAAAAA 1679
RESULT 85
ADDS1281
ID ADDS1281 standard; cDNA; 1679 BP.
XX
AC ADDS1281;
XX
DT 15-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;
KW vulnary; antileukemic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
XX gene therapy.
XX
OS Homo sapiens.
XX
PN US2003105289-A1.
XX
PD 05-JUN-2003.
XX
PF 13-AUG-2002; 2002US-00219472.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-829359/77.
DR P-PSDE; ADDS1282.
XX
PT New isolated nucleic acids and their encoded secreted and transmembrane
PT polypeptides (PRO), useful e.g. for stimulating cell proliferation or
PT differentiation and for diagnosis of cancer.
XX

Claim 2; Fig 125; 308pp; English.

The invention describes an isolated PRO (secreted and transmembrane) polypeptide (I). PRO982, PRO1167 or PRO1329 polypeptide are useful for stimulating the proliferation of or gene expression in pericyte cells. PRO357, PRO1272 or PRO4405 polypeptide are useful for stimulating the proliferation or differentiation of chondrocyte cells. PRO357, PRO725, PRO1155, PRO1306 or PRO419 polypeptide are useful for stimulating the release of tumour necrosis factor (TNF) - alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214, PRO337, PRO326, PRO363, PRO531, PRO1083, PRO840, PRO1080, PRO1478, PRO1334, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309, PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412, PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338, PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567, PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322, PRO9840, PRO6079, PRO9836 or PRO10096 polypeptide are useful for stimulating the proliferation of normal human dermal fibroblasts cells. PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408, PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for inhibiting the proliferation of normal human dermal fibroblast cells. PRO polypeptides such as PRO6004, PRO4981, PRO174, PRO5778, PRO4332, etc., are useful for detecting the presence of tumour in a mammal which involves comparing the level of expression of the above PRO polypeptides in a test sample of cells taken from the mammal, and a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptides in the test sample as compared to the control sample is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for chromosome and gene mapping or gene therapy. (II) is useful for generating transgenic animals or knock-out animals which are useful screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide is useful for treating bone and/or cartilage disorders (e.g., arthritis sport injuries). This sequence encodes a human secreted and transmembrane PRO polypeptide.

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCTCTTGACAAAGTTGAGAGCAAC 60
Db 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCTCTTGACAAAGTTGAGAGCAAC 60

Qy 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

Qy 121 AAGAAAAAATCATCAAAACCATCCAGCCAAAATGCAAAATTCATCTCTTGGGCAAT 180
Db 121 AAGAAAAAATCATCAAAACCATCCAGCCAAAATGCAAAATTCATCTCTTGGGCAAT 180

Qy 181 CTTTCAGGGGCTGGCTGCTGTGTCTCTTCCAGAGTGGCCGTGGCAGCGAGATGC 240
Db 181 CTTTCAGGGGCTGGCTGCTGTGTCTCTTCCAGAGTGGCCGTGGCAGCGAGATGC 240

Qy 241 CACCTTCCCAAGCTATGGAACAACGTGACGCTCCGGCAGGGGAGAGCGCCACCTCAG 300
Db 241 CACCTTCCCAAGCTATGGAACAACGTGACGCTCCGGCAGGGGAGAGCGCCACCTCAG 300

Qy 301 GTGCACTATTGACAAACGGGTGACCCGGTGGCTGGCTTAACCGCAGCAACATCTCTTA 360
Db 301 GTGCACTATTGACAAACGGGTGACCCGGTGGCTGGCTTAACCGCAGCAACATCTCTTA 360

Qy 361 TGTGGGAATGACAGTGGTGGCTGGATCCTCGCTGGTCTTCTTGAGCAACACCCAAAC 420
Db 361 TGTGGGAATGACAGTGGTGGCTGGATCCTCGCTGGTCTTCTTGAGCAACACCCAAAC 420

Qy 421 GCAGTACAGCATCCAGATCCAGAACTGGATGTGTATGACGAGGGCCCTTACACTGCTC 480

Db 1501 TCTGCCACAGAGTGCCTCCACGTCGGAACATCTCTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACGAACAGATGAGACCTTCGCGGCCAAGCGTGGCGCTGCGGGCACTTTG 1620
Db 1561 GTCCATAGAGACGAACAGATGAGACCTTCGCGGCCAAGCGTGGCGCTGCGGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACACGCGGTGTGTGTGAAACGTGAAATATAAAGAGCAAAAAAAA 1679
Db 1621 GTAGACTGTGCCACACGCGGTGTGTGTGAAACGTGAAATATAAAGAGCAAAAAAAA 1679
RESULT 86
ADE49556
ID ADE49556 standard; cDNA; 1679 bp.
AC ADE49556;
XX
DT
XX 29-JAN-2004 (first entry)
XX Human cDNA encoding secreted/transmembrane protein, PRO337.
XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cystostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
XX US2003096744-A1.
XX
XX 22-MAY-2003.
XX
XX 28-JAN-2002; 2002US-00978187.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079456P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 30-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 31-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 15-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085589P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 98WO-US000106.
PR 05-MAR-1999; 98US-00254465.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98US-00265686.
PR 10-MAR-1999; 98WO-US005190.

Db 1081 CAGCGAGGTGAGCAACGGCACGTCGAGGAGGCGAGGCTGCGTCTGGCTCTTCT 1140
Qy 1141 GGTCTTGACCTGCTTCTCAAAATTTTGATGTGAGTGCCACATTCCTCCACCGGGAAGGCT 1200
Db 1141 GGTCTTGACCTGCTTCTCAAAATTTTGATGTGAGTGCCACATTCCTCCACCGGGAAGGCT 1200
Qy 1201 GCGGCCACACACACACACACACAGCAATGGGCAACACCGACAGCAACCAATCAGATA 1260
Db 1201 GCGGCCACACACACACACACACAGCAATGGGCAACACCGACAGCAACCAATCAGATA 1260
Qy 1261 TATACAAATGAATATAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC 1320
Db 1261 TATACAAATGAATATAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC 1320
Qy 1321 AAGAAATCTTGGGGGGAAGAGATTTTAAAAAGAAATTTGAAATTTGCCCTTGAGATA 1380
Db 1321 AAGAAATCTTGGGGGGAAGAGATTTTAAAAAGAAATTTGAAATTTGCCCTTGAGATA 1380
Qy 1381 TTTAGGTCAATGGAGTTTCTTTTCCCAACCGGGAAGAACACAGCACACCGGCTTGGGA 1440
Db 1381 TTTAGGTCAATGGAGTTTCTTTTCCCAACCGGGAAGAACACAGCACACCGGCTTGGGA 1440
Qy 1441 CCACCTGCAAGCTGCATCTGCAACCTTTTGGTGCAGTGTGGCAAGGGCTCAGCCTC 1500
Db 1441 CCACCTGCAAGCTGCATCTGCAACCTTTTGGTGCAGTGTGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCCCACAGAGTGCCTCCACGTGGAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCCCACAGAGTGCCTCCACGTGGAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGGCACTTTG 1620
Db 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACACCGCGGTGTGTGAACTGAAATATAAAGAGCAAAAAAAA 1679
Db 1621 GTAGACTGTGCCACACCGCGGTGTGTGAACTGAAATATAAAGAGCAAAAAAAA 1679

RESULT 87

ADD92509
ID ADD92509 standard; cDNA; 1679 BP.
AC ADD92509;
XX 29-JAN-2004 (first entry)
XX Human PRO polynucleotide #188.
XX Human; gene; es; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS
XX US2003199030-A1.
PN
XX 23-OCT-2003.
PD
XX 28-MAY-2002; 2002US-00156841.
PF
XX 03-MAR-2000; 2000US-0187202P.
PR
XX 01-DEC-2000; 2000WO-US032678.
PR
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.

XX Baker KP, Bersini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Garritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-900159/82.
DR P-PSDB; ADD92510.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
XX Claim 2; SEQ ID NO 375; 636pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTTGTGCTCTCAGCAAAACAGTGGATTTAAATCTCTTGCAACAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTCTCAGCAAAACAGTGGATTTAAATCTCTTGCAACAGCTTGAGAGCAAC 60
Qy 61 AATCTATCAGGAAAGAAAGAAAGAAACCGAACCTGACAAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAAGAAAGAAAGAAACCGAACCTGACAAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAAAATCATCAAAACCATCCAGCAAAATGCAATTTCTATCTCTTGGGCAAT 180
Db 121 AAGAAAAAATCATCAAAACCATCCAGCAAAATGCAATTTCTATCTCTTGGGCAAT 180
Qy 181 CTTTCAGGGGCTGGCTGCTCTGTCTCTTTCAGAGAGTGCCTGCGGAGGAGATGC 240
Db 181 CTTTCAGGGGCTGGCTGCTCTGTCTCTTTCAGAGAGTGCCTGCGGAGGAGATGC 240
Qy 241 CACCTTCCCCAAAGCTATGCAACAACTGACGGTCCGGCAGGGGAGAGGCCACCTCAG 300
Db 241 CACCTTCCCCAAAGCTATGCAACAACTGACGGTCCGGCAGGGGAGAGGCCACCTCAG 300

QY 301 GTGCACTATTGCAACCGGGTCAACCGGGTGGCTTAACCGCAGCACCATCTCTCTA 360
DB |||||
QY 301 GTGCACTATTGCAACCGGGTCAACCGGGTGGCTTAACCGCAGCACCATCTCTCTA 360
DB |||||
QY 361 TGCCTGGGAATGAAAGTGGTGGCTGGATCCTCGCGTGGTCTTCTTGAGCAACACCCAAAC 420
DB |||||
QY 361 TGCCTGGGAATGAAAGTGGTGGCTGGATCCTCGCGTGGTCTTCTTGAGCAACACCCAAAC 420
DB |||||
QY 421 GCAGTACAGCATCGAGATCCAGACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
DB |||||
QY 421 GCAGTACAGCATCGAGATCCAGACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
DB |||||
QY 481 GGTGACAGACAGCAACACCCAAAGACCTCTAGGGTCCACCTCACTGTGCAAGTATCTCC 540
DB |||||
QY 481 GGTGACAGACAGCAACACCCAAAGACCTCTAGGGTCCACCTCACTGTGCAAGTATCTCC 540
DB |||||
QY 541 CAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCTCAC 600
DB |||||
QY 541 CAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCTCAC 600
DB |||||
QY 601 CTGCATAGCAACTGTGTAGACAGAGCTTACGGTTACTTGGAGACACATCTCTCCCAAAGC 660
DB |||||
QY 601 CTGCATAGCAACTGTGTAGACAGAGCTTACGGTTACTTGGAGACACATCTCTCCCAAAGC 660
DB |||||
QY 661 GGTGGCTTTGTGAGTGAAGAGCAATACCTTGGAATTCAGGGCATCACCGGAGGAGTC 720
DB |||||
QY 661 GGTGGCTTTGTGAGTGAAGAGCAATACCTTGGAATTCAGGGCATCACCGGAGGAGTC 720
DB |||||
QY 721 AGGGGACTAGAGTGCAGTGCCTCCCAATGACGTGGCGCGCGCTGGTACGAGAGTAAA 780
DB |||||
QY 721 AGGGGACTAGAGTGCAGTGCCTCCCAATGACGTGGCGCGCGCTGGTACGAGAGTAAA 780
DB |||||
QY 781 GGTCAACCGTGAATATCCACATACATTTAGAAAGCCAAAGGGTACAGGTGTCCCGTGGG 840
DB |||||
QY 781 GGTCAACCGTGAATATCCACATACATTTAGAAAGCCAAAGGGTACAGGTGTCCCGTGGG 840
DB |||||
QY 841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGAGTCCCTCAGCAGAGATTCAGGTGTA 900
DB |||||
QY 841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGAGTCCCTCAGCAGAGATTCAGGTGTA 900
DB |||||
QY 901 CAAGGATGACAAAGACTGATTGAAGGAAGAAAGGGTGAAGTGGAAAAACAGACCTTT 960
DB |||||
QY 901 CAAGGATGACAAAGACTGATTGAAGGAAGAAAGGGTGAAGTGGAAAAACAGACCTTT 960
DB |||||
QY 961 CCTCTCAAACTCATCTTCTCAATCTCTGACATGATATGGGAACTACATCTGGCT 1020
DB |||||
QY 961 CCTCTCAAACTCATCTTCTCAATCTCTGACATGATATGGGAACTACATCTGGCT 1020
DB |||||
QY 1021 GGCCTCCAAAGTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
DB |||||
QY 1021 GGCCTCCAAAGTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
DB |||||
QY 1081 CAGGAGGTGAGCAACGGCAGCTGAGAGGGGAGGCTGGTGGTGGTGGTGGTGGTGGTGGT 1140
DB |||||
QY 1081 CAGGAGGTGAGCAACGGCAGCTGAGAGGGGAGGCTGGTGGTGGTGGTGGTGGTGGTGGT 1140
DB |||||
QY 1141 GGTCTTCACCTGCTCTCAAAATTTGATGTGAGTGCACCTTCCCAACCGGGAAGAGGT 1200
DB |||||
QY 1141 GGTCTTCACCTGCTCTCAAAATTTGATGTGAGTGCACCTTCCCAACCGGGAAGAGGT 1200
DB |||||
QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
DB |||||
QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
DB |||||
QY 1261 TATCAAAATGAATTTAGAGAAACACAGCTCTATGGGACAGAAATTTAGGGAGGGGAAC 1320
DB |||||
QY 1261 TATCAAAATGAATTTAGAGAAACACAGCTCTATGGGACAGAAATTTAGGGAGGGGAAC 1320
DB |||||
QY 1321 AAAGAACTATTGGGGGGAAGAGTTTAAAAAGAAATTTAAAAATTTGCTTGCAGATA 1380
DB |||||
QY 1321 AAAGAACTATTGGGGGGAAGAGTTTAAAAAGAAATTTAAAAATTTGCTTGCAGATA 1380
DB |||||

QY 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAAAACGGGAAGAACACAGCACACCGGGTTGGA 1440
DB |||||
QY 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAAAACGGGAAGAACACAGCACACCGGGTTGGA 1440
DB |||||
QY 1441 CCACACTGCAAGCTGCATCTGTGGAACCTTCTGTGCAAGTGTGGCAAGGGCTCAGCCTC 1500
DB |||||
QY 1441 CCACACTGCAAGCTGCATCTGTGGAACCTTCTGTGCAAGTGTGGCAAGGGCTCAGCCTC 1500
DB |||||
QY 1501 TCTGCCACACAGAGTGGCCCCCAGCGTGGAAATCTTGGAGCTGGCCATCCCAAAATTCATCA 1560
DB |||||
QY 1501 TCTGCCACACAGAGTGGCCCCCAGCGTGGAAATCTTGGAGCTGGCCATCCCAAAATTCATCA 1560
DB |||||
QY 1561 GTCCATAGACAGCAACAGAAATGAGACTTCCGCCCCAAGCGTGGCGCTGGCGGACCTTTG 1620
DB |||||
QY 1561 GTCCATAGACAGCAACAGAAATGAGACTTCCGCCCCAAGCGTGGCGCTGGCGGACCTTTG 1620
DB |||||
QY 1621 GTAGCTGTGCCACACCGCGTGTGTGAAACGTGAAATATAAAAGAGCAAAAAAAA 1679
DB |||||
QY 1621 GTAGCTGTGCCACACCGCGTGTGTGAAACGTGAAATATAAAAGAGCAAAAAAAA 1679
DB |||||

RESULT 88
ADD91405
ID ADD91405 standard; cDNA; 1679 BP.
XX
AC ADD91405;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
XX
KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199055-A1.
XX
PD 23-OCT-2003.
XX
PF 12-APR-2002; 2002US-00121063.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 2000WO-US006319.
PR 14-MAY-1999; 99WO-US008615.
PR 02-JUN-1999; 99WO-US010733.
PR 01-SEP-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.

PR	08-SEP-1999;	99WO-US020594.
PR	13-SEP-1999;	99WO-US020944.
PR	15-SEP-1999;	99WO-US021090.
PR	15-SEP-1999;	99WO-US021547.
PR	05-OCT-1999;	99WO-US023089.
PR	29-NOV-1999;	99WO-US028214.
PR	30-NOV-1999;	99WO-US028313.
PR	20-NOV-1999;	99WO-US028409.
PR	01-DEC-1999;	99WO-US028301.
PR	01-DEC-1999;	99WO-US028634.
PR	02-DEC-1999;	99WO-US028551.
PR	02-DEC-1999;	99WO-US028564.
PR	16-DEC-1999;	99WO-US028565.
PR	20-DEC-1999;	99WO-US030095.
PR	20-DEC-1999;	99WO-US030911.
PR	20-DEC-1999;	99WO-US030999.
PR	22-DEC-1999;	99WO-US030720.
PR	30-DEC-1999;	99WO-US031243.
PR	30-DEC-1999;	99WO-US031274.
PR	05-JAN-2000;	2000WO-US000219.
PR	06-JAN-2000;	2000WO-US000277.
PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US000356S.
PR	18-FEB-2000;	2000WO-US004341.
PR	18-FEB-2000;	2000WO-US004342.
PR	22-FEB-2000;	2000WO-US004414.
PR	24-FEB-2000;	2000WO-US004914.
PR	24-FEB-2000;	2000WO-US005004.
PR	01-MAR-2000;	2000WO-US005601.
PR	02-MAR-2000;	2000WO-US005746.
PR	02-MAR-2000;	2000WO-US005841.
PR	15-MAR-2000;	2000WO-US006884.
PR	20-MAR-2000;	2000WO-US007377.
PR	21-MAR-2000;	2000WO-US007532.
PR	30-MAR-2000;	2000WO-US008439.
PR	17-MAY-2000;	2000WO-US013709.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	28-JUL-2000;	2000WO-US020710.
PR	11-AUG-2000;	2000WO-US020231.
PR	23-AUG-2000;	2000WO-US023522.
PR	24-AUG-2000;	2000WO-US023328.
PR	08-NOV-2000;	2000WO-US030952.
PR	10-NOV-2000;	2000WO-US030873.
PR	01-DEC-2000;	2000WO-US032678.
PR	20-DEC-2000;	2000US-00747259.
PR	20-DEC-2000;	2000WO-US034956.
PR	28-FEB-2001;	2001US-00796498.
PR	28-FEB-2001;	2001WO-US006520.
PR	03-MAR-2001;	2001WO-US009666.
PR	03-MAR-2001;	2001US-00802706.
PR	14-MAR-2001;	2001US-00808689.
PR	22-MAR-2001;	2001US-00816744.
PR	05-APR-2001;	2001US-00828366.
PR	10-MAY-2001;	2001US-00854208.
PR	10-MAY-2001;	2001US-00854280.
PR	18-MAY-2001;	2001US-00860216.
PR	25-MAY-2001;	2001US-00866028.
PR	25-MAY-2001;	2001US-00866034.
PR	25-MAY-2001;	2001WO-US017092.
PR	01-JUN-2001;	2001US-00872035.
PR	01-JUN-2001;	2001WO-US017800.
PR	05-JUN-2001;	2001US-00874503.
PR	14-JUN-2001;	2001US-00882636.
PR	19-JUN-2001;	2001US-00886342.
PR	20-JUN-2001;	2001WO-US019692.
PR	21-JUN-2001;	2001US-00887879.
PR	22-JUN-2001;	2001WO-US020116.
PR	23-JUN-2001;	2001WO-US021066.
PR	03-JUL-2001;	2001WO-US021735.
PR	18-JUL-2001;	2001US-00908827.
PR	06-AUG-2001;	2001US-00924419.
PR	09-AUG-2001;	2001US-00927796.
PR	16-AUG-2001;	2001US-00931836.
PR	19-DEC-2001;	2001US-00028072.
XX	(GETH) GENENTECH INC.	
PI	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	
XX	WPI; 2003-900165/82.	
DR	P-PDDB; ADD91406.	
PT	Two hundred and seventy five nucleic acids encoding PRO polypeptides, useful for treating pericyte-associated tumors, diabetes and various bone and/or cartilage disorders, e.g. arthritis.	
PS	Claim 2; SEQ ID NO 375; 636pp; English.	
CC	The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.	
SQ	Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;	
	Query Match 100.0%; Score 1679; DB 1; Length 1679;	
	Best Local Similarity 100.0%; Pred. No. 6.7e-05;	
	Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0	
QY	1 GTTGTGTCCTTCAGCAAAACAGTGCGATTTAATCTCCTTCACACAGCTTGAGCA	

22-JUN-2001; 2001WO-US020116.
23-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
09-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.
(GETH) GENENTECH INC.
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Garritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-900167/82.
P-PSDB; ADE04020.
Two hundred and seventy five nucleic acids encoding PRO polypeptides,
useful for treating pericyte-associated tumors, diabetes and various bone
and/or cartilage disorders, e.g. arthritis.
Claim 2; Fig 375; 637pp; English.
The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems,
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence represents a human PRO polynucleotide of the invention. Note:
The sequence data for this patent is also available in electronic format
from USPTO at seqdata.uspto.gov/sequence.html.
Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0
Qy 1 GTTGTGTCCTTCAGCAAAAACAGTGGATTAAATCTCTTGCCAAAGCTTGAGCAACAC 60
Db 1 GTTGTGTCCTTCAGCAAAAACAGTGGATTAAATCTCTTGCCAAAGCTTGAGCAACAC 60
Qy 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAAAAATCATGAAACCATCCAGCAAAAATGCAAAATCTTCTTTGGGCAAT 180

Db 121 |||||ATGAAAAAATCATGAAACCATCAGCCAAATATGCAATTCATCTCTTGGGCAAT 180
Qy 181 CTTACGGGGCTGGCTGCTCTGTGTCTCTTCAAGGAGTGCCGTGCGCAGCGGAGATGC 240
Db 181 CTTACGGGGCTGGCTGCTCTGTGTCTCTTCAAGGAGTGCCGTGCGCAGCGGAGATGC 240
Qy 241 CACCTTCCCAAGCTATATGCAAACTGACGGTTCGGGCGAGGGGAGAGCGCCACCTCTAG 300
Db 241 CACCTTCCCAAGCTATATGCAAACTGACGGTTCGGGCGAGGGGAGAGCGCCACCTCTAG 300
Qy 301 GTGCACTATTGACAACTGGGTACCCCGGTGGCTTAAACCGCAGCACCACCTCTCTA 360
Db 301 GTGCACTATTGACAACTGGGTACCCCGGTGGCTTAAACCGCAGCACCACCTCTCTA 360
Qy 361 TGTGGGAATGACAACTGGGTGGCTTAAACCGCAGCACCACCTCTCTA 420
Db 361 TGTGGGAATGACAACTGGGTGGCTTAAACCGCAGCACCACCTCTCTA 420
Qy 421 GCAGTACAGCATCGAGATCCAGAACTGGATGTATGACGAGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACTGGATGTATGACGAGGGCCCTTACACCTGCTC 480
Qy 481 GGTGCGAGACAGACCAACCCAAAGACCTTCTAGGGTCCAACCTTCTGTCGAAAGTATCTCC 540
Db 481 GGTGCGAGACAGACCAACCCAAAGACCTTCTAGGGTCCAACCTTCTGTCGAAAGTATCTCC 540
Qy 541 CAAAATTGTAGATTTCTTCAATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
Db 541 CAAAATTGTAGATTTCTTCAATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
Qy 601 CTGCATAGCAACTGTGAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCATAGCAACTGTGAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
Qy 661 GGTGGCTTTGAGTGAAGACCAATCTTGGAATTCAGGCGATCACCGGAGCAGTC 720
Db 661 GGTGGCTTTGAGTGAAGACCAATCTTGGAATTCAGGCGATCACCGGAGCAGTC 720
Qy 721 AGGGGACTACAGTGCAGTCCCTCCATGACGTGGCGCGCCGCTGCTACGAGAGATAA 780
Db 721 AGGGGACTACAGTGCAGTCCCTCCATGACGTGGCGCGCCGCTGCTACGAGAGATAA 780
Qy 781 GGTACCGTGAATCTACCACTATCTTCAAGGCGAAGGGTACAGGTGTCCTCCGTTGG 840
Db 781 GGTACCGTGAATCTACCACTATCTTCAAGGCGAAGGGTACAGGTGTCCTCCGTTGG 840
Qy 841 ACAAAGGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACAAAGGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Qy 901 CAAGGATGACAAAGACTGATTGAAGGAAAGAGGGTGAAAGTGGAACTACACTTGGT 960
Db 901 CAAGGATGACAAAGACTGATTGAAGGAAAGAGGGTGAAAGTGGAACTACACTTGGT 960
Qy 961 CCTCTCAAACTCATCTTCTCAATGTCTCTGAACATGATATGGGAACTACACTTGGT 1020
Db 961 CCTCTCAAACTCATCTTCTCAATGTCTCTGAACATGATATGGGAACTACACTTGGT 1020
Qy 1021 GGCCTCAAAAGCTGGGCGACCACTATGTCATCTATTTGGTCCAGGCGCGT 1080
Db 1021 GGCCTCAAAAGCTGGGCGACCACTATGTCATCTATTTGGTCCAGGCGCGT 1080
Qy 1081 CAGGAGGTGACGACCGGACGTGAGGAGGCGAGGCTGGCTGGCTGGCTGGCTGGCT 1140
Db 1081 CAGGAGGTGACGACCGGACGTGAGGAGGCGAGGCTGGCTGGCTGGCTGGCTGGCT 1140
Qy 1141 GGTCTTCACTGCTTCTCAAAATTTGATGTGAGTGCACCTTCCCAACCGGAAAGGCT 1200
Db 1141 GGTCTTCACTGCTTCTCAAAATTTGATGTGAGTGCACCTTCCCAACCGGAAAGGCT 1200
Qy 1201 GCCGCCACCCACCAACCAACAGCAATGGCAACCGGACCGGACCAACCAATCAGATA 1260

Db 1201 GCCGCCACCCACCCACCAACCAACAGCAATGGCAACCCGACAGCAACCAATCAGATA 1260
Qy 1261 TATACAAATCAAAATTAAGAAACACAGCCTCATGGACAGAAATTTGAGGAGGGGAAC 1320
Db 1261 TATACAAATCAAAATTAAGAAACACAGCCTCATGGACAGAAATTTGAGGAGGGGAAC 1320
Qy 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTTGCAGATA 1380
Db 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTTGCAGATA 1380
Qy 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACCGGAAAGAAACACAGCACACCCGCTTGA 1440
Db 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACCGGAAAGAAACACAGCACACCCGCTTGA 1440
Qy 1441 CCCACTGCAAGCTCATCTGCAACCTTCTTTGTCGCACTGTGGGAGAGGCTCAGGCTC 1500
Db 1441 CCCACTGCAAGCTCATCTGCAACCTTCTTTGTCGCACTGTGGGAGAGGCTCAGGCTC 1500
Qy 1501 TCTGCCACAGAGTGCCTCCCAACCTGGAACATTTCTGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCCAACCTGGAACATTTCTGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGACAGCAAGATGAGACCTTCGGCCCAAGCGTGGCGCTGCGGCACTTTG 1620
Db 1561 GTCCATAGACAGCAAGATGAGACCTTCGGCCCAAGCGTGGCGCTGCGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACACCGCGTGTGTGAAACGTGAAATATAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACACCGCGTGTGTGAAACGTGAAATATAAGAGCAAAAAA 1679

RESULT 90
ADE32316

ID ADE32316 standard; cDNA; 1679 BP.

XX ADE32316;

XX 29-JAN-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO337 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene; ss;

KW Tumor necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

OS US2003194765-A1.

XX 16-OCT-2003.

XX 09-MAY-2002; 2002US-00142889.

XX 03-MAR-2000; 2000US-0187202P.

XX 01-DEC-2000; 2000WO-0032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;

XX WPI; 2003-899784/82.

XX P-PSDB; ADE32317.

XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,

PT useful for treating pericyte-associated tumors, diabetes and various bone

PT and/or cartilage disorders, e.g. arthritis.
 XX Claim 2; SEQ ID NO 375; 636pp; English.
 XX The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PMBC cells, for inhibiting the binding of A-peptide to factor V1RA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCCCTTGCAAGCTTGAGAGCAACAC 60
 DB 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCCCTTGCAAGCTTGAGAGCAACAC 60
 QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 DB 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 QY 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
 DB 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
 QY 181 CTTACGGGGCTGGCTGCTGTGTCTCTTCAAGAGAGTGCCTGCGCAGCGAGATGC 240
 DB 181 CTTACGGGGCTGGCTGCTGTGTCTCTTCAAGAGAGTGCCTGCGCAGCGAGATGC 240
 QY 241 CACCTTCCCAAGCTATGGCAAGTCAAGTCCGCGAGGGGAGAGCGCCACCCCTCAG 300
 DB 241 CACCTTCCCAAGCTATGGCAAGTCAAGTCCGCGAGGGGAGAGCGCCACCCCTCAG 300
 QY 301 GTGCACTATTGCAACCCGGGTCAACCCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360
 DB 301 GTGCACTATTGCAACCCGGGTCAACCCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360
 QY 361 TCGTGGGAATGCAAGTGGTGGCTGGATCTCGGTGGTCTCTGAGCAACACCCAAAC 420
 DB 361 TCGTGGGAATGCAAGTGGTGGCTGGATCTCGGTGGTCTCTGAGCAACACCCAAAC 420
 QY 421 GCAGTACAGCATCGAGATCCAGAAAGTGGATGTGTATGACGAGGGCCCTTACCTGCTC 480
 DB 421 GCAGTACAGCATCGAGATCCAGAAAGTGGATGTGTATGACGAGGGCCCTTACCTGCTC 480
 QY 481 GGTGACAGACACACCAACCAAGACCTTAGGCTCCACCTCATTTGTCAGTATCTCC 540

DB 481 GGTGACAGACAGAAACCCCAAGACCTTAGGTCACCTCATTTGTGAAGTATCTCC 540
 QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAACAATATTAGCTCAC 600
 DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAACAATATTAGCTCAC 600
 QY 601 CTGCATAGCACTGTGTAGACAGACCCCTACGGTACTCTTTGAGAGACACATCTCTCCAAAGC 660
 DB 601 CTGCATAGCACTGTGTAGACAGACCCCTACGGTACTCTTTGAGAGACACATCTCTCCAAAGC 660
 QY 661 GGTGGCTTTGTGAGTGAAGAGCATCTTGGAAATTCAGGGCATCCCGGGAGCAGTC 720
 DB 661 GGTGGCTTTGTGAGTGAAGAGCATCTTGGAAATTCAGGGCATCCCGGGAGCAGTC 720
 QY 721 AGGGACATACGAGTGCAGTGCCTCAATGAGCGTGGCCCGCCGGTGGTACGGAGAGTAAA 780
 DB 721 AGGGACATACGAGTGCAGTGCCTCAATGAGCGTGGCCCGCCGGTGGTACGGAGAGTAAA 780
 QY 781 GGTACCGTGAAGTACTTCCACCATCATTTTCAAGACCAAGGTCAGGTGTCCCGCTGG 840
 DB 781 GGTACCGTGAAGTACTTCCACCATCATTTTCAAGACCAAGGTCAGGTGTCCCGCTGG 840
 QY 841 ACAAAGGGGACACTGCACTGAGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
 DB 841 ACAAAGGGGACACTGCACTGAGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
 QY 901 CAAGGATGACAAAGACATGATTTGAAGGAAAGAAAGGGGTGAAGTGAAGGAAAGAAAG 960
 DB 901 CAAGGATGACAAAGACATGATTTGAAGGAAAGAAAGGGGTGAAGTGAAGGAAAGAAAG 960
 QY 961 CCTCTCAAAACATCATCTTCTTCAATGTCTCTGAACATGACTATGGGAATCTACACTTGG 1020
 DB 961 CCTCTCAAAACATCATCTTCTTCAATGTCTCTGAACATGACTATGGGAATCTACACTTGG 1020
 QY 1021 GGCCTCCACAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGCTCCAGGCGCGCT 1080
 DB 1021 GGCCTCCACAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGCTCCAGGCGCGCT 1080
 QY 1081 CAGCGAGTGTAGCAACCGCACCGTCGAGGAGGGCAGGCTGCGTCTGCTGCTCTTCT 1140
 DB 1081 CAGCGAGTGTAGCAACCGCACCGTCGAGGAGGGCAGGCTGCGTCTGCTGCTCTTCT 1140
 QY 1141 GGTCTTGACCTGCTTCTCAAAATTTTGAATGAGTGCACCTTCCCGCACCCCGGAAAGCT 1200
 DB 1141 GGTCTTGACCTGCTTCTCAAAATTTTGAATGAGTGCACCTTCCCGCACCCCGGAAAGCT 1200
 QY 1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
 DB 1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
 QY 1261 TATACAAATGAAATTTAGAGAAACACACCTCATGGGACAGAAATTTGAGGGAGGGAG 1320
 DB 1261 TATACAAATGAAATTTAGAGAAACACACCTCATGGGACAGAAATTTGAGGGAGGGAG 1320
 QY 1321 AAGAATATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
 DB 1321 AAGAATATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
 QY 1381 TTTAGTACAAATGGAGTTTCTTTTCCAAACCGGGAAGAAACACACACCCCGCTTGA 1440
 DB 1381 TTTAGTACAAATGGAGTTTCTTTTCCAAACCGGGAAGAAACACACACCCCGCTTGA 1440
 QY 1441 CCCACTGCAAGTGCATCGTCAACCTCTTTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1500
 DB 1441 CCCACTGCAAGTGCATCGTCAACCTCTTTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1500
 QY 1501 TCTGCCCAACAGAGTGCCTTCCAGACCTTCCGCGCCCAACCGCTGGCGCTCGCGGCACTT 1560
 DB 1501 TCTGCCCAACAGAGTGCCTTCCAGACCTTCCGCGCCCAACCGCTGGCGCTCGCGGCACTT 1560
 QY 1561 GTCCATAGAGACGACAGAAATGAGACCTTCCGCGCCCAACCGCTGGCGCTCGCGGCACTT 1620
 DB 1561 GTCCATAGAGACGACAGAAATGAGACCTTCCGCGCCCAACCGCTGGCGCTCGCGGCACTT 1620

and/or cartilage disorders, e.g. arthritis.

Claim 2; Fig 375; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 1 GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTCTTGACACAGCTTGAGAGCAAC 60
DB 1 GTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTCTTGACACAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
DB 121 AAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
QY 181 CTTTCAGGGGCTGGTCTGTCTGTCTCTTCAAGAGTGGCCGCGCAGCGAGATGC 240
DB 181 CTTTCAGGGGCTGGTCTGTCTGTCTCTTCAAGAGTGGCCGCGCAGCGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGAACAAAGTACGCTCGGCAAGAGGAGAGCGGCAACCTCAG 300
DB 241 CACCTTCCCAAGCTATGGAACAAAGTACGCTCGGCAAGAGGAGAGCGGCAACCTCAG 300
QY 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCCTCTTA 360
DB 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCCTCTTA 360
QY 361 TGCTGGGAATGACAAAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 420
DB 361 TGCTGGGAATGACAAAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 420
QY 421 GCAGTACAGATCGAGATCCAGACGTTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480

```

```

DB 421 GCAGTACAGATCGAGATCCAGACGTTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGCAGACAGACACACACACACACACACACACACACACACACACACACACACACACAC 540
DB 481 GGTGCAGACAGACACACACACACACACACACACACACACACACACACACACACACACAC 540
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTTAATGAAGGGAACAATATTAGCCTCAC 600
DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTTAATGAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGTGTAGACACAGAGCTACCGTCTTACTTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCAACTGTGTAGACACAGAGCTACCGTCTTACTTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTTCGCTTTGTAGTGAAGAGCAATATCTTGAATTCAGGGCATCACCCGGGACAGTTC 720
DB 661 GGTTCGCTTTGTAGTGAAGAGCAATATCTTGAATTCAGGGCATCACCCGGGACAGTTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCGCGCGCGCGCGCGCGCGCGCG 780
DB 721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCGCGCGCGCGCGCGCGCGCGCG 780
QY 781 GGTACCGTGAATCTCCACCATACATTTTCAAGAGCAAGGTACAGGTGTCCCGTGGG 840
DB 781 GGTACCGTGAATCTCCACCATACATTTTCAAGAGCAAGGTACAGGTGTCCCGTGGG 840
QY 841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGATGACAAAGACTGATTTGAAGAAAGAAAGGGTGAAGTGGAAACACAGACCTTT 960
DB 901 CAAGATGACAAAGACTGATTTGAAGAAAGAAAGGGTGAAGTGGAAACACAGACCTTT 960
QY 961 CCTCTCAAACTCATCTTCTCAATGTCTCTCAATGACTATGGAACTACACTTGCGT 1020
DB 961 CCTCTCAAACTCATCTTCTCAATGTCTCTCAATGACTATGGAACTACACTTGCGT 1020
QY 1021 GGCTTCAACAAAGCTGGGCGACCAATGCCAGCATCATGTATTTGTCFCAAGGGCGCT 1080
DB 1021 GGCTTCAACAAAGCTGGGCGACCAATGCCAGCATCATGTATTTGTCFCAAGGGCGCT 1080
QY 1081 CAGCAGGTGAGCAACGGCAGCTCGAGGAGGCGAGCTGCGTCTGCTGCTGCTCTCTCT 1140
DB 1081 CAGCAGGTGAGCAACGGCAGCTCGAGGAGGCGAGCTGCGTCTGCTGCTGCTCTCTCT 1140
QY 1141 GGTCTTGCACCTGCTCTCAAAATTTTGAATGTGAGTGCCACTTTCCCAACCCCGGGAAGGT 1200
DB 1141 GGTCTTGCACCTGCTCTCAAAATTTTGAATGTGAGTGCCACTTTCCCAACCCCGGGAAGGT 1200
QY 1201 GCGCCACCAACACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
DB 1201 GCGCCACCAACACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
QY 1261 TATACAAATGAAATTAAGAAAGAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
DB 1261 TATACAAATGAAATTAAGAAAGAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
QY 1321 AAGAAATATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTCGAAATTCGCTTGCAGATA 1380
DB 1321 AAGAAATATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTCGAAATTCGCTTGCAGATA 1380
QY 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGA 1440
DB 1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGA 1440
QY 1441 CCCACTGCAAGCTGATCGTGCACCTCTTTGGTGCAGTGTGGGCAAGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGATCGTGCACCTCTTTGGTGCAGTGTGGGCAAGGCTCAGCCTC 1500
QY 1501 TCTGCCCAACAGAGTGGCCCCCAAGTGGAAATTTCTGAGGTGGCCATCCCAAAATTCATCA 1560

```


CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence encodes a PRO protein.
XX
SQ

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	GTGTGTCTTCAGCAAAACAGTGGATTTAAATCTCTCTGCAACAGCTTGAGAGCAACAC	60
Db	1	GTGTGTCTTCAGCAAAACAGTGGATTTAAATCTCTCTGCAACAGCTTGAGAGCAACAC	60
Qy	61	AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
Db	61	AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
Qy	121	ARGAAAAAATCATGAAACCATCCAGCCAAAAATGCAAAATCTCTCTTGGCAAT	180
Db	121	ARGAAAAAATCATGAAACCATCCAGCCAAAAATGCAAAATCTCTCTTGGCAAT	180
Qy	181	CTTCACGGGCTGGCT	240
Db	181	CTTCACGGGCTGGCT	240
Qy	241	CACCTTCCCAAGCTATGACAAACGTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG	300
Db	241	CACCTTCCCAAGCTATGACAAACGTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG	300
Qy	301	GTGCACATTTGACAAACCGGCTCACCGGGTGGCTTAAACCGGAGCACCCTCTCTA	360
Db	301	GTGCACATTTGACAAACCGGCTCACCGGGTGGCTTAAACCGGAGCACCCTCTCTA	360
Qy	361	TGCTGGCAATGACAAAGTGGTGGTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT	420
Db	361	TGCTGGCAATGACAAAGTGGTGGTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT	420
Qy	421	GCAGTACAGCATCGAGATCCAGAAAGTGGATGTGTATGACAGGGGCTTACACCTGCTC	480
Db	421	GCAGTACAGCATCGAGATCCAGAAAGTGGATGTGTATGACAGGGGCTTACACCTGCTC	480
Qy	481	GGTCGACAGCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC	540
Db	481	GGTCGACAGCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC	540
Qy	541	CAAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAAACAAATTTAGCCTC	600
Db	541	CAAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAAACAAATTTAGCCTC	600
Qy	601	CTGCATAGCACTGGTACAGAGAGCTTACGTTTCTTGGAGACACATCTCTCCAAAGC	660
Db	601	CTGCATAGCACTGGTACAGAGAGCTTACGTTTCTTGGAGACACATCTCTCCAAAGC	660
Qy	661	GGTTGGCTTTGTAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCCGGAGCAGTC	720
Db	661	GGTTGGCTTTGTAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCCGGAGCAGTC	720
Qy	721	AGGGGATCAGAGTGCAGTCCCAATGAGTGGCGCGCCGCTGTAGCGAGAGTAA	780
Db	721	AGGGGATCAGAGTGCAGTCCCAATGAGTGGCGCGCCGCTGTAGCGAGAGTAA	780
Qy	781	GGTCACCGTGAACATATCCACCATACATTTGAGAGGCAAGGGTACAGGTCTCCCGTGG	840
Db	781	GGTCACCGTGAACATATCCACCATACATTTGAGAGGCAAGGGTACAGGTCTCCCGTGG	840
Qy	841	ACAAAGGGGACATGAGTGTGAGGCTCAGCATCCCTCAGCAGAAATTCAGTGGA	900
Db	841	ACAAAGGGGACATGAGTGTGAGGCTCAGCATCCCTCAGCAGAAATTCAGTGGA	900

Qy	901	CAAGATGACAAAAGACTGATTGAGAAAGAAAGGGGTGAAAGTGAAAGACAGACCTTT	960
Db	901	CAAGATGACAAAAGACTGATTGAGAAAGAAAGGGGTGAAAGTGAAAGACAGACCTTT	960
Qy	961	CCTCTCAAACTCATCTCTTCAATGCTCTGAACATGACTATGAGGAACTACACTTCGCT	1020
Db	961	CCTCTCAAACTCATCTCTTCAATGCTCTGAACATGACTATGAGGAACTACACTTCGCT	1020
Qy	1021	GGCTTCCAAAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT	1080
Db	1021	GGCTTCCAAAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT	1080
Qy	1081	CAGGAGTGTGACAAACCGCAGCTCGAGAGGGCAGGCTGGCTGCTGGCTGCTCTCTCT	1140
Db	1081	CAGGAGTGTGACAAACCGCAGCTCGAGAGGGCAGGCTGGCTGCTGGCTGCTCTCTCT	1140
Qy	1141	GGTCTTGCACTGCTCTCTCAAAATTTGATGTAGTGCACCTTCCCAACCCGGGAAAGCT	1200
Db	1141	GGTCTTGCACTGCTCTCTCAAAATTTGATGTAGTGCACCTTCCCAACCCGGGAAAGCT	1200
Qy	1201	GGCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA	1260
Db	1201	GGCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA	1260
Qy	1261	TATACAAATGAAATTTAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAC	1320
Db	1261	TATACAAATGAAATTTAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAC	1320
Qy	1321	AAAGATATCTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA	1380
Db	1321	AAAGATATCTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA	1380
Qy	1381	TTTAGGTACATGAGTGTCTTTTCCCAACGGGAAAGAACACAGCACCACCCGGCTTGGGA	1440
Db	1381	TTTAGGTACATGAGTGTCTTTTCCCAACGGGAAAGAACACAGCACCACCCGGCTTGGGA	1440
Qy	1441	CCCACTGCAAGTGCATGTCGCAACCTTTTGGTGTGCGAGTGTGGCAAGGCTCAGCCTC	1500
Db	1441	CCCACTGCAAGTGCATGTCGCAACCTTTTGGTGTGCGAGTGTGGCAAGGCTCAGCCTC	1500
Qy	1501	TCGTGCCACAGAGTGCCTCCACGCTGGAAATCTTGGAGCTGGCCATCCCAATTCATCA	1560
Db	1501	TCGTGCCACAGAGTGCCTCCACGCTGGAAATCTTGGAGCTGGCCATCCCAATTCATCA	1560
Qy	1561	GTCCATAGAGACGAACAGATGAGACCTTCGGGCCAAAGCGTGGCGTGGCGGCACTTTG	1620
Db	1561	GTCCATAGAGACGAACAGATGAGACCTTCGGGCCAAAGCGTGGCGTGGCGGCACTTTG	1620
Qy	1621	GTAGACTGTGCCACCGCGCTGTGTGTGAAACGTGAAATGAAAGAGCAAAAAA	1679
Db	1621	GTAGACTGTGCCACCGCGCTGTGTGTGAAACGTGAAATGAAAGAGCAAAAAA	1679

RESULT 94

AD16724

ID AD16724 standard; cDNA; 1679 BP.

XX AD16724;

XX 29-JAN-2004 (first entry)

XX Human cDNA encoding secreted/transmembrane protein, PRO337.

Human; ss; gene; secreted protein; transmembrane protein; PRO;
cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
vulvar; auditory; tumour growth; retinal disorder;
sports-related joint problem; articular cartilage defects;
osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.

OS Homo sapiens.

XX US2003203435-A1.

XX

30-OCT-2003.
18-OCT-2001; 2001US-00145092.
30-APR-1998; 98US-0083742P.
08-MAR-1999; 98WO-US005028.
23-JUN-1999; 99US-0141037P.
25-AUG-1999; 99US-00380138.
18-FEB-2000; 2000WO-US004341.
30-JUL-2001; 2001US-00918585.
(GETH) GENENTECH INC.
Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
Klavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
Stewart TA, Tumas D, Williams PM, Wood W;
WPI; 2003-875642/81.
P-PSDB; ADE16725.
New genes, and its encoded secreted and transmembrane polypeptides,
useful for treating e.g. lung or breast tumors, osteoarthritis,
rheumatoid arthritis, obesity, diabetes, hyperinsulinemia,
hypoinsulinemia or wounds.
Claim 2; SEQ ID NO 522; 452pp; English.
The invention relates to an isolated PRO polypeptide (secreted or
transmembrane protein) having at least 80% amino acid sequence identity
to an amino acid sequence chosen from 94 fully defined sequences as given
in the specification (including PRO lacking its associated signal
peptide, a PRO extracellular domain with or without its associated signal
peptide). Also included are nucleic acids encoding the PRO proteins
mentioned above, a vector comprising a PRO nucleic acid, a host cell
comprising the vector and producing PRO, a chimeric molecule comprising
PRO fused to a heterologous amino acid sequence, and an anti-PRO
antibody. PRO337 polypeptide is useful for detecting a PRO4993
polypeptide in a sample suspected of containing PRO4993 polypeptide.
Similarly, PRO4993 polypeptide is useful for detecting PRO337
polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
causes death of the cell. PRO337 polypeptide is useful for linking a
bioactive molecule to a cell expressing PRO4993 polypeptide. PRO725,
PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
useful for linking a bioactive molecule to a cell expressing PRO725,
PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
polypeptide is useful for modulating at least one biological activity of
the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
polypeptide or anti-PRO4993 polypeptide is useful for modulating the
biological activity of the cell expressing PRO4993 polypeptide. PRO725,
PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
modulating the biological activity of the cell expressing PRO1559
polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
PRO739 polypeptide is useful for modulating the biological activity of
the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
polypeptides are useful for inhibiting tumour growth, retinal disorders,
sports-related joint problems, articular cartilage defects,
osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
mammals. The present sequence encodes a PRO protein.
Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTTGAGAGCAAC 60

Db Qy
1 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTTGAGAGCAAC 60
61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
121 AAGAAAAAATCATGAAATCATGAAATCATGAAATCATGAAATCATGAAATCATG 180
121 AAGAAAAAATCATGAAATCATGAAATCATGAAATCATGAAATCATGAAATCATG 180
181 CTTTCAGGGGCTGGCTGCTCTCTTCCAGAGAGTGCCTGCGGAGGAGATGTC 240
181 CTTTCAGGGGCTGGCTGCTCTCTTCCAGAGAGTGCCTGCGGAGGAGATGTC 240
241 CACCTTCCCAAGCTATGGAACAACGATGCGGAGGAGGAGGAGGAGGAGGAGGAG 300
241 CACCTTCCCAAGCTATGGAACAACGATGCGGAGGAGGAGGAGGAGGAGGAGGAG 300
301 GTGCACATTTGACACACCGGCTCACCGGCTGCTGCTTAAACCGCAGCACCATTCT 360
301 GTGCACATTTGACACACCGGCTCACCGGCTGCTGCTTAAACCGCAGCACCATTCT 360
361 TGTGGGAAATGACACAGTGGTGGTCTGATCCTCGGTGGTCTTCTGAGCAACACCA 420
361 TGTGGGAAATGACACAGTGGTGGTCTGATCCTCGGTGGTCTTCTGAGCAACACCA 420
421 GCAGTACAGATCGAGATCCAGAACGTGGTGTGATGACGAGGCGCTTACACCTGTC 480
421 GCAGTACAGATCGAGATCCAGAACGTGGTGTGATGACGAGGCGCTTACACCTGTC 480
481 GGTGCAGACAGACCAACCCCAAGACCTCTAGGCTCCACCTCTTGTGCAAGTATCTCC 540
481 GGTGCAGACAGACCAACCCCAAGACCTCTAGGCTCCACCTCTTGTGCAAGTATCTCC 540
541 CAAATTTGAGAGATTTCTTCAATATTCATGAGGAGGAGGAGGAGGAGGAGGAG 600
541 CAAATTTGAGAGATTTCTTCAATATTCATGAGGAGGAGGAGGAGGAGGAGGAG 600
601 CTGCATAGCACTGGTAGACAGAGCTACGCTTACTTGGAGACACATCTCTCCCAAGC 660
601 CTGCATAGCACTGGTAGACAGAGCTACGCTTACTTGGAGACACATCTCTCCCAAGC 660
661 GGTGGCTTTGAGTGAAGAGAGATCTTGAATTTAGGAGGAGGAGGAGGAGGAGGAG 720
661 GGTGGCTTTGAGTGAAGAGAGATCTTGAATTTAGGAGGAGGAGGAGGAGGAGGAG 720
721 AGGGGACTACGAGTGCAGTGCCTTCAATGACGCTGGCGCGCGCTGCTACGAGAGTAAA 780
721 AGGGGACTACGAGTGCAGTGCCTTCAATGACGCTGGCGCGCGCTGCTACGAGAGTAAA 780
781 GGTACCGTGAATATCCACCATATCAATTTGAGAGGAGGAGGAGGAGGAGGAGGAG 840
781 GGTACCGTGAATATCCACCATATCAATTTGAGAGGAGGAGGAGGAGGAGGAGGAG 840
841 ACAAAGGGGAGCACTGAGTGAAGGCTTCCAGTCCCTCAGCAGAGATTCAGTGGTA 900
841 ACAAAGGGGAGCACTGAGTGAAGGCTTCCAGTCCCTCAGCAGAGATTCAGTGGTA 900
901 CAAAGGATGACAAAGACTGATTGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 960
901 CAAAGGATGACAAAGACTGATTGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 960
961 CTTCTCAAACTCATCTTCTTCAATGCTCTGAAATGACTATGGGAACTACACTTGGCT 1020
961 CTTCTCAAACTCATCTTCTTCAATGCTCTGAAATGACTATGGGAACTACACTTGGCT 1020
1021 GGCTTCAACAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGGGCGCT 1080
1021 GGCTTCAACAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGGGCGCT 1080
1081 CAGCGAGGTGAGCAACGGCAGCTCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1140

Db 181 CTTTCAGGGGCTGGCTCTCTGTGTCTCTTCAAGGAGTCCCTGTCGCGAGCGAGATGC 240
Qy 241 CACCTTCCCAAGCTATGAGCAACGCTGACGGTCCGGCAGGGGAGAGCGCCACCTCTCAG 300
Db 241 CACCTTCCCAAGCTATGAGCAACGCTGACGGTCCGGCAGGGGAGAGCGCCACCTCTCAG 300
Qy 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGTGATGACCGGAGCAGCATCTCTTA 360
Db 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGTGATGACCGGAGCAGCATCTCTTA 360
Qy 361 TCGTGGGAATGCAAGTGTGCTGGATCTCTGGGTGCTCTCTGAGCAACACCAAC 420
Db 361 TCGTGGGAATGCAAGTGTGCTGGATCTCTGGGTGCTCTCTGAGCAACACCAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGAACGCTGGATGTGATGACGAGGGCCCTTACACTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACGCTGGATGTGATGACGAGGGCCCTTACACTGCTC 480
Qy 481 GGTGAGAGCAGACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 540
Db 481 GGTGAGAGCAGACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 540
Qy 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTAC 600
Db 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTAC 600
Qy 601 CTGCATAGCAACTGTGAGCAGAGCCTACGTTACTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCATAGCAACTGTGAGCAGAGCCTACGTTACTTGGAGACACATCTCTCCCAAGC 660
Qy 661 GGTGGCTTTGTGAGTGAAGAGCAATATCTTGAAATTCAGGGCATCACCGGGAGCAGTC 720
Db 661 GGTGGCTTTGTGAGTGAAGAGCAATATCTTGAAATTCAGGGCATCACCGGGAGCAGTC 720
Qy 721 AGGGGACTACGAGTGCAGTCCCAATGACGTGCGCGCCCGTGTACGGAGAGTAA 780
Db 721 AGGGGACTACGAGTGCAGTCCCAATGACGTGCGCGCCCGTGTACGGAGAGTAA 780
Qy 781 GGTCAACCGTGAATTCACCAATATATTCAGAACCAAGGATACAGTGTCCCGTGGG 840
Db 781 GGTCAACCGTGAATTCACCAATATATTCAGAACCAAGGATACAGTGTCCCGTGGG 840
Qy 841 ACAAAGGGGACACTGCACTGTGAAGCCTTCAGCAGTCCCTCAGCAGAAATTCAGTGGA 900
Db 841 ACAAAGGGGACACTGCACTGTGAAGCCTTCAGCAGTCCCTCAGCAGAAATTCAGTGGA 900
Qy 901 CAAGGATCAAAAGACTGATTGAAGGAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
Db 901 CAAGGATCAAAAGACTGATTGAAGGAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
Qy 961 CCTCTCAAAACTCATCTTCTCAATGTCTCTGAAACATGATGAGAACTACATTTGGT 1020
Db 961 CCTCTCAAAACTCATCTTCTCAATGTCTCTGAAACATGATGAGAACTACATTTGGT 1020
Qy 1021 GGCTCCAAAGCTGGGACACCAATCCAGCATCATGCTATTGTTGTCAGGCGCGT 1080
Db 1021 GGCTCCAAAGCTGGGACACCAATCCAGCATCATGCTATTGTTGTCAGGCGCGT 1080
Qy 1081 CAGCAGGTGAGCAACCGGACGTCGAGGAGGAGCAGCTGCGTCTGGCTGCTCTCTCT 1140
Db 1081 CAGCAGGTGAGCAACCGGACGTCGAGGAGGAGCAGCTGCGTCTGGCTGCTCTCTCT 1140
Qy 1141 GGTCTTGACCTCTCTCAATTTTGTGAGTGGCCTCTCTCTCTCTCTCTCTCTCTCT 1200
Db 1141 GGTCTTGACCTCTCTCAATTTTGTGAGTGGCCTCTCTCTCTCTCTCTCTCTCTCT 1200
Qy 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
Db 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
Qy 1261 TATACAAATGAAATAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320

Db 1261 TATACAAATGAAATAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320
Qy 1321 AAAGAATACTTTGGGGGAAAAGAGTTTTTAAAAAAGAAATTTGAAATTTGCCTTGCAGATA 1380
Db 1321 AAAGAATACTTTGGGGGAAAAGAGTTTTTAAAAAAGAAATTTGAAATTTGCCTTGCAGATA 1380
Qy 1381 TTTAGTACAATGGAGTTTTCTTTTCCCAACGGGAAGAACACAGACACACCGGCTTGA 1440
Db 1381 TTTAGTACAATGGAGTTTTCTTTTCCCAACGGGAAGAACACAGACACACCGGCTTGA 1440
Qy 1441 CCACCTGCAAGCTGCAATCGTGCAACCTCTTTGGTCCCAAGTGTGGCAAGGGCTCAGCCTC 1500
Db 1441 CCACCTGCAAGCTGCAATCGTGCAACCTCTTTGGTCCCAAGTGTGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCCAAGAGTGGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1560
Db 1501 TCTGCCCAAGAGTGGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1560
Qy 1561 GTCCATAGAGAGCAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGGCGGCGGCGGCGG 1620
Db 1561 GTCCATAGAGAGCAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGGCGGCGGCGGCGG 1620
Qy 1621 GTAGACTGTGCCACCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1679
Db 1621 GTAGACTGTGCCACCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1679

RESULT 96

ADE42008

ID ADE42008 standard; cDNA; 1679 BP.

XX ADE42008;

XX 29-JAN-2004 (first entry)

XX Human PRO polynucleotide #188.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; FFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
XX immune system cell infiltration.

XX Homo sapiens.

XX OS US2003194772-A1.

XX PD 16-OCT-2003.

XX PP 21-MAY-2002; 2002US-00152386.

XX PR 03-MAR-2000; 2000US-0187202P.

XX PR 01-DEC-2000; 2000MO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI; 2003-899788/82.

XX DR P-PSDB; ADE42009.

XX PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,

XX PT useful for treating pericyte-associated tumors, diabetes and various bone

XX PT and/or cartilage disorders, e.g. arthritis.

XX XX

QY 1561 GTCCATAGAGCGAAGAGACCTTCCGGCCCAAGCGTGGCGTGGCGGCACTTTG 1620
Dd |||||
QY 1561 GTCCATAGAGCGAAGAGACCTTCCGGCCCAAGCGTGGCGTGGCGGCACTTTG 1620
Dd |||||
QY 1621 GTAGACTGTGCGCCACCGCGTGTGTGTAACGTAATAAAGAGCAAAAAA 1679
Dd |||||
QY 1621 GTAGACTGTGCGCCACCGCGTGTGTGTAACGTAATAAAGAGCAAAAAA 1679
Dd |||||
RESULT 97
ADE17825
ID ADE17825 standard; cDNA; 1679 BP.
XX
AC ADE17825;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
FN US2003199023-A1.
XX
PD 23-OCT-2003.
XX
PF 17-APR-2002; 2002US-00124821.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 28-OCT-1998; 98WO-US022991.
PR 28-OCT-1998; 98WO-US022992.
PR 23-NOV-1998; 98WO-US024655.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US006319.
PR 14-MAY-1999; 99WO-US008615.
PR 02-JUN-1999; 99WO-US010733.
PR 01-SEP-1999; 99WO-US012252.
PR 08-SEP-1999; 99WO-US020111.
PR 13-SEP-1999; 99WO-US020594.
PR 15-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 05-OCT-1999; 99WO-US021547.
PR 23-NOV-1999; 99WO-US022814.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 15-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US006884.
PR 21-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US007532.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US033678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00884636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00905827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-900155/82.
DR P-PSDB; ADE17825.

QY 1501 TCTGCCACAGAGTGCCTCCACGCTGGACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 20-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 03-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001US-00802706.
PR 09-MAR-2001; 2001WO-US006666.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-0082366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00871092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
FA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX
PI

QY 1501 TCTGCCACAGAGTGCCTCCACGCTGGACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCACGCTGGACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACGAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGTGGCGGCACTTTG 1620
Db 1561 GTCCATAGAGACGAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGTGGCGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACACGCGTGTCTGTGAACGTGAATATAAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACACGCGTGTCTGTGAACGTGAATATAAAGAGCAAAAAA 1679

RESULT 98
ADD91957
ID ADD91957 standard; cDNA; 1679 BP.
XX
AC ADD91957;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear intracellular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199053-A1.
XX
PD 23-OCT-2003.
XX
PF 12-APR-2002; 2002US-00121053.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 17-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98WO-US019437.
PR 29-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.

PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S, Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z; WPI: 2003-900164/82. P-PSDB; ADD91959.	Db	301	GTGACATATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTCTA	360
XX		Qy	361	TGCTGGGAATGACAAAGTGGTCCCTGGGATCCCTGGGTTGGTCTTCTGAGCAACACCCAAAC	420
DR		Db	361	TGCTGGGAATGACAAAGTGGTGGCTGGATCTCTGGGTTGGTCTTCTGAGCAACACCCAAAC	420
XX		Qy	421	GCAGTACAGATCGAGATCCAGAAACGTTGGATGTGTATGACGAGGGCCCTTACCTGCTC	480
PT		Db	421	GCAGTACAGATCGAGATCCAGAAACGTTGGATGTGTATGACGAGGGCCCTTACCTGCTC	480
XX		Qy	481	GGTGACAGACACCAACACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540
XX		Db	481	GGTGACAGACACCAACACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540
CC		Qy	541	CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC	600
CC		Db	541	CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC	600
CC		Qy	601	CTGCATACCACTGGTACAGACAGCCCTACGGTTACTTGGAGACACATCTCTCCCAAGC	660
CC		Db	601	CTGCATACCACTGGTACAGACAGCCCTACGGTTACTTGGAGACACATCTCTCCCAAGC	660
CC		Qy	661	GGTTGGCTTTGTGAGTGAAGACGAATATCTCGAAATTCAGGGCATCACCCGGGAGCAGTC	720
CC		Db	661	GGTTGGCTTTGTGAGTGAAGACGAATATCTCGAAATTCAGGGCATCACCCGGGAGCAGTC	720
CC		Qy	721	AGGGGACTACGAGTGCAGTCCCAATGAGTGCSCCGCCCTGGTACGAGAGTAA	780
CC		Db	721	AGGGGACTACGAGTGCAGTCCCAATGAGTGCSCCGCCCTGGTACGAGAGTAA	780
CC		Qy	781	GGTCAACCGTGAACATATCACCATATATTTCAAGAACCAAGGGTACAGGTCTCCCCGGGG	840
CC		Db	781	GGTCAACCGTGAACATATCACCATATATTTCAAGAACCAAGGGTACAGGTCTCCCCGGGG	840
CC		Qy	841	ACAAAGGGGACATGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAGATTTCCAGTGTGA	900
CC		Db	841	ACAAAGGGGACATGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAGATTTCCAGTGTGA	900
CC		Qy	901	CAAGATGACAAAGACATGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT	960
CC		Db	901	CAAGATGACAAAGACATGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT	960
CC		Qy	961	CTCTCAAAATCTATCTTCTTCAATGTCTTGAACATGACTATGGGAACTACATCTGGCT	1020
CC		Db	961	CTCTCAAAATCTATCTTCTTCAATGTCTTGAACATGACTATGGGAACTACATCTGGCT	1020
CC		Qy	1021	GGCTCCCAACAGCTGGGCGCACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGCT	1080
CC		Db	1021	GGCTCCCAACAGCTGGGCGCACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGCT	1080
CC		Qy	1081	CAGCGAGGTGACAAACCGCACGTCGAGGAGGCGAGCTCGCTCTGGCTCTCTCTCT	1140
CC		Db	1081	CAGCGAGGTGACAAACCGCACGTCGAGGAGGCGAGCTCGCTCTGGCTCTCTCTCTCT	1140
CC		Qy	1141	GGTCTGACCTGCTTCTCAAAATTTTGTGAGTGGCCACTTCCCAACCGGGAAGGCT	1200
CC		Db	1141	GGTCTGACCTGCTTCTCAAAATTTTGTGAGTGGCCACTTCCCAACCGGGAAGGCT	1200
CC		Qy	1201	GGCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA	1260
CC		Db	1201	GGCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA	1260
CC		Qy	1261	TATACAAATGAATTAGAAGAACACAGCTCATGGACAGAAATTTGAGGAGGGGAGAC	1320
CC		Db	1261	TATACAAATGAATTAGAAGAACACAGCTCATGGACAGAAATTTGAGGAGGGGAGAC	1320
CC		Qy	1321	AAAGATACTTTGGGGGAAAAAGAGTTTTTAAAAAAGAAATTTGAGGAGGGGAGAC	1380
CC		Db	1321	AAAGATACTTTGGGGGAAAAAGAGTTTTTAAAAAAGAAATTTGAGGAGGGGAGAC	1380
CC		Qy	1381	TTTAGGTAACAATGAGAGTTTTTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGA	1440
CC		Db	1381	TTTAGGTAACAATGAGAGTTTTTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGA	1440

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z; WPI: 2003-900164/82. P-PSDB; ADD91959.

XX Two hundred and seventy five nucleic acids encoding PRO polypeptides, useful for treating pericyte-associated tumors, diabetes and various bone and/or cartilage disorders, e.g. arthritis.

PT Claim 2; SEQ ID NO 375; 636bp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6,7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTGTGCTTTCAGCAAAACAGTGGATTAAATCTCTTGGCACAAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTTTCAGCAAAACAGTGGATTAAATCTCTTGGCACAAGCTTGAGAGCAAC 60

Qy 61 AATCTATCAGGAAGAAGAAAGAAAAACCGAACCTGACAAAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAGAAAGAAAAACCGAACCTGACAAAAAGAAAGAAAG 120

Qy 121 AAGAAAAAATCATGAACCAATCCAGCAAAATGCAAAATCTCTTGGGCAAT 180
Db 121 AAGAAAAAATCATGAACCAATCCAGCAAAATGCAAAATCTCTTGGGCAAT 180

Qy 181 CTTTCAGGGGCTGGTCTGTGTCTTCTTCAAGGAGTGCCGTGCGCAGCGAGATGC 240
Db 181 CTTTCAGGGGCTGGTCTGTGTCTTCTTCAAGGAGTGCCGTGCGCAGCGAGATGC 240

Qy 241 CACCTTCCCAAGATGACAGTGCAGCGTCCGGCAGGGGAGAGCGCCACCTTCAG 300
Db 241 CACCTTCCCAAGATGACAGTGCAGCGTCCGGCAGGGGAGAGCGCCACCTTCAG 300

Qy 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360

Db 1381 TTAGGTACATGAGTTTCTTTTCCCAACGGGAAGAACACACAGCACACCCGGCTTGGGA 1440
Qy 1441 CCACATGCAAGTGCATCGTGCACACCTTTGGTCCAGTGTGGCAGAGGCTCAGCCTC 1500
Db 1441 CCACATGCAAGTGCATCGTGCACACCTTTGGTCCAGTGTGGCAGAGGCTCAGCCTC 1500
Qy 1501 TCTGCCCCAGAGTGCCTCCACGTCGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCACGTCGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGAGCAACAGAACTTCCGGCCCAAGCGTGGCGTGGCGGCACTTTG 1620
Db 1561 GTCCATAGAGAGCAACAGAACTTCCGGCCCAAGCGTGGCGTGGCGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACACGCGCTGTCTGTGAACCTGAAATATAAAGAGCAAAAAAAA 1679
Db 1621 GTAGACTGTGCCACACGCGCTGTCTGTGAACCTGAAATATAAAGAGCAAAAAAAA 1679
RESULT 99
ADE33420
ID ADE33420 standard; cDNA; 1679 BP.
XX
AC ADE33420;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; Gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003194767-A1.
XX
PD 16-OCT-2003.
XX
PP 16-MAY-2002; 2002US-00147497.
XX
PR 26-AUG-1998; 98US-0097951P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
WPI; 2003-999786/82.
DR P-PSDB; ADE33421.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; SEQ ID NO 375; 636pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,

CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTGTGTCTCTCAGCAAAACAGTGGATTAAATCTCTTGCACAACTTGCAGCAACAC 60
Db 1 GTGTGTCTCTCAGCAAAACAGTGGATTAAATCTCTTGCACAACTTGCAGCAACAC 60
Qy 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAGAAATCATGAAACCATCCAGCAAAATTCACAAATTCATCTTGGCCAT 180
Db 121 AAGAAAGAAATCATGAAACCATCCAGCAAAATTCACAAATTCATCTTGGCCAT 180
Qy 181 CTTACGGGGCTGGCTGTCTGTGTCTCTTCCAAAGAGTGCCTGCGCAGCGGAGATGC 240
Db 181 CTTACGGGGCTGGCTGTCTGTGTCTCTTCCAAAGAGTGCCTGCGCAGCGGAGATGC 240
Qy 241 CACCTTCCCCAAGCTATGCAACAGTGCAGTCCGGCAGGGGAGAGCGCCACCTCAG 300
Db 241 CACCTTCCCCAAGCTATGCAACAGTGCAGTCCGGCAGGGGAGAGCGCCACCTCAG 300
Qy 301 GTGCACCTATTGCAACACCGGCTCACCCGGTGGCTGGCTTAAACCCGAGCACCCTCTA 360
Db 301 GTGCACCTATTGCAACACCGGCTCACCCGGTGGCTGGCTTAAACCCGAGCACCCTCTA 360
Qy 361 TGCTGGGAATGACAAGTGGTGGCTGGATCTGCTGGTGGTCTCTTGAGCAACACCCAAAC 420
Db 361 TGCTGGGAATGACAAGTGGTGGCTGGATCTGCTGGTGGTCTCTTGAGCAACACCCAAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACGAGGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACGAGGGGCCCTTACACCTGCTC 480
Qy 481 GGTGCGACAGACAACACCCAAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGCGACAGACAACACCCAAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Qy 541 CAAAAATTGTAGAGATTCTTCAGATATCTCCATTAAATGAAGGGAACAATATTAGCCTCAC 600
Db 541 CAAAAATTGTAGAGATTCTTCAGATATCTCCATTAAATGAAGGGAACAATATTAGCCTCAC 600
Qy 601 CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAAGC 660
Db 601 CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAAGC 660

Qy	661	GGTTGGCTTTGTGAGTGAAGACGAATACCTTGGAATTCAGGGCATCACCGGGAGCAGTC	720
Db	661	GGTTGGCTTTGTGAGTGAAGACGAATACCTTGGAATTCAGGGCATCACCGGGAGCAGTC	720
Qy	721	AGGGGACTACGAGTGCAGTGCCTCCCAATGACGTGGCGGCCCGTGGTACGAGAGTAA	780
Db	721	AGGGGACTACGAGTGCAGTGCCTCCCAATGACGTGGCGGCCCGTGGTACGAGAGTAA	780
Qy	781	GGTCACGCTGAATCATCCACATACATTTGAGAGCCCAAGGGTACAGGTGTCCCGTGGG	840
Db	781	GGTCACGCTGAATCATCCACATACATTTGAGAGCCCAAGGGTACAGGTGTCCCGTGGG	840
Qy	841	ACAAAAGGGGACACCTGCAGTGTGAAGCTCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
Db	841	ACAAAAGGGGACACCTGCAGTGTGAAGCTCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
Qy	901	CAAGGATGACAAAAGACTGATTAAGGAAAGAAAGGGGTGAAGTGGAAAACAGACCTTT	960
Db	901	CAAGGATGACAAAAGACTGATTAAGGAAAGAAAGGGGTGAAGTGGAAAACAGACCTTT	960
Qy	961	CCTCTCAAACTCATCTTCTCAATGCTCTGAACATGATGAGAACTACACTTTCGT	1020
Db	961	CCTCTCAAACTCATCTTCTCAATGCTCTGAACATGATGAGAACTACACTTTCGT	1020
Qy	1021	GGCCTCCAAAGCTGGGCGCACCAATGCCAGCATCATCTATTTGGTCCAGGCGCGT	1080
Db	1021	GGCCTCCAAAGCTGGGCGCACCAATGCCAGCATCATCTATTTGGTCCAGGCGCGT	1080
Qy	1081	CAGCGAGGTGAGCAACCGCAGCTGCAGAGGCGAGGTGGTCTGGCTGTGCTTCT	1140
Db	1081	CAGCGAGGTGAGCAACCGCAGCTGCAGAGGCGAGGTGGTCTGGCTGTGCTTCT	1140
Qy	1141	GGTCTTGACCTGCTTCTCAAAATTTGATGTGAGTGCACCTTCCCAACCGCGGAAAGGCT	1200
Db	1141	GGTCTTGACCTGCTTCTCAAAATTTGATGTGAGTGCACCTTCCCAACCGCGGAAAGGCT	1200
Qy	1201	GCCGCCACCCACCAACACACAGCAATGGCAACCGCAGCAGCAACCAATTCAGATA	1260
Db	1201	GCCGCCACCCACCAACACACAGCAATGGCAACCGCAGCAGCAACCAATTCAGATA	1260
Qy	1261	TATCAATGAAATTTAGAGAAACACAGCTCTATGGGACAGAAATTTAGGGAGGGGAAAC	1320
Db	1261	TATCAATGAAATTTAGAGAAACACAGCTCTATGGGACAGAAATTTAGGGAGGGGAAAC	1320
Qy	1321	AAAGAACTCTTTGGGGGAAAAGAGTTTAAAGAAATTTGAAATTTGCCCTTGCAGATA	1380
Db	1321	AAAGAACTCTTTGGGGGAAAAGAGTTTAAAGAAATTTGAAATTTGCCCTTGCAGATA	1380
Qy	1381	TTTAGGTACATGAGTGTCTTTTCCAAACGGGAGAGAACACAGCACCCCGCTTGA	1440
Db	1381	TTTAGGTACATGAGTGTCTTTTCCAAACGGGAGAGAACACAGCACCCCGCTTGA	1440
Qy	1441	CCCACTGCAAGCTGCATCGTGCAACCTCTTTGGTGGCAGTGTGGGCAAGGGCTCAGCCTC	1500
Db	1441	CCCACTGCAAGCTGCATCGTGCAACCTCTTTGGTGGCAGTGTGGGCAAGGGCTCAGCCTC	1500
Qy	1501	TCTGCCACAGAGTGCCTCCCAAGTGAACATTCCTGGAGCTGGCCATCCCAAAATTCATCA	1560
Db	1501	TCTGCCACAGAGTGCCTCCCAAGTGAACATTCCTGGAGCTGGCCATCCCAAAATTCATCA	1560
Qy	1561	GTCCATGAGACGACAGAAATGAGACCTTCGGGCCCAAGCGTGCCTGCGGCACCTTG	1620
Db	1561	GTCCATGAGACGACAGAAATGAGACCTTCGGGCCCAAGCGTGCCTGCGGCACCTTG	1620
Qy	1621	GTAGACTGTGCCACACCGGCGTGTGTTGTAAGCTGAATATAAAGAGCAAAAAA	1679
Db	1621	GTAGACTGTGCCACACCGGCGTGTGTTGTAAGCTGAATATAAAGAGCAAAAAA	1679

RESULT 100
ADE33972

ID ADE33972 standard; cDNA; 1679 BP.

XX AC ADE33972;
XX DT 29-JAN-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX OS Homo sapiens.
XX PN US2003194791-A1.
XX PD 16-OCT-2003.
XX PF 11-APR-2002; 2002US-00121046.
XX PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 17-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US006319.
PR 14-MAY-1999; 99WO-US008615.
PR 02-JUN-1999; 99WO-US010733.
PR 01-SEP-1999; 99WO-US012252.
PR 08-SEP-1999; 99WO-US020111.
PR 13-SEP-1999; 99WO-US020594.
PR 15-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 05-OCT-1999; 99WO-US021547.
PR 29-NOV-1999; 99WO-US023089.
PR 30-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028554.
PR 16-DEC-1999; 99WO-US028565.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-2000; 99WO-US031274.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.

24-FEB-2000; 2000WO-US004914.
 24-FEB-2000; 2000WO-US005004.
 01-MAR-2000; 2000WO-US005060.
 02-MAR-2000; 2000WO-US005746.
 02-MAR-2000; 2000WO-US005841.
 15-MAR-2000; 2000WO-US005884.
 20-MAR-2000; 2000WO-US007777.
 21-MAR-2000; 2000WO-US007532.
 30-MAR-2000; 2000WO-US008439.
 17-MAY-2000; 2000WO-US013705.
 22-MAY-2000; 2000WO-US014042.
 30-MAY-2000; 2000WO-US014941.
 02-JUN-2000; 2000WO-US015264.
 28-JUL-2000; 2000WO-US020710.
 11-AUG-2000; 2000WO-US022031.
 23-AUG-2000; 2000WO-US023522.
 24-AUG-2000; 2000WO-US023328.
 08-NOV-2000; 2000WO-US030952.
 10-NOV-2000; 2000WO-US030873.
 01-DEC-2000; 2000WO-US032678.
 20-DEC-2000; 2000US-00747259.
 20-DEC-2000; 2000WO-US034956.
 28-FEB-2001; 2001US-00796498.
 28-FEB-2001; 2001WO-US006520.
 01-MAR-2001; 2001WO-US006666.
 09-MAR-2001; 2001US-00802706.
 14-MAR-2001; 2001US-00808689.
 22-MAR-2001; 2001US-00816744.
 05-APR-2001; 2001US-00828366.
 10-MAY-2001; 2001US-00854208.
 10-MAY-2001; 2001US-00854280.
 18-MAY-2001; 2001US-00860216.
 25-MAY-2001; 2001US-00866028.
 25-MAY-2001; 2001US-00866034.
 25-MAY-2001; 2001WO-US017092.
 01-JUN-2001; 2001US-00872035.
 01-JUN-2001; 2001WO-US017800.
 05-JUN-2001; 2001US-00874503.
 14-JUN-2001; 2001US-00882636.
 19-JUN-2001; 2001US-00886342.
 20-JUN-2001; 2001WO-US019692.
 21-JUN-2001; 2001US-00887879.
 22-JUN-2001; 2001WO-US020116.
 29-JUN-2001; 2001WO-US021066.
 09-JUL-2001; 2001WO-US021735.
 18-JUL-2001; 2001US-00908827.
 06-AUG-2001; 2001US-00924419.
 09-AUG-2001; 2001US-00927796.
 16-AUG-2001; 2001US-00931836.
 19-DEC-2001; 2001US-00028072.
 (GETH) GENENTECH INC.
 Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 WPI; 2003-899790/82.
 P-PSDB; ADE33973.
 Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 useful for treating pericyte-associated tumors, diabetes and various bone
 and/or cartilage disorders, e.g. arthritis.
 Claim 2; SEQ ID NO 375; 636pp; English.
 The invention describes 305 nucleic acids encoding PRO (secreted and
 transmembrane) polypeptides (I). (I) is useful for stimulating the
 release of TNF-alpha from human blood, for modulating the uptake of
 glucose or FFA by skeletal muscle cells or adipocyte cells, for
 stimulating the proliferation or differentiation of chondrocyte cells,
 for stimulating the proliferation of or gene expression in pericyte
 cells, for stimulating the release of proteoglycans from cartilage, for

stimulating the proliferation of inner ear utricular supporting cells,
 for stimulating the proliferation of T-lymphocyte cells, for stimulating
 the release of a cytokine from PBMC cells, for inhibiting the binding of
 A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 cells, for stimulating proliferation of endothelial cells, for detecting
 the presence of tumour in a mammal. The tumour is lung, colon, breast,
 prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 are useful for isolating genomic and cDNA nucleotide sequences or
 antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 in assays to identify other proteins or molecules involved in binding
 interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 and gene mapping, in generation of antisense RNA and DNA, in the
 preparation of PRO polypeptide, for generating transgenic animals or
 knockout animals which in turn are useful in the development and
 screening of therapeutically useful reagents, in gene therapy, for
 chromosome identification, as chromosome marker, and for generating
 probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 detecting its expression in specific cells, tissues or serum, and for
 affinity purification of PRO from recombinant cell culture or natural
 sources. (I) and (II) are useful for tissue typing. This sequence encodes
 a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTCTTGCACAGCTTGAGAGCAAC 60
 DB 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTCTTGCACAGCTTGAGAGCAAC 60
 QY 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 DB 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 QY 121 AAGAAAAAATCATGAAACCATCCAGCCAAAATGCAAAATTCATCTCTTGGCAAT 180
 DB 121 AAGAAAAAATCATGAAACCATCCAGCCAAAATGCAAAATTCATCTCTTGGCAAT 180
 QY 181 CTTTCACGGGCTGGCTGCTCTGTGTCTCTTCCAAAGAGTCCCGTCCGAGCGGAGATGC 240
 DB 181 CTTTCACGGGCTGGCTGCTCTGTGTCTCTTCCAAAGAGTCCCGTCCGAGCGGAGATGC 240
 QY 241 CACCTTCCCAAGCTATGGACAACTGACGCTCCGAGGGGGAGAGCGCCACCTCAG 300
 DB 241 CACCTTCCCAAGCTATGGACAACTGACGCTCCGAGGGGGAGAGCGCCACCTCAG 300
 QY 301 GTGCACCTATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360
 DB 301 GTGCACCTATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA 360
 QY 361 TGTGGGAATGACAAAGTGGTCTCGCTGGATCTCTCGCTGGTCTCTTGTAGCAACCCAAAC 420
 DB 361 TGTGGGAATGACAAAGTGGTCTCGCTGGATCTCTCGCTGGTCTCTTGTAGCAACCCAAAC 420
 QY 421 GCAGTACAGCATCGAGATCCAGAACTGGATGTGTATGACAGGGGCCCTTACACCTGCTC 480
 DB 421 GCAGTACAGCATCGAGATCCAGAACTGGATGTGTATGACAGGGGCCCTTACACCTGCTC 480
 QY 481 GGTGCAGACAGACAAACCCAAAGACCTTAGGGTCCACCTCATTTGTGAAGATATCTCC 540
 DB 481 GGTGCAGACAGACAAACCCAAAGACCTTAGGGTCCACCTCATTTGTGAAGATATCTCC 540
 QY 541 CAAAATTTAGAGATTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTTCAC 600
 DB 541 CAAAATTTAGAGATTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTTCAC 600
 QY 601 CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAAGC 660
 DB 601 CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAAGC 660
 QY 661 GGTGGCTTTGTGAGTGAAGACGAAATCTTGGAAATTCAGGGCATCACCGGAGGAGTC 720

Db 661 GGTGGCTTTGTGAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Qy 721 AGGGGACTAGAGTGCAGTGCCTCCCAATGAGTGGCGCGCGTGGTACGAGAGTAA 780
Db 721 AGGGGACTAGAGTGCAGTGCCTCCCAATGAGTGGCGCGCGTGGTACGAGAGTAA 780
Qy 781 GGTACCGGTGAATATCCACATACATTTTCAGAAAGCAAGGGTACAGGTGTCCTCGGTGG 840
Db 781 GGTACCGGTGAATATCCACATACATTTTCAGAAAGCAAGGGTACAGGTGTCCTCGGTGG 840
Qy 841 ACAAAGGGGACACTGAGTGTGAAGCAAGCAAGTCCCTCAGCAGATTCAGAGTGA 900
Db 841 ACAAAGGGGACACTGAGTGTGAAGCAAGCAAGTCCCTCAGCAGATTCAGAGTGA 900
Qy 901 CAAGGATGACAAAGACTGATTGAAGGAAAGAGGGGTGAAAGTGGAAAAACAGACCTTT 960
Db 901 CAAGGATGACAAAGACTGATTGAAGGAAAGAGGGGTGAAAGTGGAAAAACAGACCTTT 960
Qy 961 CCTCTCAAACTCATCTTCTCAATGCTCTGACATGATGGAATGGAATTCAGTGGT 1020
Db 961 CCTCTCAAACTCATCTTCTCAATGCTCTGACATGATGGAATGGAATTCAGTGGT 1020
Qy 1021 GGCTCCAAAGTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGGGCGCT 1080
Db 1021 GGCTCCAAAGTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGGGCGCT 1080
Qy 1081 CAGGAGTGAAGCAAGGACGTCGAGAGGGGAGGCTGGTCTGCTGCTCTTCT 1140
Db 1081 CAGGAGTGAAGCAAGGACGTCGAGAGGGGAGGCTGGTCTGCTGCTCTTCT 1140
Qy 1141 GGTCTGACCTGCTCTCAATTTTGAATGAGTGCCTCTCCCAAGGGGAAAGGCT 1200
Db 1141 GGTCTGACCTGCTCTCAATTTTGAATGAGTGCCTCTCCCAAGGGGAAAGGCT 1200
Qy 1201 GCGGCCAC 1260
Db 1201 GCGGCCAC 1260
Qy 1261 TATCAAAATGAATTTAGAGAAACACACACACACACACACACACACACACACAC 1320
Db 1261 TATCAAAATGAATTTAGAGAAACACACACACACACACACACACACACACACAC 1320
Qy 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Qy 1381 TTTAGGTACAAATGAGTTTCTTTTCCCAACCGGAGAACACACACACACACACAC 1440
Db 1381 TTTAGGTACAAATGAGTTTCTTTTCCCAACCGGAGAACACACACACACACACAC 1440
Qy 1441 CCCACTGCAAGTGCATCGTGCACCTCTTTGGTGGCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGTGCATCGTGCACCTCTTTGGTGGCAGTGTGGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGCCTCCCAAGTGGAACTTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCCAAGTGGAACTTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCCTGGGCAAGGGCTGCGGGCACTTTG 1620
Db 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCCTGGGCAAGGGCTGCGGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACACGCGGTGTGTGTAACCTGTAATTAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACACGCGGTGTGTGTGTAACCTGTAATTAAGAGCAAAAAA 1679

RESULT 101
ADD80024
ID ADD80024 standard; cDNA; 1679 BP.
XX
AC ADD80024;

XX DT 29-JAN-2004 (first entry)
XX cDNA encoding human PRO polypeptide #188.
XX Human; gene; ss: PRO; secreted polypeptide; transmembrane polypeptide;
XX tumor necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; FFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX immune system cell infiltration.
XX Homo sapiens.
XX OS
XX US2003207417-A1.
XX PN
XX 06-NOV-2003.
XX PD
XX
XX PF 07-MAY-2002; 2002US-00140805.
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US017888.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98WO-US019093.
XX 14-SEP-1998; 98WO-US019094.
XX 14-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US019437.
XX 07-OCT-1998; 98WO-US021141.
XX 29-OCT-1998; 98WO-US022591.
XX 29-OCT-1998; 98WO-US022592.
XX 20-NOV-1998; 98WO-US024855.
XX 01-DEC-1998; 98WO-US025108.
XX 05-JAN-1999; 99WO-US000106.
XX 08-MAR-1999; 99WO-US005028.
XX 10-MAR-1999; 99WO-US005190.
XX 10-MAR-1999; 2000WO-US006319.
XX 20-APR-1999; 99WO-US008615.
XX 14-MAY-1999; 99WO-US010733.
XX 02-JUN-1999; 99WO-US012252.
XX 01-SEP-1999; 99WO-US020111.
XX 08-SEP-1999; 99WO-US020594.
XX 13-SEP-1999; 99WO-US020944.
XX 15-SEP-1999; 99WO-US021090.
XX 15-SEP-1999; 99WO-US021547.
XX 05-OCT-1999; 99WO-US023089.
XX 29-NOV-1999; 99WO-US028214.
XX 30-NOV-1999; 99WO-US028313.
XX 30-NOV-1999; 99WO-US028409.
XX 01-DEC-1999; 99WO-US028301.
XX 01-DEC-1999; 99WO-US028634.
XX 02-DEC-1999; 99WO-US028551.
XX 02-DEC-1999; 99WO-US028564.
XX 02-DEC-1999; 99WO-US028565.
XX 20-DEC-1999; 99WO-US030911.
XX 20-DEC-1999; 99WO-US030999.
XX 22-DEC-1999; 99WO-US030720.
XX 30-DEC-1999; 99WO-US031243.
XX 05-JAN-2000; 99WO-US031274.
XX 06-JAN-2000; 2000WO-US000219.
XX 06-JAN-2000; 2000WO-US000277.
XX 11-FEB-2000; 2000WO-US000376.
XX 18-FEB-2000; 2000WO-US003565.
XX 18-FEB-2000; 2000WO-US004341.
XX 22-FEB-2000; 2000WO-US004342.
XX 22-FEB-2000; 2000WO-US004414.

```
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00867092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 08-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-875867/81.
XX P-PSDB; ADD80025.
XX
XX New PRO nucleic acid, useful for manufacturing a medicament for
XX diagnosing or treating tumor, for chromosome mapping or for tissue
XX typing.
XX
XX Claim 2; Fig 375; 639pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumor necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
```

```
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
```

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTCTTGCAACGCTTGAGAGCAACAC 60
DB 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTCTTGCAACGCTTGAGAGCAACAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGACAAAAGAAAGAAAGAAAGAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGACAAAAGAAAGAAAGAAAGAG 120
QY 121 AAGAAAAAATCATGAAAAACCATCCAGGCCAAATGCAATTTCTATCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAAAACCATCCAGGCCAAATGCAATTTCTATCTCTTGGGCAAT 180
QY 181 CTTCACGGGGCTGGCTGCTCTGTGCTCTTTCAGAGAGTGCCGCGGAGCGGAGATGC 240
DB 181 CTTCACGGGGCTGGCTGCTCTGTGCTCTTTCAGAGAGTGCCGCGGAGCGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGACAAAGTGACGCTCCGCGAGGGGAGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAGCTATGACAAAGTGACGCTCCGCGAGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCACATTATTGACAAACCGGCTCACCCGGTGGCTGGCTAAACCCGAGCAACCCCTTA 360
DB 301 GTGCACATTATTGACAAACCGGCTCACCCGGTGGCTGGCTAAACCCGAGCAACCCCTTA 360
QY 361 TGCTGGGAATGACAAAGTGCTGCTGGATCCTCGCTGGTCTCTTCTGAGCAACCCCAAC 420
DB 361 TGCTGGGAATGACAAAGTGCTGCTGGATCCTCGCTGGTCTCTTCTGAGCAACCCCAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACGTTGATGTATGACAGAGGCGCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACGTTGATGTATGACAGAGGCGCTTACACCTGCTC 480
QY 481 GGTGCGAGCAGCAACCCAGCAAGCTCTAGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGCGAGCAGCAACCCAGCAAGCTCTAGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
DB 541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
```

601 CTGATAGCACTGGTGTAGACAGAGCTACGGTTACTTGGAGACATCTCTCCAAAGC 660
601 CTGATAGCACTGGTGTAGACAGAGCTACGGTTACTTGGAGACATCTCTCCAAAGC 660
661 GGTGGCTTTGTGAGTGAAGCAATACATTGGAAATTCAGGCAATCACCGGGAGCAGTC 720
661 GGTGGCTTTGTGAGTGAAGCAATACATTGGAAATTCAGGCAATCACCGGGAGCAGTC 720
721 AGGGACTAGAGTGCAGTCCCTCCATAGCTGGCGGCCCGTGGTAGGAGATAA 780
721 AGGGACTAGAGTGCAGTCCCTCCATAGCTGGCGGCCCGTGGTAGGAGATAA 780
781 GGTCAACGCTGACTATCCACATACATTTTCAAGAGCAAGGATACAGGTGTCCCGGTGG 840
781 GGTCAACGCTGACTATCCACATACATTTTCAAGAGCAAGGATACAGGTGTCCCGGTGG 840
841 AAAAAAGGAGCACTGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
841 AAAAAAGGAGCACTGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAGGGTGAAGTGAAGAAACAGACTTT 960
901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAGGGTGAAGTGAAGAAACAGACTTT 960
961 CCTCTCAAACTCATCTTTCTCAATGTCTTGAACTATGAGTGGAACTACACTTGGCT 1020
961 CCTCTCAAACTCATCTTTCTCAATGTCTTGAACTATGAGTGGAACTACACTTGGCT 1020
1021 GGCCTCAACAGCTGGGGCACACCAATGCTGAGTCCATCTATTTGGTCCAGCGCGT 1080
1021 GGCCTCAACAGCTGGGGCACACCAATGCTGAGTCCATCTATTTGGTCCAGCGCGT 1080
1081 CAGCGAGTGAAGCAACGGCAGCTGAGGAGGCGAGTCTGGCTGTGCTCTTCT 1140
1081 CAGCGAGTGAAGCAACGGCAGCTGAGGAGGCGAGTCTGGCTGTGCTCTTCT 1140
1141 GGTCTTGCACTGTTCTCAATTTTGAATGATGAGTCCATCTCCCAACCGGAAAGGCT 1200
1141 GGTCTTGCACTGTTCTCAATTTTGAATGATGAGTCCATCTCCCAACCGGAAAGGCT 1200
1201 GCCGCCACCAACCAACCAACAGCAATGCAACACCGCAGCAACCAATCAGATA 1260
1201 GCCGCCACCAACCAACCAACAGCAATGCAACACCGCAGCAACCAATCAGATA 1260
1261 TATCAAAATGAATAGAGAAACACAGCTCTATGGGACAGAAATTTGAGGGAGGGGAC 1320
1261 TATCAAAATGAATAGAGAAACACAGCTCTATGGGACAGAAATTTGAGGGAGGGGAC 1320
1321 AAGGAATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
1321 AAGGAATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
1381 TTTAGGTACAATGAGTTTCTTTTCCAAACGGGAGAAACACAGCACACCGGCTTGA 1440
1381 TTTAGGTACAATGAGTTTCTTTTCCAAACGGGAGAAACACAGCACACCGGCTTGA 1440
1441 CCCACTGCACTGCTGCTCAACCTTTTGGTGGCAGTGGGCAAGGCTCAGGCTC 1500
1441 CCCACTGCACTGCTGCTCAACCTTTTGGTGGCAGTGGGCAAGGCTCAGGCTC 1500
1501 TCTGCCACAGAGTGGCCCACTGAGCAATTTGAGTGGCCATCCCAATTCATCA 1560
1501 TCTGCCACAGAGTGGCCCACTGAGCAATTTGAGTGGCCATCCCAATTCATCA 1560
1561 GTCCATAGAGACAGCAATGAGACCTTCGGGCCCAAGCTGGCGTGGGCACTTTG 1620
1561 GTCCATAGAGACAGCAATGAGACCTTCGGGCCCAAGCTGGCGTGGGCACTTTG 1620
1621 GTAGACTGTGCCACCAAGCGCTGTGTGTGAAGCTGAAATTAAGAGAGCAAAAAA 1679
1621 GTAGACTGTGCCACCAAGCGCTGTGTGTGAAGCTGAAATTAAGAGAGCAAAAAA 1679

RESULT 102
ADD93061
ID ADD93061 standard; cDNA; 1679 BP.
XX
AC ADD93061;
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; pericyte; rectum; kidney; cervix;
liver; microvascular endothelial cell; gliocyte; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194768-A1.
XX
PD 16-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152371.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
(GETH) GENENTECH INC.
XX
PI Baker KF, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;
XX
DR WPI; 2003-899787/82.
XX
P-PSDB; ADD93062.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
useful for treating pericyte-associated tumors, diabetes and various bone
and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; SEQ ID NO 375; 636pp; English.
XX

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC from cartilage are useful for treating sports-related joint problems, CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO CC polypeptides are also useful for treating various mammalian haemoglobin- CC associated disorders such as various thalassemias and conditions which CC may benefit from enhanced local immune system cell infiltration. This CC sequence represents a human PRO polynucleotide of the invention. Note: CC The sequence data for this patent is also available in electronic format CC from USPTO at seqdata.uspto.gov/sequence.html. XX

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTGTGTCCTTCAGCAAAACAGTGAATTAATCTCTTGTGCAAAAGCTTGAGCAAC 60
DB 1 GTGTGTCCTTCAGCAAAACAGTGAATTAATCTCTTGTGCAAAAGCTTGAGCAAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAAAACCATCAGCCAAAAATGCAAAATTCATCTCTTGGCAAT 180
DB 121 AAGAAAAAATCATGAAAAACCATCAGCCAAAAATGCAAAATTCATCTCTTGGCAAT 180
QY 181 CTTTCAGGGGCTGGCTGCTCTGTGCTCTTCCAAAGAGTGCCGTCAGCGGAGATGC 240
DB 181 CTTTCAGGGGCTGGCTGCTCTGTGCTCTTCCAAAGAGTGCCGTCAGCGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGAACAAGTGCAGCTCCGGCAGGGGAGAGCGCCCTCAG 300
DB 241 CACCTTCCCAAGCTATGGAACAAGTGCAGCTCCGGCAGGGGAGAGCGCCCTCAG 300
QY 301 GTGCATATGCAACCGGTGTCACCGGTGTCGCTTAAACCGCAGCAGCATCTCTA 360
DB 301 GTGCATATGCAACCGGTGTCACCGGTGTCGCTTAAACCGCAGCAGCATCTCTA 360
QY 361 TGTGCGGAATGCAAGTGTGCTGATCTCTGCGTGGTCCCTTCTGAGCAACCCCAAC 420
DB 361 TGTGCGGAATGCAAGTGTGCTGATCTCTGCGTGGTCCCTTCTGAGCAACCCCAAC 420
QY 421 GCATGACATGAGATGATCAGAAAGTGTATGATGAGAGGCGCTTACCTGCTC 480
DB 421 GCATGACATGAGATGATCAGAAAGTGTATGATGAGAGGCGCTTACCTGCTC 480
QY 481 GGTGACAGACAGCAACCCAGACCTCTAGGGTCCACCTCATTGTGCAAGTATCTCC 540
DB 481 GGTGACAGACAGCAACCCAGACCTCTAGGGTCCACCTCATTGTGCAAGTATCTCC 540
QY 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAAACAATATTAGCCTCAC 600
DB 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGTGAGACAGAGCTACGGTACTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCAACTGTGAGACAGAGCTACGGTACTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGCTTTGTGAGTGAAGAGAAATATTGGAATTTACAGGCATCACCGGGAGCAGTC 720
DB 661 GGTGCTTTGTGAGTGAAGAGAAATATTGGAATTTACAGGCATCACCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTCTCCAAATGACGTGGCGCGCCGCTGATCGAGAGTAA 780
DB 721 AGGGGACTACGAGTGCAGTCTCCAAATGACGTGGCGCGCCGCTGATCGAGAGTAA 780
QY 781 GGTACCGTGAATATCCACCAATATATTTCAGAGCGAAAGGTA CAGGTGTCCTCGGG 840
DB 781 GGTACCGTGAATATCCACCAATATATTTCAGAGCGAAAGGTA CAGGTGTCCTCGGG 840
QY 841 ACAAAGGGGACACTGCACTGTGAGAGCTCAGAGTCCCTCAGCAGAAATCCAGTGTA 900

DB 841 ACAAAGGGGACACTGCACTGTGAGAGCTCAGAGTCCCTCAGCAGAAATCCAGTGTA 900
QY 901 CAAAGGATGACAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAGATGGAAGAAACAGACCTTT 960
DB 901 CAAAGGATGACAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAGATGGAAGAAACAGACCTTT 960
QY 961 CTTCTAAAACACTCATCTTCTTCAATGCTCTGAAACATGATGATGGAACACTACACTTGGT 1020
DB 961 CTTCTAAAACACTCATCTTCTTCAATGCTCTGAAACATGATGATGGAACACTACACTTGGT 1020
QY 1021 GGCTCCAAACAGCTGGGCGCACACCAATGCCAGCATCATGCTATTGGTCCAGGGCGCT 1080
DB 1021 GGCTCCAAACAGCTGGGCGCACACCAATGCCAGCATCATGCTATTGGTCCAGGGCGCT 1080
QY 1081 CAGCGAGTGAAGCAACCGGACGCTGAGAGAGGAGGCTGCTGCTGCTGCTGCTGCTTCT 1140
DB 1081 CAGCGAGTGAAGCAACCGGACGCTGAGAGAGGAGGCTGCTGCTGCTGCTGCTGCTTCT 1140
QY 1141 GGTCTTGCACTCTCTTCAAAATTTGATGTGAGTGCCACTTCCCCACCGGGAAGGCT 1200
DB 1141 GGTCTTGCACTCTCTTCAAAATTTGATGTGAGTGCCACTTCCCCACCGGGAAGGCT 1200
QY 1201 GCGGCCACACCAACCAACAGCAATGGCAACCCAGCAGCAACCAATCAGATA 1260
DB 1201 GCGGCCACACCAACCAACAGCAATGGCAACCCAGCAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAAATTAAGAAAGACAGAGCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320
DB 1261 TATACAAATGAAATTAAGAAAGACAGAGCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320
QY 1321 AAGAATATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB 1321 AAGAATATCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGGTACAAATGGAGTTTCTTCCAAACGGGAGAAACACAGCACACCGGCTTGA 1440
DB 1381 TTTAGGTACAAATGGAGTTTCTTCCAAACGGGAGAAACACAGCACACCGGCTTGA 1440
QY 1441 CCCACTGCAAGTGCATCTGTCAACTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGTGCATCTGTCAACTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCCCACAGAGTGCCTCCCGTGGAAACATTTGGAGCTGGCCATCCCAAAATTCATCA 1560
DB 1501 TCTGCCCCACAGAGTGCCTCCCGTGGAAACATTTGGAGCTGGCCATCCCAAAATTCATCA 1560
QY 1561 GTCCATAGACAGCAACAGAAATGAGACCTTCCGGCCCAAGCTGGCGCTCGGGCACTTTG 1620
DB 1561 GTCCATAGACAGCAACAGAAATGAGACCTTCCGGCCCAAGCTGGCGCTCGGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCGGCTGTGTGTGAAACGTGAAATTAAGAGACCAAAAAA 1679
DB 1621 GTAGACTGTGCCACCGGCTGTGTGTGAAACGTGAAATTAAGAGACCAAAAAA 1679

RESULT 103

ADD72697

ID ADD72697 standard; cDNA; 1679 BP.

XX AC ADD72697;

XX DT 29-JAN-2004 (first entry)

XX DE Human cDNA encoding secreted/transmembrane protein, PRO337.

XX KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
XX cytosolic; optimaological; antiarthritis; osteopathic; antirheumatic;
XX vulnerable; auditory; tumour growth; retinal disorder;
XX sports-related joint problem; articular cartilage defects;
XX osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.

XX OS Homo sapiens.

XX XX

PN US2003194781-A1.
XX 16-OCT-2003.
XX 19-OCT-2001; 2001US-00164929.
XX 30-MAR-1998; 98US-00779920P.
XX 07-OCT-1998; 98WO-US021141.
XX 20-NOV-1998; 98WO-US0204855.
XX 05-JAN-1999; 99WO-US000106.
XX 08-MAR-1999; 99WO-US0005028.
XX 10-MAR-1999; 99WO-US0005190.
XX 15-APR-1999; 99WO-US0008313.
XX 14-MAY-1999; 99WO-US010733.
XX 02-JUN-1999; 99WO-US012252.
XX 25-AUG-1999; 99US-00380138.
XX 30-NOV-1999; 99WO-US028313.
XX 02-DEC-1999; 99WO-US028551.
XX 02-DEC-1999; 99WO-US028565.
XX 16-DEC-1999; 99WO-US030095.
XX 30-DEC-1999; 99WO-US031243.
XX 30-DEC-1999; 99WO-US031274.
XX 05-JAN-2000; 2000WO-US000219.
XX 06-JAN-2000; 2000WO-US000277.
XX 06-JAN-2000; 2000WO-US000376.
XX 11-FEB-2000; 2000WO-US003365.
XX 18-FEB-2000; 2000WO-US004341.
XX 24-FEB-2000; 2000WO-US005004.
XX 02-MAR-2000; 2000WO-US005841.
XX 10-MAR-2000; 2000WO-US006319.
XX 21-MAR-2000; 2000WO-US007532.
XX 30-MAR-2000; 2000WO-US008439.
XX 17-MAY-2000; 2000WO-US013705.
XX 22-MAY-2000; 2000WO-US014042.
XX 30-MAY-2000; 2000WO-US014941.
XX 02-JUN-2000; 2000WO-US015264.
XX 28-JUN-2000; 2000WO-US020710.
XX 24-AUG-2000; 2000WO-US023328.
XX 01-DEC-2000; 2000WO-US032878.
XX 20-DEC-2000; 2000WO-US034956.
XX 28-FEB-2001; 2001WO-US006520.
XX 22-MAR-2001; 2001WO-US009552.
XX 25-MAY-2001; 2001WO-US017092.
XX 01-JUN-2001; 2001WO-US017800.
XX 20-JUN-2001; 2001WO-US019692.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-JUL-2001; 2001WO-US021735.
XX 30-JUL-2001; 2001US-00918585.
XX (GETH) GENENTECH INC.
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen WE;
PI Goddard A, Godowski P, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tunas D, Williams PM, Wood WI;
XX WPI; 2003-852598/79.
DR P-PSDB; ADD72698.
XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PI for stimulating the release of tumor necrosis factor alpha from human
PI blood and stimulating the proliferation of differentiation of chondrocyte
PI cells.
XX Claim 2; SEQ ID NO 522; 462pp; English.
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins

CC mentioned above, a vector comprising a PRO nucleic acid), a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC causes death of the cell. PRO337 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
CC useful for linking a bioactive molecule to a cell expressing PRO725,
CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
CC polypeptide is useful for modulating at least one biological activity of
CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the
CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC modulating the biological activity of the cell expressing PRO1559
CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence encodes a PRO protein.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6,7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTCTTCAGCAACAGTGGATTAAATCTCTTCGACAGCTTGAGCAACAC 60
DB 1 GTTGTGCTCTTCAGCAACAGTGGATTAAATCTCTTCGACAGCTTGAGCAACAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAGAAATCATGAAACCTCCAGCAACAAATGCAATCTCTCTTGGCAAT 180
DB 121 AAGAAAGAAATCATGAAACCTCCAGCAACAAATGCAATCTCTCTTGGCAAT 180
QY 181 CTTACGGGGCTGGCTGCTCTCTCTTCCAGGAGTGCCTGCGCAGCGGAGATGC 240
DB 181 CTTACGGGGCTGGCTGCTCTCTCTTCCAGGAGTGCCTGCGCAGCGGAGATGC 240
QY 241 CACCTTCCCAAGTATGGAACAGTCAACGGTCCGGCAGGGGAGAGCGGCACCTCAG 300
DB 241 CACCTTCCCAAGTATGGAACAGTCAACGGTCCGGCAGGGGAGAGCGGCACCTCAG 300
QY 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCATCTCTTA 360
DB 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCATCTCTTA 360
QY 361 TGCTGGGAATGACAAAGTGGTGGTGGATCTCTCGCGTGGTCTCTTGTAGCAACACCAAC 420
DB 361 TGCTGGGAATGACAAAGTGGTGGTGGATCTCTCGCGTGGTCTCTTGTAGCAACACCAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACTGTGTATCATCGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACTGTGTATCATCGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGCAAGACAGCAACACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGCAAGACAGCAACACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540

541 CAAATTTGAGAGATTTCTTCCAGATATCTCCATTAAAGAGGCAACATATTAGCCTCAC 600
541 CAAATTTGAGAGATTTCTTCCAGATATCTCCATTAAAGAGGCAACATATTAGCCTCAC 600
601 CTGCATAGCACTGGTAGCAGAGAGCTACGGTACTTTGGAGACACATCTCTCCCAAGC 660
601 CTGCATAGCACTGGTAGCAGAGAGCTACGGTACTTTGGAGACACATCTCTCCCAAGC 660
661 GGTGGCTTTGTGAGTGAAGAGCAATACCTTGAAATTCAGGGCATCACCCGGAGCAGTC 720
661 GGTGGCTTTGTGAGTGAAGAGCAATACCTTGAAATTCAGGGCATCACCCGGAGCAGTC 720
721 AGGGGACTACGAGTGAGTGCTCCATGACGTGGCGCGCCCGTGGTACGGAGAGTAA 780
721 AGGGGACTACGAGTGAGTGCTCCATGACGTGGCGCGCCCGTGGTACGGAGAGTAA 780
781 GGTACCGTGAATATCCACCATACATTTTCAAGGCAAGGTTACAGTGTCCCGTGGG 840
781 GGTACCGTGAATATCCACCATACATTTTCAAGGCAAGGTTACAGTGTCCCGTGGG 840
841 ACAAAGGGGACATGCTGAGTGAAGCTTCAGCATGCTCCCTCAGCAGATTCCTAGTGTA 900
841 ACAAAGGGGACATGCTGAGTGAAGCTTCAGCATGCTCCCTCAGCAGATTCCTAGTGTA 900
901 CAAGGATGACAAAGACTGATTGAAGGAAGAGGGGTGAAGTGAAGAAACAGACCTTT 960
901 CAAGGATGACAAAGACTGATTGAAGGAAGAGGGGTGAAGTGAAGAAACAGACCTTT 960
961 CTTCTCAAACTCATCTTCTCAATGTCTCTGAAATGATGGAATCACTATGCGT 1020
961 CTTCTCAAACTCATCTTCTCAATGTCTCTGAAATGATGGAATCACTATGCGT 1020
1021 GCGCTCCACAGCTGGGCGACACCAATGCGCAGCATCATGCTATTGCTCAGGCGCGT 1080
1021 GCGCTCCACAGCTGGGCGACACCAATGCGCAGCATCATGCTATTGCTCAGGCGCGT 1080
1081 CAGCAGGTGAGCAACCGCACCTCGAGGAGGCGGCTGCTGCTGCTGCTCTCTTCT 1140
1081 CAGCAGGTGAGCAACCGCACCTCGAGGAGGCGGCTGCTGCTGCTGCTCTCTTCT 1140
1141 GGTCTGACCTGCTCTCTCAATTTTGAATGCTGAGTGCCTCTCCACCGGGAAGGCT 1200
1141 GGTCTGACCTGCTCTCTCAATTTTGAATGCTGAGTGCCTCTCCACCGGGAAGGCT 1200
1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1261 TATACAAATGAATTTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAC 1320
1261 TATACAAATGAATTTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAC 1320
1321 AAAGATATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
1321 AAAGATATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
1381 TTTAGTCAATGGAGTTTCTTTTCCAAACGGGAGAGAACACAGCACACCCGGGTTGA 1440
1381 TTTAGTCAATGGAGTTTCTTTTCCAAACGGGAGAGAACACAGCACACCCGGGTTGA 1440
1441 CCACCTGCAAGCTGCTGCAACCTCTTTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1500
1441 CCACCTGCAAGCTGCTGCAACCTCTTTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1500
1501 TTTGCCACAGAGTGCCCGACAGTGAACATTTCTGGAGTGGCGATCCCAATTTCAATCA 1560
1501 TTTGCCACAGAGTGCCCGACAGTGAACATTTCTGGAGTGGCGATCCCAATTTCAATCA 1560
1561 GTCCATAGAGACGAACAGATGAGCTTTCCCGCCCAAGCGTGGGCTGCGGCACTTTG 1620
1561 GTCCATAGAGACGAACAGATGAGCTTTCCCGCCCAAGCGTGGGCTGCGGCACTTTG 1620
1621 GTAGACTGTGCCACCAACCGCGTGTGTGTGAACAGTGAATTAAGAGCAAAAAA 1679

1621 GTAGACTGTGCCACCAACCGCGTGTGTGTGAACAGTGAATTAAGAGCAAAAAA 1679
RESULT 104
ADE19481
ID ADE19481 standard; cDNA; 1679 BP.
XX AC ADE19481;
XX XX
DT 29-JAN-2004 (first entry)
XX XX
DE Human PRO polynucleotide #188.
XX XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; Glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear uricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
immune system cell infiltration.
XX XX
OS Homo sapiens.
XX XX
FN US2003199025-A1.
XX XX
PD 23-OCT-2003.
XX XX
PF 21-MAY-2002; 2002US-00152385.
XX XX
PR 03-MAR-2000; 2000US-0187202P.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX XX
PA (GETH) GENENTECH INC.
XX XX
PI Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX XX
DR WPI; 2003-900156/82.
DR P-PSDB; ADE19482.
XX XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
useful for treating pericyte-associated tumors, diabetes and various bone
and/or cartilage disorders, e.g. arthritis.
XX XX
PS Claim 2; SEQ ID NO 375; 648pp; English.
XX XX
CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating

CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis.
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTTCCAGAAAAGAGTGGATTAAATCTCTCTGCAAGCTTGAGAGCAACAC 60
DB |||||||
QY 1 GTTGTGCTTCCAGAAAAGAGTGGATTAAATCTCTCTGCAAGCTTGAGAGCAACAC 60
DB |||||||
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB |||||||
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB |||||||
QY 121 AAGAAAATAATCATGAACCATCCAGCCAAATATGCAATCTCTCTGCGCAAT 180
DB |||||||
QY 121 AAGAAAATAATCATGAACCATCCAGCCAAATATGCAATCTCTCTGCGCAAT 180
DB |||||||
QY 181 CTTACAGGGGCTGGCTGCTCTGTCTCTCTTCCAGAGAGTCCCGTGGCGAGATGC 240
DB |||||||
QY 181 CTTACAGGGGCTGGCTGCTCTGTCTCTCTTCCAGAGAGTCCCGTGGCGAGATGC 240
DB |||||||
QY 241 CACCTTCCCAAGCTATGACACAGTACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
DB |||||||
QY 241 CACCTTCCCAAGCTATGACACAGTACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
DB |||||||
QY 301 GTGCACTATTGACAAACCGGGTACCCGGTGGCTGCTTAAACCGCAGCAACATCTCTA 360
DB |||||||
QY 301 GTGCACTATTGACAAACCGGGTACCCGGTGGCTGCTTAAACCGCAGCAACATCTCTA 360
DB |||||||
QY 361 TGCTGGGAATGCAAGTGGTGGCTGATTCCTCGGTGGTTCCTTGAGCAACACCAAC 420
DB |||||||
QY 361 TGCTGGGAATGCAAGTGGTGGCTGATTCCTCGGTGGTTCCTTGAGCAACACCAAC 420
DB |||||||
QY 421 GCAGTACAGCATCCAGATCCAGAACGTTGGATGCTATGACGAGGGCCCTTACACCTGCTC 480
DB |||||||
QY 421 GCAGTACAGCATCCAGATCCAGAACGTTGGATGCTATGACGAGGGCCCTTACACCTGCTC 480
DB |||||||
QY 481 GGTGAGACAGACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB |||||||
QY 481 GGTGAGACAGACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB |||||||
QY 541 CAAAATTGTAGAGATTCTTCCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAC 600
DB |||||||
QY 541 CAAAATTGTAGAGATTCTTCCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAC 600
DB |||||||
QY 601 CTGCATAGCAACTGGTAGACAGACCTTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
DB |||||||
QY 601 CTGCATAGCAACTGGTAGACAGACCTTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
DB |||||||
QY 661 GGTGGCTTTGTAGTGAAGCGAATACCTTGGAAATTCAGGGGCATCACCCGGGAGCAGTC 720
DB |||||||
QY 661 GGTGGCTTTGTAGTGAAGCGAATACCTTGGAAATTCAGGGGCATCACCCGGGAGCAGTC 720
DB |||||||
QY 721 AGGGGACTTACAGTGCAGTGCCTCCAATGACGTGGCGCGCCCGTGGTACGGAGGTAAA 780
DB |||||||
QY 721 AGGGGACTTACAGTGCAGTGCCTCCAATGACGTGGCGCGCCCGTGGTACGGAGGTAAA 780
DB |||||||
QY 781 GGTACCCGTGAATATCCACCATACATTTTGAAGAGCAAGGGTACAGGTGCCCGGTGGG 840

DB 781 GGTACCCGTGAATATCCACCATACATTTTCAAGAGCCAGGGTACAGGTGCCCGGTGGG 840
QY 841 ACAAAGGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTTCCAGTGTA 900
DB 841 ACAAAGGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTTCCAGTGTA 900
QY 901 CAGGATCACAAGAGACTGATTGAGGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
DB 901 CAGGATCACAAGAGACTGATTGAGGAAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
QY 961 CTTCTCAAAACTCATCTCTTCTTCAATGTCTCTGAACATGACTATGGGAACTACCTTGGT 1020
DB 961 CTTCTCAAAACTCATCTCTTCTTCAATGTCTCTGAACATGACTATGGGAACTACCTTGGT 1020
QY 1021 GGCCTCCAAAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
DB 1021 GGCCTCCAAAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
QY 1081 CAGCGAGGTGAGCAACCGCAGCTCGAGGAGGCGAGCTGCGTCTGGCTGCTCTTCT 1140
DB 1081 CAGCGAGGTGAGCAACCGCAGCTCGAGGAGGCGAGCTGCGTCTGGCTGCTCTTCT 1140
QY 1141 GGTCTTGAACCTGCTCTTCAAAATTTTGTATGTGAGTGCCACTTCCCAACCGGGAAGCT 1200
DB 1141 GGTCTTGAACCTGCTCTTCAAAATTTTGTATGTGAGTGCCACTTCCCAACCGGGAAGCT 1200
QY 1201 GCGCCACACCAACCAACCAACAGCAATGGCAACACCAAGCAAGCAACCAATCAGATA 1260
DB 1201 GCGCCACACCAACCAACCAACAGCAATGGCAACACCAAGCAAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATTTAGAGAAACACACGCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
DB 1261 TATACAAATGAATTTAGAGAAACACACGCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
QY 1321 AAGAAATCTTTGGGGGAAAGAGCTTTTAAAGAAAGAAATTTGAAATTTGCCCTTGCAGATA 1380
DB 1321 AAGAAATCTTTGGGGGAAAGAGCTTTTAAAGAAAGAAATTTGAAATTTGCCCTTGCAGATA 1380
QY 1381 TTTAGGTACAAATGGAGTTTTCTTTTCCAAACGGGAAAGAACACAGCACACCGGCTTGG 1440
DB 1381 TTTAGGTACAAATGGAGTTTTCTTTTCCAAACGGGAAAGAACACACAGCACACCGGCTTGG 1440
QY 1441 CCCACTGCAAGCTGATGTCGCACTCTTTGGTCCAGTGTGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGATGTCGCACTCTTTGGTCCAGTGTGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCCAAGAGTCCCGCCACGTTGGAACATTTCTGGAGCTGGCCATCCCAATTTCAATCA 1560
DB 1501 TCTGCCCAAGAGTCCCGCCACGTTGGAACATTTCTGGAGCTGGCCATCCCAATTTCAATCA 1560
QY 1561 GTCCATAGAGACGAAACAGATGAGACCTTCGGGCCCAAGCGTGGCGCTCGCGGCACTTTG 1620
DB 1561 GTCCATAGAGACGAAACAGATGAGACCTTCGGGCCCAAGCGTGGCGCTCGCGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCAAGCGCTGTGTGTGAAACGTTGAAATTAAGGAGCAAGGAAAAA 1679
DB 1621 GTAGACTGTGCCACCAAGCGCTGTGTGTGAAACGTTGAAATTAAGGAGCAAGGAAAAA 1679

RESULT 105

ADE18929
ID ADE18929 standard; cDNA; 1679 BP.

XX ADE18929;

AC AC

XX 29-JAN-2004 (first entry)

DT Human PRO polynucleotide #188.

DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003199026-A1.

XX 23-OCT-2003.

XX 20-MAY-2002; 2002US-00152393.

XX 03-MAR-2000; 2000US-0187202P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-900157/82.

XX P-PSDB; ADE18930.

XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.

XX Claim 2; SEQ ID NO 375; 636pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6.7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	GTGTGTGCTTTCAGCAAAACAGTGGATTTAAATCTCTTGTGCAACAGCTTGAGAGCAAC	60
Db	1	GTGTGTGCTTTCAGCAAAACAGTGGATTTAAATCTCTTGTGCAACAGCTTGAGAGCAAC	60
Qy	61	AATCTATCAGGAAGAAAGAAAGAAACCCGAACTTCTGACAAAAGAAAGAAAG	120
Db	61	AATCTATCAGGAAGAAAGAAAGAAACCCGAACTTCTGACAAAAGAAAGAAAG	120
Qy	121	AAGAAAAAATCATGAAACCATTCAGCAAAATGCAAAATCTCTTCTTGGGCAAT	180
Db	121	AAGAAAAAATCATGAAACCATTCAGCAAAATGCAAAATCTCTTCTTGGGCAAT	180
Qy	181	CTTCACGGGGCTGGCTGTCTGTCTCTTCCAAAGAGTGCCTGCGCAGGGAGATGC	240
Db	181	CTTCACGGGGCTGGCTGTCTGTCTCTTCCAAAGAGTGCCTGCGCAGGGAGATGC	240
Qy	241	CACCTTCCCAAGAGCTATGCAACAGTGCAGCGTCCGCGAGGGGAGAGCGCACCTCAG	300
Db	241	CACCTTCCCAAGAGCTATGCAACAGTGCAGCGTCCGCGAGGGGAGAGCGCACCTCAG	300
Qy	301	GTGCACCTATTGACACCGGGTCAACCGGGTGGCTGGCTAAACCCGAGCACCATCTCTA	360
Db	301	GTGCACCTATTGACACCGGGTCAACCGGGTGGCTGGCTAAACCCGAGCACCATCTCTA	360
Qy	361	TGCTGGGAATGACAGTGGTGGTCTGATCCTCGCGTGGTCTCTTGAGCAACACCCAAAC	420
Db	361	TGCTGGGAATGACAGTGGTGGTCTGATCCTCGCGTGGTCTCTTGAGCAACACCCAAAC	420
Qy	421	GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACAGGGGCCCTTACACCTGCTC	480
Db	421	GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACAGGGGCCCTTACACCTGCTC	480
Qy	481	GGTGCAGACAGCAACCCCAAGACCTTAGGTCCACCTCATTTGCAAGTATCTCC	540
Db	481	GGTGCAGACAGCAACCCCAAGACCTTAGGTCCACCTCATTTGCAAGTATCTCC	540
Qy	541	CAAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC	600
Db	541	CAAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC	600
Qy	601	CTGCATAGCAACTGGTAGACAGAGCTACGTTTACTTGGAGACACATCTCTCCCAAGC	660
Db	601	CTGCATAGCAACTGGTAGACAGAGCTACGTTTACTTGGAGACACATCTCTCCCAAGC	660
Qy	661	GGTTGGCTTTGTGAGTGAAGACCAATCTTGGAAATTCAGGGCATCACCGGGAGCAGTTC	720
Db	661	GGTTGGCTTTGTGAGTGAAGACCAATCTTGGAAATTCAGGGCATCACCGGGAGCAGTTC	720
Qy	721	AGGGGACTACGAGTGCAGTCCCTCAATGACGTGGCGCGCCCGTGTACGGAGATGTA	780
Db	721	AGGGGACTACGAGTGCAGTCCCTCAATGACGTGGCGCGCCCGTGTACGGAGATGTA	780
Qy	781	GGTCACCGTCAACTATCCACATACATTTTCAGAAAGCAAGGGTACAGGTGTCCCCGTGG	840
Db	781	GGTCACCGTCAACTATCCACATACATTTTCAGAAAGCAAGGGTACAGGTGTCCCCGTGG	840
Qy	841	ACAAAAGGGGACACTGCGAGTGTGAAGCTTCAGAGTCCCTTCAGCAGAAATTCAGTGGTA	900
Db	841	ACAAAAGGGGACACTGCGAGTGTGAAGCTTCAGAGTCCCTTCAGCAGAAATTCAGTGGTA	900
Qy	901	CAAGATGACAAAGAGCTGATTCAAGAAAGAAAGGGGTGAAAGTGGAAACACAGACTTT	960
Db	901	CAAGATGACAAAGAGCTGATTCAAGAAAGAAAGGGGTGAAAGTGGAAACACAGACTTT	960
Qy	961	CTCTCAAAACTCATCTTCTTCAATGTCTGAAACATGACTATGGGAACTATCACTTGGCGT	1020
Db	961	CTCTCAAAACTCATCTTCTTCAATGTCTGAAACATGACTATGGGAACTATCACTTGGCGT	1020
Qy	1021	GGCTCCCAAGCTGGGCCACACCAATGCCAGCATCATGTCTATTTGGTCCAGGCCCGT	1080
Db	1021	GGCTCCCAAGCTGGGCCACACCAATGCCAGCATCATGTCTATTTGGTCCAGGCCCGT	1080

QY 241 CACCTTCCCAAGCTATGGCAACGTCACGGTCGGGAGAGGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAGCTATGGCAACGTCACGGTCGGGAGAGGAGCGCCACCTCAG 300
QY 301 GTGCACTATTGCAACACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCATCTCTA 360
DB 301 GTGCACTATTGCAACACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCATCTCTA 360
QY 361 TGTCTGGATGACAGTGTGCTGGATCTCGCTGTCTCTCTGAGCAACACCGCAAC 420
DB 361 TGTCTGGATGACAGTGTGCTGGATCTCGCTGTCTCTCTGAGCAACACCGCAAC 420
QY 421 GCAGTACAGATCGAGATCCAGAACGTTGATGATGACAGAGGCGCTTACACCTGCTC 480
DB 421 GCAGTACAGATCGAGATCCAGAACGTTGATGATGACAGAGGCGCTTACACCTGCTC 480
QY 481 GTGCGAGACAGACACCGCAACGCTCTAGGTCACCTCATTTGTGGAAGTATCTCC 540
DB 481 GTGCGAGACAGACACCGCAACGCTCTAGGTCACCTCATTTGTGGAAGTATCTCC 540
QY 541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAC 600
DB 541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAC 600
QY 601 CTGATAGCAACTGTGAGACGAGCTACGTTACTTTGGAGACACATCTCTCCAAAGC 660
DB 601 CTGATAGCAACTGTGAGACGAGCTACGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGAGCAATCTTGAAATTCAGGGCATCACCGGAGCAGTC 720
DB 661 GGTGGCTTTGTGAGTGAAGAGCAATCTTGAAATTCAGGGCATCACCGGAGCAGTC 720
QY 721 AGGGGACTACGAGTCAGTCTCCAAATGACGTGCGCGCGCGGTGTAACGAGATGAA 780
DB 721 AGGGGACTACGAGTCAGTCTCCAAATGACGTGCGCGCGGTGTAACGAGATGAA 780
QY 781 GGTCCCGTGAATCTCCACCATATATTCAGAGCCAGGATACAGTGTCCCGTGGG 840
DB 781 GGTCCCGTGAATCTCCACCATATATTCAGAGCCAGGATACAGTGTCCCGTGGG 840
QY 841 ACAAAGGGGACACTGCACTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTA 900
DB 841 ACAAAGGGGACACTGCACTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTA 900
QY 901 CAAGGATGACAAAGACTATTTGAAGGAAAGAGGGGTGAAGTGAAGGAAACAGCTTT 960
DB 901 CAAGGATGACAAAGACTATTTGAAGGAAAGAGGGGTGAAGTGAAGGAAACAGCTTT 960
QY 961 CCTCTCAAACTCATCTCTTCAATGCTCTGAAATGACTATGGGAATCTACCTTGGT 1020
DB 961 CCTCTCAAACTCATCTCTTCAATGCTCTGAAATGACTATGGGAATCTACCTTGGT 1020
QY 1021 GGGCTCCAAAGCTGGGCGCACACCAATGCCAGCATCTAGCTATTTGGTCCAGGCGGT 1080
DB 1021 GGGCTCCAAAGCTGGGCGCACACCAATGCCAGCATCTAGCTATTTGGTCCAGGCGGT 1080
QY 1081 CAGCGAGTGAAGCAACGGCACTCGAGGAGGCGAGGCTGCGTCTGGCTGCTCTTCT 1140
DB 1081 CAGCGAGTGAAGCAACGGCACTCGAGGAGGCGAGGCTGCGTCTGGCTGCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTGAGTGGCCATCTCCACCGGGAAGGCT 1200
DB 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTGAGTGGCCATCTCCACCGGGAAGGCT 1200
QY 1201 GCGGCCACCAACCAACCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
DB 1201 GCGGCCACCAACCAACCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATATGAAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAA 1320
DB 1261 TATACAAATGAATATGAAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAA 1320
QY 1321 AAAGAATACTTTGGGGGGAAGAGAGTTTAAAAAAGAAATTCAGAAATTCGCTTGCAGATA 1380

DB 1321 AAAGAATACTTTGGGGGGAAGAGTTTAAAAAAGAAATTCAGAAATTCGCTTGCAGATA 1380
QY 1381 TTTAGTACAATGGAGTTTCTTTTCCCAAAACGGGAAGAACACAGCACACCGGCTTGA 1440
DB 1381 TTTAGTACAATGGAGTTTCTTTTCCCAAAACGGGAAGAACACAGCACACCGGCTTGA 1440
QY 1441 CCCACTGCAAGCTGCAATCGTCAACCTCTTTGGTGGCAGTGTGGGAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGCAATCGTCAACCTCTTTGGTGGCAGTGTGGGAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACACAGAGTGGCCCAACGTCAGTGAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACACAGAGTGGCCCAACGTCAGTGAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACGACAGAAATGAGACCTTCCGCGCCCAACGTCGGCGCTGCGGCGCTTTG 1620
DB 1561 GTCCATAGAGACGACAGAAATGAGACCTTCCGCGCCCAACGTCGGCGCTGCGGCGCTTTG 1620
QY 1621 GTAGACTGTGCCACACGCGGTGTGTTGTGAACGTTGAAATAAAAAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACACGCGGTGTGTTGTGAACGTTGAAATAAAAAGAGCAAAAAA 1679

RESULT 107
ADD95914
ID ADD95914 standard; cDNA; 1679 BP.
XX
AC ADD95914;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX
OS Homo sapiens.
XX
FN US2003199059-A1.
XX
PD 23-OCT-2003.
XX
PF 15-APR-2002; 2002US-00123322.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.

[illegible]

181 CTTCAACGGGCTGGCTGCTCTGTCTCTTCCAAAGGAGTGCCCTGCGCAGCGAGATGC 240
Db CTTCAACGGGCTGGCTGCTCTGTCTCTTCCAAAGGAGTGCCCTGCGCAGCGAGATGC 240
QY CACCTTCCCAAGCTATGGACAACGTCACGCTCCGGCAGGGGAGAGCGCACCTTCAG 300
Db CACCTTCCCAAGCTATGGACAACGTCACGCTCCGGCAGGGGAGAGCGCACCTTCAG 300
QY GTGCATATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCATTCTTA 360
Db GTGCATATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCATTCTTA 360
QY TGCTGGGAATGACAGTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG 420
Db TGCTGGGAATGACAGTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG 420
QY GCAGTACAGCTACGAGATCCAGAAAGCTGGATGTGTATGACAGGGCCCTTTACCTGCTC 480
Db GCAGTACAGCTACGAGATCCAGAAAGCTGGATGTGTATGACAGGGCCCTTTACCTGCTC 480
QY GGTGACAGACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 540
Db GGTGACAGACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 540
QY CAAAAATTGAGAGATTTCTTCAGATATCTCCATTAAATGAAGGGAACCAATATTAGCCTCAC 600
Db CAAAAATTGAGAGATTTCTTCAGATATCTCCATTAAATGAAGGGAACCAATATTAGCCTCAC 600
QY CTGCTAGCACTGTGACAGCAGCCTACGTTACTTTGGAGACACATCTTCCCAAGC 660
Db CTGCTAGCACTGTGACAGCAGCCTACGTTACTTTGGAGACACATCTTCCCAAGC 660
QY GGTGGCTTTGTGAGTGAAGACGAATATCTTGAATTCAGGGCATCACCCGGGAGCAGTC 720
Db GGTGGCTTTGTGAGTGAAGACGAATATCTTGAATTCAGGGCATCACCCGGGAGCAGTC 720
QY AGGGGACTACGAGTGCAGTGCCTCAATGAACGTCGCGCGCGCGCGCGCGCGCGCGCG 780
Db AGGGGACTACGAGTGCAGTGCCTCAATGAACGTCGCGCGCGCGCGCGCGCGCGCGCG 780
QY GGTCAACCGTGAATTCACCACTATATTCAGAACCAAGGTTACAGGTGTCCCGTGGG 840
Db GGTCAACCGTGAATTCACCACTATATTCAGAACCAAGGTTACAGGTGTCCCGTGGG 840
QY ACAAAGGGGACACTGCAAGTGAAGCTTCAGCAGTCCCTCAGCAGAAATTCAGAGTGTA 900
Db ACAAAGGGGACACTGCAAGTGAAGCTTCAGCAGTCCCTCAGCAGAAATTCAGAGTGTA 900
QY CAAGGATGACAAAGACTGATTGAAGGAAGAAAGGGGTGAAGTGAAGGAACAGACCTTT 960
Db CAAGGATGACAAAGACTGATTGAAGGAAGAAAGGGGTGAAGTGAAGGAACAGACCTTT 960
QY CCTCTCAAAACTCATCTTCTCAATGTCTCTGAAACATGATATGGGAACTACCTTGGT 1020
Db CCTCTCAAAACTCATCTTCTCAATGTCTCTGAAACATGATATGGGAACTACCTTGGT 1020
QY GGCCTCCACAGCTGGGCGCACCAATGCGAGCATCTGCTATTGTCAGGGCGCGGT 1080
Db GGCCTCCACAGCTGGGCGCACCAATGCGAGCATCTGCTATTGTCAGGGCGCGGT 1080
QY CAGCGAGGTGAGCAACGCGACGTCGAGGAGGCGAGCTGCGTCTGGCTGCTGCTCTTCT 1140
Db CAGCGAGGTGAGCAACGCGACGTCGAGGAGGCGAGCTGCGTCTGGCTGCTGCTCTTCT 1140
QY GGTCTTGCACCTGCTTCTCAATTTTGTATGAGTGCACATCTTCCCAACCGGGAAGGCT 1200
Db GGTCTTGCACCTGCTTCTCAATTTTGTATGAGTGCACATCTTCCCAACCGGGAAGGCT 1200
QY GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA 1260
Db GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA 1260

QY 1261 TATACAAATGAATTTAGAGAAACACACGCTCATGGGACAGAAATTTTGGGGGGGGAAC 1320
Db 1261 TATACAAATGAATTTAGAGAAACACACGCTCATGGGACAGAAATTTTGGGGGGGGAAC 1320
QY 1321 AAAGAATACTTTTGGGGGGAAGAGTGTAAAAAAGAAATTTGAAATTTGCCTTGCAGATA 1380
Db 1321 AAAGAATACTTTTGGGGGGAAGAGTGTAAAAAAGAAATTTGAAATTTGCCTTGCAGATA 1380
QY 1381 TTAGGTACAAATGGAGTGTCTTTTCCAAACGGGAAGAACACACACCCCGGCTTGA 1440
Db 1381 TTAGGTACAAATGGAGTGTCTTTTCCAAACGGGAAGAACACACACCCCGGCTTGA 1440
QY 1441 CCACCTGCAAGCTGCATCGTGCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCACCTGCAAGCTGCATCGTGCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCACAGTGGAACTTCTGGAGTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCACAGTGGAACTTCTGGAGTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGAGCAACAGAAATGAGACCTTCCGGGCGCAAGCGTGGCGCTGCGGGCACTTTG 1620
Db 1561 GTCCATAGAGAGCAACAGAAATGAGACCTTCCGGGCGCAAGCGTGGCGCTGCGGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACACACGCGCTGTGTGTGAAACGTGAAATTTAAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACACACGCGCTGTGTGTGAAACGTGAAATTTAAAGAGCAAAAAA 1679

RESULT 108

ADE22800

ID ADE22800 standard; cDNA; 1679 BP.

XX AC ADE22800;

XX AC ADE22800;

DT 29-JAN-2004 (first entry)

XX cDNA encoding human PRO polypeptide #188.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
immune system cell infiltration.

XX Homo sapiens.

OS Homo sapiens.

XX US2003199064-A1.

XX 23-OCT-2003.

XX 19-APR-2002; 2002US-00125932.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022991.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

```
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US0005028.
PR 10-MAR-1999; 99WO-US0005190.
PR 10-MAR-1999; 2000WO-US0006319.
PR 20-APR-1999; 99WO-US0008615.
PR 24-MAY-1999; 99WO-US0010733.
PR 02-JUN-1999; 99WO-US0012252.
PR 01-SEP-1999; 99WO-US0201111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US021089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.

PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-900169/82.
XX P-PSDB; ADE22801.
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX Claim 2; Fig 375; 638pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems, PRO
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence encodes a human PRO polypeptide of the invention. Note: The
XX sequence data for this patent is also available in electronic format from
XX the USPTO website at seqdata.uspto.gov.
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
XX Query Match 100.0%; Score 1679; DB 1; Length 1679;
XX Best Local Similarity 100.0%; Pred. No. 6.7e-05;
XX Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTTCGCAACAGCTTGAGGCAAC 60
DB 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTTCGCAACAGCTTGAGGCAAC 60
QY 61 AATCTATCAGGAAGCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 120
|||||
```

Db	61	AATCTATCAGGAAAGAAAGAAAAAACCGAACCTTGACAAAAAGAAAGAAAAAGAAAG	120
Qy	121	AAGAAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAAATCTATCTCTTGGGCAAT	180
Db	121	AAGAAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAAAATCTATCTCTTGGGCAAT	180
Qy	181	CTTCAGGGGCTGGCTCTGTGCTCTCTCCAAAGGAGTCCCGTGCAGCGGAGATGC	240
Db	181	CTTCAGGGGCTGGCTCTGTGCTCTCTCCAAAGGAGTCCCGTGCAGCGGAGATGC	240
Qy	241	CACCTTCCCAAGCTATGGAACAACTGACGGTCCGGCAGGGGGAGAGGCCACCTCAG	300
Db	241	CACCTTCCCAAGCTATGGAACAACTGACGGTCCGGCAGGGGGAGAGGCCACCTCAG	300
Qy	301	GTCCACTATTGTGCAACACGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA	360
Db	301	GTGCATATTGTGCAACACGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTA	360
Qy	361	TGCTGGGAATGACAAAGTGTGCTCGATCTCTCGGTGGTCCCTTGTAGCAACACCCAAAC	420
Db	361	TGCTGGGAATGACAAAGTGTGCTCGATCTCTCGGTGGTCCCTTGTAGCAACACCCAAAC	420
Qy	421	GCAGTACAGCATCGAGATCCAGAACTGGGATGTATGACGAGGGGCCCTTACACCTGCTC	480
Db	421	GCAGTACAGCATCGAGATCCAGAACTGGGATGTATGACGAGGGGCCCTTACACCTGCTC	480
Qy	481	GGTGACAGACAAACACCCAAAGACCTCTAGGTCACCTCATTTGTGGAAGTATCTCC	540
Db	481	GGTGACAGACAAACACCCAAAGACCTCTAGGTCACCTCATTTGTGGAAGTATCTCC	540
Qy	541	CAAAATTTGTAGAGATTCTTTCAGATATCTCCATTAATGAAGGAAACAAATATTAGCCTCAC	600
Db	541	CAAAATTTGTAGAGATTCTTTCAGATATCTCCATTAATGAAGGAAACAAATATTAGCCTCAC	600
Qy	601	CTGCATAGCAACTGCTGTAGACAGAGCCTACGGTTACTTGGAGACACATCTCTCCAAAGC	660
Db	601	CTGCATAGCAACTGCTGTAGACAGAGCCTACGGTTACTTGGAGACACATCTCTCCAAAGC	660
Qy	661	GGTTGGCTTTGTGAGTGAAGACGAATACTTTGGAAATTCAGGGGCATCACCCGGGAGCAGTC	720
Db	661	GGTTGGCTTTGTGAGTGAAGACGAATACTTTGGAAATTCAGGGGCATCACCCGGGAGCAGTC	720
Qy	721	AGGGGACTACAGTGCAGTGCCTCCAATGACGTGGCGCGCCCGTGGTACGGAGATGAA	780
Db	721	AGGGGACTACAGTGCAGTGCCTCCAATGACGTGGCGCGCCCGTGGTACGGAGATGAA	780
Qy	781	GGTCACCGTGAACTATCCACATACATTTCCAGAAAGCCAAAGGATACAGGTGTCCTCCGTGG	840
Db	781	GGTCACCGTGAACTATCCACATACATTTCCAGAAAGCCAAAGGATACAGGTGTCCTCCGTGG	840
Qy	841	ACAAAAGGGACACTGCAGTGTGAGCCCTCAGCAGTCCCTCAGCAGATTCACAGTGGTA	900
Db	841	ACAAAAGGGACACTGCAGTGTGAGCCCTCAGCAGTCCCTCAGCAGATTCACAGTGGTA	900
Qy	901	CAAGGATGACAAAAGACTGATTGAAGAAAGAAAGGGGTGAAAGTGGAAACACAGACTTT	960
Db	901	CAAGGATGACAAAAGACTGATTGAAGAAAGAAAGGGGTGAAAGTGGAAACACAGACTTT	960
Qy	961	CCTCTCAAACTCATCTTCTTCAATGTCTGACATGACTATGGGAATTCACACTTGGCT	1020
Db	961	CCTCTCAAACTCATCTTCTTCAATGTCTGACATGACTATGGGAATTCACACTTGGCT	1020
Qy	1021	GGCCTCCAAAGCTGGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGGT	1080
Db	1021	GGCCTCCAAAGCTGGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGGT	1080
Qy	1081	CAGCGAGTGACAAACGGCAGTGCAGGAGCGGAGGCTGCTTGGCTGTGGCTCTTCT	1140
Db	1081	CAGCGAGTGACAAACGGCAGTGCAGGAGCGGAGGCTGCTTGGCTGTGGCTCTTCT	1140
Qy	1141	GGTCTTGACCTGCTTCTCAAAATTTGATGTAGTGCCACTTCCCAACCCGGGAAAGGCT	1200
Db	1141	GGTCTTGACCTGCTTCTCAAAATTTGATGTAGTGCCACTTCCCAACCCGGGAAAGGCT	1200

Qy	1201	GGCGCCACCA	CCACCA	CAACAGCA	CAAGCA	CAATGG	CAACAC	CCGAC	AGCA	ACCAAT	CAGATA	1260
Db	1201	GGCGCCACCA	CCACCA	CAACAGCA	CAAGCA	CAATGG	CAACAC	CCGAC	AGCA	ACCAAT	CAGATA	1260
Qy	1261	TATACAAATG	AAATAG	AGAAAC	CACAGC	CTCAT	GGGAC	GAGAAA	TTTG	AGGGAG	GGGAAC	1320
Db	1261	TATACAAATG	AAATAG	AGAAAC	CACAGC	CTCAT	GGGAC	GAGAAA	TTTG	AGGGAG	GGGAAC	1320
Qy	1321	AAAGAAATAC	TTTGGG	GGGAAA	AGAGTTT	TAAAA	AGAAA	TTGAAA	AAATTC	GCTTGC	CAGATA	1380
Db	1321	AAAGAAATAC	TTTGGG	GGGAAA	AGAGTTT	TAAAA	AGAAA	TTGAAA	AAATTC	GCTTGC	CAGATA	1380
Qy	1381	TTTAGGTG	TACAA	TGGAGT	TTTCTT	TTCC	CAAA	CGGGA	AGAA	CACAG	CACAC	1440
Db	1381	TTTAGGTG	TACAA	TGGAGT	TTTCTT	TTCC	CAAA	CGGGA	AGAA	CACAG	CACAC	1440
Qy	1441	CCCACTG	CAAGT	GCAT	CGTG	CAACT	CTTT	TGTC	GCAG	TGGG	CAAGGG	1500
Db	1441	CCCACTG	CAAGT	GCAT	CGTG	CAACT	CTTT	TGTC	GCAG	TGGG	CAAGGG	1500
Qy	1501	TCGTG	CCCCAC	AGAGT	GCC	CCCA	CGTGT	GAA	CATT	CTG	GAGCT	1560
Db	1501	TCGTG	CCCCAC	AGAGT	GCC	CCCA	CGTGT	GAA	CATT	CTG	GAGCT	1560
Qy	1561	GTC	CATAG	AGAC	GAAC	AGAA	TGAG	ACTT	CCG	CCCA	AGGTGG	1620
Db	1561	GTC	CATAG	AGAC	GAAC	AGAA	TGAG	ACTT	CCG	CCCA	AGGTGG	1620
Qy	1621	GTAG	CTGTG	CCCA	CCAG	CGG	CTG	CTGT	GTGA	ACGTGA	ATAA	1679
Db	1621	GTAG	CTGTG	CCCA	CCAG	CGG	CTG	CTGT	GTGA	ACGTGA	ATAA	1679

RESULT 109

ADD78918

ID ADD78918 standard; cdna; 1679 BP.

XX AC ADD78918;

XX DT 29-JAN-2004 (first entry)

XX DE cDNA encoding human PRO polypeptide #188.

XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

XX KW tumour necrosis factor- α ; TNF- α ; chondrocyte cell; tumour;

XX KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX KW liver; macrovascular endothelial cell; glucose; FFA;

XX KW skeletal muscle cell; adipocyte cell; pericyte cell;

XX KW inner ear utricular supporting cell; T-lymphocyte cell;

XX KW endothelial cell tube formation; bone disorder; cartilage disorder;

XX KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

XX KW immune system cell infiltration.

XX OS Homo sapiens.

XX FN US2003203429-A1.

XX PD 30-OCT-2003.

XX PF 22-APR-2002; 2002US-00127900.

XX PR 05-JUN-2000; 2000US-0209832P.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Bereini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

DR WPI: 2003-875636/81.
 XX P-PSDB; ADD78919.
 PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
 PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
 PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
 XX tumors.
 PS Claim 2; Fig 375; 637pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence encodes a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.
 XX
 SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 1 GTTGTGTCCTTCAGCAAAAACAGTGGATTAAATCTCCTTGCAACAAGCTTGAGAGCAACAC 60
 1 GTTGTGTCCTTCAGCAAAAACAGTGGATTAAATCTCCTTGCAACAAGCTTGAGAGCAACAC 60
 61 AATCTATCAGGAAGAAGAAAGAAACCGAACCTGACAAAAGAAAGAAAGAAAG 120
 61 AATCTATCAGGAAGAAGAAAGAAACCGAACCTGACAAAAGAAAGAAAGAAAG 120
 121 AAGAAAAAATCATGAAACCACTCCAGCCAAAATTCACAAATTCCTCTCTGGGCAAT 180
 121 AAGAAAAAATCATGAAACCACTCCAGCCAAAATTCACAAATTCCTCTCTGGGCAAT 180
 181 CTTCAAGGGGTGGCTGCTGTGTCTCTCTTCAAGGAGTCCCGTGCAGCGGAGATGC 240
 181 CTTCAAGGGGTGGCTGCTGTGTCTCTCTTCAAGGAGTCCCGTGCAGCGGAGATGC 240
 241 CACCTTCCCAAGCTATGACACAGTGGCTCCGCGAGGGGAGAGCGCCACCTTCAG 300
 241 CACCTTCCCAAGCTATGACACAGTGGCTCCGCGAGGGGAGAGCGCCACCTTCAG 300
 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAACCGCAGACCAATCCTCTA 360
 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAACCGCAGACCAATCCTCTA 360

QY 361 TGCTGGGAATGACAAGTGGTCCCTGGATCCTCGCGTGGTCTCTTCTGAGCAACACCCAAAC 420
 DB 361 TGCTGGGAATGACAAGTGGTCCCTGGATCCTCGCGTGGTCTCTTCTGAGCAACACCCAAAC 420
 QY 421 GCATACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGCGCTTACACCTGCTC 480
 DB 421 GCATACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGCGCTTACACCTGCTC 480
 QY 481 GGTCCAGACAGAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
 DB 481 GGTCCAGACAGAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
 QY 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGGAACAATATTAGCCTCAC 600
 DB 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGGAACAATATTAGCCTCAC 600
 QY 601 CTGCATAGCACTGGTAGACAGACAGCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
 DB 601 CTGCATAGCACTGGTAGACAGACAGCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
 QY 661 GTTTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
 DB 661 GTTTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
 QY 721 AGGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCCCTGGTACGAGAGTAA 780
 DB 721 AGGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCCCTGGTACGAGAGTAA 780
 QY 781 GGTCAACCGTGAACATATCACCATATCATTTCAGAAAGCCAAAGGTACAGGTGTCCCCTGGG 840
 DB 781 GGTCAACCGTGAACATATCACCATATCATTTCAGAAAGCCAAAGGTACAGGTGTCCCCTGGG 840
 QY 841 ACAAAAGGGACATCGAGTGTGAAGCTCAGAGTCCCTCAGCAAGTAATTCAGAGTGA 900
 DB 841 ACAAAAGGGACATCGAGTGTGAAGCTCAGAGTCCCTCAGCAAGTAATTCAGAGTGA 900
 QY 901 CAAGGATGACAAAAAGACTGATTGAAGGAAGAAAGGGGTGAAAGTGGAAGAACACACCTTT 960
 DB 901 CAAGGATGACAAAAAGACTGATTGAAGGAAGAAAGGGGTGAAAGTGGAAGAACACACCTTT 960
 QY 961 CCTCTCAAACTCATCTTCTTCAATGTCTGAAACATGACATNTGGGAACATACACTTGGT 1020
 DB 961 CCTCTCAAACTCATCTTCTTCAATGTCTGAAACATGACATNTGGGAACATACACTTGGT 1020
 QY 1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGTTTGGTCCAGCGCGCT 1080
 DB 1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGTTTGGTCCAGCGCGCT 1080
 QY 1081 CAGCGAGTGAAGCAACCGCACTGAGAGGGGAGGTGGCTCTGGCTGTGCCTCTTCT 1140
 DB 1081 CAGCGAGTGAAGCAACCGCACTGAGAGGGGAGGTGGCTCTGGCTGTGCCTCTTCT 1140
 QY 1141 GGTCTTGCACTGTCTTCTCAAAATTTTGATGTGAGTGGCCACTTCCCACCGGGAAAGCT 1200
 DB 1141 GGTCTTGCACTGTCTTCTCAAAATTTTGATGTGAGTGGCCACTTCCCACCGGGAAAGCT 1200
 QY 1201 GCCGCCACCAACCAACCAACCAAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
 DB 1201 GCCGCCACCAACCAACCAACCAAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
 QY 1261 TATACAAATGAATTTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
 DB 1261 TATACAAATGAATTTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
 QY 1321 AAAGAATATCTTTGGGGGAAAGAGTGTAAAAAAGAAATTTGAAATTTGCCTTTCAGATA 1380
 DB 1321 AAAGAATATCTTTGGGGGAAAGAGTGTAAAAAAGAAATTTGAAATTTGCCTTTCAGATA 1380
 QY 1381 TTTAGGTACATGAGTGTCTTTTCCCAACGGGAAGAACACACACACCGGCTTGA 1440
 DB 1381 TTTAGGTACATGAGTGTCTTTTCCCAACGGGAAGAACACACACACCGGCTTGA 1440

QY 1441 CCCACTGCAAGTGCATCGTGCACACCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGTGCATCGTGCACACCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTSCCCGCCAGTGGACATCTCTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTSCCCGCCAGTGGACATCTCTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACGACAGAAATGAGACCTTCGGGCCAAGCGTGGCTGGGGCAGCTTTG 1620
Db 1561 GTCCATAGAGACGACAGAAATGAGACCTTCGGGCCAAGCGTGGCTGGGGCAGCTTTG 1620
QY 1621 GTAGACTGTGCCACACCGCGTGTGTGTAAGCTGTAATTAAGAGCAAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACACCGCGTGTGTGTAAGCTGTAATTAAGAGCAAGCAAAAAA 1679
RESULT 110
ADE32868
ID ADE32868 standard; cDNA; 1679 BP.
XX ADE32868;
AC ADE32868;
XX ADE32868;
DT 29-JAN-2004 (first entry)
XX Novel human secreted and transmembrane protein PRO337 cDNA.
DE Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
OS Homo sapiens.
XX US2003194766-A1.
PN US2003194766-A1.
XX 16-OCT-2003.
PD 16-OCT-2003.
XX 14-MAY-2002; 2002US-00145874.
PF 14-MAY-2002; 2002US-00145874.
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CX, Wood WL, Zhang Z;
XX WPI; 2003-899785/82.
DR P-PSDB; ADE32869.
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; SEQ ID NO 375; 636pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of

CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAACAC 60
Db 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAACAC 60
QY 61 ATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 ATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAAATCATGAAAAACCATCCAGCAAAATGCACAAATCTATCTCTTGGGCAAT 180
Db 121 AAGAAAAAAATCATGAAAAACCATCCAGCAAAATGCACAAATCTATCTCTTGGGCAAT 180
QY 181 CTTACGGGGCTGGCTGCTCTGTCTCTTCCAAAGAGTGGCCGTCGAGCGGAGATGC 240
Db 181 CTTACGGGGCTGGCTGCTCTGTCTCTTCCAAAGAGTGGCCGTCGAGCGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGAACAAAGTACGGTCCGGCAGGGGGAGAGCGCCACCTCAG 300
Db 241 CACCTTCCCAAGCTATGGAACAAAGTACGGTCCGGCAGGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCATATGACACCGGGTCAACCGGGTGGCTGGCTAAACCGGAGAGCAATCCTCTA 360
Db 301 GTGCATATGACACCGGGTCAACCGGGTGGCTGGCTAAACCGGAGAGCAATCCTCTA 360
QY 361 TGTGGAATGACAGTGTGCTGGATCTCTGGTGGTCTCTTCTGAGCAACACCAAC 420
Db 361 TGTGGAATGACAGTGTGCTGGATCTCTGGTGGTCTCTTCTGAGCAACACCAAC 420
QY 421 GCAGTACAGATCGAGATCCAGAACGTTGATGTATGACAGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGATCGAGATCCAGAACGTTGATGTATGACAGGGCCCTTACACCTGCTC 480
QY 481 GGTGCAGACAGACACCCCAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGCAGACAGACACCCCAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTAC 600
Db 541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTAC 600
QY 601 CTCATAGCACTGGTAGACAGGCTAGCTTACTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTCATAGCACTGGTAGACAGGCTAGCTTACTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGCAATACATTGGAATTCAGGGCATCCCGGAGCAGTTC 720
Db 661 GGTGGCTTTGTGAGTGAAGCAATACATTGGAATTCAGGGCATCCCGGAGCAGTTC 720

721 AGGGGACTAGAGTGCAGTGCCTCCATGACGTGGCGCGCCGTTGTTACGAGAGTAAA 780
721 AGGGGACTAGAGTGCAGTGCCTCCATGACGTGGCGCGCGTTGTTACGAGAGTAAA 780
781 GGTCCCGTGAATATCCACATATTTTTCAGAGCCAGAGGTACAGGTGTCCTCCGTTGG 840
781 GGTCCCGTGAATATCCACATATTTTTCAGAGCCAGAGGTACAGGTGTCCTCCGTTGG 840
841 ACAAAGGGGACACTGTCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
841 ACAAAGGGGACACTGTCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
901 CAAGGATGACAAAGACTGATGAGGAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
901 CAAGGATGACAAAGACTGATGAGGAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
961 CCTCTCAAACTCATCTTCTCAATGTCTGAAACATGATATGGGAACTACACCTTGGCT 1020
961 CCTCTCAAACTCATCTTCTCAATGTCTGAAACATGATATGGGAACTACACCTTGGCT 1020
1021 GGCTTCCAAACAGTGGGCGACACCAATGTCAGCATCATCTATTTTGGTCCAGGCGCCT 1080
1021 GGCTTCCAAACAGTGGGCGACACCAATGTCAGCATCATCTATTTTGGTCCAGGCGCCT 1080
1081 CAGGAGGTGAGCAACCGGACGTCGAGGAGGCGGCTGCTGCTGCTGCTGCTGCTTCT 1140
1081 CAGGAGGTGAGCAACCGGACGTCGAGGAGGCGGCTGCTGCTGCTGCTGCTGCTTCT 1140
1141 GGTCTTCACCTGCTTCTCAAAATTTTGAATGATGAGTGCCTTCCCAACCGGGAAGGCT 1200
1141 GGTCTTCACCTGCTTCTCAAAATTTTGAATGATGAGTGCCTTCCCAACCGGGAAGGCT 1200
1201 GCCGCCACACCCACCAACACACAGCATGTCGACACCGGACGACCAACCAATCAGATA 1260
1201 GCCGCCACACCCACCAACACACAGCATGTCGACACCGGACGACCAACCAATCAGATA 1260
1261 TATACAAATGAATTTAGAGAAACACACAGCTCTATGGGACAGAAATTTAGGGAGGGAAC 1320
1261 TATACAAATGAATTTAGAGAAACACACAGCTCTATGGGACAGAAATTTAGGGAGGGAAC 1320
1321 AAGAATACCTTGGGGGGAAGAGTTTAAAAAGAAATTTGCTTGGCAGATA 1380
1321 AAGAATACCTTGGGGGGAAGAGTTTAAAAAGAAATTTGCTTGGCAGATA 1380
1381 TTTAGTACATGAGTGTCTTTTCCAAACCGGGAAGAACACAGACACACCGGCTTGG 1440
1381 TTTAGTACATGAGTGTCTTTTCCAAACCGGGAAGAACACAGACACACCGGCTTGG 1440
1441 CCCACTGCACTGCATGTCGACCTCTTTGGTCCAGTGTGGGCAAGGCTCAGCCTC 1500
1441 CCCACTGCACTGCATGTCGACCTCTTTGGTCCAGTGTGGGCAAGGCTCAGCCTC 1500
1501 TCTGCCACAGAGTGCCTCCACGTCGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
1501 TCTGCCACAGAGTGCCTCCACGTCGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
1561 GTCCATAGACGACAGAAATGAGACCTTCGCGCCCAAGGCTGCGCTGGGCACTTTG 1620
1561 GTCCATAGACGACAGAAATGAGACCTTCGCGCCCAAGGCTGCGCTGGGCACTTTG 1620
1621 GTAGACTGTCCACACCGGCTGTGTGTGAACCTGAAATTAAGAGCAAGCAAAAAA 1679
1621 GTAGACTGTCCACACCGGCTGTGTGTGAACCTGAAATTAAGAGCAAGCAAAAAA 1679

RESULT 111
ADE42560
ID ADE42560 standard; cDNA; 1679 BP.
XX
AC ADE42560;
XX
DT 29-JAN-2004 (first entry)
XX

DE Human PRO polynucleotide #188.
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW cancer necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW tumour; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS
PN US2003199032-A1.
XX 23-OCT-2003.
PD
XX 28-MAY-2002; 2002US-00156844.
PF
XX 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000MO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX WPI; 2003-900161/82.
DR P-PSDB; ADE42561.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
XX useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.
XX
XX Claim 2; Fig 375; 636pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems, PRO
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polynucleotide of the invention. Note:
XX The sequence data for this patent is also available in electronic format
XX from USPTO at seqdata.uspto.gov/sequence.html.

05-JAN-1999; 99WO-US000106.
08-MAR-1999; 99WO-US005028.
12-APR-1999; 99US-00284291.
25-AUG-1999; 99US-00380138.
18-FEB-2000; 2000WO-US004341.
30-JUL-2001; 2001US-00918585.
(GETH) GENENTECH INC.
Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,
Ferrara N, Filvaroff E, Fong S, Gao W, Garber H, Gerritsen ME,
Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Shelton DL,
Kiljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Stewart TA,
Stewart TA, Tumas D, Williams PM, Wood WI;
WPI; 2003-875640/81.
P-PSDB; ADE17349.
New genes, and its encoded secreted and transmembrane polypeptides,
useful for treating e.g. lung or breast tumors, osteoarthritis,
rheumatoid arthritis, obesity, diabetes, hyperinsulinemia,
hypoinsulinemia or wounds.
PS Claim 2; SEQ ID NO 522; 459pp; English.
CC The invention relates to an isolated PRO polypeptide (secreted or
transmembrane protein) having at least 80% amino acid sequence identity
to an amino acid sequence chosen from 94 fully defined sequences as given
in the specification (including PRO lacking its associated signal
peptide, a PRO extracellular domain with or without its associated signal
peptide). Also included are nucleic acids encoding the PRO proteins
mentioned above, a vector comprising a PRO nucleic acid, a host cell
comprising the vector and producing PRO, a chimeric molecule comprising
PRO fused to a heterologous amino acid sequence, and an anti-PRO
antibody. PRO337 polypeptide is useful for detecting a PRO4993
polypeptide in a sample suspected of containing PRO4993 polypeptide.
Similarly, PRO4993 polypeptide is useful for detecting PRO337
polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
causes death of the cell. PRO337 polypeptide is useful for linking a
bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
useful for linking a bioactive molecule to a cell expressing PRO725,
PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
polypeptide is useful for modulating at least one biological activity of
the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
polypeptide or anti-PRO4993 polypeptide is useful for modulating the
biological activity of the cell expressing PRO4993 polypeptide; PRO725,
PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
modulating the biological activity of the cell expressing PRO1559
polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
PRO739 polypeptide is useful for modulating the biological activity of
the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
polypeptides are useful for inhibiting tumour growth, retinal disorders,
sports-related joint problems, articular cartilage defects,
osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
mammals. The present sequence encodes a PRO protein.
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTTCAGCAACAGAGTGGATTAAATCTCTCCGACCAAGCTTGAGGCAACAC 60
Db 1 GTTGTGCTTCAGCAACAGAGTGGATTAAATCTCTCCGACCAAGCTTGAGGCAACAC 60
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

Db 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAACCAATCCAGCCCAAAATGCAAAATCTATCTCTTGGGCAAT 180
Db 121 AAGAAAAAATCATGAACCAATCCAGCCCAAAATGCAAAATCTATCTCTTGGGCAAT 180
QY 181 CTTTCAAGGGGCTGCTCTCTGTGTCTCTTCCAGAGAGTCCCGTGGCAGCGAGATGC 240
Db 181 CTTTCAAGGGGCTGCTCTCTGTGTCTCTTCCAGAGAGTCCCGTGGCAGCGAGATGC 240
QY 241 CACCTTCCCAAGAGTATGACACAGTGGAGTCCCGCAGGGGAGAGAGCCACCTCAG 300
Db 241 CACCTTCCCAAGAGTATGACACAGTGGAGTCCCGCAGGGGAGAGAGCCACCTCAG 300
QY 301 GTGCACATATTGACCAACCGGGTCAACCCGGGTGGCTGGCTAAACCGCAGCACCATCTCTTA 360
Db 301 GTGCACATATTGACCAACCGGGTCAACCCGGGTGGCTGGCTAAACCGCAGCACCATCTCTTA 360
QY 361 TGTCTGGAGATGACAAAGTGGTGGCTGGATCTCTGGGTGGTCTTCTGAGCAACACCCAAAC 420
Db 361 TGTCTGGAGATGACAAAGTGGTGGCTGGATCTCTGGGTGGTCTTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGAGAGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGAGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGACAGACAGCAACCAACCCAGAGCTCTAGGGTCCAGCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGACAGACAGCAACCAACCCAGAGCTCTAGGGTCCAGCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTGACAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
Db 541 CAAATTTGACAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGGTACAGACAGCTTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
Db 601 CTGCATAGCAACTGGTACAGACAGCTTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GTTGTGGCTTGTGAGTGAAGACAGTAATCTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
Db 661 GTTGTGGCTTGTGAGTGAAGACAGTAATCTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
QY 721 AGGGGACTACAGTGCAGTGCCTCCAATGACGTGGCGCGCCCGTGTGTCAGGAGAGTAAA 780
Db 721 AGGGGACTACAGTGCAGTGCCTCCAATGACGTGGCGCGCCCGTGTGTCAGGAGAGTAAA 780
QY 781 GGTACCGTGAACATATCCACCATATCTTCAATGACGTGGCGCGCCCGTGTGTCAGGAGAGTAAA 840
Db 781 GGTACCGTGAACATATCCACCATATCTTCAATGACGTGGCGCGCCCGTGTGTCAGGAGAGTAAA 840
QY 841 ACAAAGGGGACACTGCGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACAAAGGGGACACTGCGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGATGACAAAAGACTGATTGAAGAAAGAGGGGTGAAGTGAAGAAACAGACCTTT 960
Db 901 CAAGATGACAAAAGACTGATTGAAGAAAGAGGGGTGAAGTGAAGAAACAGACCTTT 960
QY 961 CCTCTCAAAATCATCTTCTTCAATGTCTTGAACATGACTATGGGAACTACACTTGGT 1020
Db 961 CCTCTCAAAATCATCTTCTTCAATGTCTTGAACATGACTATGGGAACTACACTTGGT 1020
QY 1021 GGCCTTCAAGCTGGGCGCACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGCT 1080
Db 1021 GGCCTTCAAGCTGGGCGCACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGCT 1080
QY 1081 CAGCGAGTGAAGCAACCGCAGCTCGAGAGGGCAGGCTGCGCTCTGGCTGCTCTTCT 1140
Db 1081 CAGCGAGTGAAGCAACCGCAGCTCGAGAGGGCAGGCTGCGCTCTGGCTGCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTGAGTGGCACTTCCCGCACCCGGGAAAGGCT 1200

17-SEP-1998;	PRR	98W0-US019437.
07-OCT-1998;	PRR	98W0-US021141.
29-OCT-1998;	PRR	98W0-US022991.
29-OCT-1998;	PRR	98W0-US022992.
20-NOV-1998;	PRR	98W0-US024855.
01-DEC-1998;	PRR	98W0-US025108.
05-JAN-1999;	PRR	99W0-US000106.
08-MAR-1999;	PRR	99W0-US005028.
10-MAR-1999;	PRR	99W0-US005190.
10-MAR-1999;	PRR	2000W0-US0056319.
20-APR-1999;	PRR	99W0-US008615.
14-MAY-1999;	PRR	99W0-US010733.
02-JUN-1999;	PRR	99W0-US012252.
01-SEP-1999;	PRR	99W0-US020111.
08-SEP-1999;	PRR	99W0-US020594.
13-SEP-1999;	PRR	99W0-US020944.
15-SEP-1999;	PRR	99W0-US021090.
15-SEP-1999;	PRR	99W0-US021547.
05-OCT-1999;	PRR	99W0-US023048.
29-NOV-1999;	PRR	99W0-US028214.
30-NOV-1999;	PRR	99W0-US028313.
30-NOV-1999;	PRR	99W0-US028409.
01-DEC-1999;	PRR	99W0-US028301.
01-DEC-1999;	PRR	99W0-US028634.
02-DEC-1999;	PRR	99W0-US028651.
02-DEC-1999;	PRR	99W0-US028564.
16-DEC-1999;	PRR	99W0-US028565.
20-DEC-1999;	PRR	99W0-US030095.
20-DEC-1999;	PRR	99W0-US030911.
20-DEC-1999;	PRR	99W0-US030999.
22-DEC-1999;	PRR	99W0-US030720.
30-DEC-1999;	PRR	99W0-US031243.
05-JAN-2000;	PRR	99W0-US031274.
05-JAN-2000;	PRR	2000W0-US00020219.
06-JAN-2000;	PRR	2000W0-US0002777.
07-JAN-2000;	PRR	2000W0-US0003366.
11-FEB-2000;	PRR	2000W0-US0003565.
18-FEB-2000;	PRR	2000W0-US004341.
18-FEB-2000;	PRR	2000W0-US004342.
22-FEB-2000;	PRR	2000W0-US004414.
24-FEB-2000;	PRR	2000W0-US004914.
01-MAR-2000;	PRR	2000W0-US005001.
01-MAR-2000;	PRR	2000W0-US005601.
02-MAR-2000;	PRR	2000W0-US005746.
02-MAR-2000;	PRR	2000W0-US005864.
15-MAR-2000;	PRR	2000W0-US006684.
20-MAR-2000;	PRR	2000W0-US007377.
21-MAR-2000;	PRR	2000W0-US007532.
30-MAR-2000;	PRR	2000W0-US008439.
17-MAY-2000;	PRR	2000W0-US013705.
22-MAY-2000;	PRR	2000W0-US014042.
30-MAY-2000;	PRR	2000W0-US014941.
02-JUN-2000;	PRR	2000W0-US015264.
28-JUL-2000;	PRR	2000W0-US020731.
11-AUG-2000;	PRR	2000W0-US022031.
23-AUG-2000;	PRR	2000W0-US023522.
24-AUG-2000;	PRR	2000W0-US023328.
08-NOV-2000;	PRR	2000W0-US030952.
10-NOV-2000;	PRR	2000W0-US030873.
01-DEC-2000;	PRR	2000W0-US032678.
20-DEC-2000;	PRR	2000US-00742529.
20-DEC-2000;	PRR	2000W0-US034956.
28-FEB-2001;	PRR	2001US-00764998.
28-FEB-2001;	PRR	2001W0-US0006520.
01-MAR-2001;	PRR	2001W0-US004666.
09-MAR-2001;	PRR	2001US-00803706.
14-MAR-2001;	PRR	2001US-00815699.
22-MAR-2001;	PRR	2001US-00816744.
05-APR-2001;	PRR	2001US-00828366.
10-MAY-2001;	PRR	2001US-00854208.
10-MAY-2001;	PRR	2001US-00854208.
18-MAY-2001;	PRR	2001US-00860620.
25-MAY-2001;	PRR	2001US-00862028.

PR	25-MAY-2001;	2001US-00866034.	QY	1	GTGTGTCCTTTCAGCAAAACAGTGGATTTAAATCTCTCTGTCACAAAGCTTGAGAGCAAC	60
PR	25-MAY-2001;	2001US-00866034.	DB	1	GTGTGTCCTTTCAGCAAAACAGTGGATTTAAATCTCTCTGTCACAAAGCTTGAGAGCAAC	60
PR	01-JUN-2001;	2001US-00872035.	QY	61	AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
PR	01-JUN-2001;	2001US-00872035.	DB	61	AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120
PR	05-JUN-2001;	2001US-00874503.	QY	121	AAGAAAAAATCATGAAAAACCATGCAAGCAAAATGCAAAATCTATCTCTGCGGAAT	180
PR	05-JUN-2001;	2001US-00874503.	DB	121	AAGAAAAAATCATGAAAAACCATGCAAGCAAAATGCAAAATCTATCTCTGCGGAAT	180
PR	14-JUN-2001;	2001US-00882636.	QY	181	CTTCAAGGGGCTGGCTCTCTGTCCTCTTCCAGGAGTCCCGTGGCGAGCGAGATGC	240
PR	14-JUN-2001;	2001US-00882636.	DB	181	CTTCAAGGGGCTGGCTCTCTGTCCTCTTCCAGGAGTCCCGTGGCGAGCGAGATGC	240
PR	20-JUN-2001;	2001US-00887879.	QY	241	CACCTTCCCAAGCTATGGAACACGTGACGGTCCGCGAGGGGAGAGCGCCACCTCAG	300
PR	20-JUN-2001;	2001US-00887879.	DB	241	CACCTTCCCAAGCTATGGAACACGTGACGGTCCGCGAGGGGAGAGCGCCACCTCAG	300
PR	22-JUN-2001;	2001US-00886342.	QY	301	GTGCACATTTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCCTCTCTA	360
PR	22-JUN-2001;	2001US-00886342.	DB	301	GTGCACATTTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCCTCTCTA	360
PR	23-JUN-2001;	2001US-00887879.	QY	361	TGCTGGGAATGACAAAGTGGTGGTCTCTCGCTGGTCTCTCTGAGCAACACCCAAAC	420
PR	23-JUN-2001;	2001US-00887879.	DB	361	TGCTGGGAATGACAAAGTGGTGGTCTCTCGCTGGTCTCTCTGAGCAACACCCAAAC	420
PR	03-JUL-2001;	2001US-00908627.	QY	421	GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACAGAGGGCCCTTACACCTGTC	480
PR	03-JUL-2001;	2001US-00908627.	DB	421	GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACAGAGGGCCCTTACACCTGTC	480
PR	06-AUG-2001;	2001US-00924419.	QY	481	GGTGACAGACACCAACCAACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540
PR	06-AUG-2001;	2001US-00924419.	DB	481	GGTGACAGACACCAACCAACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540
PR	09-AUG-2001;	2001US-00927796.	QY	541	CAAAATTTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGGAAACAATATTAGCCTCAC	600
PR	09-AUG-2001;	2001US-00927796.	DB	541	CAAAATTTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGGAAACAATATTAGCCTCAC	600
PR	16-AUG-2001;	2001US-00931836.	QY	601	CTGCATACCAACTGGTAGACAGAGCTTACGGTCTTCTGAGAGACACATCTCTCCCAAGC	660
PR	16-AUG-2001;	2001US-00931836.	DB	601	CTGCATACCAACTGGTAGACAGAGCTTACGGTCTTCTGAGAGACACATCTCTCCCAAGC	660
PR	19-DEC-2001;	2001US-00028072.	QY	661	GGTTGGCTTTGTAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720
PR	19-DEC-2001;	2001US-00028072.	DB	661	GGTTGGCTTTGTAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720
PR			QY	721	AGGGGACTACGAGTGCAGTCCCAATGACGTGCGCGCCCGTGGTACGAGAGTAAA	780
PR			DB	721	AGGGGACTACGAGTGCAGTCCCAATGACGTGCGCGCCCGTGGTACGAGAGTAAA	780
PR			QY	781	GGTCAACCGTGAACATATCCACATATTTTCAAGAGCCCAAGGGTACAGGTGTCCCGTGGG	840
PR			DB	781	GGTCAACCGTGAACATATCCACATATTTTCAAGAGCCCAAGGGTACAGGTGTCCCGTGGG	840
PR			QY	841	ACAAAGGGGACACTGAGTGTGAGCTCAGAGTCCCTCAGCAGAAATTCAGAGTGTA	900
PR			DB	841	ACAAAGGGGACACTGAGTGTGAGCTCAGAGTCCCTCAGCAGAAATTCAGAGTGTA	900
PR			QY	901	CAAGGATCAAAAAGACACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT	960
PR			DB	901	CAAGGATCAAAAAGACACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT	960
PR			QY	961	CGCTCAAAATCATCTTCTTCAATGTCTGAAACATGACTATGGGAATACACTTGGGT	1020
PR			DB	961	CGCTCAAAATCATCTTCTTCAATGTCTGAAACATGACTATGGGAATACACTTGGGT	1020
PR			QY	1021	GGCTCCCAAGCTGGGCCACACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGT	1080
PR			DB	1021	GGCTCCCAAGCTGGGCCACACCAATGCCAGCATCATGTATTTGGTCCAGGCGCGT	1080
PR			QY	1081	CAGCAGGTGAGCAACCGGACGTCGAGAGGGGAGGCTGGCTGGCTGGCTCTCTCTCT	1140

25-MAY-2001; 2001US-00866034.
 25-MAY-2001; 2001US-00866034.
 01-JUN-2001; 2001US-00872035.
 01-JUN-2001; 2001US-00872035.
 05-JUN-2001; 2001US-00874503.
 05-JUN-2001; 2001US-00874503.
 14-JUN-2001; 2001US-00882636.
 14-JUN-2001; 2001US-00882636.
 20-JUN-2001; 2001US-00887879.
 20-JUN-2001; 2001US-00887879.
 22-JUN-2001; 2001US-00886342.
 22-JUN-2001; 2001US-00886342.
 23-JUN-2001; 2001US-00887879.
 23-JUN-2001; 2001US-00887879.
 03-JUL-2001; 2001US-00908627.
 03-JUL-2001; 2001US-00908627.
 06-AUG-2001; 2001US-00924419.
 06-AUG-2001; 2001US-00924419.
 09-AUG-2001; 2001US-00927796.
 09-AUG-2001; 2001US-00927796.
 16-AUG-2001; 2001US-00931836.
 16-AUG-2001; 2001US-00931836.
 19-DEC-2001; 2001US-00028072.
 19-DEC-2001; 2001US-00028072.
 (GETH) GENENTECH INC.
 Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 WPI: 2003-875868/81.
 P-PSDB; ADD80577.
 New PRO nucleic acid, useful for manufacturing a medicament for
 diagnosing or treating tumor, for chromosome mapping or for tissue
 typing.
 Claim 2; Fig 375; 638pp; English.
 The invention relates to isolated human PRO polypeptides (secreted and
 transmembrane polypeptides) and the polynucleotides encoding them. The
 invention also relates to an antibody which specifically binds to a PRO
 polypeptide, a method for stimulating the release of tumor necrosis
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 proliferation or differentiation of chondrocyte cells and a method for
 detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 polynucleotides are useful in molecular biology, including uses as
 hybridisation probes, in chromosome and gene mapping, in generating
 antisense RNA and DNA and in gene therapy. The polynucleotides may also
 be used in preparing PRO polypeptides by recombinant techniques and in
 generating either transgenic animals or knock-out animals which are
 useful in the development and screening of therapeutically useful
 reagents. The PRO polypeptides or antibodies are used in preparing a
 medicament for treating a condition responsive to the polypeptides or
 antibodies, such as tumours, for stimulating and inhibiting proliferation
 of human microvascular endothelial cells, for modulating the uptake of
 glucose or FFA by skeletal muscle cells or adipocyte cells, for
 stimulating differentiation of adipocyte cells, for stimulating
 proliferation of or gene expression in pericyte cells, for stimulating
 cells, for inducing endothelial cell tube formation and for treating
 various bone and/or cartilage disorders such as sports injuries and
 arthritis. PRO polypeptides which stimulate the release of proteoglycans
 from cartilage are useful for treating sports-related joint problems,
 articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 polypeptides are also useful for treating various mammalian haemoglobin-
 associated disorders such as various thalassemias and conditions which
 may benefit from enhanced local immune system cell infiltration. This
 sequence encodes a human PRO polypeptide of the invention. Note: The
 sequence data for this patent is also available in electronic format
 the USPTO website at seqdata.uspto.gov.
 Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 241 CACCTTCCCAAGACTATGGA CAA CGTGACGTCCGGCAGCGGGAGAGCGCCACCTCAG 300
Qy 301 GTGCACTATTGCAACCCGGGT CACCGGGTGGCTGGCTAAACCGCAGACCAATCCTCTA 360
Db 301 GTGCACTATTGCAACCCGGGT CACCGGGTGGCTGGCTAAACCGCAGCACCATCCTCTA 360
Qy 361 TCGTGGGATGCAAGTGGTGGCTGATCCTCGCGTGGTCTTCTGAGCAACACCCAAAC 420
Db 361 TCGTGGGATGCAAGTGGTGGCTGATCCTCGCGTGGTCTTCTGAGCAACACCCAAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTGATGACGAGGCGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTGATGACGAGGCGCCCTTACACCTGCTC 480
Qy 481 GGTGACAGACAGCAACCCAGACCTCTAGGCTCCACCTCATGTGCAAGTATCTCC 540
Db 481 GGTGACAGACAGCAACCCAGACCTCTAGGCTCCACCTCATGTGCAAGTATCTCC 540
Qy 541 CAAAAATTGTAGAGATTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAC 600
Db 541 CAAAAATTGTAGAGATTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAC 600
Qy 601 CTGCTAGCAACTGTGACAGAGAGCTAGGTTACTTGGAGACACATCTTCCCAAGC 660
Db 601 CTGCTAGCAACTGTGACAGAGAGCTAGGTTACTTGGAGACACATCTTCCCAAGC 660
Qy 661 GGTGGCTTTGTGAGTGAAGCAATACCTTGGAAATTCAGGGCATCACCGGGGAGCAGTC 720
Db 661 GGTGGCTTTGTGAGTGAAGCAATACCTTGGAAATTCAGGGCATCACCGGGGAGCAGTC 720
Qy 721 AGGGGACTACAGTGCAGTGCCTCCAAATGACGTGGCGCGCCGTGGTACCGAGAGTAAA 780
Db 721 AGGGGACTACAGTGCAGTGCCTCCAAATGACGTGGCGCGCCGTGGTACCGAGAGTAAA 780
Qy 781 GGTCCCGTGAATTCACCATACATTTTCAGAAAGCCAAAGGTACAGGTGTCCCGTGGG 840
Db 781 GGTCCCGTGAATTCACCATACATTTTCAGAAAGCCAAAGGTACAGGTGTCCCGTGGG 840
Qy 841 AAAAAAGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 AAAAAAGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Qy 901 CAAGGATGACAAAGACTGATTCAGGAAGAAAGGGGTGAAGTGAAGAAACAGACTTT 960
Db 901 CAAGGATGACAAAGACTGATTCAGGAAGAAAGGGGTGAAGTGAAGAAACAGACTTT 960
Qy 961 CCTCTCAAAACTCATCTTCTCAATGTCTCTGAACATGACTATGGGAACTACACTTGCCT 1020
Db 961 CCTCTCAAAACTCATCTTCTCAATGTCTCTGAACATGACTATGGGAACTACACTTGCCT 1020
Qy 1021 GGCTTCAACAGCTGGGTCACACCAATGCCAGCATGCTATTTGGTCCAGCGCGCT 1080
Db 1021 GGCTTCAACAGCTGGGTCACACCAATGCCAGCATGCTATTTGGTCCAGCGCGCT 1080
Qy 1081 CAGCGAGGTGAGCAACCGGACGTCGAGGAGGCGAGGCTGCTGGCTGCTGCTTCT 1140
Db 1081 CAGCGAGGTGAGCAACCGGACGTCGAGGAGGCGAGGCTGCTGGCTGCTGCTTCT 1140
Qy 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTGAGTGCACCTTCCCAACCGGGAAGGCT 1200
Db 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTGAGTGCACCTTCCCAACCGGGAAGGCT 1200
Qy 1201 GCGGCCACCAACCAACCAACAGCAATGGCAACCGCAGCAACCAATCAGATA 1260
Db 1201 GCGGCCACCAACCAACCAACAGCAATGGCAACCGCAGCAACCAATCAGATA 1260
Qy 1261 TATCAAAATGAATTAGAGAAACACAGCCTCATGGGACAGAAATTTAGGGAGGGGAAC 1320
Db 1261 TATCAAAATGAATTAGAGAAACACAGCCTCATGGGACAGAAATTTAGGGAGGGGAAC 1320
Qy 1321 AAGAATACCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAGAATACCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380

Qy 1381 TTTAGGTACATGGAGTTTCTTTTCCRAACGGGAAGACACAGCACACCCGGCTTGA 1440
Db 1381 TTTAGGTACATGGAGTTTCTTTTCCRAACGGGAAGACACAGCACACCCGGCTTGA 1440
Qy 1441 CCCACTCAAGCTGCATCGTGCACACCTCTTTGTGCCAGTGTGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTCAAGCTGCATCGTGCACACCTCTTTGTGCCAGTGTGGCAAGGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGGCCCCACGCTGGACATTTGAGCTGGGCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGGCCCCACGCTGGACATTTGAGCTGGGCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGACGAACAAAGAAATGAGACCTTCCGGCCCAAGCGTGGCGCTCGGGCCTTTG 1620
Db 1561 GTCCATAGAGACGAACAAAGAAATGAGACCTTCCGGCCCAAGCGTGGCGCTCGGGCCTTTG 1620
Qy 1621 GTAGACTGTGCCACACGCGGTGTGTGTAACCTGAATATAAAGAGCAAAAAAAA 1679
Db 1621 GTAGACTGTGCCACACGCGGTGTGTGTAACCTGAATATAAAGAGCAAAAAAAA 1679

RESULT 115

ADE40888 standard; cDNA; 1679 BP.

AC ADE40888;

DT 29-JAN-2004 (first entry)

DE Human PRO polynucleotide #188.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumor necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; PPA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

OS Homo sapiens.

FN US2003199031-A1.

PD 23-OCT-2003.

PF 28-MAY-2002; 2002US-00156842.

PR 05-JUN-2000; 2000US-0209832P.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-900160/82.

DR P-PSDB; ADE40889.

XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,

PT useful for treating pericyte-associated tumors, diabetes and various bone

PT and/or cartilage disorders, e.g. arthritis.

XX Claim 2; Fig 375; 637pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO

polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems. PRO articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6.7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 GTTGTGTCCTCAGCAAAACAGTGATTTAAATCTCTCTGCAACAGCTTGAGCAACAC 60
DB 1 GTTGTGTCCTCAGCAAAACAGTGATTTAAATCTCTCTGCAACAGCTTGAGCAACAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAGAAATCATGAAACCATCCAGCCAAATATGCAAAATTCCTCTCTGGGCAAT 180
DB 121 AAGAAAGAAATCATGAAACCATCCAGCCAAATATGCAAAATTCCTCTCTGGGCAAT 180
QY 181 CTTACGGGGCTGGCTGCTGTGTCTCTTCAAGAGTGCCCGCGCAGCGAGATGC 240
DB 181 CTTACGGGGCTGGCTGCTGTGTCTCTTCAAGAGTGCCCGCGCAGCGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGAACAACTGACGTGTCGGGAGGGGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAGCTATGGAACAACTGACGTGTCGGGAGGGGAGCGCCACCTCAG 300
QY 301 GTGCACTATTGACACCGGGTCAACCGGGTGGCTGATTAACCGCAGCACCCTCTTA 360
DB 301 GTGCACTATTGACACCGGGTCAACCGGGTGGCTGATTAACCGCAGCACCCTCTTA 360
QY 361 TGCTGGGAATGCAAGTGTGCTGATCTCTCGCGTGTCTCTTCTGAGCAACCCCAAC 420
DB 361 TGCTGGGAATGCAAGTGTGCTGATCTCTCGCGTGTCTCTTCTGAGCAACCCCAAC 420
QY 421 GCAGTACAGATCGAGATCCAGAACGTGATGTATGACAGGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGATCGAGATCCAGAACGTGATGTATGACAGGGGCCCTTACACCTGCTC 480
QY 481 GGTGCAGACAGCAACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGCAGACAGCAACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
```

```
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGACAAATATTAGCCTCAC 600
DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGACAAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGTGTAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
DB 601 CTGCATAGCAACTGTGTAGACAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGTGCTTTGTGAGTGAAGACGATATCTTGAATTCAGGGCATCACCCTGGAGAGTGC 720
DB 661 GGTGTGCTTTGTGAGTGAAGACGATATCTTGAATTCAGGGCATCACCCTGGAGAGTGC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGCTGCGCGCCGCTGGTACGAGAGTAAA 780
DB 721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGCTGCGCGCCGCTGGTACGAGAGTAAA 780
QY 781 GGTACCGTGAATATTCACCATATCATTTTCAAGACCAAGGTGAAAGTGGAAACAGACCTTT 840
DB 781 GGTACCGTGAATATTCACCATATCATTTTCAAGACCAAGGTGAAAGTGGAAACAGACCTTT 840
QY 841 ACAAAGGGGACACTGTCAGTGTGAAGCCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
DB 841 ACAAAGGGGACACTGTCAGTGTGAAGCCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
QY 901 CAAAGATGACAAAGACTGATTTGAAGGAAAGAAAGGTGAAAGTGGAAACAGACCTTT 960
DB 901 CAAAGATGACAAAGACTGATTTGAAGGAAAGAAAGGTGAAAGTGGAAACAGACCTTT 960
QY 961 CCTCTCAAAACTCATCTCTTCAATGTCTCTGAAACATGACTATGGAACTACACTTGGT 1020
DB 961 CCTCTCAAAACTCATCTCTTCAATGTCTCTGAAACATGACTATGGAACTACACTTGGT 1020
QY 1021 GGCTCTCAAAAGCTGGGCGACACCAATGCCAGCATCATGCTATTGTTGTCAGGGCGCT 1080
DB 1021 GGCTCTCAAAAGCTGGGCGACACCAATGCCAGCATCATGCTATTGTTGTCAGGGCGCT 1080
QY 1081 CACGAGGTGAGCAACGGCAGCTCGAGGAGGCGAGCTGCTGCTGCTGCTGCTGCTGCT 1140
DB 1081 CACGAGGTGAGCAACGGCAGCTCGAGGAGGCGAGCTGCTGCTGCTGCTGCTGCTGCT 1140
QY 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCAACCCCGGAAAGGT 1200
DB 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCAACCCCGGAAAGGT 1200
QY 1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA 1260
DB 1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA 1260
QY 1261 TATACAAATGAAATTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAAC 1320
DB 1261 TATACAAATGAAATTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAAC 1320
QY 1321 AAGAAATCTTTGGGGGAAAGAGTTTTAAAGAAAGATTTGAAATTTGCTTGCAGATA 1380
DB 1321 AAGAAATCTTTGGGGGAAAGAGTTTTAAAGAAAGATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGGTACAAATGGAGTTTTTTTCCCAACCGGGAAGAACACAGCACACCCCGCTTGA 1440
DB 1381 TTTAGGTACAAATGGAGTTTTTTTCCCAACCGGGAAGAACACAGCACACCCCGCTTGA 1440
QY 1441 CCACCTGCACTGCACTGCACTGCACTGCACTGCACTGCACTGCACTGCACTGCACTGCACT 1500
DB 1441 CCACCTGCACTGCACTGCACTGCACTGCACTGCACTGCACTGCACTGCACTGCACTGCACT 1500
QY 1501 TCTGCCCCACAGAGTGGCCCCCAGCTGGAAATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
DB 1501 TCTGCCCCACAGAGTGGCCCCCAGCTGGAAATTTCTGGAGCTGGCCATCCCAAAATTCATCA 1560
QY 1561 GTCCATAGACGAAACAGAAATGAGACTTCCGGCCCAAGGCTGGCGCTGGGCACTTTG 1620
DB 1561 GTCCATAGACGAAACAGAAATGAGACTTCCGGCCCAAGGCTGGCGCTGGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACACAGCGGCTGTGTGTGAAACGTTGAAATATAAAGAGCAAAAAA 1679
```

DB 1621 GTAGACTGTCCACCGCGGTGTGTGTAACGTAATAAAGAGCAAAAAA 1679

RESULT 116
ADE04687
ID ADE04687 standard; cDNA; 1679 BP.
AC ADE04687;
AC ADE04687;
DT 29-JAN-2004 (first entry)
XX Human PRO polynucleotide #188.

Human; gene; se; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

XX Homo sapiens.
XX US2003199034-A1.
XX 23-OCT-2003.
XX 28-MAY-2001; 2001US-00156846.
XX 03-MAR-2000; 2000US-0187202P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Bresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX P-PSDB; ADE04688.
XX WPI; 2003-900163/82.
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX Claim 2; Fig 375; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTCACCAAGCTTGAGAGCAACAC 60
DB 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTCACCAAGCTTGAGAGCAACAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAAACCGAACCTTGACAAAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAAACCGAACCTTGACAAAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAAAACCATCCAGCAAAATGCACAAATCTCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAAAACCATCCAGCAAAATGCACAAATCTCTCTTGGGCAAT 180
QY 181 CTTACGGGGTGGTGTCTGTGTCTTTCAAGAGTGGCCGTGCGCAGCGGAGATGC 240
DB 181 CTTACGGGGTGGTGTCTGTGTCTTTCAAGAGTGGCCGTGCGCAGCGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGCAAGCTGCGTCCGGCAGGGGAGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAGCTATGGCAAGCTGCGTCCGGCAGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCACTATTGACAAACCGGGTCAACCCGGGTGGCTGGCTTAAACCGCAGCACCCTCTA 360
DB 301 GTGCACTATTGACAAACCGGGTCAACCCGGGTGGCTGGCTTAAACCGCAGCACCCTCTA 360
QY 361 TGTGGGAATGACAAAGTGTGCTGGATCTCGCTGGTCTCTTCTGAGCAACACCCCAAC 420
DB 361 TGTGGGAATGACAAAGTGTGCTGGATCTCGCTGGTCTCTTCTGAGCAACACCCCAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGCAAGACACACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGCAAGACACACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAAATGAAGGGAACAATATTAGCCTCAC 600
DB 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAAATGAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGGTGGAGACGAGCCTACGGTACTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCAACTGGTGGAGACGAGCCTACGGTACTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTAGTGAAGACGAATACCTTGAATAATTCAGGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTAGTGAAGACGAATACCTTGAATAATTCAGGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTCCCTTCCAAATCAAGTGGCCGCCCGTGGTACGGAGAGTAA 780
DB 721 AGGGGACTACGAGTGCAGTCCCTTCCAAATCAAGTGGCCGCCCGTGGTACGGAGAGTAA 780
QY 781 GGTCAACGTGAACATCCACCATACATTTTCAGAGCCCAAGGTACAGAGTGTCCCGTGG 840
DB 781 GGTCAACGTGAACATCCACCATACATTTTCAGAGCCCAAGGTACAGAGTGTCCCGTGG 840

Db 781 GGTCAACCTGTAATATCCACCATACATTTTCAGAGCCAAAGGTACAGGTGTCCCGTGGG 840
Qy 841 ACAAAGGGGACATCTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGATTCAGTGGTA 900
Db 841 ACAAAGGGGACATCTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGATTCAGTGGTA 900
Qy 901 CAAGGATGACAAAACACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAAACAGACCTTT 960
Db 901 CAAGGATGACAAAACACTGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAAACAGACCTTT 960
Qy 961 CTTCTCAAACTCATCTCTTCTCAATGTCTCTGAACATGACTATGGGAACATCACTTCGGT 1020
Db 961 CTTCTCAAACTCATCTCTTCTCAATGTCTCTGAACATGACTATGGGAACATCACTTCGGT 1020
Qy 1021 GGCCTCCAAAGCTGGGCGCACCAATATCCAGCATCATGCTATTGTGTCAGGCGCGGT 1080
Db 1021 GGCCTCCAAAGCTGGGCGCACCAATATCCAGCATCATGCTATTGTGTCAGGCGCGGT 1080
Qy 1081 CAGCGAGTGAAGCAACCGCATCTGAGAGGGCGAGCTGCGTGTGCTGCTCTCTCT 1140
Db 1081 CAGCGAGTGAAGCAACCGCATCTGAGAGGGCGAGCTGCGTGTGCTGCTCTCTCT 1140
Qy 1141 GGTCTTGCACTGCTCTCTCAATTTTGTGAGTGGCATCTCCACCCCGGGAAGGCT 1200
Db 1141 GGTCTTGCACTGCTCTCTCAATTTTGTGAGTGGCATCTCCACCCCGGGAAGGCT 1200
Qy 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Db 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Qy 1261 TATACAAATGAATATAGAAAGCAACAGCTCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
Db 1261 TATACAAATGAATATAGAAAGCAACAGCTCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
Qy 1321 AAAGAAATCTTTGGGGGAAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAAGAAATCTTTGGGGGAAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Qy 1381 TTTAGTCAATGAGTCTTTCTTTCCCAACGGGAAAGCAACAGCACACACCGGCTTGGGA 1440
Db 1381 TTTAGTCAATGAGTCTTTCTTTCCCAACGGGAAAGCAACAGCACACACCGGCTTGGGA 1440
Qy 1441 CCACCTGCAAGCTGCACTGCAACCTTTTGGTGCAGTGTGGGCAAGGGCTCAGCGCTC 1500
Db 1441 CCACCTGCAAGCTGCACTGCAACCTTTTGGTGCAGTGTGGGCAAGGGCTCAGCGCTC 1500
Qy 1501 TCTGCCCCACAGTGTGCCCCACGTCGAAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCCCACAGTGTGCCCCACGTCGAAACATTTCTGGAGTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGAGACGAACAGATGAGACTTTCCGCGCCCAAGCGTGGCGCTGCGGGCACTTTG 1620
Db 1561 GTCCATAGAGACGAACAGATGAGACTTTCCGCGCCCAAGCGTGGCGCTGCGGGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACCGGGGTGTGTGCAACCTGAAATTAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACCGGGGTGTGTGCAACCTGAAATTAAGAGCAAAAAA 1679

RESULT 117

ADC48828

ID ADC48828 standard; cDNA; 1679 BP.

XX AC ADC48828;

XX AC

DT 15-JAN-2004 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO337 cDNA.

XX KW

human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;

KW vulnary; antarthritic; pericyte cell proliferation;

KW pericyte cell differentiation; chondrocyte cell proliferation;

KW chondrocyte cell differentiation; tumour necrosis factor alpha release;

(TNF)-alpha release; dermal fibroblast cell proliferation;
dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
colon tumour; breast tumour; prostate tumour; rectal tumour;
liver tumour; tissue typing; chromosome mapping; gene mapping;
gene therapy.

Homo sapiens.

OS
US2003092888-A1.

XX

XX

PD 15-MAY-2003.

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

Claim 2; SEQ ID NO 125; 308pp; English.

The invention describes an isolated PRO (secreted and transmembrane) polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are useful for stimulating the proliferation of or gene expression in pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful for stimulating the proliferation or differentiation of chondrocyte cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide are useful for stimulating the release of tumour necrosis factor (TNF)-alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214, PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080, PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309, PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412, PRO1236, PRO1330, PRO1347, PRO1305, PRO1305, PRO1279, PRO1340, PRO1338, PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567, PRO1887, PRO1938, PRO3441, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322, PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for stimulating the proliferation of normal human dermal fibroblasts cells.

PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408, PRO5723, PRO5725, PRO154, or PRO7425 polypeptide are useful for inhibiting the proliferation of normal human dermal fibroblast cells. PRO polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc., are useful for detecting the presence of tumour in a mammal which involves comparing the level of expression of the above PRO polypeptides in a test sample of cells taken from the mammal, and a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptides in the test sample as compared to the control sample is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for chromosome and gene mapping or gene therapy. (II) is useful for generating transgenic animals or knock-out animals which are useful screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide is useful for treating bone and/or cartilage disorders (e.g., arthritis, sport injuries). This sequence encodes a human secreted and transmembrane PRO polypeptide.

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query March 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6.7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGTCCTTCAGCAAAACAGTGAATTTAAATCTCTTGTGCAAAAGCTGTGAGCAAC 60
Db |||||
QY 1 GTTGTGTCCTTCAGCAAAACAGTGAATTTAAATCTCTTGTGCAAAAGCTGTGAGCAAC 60
Db |||||
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db |||||
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db |||||
QY 121 AAGAAAAAATCATGAAAAACCATCAGCCAAAAATGCAAAATCTATCTCTTGGGCAAT 180
Db |||||
QY 181 CTTACGGGGCTGGCTGCTGTGTCTCTTCAAGAGAGTGGCGGTCCGAGCGGAGATGC 240
Db |||||
QY 181 CTTACGGGGCTGGCTGCTGTGTCTCTTCAAGAGAGTGGCGGTCCGAGCGGAGATGC 240
Db |||||
QY 241 CACCTTCCCAAGCTATGACAACTGACGGTCCGGCAGGGGGAGAGCGCCACCTCAG 300
Db |||||
QY 241 CACCTTCCCAAGCTATGACAACTGACGGTCCGGCAGGGGGAGAGCGCCACCTCAG 300
Db |||||
QY 301 GTGCATTTGACAAACGGGTACCCGGGTGGCTGGCTAAACCGCAGCACCACCTCTTA 360
Db |||||
QY 301 GTGCATTTGACAAACGGGTACCCGGGTGGCTGGCTAAACCGCAGCACCACCTCTTA 360
Db |||||
QY 361 TGTGGGAATGACAAGTGTGCTCGATCCTCGGTGGTCTTCTGAGCAACACCCAAAC 420
Db |||||
QY 361 TGTGGGAATGACAAGTGTGCTCGATCCTCGGTGGTCTTCTGAGCAACACCCAAAC 420
Db |||||
QY 421 GCAGTACAGCATCAGATCAGAAAGTGTGATGAGAGGGGCTTACACCTGCTC 480
Db |||||
QY 421 GCAGTACAGCATCAGATCAGAAAGTGTGATGAGAGGGGCTTACACCTGCTC 480
Db |||||
QY 481 GGTGCGAGACAGCAACACCAAGACCTCTAGGGTCCACCTCATTTGTCAGATCTCC 540
Db |||||
QY 481 GGTGCGAGACAGCAACACCAAGACCTCTAGGGTCCACCTCATTTGTCAGATCTCC 540
Db |||||
QY 541 CAAAAATTGTAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTAC 600
Db |||||
QY 541 CAAAAATTGTAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTAC 600
Db |||||
QY 601 CTGCNTAGCACTGGTAGCCAGGCTACGGTACTTGGAGACACATCTCTCCAAAGC 660
Db |||||
QY 601 CTGCNTAGCACTGGTAGCCAGGCTACGGTACTTGGAGACACATCTCTCCAAAGC 660
Db |||||
QY 661 GGTGGCTTTGTGAGTGAAGCAAGAAATCTTGGAAATTCAGGGCATCACCCGGAGCAGTC 720
Db |||||
QY 661 GGTGGCTTTGTGAGTGAAGCAAGAAATCTTGGAAATTCAGGGCATCACCCGGAGCAGTC 720
Db |||||
QY 721 AGGGGACTACGAGTGCCTCCATGACGTGGCGCGCCGCTGTGAGGAGTAA 780
Db |||||
QY 721 AGGGGACTACGAGTGCCTCCATGACGTGGCGCGCCGCTGTGAGGAGTAA 780
Db |||||
QY 781 GGTCAACGTGAATCATCCACCATACATTTGAGAGCCCAAGGGTACAGGTGTCCCGTGGG 840
Db |||||
QY 781 GGTCAACGTGAATCATCCACCATACATTTGAGAGCCCAAGGGTACAGGTGTCCCGTGGG 840
Db |||||
QY 841 ACAAAAGGGGACATGAGTGTGAGGCTCAGCAGTCCCTCAGCAGCAATTCAGTGGTA 900
Db |||||
QY 841 ACAAAAGGGGACATGAGTGTGAGGCTCAGCAGTCCCTCAGCAGCAATTCAGTGGTA 900
Db |||||
QY 901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGAAGAACAGACCTTT 960
Db |||||
QY 901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGAAGAACAGACCTTT 960
Db |||||
QY 961 CCTCTCAAAATCATCTTTCAATGTCTCTGAAATGACATATGGGAACTACATTCGCT 1020
Db |||||
QY 961 CCTCTCAAAATCATCTTTCAATGTCTCTGAAATGACATATGGGAACTACATTCGCT 1020
Db |||||
QY 1021 GGCCTCCAAAGCTGGGCCACCAATGCCAGCATCATGTATTTGCTCCAGCGCGCT 1080
Db |||||
QY 1021 GGCCTCCAAAGCTGGGCCACCAATGCCAGCATCATGTATTTGCTCCAGCGCGCT 1080
Db |||||

QY 1081 CAGCGAGGTGAGCAACGGCACGTCGAGGAGGGCAGGCTGCGTCTGGCTGCTGCTCTTCT 1140
Db |||||
QY 1081 CAGCGAGGTGAGCAACGGCACGTCGAGGAGGGCAGGCTGCGTCTGGCTGCTGCTCTTCT 1140
Db |||||
QY 1141 GGTCTTGACCTCTCTTCAAAATTTGATGTAGTGCACCTTCCCAACCCGGGAAAGGCT 1200
Db |||||
QY 1141 GGTCTTGACCTCTCTTCAAAATTTGATGTAGTGCACCTTCCCAACCCGGGAAAGGCT 1200
Db |||||
QY 1201 GCGGCCACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA 1260
Db |||||
QY 1201 GCGGCCACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA 1260
Db |||||
QY 1261 TATACAAATGAAATTTAGAGAAACACAGCCTCATGGACAGAAATTTGAGGAGGGGAAC 1320
Db |||||
QY 1261 TATACAAATGAAATTTAGAGAAACACAGCCTCATGGACAGAAATTTGAGGAGGGGAAC 1320
Db |||||
QY 1321 AAAGAAATCTTTGGGGGAAAGAGTTTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db |||||
QY 1321 AAAGAAATCTTTGGGGGAAAGAGTTTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db |||||
QY 1381 TTTAGGTACAAATGAGATTTTCTTTTCCCAACCGGGAAGAAACACAGCACACCCGGCTTGA 1440
Db |||||
QY 1381 TTTAGGTACAAATGAGATTTTCTTTTCCCAACCGGGAAGAAACACAGCACACCCGGCTTGA 1440
Db |||||
QY 1441 CCCACTGCAAGCTCATCGTGCAACCTTTTGTGTCAGTGTGGGCAAGGCTCAGGCTC 1500
Db |||||
QY 1441 CCCACTGCAAGCTCATCGTGCAACCTTTTGTGTCAGTGTGGGCAAGGCTCAGGCTC 1500
Db |||||
QY 1501 TCTGCCACAGAGTGCCTCCACCGTGAACATTTCTGAGCTGGCCATCCCAAAATTCATCA 1560
Db |||||
QY 1501 TCTGCCACAGAGTGCCTCCACCGTGAACATTTCTGAGCTGGCCATCCCAAAATTCATCA 1560
Db |||||
QY 1561 GTCCATAGAGACGAACAGATGAGACCTTCCGGCCCAAGCGTGGCGTGGCGGACCTTTG 1620
Db |||||
QY 1561 GTCCATAGAGACGAACAGATGAGACCTTCCGGCCCAAGCGTGGCGTGGCGGACCTTTG 1620
Db |||||
QY 1621 GTAGACTGTGCGCACCGCGGTGTGTGAAACGCTGAAATATAAAGAGCAAAAAAAA 1679
Db |||||
QY 1621 GTAGACTGTGCGCACCGCGGTGTGTGAAACGCTGAAATATAAAGAGCAAAAAAAA 1679
Db |||||

RESULT 118
ADC81112
ID ADC81112 standard; cDNA, 1679 BP.
XX
AC ADC81112;
XX
DT 15-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003092115-A1.
PN
XX
XX 15-MAY-2003.
PD
XX
XX 30-MAY-2002; 2002US-00158785.
PF
XX
XX 05-JUN-2000; 2000US-0209832P.
PR

181	DB	CTTCA	CGGGGCTGGCTGCTCTGTGTCTCTTCC	AAGGAGTGC	CCGTCG	CAGCGGAGATGC	240	
241	QY	CAC	CTTCCCA	AAAGCTATGG	CAACGTGACGGTCCG	CAGAGGGGAGAGCGCCACCTCTCAG	300	
241	DB	CAC	CTTCCCA	AAAGCTATGG	CAACGTGACGGTCCG	CAGAGGGGAGAGCGCCACCTCTCAG	300	
301	QY	GTG	CAC	TATTG	CAACACGGGTCA	CCCGGGTGGCTCTGCTAAACG	CAGACCACTCTCTA	360
301	DB	GTG	CAC	TATTG	CAACACGGGTCA	CCCGGGTGGCTCTGCTAAACG	CAGACCACTCTCTA	360
361	QY	TGCT	GGGAATG	ACAA	GTGTGCTGGATCTCTG	GGTGGTCTCTTGAGCAACACCCAAAC	420	
361	DB	TGCT	GGGAATG	ACAA	GTGTGCTGGATCTCTG	GGTGGTCTCTTGAGCAACACCCAAAC	420	
421	QY	GCAG	TACAGCATCG	AGATCC	AGACGCTGGATGTGTATG	ACAGAGGGCCCTTACACCTGCTC	480	
421	DB	GCAG	TACAGCATCG	AGATCC	AGACGCTGGATGTGTATG	ACAGAGGGCCCTTACACCTGCTC	480	
481	QY	GGT	GCAGACAG	CAACCC	CAAGACCTCTAG	GGTCCACCTCAATGTGCAAGTATCTCC	540	
481	DB	GGT	GCAGACAG	CAACCC	CAAGACCTCTAG	GGTCCACCTCAATGTGCAAGTATCTCC	540	
541	QY	CAAA	TTGTG	AGATTTCTT	CAGATATCTCC	ATTAATGAAGGGAAACAATATTAGCCTCAC	600	
541	DB	CAAA	TTGTG	AGATTTCTT	CAGATATCTCC	ATTAATGAAGGGAAACAATATTAGCCTCAC	600	
601	QY	CTGC	ATAGCAACTGTG	TAGACAGAGCCTAC	GGTACTTCTTGG	AGACACATCTCTCCCAAAGC	660	
601	DB	CTGC	ATAGCAACTGTG	TAGACAGAGCCTAC	GGTACTTCTTGG	AGACACATCTCTCCCAAAGC	660	
661	QY	GGTT	TGGCTTTGT	CGAGTGA	AGACGAATPACTT	GGAAATTCAGGGCATCACCGGAGAGCATC	720	
661	DB	GGTT	TGGCTTTGT	CGAGTGA	AGACGAATPACTT	GGAAATTCAGGGCATCACCGGAGAGCATC	720	
721	QY	AGGG	GACTAC	AGTGCAGTGCCT	CCAAAGACGTG	CGCGCGCCGTGGTACGAGAGTAAA	780	
721	DB	AGGG	GACTAC	AGTGCAGTGCCT	CCAAAGACGTG	CGCGCGCCGTGGTACGAGAGTAAA	780	
781	QY	GGT	CAC	CGTGAACTAT	CCACATACATTT	CAGAGCCCAAGGGTACAGGTGTCCCGTGGG	840	
781	DB	GGT	CAC	CGTGAACTAT	CCACATACATTT	CAGAGCCCAAGGGTACAGGTGTCCCGTGGG	840	
841	QY	ACAAA	GGGACACTG	CGAGTGTGA	AGCCTCAG	CACTCCCTCAGCAGAAATTCACAGTGGTA	900	
841	DB	ACAAA	GGGACACTG	CGAGTGTGA	AGCCTCAG	CACTCCCTCAGCAGAAATTCACAGTGGTA	900	
901	QY	CAAG	GATG	CAAAAGACTG	ATTGAAGGAAAG	AGGGGTGAAGTGGNAACACAGACCTTT	960	
901	DB	CAAG	GATG	CAAAAGACTG	ATTGAAGGAAAG	AGGGGTGAAGTGGNAACACAGACCTTT	960	
961	QY	CCT	CTCAAA	ACTCATCTT	CTTCAATGTCTCT	GAAATGACTATGGGAACACTACCTTGGT	1020	
961	DB	CCT	CTCAAA	ACTCATCTT	CTTCAATGTCTCT	GAAATGACTATGGGAACACTACCTTGGT	1020	
1021	QY	GGCT	CTCAAC	AGCTGGG	CCACACAAATCC	CAGCATCATGCTATTTGGTCCAGGGCGGT	1080	
1021	DB	GGCT	CTCAAC	AGCTGGG	CCACACAAATCC	CAGCATCATGCTATTTGGTCCAGGGCGGT	1080	
1081	QY	CAG	CGAGT	GAGCAACGG	CACGCTG	CAGGAGGGCAGGCTGGCTGTGGCTGTGCTCTTCT	1140	
1081	DB	CAG	CGAGT	GAGCAACGG	CACGCTG	CAGGAGGGCAGGCTGGCTGTGGCTGTGCTCTTCT	1140	
1141	QY	GGT	CTTG	CACCTGCTT	CTCAATTTTGATG	TGAGTGCCACTTCCCAACCCGGGAAGGCT	1200	
1141	DB	GGT	CTTG	CACCTGCTT	CTCAATTTTGATG	TGAGTGCCACTTCCCAACCCGGGAAGGCT	1200	
1201	QY	GCC	CCAC	CCACCA	CCAA	CACACAGCAATGGCAACCCGACAGCAACCAATCAGATA	1260	
1201	DB	GCC	CCAC	CCACCA	CCAA	CACACAGCAATGGCAACCCGACAGCAACCAATCAGATA	1260	
1261	QY	TAT	CAAT	GAATTA	GAGAAAC	CAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC	1320	
1261	DB	TAT	CAAT	GAATTA	GAGAAAC	CAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC	1320	

QY	1321	AAAGAAATAC	TTTGGGGGAAAAAGAGTTTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA	1380
DB	1321	AAAGAAATAC	TTTGGGGGAAAAAGAGTTTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA	1380
QY	1381	TTTAGGTACA	ATCGAGTGTTCCTTTCCAAACGGGAAGAACACAGCACACCCCGCTTGA	1440
DB	1381	TTTAGGTACA	ATCGAGTGTTCCTTTCCAAACGGGAAGAACACAGCACACCCCGCTTGA	1440
QY	1441	CCCACTGCAAGCT	GCATCGTCGCAACCTCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC	1500
DB	1441	CCCACTGCAAGCT	GCATCGTCGCAACCTCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC	1500
QY	1501	TTCTGCCCA	CAGAGTGCCCCCACTGTGGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA	1560
DB	1501	TTCTGCCCA	CAGAGTGCCCCCACTGTGGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA	1560
QY	1561	GTCCATAGAC	AGCAAGATGACACTTCCGGGCCAAAGCGTGGCGCTCGGGGCACTTTG	1620
DB	1561	GTCCATAGAC	AGCAAGATGACACTTCCGGGCCAAAGCGTGGCGCTCGGGGCACTTTG	1620
QY	1621	GTAGACTGT	GCCACCAACGGCGTGTGTGTGAACGTGAATATAAAAGAGCAAAAAAAA	1679
DB	1621	GTAGACTGT	GCCACCAACGGCGTGTGTGTGAACGTGAATATAAAAGAGCAAAAAAAA	1679
RESULT	119			
ADBE20999				
ID	ADBE20999	standard; cdna; 1679 BP.		
XX	AC	ADBE20999;		
XX	AC			
DT	29-JAN-2004	(first entry)		
XX				
DE		Novel human secreted and transmembrane protein PRO337 cDNA.		
XX				
KW		Human; secreted and transmembrane protein; PRO; gene; ss; cytosstatic;		
KW		vulnary; antiarthritic; pericyte cell proliferation;		
KW		pericyte cell differentiation; chondrocyte cell proliferation;		
KW		chondrocyte cell differentiation; tumour necrosis factor alpha release;		
KW		(TNF)-alpha release; dermal fibroblast cell proliferation;		
KW		dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;		
KW		colon tumour; breast tumour; prostate tumour; rectal tumour;		
KW		liver tumour; tissue typing; chromosome mapping; gene mapping;		
XX		gene therapy.		
XX				
OS		Homo sapiens.		
XX				
PN	US2003100735-A1.			
XX				
PD	29-MAY-2003.			
XX				
PF	28-AUG-2002; 2002US-00230433.			
XX				
PR	01-JUN-2001; 2001WO-US017800.			
PR	29-JUN-2001; 2001WO-US021066.			
PR	09-APR-2002; 2002US-00119480.			
XX				
XX		(GETH) GENENTECH INC.		
XX				
PI	Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;			
PI	Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WL;			
XX				
DR	WPI; 2004-008985/01.			
DR	P-PSDB; ADE21000.			
XX				
PT	New PRO polypeptides and nucleic acids encoding the polypeptides, useful			
PT	in gene therapy, chromosome identification, tissue typing, or as			
PT	hybridization probes in chromosome and gene mapping.			
XX				
XX	Claim 2; Fig 125; 308pp; English.			
PS				
CC	The invention describes an isolated PRO (secreted and transmembrane)			

481 GGTGAGACAGACACACACACACACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
481 GGTGAGACAGACACACACACACACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
541 CAAATTTGTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
601 CTGCATAGCACTGTGTAGACCGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
601 CTGCATAGCACTGTGTAGACCGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
661 GGTTCGCTTTGTGAGTGAAGACCAATACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
661 GGTTCGCTTTGTGAGTGAAGACCAATACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
721 AGGGACTACGAGTGAAGTGCCTCCAAATGAGTGGCCGCGCCGTGTGACGAGAGTAAA 780
721 AGGGACTACGAGTGAAGTGCCTCCAAATGAGTGGCCGCGCCGTGTGACGAGAGTAAA 780
781 GTTCACCGTGAATCTATCCACCATATATTTCAGAACCCCAAGGATACAGGTGTCCTGGGG 840
781 GTTCACCGTGAATCTATCCACCATATATTTCAGAACCCCAAGGATACAGGTGTCCTGGGG 840
841 ACAAAGGGGACACTGCACTGTGAAGCTTCAGACGTCCCTCAGCAGAAATTCAGTGTGTA 900
841 ACAAAGGGGACACTGCACTGTGAAGCTTCAGACGTCCCTCAGCAGAAATTCAGTGTGTA 900
901 CAGGATGACAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAGTGAAGTGAAGTGAAGTGA 960
901 CAGGATGACAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAGTGAAGTGAAGTGAAGTGA 960
961 CCTCTCAAAACTCATCTTCTCAATGTCTCTGAAATGATGATGATGATGATGATGATGAT 1020
961 CCTCTCAAAACTCATCTTCTCAATGTCTCTGAAATGATGATGATGATGATGATGATGAT 1020
1021 GGCCTTCACAGCTGGGACACACCAATGCCAGCATCATGCTATTTGTTCAGAGGCGCGT 1080
1021 GGCCTTCACAGCTGGGACACACCAATGCCAGCATCATGCTATTTGTTCAGAGGCGCGT 1080
1081 CAGCAGGTGAGCAACCGGACCTTCAGAGGAGGCGAGCTGCTGCTGCTGCTGCTGCTTCT 1140
1081 CAGCAGGTGAGCAACCGGACCTTCAGAGGAGGCGAGCTGCTGCTGCTGCTGCTGCTTCT 1140
1141 GGTCTTGACCTGCTTCTCAATTTTGTGATGATGATGATGATGATGATGATGATGATGAT 1200
1141 GGTCTTGACCTGCTTCTCAATTTTGTGATGATGATGATGATGATGATGATGATGATGAT 1200
1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAC 1320
1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAC 1320
1321 AAGAATATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGAAATTTGAAATTTG 1380
1321 AAGAATATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGAAATTTGAAATTTG 1380
1381 TTTAGTCAATGGAATTTCTTTTCCAAACCGGGAAGAACACAGCACACCCGGGTTGGA 1440
1381 TTTAGTCAATGGAATTTCTTTTCCAAACCGGGAAGAACACAGCACACCCGGGTTGGA 1440
1441 CCCACTGCAAGCTGCTGCAACCTCTTTGTCAGTGTGGGCAAGGGCTCAGCCTC 1500
1441 CCCACTGCAAGCTGCTGCAACCTCTTTGTCAGTGTGGGCAAGGGCTCAGCCTC 1500
1501 TCTGCCACAGAGTGCCTCCACAGTGAACATTTCTGAGCTGGCCATCCCAATTAATCA 1560
1501 TCTGCCACAGAGTGCCTCCACAGTGAACATTTCTGAGCTGGCCATCCCAATTAATCA 1560
1561 GTCCATAGAGACGACAGATGAGACCTTCGGGCCCAAGCGTGGGCTCGCGGCACTTTG 1620

1561 GTCCATAGAGACAGACATGAGACCTTCGGCCCAAGCGTGGCGCTGGGCACTTTG 1620
1621 GTAGACTGTGCCACACCGCGCTGTGTGTAACCTGAAATTAAGAGCAAAAAA 1679
1621 GTAGACTGTGCCACACCGCGCTGTGTGTAACCTGAAATTAAGAGCAAAAAA 1679

RESULT 120
ADE05843
ID ADE05843 standard; cDNA; 1679 BP.
XX ADE05843;
XX AC
XX XX
XX 29-JAN-2004 (first entry)
XX XX
XX Human PRO polynucleotide #63.
XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW arthritis; sports injury; cytostatic; antiarthritic.
XX
OS Homo sapiens.
XX
XX US2003100728-A1.
XX XX
XX 29-MAY-2003.
XX PD
XX 28-AUG-2002; 2002US-00230024.
XX PF
XX 01-JUN-2001; 2001WO-US017800.
XX PR
XX 29-JUN-2001; 2001WO-US021066.
XX PR
XX 09-APR-2002; 2002US-00119480.
XX XX
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephen JF, Watanabe CK, Wood WI;
XX WPI; 2004-008978/01.
XX P-PSDB; ADE05844.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
XX in gene therapy, or for preparing a medicament for treating a condition
XX that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
XX cancer.
XX Claim 2; Fig 125; 308pp; English.
XX
XX The invention relates to human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the PRO polynucleotides encoding them.
XX The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
XX diagnostics, biosensors or bioreactors. They are particularly useful for
XX detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
XX prostate tumour, rectal tumour or liver tumour) in a mammal, for
XX stimulating the release of tumour necrosis factor (TNF)-alpha from human
XX blood, for stimulating the proliferation or differentiation of
XX chondrocyte cells, for stimulating the proliferation of or gene
XX expression in pericyte cells or for stimulating the proliferation of
XX normal human dermal fibroblasts. The PRO nucleic acids are useful as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA, in preparing PRO polypeptides, by recombinant
XX technology, in generating transgenic animals or knock-out animals which
XX may be used in the development and screening of therapeutically useful
XX reagents, in gene therapy, in chromosome identification, as chromosome
XX markers, in generating probes. The PRO polypeptides, or anti-PRO
XX antibodies, are useful for preparing a medicament for treating a
XX condition which is responsive to the PRO polypeptides or anti-PRO
XX antibodies, such as pericyte-associated tumours and bone and/or cartilage
XX disorders (e.g. arthritis, sports injuries), involving inducing the re-
XX differentiation of chondrocytes. The PRO polypeptides are useful as

CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention.

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6,7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	GTGTGTCCTTACGAAACAGTGGATTAAATCTCTCTGCAACAGCTTGAGAGCAAC	60
Db	1	GTGTGTCCTTACGAAACAGTGGATTAAATCTCTCTGCAACAGCTTGAGAGCAAC	60
Qy	61	AATCTATCAGGAAGAAAGAAAGAAACCGAACTGACAAAGAAAGAAAGAAAG	120
Db	61	AATCTATCAGGAAGAAAGAAAGAAACCGAACTGACAAAGAAAGAAAGAAAG	120
Qy	121	AAGAAAAAATCATGAARACCATCCAGCCAAATAATGCAATCTCTCTTGGCAAT	180
Db	121	AAGAAAAAATCATGAARACCATCCAGCCAAATAATGCAATCTCTCTTGGCAAT	180
Qy	181	CTTCAAGGGGTGGCTGCTCTGTCTCTTCCAGAGTGGCCGTGCGAGCGGAGATGC	240
Db	181	CTTCAAGGGGTGGCTGCTCTGTCTCTTCCAGAGTGGCCGTGCGAGCGGAGATGC	240
Qy	241	CACCTTCCCAAGCTATGACACGTGACGGTCCGGCAGGGGGAGCGCCACCTCAG	300
Db	241	CACCTTCCCAAGCTATGACACGTGACGGTCCGGCAGGGGGAGCGCCACCTCAG	300
Qy	301	GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCATCTCTA	360
Db	301	GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCATCTCTA	360
Qy	361	TGCTGGGAATGCAAGTGGTGGTGGATCTCTGGTGGTGGTCTTCTGAGCAACCCAAAC	420
Db	361	TGCTGGGAATGCAAGTGGTGGTGGATCTCTGGTGGTGGTCTTCTGAGCAACCCAAAC	420
Qy	421	GCAGTACAGCATCAGATCCAGAACGTGGATGTATGACGAGGGCCCTTACACCTGCTC	480
Db	421	GCAGTACAGCATCAGATCCAGAACGTGGATGTATGACGAGGGCCCTTACACCTGCTC	480
Qy	481	GGTCAGACAGCAACCAACCAAGACCTCTAGGGTCCACTCATTTGTGCAAGTATCTCC	540
Db	481	GGTCAGACAGCAACCAACCAAGACCTCTAGGGTCCACTCATTTGTGCAAGTATCTCC	540
Qy	541	CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC	600
Db	541	CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC	600
Qy	601	CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTTGAGAGACATCTCTCCCAAAGC	660
Db	601	CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTTGAGAGACATCTCTCCCAAAGC	660
Qy	661	GGTTGGCTTTGTGAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720
Db	661	GGTTGGCTTTGTGAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720
Qy	721	AGGGGACTACGAGTGCAGTGCCTTCCAAATGAGCTGGCCGCGCTGGTGTACGGAGATAA	780
Db	721	AGGGGACTACGAGTGCAGTGCCTTCCAAATGAGCTGGCCGCGCTGGTGTACGGAGATAA	780
Qy	781	GCTCACCGTGAATCTATCCACATCATTTGAGAGCAAGGTACAGCTTCCCGTGG	840
Db	781	GCTCACCGTGAATCTATCCACATCATTTGAGAGCAAGGTACAGCTTCCCGTGG	840
Qy	841	ACAAAGGGGACACTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAATTCAGTGGTA	900
Db	841	ACAAAGGGGACACTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAATTCAGTGGTA	900
Qy	901	CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT	960
Db	901	CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT	960

Qy	961	CCTCTCAAAACTCATCTCTTCAATGCTCTGAAACATGATGGAACTACACTTCGCT	1020
Db	961	CCTCTCAAAACTCATCTCTTCAATGCTCTGAAACATGATGGAACTACACTTCGCT	1020
Qy	1021	GGCTTCCAAACAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT	1080
Db	1021	GGCTTCCAAACAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT	1080
Qy	1081	CAGCGAGTGAAGCAACCGCACGTCGAGGAGGCGAGGTGGCTGTGGTGTCTCTTCT	1140
Db	1081	CAGCGAGTGAAGCAACCGCACGTCGAGGAGGCGAGGTGGCTGTGGTGTCTCTTCT	1140
Qy	1141	GGTCTTGCACTGCTTCTCAAAATTTGATGTAGTGCACCTTCCACCCGGGAAAGCT	1200
Db	1141	GGTCTTGCACTGCTTCTCAAAATTTGATGTAGTGCACCTTCCACCCGGGAAAGCT	1200
Qy	1201	GCCGCCACACACACCAACCAACAGCAATGCAACAGCAGCAAGCAACCAATCAGATA	1260
Db	1201	GCCGCCACACACACCAACCAACAGCAATGCAACAGCAGCAAGCAACCAATCAGATA	1260
Qy	1261	TATACAAATGAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAAC	1320
Db	1261	TATACAAATGAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAAC	1320
Qy	1321	AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCCCTTCAGATA	1380
Db	1321	AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCCCTTCAGATA	1380
Qy	1381	TTTAGGTAACAATGAGATTTCTTTCCAAACGGGAAAGAACACAGCACACCCGGCTTGGG	1440
Db	1381	TTTAGGTAACAATGAGATTTCTTTCCAAACGGGAAAGAACACAGCACACCCGGCTTGGG	1440
Qy	1441	CCACTGCAAGCTGATCGTCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC	1500
Db	1441	CCACTGCAAGCTGATCGTCAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC	1500
Qy	1501	TCGCCCCACAGAGTCCCGCCACGTGGAAACATCTTGGAGCTGGCCATCCCAATTCATCA	1560
Db	1501	TCGCCCCACAGAGTCCCGCCACGTGGAAACATCTTGGAGCTGGCCATCCCAATTCATCA	1560
Qy	1561	GTCCATAGAGAGCAAGCAATGAGACCTTCCGGCCAGCGTGGCGTCCGGGCACTTTG	1620
Db	1561	GTCCATAGAGAGCAAGCAATGAGACCTTCCGGCCAGCGTGGCGTCCGGGCACTTTG	1620
Qy	1621	GTAGACTGTGCCACACCGCGTGTGTGTGAAACGTGAAATATAAAGAGCAAAAAAAA	1679
Db	1621	GTAGACTGTGCCACACCGCGTGTGTGTGAAACGTGAAATATAAAGAGCAAAAAAAA	1679

RESULT 121
ADD76560
ID ADD76560 standard; cDNA; 1679 BP.

XX AC ADD76560;

XX XX 29-JAN-2004 (first entry)

XX DE Human PRO polynucleotide #188.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

OS Homo sapiens.

XX XX US2003100087-A1.

PN

XX PD 29-MAY-2003.
XX PF 16-APR-2002; 2002US-00123912.
XX PF 31-MAR-1997; 97WO-US0052230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 17-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98WO-US019437.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 05-OCT-1999; 99WO-US021547.
PR 25-NOV-1999; 99WO-US023089.
PR 30-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 08-JAN-2000; 2000WO-US000277.
PR 08-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 11-JUL-2000; 2000WO-US020710.
PR 28-JUL-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.

01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000US-00747259.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001US-00796498.
28-FEB-2001; 2001WO-US006520.
01-MAR-2001; 2001WO-US006666.
09-MAR-2001; 2001US-00802706.
14-MAR-2001; 2001US-00806889.
22-MAR-2001; 2001US-00816744.
05-APR-2001; 2001US-00828366.
10-MAY-2001; 2001US-00854208.
10-MAY-2001; 2001US-00854280.
18-MAY-2001; 2001US-00860216.
25-MAY-2001; 2001US-00866028.
25-MAY-2001; 2001US-00866034.
25-MAY-2001; 2001WO-US017092.
01-JUN-2001; 2001US-00872035.
01-JUN-2001; 2001WO-US017800.
05-JUN-2001; 2001US-00874503.
14-JUN-2001; 2001US-00882636.
19-JUN-2001; 2001US-00886342.
20-JUN-2001; 2001WO-US019692.
21-JUN-2001; 2001US-00887879.
22-JUN-2001; 2001WO-US020116.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
09-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2004-0089956/01.
P-PSDB; ADD76561.
New PRO nucleic acid, useful for recombinantly producing a PRO polypeptide and for manufacturing a medicament for diagnosing or treating a tumor.
Claim 2; Fig 375; 63pp; English.
The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems,

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGTGCAAGACTTGGAGCAACAC 60
DB 1 GTTGTCTCTTCAGCAAAACAGTGGATTAAATCTCTTGTGCAAGACTTGGAGCAACAC 60
QY 61 ATCTATCAGGAAGAAAGAAAGAAAAACCGAACCTGACAAAAAAGAAAAAGAAAG 120
DB 61 ATCTATCAGGAAGAAAGAAAGAAAAACCGAACCTGACAAAAAAGAAAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAACCAATCAGCCAAATTCGCAAAATTCATCTCTTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAACCAATCAGCCAAATTCGCAAAATTCATCTCTTTGGGCAAT 180
QY 181 CTTTCAGGGGCTGGCTGCTGTGTCTCTTCCAGGAGTCCCGTGCAGCGGAGATGC 240
DB 181 CTTTCAGGGGCTGGCTGCTGTGTCTCTTCCAGGAGTCCCGTGCAGCGGAGATGC 240
QY 241 CACCTTCCCCAAAGCTATGGAACAGTGGTTCGGGTCAGGAGGAGCGCCACCTCTCAG 300
DB 241 CACCTTCCCCAAAGCTATGGAACAGTGGTTCGGGTCAGGAGGAGCGCCACCTCTCAG 300
QY 301 GTGCACTATTGACACCGGCTACCGGGTGGCTGGCTTAAACCGCAGCACCATCTCTTA 360
DB 301 GTGCACTATTGACACCGGCTACCGGGTGGCTTAAACCGCAGCACCATCTCTTA 360
QY 361 TGTGGGAATGACAAGTGGTGGCTGGATCTCTCGGTGGTCTTCTTGTGCAAGTATCTCC 420
DB 361 TGTGGGAATGACAAGTGGTGGCTGGATCTCTCGGTGGTCTTCTTGTGCAAGTATCTCC 420
QY 421 GCAGTACAGCATCGAGATCAGAAACGTGGATGTGTATGACGAGGGGCGCTTACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCAGAAACGTGGATGTGTATGACGAGGGGCGCTTACCTGCTC 480
QY 481 GGTGCAAGACAGAACCAACCAAGACCTTAGGGTCCACTTATGTGCAAGTATCTCC 540
DB 481 GGTGCAAGACAGAACCAACCAAGACCTTAGGGTCCACTTATGTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCACTGGTAGACAGAGCCTACGGTTACTTTGAGAGACATCTCTCCAAAGC 660
DB 601 CTGCATAGCACTGGTAGACAGAGCCTACGGTTACTTTGAGAGACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTCCCTCCATGACGTGGCGCGCCCGTGTACGGAGAGTAA 780
DB 721 AGGGGACTACGAGTGCAGTCCCTCCATGACGTGGCGCGCCCGTGTACGGAGAGTAA 780
QY 781 GGTCAACCGTGAACATATCCACCATATCTTCAAGAGCCAGGGTACAGGTGTCCCGTGG 840
DB 781 GGTCAACCGTGAACATATCCACCATATCTTCAAGAGCCAGGGTACAGGTGTCCCGTGG 840
QY 841 ACAAAGGGGACACTGAGTGTGAGCTCAGCAAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 ACAAAGGGGACACTGAGTGTGAGCTCAGCAAGTCCCTCAGCAGAAATTCAGTGGTA 900
```

```
QY 901 CAAGGATGACAAAGACTGATTGAAGCAAGAAAGGGTGAAGTGGAAAAACAGACCTTT 960
DB 901 CAAGGATGACAAAGACTGATTGAAGCAAGAAAGGGTGAAGTGGAAAAACAGACCTTT 960
QY 961 CCTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGAACCTACACTTGC 1020
DB 961 CCTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGAACCTACACTTGC 1020
QY 1021 GGCTTCCAAAGCTGGGCCACACCAATGCCAGCATCTGCTATTTGGTCCAGGCGCGT 1080
DB 1021 GGCTTCCAAAGCTGGGCCACACCAATGCCAGCATCTGCTATTTGGTCCAGGCGCGT 1080
QY 1081 CAGCGAGTGCAGCAACCGGCACGCTCGAGGAGGGCAGGCTCTGGCTGTGGCTCTTCT 1140
DB 1081 CAGCGAGTGCAGCAACCGGCACGCTCGAGGAGGGCAGGCTCTGGCTGTGGCTCTTCT 1140
QY 1141 GGTCTTGCACCTGCTTCTCAAAATTTGATGTGTGTCACCTTCCCAACCCGGGAAAGGCT 1200
DB 1141 GGTCTTGCACCTGCTTCTCAAAATTTGATGTGTGTCACCTTCCCAACCCGGGAAAGGCT 1200
QY 1201 GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAT 1260
DB 1201 GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAT 1260
QY 1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATGGACAGAAATTTGAGGGAGGGAAC 1320
DB 1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATGGACAGAAATTTGAGGGAGGGAAC 1320
QY 1321 AAGAATACCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB 1321 AAGAATACCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGGTACATGGAGTTTCTTTTCCAAAACGGGAGAAACACAGCACACCCGGCTTGA 1440
DB 1381 TTTAGGTACATGGAGTTTCTTTTCCAAAACGGGAGAAACACAGCACACCCGGCTTGA 1440
QY 1441 CCCACTGCAAGCTGCATCGTGCACCTTTTGGTGGCAGTGGGCAAGGCTCAGGCTC 1500
DB 1441 CCCACTGCAAGCTGCATCGTGCACCTTTTGGTGGCAGTGGGCAAGGCTCAGGCTC 1500
QY 1501 TCTGCCCAACAGAGTGGCCCAACGTCGGAACATTTCTGGAGCTGGCCATCCCAATTC 1560
DB 1501 TCTGCCCAACAGAGTGGCCCAACGTCGGAACATTTCTGGAGCTGGCCATCCCAATTC 1560
QY 1561 GTCCATAGAGACGAACAGAAATGAGACCTTCCGGCCCAAGCGTGGGCTGCGGCACTTTG 1620
DB 1561 GTCCATAGAGACGAACAGAAATGAGACCTTCCGGCCCAAGCGTGGGCTGCGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCAACCGCGCTGTGTGTGAAACGTGAAATATAAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACCAACCGCGCTGTGTGTGAAACGTGAAATATAAGAGCAAAAAA 1679
```

RESULT 122

ADD75072

ID ADD75072 standard; cDNA; 1679 BP.

XX ADD75072;

XX 29-JAN-2004 (first entry)

XX Human PRO polynucleotide #63.

XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
XX tumour; cancer; lung; colon; breast; prostate; liver;
XX tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
XX pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
XX arthritis; sports injury; cytostatic; antiarthritic.

OS Homo sapiens.

XX US2003100712-A1.

PN

XX PD 29-MAY-2003.
XX PF 09-AUG-2002; 2002US-00216168.
XX PR 01-JUN-2001; 2001WO-US017800.
XX PR 29-JUN-2001; 2001WO-US021066.
XX PR 09-APR-2002; 2002US-00119480.
XX PA (GETH) GENENTECH INC.
XX PI Baker KP, Deenoyers L, Gerritsen ME, Goddard A, Godowski PV;
XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JP, Watanabe CK, Wood WI;
XX DR WPI; 2004-008962/01.
XX DR P-PSDB; ADD75073.
XX PT New secreted and transmembrane PRO polypeptide useful for preparing a
XX PT medicament for treating a condition that is responsive to the PRO
XX PT polypeptide or anti-PRO antibody, e.g. cancer.
XX PS Claim 2; Fig 125; 308pp; English.
XX CC The invention relates to human PRO polypeptides (secreted and
XX CC transmembrane polypeptides) and the PRO polynucleotides encoding them.
XX CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
XX CC diagnostics, biosensors or bioreactors. They are particularly useful for
XX CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
XX CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
XX CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
XX CC blood, for stimulating the proliferation or differentiation of
XX CC chondrocyte cells, for stimulating the proliferation of or gene
XX CC expression in pericyte cells or for stimulating the proliferation of
XX CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
XX CC hybridisation probes, in chromosome and gene mapping, in generating
XX CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
XX CC technology, in generating transgenic animals or knock-out animals which
XX CC may be used in the development and screening of therapeutically useful
XX CC reagents, in gene therapy, in chromosome identification, as chromo-
XX CC markers and in generating probes. The PRO polypeptides, or anti-PRO
XX CC antibodies, are useful for preparing a medicament for treating a
XX CC condition which is responsive to the PRO polypeptides or anti-PRO
XX CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
XX CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
XX CC differentiation of chondrocytes. The PRO polypeptides are useful as
XX CC molecular markers for protein electrophoresis, and in tissue typing. This
XX CC sequence represents a human PRO polynucleotide of the invention. Note:
XX CC The sequence data for this patent can also be obtained in electronic
XX CC format directly from USPTO at seqdata.uspto.gov/sequence.html.
XX SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6,7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCTTGACAAAGCTTGAGCAACAC 60
DB 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCTTGACAAAGCTTGAGCAACAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAGAAATCATGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
DB 121 AAGAAAGAAATCATGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
QY 181 CTTTCAGGGGGCTGGCTGTCTGTCTCTTCCAGGAGTCCCGTCCAGCGAGATGC 240
DB 181 CTTTCAGGGGGCTGGCTGTCTGTCTCTTCCAGGAGTCCCGTCCAGCGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGACAAAGTACGGTCCGGCGGGGAGAGCGCCACCTTCAG 300

DB 241 CACCTTCCCAAGCTATGGACAAAGTACGGTCCGGCGGGGAGAGCGCCACCTTCAG 300
QY 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGACCACTCTCTA 360
DB 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGACCACTCTCTA 360
QY 361 TCGTGGATGACAAAGTGGTGGATCCCTGGATCCCTGGTGGTCTCTTGAGACACACCAAC 420
DB 361 TCGTGGATGACAAAGTGGTGGATCCCTGGATCCCTGGTGGTCTCTTGAGACACACCAAC 420
QY 421 CAGATACAGCATCGAGATCCAGAAAGTGGATGTGTATGACGAGGCGCTTACACCTGTC 480
DB 421 CAGATACAGCATCGAGATCCAGAAAGTGGATGTGTATGACGAGGCGCTTACACCTGTC 480
QY 481 GTGCAAGACAGCAACCAACCGGCTTAGGGTCCAGCTCATTTGCAAGTATCTCC 540
DB 481 GTGCAAGACAGCAACCAACCGGCTTAGGGTCCAGCTCATTTGCAAGTATCTCC 540
QY 541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
DB 541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCACTGTAGACAGACCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
DB 601 CTGCATAGCACTGTAGACAGACCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTAGTGAAGACCAATATCTGAAATTCAGGSCATCACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTAGTGAAGACCAATATCTGAAATTCAGGSCATCACCCGGGAGCAGTC 720
QY 721 AGGGACTACGAGTGCCTCAATGACGTGGCGCGCGCGCGGTGGTACGGAGAGTAAA 780
DB 721 AGGGACTACGAGTGCCTCAATGACGTGGCGCGCGCGCGGTGGTACGGAGAGTAAA 780
QY 781 GGTACCGTGAATCTACCACTATCAATTTCAAGCCAAAGGTACAGGTGTCCCGTGG 840
DB 781 GGTACCGTGAATCTACCACTATCAATTTCAAGCCAAAGGTACAGGTGTCCCGTGG 840
QY 841 ACAAAGGGGACACTGAGTGAAGCTTCAAGCTTCCAGTGTCCCTCAGCAGAAATTCAGTGT 900
DB 841 ACAAAGGGGACACTGAGTGAAGCTTCAAGCTTCCAGTGTCCCTCAGCAGAAATTCAGTGT 900
QY 901 CAGGATGACAAAGACTGATTGAAGGAAAGAAAGGTTGAAGTGAAGTGAAGTGAAGTGAAGT 960
DB 901 CAGGATGACAAAGACTGATTGAAGGAAAGAAAGGTTGAAGTGAAGTGAAGTGAAGTGAAGT 960
QY 961 CTTCTCAAAACTCATCTTCTCAATGTCTCTCAATGTCTCTCAATGTCTCTCAATGTCTCT 1020
DB 961 CTTCTCAAAACTCATCTTCTCAATGTCTCTCAATGTCTCTCAATGTCTCTCAATGTCTCT 1020
QY 1021 GGCCTCCAAAGCTGGGCGCACCAATGCCAGCATCATGCTATTGTTGTCAGGCGCGT 1080
DB 1021 GGCCTCCAAAGCTGGGCGCACCAATGCCAGCATCATGCTATTGTTGTCAGGCGCGT 1080
QY 1081 CAGCGAGGTGAGCAACCGGCACTGAGGAGGCGAGGCTGCGTCTGCTGCTGCTCTTCT 1140
DB 1081 CAGCGAGGTGAGCAACCGGCACTGAGGAGGCGAGGCTGCGTCTGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGCACCTGCTCTCAATTTTGTGAGTGCCACTTCCCGCCCGGGGAGGCT 1200
DB 1141 GGTCTTGCACCTGCTCTCAATTTTGTGAGTGCCACTTCCCGCCCGGGGAGGCT 1200
QY 1201 GCGGCCACCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
DB 1201 GCGGCCACCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
QY 1261 TATACAAATGAATTTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAC 1320
DB 1261 TATACAAATGAATTTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAC 1320
QY 1321 AAGAAATATCTTTGGGGGAGAGAGTTTTTAAAAAGAAATTTGAAATTTCCCTTGCAGATA 1380

CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (III) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO229, PRO1272 or PRO405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.

XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTCTGCAAAAGTTGAGAGCAACAC 60
DB 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTCTGCAAAAGTTGAGAGCAACAC 60
QY 61 AATCTATCAGGAAGAAGAAAGAAACCGAACTTGACAAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAGAAAGAAACCGAACTTGACAAAAGAAAGAAAG 120
QY 121 AAGAAATAATCATGAAACCATCCAGCCAAATTCACAAATTCCTCTGCGCAAT 180
DB 121 AAGAAATAATCATGAAACCATCCAGCCAAATTCACAAATTCCTCTGCGCAAT 180
QY 181 CTTCAAGGGGTGGCTGCTCTGTGTCTCTTCCAGGAGTGGCGTGGCAGCGAGATGC 240
DB 181 CTTCAAGGGGTGGCTGCTCTGTGTCTCTTCCAGGAGTGGCGTGGCAGCGAGATGC 240
QY 241 CACTTCCCAAGCTATGACACCTGACAGCTGAGCTCGGCGGGGAGCGCCACCTCAG 300
DB 241 CACTTCCCAAGCTATGACACCTGACAGCTGAGCTCGGCGGGGAGCGCCACCTCAG 300
QY 301 GTGCACTATTGCAACCGGGTCAACCGGGTGGCTTAAACCGGAGCACTCTCTTA 360
DB 301 GTGCACTATTGCAACCGGGTCAACCGGGTGGCTTAAACCGGAGCACTCTCTTA 360
QY 361 TGCTGGAGATGCAAGTGGTGGCTGGATCTCTGGTGGTCTCTTGAGCAACCCAAAC 420
DB 361 TGCTGGAGATGCAAGTGGTGGCTGGATCTCTGGTGGTCTCTTGAGCAACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTATGACGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTATGACGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGACAGACAGCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGACAGACAGCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAATAATTGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
DB 541 CAATAATTGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGATAGCAACTCGGTAGACAGAGCCTACGGTTACTTTGAGAGACATCTCTCCAAAGC 660
DB 601 CTGATAGCAACTCGGTAGACAGAGCCTACGGTTACTTTGAGAGACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGCAATCTTGGAAATTCAGGGCATCACCCGGAGCAGTC 720
DB 661 GGTGGCTTTGTGAGTGAAGCAATCTTGGAAATTCAGGGCATCACCCGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTTCAATGACGTGGCGCCCGCTGTGTA CGGAGATPAA 780
DB 721 AGGGGACTACGAGTGCAGTGCCTTCAATGACGTGGCGCCCGCTGTGTA CGGAGATPAA 780
QY 781 GGTCAACCGTGACATATCCACCATATTCAGAGCCAGGGGTACAGTGTCCCGCTGGG 840

DB 781 GGTCAACCGTGACATATCCACCATATTTTCCAGAGCCAGGGTACAGGTGTCCCGTGGG 840
QY 841 ACAAAGGGGAGCACTGAGTGTGAAGCTTGAAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 ACAAAGGGGAGCACTGAGTGTGAAGCTTGAAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGGATCAGAAAAGACTGATTGAAGCAAGAAAGGGGTGAAAGTGGAAAACAGACCTTT 960
DB 901 CAAGGATCAGAAAAGACTGATTGAAGCAAGAAAGGGGTGAAAGTGGAAAACAGACCTTT 960
QY 961 CCTCTCAAAACTCATCTCTTCAATGTCTTGAACATGATCTATGGAACATACACTTGGT 1020
DB 961 CCTCTCAAAACTCATCTCTTCAATGTCTTGAACATGATCTATGGAACATACACTTGGT 1020
QY 1021 GGCCTCCAAACAGCTGGGCCACACCAATGCCAGCATCATGTATTTGGTCCAGCGCCGT 1080
DB 1021 GGCCTCCAAACAGCTGGGCCACACCAATGCCAGCATCATGTATTTGGTCCAGCGCCGT 1080
QY 1081 CAGCGAGTGTAGCAACCGCACGTGAGGAGGCGAGGTGCGTCTGGTGTCTCTTCT 1140
DB 1081 CAGCGAGTGTAGCAACCGCACGTGAGGAGGCGAGGTGCGTCTGGTGTCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTCTCAAAATTTTGAATGTGAGTGGCCACTTCCCAACCGGGAAGGCT 1200
DB 1141 GGTCTTGACCTGCTCTCAAAATTTTGAATGTGAGTGGCCACTTCCCAACCGGGAAGGCT 1200
QY 1201 GCGCCACCAACCAACCAACCAACAGCAATGCAACAGCAAGCAACCAATCAGATA 1260
DB 1201 GCGCCACCAACCAACCAACCAACAGCAATGCAACAGCAAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATTTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
DB 1261 TATACAAATGAATTTAGAGAAACACAGCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
QY 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCCCTTCAGATA 1380
DB 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCCCTTCAGATA 1380
QY 1381 TTTAGGTCAATGAGTTTCTTTTCCAAACGGGAGAACACAGCACACCGGCTTGA 1440
DB 1381 TTTAGGTCAATGAGTTTCTTTTCCAAACGGGAGAACACAGCACACCGGCTTGA 1440
QY 1441 CCCACTGCAAGCTGATCGTCAACCTCTTTGGTGGCAGTGTGGCAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGATCGTCAACCTCTTTGGTGGCAGTGTGGCAGGGCTCAGCCTC 1500
QY 1501 TCTGCCCAAGAGTCCCCCAGTGGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCCAAGAGTCCCCCAGTGGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGCGACAGATGAGACCTTCCGGCCCAAGCTGGCGCTGGCGGCACTTTG 1620
DB 1561 GTCCATAGAGCGACAGATGAGACCTTCCGGCCCAAGCTGGCGCTGGCGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCAACCGCTGTGTGTGAAACGTGAAATTAAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACCAACCGCTGTGTGTGAAACGTGAAATTAAGAGCAAAAAA 1679

RESULT 125

ADD86876
ID ADD86876 standard; cDNA; 1679 BP.

XX

AC ADD86876;

XX
DT 29-JAN-2004 (first entry)

XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.

XX
KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnery; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;

Db 1021 GGCCTCCAAAGCTGGGCCACCAACATGCGCAGCATCATGCTATTGTTGCTCCAGGCGCGT 1080
Qy 1081 CAGCGAGGTGAGCAACGGCAGCTCGAGAGGGCAGCGCTGCTGCTGCTGCTGCTTCT 1140
Db 1081 CAGCGAGGTGAGCAACGGCAGCTCGAGAGGGCAGCGCTGCTGCTGCTGCTTCT 1140
Qy 1141 GGTCTTGGACCTGCTTCTCAAAATTTTGTATGAGTGCCACTTCCCGCAGCGGAAAGCT 1200
Db 1141 GGTCTTGGACCTGCTTCTCAAAATTTTGTATGAGTGCCACTTCCCGCAGCGGAAAGCT 1200
Qy 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Db 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Qy 1261 TATACAAATGAATATGAGAAACACAGAGCTCATGGGACAGAAATTTGAGGAGGCGGAAC 1320
Db 1261 TATACAAATGAATATGAGAAACACAGAGCTCATGGGACAGAAATTTGAGGAGGCGGAAC 1320
Qy 1321 AAAGAATACCTTTGGGGGAAAGAGTTTAAAGAAATGAAATGCAATGCGTTGAGATA 1380
Db 1321 AAAGAATACCTTTGGGGGAAAGAGTTTAAAGAAATGCAATGCGTTGAGATA 1380
Qy 1381 TTTAGTACATGAGTGTCTTTTCCCAACGGGAGAACACAGACACACCGCGCTTGA 1440
Db 1381 TTTAGTACATGAGTGTCTTTTCCCAACGGGAGAACACAGACACACCGCGCTTGA 1440
Qy 1441 CCCACTGCAAGCTGCACTGTCGAACCTTTTGTGTCAGCTGGGCAAGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGCACTGTCGAACCTTTTGTGTCAGCTGGGCAAGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGCCTCCACAGCTGGAACATTTCTGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCACAGCTGGAACATTTCTGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGACAGCAAGATGAGACTTCCGGCCCAAGCGTGGCGCTCGGCGCACTTTG 1620
Db 1561 GTCCATAGACAGCAAGATGAGACTTCCGGCCCAAGCGTGGCGCTCGGCGCACTTTG 1620
Qy 1621 GTAGACTGTCCACCGCGCTGTGTTGTGAACGTTGTTGAAACGTTGAAATATAAGACCAAAAA 1679
Db 1621 GTAGACTGTCCACCGCGCTGTGTTGTGAACGTTGTTGAAACGTTGAAATATAAGACCAAAAA 1679

RESULT 126
ADE20753
ID ADE20753 standard; cDNA; 1679 BP.
XX
AC ADE20753;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnery; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
FN US2003100734-A1.
XX
PD 29-MAY-2003.
XX
FF 28-AUG-2002; 2002US-00230427.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.

PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
PA Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
PI WPI; 2004-008984/01.
XX P-PSDB; ADE20754.
XX
PT New PRO polypeptide and nucleic acid encoding the polypeptide, useful in
PT gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX
PS Claim 2; Fig 125; 308pp; English.
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO259, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGAGCAAC 60
Qy 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAAAATCATGAAAAACCATCCAGCAAAATGCAAAATCTATCTCTTGGGCAAT 180
Db 121 AAGAAAAAATCATGAAAAACCATCCAGCAAAATGCAAAATCTATCTCTTGGGCAAT 180
Qy 181 CTTTCAGGGGCTGGCTGCTCTGTGTCTCTTTCAGAGAGTGCCTGCGCAGCGGAGATGC 240
Db 181 CTTTCAGGGGCTGGCTGCTCTGTGTCTCTTTCAGAGAGTGCCTGCGCAGCGGAGATGC 240

QY 241 CACCTTCCCAAGCTATGGAACACGTCGCGTCCGACGGGGAGAGCCCACTCTCAG 300
DB 241 CACCTTCCCAAGCTATGGAACACGTCGCGTCCGACGGGGAGAGCCCACTCTCAG 300
QY 301 GTGCACCTATTGACAAACCGGCTCACCCGGGTGGCTGGCTTAAACCGCAGCACCACTCTCTA 360
DB 301 GTGCACCTATTGACAAACCGGCTCACCCGGGTGGCTGGCTTAAACCGCAGCACCACTCTCTA 360
QY 361 TGCTGGGAATGACAAGTGGTGGTCCCTGGATCCTCGCGTGGTCTCTCTGAGCAACACCCAAAC 420
DB 361 TGCTGGGAATGACAAGTGGTGGTCCCTGGATCCTCGCGTGGTCTCTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACGAGTACGAGATCCAGACCTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACGAGTACGAGATCCAGACCTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGCAGACACAAACCAACCAAGAGCCTTAGGGTCCACTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGCAGACACAAACCAACCAAGAGCCTTAGGGTCCACTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGGAAACAATATTAGCCTCAC 600
DB 541 CAAATTTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGGAAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGTGACAGAGCCTTAGCGTTACTTTGGAGACACATCTCTCCAAAGC 660
DB 601 CTGCATAGCAACTGTGACAGAGCCTTAGCGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTAGTGAAGACGAATATCTGGAATTCAGGGCATACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTAGTGAAGACGAATATCTGGAATTCAGGGCATACCCGGGAGCAGTC 720
QY 721 AGGGACCTACGAGTGCAGTGCCTCAATGAGTGGCGCGCGCTGTGAGAGAGTAAA 780
DB 721 AGGGACCTACGAGTGCAGTGCCTCAATGAGTGGCGCGCGCTGTGAGAGAGTAAA 780
QY 781 GGTCAACCGTGAACATACCAACATANTTCAGAACCCAGGGTACAGGTGTCCTCGTGG 840
DB 781 GGTCAACCGTGAACATACCAACATANTTCAGAACCCAGGGTACAGGTGTCCTCGTGG 840
QY 841 ACAAAGGGGACATCGAGTGTGAGCCTCAGCAGTCCCTCAGCAGATTCACAGTGGTA 900
DB 841 ACAAAGGGGACATCGAGTGTGAGCCTCAGCAGTCCCTCAGCAGATTCACAGTGGTA 900
QY 901 CAAGGATGACAAAGACTGATTGAAGGAAGAGGGGTGAAAGTGGAACACAGACCTTT 960
DB 901 CAAGGATGACAAAGACTGATTGAAGGAAGAGGGGTGAAAGTGGAACACAGACCTTT 960
QY 961 CCTCTCAAACTCATCTCTTCAATGTCTCTGACATGACTATGGGACTACACTGGCT 1020
DB 961 CCTCTCAAACTCATCTCTTCAATGTCTCTGACATGACTATGGGAACTACACTTGGCT 1020
QY 1021 GGCCTCCAAAGCTGGGCGCACCAATGCCAGCATCATGCTATTGTCAGGCGCGCT 1080
DB 1021 GGCCTCCAAAGCTGGGCGCACCAATGCCAGCATCATGCTATTGTCAGGCGCGCT 1080
QY 1081 CAGCAGGTGAGCAACGGCAGCGTCGAGAGGGCAGGCTGCGTCTGGCTGCTCTCTCT 1140
DB 1081 CAGCAGGTGAGCAACGGCAGCGTCGAGAGGGCAGGCTGCGTCTGGCTGCTCTCTCTCT 1140
QY 1141 GGTCTTGCACTGCTCTCTCAATTTTGTGAGTGGCCACTTCCCAACCCGGGAAAGGCT 1200
DB 1141 GGTCTTGCACTGCTCTCTCAATTTTGTGAGTGGCCACTTCCCAACCCGGGAAAGGCT 1200
QY 1201 GCGGCGACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
DB 1201 GCGGCGACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
QY 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATCGGACAGAAATTTGAGGAGGGGAAC 1320
DB 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATCGGACAGAAATTTGAGGAGGGGAAC 1320

QY 1321 AAAGATACCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB 1321 AAAGATACCTTTGGGGGAAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGGTACAATGAGAGTTTCTTTTCCCAACCGGGAAGAAACACAGCACACCCGCTTGA 1440
DB 1381 TTTAGGTACAATGAGAGTTTCTTTTCCCAACCGGGAAGAAACACAGCACACCCGCTTGA 1440
QY 1441 CCCACTGCAAGCTGTCATCGTCAACCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGTCATCGTCAACCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACACAGTGTCCCGCCACGTCGGAACATCTCTGGAGCTGCCATCCCAAAATCAATCA 1560
DB 1501 TCTGCCACACAGTGTCCCGCCACGTCGGAACATCTCTGGAGCTGCCATCCCAAAATCAATCA 1560
QY 1561 GTCCATAGAGACGAACAGAAATGAGACCTTCCGCGCCCAAGCGCTGCGGCACTTTG 1620
DB 1561 GTCCATAGAGACGAACAGAAATGAGACCTTCCGCGCCCAAGCGCTGCGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACACGCGCTGTCTGTGAAACGTGAAATATAAAAGAGCAAAAAAAA 1679
DB 1621 GTAGACTGTGCCACACGCGCTGTCTGTGAAACGTGAAATATAAAAGAGCAAAAAAAA 1679

RESULT 127

ADE39050

ID ADE39050 standard; cDNA; 1679 BP.

AC ADE39050;

XX 29-JAN-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO337 cDNA.

Human; secreted and transmembrane protein; PRO; Gene; ss; cytostatic;
vulnerary; antiarthritic; pericyte cell proliferation;
pericyte cell differentiation; chondrocyte cell proliferation;
chondrocyte cell differentiation; tumour necrosis factor alpha release;
(TNF)-alpha release; dermal fibroblast cell proliferation;
dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
colon tumour; breast tumour; prostate tumour; rectal tumour;
liver tumour; tissue typing; chromosome mapping; gene mapping;
gene therapy.

XX Homo sapiens.

XX US2003096362-A1.

XX 22-MAY-2003.

XX 29-AUG-2002; 2002US-00233205.

XX 25-JUL-2000; 2000US-0220585P.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

(GETH) GENENTECH INC.

Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

Grimaldi JC, Gurney AL, Smith V, Stephen JF, Watanabe CK, Wood WI;

P-PSDB; ADE39051.

WPI; 2004-008944/01.

XX New isolated, secreted and transmembrane PRO polypeptide for diagnosing,

XX preventing and/or treating tumors, such as lung, colon, breast, prostate,

XX rectal, and/or liver tumors.

XX Claim 2; Fig 125; 308pp; English.

XX The invention describes an isolated PRO (secreted and transmembrane)

CC

CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO329, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO533, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO5940, PRO6079, PRO9836 or PRO1096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblast cells.
CC PRO181, PRO259, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGAGCAAC 60
DB 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAAAACCATCCAGCAAAAATGCAAAATCTATCTCTTGGCAAT 180
DB 121 AAGAAAAAATCATGAAAAACCATCCAGCAAAAATGCAAAATCTATCTCTTGGCAAT 180
QY 181 CTTCCAGGGGCTGGCTCTCTGTCTCTTCCAGGAGTGCCTGCGCAGCGGAGATGC 240
DB 181 CTTCCAGGGGCTGGCTCTGTGTCTCTTCCAGGAGTGCCTGCGCAGCGGAGATGC 240
QY 241 CACTTCCCCAAAGCTATGACAAACGTGAGGCTCCGCGAGGGGAGAGCGCCACCTCAG 300
DB 241 CACTTCCCCAAAGCTATGACAAACGTGAGGCTCCGCGAGGGGAGAGCGCCACCTCAG 300
QY 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCAACCTCTCTA 360
DB 301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTTAAACCGCAGCAACCTCTCTA 360
QY 361 TGCTGGGAATGCAAAAGTGGTCTGGATCTCTGGGTCCTTCTTGAGCAACCCCAAC 420
DB 361 TGCTGGGAATGCAAAAGTGGTCTGGATCTCTGGGTCCTTCTTGAGCAACCCCAAC 420
QY 421 GCATGACAGATCCAGATCCAGATCGATGATGATGAGAGGGCCCTTACACCTGCTC 480
DB 421 GCATGACAGATCCAGATCCAGATCGATGATGATGAGAGGGCCCTTACACCTGCTC 480

QY 481 GGTGACAGACAGCAACCAACCAAGAGCCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGACAGACAGCAACCAACCAAGAGCCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
DB 541 CAAATTTGTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGGCTTTCTGAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGGGCTTTCTGAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCCGTGTCAGGAGAGTAAA 780
DB 721 AGGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCCGTGTCAGGAGAGTAAA 780
QY 781 GGTCAACGTGAACATATCACCATATCTTCAAGAGCAAGGATACAGGTGTCCTCCGTGGG 840
DB 781 GGTCAACGTGAACATATCACCATATCTTCAAGAGCAAGGATACAGGTGTCCTCCGTGGG 840
QY 841 ACAAAGGGGACACTGCGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 ACAAAGGGGACACTGCGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGATGACAAAAGACTGATTGAAGGAAGAAAGAGGAGTGAAGTGAAGAAACAGACCTTT 960
DB 901 CAAGATGACAAAAGACTGATTGAAGGAAGAAAGAGGAGTGAAGTGAAGAAACAGACCTTT 960
QY 961 CTTCTCAAAACTCATCTTTCTTCAATGTCTTGAAACATGATATGGAACATACACTTGGT 1020
DB 961 CTTCTCAAAACTCATCTTTCTTCAATGTCTTGAAACATGATATGGAACATACACTTGGT 1020
QY 1021 GGCCTTCAAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGCGCGCT 1080
DB 1021 GGCCTTCAAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGCGCGCT 1080
QY 1081 CAGCGAGTGTGAGCAACCGCAGCTCGAGAGGCGAGGCTGCGTCTGGCTGCTCTTCT 1140
DB 1081 CAGCGAGTGTGAGCAACCGCAGCTCGAGAGGCGAGGCTGCGTCTGGCTGCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTGAGTGCACCTTCCGCCACCCGGGAAAGCT 1200
DB 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTGAGTGCACCTTCCGCCACCCGGGAAAGCT 1200
QY 1201 GCGCGCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
DB 1201 GCGCGCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
QY 1261 TATACAAATGAAATTTAGAAAGAAACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
DB 1261 TATACAAATGAAATTTAGAAAGAAACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
QY 1321 AAAGAAATCTTTGGGGGAAAGAGTGTAAAGAAATTTGAAATTTGAAATTTGAAATTTG 1380
DB 1321 AAAGAAATCTTTGGGGGAAAGAGTGTAAAGAAATTTGAAATTTGAAATTTGAAATTTG 1380
QY 1381 TTTAGGTA CAATGGAGTTTCTTTTCCAAACGGGAAAGAAACAGCAACCCGGGCTTGA 1440
DB 1381 TTTAGGTA CAATGGAGTTTCTTTTCCAAACGGGAAAGAAACAGCAACCCGGGCTTGA 1440
QY 1441 CCCACTGCAAGCTGCATCGTGCACCTCTTTGGTCCAGTGTGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGCATCGTGCACCTCTTTGGTCCAGTGTGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCCA CAGAGTCCCCCAGCTGGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCCA CAGAGTCCCCCAGCTGGAAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGCAACAGATGAGACCTTCCGGCCCCAGCGTGGCGCTGCGGCACTTTG 1620

Db 1561 GTCCATAGAGCAAGCAATGAGACCTTCGGGCCCAAGCGTGCGCTGGGGCACTTTG 1620
Qy 1621 GTAGACTGTGCACACCGCGTGTGTGTAACGTGAATATAAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCACACCGCGTGTGTGTAACGTGAATATAAAGAGCAAAAAA 1679
RESULT 128
ADD87924
ID ADD87924 standard; cDNA; 1679 BP.
AC ADD87924;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003092113-A1.
XX
PD 15-MAY-2003.
XX
PF 16-MAY-2002; 2002US-00147523.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
DR WPI: 2004-02037/02.
DR P-PSDB; ADD87925.
XX
XX New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
PS Claim 2; Fig 375; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
SQ
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGCAACAC 60
Db 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGCAACAC 60
Qy 61 AATCTATCAGGAAAGAAAGAAAGAAACCGAACCTTGACAAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAAGAAAGAAAGAAACCGAACCTTGACAAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAAAATCATGAAACCATCCAGCAAAAATGCACAAATTCATCTCTTGGGCAAT 180
Db 121 AAGAAAAAATCATGAAACCATCCAGCAAAAATGCACAAATTCATCTCTTGGGCAAT 180
Qy 181 CTTACGGGGCTGGTGCTCTGTCTCTTCAAGAGTGCCCGTGGCAGCGGAGATGC 240
Db 181 CTTACGGGGCTGGTGCTCTGTCTCTTCAAGAGTGCCCGTGGCAGCGGAGATGC 240
Qy 241 CACCTTCCCAAGCTATGACAACTGACGCGTCCGGCAGGGGAGAGCCACCCCTCAG 300
Db 241 CACCTTCCCAAGCTATGACAACTGACGCGTCCGGCAGGGGAGAGCCACCCCTCAG 300
Qy 301 GTGCACATTTGACACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCCTCTTA 360
Db 301 GTGCACATTTGACACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCCTCTTA 360
Qy 361 TGTGCGGAATGACAGTGGTGCTGATCTCTCGCTGGTCTTCTGAGCAACACCCAAAC 420
Db 361 TGTGCGGAATGACAGTGGTGCTGATCTCTCGCTGGTCTTCTGAGCAACACCCAAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGCCCTTACACCTGCTC 480
Qy 481 GGTGCGAGACAGACCCCAAGACCTTAGGGTCCACCTCATTTGCAAGTATCTCC 540
Db 481 GGTGCGAGACAGACCCCAAGACCTTAGGGTCCACCTCATTTGCAAGTATCTCC 540
Qy 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
Db 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
Qy 601 CTCATAGCACTGGTAGACAGGCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTCATAGCACTGGTAGACAGGCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
Qy 661 GGTGGCTTTGTGAGTGAAGCAAACTACTTGGAAATTCAGGGGCATACCCGGGAGCAGTC 720
Db 661 GGTGGCTTTGTGAGTGAAGCAAACTACTTGGAAATTCAGGGGCATACCCGGGAGCAGTC 720
Qy 721 AGGGGACTACGAGTGCAGTGCCTTCAATGACGTGGCGCGCGCGTGGTACGAGAGATAA 780

Db 721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCGCGCCGCTGATACGAGAGTAA 780
Qy 781 GGTTCACCGTGAATATCCACCATACATTTCAAGCCCAAGGGTACAGGTGTCCTCGTGGG 840
Db 781 GGTTCACCGTGAATATCCACCATACATTTCAAGCCCAAGGGTACAGGTGTCCTCGTGGG 840
Qy 841 ACAAAAGGGGACATGTCAGTGTGAAGCCCTCAGAGTTCCTCAGCAGAAATTCAGTGTGA 900
Db 841 ACAAAAGGGGACATGTCAGTGTGAAGCCCTCAGAGTTCCTCAGCAGAAATTCAGTGTGA 900
Qy 901 CAAAGGATGACAAAGAGTCTGATGAGGAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
Db 901 CAAAGGATGACAAAGAGTCTGATGAGGAAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
Qy 961 CTTCTCAAAACTCATCTTCTCAATGCTCTGAACATGATATGGGAACTACACTTGGGT 1020
Db 961 CTTCTCAAAACTCATCTTCTCAATGCTCTGAACATGATATGGGAACTACACTTGGGT 1020
Qy 1021 GGCTCTCAACAGCTGGGACACCAATGCGAGCATGCTATTTGGTCCAGGCGCGGT 1080
Db 1021 GGCTCTCAACAGCTGGGACACCAATGCGAGCATGCTATTTGGTCCAGGCGCGGT 1080
Qy 1081 CAGCGAGGTGAGCAAGCGCAGCTCGAGGAGGCGAGGCTGCTGCTGCTCTTCT 1140
Db 1081 CAGCGAGGTGAGCAAGCGCAGCTCGAGGAGGCGAGGCTGCTGCTGCTCTTCT 1140
Qy 1141 GGTCTTGACCTGCTCTCAATTTTGAATGTCAGTTCCTCCACCGGGAAGGCT 1200
Db 1141 GGTCTTGACCTGCTCTCAATTTTGAATGTCAGTTCCTCCACCGGGAAGGCT 1200
Qy 1201 GCGCGCACACACCAACCAACACAGCAATGGCAACCGACAGCAACCAATCAGATA 1260
Db 1201 GCGCGCACACACCAACCAACACAGCAATGGCAACCGACAGCAACCAATCAGATA 1260
Qy 1261 TATACAAATGAATTAAGAAAGAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAA 1320
Db 1261 TATACAAATGAATTAAGAAAGAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAA 1320
Qy 1321 AAGGATACCTTGGGGGGAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAGGATACCTTGGGGGGAAGAGTTTAAAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Qy 1381 TTTAGTACAAATGAGTGTCTTTTCCAAACCGGGAAGAACACAGCACCCTGGCTTGA 1440
Db 1381 TTTAGTACAAATGAGTGTCTTTTCCAAACCGGGAAGAACACAGCACCCTGGCTTGA 1440
Qy 1441 CCACTGCAAGCTGCACTGTCGACCTCTTTGGTCCAGTGTGGGCAAGGCTCAGCCTC 1500
Db 1441 CCACTGCAAGCTGCACTGTCGACCTCTTTGGTCCAGTGTGGGCAAGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGCCTCCACGTCGAACTTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCACGTCGAACTTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATGAGACGAAAGATGAGACCTTCCGGCCGAGCGTGGCGTGGCGGACCTTTG 1620
Db 1561 GTCCATGAGACGAAAGATGAGACCTTCCGGCCGAGCGTGGCGTGGCGGACCTTTG 1620
Qy 1621 GTAGACTGTGCCACCGGCTGTGTTGTGAACCTGAAATATAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACCGGCTGTGTTGTGAACCTGAAATATAAGAGCAAAAAA 1679

RESULT 129
ADD86328
ID ADD86328 standard; cDNA; 1679 BP.
XX
AC ADD86328;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.

XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; connective tissue; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
XX US2003203440-A1.
XX 30-OCT-2003.
XX 29-MAY-2002; 2002US-00157798.
XX 05-JUN-2000; 2000US-0209832P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerlitsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-021363/02.
XX P-PSDB; ADD86329.
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO114 or
XX PRO4978, useful in molecular biology, chromosome and gene mapping, in
XX generating antisense RNA and DNA, and in gene therapy.
XX Claim 2; Fig 375; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon,
XX breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems, PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polynucleotide of the invention. Note:
XX The sequence data for this patent is also available in electronic format
XX from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6,7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTTTACGAAACAGTGGATTTAAATCTCTTGCACAAGCTTGAGAGCAAC 60
DB 1 GTTGTGCTTTACGAAACAGTGGATTTAAATCTCTTGCACAAGCTTGAGAGCAAC 60

QY 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

QY 121 AAGAAAAAATCATGAAAAATCATGAAAAATCATGAAAAATCATGAAAAATCATG 180
DB 121 AAGAAAAAATCATGAAAAATCATGAAAAATCATGAAAAATCATGAAAAATCATG 180

QY 181 CTTACGGGGTGGTGTCTGTCTCTTCCAGAGAGTCCGTCGCGCAGCGAGATGC 240
DB 181 CTTACGGGGTGGTGTCTGTCTCTTCCAGAGAGTCCGTCGCGCAGCGAGATGC 240

QY 241 CACCTTCCCAAGATATGGAACAAGTGAACGTCGCGCAGCGAGAGCGCCACCTCAG 300
DB 241 CACCTTCCCAAGATATGGAACAAGTGAACGTCGCGCAGCGAGAGCGCCACCTCAG 300

QY 301 GTGCACTATTGACAAACCGGCTCACCCGGTGGCTTGGCTTAACCGCAGCACCATCTCTA 360
DB 301 GTGCACTATTGACAAACCGGCTCACCCGGTGGCTTGGCTTAACCGCAGCACCATCTCTA 360

QY 361 TCGTGGGAATCAAGTGGTGGTCTCGATCTCGGTGGTCTCGGTGGTCTCGGTGGT 420
DB 361 TCGTGGGAATCAAGTGGTGGTCTCGATCTCGGTGGTCTCGGTGGTCTCGGTGGT 420

QY 421 GCAGTACAGATCGAGATCGAGAGCGTGGATGTATGACAGAGGCGCTTACACTGCTC 480
DB 421 GCAGTACAGATCGAGATCGAGAGCGTGGATGTATGACAGAGGCGCTTACACTGCTC 480

QY 481 GGTGACAGACAGAACACCAAGACCTTAGGTGCTCACTTGTGCAAGTATCTCC 540
DB 481 GGTGACAGACAGAACACCAAGACCTTAGGTGCTCACTTGTGCAAGTATCTCC 540

QY 541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTTAATGAAGGGAACAATATTAGCCTC 600
DB 541 CAAATTTGAGAGATTTCTTCAGATATCTCCATTTAATGAAGGGAACAATATTAGCCTC 600

QY 601 CTGCATAGCAACTGGTAGACAGACCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
DB 601 CTGCATAGCAACTGGTAGACAGACCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660

QY 661 GGTGGCTTTGTGAGTGAAGACGAATACCTTGGAAATTCAGGGCATCACCCGGAGCAGTC 720
DB 661 GGTGGCTTTGTGAGTGAAGACGAATACCTTGGAAATTCAGGGCATCACCCGGAGCAGTC 720

QY 721 AGGGGACTACGAGTGCAGTGCCTCCCAATGACGTGGCGCGCGCTGAGTACGAGAGTAA 780
DB 721 AGGGGACTACGAGTGCAGTGCCTCCCAATGACGTGGCGCGCGCTGAGTACGAGAGTAA 780

QY 781 GGTCAACGCTGAATATCCACCATATATTGAGAGCCCAAGGTTACAGTGTCCCGTGG 840
DB 781 GGTCAACGCTGAATATCCACCATATATTGAGAGCCCAAGGTTACAGTGTCCCGTGG 840

QY 841 ACAAAGGGGACATGCGAGTGTGAAGCTTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
DB 841 ACAAAGGGGACATGCGAGTGTGAAGCTTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900

QY 901 CAAGGATGACAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
DB 901 CAAGGATGACAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960

QY 961 CCTCTCAAACTCATCTTCTCAATGTCTCTGAAATGACTATGGAACACTACCTGGT 1020
DB 961 CCTCTCAAACTCATCTTCTCAATGTCTCTGAAATGACTATGGAACACTACCTGGT 1020

QY 1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCAGGCGCGT 1080
DB 1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCAGGCGCGT 1080

QY 1081 CAGCGAGTGAAGCAACGCGACGTCGAGAGGCGAGGCTGCGTCTGGTCTGCTCTTCT 1140
DB 1081 CAGCGAGTGAAGCAACGCGACGTCGAGAGGCGAGGCTGCGTCTGGTCTGCTCTTCT 1140

QY 1141 GGTCTTGACCTGCTTCTCAAATTTTGAATGTGAGTGCACCTTCCCAACCCCGGAAAGGCT 1200
DB 1141 GGTCTTGACCTGCTTCTCAAATTTTGAATGTGAGTGCACCTTCCCAACCCCGGAAAGGCT 1200

QY 1201 GCGGCCACACCAACCAACACACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
DB 1201 GCGGCCACACCAACCAACACACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260

QY 1261 TATACAAATAGAAATTTAGAAGAAACACACGCTCATGGGACAGAAATTTGAGGGAGGGAAAC 1320
DB 1261 TATACAAATAGAAATTTAGAAGAAACACACGCTCATGGGACAGAAATTTGAGGGAGGGAAAC 1320

QY 1321 AAGAATATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCCCTTGCAGATA 1380
DB 1321 AAGAATATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCCCTTGCAGATA 1380

QY 1381 TTTAGTACAATGGAGTTTCTTTTCCCAACCGGGAAGAACACACACACCCGGCTTGA 1440
DB 1381 TTTAGTACAATGGAGTTTCTTTTCCCAACCGGGAAGAACACACACACCCGGCTTGA 1440

QY 1441 CCCACTGCAAGCTGCATCTGCAACCTCTTTGGTCCAGTGTGGCAAGGGCTCAGCTC 1500
DB 1441 CCCACTGCAAGCTGCATCTGCAACCTCTTTGGTCCAGTGTGGCAAGGGCTCAGCTC 1500

QY 1501 TCTGCCACAGAGTGCCTCCACGTCGAAATCTCGAGCTGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTGCCTCCACGTCGAAATCTCGAGCTGCCATCCCAATTCATCA 1560

QY 1561 GTCCATAGAGACGAAACAGAAATCAGACCTTCCGGCCCAAGCGTGGCGCTGCGGGCACTTTG 1620
DB 1561 GTCCATAGAGACGAAACAGAAATCAGACCTTCCGGCCCAAGCGTGGCGCTGCGGGCACTTTG 1620

QY 1621 GTAGACTGTGCCACACCGCGCTGTGTGTGAACCTGAAATTAAGAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACACCGCGCTGTGTGTGAACCTGAAATTAAGAGAGCAAAAAA 1679

RESULT 130

ADE05597

ID ADE05597 standard; cDNA; 1679 BP.

XX ADE05597;

XX ADE05597;

XX ADE05597;

XX 29-JAN-2004 (first entry)

XX Human PRO polynucleotide #63.

Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
tumour; cancer; lung; colon; breast; prostate; rectum; liver;
tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
arthritis; sports injury; cytostatic; antiarthritic.

OS Homo sapiens.

XX US2003100727-A1.

XX 29-MAY-2003.

XX 28-AUG-2002; 2002US-00229974.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2004-008977/01.
XX P-PSDB; ADE05598.
XX
XX New secreted and transmembrane PRO polypeptide useful for preparing a
XX medicament for treating a condition that is responsive to the PRO
XX polypeptide or anti-PRO antibody, e.g. cancer.
XX
XX Claim 2; Fig 125; 308pp; English.
XX
XX The invention relates to human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the PRO polynucleotides encoding them.
XX The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
XX diagnostics, biosensors or bioreactors. They are particularly useful for
XX detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
XX prostate tumour, rectal tumour or liver tumour) in a mammal, for
XX stimulating the release of tumour necrosis factor (TNF)-alpha from human
XX blood, for stimulating the proliferation or differentiation of
XX chondrocyte cells, for stimulating the proliferation of or gene
XX expression in pericyte cells or for stimulating the proliferation of
XX normal human dermal fibroblasts. The PRO nucleic acids are useful as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA, in preparing PRO polypeptides by recombinant
XX technology, in generating transgenic animals or knock-out animals which
XX may be used in the development and screening of therapeutically useful
XX reagents, in gene therapy, in chromosome identification, as chromosome
XX markers, and in generating probes. The PRO polypeptides, or anti-PRO
XX antibodies, are useful for preparing a medicament for treating a
XX condition which is responsive to the PRO polypeptides or anti-PRO
XX antibodies, such as pericyte-associated tumours and bone and/or cartilage
XX disorders (e.g. arthritis, sports injuries), involving inducing the re-
XX differentiation of chondrocytes. The PRO polypeptides are useful as
XX molecular markers for protein electrophoresis, and in tissue typing. This
XX sequence represents a human PRO polynucleotide of the invention.
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
XX
XX Query Match 100.0%; Score 1679; DB 1; Length 1679;
XX Best Local Similarity 100.0%; Pred. No. 6.7e-05;
XX Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 GTTCTGCTTCAGAAAAGAGTGGATTAAATCTCTTGCACAGCTTGAGAGCAAC 60
XX 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGAGCAAC 60
XX
XX 61 AATCTATCAGAAAAGAAAAGAAAACCGAACCTGACAAAAGAGAAAAGAAAG 120
XX 61 AATCTATCAGAAAAGAAAAGAAAACCGAACCTGACAAAAGAGAAAAGAAAG 120
XX
XX 121 AAGAAAAAATCATGAACCATCCAGCCAAAATGCATAATCTATCTCTTGGGCAAT 180
XX 121 AAGAAAAAATCATGAACCATCCAGCCAAAATGCATAATCTATCTCTTGGGCAAT 180
XX
XX 181 CTTCAAGGGGTGGCTGCTGTGTCTCTTCCAGAGAGTGCCTGCGCAGCGGAGATGC 240
XX 181 CTTCAAGGGGTGGCTGCTGTGTCTCTTCCAGAGAGTGCCTGCGCAGCGGAGATGC 240
XX
XX 241 CACCTTCCCAAGCTATGACAAAGTGCAGCGTCCCGCAGGGGGAGAGCCCACTCTAG 300
XX 241 CACCTTCCCAAGCTATGACAAAGTGCAGCGTCCCGCAGGGGGAGAGCCCACTCTAG 300
XX
XX 301 GTGCACATTTACAAACCGGGTACCCGGGTGGCTTAAACCGCAGACCAATCTCTTA 360
XX 301 GTGCACATTTACAAACCGGGTACCCGGGTGGCTTAAACCGCAGACCAATCTCTTA 360
XX
XX 361 TGCTGGGAATGCAAGTGGTGGATCTCTGCGTGGTCTCTTGAGCAACCCCAAC 420
XX 361 TGCTGGGAATGCAAGTGGTGGATCTCTGCGTGGTCTCTTGAGCAACCCCAAC 420

QY 421 GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGACAGACAGAACACACCCAAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGACAGACAGAACACACCCAAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
DB 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGGTAGACCCAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCAACTGGTAGACCCAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTTCGGCTTTGTAGTGAAGACGAATACTGTGAAATTCAGGGCATCACCCGGAGCAGTC 720
DB 661 GGTTCGGCTTTGTAGTGAAGACGAATACTGTGAAATTCAGGGCATCACCCGGAGCAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCCGCCGCCGTGACGAGAGTAAA 780
DB 721 AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCCGCCGCCGTGACGAGAGTAAA 780
QY 781 GGTCAACCGTGAACCTACCATATCTTCAGAAACCAAGGATACAGTGTCCCGTGG 840
DB 781 GGTCAACCGTGAACCTACCATATCTTCAGAAACCAAGGATACAGTGTCCCGTGG 840
QY 841 ACAAAGGGGACACTGACAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATCCAGTGCTA 900
DB 841 ACAAAGGGGACACTGACAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATCCAGTGCTA 900
QY 901 CAAGATCACAAGACCTGATTGAGGAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
DB 901 CAAGATCACAAGACCTGATTGAGGAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
QY 961 CCTCTCAAAACCTCATCTCTTCTTCAATGTCTCTGAACATGACTATGGGAATACACTTGGT 1020
DB 961 CCTCTCAAAACCTCATCTCTTCTTCAATGTCTCTGAACATGACTATGGGAATACACTTGGT 1020
QY 1021 GGCCTCCAAACAGCTGGGCCACACCAATGCCAGCATCATGCTATTGTCAGGGCGCT 1080
DB 1021 GGCCTCCAAACAGCTGGGCCACACCAATGCCAGCATCATGCTATTGTCAGGGCGCT 1080
QY 1081 CAGCGAGGTGAGCAACGGCAGCTCGAGGAGGCGAGGCTCTGCTGCTGCTCTTCT 1140
DB 1081 CAGCGAGGTGAGCAACGGCAGCTCGAGGAGGCGAGGCTCTGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGCACTGCTTCTCAATTTTGTATGTAGTGCCACTTCCCACCCCGGGAAGGCT 1200
DB 1141 GGTCTTGCACTGCTTCTCAATTTTGTATGTAGTGCCACTTCCCACCCCGGGAAGGCT 1200
QY 1201 GCGGCCACCCACCAACCAACACACAGCAATGGCAACCGACAGCAACCAATCAGATA 1260
DB 1201 GCGGCCACCCACCAACCAACACACAGCAATGGCAACCGACAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
DB 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
QY 1321 AAGAAATCTTTGGGGGGAAGAGTGTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB 1321 AAGAAATCTTTGGGGGGAAGAGTGTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGGTAATTTAGGAGTGTCTTTTCCAAACGGGAAGAACACAGCACACCCCGGTTGGA 1440
DB 1381 TTTAGGTAATTTAGGAGTGTCTTTTCCAAACGGGAAGAACACAGCACACCCCGGTTGGA 1440
QY 1441 CCACTGCAAGCTGATCGTGAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500
DB 1441 CCACTGCAAGCTGATCGTGAACCTCTTTGGTCCAGTGTGGGCAAGGGCTCAGCCTC 1500

QY 1501 TCTCCCAACAGAGTCCCAACGTCGGAACATCTGGAGCTGGCCATCCCAATTCATCA 1560
Dd 1501 TCTCCCAACAGAGTCCCAACGTCGGAACATCTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCGGGCCCAAGCGTGGCGTGGCGCACTTTG 1620
Dd 1561 GTCCATAGAGACGAAACAGAAATGAGACCTTCGGGCCCAAGCGTGGCGTGGCGCACTTTG 1620
QY 1621 GTAGACTGTGCCACACAGCGGTGTGTGTGAACGTGAATTAAGAGCAAGAAAAA 1679
Dd 1621 GTAGACTGTGCCACACAGCGGTGTGTGTGAACGTGAATTAAGAGCAAGAAAAA 1679

RESULT 131

ADD73582

ID ADD73582 standard; cDNA; 1679 BP.

XX AC

XX AC

XX DT

XX 29-JAN-2004 (first entry)

XX DE

XX Human PRO polynucleotide #63.

XX KW

KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;

KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;

KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;

KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;

KW arthritis; sports injury; cytostatic; antiarthritic.

XX OS

OS Homo sapiens.

XX PN

PN US2003100711-A1.

XX PD

PD 29-MAY-2003.

XX PF

PF 09-AUG-2002; 2002US-00216167.

XX PR

PR 05-JUN-2000; 2000US-0209832P.

PR 15-SEP-2000; 2000US-0232887P.

PR 01-JUN-2001; 2001WO-US017800.

PR 29-JUN-2001; 2001WO-US021066.

PR 09-APR-2002; 2002US-00119480.

XX PA

PA (GETH) GENENTECH INC.

XX PI

PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX P-PSDB; ADD73583.

XX WPI; 2004-008961/01.

XX DR

DR New secreted and transmembrane PRO polypeptide useful for preparing a

PT medicament for treating a condition that is responsive to the PRO

PT polypeptide or anti-PRO antibody, e.g. cancer.

XX PS

PS Claim 2; Fig 125; 309pp; English.

XX CC

CC The invention relates to human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the PRO polynucleotides encoding them.

CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,

CC diagnostics, biosensors or bioeffectors. They are particularly useful for

CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,

CC prostate tumour, rectal tumour or liver tumour) in a mammal, for

CC stimulating the release of tumour necrosis factor (TNF)-alpha from human

CC blood, for stimulating the proliferation or differentiation of

CC chondrocyte cells, for stimulating the proliferation of or gene

CC expression in pericyte cells or for stimulating the proliferation of

CC normal human dermal fibroblasts. The PRO nucleic acids are useful as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant

CC technology, in generating transgenic animals or knock-out animals which

CC may be used in the development and screening of therapeutically useful

CC reagents, in gene therapy, in chromosome identification, as chromosome

CC

CC

CC

CC

CC

CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC at seqdata.uspto.gov/sequence.html.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

SQ Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6.7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCTTGCAACAGCTTGAGACAACAC 60

Dd 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCTTGCAACAGCTTGAGACAACAC 60

QY 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGACAAAAAGAAAGAAAG 120

Dd 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGACAAAAAGAAAGAAAG 120

QY 121 AAGAAAAAATCATGAAAAACATCCAGCCAAAAATGCAATCTCTTCTGGCAAT 180

Dd 121 AAGAAAAAATCATGAAAAACATCCAGCCAAAAATGCAATCTCTTCTGGCAAT 180

QY 181 CTTTACGGGGCTGGCTGCTCTCTTCCAAAGAGTGCCTGGCGACGAGATGC 240

Dd 181 CTTTACGGGGCTGGCTGCTCTCTTCCAAAGAGTGCCTGGCGACGAGATGC 240

QY 241 CACCTTCCCAAGCTATGGAACAAGTCCGGTCCGGCAGGGGAGAGCGCCCTCAG 300

Dd 241 CACCTTCCCAAGCTATGGAACAAGTCCGGTCCGGCAGGGGAGAGCGCCCTCAG 300

QY 301 GTGCACTATTGACAAACCGGGTCACCCGGGTGGCTGCTTAAACCGCAGCACCCTCTA 360

Dd 301 GTGCACTATTGACAAACCGGGTCACCCGGGTGGCTGCTTAAACCGCAGCACCCTCTA 360

QY 361 TGTGGGAATGACAAAGTGGTGGATCTCTGGGTGGTCTTCTTGAGCAACACCAAC 420

Dd 361 TGTGGGAATGACAAAGTGGTGGATCTCTGGGTGGTCTTCTTGAGCAACACCAAC 420

QY 421 GCAGTACAGCATCGAGATCCAGAGCTGATGATGACGAGGGCCCTTACACTGCTC 480

Dd 421 GCAGTACAGCATCGAGATCCAGAGCTGATGATGACGAGGGCCCTTACACTGCTC 480

QY 481 GGTGACAGACAGAACCCACCCAGACCTCTAGGGTCCACCTCATTTGCAAGTATCTCC 540

Dd 481 GGTGACAGACAGAACCCACCCAGACCTCTAGGGTCCACCTCATTTGCAAGTATCTCC 540

QY 541 CAAATTTGTAGAGATTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAC 600

Dd 541 CAAATTTGTAGAGATTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAC 600

QY 601 CTGCTATAGCAACTGGTAGACAGACCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660

Dd 601 CTGCTATAGCAACTGGTAGACAGACCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660

QY 661 GGTGGCTTTGTAGTGAAGACAAATCTTGAATTCAGGCAATCCCGGGGAGCAGTC 720

Dd 661 GGTGGCTTTGTAGTGAAGACAAATCTTGAATTCAGGCAATCCCGGGGAGCAGTC 720

QY 721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCGCGCCCGTGTGACGAGAGTAAA 780

Dd 721 AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTGGCGCGCCCGTGTGACGAGAGTAAA 780

QY 781 GGTACCGTGAATCTATCCACCATACATTTCAAGCCAGGGGTACAGGTGTCCTGGG 840

Dd 781 GGTACCGTGAATCTATCCACCATACATTTCAAGCCAGGGGTACAGGTGTCCTGGG 840

QY 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCCTTGCCACAAAGCTTGAGAGCAAC 60
 Db 1 GTTGTGCTCTCAGCAAAACAGTGGATTAAATCTCCTTGCCACAAAGCTTGAGAGCAAC 60
 QY 61 AATCTATCAGGAAAGAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 Db 61 AATCTATCAGGAAAGAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 QY 121 AAGAAAGAAATCATGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
 Db 121 AAGAAAGAAATCATGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 180
 QY 181 CTTTCAGGGGGCTGGCTGCTCTGCTCTCTTCTCAAGAGAGTGGCCGTCGCGAGGAGATGC 240
 Db 181 CTTTCAGGGGGCTGGCTGCTCTGCTCTCTTCTCAAGAGAGTGGCCGTCGCGAGGAGATGC 240
 QY 241 CACCTTCCCAAGCTATGGAACAAAGTGAAGTGGTGGTGGTGGTGGTGGTGGTGGTGG 300
 Db 241 CACCTTCCCAAGCTATGGAACAAAGTGAAGTGGTGGTGGTGGTGGTGGTGGTGGTGG 300
 QY 301 GTGCATATTGACAAACCGGGTCAACCGGGTGGCTGGCTGGCTGGCTGGCTGGCTGGCT 360
 Db 301 GTGCATATTGACAAACCGGGTCAACCGGGTGGCTGGCTGGCTGGCTGGCTGGCTGGCT 360
 QY 361 TGTGGGAATGACAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 420
 Db 361 TGTGGGAATGACAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 420
 QY 421 GCAGTACAGCTGAGATCCAGAACTGGATGTGATGACAGAGGCGCTTACACCTGCTC 480
 Db 421 GCAGTACAGCTGAGATCCAGAACTGGATGTGATGACAGAGGCGCTTACACCTGCTC 480
 QY 481 GGTGACAGACAAACCAACCAAGCTCTAGGTCACCTCATTTGTGCAAGTATCTCC 540
 Db 481 GGTGACAGACAAACCAACCAAGCTCTAGGTCACCTCATTTGTGCAAGTATCTCC 540
 QY 541 CAAATTGTGAGAGATTTCTTCAATATCTCCATTAATGAAGGAAACAAATATTAGCTCAC 600
 Db 541 CAAATTGTGAGAGATTTCTTCAATATCTCCATTAATGAAGGAAACAAATATTAGCTCAC 600
 QY 601 CTGCATAGCAACTGTGAGACGAGCTACGTTACTTGGAGACACATCTCTCCCAAGC 660
 Db 601 CTGCATAGCAACTGTGAGACGAGCTACGTTACTTGGAGACACATCTCTCCCAAGC 660
 QY 661 GGTGGCTTTGTGAGTGAAGAGCAATCTTGAAATTCAGGGCATCACCGGGAGCAGTC 720
 Db 661 GGTGGCTTTGTGAGTGAAGAGCAATCTTGAAATTCAGGGCATCACCGGGAGCAGTC 720
 QY 721 AGGGGACTACGAGTGCAGTCCCTCCAAATGACGTGGCGCGCGCGCGCGCGCGCGCG 780
 Db 721 AGGGGACTACGAGTGCAGTCCCTCCAAATGACGTGGCGCGCGCGCGCGCGCGCGCG 780
 QY 781 GGTCAAGTGAAGTACCACTACCACTACCACTACCACTACCACTACCACTACCACTAC 840
 Db 781 GGTCAAGTGAAGTACCACTACCACTACCACTACCACTACCACTACCACTACCACTAC 840
 QY 841 ACAAAGGGGACACTGCACTGTGGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
 Db 841 ACAAAGGGGACACTGCACTGTGGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
 QY 901 CAAAGGATGACAAAGACTGATTGAAGAAAGAAAGGGGTGAAGTGAAGAAAGAAAG 960
 Db 901 CAAAGGATGACAAAGACTGATTGAAGAAAGAAAGGGGTGAAGTGAAGAAAGAAAG 960
 QY 961 CCTCTCAAACTCATCTCTCAATGTCTGAAATGATGATGGAACACTACCTTGGT 1020
 Db 961 CCTCTCAAACTCATCTCTCAATGTCTGAAATGATGATGGAACACTACCTTGGT 1020
 QY 1021 GGCCTCCAAAGCTGGGCAACCAATGCGAGCATCATGCTATTGTCAGAGGCGCGT 1080
 Db 1021 GGCCTCCAAAGCTGGGCAACCAATGCGAGCATCATGCTATTGTCAGAGGCGCGT 1080
 QY 1081 CAGCGAGGTGAGCAACCGGACGTCGAGGAGGCGAGGCTCGCTGCTGCTGCTCTCTCT 1140

Db 1081 CAGCGAGGTGAGCAACCGGACGTCGAGGAGGCGAGGCTGGCTGCTGCTGCTCTCTCT 1140
 QY 1141 GGTCTTGCACTGCTCTCTCAAAATTTGATGTGAGTGCCACTTCCCAACCCGGAAGGCT 1200
 Db 1141 GGTCTTGCACTGCTCTCTCAAAATTTGATGTGAGTGCCACTTCCCAACCCGGAAGGCT 1200
 QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAT 1260
 Db 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAT 1260
 QY 1261 TATACAAATGAATTTAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGAAC 1320
 Db 1261 TATACAAATGAATTTAGAAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGAAC 1320
 QY 1321 AAGAATACTTTGGGGGAAAGAGTTTTTAAAAAGAAATTCAAAATTCCTTTGAGATA 1380
 Db 1321 AAGAATACTTTGGGGGAAAGAGTTTTTAAAAAGAAATTCAAAATTCCTTTGAGATA 1380
 QY 1381 TTTAGTACAAATGAGAGTTTCTTTTCCAAAACGGGAAGAAACACAGCAACCCGGCTTGA 1440
 Db 1381 TTTAGTACAAATGAGAGTTTCTTTTCCAAAACGGGAAGAAACACAGCAACCCGGCTTGA 1440
 QY 1441 CCCACTGCAAGCTGCAATCGTCAACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
 Db 1441 CCCACTGCAAGCTGCAATCGTCAACCTCTTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
 QY 1501 TCTGCCACAGAGTGCCTCCCAACGTGAAACATTTGGAGTGGCCATCCCAATTCATCA 1560
 Db 1501 TCTGCCACAGAGTGCCTCCCAACGTGAAACATTTGGAGTGGCCATCCCAATTCATCA 1560
 QY 1561 GTCCATAGACAGCAACAGATGAGACCTTCCGCGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
 Db 1561 GTCCATAGACAGCAACAGATGAGACCTTCCGCGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
 QY 1621 GTAGACTGTGCCACCAACCGCGCTGTGTGTAACCTGTAACCTGTAACCTGTAACCT 1679
 Db 1621 GTAGACTGTGCCACCAACCGCGCTGTGTGTAACCTGTAACCTGTAACCTGTAACCT 1679

RESULT 133

AD48856
 ID AD48856 standard; cDNA; 1679 BP.

XX AD48856;

XX 29-JAN-2004 (first entry)

XX Human cDNA encoding secreted/transmembrane protein, PRO337.

Human; ss; Gene; secreted protein; transmembrane protein; PRO;
 cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
 vulnery; auditory; tumour growth; retinal disorder;
 sports-related joint problem; articular cartilage defects;
 osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.

OS Homo sapiens.

XX US2003104536-A1.

XX 05-JUN-2003.

XX 19-OCT-2001; 2001US-00166709.

XX 07-OCT-1998; 98WO-US021141.

XX 20-NOV-1998; 98WO-US024855.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99WO-US005190.

XX 14-MAY-1999; 99WO-US010733.

XX 30-JUN-1999; 99WO-US012252.

XX 30-NOV-1999; 99WO-US028313.

XX 02-DEC-1999; 99WO-US028551.

polypeptide or anti-PRO4993 polypeptide is useful for modulating the biological activity of the cell expressing PRO4993 polypeptide; PRO725, PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for modulating the biological activity of the cell expressing PRO1559 polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-PRO739 polypeptide is useful for modulating the biological activity of the cell expressing PRO725, PRO700 or PRO739 polypeptide. The polypeptides are useful for inhibiting tumor growth, retinal disorders, sports-related joint problems, articular cartilage defects, osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in mammals. The present sequence encodes a PRO protein.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6,7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTTTCAGCAAAACAGTGGATTAAATCTCTTGCACAACTTGTAGAGCAACAC 60
 DB 1 GTTGTGCTTTCAGCAAAACAGTGGATTAAATCTCTTGCACAACTTGTAGAGCAACAC 60

QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 DB 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

QY 121 AAGAAATATCATGAAATCCATCCAGCCAAATATTCATCTCTTGGGCAAT 180
 DB 121 AAGAAATATCATGAAATCCATCCAGCCAAATATTCATCTCTTGGGCAAT 180

QY 181 CTTTCACGGGGCTGCTCTCTGTCTCTTCTTCCAGGAGTGCCTGCGGAGGAGATGC 240
 DB 181 CTTTCACGGGGCTGCTCTCTGTCTCTTCTTCCAGGAGTGCCTGCGGAGGAGATGC 240

QY 241 CACCTTCCCAAGCTATGAGCAACAGTGCAGCTCCGGGAGGAGGAGGAGGAGGAG 300
 DB 241 CACCTTCCCAAGCTATGAGCAACAGTGCAGCTCCGGGAGGAGGAGGAGGAGGAG 300

QY 301 GTGCACATATTGACAAACCGGGTCCACCGGGTGGCTCTGCTTAAACCGGAGCAATCTCTA 360
 DB 301 GTGCACATATTGACAAACCGGGTCCACCGGGTGGCTCTGCTTAAACCGGAGCAATCTCTA 360

QY 361 TGCTGGGAATGACAAAGTGGTGGCTCTGCTTAAACCGGAGCAATCTCTA 420
 DB 361 TGCTGGGAATGACAAAGTGGTGGCTCTGCTTAAACCGGAGCAATCTCTA 420

QY 421 GCAGTACAGCATCGAGATCCAGAAACGTTGATGTATGACAGGGGCTTACACCTGCTC 480
 DB 421 GCAGTACAGCATCGAGATCCAGAAACGTTGATGTATGACAGGGGCTTACACCTGCTC 480

QY 481 GGTCCAGACAGCAACCAACCAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
 DB 481 GGTCCAGACAGCAACCAACCAAGACCTTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540

QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTC 600
 DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTC 600

QY 601 CTGCATAGCACTGGTAGACAGAGCTAGGTTATCTTGGAGACACATCTCTCCCAAGC 660
 DB 601 CTGCATAGCACTGGTAGACAGAGCTAGGTTATCTTGGAGACACATCTCTCCCAAGC 660

QY 661 GTTGGCTTTGTGAGTGAAGACCAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
 DB 661 GTTGGCTTTGTGAGTGAAGACCAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720

QY 721 AGGGGACTAGAGTGCAGTGCCTTCCATGACGTGGGCGGCGCGGTGGTACGGAGAGTAA 780
 DB 721 AGGGGACTAGAGTGCAGTGCCTTCCATGACGTGGGCGGCGCGGTGGTACGGAGAGTAA 780

QY 781 GGTCCACCGTGAATCTTCCACATACATTTTTCAGAAAGCAAGGGGTACAGGTGTCTCCCGTGG 840
 DB 781 GGTCCACCGTGAATCTTCCACATACATTTTTCAGAAAGCAAGGGGTACAGGTGTCTCCCGTGG 840

02-DEC-1999; 99WO-US028565.
 16-DEC-1999; 99WO-US030095.
 30-DEC-1999; 99WO-US031243.
 30-DEC-1999; 99WO-US031274.
 05-JAN-2000; 2000WO-US000219.
 06-JAN-2000; 2000WO-US000277.
 06-JAN-2000; 2000WO-US000376.
 11-FEB-2000; 2000WO-US003565.
 18-FEB-2000; 2000WO-US004341.
 24-FEB-2000; 2000WO-US005004.
 02-MAR-2000; 2000WO-US005841.
 10-MAR-2000; 2000WO-US006319.
 21-MAR-2000; 2000WO-US007532.
 30-MAR-2000; 2000WO-US008439.
 17-MAY-2000; 2000WO-US013705.
 22-MAY-2000; 2000WO-US014042.
 30-MAY-2000; 2000WO-US014941.
 02-JUN-2000; 2000WO-US015264.
 28-JUL-2000; 2000WO-US020710.
 24-AUG-2000; 2000WO-US023328.
 01-DEC-2000; 2000WO-US032678.
 20-DEC-2000; 2000WO-US034956.
 28-FEB-2001; 2001WO-US006520.
 22-MAR-2001; 2001WO-US009552.
 25-MAY-2001; 2001WO-US017092.
 01-JUN-2001; 2001WO-US017800.
 20-JUN-2001; 2001WO-US019692.
 29-JUN-2001; 2001WO-US021086.
 09-JUL-2001; 2001WO-US021735.
 30-JUL-2001; 2001US-00918585.
 (GETH) GENENTECH INC.

XX Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Eaton DL;
 XX Perrera N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
 XX Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillian KJ;
 XX Klijavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
 XX Stewart TA, Tumas D, Williams PM, Wood W;
 XX WPI; 2004-008994/01.
 XX P-PSDB; ADE48857.

PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO4993 or
 PT PRO337, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.

XX Claim 2; SEQ ID NO 522; 460pp; English.

XX The invention relates to an isolated PRO polypeptide (secreted or
 XX transmembrane protein) having at least 80% amino acid sequence identity
 XX to an amino acid sequence chosen from 94 fully defined sequences as given
 XX in the specification (including PRO lacking its associated signal
 XX peptide, a PRO extracellular domain with or without its associated signal
 XX peptide). Also included are nucleic acids encoding the PRO proteins
 XX mentioned above, a vector comprising a PRO nucleic acid, a host cell
 XX comprising the vector and producing PRO, a chimeric molecule comprising
 XX PRO fused to a heterologous amino acid sequence, and an anti-PRO
 XX antibody. PRO337 polypeptide is useful for detecting a PRO4993
 XX polypeptide in a sample suspected of containing PRO4993 polypeptide.
 XX Similarly, PRO4993 polypeptide is useful for detecting PRO337
 XX polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
 XX PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
 XX PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
 XX bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
 XX molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
 XX causes death of the cell. PRO337 polypeptide is useful for linking a
 XX bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
 XX PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
 XX to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
 XX useful for linking a bioactive molecule to a cell expressing PRO725,
 XX PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
 XX polypeptide is useful for modulating at least one biological activity of
 XX the cell expressing PRO337 polypeptide, where the cell is killed. PRO337

QY 841 ACAAAGGGGACATGCGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACAAAGGGGACATGCGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGGATGACAAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAGTGAAGAAACGACCTTT 960
Db 901 CAAGGATGACAAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAGTGAAGAAACGACCTTT 960
QY 961 CCTCTCAAAATCTCATCTCTCTCAATGCTCTGAACATGACTATGCGGAATACACTTGGCT 1020
Db 961 CCTCTCAAAATCTCATCTCTCTCAATGCTCTGAACATGACTATGCGGAATACACTTGGCT 1020
QY 1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGCGCGCT 1080
Db 1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGCGCGCT 1080
QY 1081 CAGCGAGGTGACACGACGCGTGGAGGAGGAGGCTGGCTGGCTGCTGCTCTTCT 1140
Db 1081 CAGCGAGGTGACACGACGCGTGGAGGAGGAGGCTGGCTGGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTTCTCAATTTTGTATGTGAGTGGCCATTCCTCCACCGCGGAAGGCT 1200
Db 1141 GGTCTTGACCTGCTTCTCAATTTTGTATGTGAGTGGCCATTCCTCCACCGCGGAAGGCT 1200
QY 1201 GCGCCACACACACCAACACACACGCAATGCGACACGACGACGACCAATCAGATA 1260
Db 1201 GCGCCACACACACCAACACACGCAATGCGACACGACGACGACCAATCAGATA 1260
QY 1261 TATACAAATGAAATTTAGAGAAACACACGCTCATGGGACGAAATTTGAGGAGGGGAAC 1320
Db 1261 TATACAAATGAAATTTAGAGAAACACACGCTCATGGGACGAAATTTGAGGAGGGGAAC 1320
QY 1321 AAAGATATCTTGGGGGAAAGAGTTTAAAGAAATTTAAAGAAATTTGAAATTTGCAATA 1380
Db 1321 AAAGATATCTTGGGGGAAAGAGTTTAAAGAAATTTAAAGAAATTTGAAATTTGCAATA 1380
QY 1381 TTTAGTCAATGAGTGTCTTTTCCCAACGGGAAAGAACACAGCACACCGCGCTTGG 1440
Db 1381 TTTAGTCAATGAGTGTCTTTTCCCAACGGGAAAGAACACAGCACACCGCGCTTGG 1440
QY 1441 CCCACTGCAAGTGCATGCTGCAACCTTTTGGTCCAGTGTGGGCAAGGCTCAGCGTC 1500
Db 1441 CCCACTGCAAGTGCATGCTGCAACCTTTTGGTCCAGTGTGGGCAAGGCTCAGCGTC 1500
QY 1501 TCTGCCACAGAGTGTCCCGCCAGTGGACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGTCCCGCCAGTGGACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACGAAAGAGTGTGCGGCGCCAGCGTGGCGTGGCGGCACTTTG 1620
Db 1561 GTCCATAGAGACGAAAGAGTGTGCGGCGCCAGCGTGGCGTGGCGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACGCGGTGTGTGAAACGTGAAATAAAGACGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACGCGGTGTGTGAAACGTGAAATAAAGACGCAAAAAA 1679

RESULT 134
ADD78422
ID ADD78422 standard; cDNA; 1679 bp.
XX AC ADD78422;
XX DT
XX 29-JAN-2004 (first entry)
XX DE
XX Novel human secreted and transmembrane protein PRO337 cDNA.
XX human; secreted and transmembrane protein; PRO; gene; ss; cytosstatic;
KW vulnarary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW Chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;

KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
XX gene therapy.
OS Homo sapiens.
XX US2003100737-A1.
XX 29-MAY-2003.
XX 28-AUG-2002; 2002US-00230438.
XX 15-SEP-2000; 2000US-0232887P.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2004-008987/01.
XX P-PSDB; ADD78423.
XX
XX New PRO polypeptide and nucleic acid encoding the polypeptide, useful for
PT gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX Claim 2; SEQ ID NO 125; 309pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO331, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1308, PRO1273, PRO1279, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1517, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO1341, PRO1801, PRO4333, PRO3543, PRO4344, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (i) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (ii) encoding (i) is
CC useful for chromosome and gene mapping or gene therapy. (ii) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCTTCAAGCAAAACAGTGGATTTAAATCTCTCTTGCACAGCTTGAGCAACAC 60
Db 1 GTTGTGCTCTTCAAGCAAAACAGTGGATTTAAATCTCTCTTGCACAGCTTGAGCAACAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAATCCATCCAGCCAAAAATGCAATTTCTATCTCTTGGCAAT 180
Db 121 AAGAAAAAATCATGAATCCATCCAGCCAAAAATGCAATTTCTATCTCTTGGCAAT 180
QY 181 CTTTCAGGGGCTGGCTCTGTCTCTTCTTCAAGAGTCCCGTCCGAGGGGAGATGC 240
Db 181 CTTTCAGGGGCTGGCTCTGTCTCTTCTTCAAGAGTCCCGTCCGAGGGGAGATGC 240
QY 241 CACCTTCCCCAAAGCTATGCAACCGTACCGTCCGAGGGGAGAGCGCCACCTCTAG 300
Db 241 CACCTTCCCCAAAGCTATGCAACCGTACCGTCCGAGGGGAGAGCGCCACCTCTAG 300
QY 301 GTGCACATATTGACACCGGTCTCCCGGTGGCTTGGCTTAAACCGCAGCACCATCTCTA 360
Db 301 GTGCACATATTGACACCGGTCTCCCGGTGGCTTGGCTTAAACCGCAGCACCATCTCTA 360
QY 361 TGCCTGGGAATGACAAGTGGTGCCTTGGATCCTCGCGTGGTCTCTTCTGAGCAACACCCAAAC 420
Db 361 TGCCTGGGAATGACAAGTGGTGCCTTGGATCCTCGCGTGGTCTCTTCTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCAGATCCAGAAACGTGGATGTGTATGACGAGGGGCTTACCTTGCTC 480
Db 421 GCAGTACAGCATCAGATCCAGAAACGTGGATGTGTATGACGAGGGGCTTACCTTGCTC 480
QY 481 GGTGCAGACAGACAAACCAACCGTGGATCTAGGGTCCACTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGCAGACAGACAAACCAACCGTGGATCTAGGGTCCACTCATTTGTGCAAGTATCTCC 540
QY 541 CAAAATTTGAGAGATTTCTTCAGATATCTCATTAATGAAGGAAACAAATTAAGCTCAC 600
Db 541 CAAAATTTGAGAGATTTCTTCAGATATCTCATTAATGAAGGAAACAAATTAAGCTCAC 600
QY 601 CTGCATAGCACTGGTAGACAGAGCTTACGGTCTTCTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCATAGCACTGGTAGACAGAGCTTACGGTCTTCTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCCGGAGCAGTC 720
Db 661 GGTGGCTTTGTAGTGAAGACGAATCTTGGAAATTCAGGGCATCACCCGGAGCAGTC 720
QY 721 AGGGGACTACAGTGCAGTCCCATGACGTGGCGCCCGTGGTACGGAGATGA 780
Db 721 AGGGGACTACAGTGCAGTCCCATGACGTGGCGCCCGTGGTACGGAGATGA 780
QY 781 GGTCAACCGTGAATCCACCATATTTTCAAGAGCCCAAGGTACAGGTGTCCCGTGG 840
Db 781 GGTCAACCGTGAATCCACCATATTTTCAAGAGCCCAAGGTACAGGTGTCCCGTGG 840
QY 841 ACRAAGGGGACACTGAGTGTGAGCTCAGCATCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACRAAGGGGACACTGAGTGTGAGCTCAGCATCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGAAGAAACAGACCTTT 960
Db 901 CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGAAGAAACAGACCTTT 960
QY 961 CCTCTAAAATCATCTTCTTAAATGTCTCTGAACATGATATGGGAACTACATCTGGCT 1020
Db 961 CCTCTAAAATCATCTTCTTAAATGTCTCTGAACATGATATGGGAACTACATCTGGCT 1020
QY 1021 GGCCTCCAAACAGCTGGGCGACACCAATGCGAGCATCATGTATTTGGTCCAGCGCGCT 1080
Db 1021 GGCCTCCAAACAGCTGGGCGACACCAATGCGAGCATCATGTATTTGGTCCAGCGCGCT 1080

QY 1081 CAGCGAGTGAAGCAACGGCAGCTCGAGAGGGCAGGCTGGTCTGGCTGCTCTTCT 1140
Db 1081 CAGCGAGTGAAGCAACGGCAGCTCGAGAGGGCAGGCTGGTCTGGCTGCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTAGTGCACCTTCCCAACCCGGGAAAGGCT 1200
Db 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTAGTGCACCTTCCCAACCCGGGAAAGGCT 1200
QY 1201 GCCGCCACCAACACCAACACAGCATGCGACACCGACAGCAACCAATCAGATA 1260
Db 1201 GCCGCCACCAACACCAACACAGCATGCGACACCGACAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGAAC 1320
Db 1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGAAC 1320
QY 1321 AAGAATATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAAAATTCCTTCAGATA 1380
Db 1321 AAGAATATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAAAATTCCTTCAGATA 1380
QY 1381 TTTAGGTACATGGAGTTTCTTTTCCAAACGGGAAAGACACAGCACACCCGGCTTGG 1440
Db 1381 TTTAGGTACATGGAGTTTCTTTTCCAAACGGGAAAGACACAGCACACCCGGCTTGG 1440
QY 1441 CCCACTGCAAGCTGATCGTGCAACCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGCTGATCGTGCAACCTTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCACGTGGACATTTCTGGAGCTGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCACGTGGACATTTCTGGAGCTGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACGAACAGAAATGAGACCTTCCGGCCCAAGCTGCGTGGCGGCACTTG 1620
Db 1561 GTCCATAGAGACGAACAGAAATGAGACCTTCCGGCCCAAGCTGCGTGGCGGCACTTG 1620
QY 1621 GTAGACTGTGCCACACCGCTGTGTGTGAACGTGAATTAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACACCGCTGTGTGTGAACGTGAATTAAGAGCAAAAAA 1679

RESULT 135
ADE41305
ID ADE41305 standard; cDNA; 1679 BP.
XX ADE41305;
XX
XX
XX 29-JAN-2004 (first entry)
XX
XX Human secreted/transmembrane PRO polypeptide cDNA #28.
DE
XX
XX ss; gene; human; secreted protein; transmembrane protein;
KW cardiovascular disorder; endothelial disorder; angiogenic disorder;
KW myocardial infarction; cardiac hypertrophy; trauma; cancer;
KW age-related macular degeneration; angiogenesis;
KW endothelial cell apoptosis; smooth muscle cell growth;
KW endothelial cell tube formation.
OS
XX Homo sapiens.
XX
XX US2003100497-A1.
XX
XX 29-MAY-2003.
XX
XX 16-AUG-2002; 2002US-00223085.
XX
XX 20-JUN-2001; 2001WO-US019692.
PR 09-JUL-2001; 2001WO-US021735.
PR 20-FEB-2002; 2002US-00081056.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI

PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;
PI Watanabe CK, Williams PM, Wood WI, Ye W;
DR WPI; 2004-008957/01.
DR P-PSDB; ADE41306.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO205 or
PT PRO214, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and for treating disorders involving
PT angiogenesis.
XX
PS Claim 2; SEQ ID NO 55; 492bp; English.
XX
CC The invention relates to an isolated nucleic acid encoding a secreted and
CC transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded
CC by the nucleic acid, or an agonist or antagonist, is used to treat a
CC cardiovascular, endothelial, or angiogenic disorder in a mammal,
CC preferably a human. The human may have suffered a myocardial infarction
CC or has cardiac hypertrophy, trauma, a cancer, or age-related macular
CC degeneration. The cardiac hypertrophy is characterised by the presence of
CC an elevated level of PGR-2 alpha. A PRO polypeptide, given in the
CC specification, or an agonist is used to inhibit or stimulate endothelial
CC cell growth in a mammal. PRO21 or an agonist is used to induce cardiac
CC hypertrophy. PRO1376 or PRO1449 is used to stimulate angiogenesis.
CC PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO
CC polypeptide, given in the specification, or an agonist is used to
CC stimulate or inhibit smooth muscle cell growth, or to induce endothelial
CC cell tube formation. The present sequence represents a cDNA encoding a
CC PRO polypeptide of the invention.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTGTGTCCTTCAGCAAAACAGTGAATTAATCTCTTGCACAGCTTGAGCCACAC 60
DB 1 GTGTGTCCTTCAGCAAAACAGTGAATTAATCTCTTGCACAGCTTGAGCCACAC 60
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAGAACATCGAGCAAAATGACAAATTCCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAGAACATCGAGCAAAATGACAAATTCCTCTTGGGCAAT 180
QY 181 CTTTCAGGGGCTGGCTGCTCTGTGTCCTTCCAGGAGTGCCTGCGCAGCGAGATGC 240
DB 181 CTTTCAGGGGCTGGCTGCTCTGTGTCCTTCCAGGAGTGCCTGCGCAGCGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGACAAAGTACGGTCCGGCAGGGGAGAGCGCCCTCAG 300
DB 241 CACCTTCCCAAGCTATGGACAAAGTACGGTCCGGCAGGGGAGAGCGCCCTCAG 300
QY 301 GTGCATATTGACAAACCGGCTCACCCTGCGCTGGCTTAACCGCAGCAACCTCTTA 360
DB 301 GTGCATATTGACAAACCGGCTCACCCTGCGCTGGCTTAACCGCAGCAACCTCTTA 360
QY 361 TGTGGGAATGACAGTGTGCTGATCTCTCGCTGCTCTTCTGAGCAACCCCAAC 420
DB 361 TGTGGGAATGACAGTGTGCTGATCTCTCGCTGCTCTTCTGAGCAACCCCAAC 420
QY 421 GCAGTACAGCTGAGATCCAGAACCTGATGATGATGATGATGATGATGATGATGAT 480
DB 421 GCAGTACAGCTGAGATCCAGAACCTGATGATGATGATGATGATGATGATGATGAT 480
QY 481 GTGTCAGACAGCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCCT 540
DB 481 GTGTCAGACAGCAACCAACCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCCT 540
QY 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAACAATATTAGCCTCAC 600

DB 541 CAAAATTGTAGAGATTTCTTCAGATATCTTCATTAATGAAGGAACAATATTAGCCTCAC 600
QY 601 CTGCATAGCAACTGGTAGACACAGACCTACCGTTACTTTGGAGACACATCTCTCCAAAGC 660
DB 601 CTGCATAGCAACTGGTAGACACAGACCTACCGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCAGGACAGTC 720
DB 661 GGTGGCTTTGTGAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCAGGACAGTC 720
QY 721 AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGCGCGCGCGCGGTGATCGGAGAGTAAA 780
DB 721 AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGCGCGCGCGGTGATCGGAGAGTAAA 780
QY 781 GGTACCGGTGAATCTCCACCATATCTTCAGAACCCAGGGTACAGGTGTCCTCCGTTGG 840
DB 781 GGTACCGGTGAATCTCCACCATATCTTCAGAACCCAGGGTACAGGTGTCCTCCGTTGG 840
QY 841 ACAAAGGGGACACTGCACTGCAAGCTTCAGAGTGCCTCAGCAGTAATTCAGTGTGTA 900
DB 841 ACAAAGGGGACACTGCACTGCAAGCTTCAGAGTGCCTCAGCAGTAATTCAGTGTGTA 900
QY 901 CAAGGATGACAAAGACTGATTTGAAGAAAGAAAGGGTGAAGTGGAAACAGACCTTT 960
DB 901 CAAGGATGACAAAGACTGATTTGAAGAAAGAAAGGGTGAAGTGGAAACAGACCTTT 960
QY 961 CCTCTCAAAACTCATCTCTTCAATGCTCTGAAACATGACTATGGAACTACACTTGGGT 1020
DB 961 CCTCTCAAAACTCATCTCTTCAATGCTCTGAAACATGACTATGGAACTACACTTGGGT 1020
QY 1021 GGCTCTCAACAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGGGCGCT 1080
DB 1021 GGCTCTCAACAGCTGGGCGCACCAATGCCAGCATCATGCTATTTGGTCCAGGGCGCT 1080
QY 1081 CAGCGAGGTGAGCAACCGCACCGTTCGAGGAGGCGAGGCTGGCTGCTGCTCTTCT 1140
DB 1081 CAGCGAGGTGAGCAACCGCACCGTTCGAGGAGGCGAGGCTGGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGCACTGCTCTTCAAAATTTTGTATGTGAGTGCCTTCCCGACCGGGGAAAGGT 1200
DB 1141 GGTCTTGCACTGCTCTTCAAAATTTTGTATGTGAGTGCCTTCCCGACCGGGGAAAGGT 1200
QY 1201 GCGGCCACACACACACCAACCAACAGCAATGGCAACACCGCACAGCAACCAATCAGATA 1260
DB 1201 GCGGCCACACACACACCAACCAACAGCAATGGCAACACCGCACAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATTAAGAAAGAACACAGCTCTCATGGGACAGAAATTTGAGGGAGGGAAAC 1320
DB 1261 TATACAAATGAATTAAGAAAGAACACAGCTCTCATGGGACAGAAATTTGAGGGAGGGAAAC 1320
QY 1321 AAGAATATCTTGGGGGAAAGAGATTTTAAAAAGAAATTTGAAATTCCTTGCAGATA 1380
DB 1321 AAGAATATCTTGGGGGAAAGAGATTTTAAAAAGAAATTTGAAATTCCTTGCAGATA 1380
QY 1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAACCGGGGAAAGAACACAGCACCCGGCTTGA 1440
DB 1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAACCGGGGAAAGAACACAGCACCCGGCTTGA 1440
QY 1441 CCCACTGCAAGCTGCATCTGTGCAACCTCTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGCATCTGTGCAACCTCTTGGTGCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCACAGTGGAAATTTCTGAGTGTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTGCCTCCACAGTGGAAATTTCTGAGTGTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGACCAACAGATGAGCTTCCCGCCCAAGCGTGGCGCTGGGGCACTTTG 1620
DB 1561 GTCCATAGACCAACAGATGAGCTTCCCGCCCAAGCGTGGCGCTGGGGCACTTTG 1620
QY 1621 GTAGCTGTGCCACCGCGCTGTGTGTGAAACGTGAAATAAAAAGAGCAAAAAA 1679

QY 841 ACAAAGGGGACATGCGAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB |||||
QY 841 ACAAAGGGGACATGCGAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB |||||
QY 901 CAAGGATGACAAAAGACATGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT 960
DB |||||
QY 901 CAAGGATGACAAAAGACATGATTGAAGGAAAGAAAGGGGTGAAAGTGGAAAAACAGACCTTT 960
DB |||||
QY 961 CTTCTCAAAATCATCTTCTTCAATGTCTCTGAAATGACATGATGGAACTACCTTGGT 1020
DB |||||
QY 961 CTTCTCAAAATCATCTTCTTCAATGTCTCTGAAATGACATGATGGAACTACCTTGGT 1020
DB |||||
QY 1021 GCGCTCCAAAGCTGGGGCCACACCAATGCCAGCATCATGCTATTGTGTCAGGCGCGT 1080
DB |||||
QY 1021 GCGCTCCAAAGCTGGGGCCACACCAATGCCAGCATCATGCTATTGTGTCAGGCGCGT 1080
DB |||||
QY 1081 CAGCGAGTGAAGCAAGCGACATGAGGAGGCGAGCTGCGTCTGCTGCTGCTCTTCT 1140
DB |||||
QY 1081 CAGCGAGTGAAGCAAGCGACATGAGGAGGCGAGCTGCGTCTGCTGCTGCTCTTCT 1140
DB |||||
QY 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCGCCGGAAGGCT 1200
DB |||||
QY 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTGAGTGCCACTTCCCGCCGGAAGGCT 1200
DB |||||
QY 1201 GCGGCCACACCAACCAACCAACCAAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
DB |||||
QY 1201 GCGGCCACACCAACCAACCAACCAAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
DB |||||
QY 1261 TATACAAATGAATATAGAAAGCAACAGCTCATGGGACAGAAATTCGAGGAGGGGAAC 1320
DB |||||
QY 1261 TATACAAATGAATATAGAAAGCAACAGCTCATGGGACAGAAATTCGAGGAGGGGAAC 1320
DB |||||
QY 1321 AAAGATACTTTGGGGGAAAAGATTTTAAAAAGAAATGAAAAATTCCTTGCAGATA 1380
DB |||||
QY 1321 AAAGATACTTTGGGGGAAAAGATTTTAAAAAGAAATGAAAAATTCCTTGCAGATA 1380
DB |||||
QY 1381 TTTAGTCAATGAGTCTTTCTTTCCCAACCGGAGGACACACACACCGGCTTGGGA 1440
DB |||||
QY 1381 TTTAGTCAATGAGTCTTTCTTTCCCAACCGGAGGACACACACACCGGCTTGGGA 1440
DB |||||
QY 1441 CCACATGCAAGTGCATGTCGCAACTTTTGGTCCAGTGTGGCAAGGCTCAGCCTC 1500
DB |||||
QY 1441 CCACATGCAAGTGCATGTCGCAACTTTTGGTCCAGTGTGGCAAGGCTCAGCCTC 1500
DB |||||
QY 1501 TCTGCCACAGAGTGCCTCCACGTCGGAATCTGGAGTGGCCATCCCAATTCATCA 1560
DB |||||
QY 1501 TCTGCCACAGAGTGCCTCCACGTCGGAATCTGGAGTGGCCATCCCAATTCATCA 1560
DB |||||
QY 1561 GTCCATAGAGACGAAACAGAAATGAGACTTCCGGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
DB |||||
QY 1561 GTCCATAGAGACGAAACAGAAATGAGACTTCCGGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
DB |||||
QY 1621 GTAGACTGTCCACACGCGCTGTGTGTAACGTGAATAAAGAGCAAAAAA 1679
DB |||||
QY 1621 GTAGACTGTCCACACGCGCTGTGTGTAACGTGAATAAAGAGCAAAAAA 1679
DB |||||

RESULT 137

AD21245
ID ADE21245 standard; cdna; 1679 BP.

AC ADE21245;

XX
DT 29-JAN-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO337 cdna.

XX Human; secreted and transmembrane protein; PRO; gene; ss; cyrostatic;
KW vulnary; antlarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;

KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
XX gene therapy.

XX Homo sapiens.

XX US2003100736-A1.

XX 29-MAY-2003.

XX 28-AUG-2002; 2002US-00230435.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2004-008986/01.

XX P-PSDB; ADE21246.

XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
XX in gene therapy, chromosome identification, tissue typing, or as
XX hybridization probes in chromosome and gene mapping.

XX Claim 2; Fig 125; 309pp; English.

XX The invention describes an isolated PRO (secreted and transmembrane)
XX polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
XX useful for stimulating the proliferation of or gene expression in
XX pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
XX for stimulating the proliferation or differentiation of chondrocyte
XX cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
XX are useful for stimulating the release of tumour necrosis factor (TNF)-
XX alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
XX PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
XX PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
XX PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
XX PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
XX PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1477, PRO1760, PRO1567,
XX PRO1887, PRO1928, PRO3441, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
XX PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
XX stimulating the proliferation of normal human dermal fibroblasts cells.

XX PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
XX PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
XX inhibiting the proliferation of normal human dermal fibroblast cells. PRO
XX polypeptides such as PRO5004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
XX are useful for detecting the presence of tumour in a mammal which
XX involves comparing the level of expression of the above PRO polypeptides
XX in a test sample of cells taken from the mammal, and a control sample of
XX normal cells of the same cell type, where a higher level of expression of
XX the PRO polypeptides in the test sample as compared to the control sample
XX is indicative of the presence of tumour in the mammal. The tumour is lung
XX tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
XX liver tumour. (I) is useful as molecular weight markers, for tissue
XX typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
XX useful for chromosome and gene mapping or gene therapy. (II) is useful
XX for generating transgenic animals or knock-out animals which are useful
XX screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
XX is useful for treating bone and/or cartilage disorders (e.g., arthritis,
XX sport injuries). This sequence encodes a human secreted and transmembrane
XX PRO polypeptide.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6.7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCTCAGCAAAACAGTGGATTTAAATCTCTTGCACAGCTTGAGCAACAC 60
DB 1 GTTGTGCTCTCAGCAAAACAGTGGATTTAAATCTCTTGCACAGCTTGAGCAACAC 60
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAACCATCAGCAAAATGCAAAATGCAAAATGCAAAATGCAAAAT 180
DB 121 AAGAAAAAATCATGAAACCATCAGCAAAATGCAAAATGCAAAATGCAAAATGCAAAAT 180
QY 181 CTTTCAAGGGGCTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 240
DB 181 CTTTCAAGGGGCTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 240
QY 241 CACCTTCCCAAGCTATGACAAACGTGACGGTCCGGGAGGGGAGGGGAGGGGAGGGGAGGG 300
DB 241 CACCTTCCCAAGCTATGACAAACGTGACGGTCCGGGAGGGGAGGGGAGGGGAGGGGAGGG 300
QY 301 GTGCACATTTGACAAACCGGGTCAACCGGGTGGCTGGCTGCTGCTGCTGCTGCTGCTGCT 360
DB 301 GTGCACATTTGACAAACCGGGTCAACCGGGTGGCTGGCTGCTGCTGCTGCTGCTGCTGCT 360
QY 361 TGTGGGAATGACAAAGTGGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 420
DB 361 TGTGGGAATGACAAAGTGGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 420
QY 421 GCAGTACAGCATCAGATCAGAAACGTGAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 480
DB 421 GCAGTACAGCATCAGATCAGAAACGTGAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 480
QY 481 GGTGACAGACAGCAACCAACCAAGACCTTAGGGTCCACTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGACAGACAGCAACCAACCAAGACCTTAGGGTCCACTCATTTGTGCAAGTATCTCC 540
QY 541 CAAAATTTGAGAGATTTCTTCAAGATCTCCATTAATGAAGGAAACAAATTAAGGCTCAC 600
DB 541 CAAAATTTGAGAGATTTCTTCAAGATCTCCATTAATGAAGGAAACAAATTAAGGCTCAC 600
QY 601 CTGCATAGCACTGGTAGACAGAGCCTAGCGTTACTTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCACTGGTAGACAGAGCCTAGCGTTACTTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGAGCAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTGAGTGAAGAGCAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACAGTGCAGTGCCTCCAATGACGTGGCGCGCGCGCGCGCGCGCGCGCGCG 780
DB 721 AGGGGACTACAGTGCAGTGCCTCCAATGACGTGGCGCGCGCGCGCGCGCGCGCGCGCG 780
QY 781 GGTCAACCGTGAATATCCACATCATTTCAAGAGCCAGGATCAGGTGTCCCGTGGG 840
DB 781 GGTCAACCGTGAATATCCACATCATTTCAAGAGCCAGGATCAGGTGTCCCGTGGG 840
QY 841 ACAAAAGGGGACACTGCACTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
DB 841 ACAAAAGGGGACACTGCACTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
QY 901 CARGATGACAAAAGACTGATGAGGAAAGAAAGGGGTGAAAGTGAAGAAACAGACCTTT 960
DB 901 CARGATGACAAAAGACTGATGAGGAAAGAAAGGGGTGAAAGTGAAGAAACAGACCTTT 960
QY 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGCAATGCTGCAATGCTGCAATGCTGCAATGCT 1020
DB 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGCAATGCTGCAATGCTGCAATGCTGCAATGCT 1020
QY 1021 GGCCTTCCAAAGCTGGGCGCACCAATGCGAGCATATGCTATTTGGTCAGGCGCGCT 1080
DB 1021 GGCCTTCCAAAGCTGGGCGCACCAATGCGAGCATATGCTATTTGGTCAGGCGCGCT 1080
QY 1081 CAGCAGGTGAGCAACGGCAGCTCAGAGGGGCGGCTGCGCTGCTGCTGCTGCTGCTTCT 1140

DB 1081 CAGCAGGTGAGCAACGGCAGCTCAGAGGGGCGGCTGCGCTGCTGCTGCTGCTTCT 1140
QY 1141 GGTCTTCCACTGCTTCTTCAAAATTTGATGAGTGCCTTCCCTCCCGGGAAGGCT 1200
DB 1141 GGTCTTCCACTGCTTCTTCAAAATTTGATGAGTGCCTTCCCTCCCGGGAAGGCT 1200
QY 1201 GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA 1260
DB 1201 GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAGATA 1260
QY 1261 TATCAAAATGAAATAGAAAGAAACAGGCTCATGGGACAGAAATTTGAGGGGAGGGAAC 1320
DB 1261 TATCAAAATGAAATAGAAAGAAACAGGCTCATGGGACAGAAATTTGAGGGGAGGGAAC 1320
QY 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTTCAGATA 1380
DB 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTTCAGATA 1380
QY 1381 TTTAGGTACAAATGAGTTTCTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGA 1440
DB 1381 TTTAGGTACAAATGAGTTTCTTTCCCAACCGGGAAGAACACAGCACACCCGGCTTGA 1440
QY 1441 CCCACTGCAAGCTCATGTCGCAACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGGCTC 1500
DB 1441 CCCACTGCAAGCTCATGTCGCAACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGGCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCACAGTGGAAACATTTCTGAGCTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTGCCTCCACAGTGGAAACATTTCTGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACGACAGAAATGAGACCTTCCCGGCCCAAGCGTGGCGTCCGGCACCTTG 1620
DB 1561 GTCCATAGAGACGACAGAAATGAGACCTTCCCGGCCCAAGCGTGGCGTCCGGCACCTTG 1620
QY 1621 GTAGACTGTGCCACCAACCGGCTGTGTTGAAACGTGAAATTAAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACCAACCGGCTGTGTTGAAACGTGAAATTAAGAGCAAAAAA 1679

RESULT 138
ADD77360
ID ADD77360 standard; cdNA; 1679 BP.

XX AC ADD77360;
XX DT 29-JAN-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO337 cDNA.
KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnery; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.

OS Homo sapiens.
XX
XX PN US2003100732-A1.
XX
XX PD 29-MAY-2003.
XX
XX PF 28-AUG-2002; 2002US-00230306.
XX
XX PR 01-JUN-2001; 2001WO-US017800.
XX PR 29-JUN-2001; 2001WO-US021066.
XX PR 09-APR-2002; 2002US-00119480.
XX
XX PA (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CX, Wood WI;
XX WPI; 2004-008982/01.
DR P-PSDB; ADD77361.
XX
PT New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT in gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX
PS Claim 2; SEQ ID NO 125; 308pp; English.
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1150, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO1272, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO1272, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO326, PRO363, PRO531, PRO1083, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
CC PRO1286, PRO1330, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO1341, PRO1801, PRO4333, PRO3543, PRO4344, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (i) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (ii) encoding (i) is
CC useful for chromosome and gene mapping or gene therapy. (ii) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTCTCTCAGCAAAAACAGTGATTTAAATCTCTTTCACCAAGCTTGAGAGCAAC 60
DB 1 GTTGTCTCTCAGCAAAAACAGTGATTTAAATCTCTTTCACCAAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAAATCATGAAAAACATCAGCAAAAATGCAATTTCTCTCTTGGGCAAT 180
DB 121 AAGAAAAAAATCATGAAAAACATCAGCAAAAATGCAATTTCTCTCTTGGGCAAT 180
QY 181 CTTACGGGGCTGGCTGTCTGTGTCTTTTCAAGAGAGTGCCCGGACGGAGATGC 240
DB 181 CTTACGGGGCTGGCTGTCTGTGTCTTTTCAAGAGAGTGCCCGGACGGAGATGC 240
QY 241 CACCTTCCCAAGCTPATGACAAAGTGACGGTCCGGCAGGGGGAGAGCGCCCTCAG 300
DB 241 CACCTTCCCAAGCTPATGACAAAGTGACGGTCCGGCAGGGGGAGAGCGCCCTCAG 300

DB 241 CACCTTCCCAAGCTPATGACAAAGTGACGGTCCGGCAGGGGGAGAGCGCCCTCAG 300
QY 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTGGCTTAAACCCGACAGCAATCTCTTA 360
DB 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTTGGCTTAAACCCGACAGCAATCTCTTA 360
QY 361 TGTGGAATGACAAAGTGTGCTGATCTCGCTGGTTCCTTCTGAGCAACACCAAC 420
DB 361 TGTGGAATGACAAAGTGTGCTGATCTCGCTGGTTCCTTCTGAGCAACACCAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGACAGACAGACACCCCAAGACCTTAGGGTCCACCTCATTTGTCAGATGTCTCC 540
DB 481 GGTGACAGACAGACACCCCAAGACCTTAGGGTCCACCTCATTTGTCAGATGTCTCC 540
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAACAAATATTAGCCTCAC 600
DB 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGAACAAATATTAGCCTCAC 600
QY 601 CTGCATAGCACTGTGTAGACCGCTTACCTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCACTGTGTAGACCGCTTACCTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGACGAATTTGGAATTTAGGGGCATCACCCGGGAGCAGTTC 720
DB 661 GGTGGCTTTGTGAGTGAAGACGAATTTGGAATTTAGGGGCATCACCCGGGAGCAGTTC 720
QY 721 AGGGGACTAGAGTGCAGTGCCTCAATACGTGGCCGGCCGGTGTGACGAGAGATAA 780
DB 721 AGGGGACTAGAGTGCAGTGCCTCAATACGTGGCCGGCCGGTGTGACGAGAGATAA 780
QY 781 GGTCAACGTGAATATCCACCATATATTTGAGAGCCAAAGGTGAGAGTGTCTCCCGTGG 840
DB 781 GGTCAACGTGAATATCCACCATATATTTGAGAGCCAAAGGTGAGAGTGTCTCCCGTGG 840
QY 841 ACAAAGGGGACACTGCAGTGTGAAGCTTCAAGAGCCAAAGGTGAGAGTGTCTCCCGTGG 900
DB 841 ACAAAGGGGACACTGCAGTGTGAAGCTTCAAGAGCCAAAGGTGAGAGTGTCTCCCGTGG 900
QY 901 CAAGGATGACAAAGACTGATTTGAAGAAAGAAAGGGTGAAGTGAAGAAACAGACCTTT 960
DB 901 CAAGGATGACAAAGACTGATTTGAAGAAAGAAAGGGTGAAGTGAAGAAACAGACCTTT 960
QY 961 CCTCTCAAACTCATCTTCTTCAATGTCTCTGAAATGATGAGTGTGAGTGTGCTGCTTCT 1020
DB 961 CCTCTCAAACTCATCTTCTTCAATGTCTCTGAAATGATGAGTGTGAGTGTGCTGCTTCT 1020
QY 1021 GGCTCTCAACAGCTGGGCCACACCAATGCCAGCATCATGCTATTGTTGGTCCAGGGCCGT 1080
DB 1021 GGCTCTCAACAGCTGGGCCACACCAATGCCAGCATCATGCTATTGTTGGTCCAGGGCCGT 1080
QY 1081 CAGCGAGGTGAGCAACCGGCAACGTGAGAGGGGAGGCTGCTGCTGCTGCTGCTTCTTCT 1140
DB 1081 CAGCGAGGTGAGCAACCGGCAACGTGAGAGGGGAGGCTGCTGCTGCTGCTGCTTCTTCT 1140
QY 1141 GGTCTTGCACCTTCTTCAATTTTGTGATGTGAGTGTGAGTGTGCTGCTGCTGCTTCTTCT 1200
DB 1141 GGTCTTGCACCTTCTTCAATTTTGTGATGTGAGTGTGAGTGTGCTTCTTCTTCTTCTTCT 1200
QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
DB 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
QY 1261 TATACAAATGAAATTTAGAGAAACACAGCTCATTTGGGACAGAAATTTGAGGGGGGAAAC 1320
DB 1261 TATACAAATGAAATTTAGAGAAACACAGCTCATTTGGGACAGAAATTTGAGGGGGGAAAC 1320
QY 1321 AAGAAATATCTTTGGGGGGGAAAGAGTTTTTAAAGAAATTTGAAATTTGCTTTCAGATA 1380
DB 1321 AAGAAATATCTTTGGGGGGGAAAGAGTTTTTAAAGAAATTTGAAATTTGCTTTCAGATA 1380

1381 TTTAGTCAATGGAGTTTCTTTCCCAACCGGAAGAACACAGACACCCGGCTTGA 1440
 1381 TTTAGTCAATGGAGTTTCTTTCCCAACCGGAAGAACACAGACACCCGGCTTGA 1440
 1441 CCACATGCAAGTGCATCTGCAACTCTTTGTGCGAGTGGGCAAGGGCTCAGCGCTC 1500
 1441 CCACATGCAAGTGCATCTGCAACTCTTTGTGCGAGTGGGCAAGGGCTCAGCGCTC 1500
 1501 TCTGCCACAGAGTGCCTCCACAGTGAACATTTCTGAGTGGCCATCCCAATTCAATCA 1560
 1501 TCTGCCACAGAGTGCCTCCACAGTGAACATTTCTGAGTGGCCATCCCAATTCAATCA 1560
 1561 GTCATAGAGACGAAAGATGAGACTTCCGGCCCAAGCGTGGCGGCACTTTG 1620
 1561 GTCATAGAGACGAAAGATGAGACTTCCGGCCCAAGCGTGGCGGCACTTTG 1620
 1621 GTAGACTGTGCCACACCGCGGTGTGTGTAACCTGTAATATAAAGAGCAAAAAA 1679
 1621 GTAGACTGTGCCACACCGCGGTGTGTGTAACCTGTAATATAAAGAGCAAAAAA 1679

RESULT 139
 ADE20507
 ID ADE20507 standard; cDNA; 1679 BP.
 AC ADE20507;
 XX
 XX 29-JAN-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO337 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss; cytosstatic;
 KW vulnary; antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX
 OS Homo sapiens.
 XX
 XX US2003100733-A1.
 XX
 XX 29-MAY-2003.
 XX
 XX 28-AUG-2002; 2002US-00230426.
 XX
 XX 01-JUN-2001; 2001WO-US017800.
 XX
 XX 29-JUN-2001; 2001WO-US021066.
 XX
 XX 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX
 XX WPI; 2004-008983/01.
 XX
 XX P-PSDB; ADE20508.
 XX
 XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
 XX in gene therapy, chromosome identification, tissue typing, or as
 XX PT hybridization probes in chromosome and gene mapping.
 XX
 XX Claim 2; Fig 125; 308pp; English.
 XX
 XX The invention describes an isolated PRO (secreted and transmembrane)
 XX polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 XX useful for stimulating the proliferation of or gene expression in
 XX CC pericyte cells. PRO357, PRO259, PRO1272 or PRO4405 polypeptide are useful
 XX for stimulating the proliferation or differentiation of chondrocyte

CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1358,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO341, PRO1801, PRO1409, PRO3543, PRO3444, PRO4332,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GTTGTGCTTTCAGCAAAACAGTGGATTTAAATCTCTTCGACAAAGCTTGAGAGCAACAC 60
 DB 1 GTTGTGCTTTCAGCAAAACAGTGGATTTAAATCTCTTCGACAAAGCTTGAGAGCAACAC 60
 QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 DB 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 QY 121 AAGAAAAAATCATGAAAAACCATTCAGCCAAATGCAAAATCTATCTCTTGGGCAAT 180
 DB 121 AAGAAAAAATCATGAAAAACCATTCAGCCAAATGCAAAATCTATCTCTTGGGCAAT 180
 QY 181 CTTACGGGGCTGGCTGCTGTGTCTCTTCCAGGAGTCCCGTGGCGAGCGAGATGC 240
 DB 181 CTTACGGGGCTGGCTGCTGTGTCTCTTCCAGGAGTCCCGTGGCGAGCGAGATGC 240
 QY 241 CACCTTCCCAAGCTATGGACAAACGTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
 DB 241 CACCTTCCCAAGCTATGGACAAACGTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
 QY 301 GTGCACCTTTGACAAACCGGGTCCACCGGGTGGCTGGCTAAACCGCAGACCACTTCTTA 360
 DB 301 GTGCACCTTTGACAAACCGGGTCCACCGGGTGGCTGGCTAAACCGCAGACCACTTCTTA 360
 QY 361 TGCTGGGAATGACAAAGTGGTGGCTTCTCGCGTGGTCTCTCTGAGCAACACCCAAAC 420
 DB 361 TGCTGGGAATGACAAAGTGGTGGCTTCTCGCGTGGTCTCTCTGAGCAACACCCAAAC 420
 QY 421 GCAGTACAGCATTCAGATTCAGAACCGTGGATGTGTATGACAGGGGCTTACACCTGCTC 480
 DB 421 GCAGTACAGCATTCAGATTCAGAACCGTGGATGTGTATGACAGGGGCTTACACCTGCTC 480
 QY 481 GGTGCAGACAGCAACACCCAAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
 DB 481 GGTGCAGACAGCAACACCCAAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;									
Query Match 100.0%; Score 1679; DB 1; Length 1679;									
Best Local Similarity 100.0%; Pred. No. 6.7e-05;									
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
Qy	1	GTGTGTCTTCAGCAAAACAGTGGATTTAAATCTCTCTGCAAAAGCTTGAGAGCAACAC	60						
Db	1	GTGTGTCTTCAGCAAAACAGTGGATTTAAATCTCTCTGCAAAAGCTTGAGAGCAACAC	60						
Qy	61	AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120						
Db	61	AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120						
Qy	121	AAGAAAAAATCATGAAACCAATCCAGCCAAATAATGCAATTTCTATCTCTTTGGGCAAT	180						
Db	121	AAGAAAAAATCATGAAACCAATCCAGCCAAATAATGCAATTTCTATCTCTTTGGGCAAT	180						
Qy	181	CTTCACGGGGTGGCTCTCTGTCTCTCTTCCTCAAGAGTCCCGTGGGAGCGGATGC	240						
Db	181	CTTCACGGGGTGGCTCTCTGTCTCTCTTCCTCAAGAGTCCCGTGGGAGCGGATGC	240						
Qy	241	CACCTTCCCAAGCTATGACAACTGACGGTCCGGCAGGGGAGAGCGCCCTCAG	300						
Db	241	CACCTTCCCAAGCTATGACAACTGACGGTCCGGCAGGGGAGAGCGCCCTCAG	300						
Qy	301	GTGCACTATTGACAAACCGGCTACCCGGGTGGCTTAAACCGGAGCAACATCTCTTA	360						
Db	301	GTGCACTATTGACAAACCGGCTACCCGGGTGGCTTAAACCGGAGCAACATCTCTTA	360						
Qy	361	TGCTGGGAATGACAAAGTGGTGGATCTCTGGGTGGTCTCTGAGCAACCAAC	420						
Db	361	TGCTGGGAATGACAAAGTGGTGGATCTCTGGGTGGTCTCTGAGCAACCAAC	420						
Qy	421	GCATACAGCATCGAGATCCAGAAACGTTGGATGTATGACGAGGGCCCTTACACCTGTC	480						
Db	421	GCATACAGCATCGAGATCCAGAAACGTTGGATGTATGACGAGGGCCCTTACACCTGTC	480						
Qy	481	GGTGCAGACGACAAACCAACGCTCTAGGGTCCACTTGTGCAAGTATCTCC	540						
Db	481	GGTGCAGACGACAAACCAACGCTCTAGGGTCCACTTGTGCAAGTATCTCC	540						
Qy	541	CAAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAAATATTAGCCTAC	600						
Db	541	CAAAATTTGAGAGATTTCTTCAGATATCTCCATTAATGAAGGAAACAAATATTAGCCTAC	600						
Qy	601	CTGCATAGCACTGGTAGACAGAGCCTACGGTTACTTGGAGACATCTCTCCCAAGC	660						
Db	601	CTGCATAGCACTGGTAGACAGAGCCTACGGTTACTTGGAGACATCTCTCCCAAGC	660						
Qy	661	GGTTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720						
Db	661	GGTTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC	720						
Qy	721	AGGGGACTACGAGTGCAGTGCTCCAAATGACGTGGCCGGCCGGTGTGACGGAGTAA	780						
Db	721	AGGGGACTACGAGTGCAGTGCTCCAAATGACGTGGCCGGCCGGTGTGACGGAGTAA	780						
Qy	781	GGTCACCGTGAATCATCCACCATACATTCAGAGGCAAGGTACAGGTGTCCCGTGGG	840						
Db	781	GGTCACCGTGAATCATCCACCATACATTCAGAGGCAAGGTACAGGTGTCCCGTGGG	840						
Qy	841	ACAAAAGGGGACATGAGCTGTGAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900						
Db	841	ACAAAAGGGGACATGAGCTGTGAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900						
Qy	901	CAAGGATGACAAAGACTGATTGAAGGAAGAAAGGGGTGAAGTGGAAACAGACCTTT	960						
Db	901	CAAGGATGACAAAGACTGATTGAAGGAAGAAAGGGGTGAAGTGGAAACAGACCTTT	960						
Qy	961	CCTCTCAAAATCTCATCTTTCAATGTCTCTGAACTGAACTATGGGAACCTACCTTGCCT	1020						
Db	961	CCTCTCAAAATCTCATCTTTCAATGTCTCTGAACTGAACTATGGGAACCTACCTTGCCT	1020						

RESULT 141

ADD74088
ID ADD74088 standard; cDNA; 1679 BP.
XX
AC ADD74088;
XX
DT 29-JAN-2004 (first entry)
XX

Human PRO polynucleotide #63.

Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
tumour; cancer; lung; colon; breast; prostate; rectum; liver;
tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
arthritis; sports injury; cytostatic; antiarthritic.

Homo sapiens.

XX
XX US2003100708-A1.

XX
XX 29-MAY-2003.

XX
XX 09-AUG-2002; 2002US-00216160.

XX
XX 01-AUG-2000; 2000US-0222425P.

PR
PR 01-JUN-2001; 2001WO-US017800.

PR
PR 29-JUN-2001; 2001WO-US021066.

09-APR-2002; 2002US-00119480.
(GETH) GENENTECH INC.
Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PU;
Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
P-PSDB; ADD74089.
WPI; 2004-008958/01.
New secreted and transmembrane PRO polypeptide useful for preparing a
medicament for treating a condition that is responsive to the PRO
polypeptide or anti-PRO antibody, e.g. cancer.
Claim 2; Fig 125; 308pp; English.
The invention relates to human PRO polypeptides (secreted and
transmembrane polypeptides) and the PRO polynucleotides encoding them.
The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
diagnostics, biosensors or bioeffectors. They are particularly useful for
detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
prostate tumour, rectal tumour or liver tumour) in a mammal, for
stimulating the release of tumour necrosis factor (TNF)-alpha from human
blood, for stimulating the proliferation or differentiation of
chondrocyte cells, for stimulating the proliferation of or gene
expression in pericyte cells or for stimulating the proliferation of
normal human dermal fibroblasts. The PRO nucleic acids are useful as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA, in preparing PRO polypeptides by recombinant
technology, in generating transgenic animals or knock-out animals which
may be used in the development and screening of therapeutically useful
reagents, in gene therapy, in chromosome identification, as chromosome
markers and in generating probes. The PRO polypeptides, or anti-PRO
antibodies, are useful for preparing a medicament for treating a
condition which is responsive to the PRO polypeptides or anti-PRO
antibodies, such as pericyte-associated tumours and bone and/or cartilage
disorders (e.g. arthritis, sports injuries), involving inducing the re-
differentiation of chondrocytes. The PRO polypeptides are useful as
molecular markers for protein electrophoresis, and in tissue typing. This
sequence represents a human PRO polynucleotide of the invention. Note:
The sequence data for this patent is also available in electronic format
at seqdata.uspto.gov/sequence.html.

Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 GTTGTCTCTTTCAGCAAAACAGTGGATTAAATCTCTTGTGCAAGCTTGAGCAACAC 60
1 GTTGTCTCTTTCAGCAAAACAGTGGATTAAATCTCTTGTGCAAGCTTGAGCAACAC 60
61 AATCTATCAGGAAG 120
61 AATCTATCAGGAAG 120
121 AG 180
121 AG 180
181 CTTTCAGGGGTGGTCTGTCTGTCTCTTCAAGAGTGGCCGTGCGCAGCGAGATGC 240
181 CTTTCAGGGGTGGTCTGTCTGTCTCTTCAAGAGTGGCCGTGCGCAGCGAGATGC 240
241 CACCTTCCCAAGAGCTATGAGCAACCGTACGGTCCGGAGAGGGGAGAGCGCCACCTCAG 300
241 CACCTTCCCAAGAGCTATGAGCAACCGTACGGTCCGGAGAGGGGAGAGCGCCACCTCAG 300
301 GTGCACTATTGACACCGGGTACCCTGGTCTAAACCGCAGCAGCATCTCTTA 360
301 GTGCACTATTGACACCGGGTACCCTGGTCTAAACCGCAGCAGCATCTCTTA 360

361 TGCTGGGAATGACAAAGTGGTGCCTCGATCCTCGCTGGTCTCTTCTGAGCAACACCCAAAC 420
361 TGCTGGGAATGACAAAGTGGTGCCTCGATCCTCGCTGGTCTCTTCTGAGCAACACCCAAAC 420
421 GCAGTACACATCGAGATCCAGAACGTGTATGATGACGAGGCGCTTACACCTGTCTC 480
421 GCAGTACACATCGAGATCCAGAACGTGTATGATGACGAGGCGCTTACACCTGTCTC 480
481 GGTGACAGACAGAACCAACCCCAAGACCTCTAGGCTCCACCTCATTTGCAAGTATCTCC 540
481 GGTGACAGACAGAACCAACCCCAAGACCTCTAGGCTCCACCTCATTTGCAAGTATCTCC 540
541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCTAC 600
541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCTCTAC 600
601 CTGCATAGCAACTGCTAGACAGAGCCTACGCTTACTTTGAGACACATCTCTCCAAAGC 660
601 CTGCATAGCAACTGCTAGACAGAGCCTACGCTTACTTTGAGACACATCTCTCCAAAGC 660
661 GGTGCTTTTGTGAGTGAAGAGATCTTGAATTCAGGACATCACCCTGGGAGCAGTC 720
661 GGTGCTTTTGTGAGTGAAGAGATCTTGAATTCAGGACATCACCCTGGGAGCAGTC 720
721 AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCGCGCGCTGGTACGAGAGTAAA 780
721 AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCGCGCGCTGGTACGAGAGTAAA 780
781 GGTACCGTGAATCTACCATATTCATTTGAGAGCCAGGCTACAGGTGTCCTCCGTTGG 840
781 GGTACCGTGAATCTACCATATTCATTTGAGAGCCAGGCTACAGGTGTCCTCCGTTGG 840
841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGTGA 900
901 CAAGGATGACAAAGACTGATTTGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 960
901 CAAGGATGACAAAGACTGATTTGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 960
961 CCTCTCAAAACTCATCTTCTCAATGCTCTGAAACATGACTATGGGAACTACACTTGGCT 1020
961 CCTCTCAAAACTCATCTTCTCAATGCTCTGAAACATGACTATGGGAACTACACTTGGCT 1020
1021 GGCTCTCAACAGCTGGGCGACACCAATGCGAGCATCTGCTATTTGGTCCAGGCGCGCT 1080
1021 GGCTCTCAACAGCTGGGCGACACCAATGCGAGCATCTGCTATTTGGTCCAGGCGCGCT 1080
1081 CAGCGAGTGCAGCAACGCGACGTCGAGGAGGCGAGCTGCTGCTGCTGCTCTTCT 1140
1081 CAGCGAGTGCAGCAACGCGACGTCGAGGAGGCGAGCTGCTGCTGCTGCTCTTCT 1140
1141 GGTCTTGCACTGCTTCTCAAAATTTTGTGATGTCGCTCTTCCCTCCCGGAGAGGCT 1200
1141 GGTCTTGCACTGCTTCTCAAAATTTTGTGATGTCGCTCTTCCCTCCCGGAGAGGCT 1200
1201 GCGCGCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
1201 GCGCGCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
1261 TATACAAATGAATTAAGAGAAACACAGCTCTATGGGACAGAAATTTGAGGGAGGGAAC 1320
1261 TATACAAATGAATTAAGAGAAACACAGCTCTATGGGACAGAAATTTGAGGGAGGGAAC 1320
1321 AAAGATACCTTTGCGGGGAGAGAGATTTTAAAGAGAAATTTGAAATTTGCTTTCAGATA 1380
1321 AAAGATACCTTTGCGGGGAGAGAGATTTTAAAGAGAAATTTGAAATTTGCTTTCAGATA 1380
1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAACCGGAGAGAACACAGCAGACCCCGCTTGA 1440
1381 TTTAGGTACAAATGGAGTTTCTTTTCCAAACCGGAGAGAACACAGCAGACCCCGCTTGA 1440
1441 CCCACTGCAAGCTGCATCGTGCACCTCTTTGGTGCAGTGTGGGAGGGCTCAGCCTC 1500

[illegible]

RESULT 142
ADD74334
ID ADD74334 standard; cDNA; 1679 BP.

Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
 tumour; cancer; lung; colon; trnf-alpha; prostate; rectum; liver;
 tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
 pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
 arthritis; sports injury; cyostatic; antiarthritic.

OS
X OS Homo sapiens.
XX
PN US2003100709-A1.
XX
PD 29-MAY-2003.
XX
PF 09-AUG-2002; 2002US-00216162.
XX
PR 23-JUL-2000; 2000US-0220585P.
PR 01-JUN-2001; 2001WO-US017800.
PR 23-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
PI WPI; 2004-008959/01.
XX P-PSDB: ADD74335.
DR

XX
PT New secreted and transmembrane PRO polypeptide useful for preparing a
PT medicament for treating a condition that is responsive to the PRO
PT polypeptide or anti-PRO antibody, e.g. cancer.

XX
PS
Claim 2; Fig 125; 309pp; English.

The invention relates to human PRO polypeptides (secreted and transmembrane polypeptides) and the PRO polynucleotides encoding them. The PRO polypeptides and polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. They are particularly useful for detecting tumours (e.g. lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour) in a mammal, for stimulating the release of tumour necrosis factor (TNF)-alpha from human chondrocyte cells, for stimulating the proliferation or differentiation of blood, for stimulating the proliferation or differentiation of or gene expression in pericyte cells or for stimulating the proliferation of normal human dermal fibroblasts. The PRO nucleic acids are useful as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, in preparing PRO polypeptides by recombinant technology, in generating transgenic animals or knock-out animals which

Db 781 GGTACCGTGAACATATCCACCATACATTTTCAGAACCCAGGTTACAGGTGTCCCGTGGG 840
Qy 841 ACAAAGGGGACATGCGAGTGTGAAGCCTCAGAGTGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACAAAGGGGACATGCGAGTGTGAAGCCTCAGAGTGTCCCTCAGCAGAAATTCAGTGGTA 900
Qy 901 CAAGGATCAAAAGACATGATTGAAGGAAAGAAAGGGGTGAAGTGCAGAAACAGACCTTT 960
Db 901 CAAGGATCAAAAGACATGATTGAAGGAAAGAAAGGGGTGAAGTGCAGAAACAGACCTTT 960
Qy 961 CCTCTCAAAATCATCTTCTTCAATGTCTCTGAACATGATATATGGGAATCATCTTCGCT 1020
Db 961 CCTCTCAAAATCATCTTCTTCAATGTCTCTGAACATGATATATGGGAATCATCTTCGCT 1020
Qy 1021 GGCCTCCAAAGCTGGGCCACACCAATGCGCAGCATCATGTATTTGGTCCAGGCGCGT 1080
Db 1021 GGCCTCCAAAGCTGGGCCACACCAATGCGCAGCATCATGTATTTGGTCCAGGCGCGT 1080
Qy 1081 CAGCAGGTGAGCAACGCGCATGAGGAGGCGAGGCTGCGTGTGGCTGTGCTCTCTCT 1140
Db 1081 CAGCAGGTGAGCAACGCGCATGAGGAGGCGAGGCTGCGTGTGGCTGTGCTCTCTCT 1140
Qy 1141 GGTCTTGACCTGCTCTCTCAATTTTGAATGAGTGCCACTTCCCAACCGGGAAGGCT 1200
Db 1141 GGTCTTGACCTGCTCTCTCAATTTTGAATGAGTGCCACTTCCCAACCGGGAAGGCT 1200
Qy 1201 GCGGCACACCAACCAACACACACCAATGCGCAACACCGCAGCAACCAATCAGATA 1260
Db 1201 GCGGCACACCAACCAACACACCAATGCGCAACACCGCAGCAACCAATCAGATA 1260
Qy 1261 TATACAAATGAATTAGAAGAAACACGCTCTGAGCAAGAAATTTGAGGAGGGGAAC 1320
Db 1261 TATACAAATGAATTAGAAGAAACACGCTCTGAGCAAGAAATTTGAGGAGGGGAAC 1320
Qy 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTTCAGATA 1380
Db 1321 AAAGAAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTTCAGATA 1380
Qy 1381 TTTAGTACATGAGTTTCTTTTCCAAACGGGAAGCAACACAGCAGCAGCCGCTTGA 1440
Db 1381 TTTAGTACATGAGTTTCTTTTCCAAACGGGAAGCAACACAGCAGCAGCCGCTTGA 1440
Qy 1441 CCCACTGCAAGTGCATGTCGAACCTCTTTGGTGCCAGTGTGGGCAAGGCTCAGCCTC 1500
Db 1441 CCCACTGCAAGTGCATGTCGAACCTCTTTGGTGCCAGTGTGGGCAAGGCTCAGCCTC 1500
Qy 1501 TCTGCCACAGAGTGCCTCCAGTGGACATCTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1501 TCTGCCACAGAGTGCCTCCAGTGGACATCTGGAGCTGGCCATCCCAATTCATCA 1560
Qy 1561 GTCCATAGACGAAACAGAAATGAGACCTTCCGGGCCAAGCGTGGCGTCCGCGCACTTTG 1620
Db 1561 GTCCATAGACGAAACAGAAATGAGACCTTCCGGGCCAAGCGTGGCGTCCGCGCACTTTG 1620
Qy 1621 GTAGACTGTGCCACAGCGCGTGTGTGAAACGTGAAATTAAGAGCAAAAAA 1679
Db 1621 GTAGACTGTGCCACAGCGCGTGTGTGAAACGTGAAATTAAGAGCAAAAAA 1679

RESULT 143

ADD76064

ID ADD76064 standard; cDNA; 1679 BP.

AC ADD76064;

XX ADD76064;

DT 29-JAN-2004 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO337 cDNA.

XX human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;

KW vulnary; antiarthritic; pericyte cell proliferation;

KW pericyte cell differentiation; chondrocyte cell proliferation;

KW chondrocyte cell differentiation; tumour necrosis factor alpha release;

KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX Homo sapiens.
XX OS
XX US2003100718-A1.
XX 29-MAY-2003.
XX 13-AUG-2002; 2002US-00219467.
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.

Baker KF, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

WPI; 2004-008968/01.

P-PSDB; ADD76065.

New secreted and transmembrane PRO polypeptides and nucleic acids, useful

in gene therapy, or for preparing a medicament for treating a condition

that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.

cancer.

Claim 2; SEQ ID NO 125; 308pp; English.

The invention describes an isolated PRO (secreted and transmembrane)

polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are

useful for stimulating the proliferation of or gene expression in

pericyte cells. PRO357, PRO329, PRO1272 or PRO4405 polypeptide are useful

for stimulating the proliferation or differentiation of chondrocyte

cells. PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide

are useful for stimulating the release of tumour necrosis factor (TNF)-

alpha from human blood. PRO982, PRO357, PRO1306, PRO1419, PRO1214,

PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,

PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,

PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,

PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,

PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567,

PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4322,

PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for

stimulating the proliferation of normal human dermal fibroblasts cells.

PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,

PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for

inhibiting the proliferation of normal human dermal fibroblast cells. PRO

polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,

are useful for detecting the presence of tumour in a mammal which

involves comparing the level of expression of the above PRO polypeptides

in a test sample of cells taken from the mammal, and a control sample of

normal cells of the same cell type, where a higher level of expression of

the PRO polypeptides in the test sample as compared to the control sample

is indicative of the presence of tumour in the mammal. The tumour is lung

tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or

liver tumour. (I) is useful as molecular weight markers, for tissue

typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is

useful for chromosome and gene mapping or gene therapy. (II) is useful

for generating transgenic animals or knock-out animals which are useful

screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide

is useful for treating bone and/or cartilage disorders (e.g., arthritis,

sport injuries). This sequence encodes a human secreted and transmembrane

PRO polypeptide.

XX

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query March 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6.7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	1 GTTGTGCTCTAGCAAAACAGTGGATTTAAATCTCTTTGCAACAAGCTTTGAGAGCAAC 60
DB	1 GTTGTGCTCTAGCAAAACAGTGGATTTAAATCTCTTTGCAACAAGCTTTGAGAGCAAC 60
QY	61 AATCTATCAGGAAGAAAGAAAGAAACCGAAGCTGCAAAAAGAAAGAAAGAAAG 120
DB	61 AATCTATCAGGAAGAAAGAAAGAAACCGAAGCTGCAAAAAGAAAGAAAGAAAG 120
QY	121 AAGAAAAAATCATGAAAAACCATCCAGGCCAAAAATGCAAAATCTATCTTTGGGCAAT 180
DB	121 AAGAAAAAATCATGAAAAACCATCCAGGCCAAAAATGCAAAATCTATCTTTGGGCAAT 180
QY	181 CTTCACGGGCTGGCTCTCTGTGTCTCTTCCAAAGAGTCCCGTGGCGAGCGGAGATGC 240
DB	181 CTTCACGGGCTGGCTCTCTGTGTCTCTTCCAAAGAGTCCCGTGGCGAGCGGAGATGC 240
QY	241 CACCTTCCCAAGCTATGACAACGTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
DB	241 CACCTTCCCAAGCTATGACAACGTGACGGTCCGGCAGGGGAGAGCGCCACCTCAG 300
QY	301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAAACGGCAGCAACATTCCTCTA 360
DB	301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAAACGGCAGCAACATTCCTCTA 360
QY	361 TGTGSGGAATGACAAGTGGTCCCTGGATCCTCGCGTGTCTCTTGTGAGCAACACCCAAAC 420
DB	361 TGTGSGGAATGACAAGTGGTCCCTGGATCCTCGCGTGTCTCTTGTGAGCAACACCCAAAC 420
QY	421 GCAGTCAGCATTCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
DB	421 GCAGTCAGCATTCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
QY	481 GGTGCGAGACAGCAACCAACCGCAAGACTCTAGGGTCCACTCATTTGTGCAAGTATCTCC 540
DB	481 GGTGCGAGACAGCAACCAACCGCAAGACTCTAGGGTCCACTCATTTGTGCAAGTATCTCC 540
QY	541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
DB	541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
QY	601 CTGCATAGCAACTGGTATAGACAGAGCCTACGGTTACTTTGAGAGACACATCTCTCCAAAGC 660
DB	601 CTGCATAGCAACTGGTATAGACAGAGCCTACGGTTACTTTGAGAGACACATCTCTCCAAAGC 660
QY	661 GGTGGCTTTCTGTAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB	661 GGTGGCTTTCTGTAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY	721 AGGGGACTACGAGTGCAGTGCCTCAATAGCGTGGCCGCGCCCGTGTGACGGAGATGAA 780
DB	721 AGGGGACTACGAGTGCAGTGCCTCAATAGCGTGGCCGCGCCCGTGTGACGGAGATGAA 780
QY	781 GGTCAAGTGAACCTATCCACCATATTCAGAGCCCAAGGATACAGGTGTCCCGGGGG 840
DB	781 GGTCAAGTGAACCTATCCACCATATTCAGAGCCCAAGGATACAGGTGTCCCGGGGG 840
QY	841 ACAAAGGGGACATGCAAGTGTGAAGCCTCAGCAGTCCCTTCAGCAGAAATTCAGTGGTA 900
DB	841 ACAAAGGGGACATGCAAGTGTGAAGCCTCAGCAGTCCCTTCAGCAGAAATTCAGTGGTA 900
QY	901 CAAGGATGACAAAAGACTGATTTGAAGGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
DB	901 CAAGGATGACAAAAGACTGATTTGAAGGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
QY	961 CCTCTCAAAATCTATCTTTCAATGTCTGTGAACATGACTATGGGAACCTACACTTCGCT 1020
DB	961 CCTCTCAAAATCTATCTTTCAATGTCTGTGAACATGACTATGGGAACCTACACTTCGCT 1020
QY	1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGGCCGT 1080
DB	1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGGCCGT 1080

Qy	1081	CAGGAGGTGAGCAACGGCAGCTCGAGGAGGCGAGCTGGCTCTGGCTGCTGCTCTCT	1144
Db	1081	CAGCGAGGTGAGCAACGGCAGCTCGAGGAGGCGAGCTGGCTCTGGCTGCTGCTCTCTCT	1140
Qy	1141	GGTCTTGCACTGCTTCTCAAAATTTTGATGTAGTGCACATTCCTCCCAACCGGGAAGGCT	1200
Db	1141	GGTCTTGCACTGCTTCTCAAAATTTTGATGTAGTGCACATTCCTCCCAACCGGGAAGGCT	1200
Qy	1201	GCGCCACACGACCCACCAACACACAGCAATGGCCACACGACAGCAACCAATCAGATA	1260
Db	1201	GCGCCACACGACCCACCAACACACAGCAATGGCCACACGACAGCAACCAATCAGATA	1260
Qy	1261	TATACAAATGAAATTAGAGAGAAACACACAGCCTCATGGACAGAAATTTGAGGAGGGGAAC	1320
Db	1261	TATACAAATGAAATTAGAGAGAAACACACAGCCTCATGGACAGAAATTTGAGGAGGGGAAC	1320
Qy	1321	AAAGAAATCTTTGGGGGAAAAGATTTTAAAGAGAAATTTGAAATTCCTTCAGATA	1380
Db	1321	AAAGAAATCTTTGGGGGAAAAGATTTTAAAGAGAAATTTGAAATTCCTTCAGATA	1380
Qy	1381	TTTAGGTACAAATGAGATTTTCTTTTCCCAACCGGGAAGAACACACAGCACCCTGGG	1440
Db	1381	TTTAGGTACAAATGAGATTTTCTTTTCCCAACCGGGAAGAACACACAGCACCCTGGG	1440
Qy	1441	CCCACTGCAAGCTGCATGTCGTCGAAACCTCTTTGGTGCCAGTGTGGGCAAGGCTCAGCCTC	1500
Db	1441	CCCACTGCAAGCTGCATGTCGTCGAAACCTCTTTGGTGCCAGTGTGGGCAAGGCTCAGCCTC	1500
Qy	1501	TCTGCCACACAGAGTCCGCCACGCTGGAAACATTTCTGGAGCTGGCCATCCCAAAATCAATCA	1560
Db	1501	TCTGCCACACAGAGTCCGCCACGCTGGAAACATTTCTGGAGCTGGCCATCCCAAAATCAATCA	1560
Qy	1561	GTCCATAGAGACGAAACAGAAATGAGACCTTCCGGGCCAAGCGTGGGCTGGGGCACTTTG	1620
Db	1561	GTCCATAGAGACGAAACAGAAATGAGACCTTCCGGGCCAAGCGTGGGCTGGGGCACTTTG	1620
Qy	1621	GTAGACTGTGCCACACAGCGGCTGTGTGTGAAAACGTGAAAATAAGAGCAAAAAAAA	1679
Db	1621	GTAGACTGTGCCACACAGCGGCTGTGTGTGAAAACGTGAAAATAAGAGCAAAAAAAA	1679
RESULT 144			
ADD85556			
ID	ADD85556	standard; cDNA; 1679 BP.	
XX	AC	ADD85556;	
XX	AC	ADD85556;	
XX	DT	29-JAN-2004 (first entry)	
XX	DE	Novel human secreted and transmembrane protein PRO337 cDNA.	
XX	KW	human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;	
XX	KW	vulvular; antiarthritic; pericyte cell proliferation;	
XX	KW	pericyte cell differentiation; chondrocyte cell proliferation;	
XX	KW	chondrocyte cell differentiation; tumor necrosis factor alpha release;	
XX	KW	(TNF)-alpha release; dermal fibroblast cell proliferation;	
XX	KW	dermal fibroblast cell differentiation inhibitor; tumor; lung tumour;	
XX	KW	colon tumour; breast tumour; prostate tumour; rectal tumour;	
XX	KW	liver tumour; tissue typing; chromosome mapping; gene mapping;	
XX	OS	Homo sapiens.	
XX	OS	Homo sapiens.	
XX	PN	US2003100721-A1.	
XX	XX	29-MAY-2003.	
XX	XX	13-AUG-2002; 2002US-00219473.	
XX	PF	01-JUN-2001; 2001WO-US017800.	
XX	PR	29-JUN-2001; 2001WO-US021066.	
XX	PR	09-APR-2002; 2002US-00119480.	

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX DR WPI: 2004-008971/01.

XX DR P-PSDB; ADD85557.

XX PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful

XX PT in gene therapy, or for preparing a medicament for treating a condition

XX PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.

XX PT cancer.

XX PS Claim 2; SEQ ID NO 125; 308pp; English.

XX CC The invention describes an isolated PRO (secreted and transmembrane)

CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO329 polypeptide are

CC useful for stimulating the proliferation of or gene expression in

CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful

CC for stimulating the proliferation or differentiation of chondrocyte

CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide

CC are useful for stimulating the release of tumour necrosis factor (TNF)-

CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,

CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,

CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,

CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,

CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,

CC PRO1343, PRO1376, PRO1387, PRO1401, PRO1474, PRO1917, PRO1567,

CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,

CC PRO3940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for

CC stimulating the proliferation of normal human dermal fibroblasts cells.

CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,

CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for

CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO

CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,

CC are useful for detecting the presence of tumour in a mammal which

CC involves comparing the level of expression of the above PRO polypeptides

CC in a test sample of cells taken from the mammal, and a control sample of

CC normal cells of the same cell type, where a higher level of expression of

CC the PRO polypeptides in the test sample as compared to the control sample

CC is indicative of the presence of tumour in the mammal. The tumour is lung

CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or

CC liver tumour. (I) is useful as molecular weight markers, for tissue

CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is

CC useful for chromosome and gene mapping or gene therapy. (II) is useful

CC for generating transgenic animals or knock-out animals which are useful

CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide

CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,

CC sport injuries). This sequence encodes a human secreted and transmembrane

CC PRO polypeptide.

XX SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Pred. No. 6,7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTTCAGCACAACAGTGGATTAAATCTCTTCGACAAAGCTTGAGACCAAC 60

DB 1 GTTGTGCTTCAGCACAACAGTGGATTAAATCTCTTCGACAAAGCTTGAGACCAAC 60

QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

QY 121 AAGAAAAAATCATGAAAAATCCAGCCAAATGCAAAATGCAAAATGCAAAATGCAAAAT 180

DB 121 AAGAAAAAATCATGAAAAATCCAGCCAAATGCAAAATGCAAAATGCAAAATGCAAAAT 180

QY 181 CTTCAAGGGGGTGGTGTCTGTGTCTCTTCCAAAGAGAGTCCCGTGGCAGCGAGATGC 240

DB 181 CTTCAAGGGGGTGGTGTCTGTGTCTCTTCCAAAGAGAGTCCCGTGGCAGCGAGATGC 240

QY 241 CACCTTCCCAAGCTATGGACAACGTCGTCGCGGAGGGGAGAGCGGCCACCCCTCAG 300

DB 241 CACCTTCCCAAGCTATGGACAACGTCGTCGCGGAGGGGAGAGCGGCCACCCCTCAG 300

QY 301 GTGCACTATTGACAAACCGGGTCACCCGGGTGGCTGCTAAACCGCAGCACCATCTCTTA 360

DB 301 GTGCACTATTGACAAACCGGGTCACCCGGGTGGCTGCTAAACCGCAGCACCATCTCTTA 360

QY 361 TGCTGGGAATGACAAAGTGGTGGATCCCTGGTGGTCTCTTCTGAGCAACACCCAAAC 420

DB 361 TGCTGGGAATGACAAAGTGGTGGATCCCTGGTGGTCTCTTCTGAGCAACACCCAAAC 420

QY 421 GCAGTACAGCATCGAGATCCAGAACGTCGATGTGTATGACGAGGGCCCTTACACCTGCTC 480

DB 421 GCAGTACAGCATCGAGATCCAGAACGTCGATGTGTATGACGAGGGCCCTTACACCTGCTC 480

QY 481 GTGCAGACAGCAACCAACCAAGACCTTAGGGTCCACCTCATTTGCAAGTATCTCC 540

DB 481 GTGCAGACAGCAACCAACCAAGACCTTAGGGTCCACCTCATTTGCAAGTATCTCC 540

QY 541 CAAAATTGTAGAGATTCTTCAGATATCTCCATTAAATGAAGGGAACAATATTAGCCTCAC 600

DB 541 CAAAATTGTAGAGATTCTTCAGATATCTCCATTAAATGAAGGGAACAATATTAGCCTCAC 600

QY 601 CTGCATAGCAACTGTAGACAGACCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660

DB 601 CTGCATAGCAACTGTAGACAGACCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660

QY 661 GGTGGCTTTGTGAGTGAAGACGATATCTTGAATTCAGGGCATCACCCGGGAGCAGTC 720

DB 661 GGTGGCTTTGTGAGTGAAGACGATATCTTGAATTCAGGGCATCACCCGGGAGCAGTC 720

QY 721 AGGGAGCTACGAGTGCAGTGCCTCAATGACGTGGCCGCGCGCTGGTACGGAGAGTAAA 780

DB 721 AGGGAGCTACGAGTGCAGTGCCTCAATGACGTGGCCGCGCGCTGGTACGGAGAGTAAA 780

QY 781 GGTACCGTGAACACTTCCACCATACATTTCAAGACCAAGGATACAGGTGTCGCCGCGG 840

DB 781 GGTACCGTGAACACTTCCACCATACATTTCAAGACCAAGGATACAGGTGTCGCCGCGG 840

QY 841 ACAAAGGGGACACTGCGAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGTGTGA 900

DB 841 ACAAAGGGGACACTGCGAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGTGTGA 900

QY 901 CAAGGATGACAAAGACCTGATTGAAGGAAGAAAGGGGTGAAGTGAAGTGAAGTGAAGT 960

DB 901 CAAGGATGACAAAGACCTGATTGAAGGAAGAAAGGGGTGAAGTGAAGTGAAGTGAAGT 960

QY 961 CCTCTCAAAACCTCATCTTCAATGTCTCTCAACATGACTATGGGAATACACTTGGGT 1020

DB 961 CCTCTCAAAACCTCATCTTCAATGTCTCTCAACATGACTATGGGAATACACTTGGGT 1020

QY 1021 GGCCTTCAAGCTGGGCGCACCAATGCCAGCATCATGCTATTGGTCCAGGGCGGT 1080

DB 1021 GGCCTTCAAGCTGGGCGCACCAATGCCAGCATCATGCTATTGGTCCAGGGCGGT 1080

QY 1081 CAGCGAGGTGAGCAACCGGCACGTCGAGGAGGGCAGGCTCGGTCTGGCTGCTCTTCT 1140

DB 1081 CAGCGAGGTGAGCAACCGGCACGTCGAGGAGGGCAGGCTCGGTCTGGCTGCTCTTCT 1140

QY 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTGAGTGGCCACTTCCCAACCGGGGAAGGT 1200

DB 1141 GGTCTTGACCTGCTTCTCAAAATTTTGTGAGTGGCCACTTCCCAACCGGGGAAGGT 1200

QY 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAT 1260

DB 1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAT 1260

QY 1261 TATCAAAATGAAATTTAGAAAGAACACAGCTCATGGGACAGAAATTTGAGGGAGGGAC 1320

DB 1261 TATCAAAATGAAATTTAGAAAGAACACAGCTCATGGGACAGAAATTTGAGGGAGGGAC 1320

QY 1321 AAAGATACCTTTGGGGGAAAGAGTTTAAAGAAATTCGAAATTCGCTTGCAGATA 1380
DB 1321 AAAGATACCTTTGGGGGAAAGAGTTTAAAGAAATTCGAAATTCGCTTGCAGATA 1380
QY 1381 TTATGATCAATGAGATTTCTTTTCCCAACCGGGAAGAACACAGACACACCCGGCTTGA 1440
DB 1381 TTATGATCAATGAGATTTCTTTTCCCAACCGGGAAGAACACAGACACACCCGGCTTGA 1440
QY 1441 CCACATGCAAGCTGCATCGTGCACCTCTTTTGTGCGCAGTGTGGGCAAGGGCTCAGCCTC 1500
DB 1441 CCACATGCAAGCTGCATCGTGCACCTCTTTTGTGCGCAGTGTGGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCTCCCAACGTCGAAATCTTGTGAGTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTGCCTCCCAACGTCGAAATCTTGTGAGTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACCAAGATGAGCTTCCCGCCCAAGCGTGGCGCTGGGGCACTTTG 1620
DB 1561 GTCCATAGAGACCAAGATGAGCTTCCCGCCCAAGCGTGGCGCTGGGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCGCGCTGTGTGTAACGTAATTAAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACCGCGCTGTGTGTAACGTAATTAAGAGCAAAAAA 1679
RESULT 145
ADE23904
ID ADE23904 standard; cDNA; 1679 BP.
AC ADE23904;
XX ADE23904;
DT 29-JAN-2004 (first entry)
XX cDNA encoding human PRO polypeptide #188.
XX Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; PFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS
XX
XX US2003092110-A1.
XX 15-MAY-2003.
XX
XX 03-MAY-2002; 2002US-00137864.
XX
XX 03-MAR-2000; 2000US-0187202P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Geirritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI: 2004-020235/02.
XX P-PSDB; ADE23905.
XX
XX New secreted and transmembrane nucleic acids and polypeptides, designated
PI as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
XX Claim 2; Fig 375; 637pp; English.
PS

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems. PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPIO website at seqdata.uspto.gov.
XX

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTCGCAAGCTTGAGACAACAC 60
DB 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTCGCAAGCTTGAGACAACAC 60
QY 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATTCATGAAAAATCCAGCCAAATATGCAAAATTCATCTCTTGGGCAAT 180
DB 121 AAGAAAAAATTCATGAAAAATCCAGCCAAATATGCAAAATTCATCTCTTGGGCAAT 180
QY 181 CTTTCACGGGCTGGCTGCTCTGTCTCTTCCAGAGAGTCCCGTGGCAGCGAGATGC 240
DB 181 CTTTCACGGGCTGGCTGCTCTGTCTCTTCCAGAGAGTCCCGTGGCAGCGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGAACAAGTGAACGGTCCGGCAGGGGAGAGCGCACCTCAG 300
DB 241 CACCTTCCCAAGCTATGGAACAAGTGAACGGTCCGGCAGGGGAGAGCGCACCTCAG 300
QY 301 GTGCACTATTGACACACCGGTCACCCGGTGGCTGGCTTAACCCGACACCATCTCTTA 360
DB 301 GTGCACTATTGACACACCGGTCACCCGGTGGCTGGCTTAACCCGACACCATCTCTTA 360
QY 361 TGCTGGGAATGACAAAGTGGTGCCTGGATCCTCGGTGGTCTCTTGTAGCAACACCCAAAC 420
DB 361 TGCTGGGAATGACAAAGTGGTGCCTGGATCCTCGGTGGTCTCTTGTAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAAAGTGTGTATGACGAGGGCCCTTACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAAAGTGTGTATGACGAGGGCCCTTACCTGCTC 480

QY	481	GGTGCAGACAGACAACACCAAGACCTT	AGGGTCCACCTCATTTGTGCAAGTATCTCC	540
DB	481	GGTGCAGACAGACAACCAACCAAGACCT	CTAGGGTCCACCTCATTTGTGCAAGTATCTCC	540
QY	541	CAAAATTTGTAGAGATTTCTT	CAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAAC	600
DB	541	CAAAATTTGTAGAGATTTCTT	CAGATATCTCCATTAATGAAGGGAACAATATTAGCTCAAC	600
QY	601	CTGCATAGCAACTGGTAGACAGAGCCT	ACGGTTACTTTGGAGACACATCTCTCCCAAAGC	660
DB	601	CTGCATAGCAACTGGTAGACAGAGCCT	ACGGTTACTTTGGAGAGACATCTCTCCCAAAGC	660
QY	661	GGTTGGCTTTGTGAGTGAAGACGAACT	TTGGAAATTCACGGGCATCACCGGAGCAGTTC	720
DB	661	GGTTGGCTTTGTGAGTGAAGACGAACT	TTGGAAATTCACGGGCATCACCGGAGCAGTTC	720
QY	721	AGGGGACTAGCAGTCAGTGCCTCC	CAATGACGTGGCGCGCTGTCGAGAGAGTAA	780
DB	721	AGGGGACTAGCAGTCAGTGCCTCC	CAATGACGTGGCGCGCTGTCGAGAGAGTAA	780
QY	781	GGTCACCGTGAACTATCCACATACAT	TTTTCAGAGCCAGGGTACAGGTGTCCCGTGGG	840
DB	781	GGTCACCGTGAACTATCCACATACAT	TTTTCAGAGCCAGGGTACAGGTGTCCCGTGGG	840
QY	841	ACAAAAGGGACACTGCAAGTGTGA	AGCGCTCAGCAGATCCCTCAGCAGAAATTC	900
DB	841	ACAAAAGGGACACTGCAAGTGTGA	AGCGCTCAGCAGATCCCTCAGCAGAAATTC	900
QY	901	CAAGGATGACAAAAGACTGATTTGA	AGAAAGAAAGGGGTGAAGTGGAAAAAC	960
DB	901	CAAGGATGACAAAAGACTGATTTGA	AGAAAGAAAGGGGTGAAGTGGAAAAAC	960
QY	961	CCTCTCAAACTCATCTTTCTCA	ATGTCCTGAACATGACTATGGAAATTC	1020
DB	961	CCTCTCAAACTCATCTTTCTCA	ATGTCCTGAACATGACTATGGAAATTC	1020
QY	1021	GGCCTCCAAAGCTGGGCCACCA	ATGCCAGATCATGTTGGTCCAGGCGCCGT	1080
DB	1021	GGCCTCCAAAGCTGGGCCACCA	ATGCCAGATCATGTTGGTCCAGGCGCCGT	1080
QY	1081	CAGCGAGGTGACAAACCGCAGCT	CGAGAGGCGAGGCTGCTGTGCTGTGCTCTCT	1140
DB	1081	CAGCGAGGTGACAAACCGCAGCT	CGAGAGGCGAGGCTGCTGTGCTGTGCTCTCT	1140
QY	1141	GGTCTTGCACTGCTTCTCAA	ATTTTGATGTAGTGCACATCCCAACCGGAAAGGCT	1200
DB	1141	GGTCTTGCACTGCTTCTCAA	ATTTTGATGTAGTGCACATCCCAACCGGAAAGGCT	1200
QY	1201	GGCGCCACCAACCAACACAC	ACAGCAATGGCACAACGAGCAACCAACCATCAGATA	1260
DB	1201	GGCGCCACCAACCAACACAC	ACAGCAATGGCACAACGAGCAACCAACCATCAGATA	1260
QY	1261	TATACAAATGAAATTTAGAA	AGAAACAACAGCCTCATGGGACAGAAATTTGAGGAGGGGGAAC	1320
DB	1261	TATACAAATGAAATTTAGAA	AGAAACAACAGCCTCATGGGACAGAAATTTGAGGAGGGGGAAC	1320
QY	1321	AAAGAAATCTTTGGGGGAAAG	AGTATTTAAAAAGAAATTTGAAATTTGCTTGCAGATA	1380
DB	1321	AAAGAAATCTTTGGGGGAAAG	AGTATTTAAAAAGAAATTTGAAATTTGCTTGCAGATA	1380
QY	1381	TTTAGGTACAATGGAGTTTCT	TTTTCCAAACCGGAAAGAACACAGCACACCCGGCTTGG	1440
DB	1381	TTTAGGTACAATGGAGTTTCT	TTTTCCAAACCGGAAAGAACACAGCACACCCGGCTTGG	1440
QY	1441	CCCACTGCAAGCTGCATCGTG	CAACCTTTTGTGTCAGGTGTGGGCAAGGGCTCAGCCTC	1500
DB	1441	CCCACTGCAAGCTGCATCGTG	CAACCTTTTGTGTCAGGTGTGGGCAAGGGCTCAGCCTC	1500
QY	1501	TCTGCCACAGAGTGCCTCC	CCAGTGGACATCTTGGAGCTGGCCATCCCAAAATTCATCA	1560
DB	1501	TCTGCCACAGAGTGCCTCC	CCAGTGGACATCTTGGAGCTGGCCATCCCAAAATTCATCA	1560
QY	1561	GTCCATAGAGACGAACA	GAATTCAGACCTTCCGGCCCAAGCGTGGCGCTGGGGCACTTTG	1620

Db	1561	GTCCATAGAGAGAAACAGAAATGAGACCTTCGCGCCCAAGCGTGCGCTGGGCACTTTG	1620
Qy	1621	GTAGACTGTGCCACCAACGCGGTGTGTGTGAACGTCGAATATAAAAGAGCAAAAAAAA	1679
Db	1621	GTAGACTGTGCCACCAACGCGGTGTGTGTGAACGTCGAATATAAAAGAGCAAAAAAAA	1679
RESULT 146			
ADE24547			
ID	XX	ADE24547 standard; cDNA; 1679 BP.	
AC	XX	ADE24547;	
XX			
DT	29-JAN-2004	(first entry)	
DE	XX	cDNA encoding human PRO polypeptide #188.	
XX	XX	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;	
XX	XX	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;	
XX	XX	cancer; adrenal, lung; colon; breast; prostate; rectum; kidney; cervix;	
XX	XX	liver; microvascular endothelial cell; glucose; PFA;	
XX	XX	skeletal muscle cell; adipocyte cell; pericyte cell;	
XX	XX	inner ear utricular supporting cell; T-lymphocyte cell;	
XX	XX	endothelial cell tube formation; bone disorder; cartilage disorder;	
XX	XX	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;	
XX	XX	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;	
XX	XX	immune system cell infiltration.	
OS	XX	Homo sapiens.	
XX	XX	US2003092111-A1.	
XX	XX	15-MAY-2003.	
PD	XX		
PF	03-MAY-2002;	2002US-00137869.	
XX	XX		
PR	03-MAR-2000;	2000US-0187202P.	
XX	XX		
PR	01-DEC-2000;	2000WO-US032678.	
XX	XX		
PR	19-DEC-2001;	2001US-00028072.	
XX	XX		
PA	(GETH) GENENTECH INC.		
XX	XX		
PI	Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;		
PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;		
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;		
XX	XX		
XX	WPI: 2004-020236/02.		
DR	P-PSDB; ADE24548.		
XX			
PT	New secreted and transmembrane nucleic acid useful for treating		
PT	inflammation, organ failure, atherosclerosis, cardiac injury,		
PT	infertility, birth defects, premature aging, acquired immunodeficiency		
PT	syndrome, or cancer.		
XX	XX		
PS	Claim 2; Fig 375; 637pp; English.		
XX	XX		
CC	The invention relates to isolated human PRO polypeptides (secreted and		
CC	transmembrane polypeptides) and the polynucleotides encoding them. The		
CC	invention also relates to an antibody which specifically binds to a PRO		
CC	polypeptide, a method for stimulating the release of tumour necrosis		
CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the		
CC	proliferation or differentiation of chondrocyte cells and a method for		
CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,		
CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The		
CC	polynucleotides are useful in molecular biology, including uses as		
CC	hybridisation probes, in chromosome and gene mapping, in generating		
CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also		
CC	be used in preparing PRO polypeptides by recombinant techniques and in		
CC	generating either transgenic animals or knock-out animals which are		
CC	useful in the development and screening of therapeutically useful		
CC	reagents. The PRO polypeptides or antibodies are used in preparing a		
CC	medicament for treating a condition responsive to the polypeptides or		

CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTGTCACAAAGCTTGAGAGCAAC 60
DB 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTGTCACAAAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAACCAATCCAGCCAAAGAAATTCATCTCTTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAACCAATCCAGCCAAAGAAATTCATCTCTTTGGGCAAT 180
QY 181 CTTACCGGGGTGGCTCTGTGTCTCTTCCAGGAGTCCCGTGGCGAGCGGAGATGC 240
DB 181 CTTACCGGGGTGGCTCTGTGTCTCTTCCAGGAGTCCCGTGGCGAGCGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGACAACTGACGCTGACGGTCCCGCAGGGGAGAGCGCCACCTCTAG 300
DB 241 CACCTTCCCAAGCTATGACAACTGACGCTGACGGTCCCGCAGGGGAGAGCGCCACCTCTAG 300
QY 301 GTGCACATATTGACAAACCGGGTCCCGGGTGGCTGCTTAAACCGGACGACCATCTCTTA 360
DB 301 GTGCACATATTGACAAACCGGGTCCCGGGTGGCTGCTTAAACCGGACGACCATCTCTTA 360
QY 361 TGCTGGGAATGACAAAGTGGTCTGATCTCTGCGTGGTCTCTTGTGAGCAACACCCAAAC 420
DB 361 TGCTGGGAATGACAAAGTGGTCTGATCTCTGCGTGGTCTCTTGTGAGCAACACCCAAAC 420
QY 421 GCAGTACAGCATCGAGATCCAGAAACGTTGATGTATGAGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCGAGATCCAGAAACGTTGATGTATGAGAGGGCCCTTACACCTGCTC 480
QY 481 GGTGACAGACAAACACCAAGAGCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGACAGACAAACACCAAGAGCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAAATTGTAGAGATTTCTCAGATATCTCAGATATCTCAATTAATGAAGGGAAACAATATTAGCTCAC 600
DB 541 CAAAATTGTAGAGATTTCTCAGATATCTCAGATATCTCAATTAATGAAGGGAAACAATATTAGCTCAC 600
QY 601 CTGCATAGCACTGGTAGACAGAGCTTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
DB 601 CTGCATAGCACTGGTAGACAGAGCTTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
QY 661 GGTGGCTTTGTAGTGAAGACGAATATCTTGAAATTCAGGGCATACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTAGTGAAGACGAATATCTTGAAATTCAGGGCATACCCGGGAGCAGTC 720
QY 721 AGGGGACTACAGTGCAGTGCCTCCAATGACGTGGCCGCGCCGCTGGTACGGAGAGTAA 780

DB 721 AGGGGACTACAGTGCAGTGCCTCCAATGACGTGGCCGCGCCGCTGGTACGGAGAGTAAA 780
QY 781 GGTCAACCGTGAACCTATCCACATATTTTCAGAAAGCCAGGGTACAGGTGTCCCGTGGG 840
DB 781 GGTCAACCGTGAACCTATCCACATATTTTCAGAAAGCCAGGGTACAGGTGTCCCGTGGG 840
QY 841 ACAAAGGGGACACTGCAAGTGTGAAGCCTCAGCAAGTCCCTCAGCAAGAAATTCAGTGGTA 900
DB 841 ACAAAGGGGACACTGCAAGTGTGAAGCCTCAGCAAGTCCCTCAGCAAGAAATTCAGTGGTA 900
QY 901 CAAGATGACAAAAGACTGATTGAAGAAAGAAAGGGGTGAAAGTGGAAACACACCTTT 960
DB 901 CAAGATGACAAAAGACTGATTGAAGAAAGAAAGGGGTGAAAGTGGAAACACACCTTT 960
QY 961 CCTCTCAAAACTCATCTCTTCTTCAATGTCTTGAACATGACTATATGCGAACTACACTTGGT 1020
DB 961 CCTCTCAAAACTCATCTCTTCTTCAATGTCTTGAACATGACTATATGCGAACTACACTTGGT 1020
QY 1021 GGCCTTCAAAAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
DB 1021 GGCCTTCAAAAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
QY 1081 CAGCGAGGTGAGCAACGCGACGTGAGGAGGCGAGGCTGCTCTGGGTGCTTGGCTCTTCT 1140
DB 1081 CAGCGAGGTGAGCAACGCGACGTGAGGAGGCGAGGCTGCTCTGGGTGCTTGGCTCTTCT 1140
QY 1141 GGTCTTGCACTGCTCTCAAAATTTTGAATGAGTGCCACTTCCCCACCCGGGAAAGGCT 1200
DB 1141 GGTCTTGCACTGCTCTCAAAATTTTGAATGAGTGCCACTTCCCCACCCGGGAAAGGCT 1200
QY 1201 GCCGCCACACCCACCAACCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
DB 1201 GCCGCCACACCCACCAACCAACAGCAATGGCAACACCGACAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAAATTTAGAAAGAAACACACCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
DB 1261 TATACAAATGAAATTTAGAAAGAAACACACCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
QY 1321 AAAGATATCTTGGGGGAAAGAGTGTAAAGAAAGAAATTTGAAATTTGAAATTTGAAATTTG 1380
DB 1321 AAAGATATCTTGGGGGAAAGAGTGTAAAGAAAGAAATTTGAAATTTGAAATTTGAAATTTG 1380
QY 1381 TTTAGGTCAATGGAGTGTCTTTTCCAAACGGGAAAGAAACACAGCACACCCGGGTTCGA 1440
DB 1381 TTTAGGTCAATGGAGTGTCTTTTCCAAACGGGAAAGAAACACAGCACACCCGGGTTCGA 1440
QY 1441 CCCACTGCAAGTGCATCGTGCAACCTTTTGGTCCAGTGTGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGTGCATCGTGCAACCTTTTGGTCCAGTGTGGCAAGGGCTCAGCCTC 1500
QY 1501 TCTGCCCAAGAGTGCCTCCACCTGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCCAAGAGTGCCTCCACCTGGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
QY 1561 GTCCATAGAGACGAAACAGATGAGACCTTCCGGCCCAAGCGTGGCGCTGCGGGCACTTG 1620
DB 1561 GTCCATAGAGACGAAACAGATGAGACCTTCCGGCCCAAGCGTGGCGCTGCGGGCACTTG 1620
QY 1621 GTAGACTGTGCCACCAAGCGGTGTCTGTGAAACCTGTAATTAAGAAAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACCAAGCGGTGTCTGTGAAACCTGTAATTAAGAAAGAGCAAAAAA 1679

RESULT 147
ADD87372
ID ADD87372 standard; cDNA; 1679 BP.
XX
AC ADD87372;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; liver; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear intracanal supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassemia; immune system cell infiltration.

Homo sapiens.

US2003203439-A1.

30-OCT-2003.

17-MAY-2002; 2002US-00147499.

04-AUG-1998; 98US-0095301P.

02-JUN-1999; 99WO-US012252.

30-MAR-2000; 2000US-00380137.

30-MAR-2000; 2000WO-US008439.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2004-021362/02.

P-PSDB; ADD87373.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or PRO4978, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy.

Claim 2; Fig 375; 649pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note:

CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTTGTGCTCTTCAGCAAAACAGTGGATTTAAATCTCTTGGACACAGCTTGGAGGACAC 60
Db 1 GTTGTGCTCTTCAGCAAAACAGTGGATTTAAATCTCTTGGACACAGCTTGGAGGACAC 60
Qy 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGCACAAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAGAAAGAAAGAAACCGAACCTGCACAAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAAAATCATGAAACCATCCAGCCAAATATGCAATTTCTATCTTGGGCAAT 180
Db 121 AAGAAAAAATCATGAAACCATCCAGCCAAATATGCAATTTCTATCTTGGGCAAT 180
Qy 181 CTTTCAGGGGCTGGCTGCTCTGTGTCTCTTCCAAAGAGTGCCTGCGCAGGGAGATGC 240
Db 181 CTTTCAGGGGCTGGCTGCTCTGTGTCTCTTCCAAAGAGTGCCTGCGCAGGGAGATGC 240
Qy 241 CACCTTCCCAAGCTATGGAACAGTGAAGTCCGGAGGGGAGAGGCCACCTCTAG 300
Db 241 CACCTTCCCAAGCTATGGAACAGTGAAGTCCGGAGGGGAGAGGCCACCTCTAG 300
Qy 301 GTGCACATTTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCATCTCTA 360
Db 301 GTGCACATTTGACAAACCGGGTCAACCGGGTGGCTGGCTTAAACCGCAGCACCATCTCTA 360
Qy 361 TGTCTGGGAATGACAAAGTGTGCTGTGATCCTGCGTGGTCTCTTGTAGCAACACCCAAAC 420
Db 361 TGTCTGGGAATGACAAAGTGTGCTGTGATCCTGCGTGGTCTCTTGTAGCAACACCCAAAC 420
Qy 421 GCAGTACAGCATCCAGATCCAGAACCTGGATGTGTATGACAGGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCCAGATCCAGAACCTGGATGTGTATGACAGGGGCCCTTACACCTGCTC 480
Qy 481 GGTGCGAGACAGCAACACCCGCTCCTAGGGTCCACCTCATTTGTGCAAGATATCTCC 540
Db 481 GGTGCGAGACAGCAACACCCGCTCCTAGGGTCCACCTCATTTGTGCAAGATATCTCC 540
Qy 541 CAAATTTGTAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAAATATTAGCCTCAC 600
Db 541 CAAATTTGTAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAAATATTAGCCTCAC 600
Qy 601 CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
Db 601 CTGCATAGCAACTGGTAGACAGAGCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
Qy 661 GGTGCTTTGTGAGTGAGAGCGAATACCTTGGAAATTCAGGGCATCCCGGGGAGCAGTC 720
Db 661 GGTGCTTTGTGAGTGAGAGCGAATACCTTGGAAATTCAGGGCATCCCGGGGAGCAGTC 720
Qy 721 AGGGGACTACGAGTGCAGTGCCTCCAAATACGCTGGCGCGCGCGTGGTACGGAGATGTA 780
Db 721 AGGGGACTACGAGTGCAGTGCCTCCAAATACGCTGGCGCGCGCGTGGTACGGAGATGTA 780
Qy 781 GGTTCGCTGAACTATCCACCATACATTTTCAGAGCCAGGGGTACAGGTGTCCCGTGGG 840
Db 781 GGTTCGCTGAACTATCCACCATACATTTTCAGAGCCAGGGGTACAGGTGTCCCGTGGG 840
Qy 841 ACAAAGGGGACACTGCAGTGTGAAGCCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACAAAGGGGACACTGCAGTGTGAAGCCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Qy 901 CAAGGATGACAAAGACTGATGAAGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960
Db 901 CAAGGATGACAAAGACTGATGAAGAAAGAAAGGGGTGAAGTGAAGAAACAGACCTTT 960

QY 961 CCTCTCAAACTCATCTTCTCAATGCTCTGACATGACTATGGAACTACACTTGGCT 1020
DB 961 CCTCTCAAACTCATCTTCTCAATGCTCTGACATGACTATGGAACTACACTTGGCT 1020
QY 1021 GGCTCTCAAACTGGGCGACACCAATGCGCATCATGCTATTTGGTCCAGGCGCGCT 1080
DB 1021 GGCTCTCAAACTGGGCGACACCAATGCGCATCATGCTATTTGGTCCAGGCGCGCT 1080
QY 1081 CAGGAGGTGAGCAACGGGACGTCGAGGAGGAGGCTGGCTGCTGCTGCTCTTCT 1140
DB 1081 CAGGAGGTGAGCAACGGGACGTCGAGGAGGAGGCTGGCTGCTGCTGCTCTTCT 1140
QY 1141 GGTCTTGCACTGCTTCTCAAAATTTTGAATGCTGAGTGCCTCTTCCCGGGAAGGCT 1200
DB 1141 GGTCTTGCACTGCTTCTCAAAATTTTGAATGCTGAGTGCCTCTTCCCGGGAAGGCT 1200
QY 1201 GCGGCMCAACACACCAACAAAGCATGCGATGCGACGACGACACCAATCAGATA 1260
DB 1201 GCGGCMCAACACACCAACAAAGCATGCGATGCGACGACGACCAATCAGATA 1260
QY 1261 TATACAAATGAATTAGAAGAAACACAGCCTCATGGACAGAAATTTGAGGAGGGGAAC 1320
DB 1261 TATACAAATGAATTAGAAGAAACACAGCCTCATGGACAGAAATTTGAGGAGGGGAAC 1320
QY 1321 AAAGAATACCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
DB 1321 AAAGAATACCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCTTGCAGATA 1380
QY 1381 TTTAGGTACATGAGTGTCTTTTCCAAACGGGAGAACACAGACACCCGGCTTGA 1440
DB 1381 TTTAGGTACATGAGTGTCTTTTCCAAACGGGAGAACACAGACACCCGGCTTGA 1440
QY 1441 CCACCTGCAAGTGCATGCTGCAACCTTTTGGTGCAGTGGGCAAGGCTCAGCCTC 1500
DB 1441 CCACCTGCAAGTGCATGCTGCAACCTTTTGGTGCAGTGGGCAAGGCTCAGCCTC 1500
QY 1501 TCTGCCACAGAGTGCCTTCTTCCAAACGGGAGAACACAGACACCCGGCTTGA 1560
DB 1501 TCTGCCACAGAGTGCCTTCTTCCAAACGGGAGAACACAGACACCCGGCTTGA 1560
QY 1561 GTCCATAGACAGCAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGCTGCGGCACTTTG 1620
DB 1561 GTCCATAGACAGCAACAGAAATGAGACCTTCCGGCCCAAGCGTGGCGCTGCGGCACTTTG 1620
QY 1621 GTAGACTGCCACCAAGCGGTGTGTGCAACGTCGAATTAAGAGCAAGCAAAAAA 1679
DB 1621 GTAGACTGCCACCAAGCGGTGTGTGCAACGTCGAATTAAGAGCAAGCAAAAAA 1679

RESULT 148
ADE05105
ID ADE05105 standard; cDNA; 1679 BP.
AC ADE05105;
XX
DT 29-JAN-2004 (first entry)
XX Human PRO polynucleotide #63.
DE
XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW arthritis; sports injury; cytostatic; antiarthritic.
XX
OS Homo sapiens.
XX
XX US2003100726-A1.
XX
XX 29-MAY-2003.
XX
XX 26-AUG-2002; 2002US-00227878.
XX

05-JUN-2000; 2000US-0209832P.
15-SEP-2000; 2000US-0232887P.
01-JUN-2001; 2001WO-US017800.
29-JUN-2001; 2001WO-US021066.
09-APR-2002; 2002US-00119480.
(GETH) GENENTECH INC.
Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
P-PSDB; ADE05106.
WPI; 2004-008976/01.
New secreted and transmembrane PRO polypeptides and nucleic acids, useful
in gene therapy, or for preparing a medicament for treating a condition
that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
cancer.
Claim 2; Fig 125; 308pp; English.
The invention relates to human PRO polypeptides (secreted and
transmembrane polypeptides) and the PRO polynucleotides encoding them.
The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
diagnostics, biosensors or bioreactors. They are particularly useful for
detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
prostate tumour, rectal tumour or liver tumour) in a mammal, for
stimulating the release of tumour necrosis factor (TNF)-alpha from human
blood, for stimulating the proliferation or differentiation of
chondrocyte cells, for stimulating the proliferation of or gene
expression in pericyte cells or for stimulating the proliferation of
normal human dermal fibroblasts. The PRO nucleic acids are useful as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA, in preparing PRO polypeptides by recombinant
technology, in generating transgenic animals or knock-out animals which
may be used in the development and screening of therapeutically useful
reagents, in gene therapy, in chromosome identification, as chromosome
markers and in generating probes. The PRO polypeptides, or anti-PRO
antibodies, are useful for preparing a medicament for treating a
condition which is responsive to the PRO polypeptides or anti-PRO
antibodies, such as pericyte-associated tumours and bone and/or cartilage
disorders (e.g. arthritis, sports injuries), involving inducing the re-
differentiation of chondrocytes. The PRO polypeptides are useful as
molecular markers for protein electrophoresis, and in tissue typing. This
sequence represents a human PRO polynucleotide of the invention.
Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGAGCAAC 60
DB 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAAAACATCCAGCCAAATGCAAAATCTATCTTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAAAACATCCAGCCAAATGCAAAATCTATCTTCTTGGGCAAT 180
QY 181 CTTTACGGGGTGGCTGCTGTGTCTTCTTCAAGGAGTCCCGTCCAGCGAGATGC 240
DB 181 CTTTACGGGGTGGCTGCTGTGTCTTCTTCAAGGAGTCCCGTCCAGCGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGAACAAGTGCAGTCCGGCAGGGGAGAGCGGCACCTCAG 300
DB 241 CACCTTCCCAAGCTATGGAACAAGTGCAGTCCGGCAGGGGAGAGCGGCACCTCAG 300
QY 301 GTGCACTATTGACACCCGGGTCAACCCGGGTGCTAAACCCGACGACCATCTCTA 360

301 GTGCACTATTGACAAACCGGTCACCCGGTGGCTGCTAAACCGCAGCACCATCTCTCTA 360
361 TGCTGGGAATGACAAAGTGGTCCCTGGATCTCTGGTGGTCTCTCTGAGCAACACCCAAAC 420
361 TGCTGGGAATGACAAAGTGGTCCCTGGATCTCTGGTGGTCTCTCTGAGCAACACCCAAAC 420
421 GCAGTACAGCATCGAGATCCAGAACCGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
421 GCAGTACAGCATCGAGATCCAGAACCGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
481 GGTGACAGACACCAACCAACGACCTCTAGGCTCCACCTCATTTGTGCAAGTATCTCC 540
481 GGTGACAGACACCAACCAACGACCTCTAGGCTCCACCTCATTTGTGCAAGTATCTCC 540
541 CAAATTTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
541 CAAATTTAGAGATTTCTTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
601 CTGCATACCAACTGGTAGACAGAGCCCTACGCTTACTTTGGAGACACATCTCTCCAAAGC 660
601 CTGCATACCAACTGGTAGACAGAGCCCTACGCTTACTTTGGAGACACATCTCTCCAAAGC 660
661 GGTGGCTTTGTGAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
661 GGTGGCTTTGTGAGTGAAGACGAATATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
721 AGGGACTACGAGTGCAGTCTCCATGAGTGGCGCCCGCTGTGAGGAGTAA 780
721 AGGGACTACGAGTGCAGTCTCCATGAGTGGCGCCCGCTGTGAGGAGTAA 780
781 GGTCAACCGTGAACATATCCACCATATATTTCAAGAACCAAGGTTACAGTGTCCCGTGGG 840
781 GGTCAACCGTGAACATATCCACCATATATTTCAAGAACCAAGGTTACAGTGTCCCGTGGG 840
841 ACAAAGGGGACATGAGTGTGAGCTGAGCTCAGAGTCCCTCAGCAGATTCAGAGTGTA 900
841 ACAAAGGGGACATGAGTGTGAGCTGAGCTCAGAGTCCCTCAGCAGATTCAGAGTGTA 900
901 CAAAGATCAGAAAGACTGATTTGAAGGAAGAAAGGGGTGAAGTGGAAACACAGACCTTT 960
901 CAAAGATCAGAAAGACTGATTTGAAGGAAGAAAGGGGTGAAGTGGAAACACAGACCTTT 960
961 CTTCTCAAAATCTATCTTTCAATGCTCTGAAATGCTGAGTGGTGGTGGTGGTGGTGGT 1020
961 CTTCTCAAAATCTATCTTTCTTCAATGCTCTGAAATGCTGAGTGGTGGTGGTGGTGGT 1020
1021 GGCCTCCAAAGCTGGGCGCACCAATGCGAGCATCATGCTATTTGGTCCAGCGCGCT 1080
1021 GGCCTCCAAAGCTGGGCGCACCAATGCGAGCATCATGCTATTTGGTCCAGCGCGCT 1080
1081 CAGCAGGTGAGCAACCGGACGCTGAGGAGGCGAGGCTGCGTCTGGCTGCTCTCTCT 1140
1081 CAGCAGGTGAGCAACCGGACGCTGAGGAGGCGAGGCTGCGTCTGGCTGCTCTCTCTCT 1140
1141 GGTCTTGACCTGCTCTTCAATTTTGTATGAGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 1200
1141 GGTCTTGACCTGCTCTTCAATTTTGTATGAGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 1200
1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1201 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
1261 TATACAAATGAATTAGAGAAACACAGCTCTGAGGACGAATTTGAGGAGGGGAG 1320
1261 TATACAAATGAATTAGAGAAACACAGCTCTGAGGACGAATTTGAGGAGGGGAG 1320
1321 AAGAATACTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGAAATTTGAAATTTGAA 1380
1321 AAGAATACTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGAAATTTGAAATTTGAA 1380
1381 TTTAGTACATGGAGTTTCTTTTCCAAACGGGAAACACAGCAGCACCCCGCTTGA 1440

1381 TTTAGTACATGGAGTTTCTTTTCCAAACGGGAAACACAGCAGCACCCCGCTTGA 1440
1441 CCCACTGCAAGTGTGATCGTCAACCTCTTTGGTGGCAGTGTGGCAGAGGCTCAGCCTC 1500
1441 CCCACTGCAAGTGTGATCGTCAACCTCTTTGGTGGCAGTGTGGCAGAGGCTCAGCCTC 1500
1501 TGTGCCACAGAGTGTGCGCCACAGTGGAAATTCAGAGCTGGCCTCCAAATTCATCA 1560
1501 TGTGCCACAGAGTGTGCGCCACAGTGGAAATTCAGAGCTGGCCTCCAAATTCATCA 1560
1561 GTCCATAGAGACGAACAGATGAGACCTTCGCGCCCAAGCGTGGCGCTGGCGGACCTTTG 1620
1561 GTCCATAGAGACGAACAGATGAGACCTTCGCGCCCAAGCGTGGCGCTGGCGGACCTTTG 1620
1621 GTAGACTGTGCCACACCGCGCTGTGTTGTAACCTGTAATTAAGAGCAAGCAAAAAA 1679
1621 GTAGACTGTGCCACACCGCGCTGTGTTGTAACCTGTAATTAAGAGCAAGCAAAAAA 1679

RESULT 149
ADD75318
ID ADD75318 standard; cDNA; 1679 BP.
XX
AC ADD75318;
XX AC
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #63.
XX
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide; tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW arthritis; sports injury; cytostatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN US2003100714-A1.
XX
PD 29-MAY-2003.
XX
PF 13-AUG-2002; 2002US-00219071.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
(GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
PI MPI; 2004-008964/01.
DR P-PSDB; ADD75319.
XX
PT New secreted and transmembrane PRO polypeptide useful for preparing a medicament for treating a condition that is responsive to the PRO polypeptide or anti-PRO antibody, e.g. cancer.
XX
PS Claim 2; Fig 125; 308pp; English.
XX
CC The invention relates to human PRO polypeptides (secreted and transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals.
CC diagnostics, biosensors or bioreactors. They are particularly useful for detecting tumours (e.g. lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour) in a mammal, for stimulating the release of tumour necrosis factor (TNF)-alpha from human blood, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells or for stimulating the proliferation of normal human dermal fibroblasts. The PRO nucleic acids are useful as hybridisation probes, in chromosome and gene mapping, in generating

pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation; lung tumour;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX
 OS Homo sapiens.
 XX
 XX US2003100715-A1.
 XX
 XX 29-MAY-2003.
 XX
 XX 13-AUG-2002; 2002US-00219074.
 XX
 XX 22-JUN-1999; 99US-0140650P.
 XX
 XX 20-MAY-2000; 2000WO-US014941.
 XX
 XX 01-JUN-2001; 2001WO-US017800.
 XX
 XX 29-JUN-2001; 2001WO-US021066.
 XX
 XX 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JP, Watanabe CK, Wood WI;
 XX
 XX WPI; 2004-008965/01.
 XX
 XX P-P8DB; ADD76863.
 XX
 XX New secreted and transmembrane PRO polypeptide useful for preparing a
 PT medicament for treating a condition that is responsive to the PRO
 PT polypeptide or anti-PRO antibody, e.g. cancer.
 XX
 XX Claim 2; SEQ ID NO 125; 308pp; English.
 XX
 XX The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1517, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 XX
 XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match	100.0%	Score 1679	DB 1	Length 1679
Best Local Similarity	100.0%	Pred. No. 6.7e-05		
Matches 1679	Conservative	0	Mismatches 0	Indels 0
Gaps	0			
QY 1	GTGTGTCTCTTACGAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAAC	60		
DB 1	GTGTGTCTCTTACGAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAAC	60		
QY 61	AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120		
DB 61	AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG	120		
QY 121	AGAAAAAATATCATGAAAACCATCCAGCCAAAATGCAATTTCTATCTCTTGGCAAT	180		
DB 121	AGAAAAAATATCATGAAAACCATCCAGCCAAAATGCAATTTCTATCTCTTGGCAAT	180		
QY 181	CTTCAGGGGCTGGCTGCTCTGTCTCTTCCAGAGAGTGGCGTGGCAGGGAGATGC	240		
DB 181	CTTCAGGGGCTGGCTGCTCTGTCTCTTCCAGAGAGTGGCGTGGCAGGGAGATGC	240		
QY 241	CACCTTCCCAAGAGCTATGGACAAAGTGAAGTCCGGCAGGGGAGAGCGCCACCTCAG	300		
DB 241	CACCTTCCCAAGAGCTATGGACAAAGTGAAGTCCGGCAGGGGAGAGCGCCACCTCAG	300		
QY 301	GTGCACCTATTGACAAACCGGCTCACCCGGTGGCTTAAACCCGAGCACCATCTCTA	360		
DB 301	GTGCACCTATTGACAAACCGGCTCACCCGGTGGCTTAAACCCGAGCACCATCTCTA	360		
QY 361	TGCTGGGAATGACAACTGTGCTGGATCCTCGCGTGTCTTCTTGAGCAACACCCAAAC	420		
DB 361	TGCTGGGAATGACAACTGTGCTGGATCCTCGCGTGTCTTCTTGAGCAACACCCAAAC	420		
QY 421	GCAGTACAGCTCGAGATCCAGAACCTGGATGATGATGATGATGATGATGATGATGAT	480		
DB 421	GCAGTACAGCTCGAGATCCAGAACCTGGATGATGATGATGATGATGATGATGATGAT	480		
QY 481	GGTGCAGACAGACACACCCACCTTAGGTCACCTCATTTGTCAAAGTATCTCC	540		
DB 481	GGTGCAGACAGACACACCCACCTTAGGTCACCTCATTTGTCAAAGTATCTCC	540		
QY 541	CAAAATGTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTAC	600		
DB 541	CAAAATGTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTAC	600		
QY 601	CTGCATAGCAACTGTGTAGACAGAGCTACCGTTCATTTGGAGACACATCTCTCCCAAAGC	660		
DB 601	CTGCATAGCAACTGTGTAGACAGAGCTACCGTTCATTTGGAGACACATCTCTCCCAAAGC	660		
QY 661	GGTTGGCTTTGTGAGTGAAGACGAATCTTGGAAATTCAGGGGATCACCCGGGAGCAGTC	720		
DB 661	GGTTGGCTTTGTGAGTGAAGACGAATCTTGGAAATTCAGGGGATCACCCGGGAGCAGTC	720		
QY 721	AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTTGGCGCGCGCGCGCGCGCGCGCG	780		
DB 721	AGGGGACTACGAGTGCAGTGCCTCCAAATGACGTTGGCGCGCGCGCGCGCGCGCGCG	780		
QY 781	GGTCAACGTAATTCACCATATATTTTCAAGGCAAGGAGTACAGGTGTCCCTGGG	840		
DB 781	GGTCAACGTAATTCACCATATATTTTCAAGGCAAGGAGTACAGGTGTCCCTGGG	840		
QY 841	ACAAAAGGAGCACTGCAGTGTGCAAGCTCCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900		
DB 841	ACAAAAGGAGCACTGCAGTGTGCAAGCTCCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900		
QY 901	CAAGGATGACAAAGACTGANTGAAGAAAGAAAGGGGTGAAGTGGAAAGCAAGACCTTT	960		
DB 901	CAAGGATGACAAAGACTGANTGAAGAAAGAAAGGGGTGAAGTGGAAAGCAAGACCTTT	960		
QY 961	CTCTCTCAAACTCATCTTCTTCAATGCTCTGAAATGATGATGATGATGATGATGATGAT	1020		
DB 961	CTCTCTCAAACTCATCTTCTTCAATGCTCTGAAATGATGATGATGATGATGATGATGAT	1020		

```
QY 1021 GGCCTCCACAGCTGGGCGCACCAACGAGCATCATGCTATTGTTGGTCCAGGCGCGT 1080
DB 1021 GGCCTCCACAGCTGGGCGCACCAACGAGCATCATGCTATTGTTGGTCCAGGCGCGT 1080
QY 1081 CAGCGAGGTGAGCAAGCGACGCTCGAGGAGGCGCTGCGTCTGGCTGCTCTTCT 1140
DB 1081 CAGCGAGGTGAGCAAGCGACGCTCGAGGAGGCGCGCTGCGTCTGGCTGCTCTTCT 1140
QY 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGAGTGCCACTTCCCAACCGGGAAGGCT 1200
DB 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGAGTGCCACTTCCCAACCGGGAAGGCT 1200
QY 1201 GCGGCCACACACACACCAACCAACAGCAACAGCAATGGCAACCGACAGCAACCAATCAGATA 1260
DB 1201 GCGGCCACACACACACCAACCAACAGCAACAGCAATGGCAACCGACAGCAACCAATCAGATA 1260
QY 1261 TATACAAATGAATTAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAC 1320
DB 1261 TATACAAATGAATTAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAC 1320
QY 1321 AAGAAATACCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCCCTTGACAGATA 1380
DB 1321 AAGAAATACCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCCCTTGACAGATA 1380
QY 1381 TTTAGTACAAATGGAGTTTCTTTTCCAAAACGGGAAGAACACAGACACACCGGCTTGA 1440
DB 1381 TTTAGTACAAATGGAGTTTCTTTTCCAAAACGGGAAGAACACAGACACACCGGCTTGA 1440
QY 1441 CCCACTCGACAGCTGATCGTGCAACCTTTTGTGCGAGTGCGGCAAGGGCTCAGCCCTC 1500
DB 1441 CCCACTCGACAGCTGATCGTGCAACCTTTTGTGCGAGTGCGGCAAGGGCTCAGCCCTC 1500
QY 1501 TCTGCCACAGAGTGCCCCCACTGGAAACATTTGAGAGTGGCCATCCCAATTTCAATCA 1560
DB 1501 TCTGCCACAGAGTGCCCCCACTGGAAACATTTGAGAGTGGCCATCCCAATTTCAATCA 1560
QY 1561 GTCCATAGACAGACAGATGAGCTTCCGCGCCAGCGTGCGTGCGGCACTTTG 1620
DB 1561 GTCCATAGACAGACAGATGAGCTTCCGCGCCAGCGTGCGTGCGGCACTTTG 1620
QY 1621 GTAGACTGTGCCACCCAGCGGTGTGTTGTGAACGTGAATTAAGAGAGCAAAAAA 1679
DB 1621 GTAGACTGTGCCACCCAGCGGTGTGTTGTGAACGTGAATTAAGAGAGCAAAAAA 1679

RESULT 151
ADD86630
ID ADD86630 standard; cDNA; 1679 BP.
AC ADD86630;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO337 cDNA.
XX
KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
FN US2003100719-A1.
XX
PD 29-MAY-2003.
XX
PF 14-AUG-2002; 2002US-00219469.
XX
```

```
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH ) GENENTECH INC.
PA Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
PI WPI; 2004-008969/01.
DR P-PSDB; ADD86631.
DR
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
XX in gene therapy, or for preparing a medicament for treating a condition
XX that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
XX cancer.
XX Claim 2; SEQ ID NO 125; 308pp; English.
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1026, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTGTGTCTCTTCAGCAAAACAGTGGATTTAAATCTCTTGGCAGAGCTTGAGGCAAC 60
DB 1 GTGTGTCTCTTCAGCAAAACAGTGGATTTAAATCTCTTGGCAGAGCTTGAGGCAAC 60
QY 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAAAACCATCCAGCAAAATGCAATTTCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAAAACCATCCAGCAAAATGCAATTTCTATCTCTTGGGCAAT 180
```

181 CTTCAAGGGGTGGTGTCTGTGTCTCTTCAAGGAGTCCCTGTGCGCAGCGAGATGC 240
181 CTTCAAGGGGTGGTGTCTGTGTCTCTTCAAGGAGTCCCTGTGCGCAGCGAGATGC 240
241 CACCTTCCCAAGAGTATGGAACAAGTCAAGTCCGCGAGGGGAGAGCGCACCTTCAG 300
241 CACCTTCCCAAGAGTATGGAACAAGTCAAGTCCGCGAGGGGAGAGCGCACCTTCAG 300
301 GTGCACTATTGGAACAAGGAGTCAAGGAGTCCGCTTAAACCGCAGCACCATCTCTTA 360
301 GTGCACTATTGGAACAAGGAGTCAAGGAGTCCGCTTAAACCGCAGCACCATCTCTTA 360
361 TGCTGGGAATGCAAGTGGTCTGGATCCCTGGTCTCTGCTGCTGCTCTGAGCAACACCAAC 420
361 TGCTGGGAATGCAAGTGGTCTGGATCCCTGGTCTCTGCTGCTGCTCTGAGCAACACCAAC 420
421 GCAGTACAGATCGAGATCCAGAACGTCGATGTGATGACAGAGGCGCTTACACTGCTC 480
421 GCAGTACAGATCGAGATCCAGAACGTCGATGTGATGACAGAGGCGCTTACACTGCTC 480
481 GGTGCAAGACAGACACCAACCAAGACCTCTAGGTCCTCACTCATTTGGCAAGTATCTCC 540
481 GGTGCAAGACAGACACCAACCAAGACCTCTAGGTCCTCACTCATTTGGCAAGTATCTCC 540
541 CAAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
541 CAAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
601 CTGCAATAGCACTGTAGACAGAGCCTACGTTACTTTGGAGACACATCTCTCCCAAGC 660
601 CTGCAATAGCACTGTAGACAGAGCCTACGTTACTTTGGAGACACATCTCTCCCAAGC 660
661 GGTGGCTTTGTGAGTGAAGACGAATACCTTGAAATTCAGGGCATCACCGGAGCAGTC 720
661 GGTGGCTTTGTGAGTGAAGACGAATACCTTGAAATTCAGGGCATCACCGGAGCAGTC 720
721 AGGGACTACGATGAGTGCCTCCATGAGCTGCGCGCGCCCTGTGTCAGGAGATGAA 780
721 AGGGACTACGATGAGTGCCTCCATGAGCTGCGCGCGCCCTGTGTCAGGAGATGAA 780
781 GGTCAAGTGAATATCCACCATATATTTCAGAACCAAGGATACAGTGTCCCGTGGG 840
781 GGTCAAGTGAATATCCACCATATATTTCAGAACCAAGGATACAGTGTCCCGTGGG 840
841 ACAAAGGGGACACTGCAAGTGTGAAGCTTCAGACATGCTCCCTCAGCAGAAATTCAGTGTGTA 900
841 ACAAAGGGGACACTGCAAGTGTGAAGCTTCAGACATGCTCCCTCAGCAGAAATTCAGTGTGTA 900
901 CAAGGATGACAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAAGTGAAGAACAGACCTTT 960
901 CAAGGATGACAAAGACTGATTTGAAGGAAAGAAAGGGGTGAAAGTGAAGAACAGACCTTT 960
961 CCTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGATATGGAACATCACTTGGCT 1020
961 CCTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGATATGGAACATCACTTGGCT 1020
1021 GGCCTCCAAAGCTGGGCGACCAACCAATGCGCAGCATCTGCTATTTGTCAGAGCGCGT 1080
1021 GGCCTCCAAAGCTGGGCGACCAACCAATGCGCAGCATCTGCTATTTGTCAGAGCGCGT 1080
1081 CAGCGAGGTGAGCAACGGCAGCTCGAGGAGGCGAGGCTGCGTGTGCTGCTCTTCT 1140
1081 CAGCGAGGTGAGCAACGGCAGCTCGAGGAGGCGAGGCTGCGTGTGCTGCTCTTCT 1140
1141 GGTCTTGCACCTGCTCTCAAAATTTGATGTGAGTGGCACTTCCCGCAGCGGAAAGCT 1200
1141 GGTCTTGCACCTGCTCTCAAAATTTGATGTGAGTGGCACTTCCCGCAGCGGAAAGCT 1200
1201 GCGGCCACCAACCAACCAACCAAGCAATGGCAACCAACCAAGCAACCAATCAGATA 1260
1201 GCGGCCACCAACCAACCAACCAAGCAATGGCAACCAACCAAGCAACCAATCAGATA 1260
1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAC 1320

1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAC 1320
1321 AAAGAAATACCTTTGGGGGAAAAGAGTTTAAAAAAGAAATTTGAAAATTTGCTTGCAGATA 1380
1321 AAAGAAATACCTTTGGGGGAAAAGAGTTTAAAAAAGAAATTTGAAAATTTGCTTGCAGATA 1380
1381 TTTAGGTACAATGGAGTTTCTTTTCCCAACCGGAAGAACACAGCACACCGCGCTTGA 1440
1381 TTTAGGTACAATGGAGTTTCTTTTCCCAACCGGAAGAACACAGCACACCGCGCTTGA 1440
1441 CCCACTGCAAGCTGCAATCGTCAACCTCTTTGTCGCAAGTGGGCAAGGGCTCAGCCTC 1500
1441 CCCACTGCAAGCTGCAATCGTCAACCTCTTTGTCGCAAGTGGGCAAGGGCTCAGCCTC 1500
1501 TCTGCCCAAGAGTGCCTCCCAAGTGGAAATCTTGGAGTGGCCATCCCAATTCATCA 1560
1501 TCTGCCCAAGAGTGCCTCCCAAGTGGAAATCTTGGAGTGGCCATCCCAATTCATCA 1560
1561 GTCCATAGAGACGAACAGAAATGAGACCTTCCGCGCCCAAGCGTGGCGCTCGGCGCACTTTG 1620
1561 GTCCATAGAGACGAACAGAAATGAGACCTTCCGCGCCCAAGCGTGGCGCTCGGCGCACTTTG 1620
1621 GTAGACTGTGCCACCGCGCTGTGTGTGAAACGTGAAATAAAAAGAGCAAAAAAAA 1679
1621 GTAGACTGTGCCACCGCGCTGTGTGTGAAACGTGAAATAAAAAGAGCAAAAAAAA 1679

RESULT 152

ADE89238

ID ADE89238 standard; cDNA; 1679 BP.

XX AC ADE89238;

XX AC ADE89238;

XX 29-JAN-2004 (first entry)

XX Human PRO polynucleotide #188.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX liver; microvascular endothelial cell; glucose; FFA;

XX skeletal muscle cell; adipocyte cell; pericyte cell;

XX inner ear utricular supporting cell; r-lymphocyte cell;

XX endothelial cell tube formation; bone disorder; cartilage disorder;

XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

XX immune system cell infiltration.

XX Homo sapiens.

XX OS

XX US2003199062-A1.

XX 23-OCT-2003.

XX 17-APR-2002; 2002US-00124823.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022991.

XX 29-OCT-1998; 98WO-US022992.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 03-JAN-1999; 99WO-US000106.

PR	08-MAR-1999;	99WO-US005028.	PR	20-JUN-2001; 2001WO-US019692.	XX	(GETH) GENENTECH INC.
PR	10-MAR-1999;	99WO-US000190.	PR	21-JUN-2001; 2001US-00887879.	XX	Baker KP, Beresini M, Deforge L, Desnoyers L, Pilvaroff E, Gao W;
PR	10-MAR-1999;	2000WO-US006319.	PR	22-JUN-2001; 2001WO-US020116.	PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PR	20-APR-1999;	99WO-US008615.	PR	29-JUN-2001; 2001WO-US021066.	PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
PR	14-MAY-1999;	99WO-US010733.	PR	09-JUL-2001; 2001WO-US021735.	XX	WPI; 2004-041360/04.
PR	02-JUN-1999;	99WO-US011252.	PR	18-JUL-2001; 2001US-00908827.	DR	P-PSDB; ADE89239.
PR	01-SEP-1999;	99WO-US020111.	PR	06-AUG-2001; 2001US-00924419.	XX	Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
PR	08-SEP-1999;	99WO-US020594.	PR	09-AUG-2001; 2001US-00927796.	PT	hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PR	13-SEP-1999;	99WO-US020944.	PR	16-AUG-2001; 2001US-00931836.	PT	attack, various coagulation disorders, tumors.
PR	15-SEP-1999;	99WO-US021090.	PR	19-DEC-2001; 2001US-00026072.	XX	Claim 2; SEQ ID NO 375; 638pp; English.
PR	05-OCT-1999;	99WO-US021547.	XX		PS	The invention relates to isolated human PRO polypeptides (secreted and
PR	29-NOV-1999;	99WO-US023089.	XX		XX	transmembrane polypeptides) and the polynucleotides encoding them. The
PR	30-NOV-1999;	99WO-US028214.	XX		CC	invention also relates to an antibody which specifically binds to a PRO
PR	30-NOV-1999;	99WO-US028313.	CC		CC	polypeptide, a method for stimulating the release of tumour necrosis
PR	01-DEC-1999;	99WO-US028409.	CC		CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the
PR	01-DEC-1999;	99WO-US028634.	CC		CC	proliferation or differentiation of chondrocyte cells and a method for
PR	02-DEC-1999;	99WO-US028551.	CC		CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
PR	02-DEC-1999;	99WO-US028564.	CC		CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
PR	02-DEC-1999;	99WO-US028565.	CC		CC	polynucleotides are useful in molecular biology, including uses as
PR	16-DEC-1999;	99WO-US030095.	CC		CC	hybridisation probes, in chromosome and gene mapping, in generating
PR	20-DEC-1999;	99WO-US030911.	CC		CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also
PR	20-DEC-1999;	99WO-US030999.	CC		CC	be used in preparing PRO polypeptides by recombinant techniques and in
PR	22-DEC-1999;	99WO-US030720.	CC		CC	generating either transgenic animals or knock-out animals which are
PR	30-DEC-1999;	99WO-US031243.	CC		CC	useful in the development and screening of therapeutically useful
PR	30-DEC-1999;	99WO-US031274.	CC		CC	reagents. The PRO polypeptides or antibodies are used in preparing a
PR	05-JAN-2000;	2000WO-US000219.	CC		CC	medicament for treating a condition responsive to the polypeptides or
PR	06-JAN-2000;	2000WO-US000277.	CC		CC	antibodies, such as tumours, for stimulating and inhibiting proliferation
PR	06-JAN-2000;	2000WO-US000376.	CC		CC	of human microvascular endothelial cells, for modulating the uptake of
PR	11-FEB-2000;	2000WO-US003565.	CC		CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for
PR	18-FEB-2000;	2000WO-US004341.	CC		CC	stimulating differentiation of adipocyte cells, for stimulating
PR	18-FEB-2000;	2000WO-US004342.	CC		CC	proliferation of or gene expression in pericyte cells, for stimulating
PR	22-FEB-2000;	2000WO-US004414.	CC		CC	the proliferation of inner ear utricular supporting cells or T-lymphocyte
PR	24-FEB-2000;	2000WO-US004914.	CC		CC	cells, for inducing endothelial cell tube formation and for treating
PR	24-FEB-2000;	2000WO-US005004.	CC		CC	various bone and/or cartilage disorders such as sports injuries and
PR	01-MAR-2000;	2000WO-US005601.	CC		CC	arthritis. PRO polypeptides which stimulate the release of proteoglycans
PR	02-MAR-2000;	2000WO-US005746.	CC		CC	from cartilage are useful for treating sports-related joint problems,
PR	02-MAR-2000;	2000WO-US005841.	CC		CC	articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
PR	15-MAR-2000;	2000WO-US006884.	CC		CC	polypeptides are also useful for treating various mammalian haemoglobin-
PR	20-MAR-2000;	2000WO-US007377.	CC		CC	associated disorders such as various thalassemias and conditions which
PR	21-MAR-2000;	2000WO-US007532.	CC		CC	may benefit from enhanced local immune system cell infiltration. This
PR	30-MAR-2000;	2000WO-US008439.	CC		CC	sequence represents a human PRO polynucleotide of the invention. Note:
PR	17-MAY-2000;	2000WO-US013705.	CC		CC	The sequence data for this patent is also available in electronic format
PR	22-MAY-2000;	2000WO-US014042.	CC		CC	from USPTO at seqdata.uspto.gov/sequence.html .
PR	30-MAY-2000;	2000WO-US014941.	CC		XX	
PR	02-JUN-2000;	2000WO-US015264.	CC		XX	
PR	28-JUL-2000;	2000WO-US020710.	CC		XX	
PR	11-AUG-2000;	2000WO-US022031.	CC		XX	
PR	23-AUG-2000;	2000WO-US023522.	CC		XX	
PR	24-AUG-2000;	2000WO-US023328.	CC		XX	
PR	08-NOV-2000;	2000WO-US030952.	CC		XX	
PR	10-NOV-2000;	2000WO-US030873.	CC		XX	
PR	01-DEC-2000;	2				

Db 1141 GGTCTTGGACCTGCTTCTCAAAATTTTGAATGTGAGTGCCACTTCCACCACCGGGAAGGCT 1200
 Qy 1201 GCGGCCACACACACACCAACCAACAGCAATGGCAACCGACAGCAACCAATCAGATA 1260
 Db 1201 GCGGCCACACACACACCAACCAACAGCAATGGCAACCGACAGCAACCAATCAGATA 1260
 Qy 1261 TATACAAATGAATTTAGAAAGCAACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
 Db 1261 TATACAAATGAATTTAGAAAGCAACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
 Qy 1321 AAAGATACTTTGGGGGGAAGAGATTTTAAAAAGAAATTTGAAATTTGCTTTGAGATA 1380
 Db 1321 AAAGATACTTTGGGGGGAAGAGATTTTAAAAAGAAATTTGAAATTTGCTTTGAGATA 1380
 Qy 1381 TTTAGTACATTTGAGATTTTCTTTTCCCAACCGGGAAGCAACAGCCTCATGGGAGGGGTTGA 1440
 Db 1381 TTTAGTACATTTGAGATTTTCTTTTCCCAACCGGGAAGCAACAGCCTCATGGGAGGGGTTGA 1440
 Qy 1441 CCACATGCAAGCTGCACTGCTGCAACCTTTTGGTGCAGATGTGGCAAGGGCTCAGCCTC 1500
 Db 1441 CCACATGCAAGCTGCACTGCTGCAACCTTTTGGTGCAGATGTGGCAAGGGCTCAGCCTC 1500
 Qy 1501 TCTGCCACAGAGTGGCCCCCAAGTGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
 Db 1501 TCTGCCACAGAGTGGCCCCCAAGTGAACATTTCTGGAGCTGGCCATCCCAATTCATCA 1560
 Qy 1561 GTCCATAGAGCAACAGAAATGAGACTTCCGGCCCCAAGCTGGCGCTGGCGGCACTTTG 1620
 Db 1561 GTCCATAGAGCAACAGAAATGAGACTTCCGGCCCCAAGCTGGCGCTGGCGGCACTTTG 1620
 Qy 1621 GTAGACTGTGCCACCAACCGCGTGTGTGTGAAACGTGAAATTTAAAAAGCAAAAAAAA 1679
 Db 1621 GTAGACTGTGCCACCAACCGCGTGTGTGTGAAACGTGAAATTTAAAAAGCAAAAAAAA 1679

RESULT 154

ADD78098
 ID ADD78098 standard; cdna; 1679 BP.
 AC ADD78098;
 XX 29-JAN-2004 (first entry)
 DE Novel human secreted and transmembrane protein PRO337 CDNA.
 KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
 KW humoral; antithrombotic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX Homo sapiens.
 OS US2003100731-A1.
 PN 29-MAY-2003.
 XX 28-AUG-2002; 2002US-00230234.
 PF 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2004-008981/01.

DR P-PSDB; ADD78099.
 XX New PRO polypeptide and nucleic acid useful for gene therapy, chromosome identification, tissue typing, or as hybridization probes in chromosome and gene mapping.
 PS Claim 2; SEQ ID NO 125; 308pp; English.
 XX The invention describes an isolated PRO (secreted and transmembrane) polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are useful for stimulating the proliferation of or gene expression in pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful for stimulating the proliferation or differentiation of chondrocyte cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide are useful for stimulating the release of tumour necrosis factor (TNF)-alpha from human blood. PRO363, PRO357, PRO725, PRO1306, PRO1419, PRO214, PRO247, PRO337, PRO526, PRO331, PRO1083, PRO840, PRO1080.
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309, PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412, PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338, PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567, PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322, PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408, PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for inhibiting the proliferation of normal human dermal fibroblast cells. PRO polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc., are useful for detecting the presence of tumour in a mammal which involves comparing the level of expression of the above PRO polypeptides in a test sample of cells taken from the mammal, and a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptides in the test sample as compared to the control sample is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for chromosome and gene mapping or gene therapy. (II) is useful for generating transgenic animals or knock-out animals which are useful screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide is useful for treating bone and/or cartilage disorders (e.g., arthritis, sport injuries). This sequence encodes a human secreted and transmembrane PRO polypeptide.

XX Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
 Qy Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Db Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Qy Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 1 GTTGTGCTTCCAGCAACAGTGGATTTAAATCTCTTGCACAACTTGAGAGCAAC 60
 Qy 1 GTTGTGCTTCCAGCAACAGTGGATTTAAATCTCTTGCACAACTTGAGAGCAAC 60
 Db 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 Qy 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 Db 121 ARGAAAAAATCATGAACCAATCCAGCCCAAAATGCAATTTCTCTTGGGCAAT 180
 Qy 121 ARGAAAAAATCATGAACCAATCCAGCCCAAAATGCAATTTCTCTTGGGCAAT 180
 Db 181 CTTCAAGGGGCTGGCTCTGTGTCTCTTCCAAAGAGTGCCTGCGCAGCGAGATGC 240
 Qy 181 CTTCAAGGGGCTGGCTCTGTGTCTCTTCCAAAGAGTGCCTGCGCAGCGAGATGC 240
 Db 241 CACCTTCCCAAGCTATGACACCTGACGCTCCCGCAGGGGAGGAGCCACCTCAG 300
 Qy 241 CACCTTCCCAAGCTATGACACCTGACGCTCCCGCAGGGGAGGAGCCACCTCAG 300
 Db 301 GTGCACTATTGACAAACCGGGTCCACCGGGTGGCTGTGCTAAACCGCAGCACCATCTCTA 360
 Qy 301 GTGCACTATTGACAAACCGGGTCCACCGGGTGGCTGTGCTAAACCGCAGCACCATCTCTA 360
 Db 301 GTGCACTATTGACAAACCGGGTCCACCGGGTGGCTGTGCTAAACCGCAGCACCATCTCTA 360

361 TGCTGGAAATGAAGAATGGTGGTGGATCTCGCGTGGTCTTCTGAGGAAACACCCAAAC 420
Db |||||
361 TGCTGGAAATGAAGAATGGTGGTGGATCTCGCGTGGTCTTCTGAGGAAACACCCAAAC 420
Qy |||||
421 GCAGTACAGCATCAGATCCAGAACTGGATGTGTATGACGAGGCGCTTACACCTGCTC 480
Db |||||
421 GCAGTACAGCATCAGATCCAGAACTGGATGTGTATGACGAGGCGCTTACACCTGCTC 480
Qy |||||
481 GGTGACAGACAGAACCAACCAAGACCTCTAGGGTCCACTCATTTGTGAAGTATCTCC 540
Db |||||
481 GGTGACAGACAGAACCAACCAAGACCTCTAGGGTCCACTCATTTGTGAAGTATCTCC 540
Qy |||||
541 CAAATTTGTAGAGATTTCTCAGATATCTCATTATTAAGAGGAAACAAATATTAGCTCAC 600
Db |||||
541 CAAATTTGTAGAGATTTCTCAGATATCTCATTATTAAGAGGAAACAAATATTAGCTCAC 600
Qy |||||
601 CTGATAGCAACTGGTAGACAGAGCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
Db |||||
601 CTGATAGCAACTGGTAGACAGAGCTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
Qy |||||
661 GGTGGCTTTGTAGTGAAGACGATATCTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
Db |||||
661 GGTGGCTTTGTAGTGAAGACGATATCTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
Qy |||||
721 AGGGCACTACAGTGCAGTGCCTCCAATGACGTGGCGCGCCGCTGGTACGGAGATAA 780
Db |||||
721 AGGGCACTACAGTGCAGTGCCTCCAATGACGTGGCGCGCCGCTGGTACGGAGATAA 780
Qy |||||
781 GGTCAAGTGAATCATCAACATACATTCGAAAGCAAGGTACAGGTGTCCCGTGGG 840
Db |||||
781 GGTCAAGTGAATCATCAACATACATTCGAAAGCAAGGTACAGGTGTCCCGTGGG 840
Qy |||||
841 ACAAAGGGGACCTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db |||||
841 ACAAAGGGGACCTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Qy |||||
901 CAAGATGACAAAGACTGATTTGAAGAAAGAGGGGTGAAGTGAAGAAACAGACCTTT 960
Db |||||
901 CAAGATGACAAAGACTGATTTGAAGAAAGAGGGGTGAAGTGAAGAAACAGACCTTT 960
Qy |||||
961 CCTCTCAAACTCATCTTCTCAATGTCTCTGACATGACTATGGGAACTACATTCGCT 1020
Db |||||
961 CCTCTCAAACTCATCTTCTCAATGTCTCTGACATGACTATGGGAACTACATTCGCT 1020
Qy |||||
1021 GGCTTCCAAAGCTGGGCCACCAATGCGAGCATCATGCTATTTGGTCCAGGCGCGT 1080
Db |||||
1021 GGCTTCCAAAGCTGGGCCACCAATGCGAGCATCATGCTATTTGGTCCAGGCGCGT 1080
Qy |||||
1081 CAGGAGGTGAGCAACGGCAGCTCGAGGAGGCGGTGGTCTGGCTGTGCTCTTCT 1140
Db |||||
1081 CAGGAGGTGAGCAACGGCAGCTCGAGGAGGCGGTGGTCTGGCTGTGCTCTTCT 1140
Qy |||||
1141 GGTCTTGCACTGCTTCTCAATTTTGTATGTAGTGCCACTTCCCGGGAAGGCT 1200
Db |||||
1141 GGTCTTGCACTGCTTCTCAATTTTGTATGTAGTGCCACTTCCCGGGAAGGCT 1200
Qy |||||
1201 GCCGCCACCAACCAACCAACAGCAATGCAACCGAGCAGCAACCAATCAGATA 1260
Db |||||
1201 GCCGCCACCAACCAACCAACAGCAATGCAACCGAGCAGCAACCAATCAGATA 1260
Qy |||||
1261 TATACAAATGAAATTAGAAGAAACACAGCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320
Db |||||
1261 TATACAAATGAAATTAGAAGAAACACAGCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320
Qy |||||
1321 AAAGAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTCAGATA 1380
Db |||||
1321 AAAGAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTCAGATA 1380
Qy |||||
1381 TTTAGTACATGAGTTTCTTTTCCAAACGGGAGAAACACAGCAGCACCCTGCTTGA 1440
Db |||||
1381 TTTAGTACATGAGTTTCTTTTCCAAACGGGAGAAACACAGCAGCACCCTGCTTGA 1440

1441 CCCACTGCAAGCTGATCGTCAACCTCTTTGGTGCCAGTGTGGGCAAGGCTCAGCTC 1500
Db |||||
1441 CCCACTGCAAGCTGATCGTCAACCTCTTTGGTGCCAGTGTGGGCAAGGCTCAGCTC 1500
Qy |||||
1501 TCTGCCCAACAGAGTCCCGCCACGTGGAAACATTTGGAGCTGGCCATCCCAAAATCAATCA 1560
Db |||||
1501 TCTGCCCAACAGAGTCCCGCCACGTGGAAACATTTGGAGCTGGCCATCCCAAAATCAATCA 1560
Qy |||||
1561 GTCCATAGAGACGACAGAAATGAGACCTTCCGGCCCAAGCTGGCGTGGCGGCACTTTG 1620
Db |||||
1561 GTCCATAGAGACGACAGAAATGAGACCTTCCGGCCCAAGCTGGCGTGGCGGCACTTTG 1620
Qy |||||
1621 GTAGACTGTGCCACCGCGCTGTGTGTGAAACGTGAAATATAAAGAGCAAAAAA 1679
Db |||||
1621 GTAGACTGTGCCACCGCGCTGTGTGTGAAACGTGAAATATAAAGAGCAAAAAA 1679

RESULT 155
ADE18377
ID ADE18377 standard; cDNA; 1679 BP.
XX
AC ADE18377;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
XX
Human; gens; ss; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX
Homo sapiens.
OS
XX
PN US2003194794-A1.
XX
PD 16-OCT-2003.
XX
PP 17-APR-2002; 2002US-00125805.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 01-DEC-1998; 98WO-US024855.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.

```

PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 31-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US074729.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US079649.
PR 28-FEB-2001; 2001WO-US008520.
PR 01-MAR-2001; 2001WO-US008666.
PR 09-MAR-2001; 2001WO-US008270.
PR 14-MAR-2001; 2001WO-US081574.
PR 22-MAR-2001; 2001WO-US081744.
PR 05-APR-2001; 2001WO-US082836.
PR 10-MAY-2001; 2001WO-US085420.
PR 10-MAY-2001; 2001WO-US085428.
PR 18-MAY-2001; 2001WO-US086021.
PR 25-MAY-2001; 2001WO-US086028.
PR 25-MAY-2001; 2001WO-US086034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US087203.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001WO-US087450.
PR 14-JUN-2001; 2001WO-US088263.
PR 19-JUN-2001; 2001WO-US088632.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001WO-US088789.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001WO-US090827.
PR 08-AUG-2001; 2001WO-US092449.
PR 09-AUG-2001; 2001WO-US092796.
PR 16-AUG-2001; 2001WO-US093183.
PR 19-DEC-2001; 2001WO-US002807.
XX

PA (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-021079/02.
DR P-PSDB; ADE18378.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, for use in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
XX Claim 2; SEQ ID NO 375; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX the proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems,
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polynucleotide of the invention. Note:
XX The sequence data for this patent is also available in electronic format
XX from USPTO at seqdata.uspto.gov/sequence.html.
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6,7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTGCAACAAGTTGAGAGCAAC 60
DB 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTGCAACAAGTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAACCCGACCTGACAAAGAGAGAGAGAGAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAACCCGACCTGACAAAGAGAGAGAGAG 120
QY 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATTCATATCTCTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATTCATATCTCTTGGGCAAT 180
QY 181 CTTTCACGGGGCTGGCTGCTCTGTGTCTCTTCCAGAGAGTCCCGTCGCGAGGATGC 240
DB 181 CTTTCACGGGGCTGGCTGCTCTGTGTCTCTTCCAGAGAGTCCCGTCGCGAGGATGC 240
QY 241 CACCTTCCCAAGATCTATGACAAACGTGACGGTCCGCGAGGAGAGGCCACCTTCAG 300
DB 241 CACCTTCCCAAGATCTATGACAAACGTGACGGTCCGCGAGGAGAGGCCACCTTCAG 300
XX
```

Db 241 CACCTTCCCAAGCTATGGAACAACGTCAGCGTCCGGCAGCGGGGAGAGCGCCACCTCAG 300
Qy 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAACCGGAGACACCATCTCTA 360
Db 301 GTGCACTATTGACAAACCGGGTCAACCGGGTGGCTGGCTTAACCGGAGACACCATCTCTA 360
Qy 361 TGTGGGAATGACAAGTGGTGGCTGGATCTCCGCTGGTCTCTCTGAGCAACACCCAAAC 420
Db 361 TGTGGGAATGACAAGTGGTGGCTGGATCTCCGCTGGTCTCTCTGAGCAACACCCAAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACGAGGGCCCTTACACCTGTCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACCTGGATGTGTATGACGAGGGCCCTTACACCTGTCTC 480
Qy 481 GGTGACAGACACAACACCCAAAGACCTTAGGTCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGACAGACACAACACCCAAAGACCTTAGGTCACCTCATTTGTGCAAGTATCTCC 540
Qy 541 CAAAATTGTAGAGATTCTTTAGATATCTCCATTAATGAGGGAACAATATTAGCCTCAC 600
Db 541 CAAAATTGTAGAGATTCTTTAGATATCTCCATTAATGAGGGAACAATATTAGCCTCAC 600
Qy 601 CTGCTAGACAACTGTGATAGACAGAGCTAGGTTACTTTGGAGACATCTCTCCGAAGC 660
Db 601 CTGCTAGACAACTGTGATAGACAGAGCTAGGTTACTTTGGAGACATCTCTCCGAAGC 660
Qy 661 GGTGGCTTTGTAGTCAAGACGAATACTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
Db 661 GGTGGCTTTGTAGTCAAGACGAATACTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
Qy 721 AGGGGAATACAGTGCAGTGCCTCCAAATGACGTGGCGCCGCGCTGGTAGCGAGATAA 780
Db 721 AGGGGAATACAGTGCAGTGCCTCCAAATGACGTGGCGCCGCGCTGGTAGCGAGATAA 780
Qy 781 GGTCAACGTAACATATCCACATACATTTTCCAGAGCCAGGGTACAGGTGTCCCGTGGG 840
Db 781 GGTCAACGTAACATATCCACATACATTTTCCAGAGCCAGGGTACAGGTGTCCCGTGGG 840
Qy 841 ACAAAGGGGACACTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 841 ACAAAGGGGACACTGAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Qy 901 CAAGGTGACAAAGACTGATTGAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
Db 901 CAAGGTGACAAAGACTGATTGAGGAAAGAAAGGGGTGAAAGTGGAAACAGACCTTT 960
Qy 961 CCTCTCAAACTCATCTTCTCAATGCTCTGAACTGACTATGGGAACCTACCTTGGT 1020
Db 961 CCTCTCAAACTCATCTTCTCAATGCTCTGAACTGACTATGGGAACCTACCTTGGT 1020
Qy 1021 GGCCTCAAACTGAGTGGGCAACCAATGACAGCATATGCTATTTGGTCCAGGCGCT 1080
Db 1021 GGCCTCAAACTGAGTGGGCAACCAATGACAGCATATGCTATTTGGTCCAGGCGCT 1080
Qy 1081 CAGGAGTGAAGCAACGGCAGCTCGAGGAGGAGGCTGGTCTGGCTGCTGCTCTTCT 1140
Db 1081 CAGGAGTGAAGCAACGGCAGCTCGAGGAGGAGGCTGGTCTGGCTGCTGCTCTTCT 1140
Qy 1141 GGTCTTGACCTGTTCTCAAAATTTGATGAGTGCATCTTCCCAACCGGGAAGGCT 1200
Db 1141 GGTCTTGACCTGTTCTCAAAATTTGATGAGTGCATCTTCCCAACCGGGAAGGCT 1200
Qy 1201 GCGGCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
Db 1201 GCGGCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAAC 1260
Qy 1261 TATCAAAATTAAGTAAAGAAACACAGCTTCATGGGACAGAAATTTAGGGGGGGAAC 1320
Db 1261 TATCAAAATTAAGTAAAGAAACACAGCTTCATGGGACAGAAATTTAGGGGGGGAAC 1320
Qy 1321 AAGAAATTTGGGGGGAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAGAAATTTGGGGGGAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380

RESULT 156

ADE88686
ID ADE88686 standard; cDNA; 1679. BP.
XX
AC ADE88686;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #188.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199054-A1.
XX
PD 23-OCT-2003.
XX
PF 12-APR-2002; 2002US-00121054.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001US-00796520.
PR 01-MAR-2001; 2001WO-US006520.
PR 09-MAR-2001; 2001WO-US006666.
PR 14-MAR-2001; 2001US-00802706.
PR 22-MAR-2001; 2001US-00808689.
PR 05-APR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00866038.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908627.

PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 13-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen WE, Goddard A, Godowski PU, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX
XX NPI; 2004-041356/04.
DR P-PSDB; ADE88687.
XX
PT Novel secreted and transmembrane polypeptides, PRO useful for treating
PT bone disorders, arthritis, heart attack, injuries, tumors, and
PT stimulating release of TNF-alpha from human blood.
XX
PS Claim 2; SEQ ID NO 375; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTGCAAGCTTGAGGACAC 60
DB 1 GTTGTGCTTCAGCAAAACAGTGGATTAAATCTCTTGCAAGCTTGAGGACAC 60
QY 61 AATCTATCAGGAAGAAAGAAAACCGAACTGCAAAAAGAGAAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAACCGAACTGCAAAAAGAGAAAAGAAAG 120
QY 121 AAGAAAAAATATGAAAAACCATCCAGCCAAAATTCATCTCTTGGGCAAT 180
DB 121 AAGAAAAAATATGAAAAACCATCCAGCCAAAATTCATCTCTTGGGCAAT 180
QY 181 CTTTCAGGGGCTGGCTGCTGTGTCTCTTCCAAAGGAGTCCCGTCGCGAGGAGATGC 240

PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080322P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 23-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 13-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087108P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113262P.
PR 05-JAN-1999; 98WO-US000106.
PR 08-JAN-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 12-MAR-1999; 98US-0123957P.
PR 29-MAR-1999; 98US-0126773P.
PR 21-APR-1999; 98US-0130232P.
PR 26-APR-1999; 98US-0131022P.
PR 28-APR-1999; 98US-0131445P.
PR 14-MAY-1999; 98US-0134287P.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 16-JUN-1999; 98US-0139557P.
PR 23-JUN-1999; 98US-0141037P.
PR 07-JUL-1999; 98US-0142680P.
PR 26-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 98US-0146222P.
PR 28-OCT-1999; 98US-0162506P.
PR 30-NOV-1999; 98WO-US028313.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 08-JAN-2000; 2000WO-US000277.
PR 08-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 23-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
(ASHK/) ASHKENAZI A J.
PA (BAKE/) BAKER K P.
PA (BOTS/) BOTSTEIN D.
PA (DESN/) DESNOYERS L.
PA (EATO/) EATON D L.
PA (FERR/) FERRARA N.
PA (FILV/) FILVAROFF E.
PA (FONG/) FONG S.
PA (GAOW/) GAO W.
PA (GERB/) GERBER H.
PA (GERR/) GERRITSEN M E.
PA (GODD/) GODDARD A.
PA (GODO/) GODOWSKI P J.
PA (GIRM/) GIRMALDI J C.
PA (GURN/) GURNEY A L.
PA (HILL/) HILLAN K J.
PA (KLJA/) KLJAVIN I J.
PA (KUOS/) KUO S S.

KW gene therapy.
 XX
 OS Homo sapiens.
 XX
 PN US2003100729-A1.
 XX
 PD 29-MAY-2003.
 XX
 PF 28-AUG-2002; 2002US-00230113.
 XX
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WJ;
 XX WPI; 2004-008979/01.
 DR P-PSDB; ADD77607.
 XX
 PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, or for preparing a medicament for treating a condition
 PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
 PT cancer.
 XX
 PS Claim 2; SEQ ID NO 125; 309pp; English.
 XX
 CC The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (i). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO331, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419,
 CC PRO247, PRO337, PRO536, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1146, PRO1186, PRO1192, PRO1244, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1405, PRO1474, PRO1917, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO3723, PRO5725, PRO7134, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (ii) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (ii) encoding (i) is
 CC useful for chromosome and gene mapping or gene therapy. (iii) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC PRO polypeptide). This sequence encodes a human secreted and transmembrane
 XX PRO polypeptide.
 SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 1 GTTGTGCTCCTCAGCAAAACAGTGGATTTAAATCTCTTGTGCAAGCTTGAGAGCAACAC 60
 |||||
 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 |||||
 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 |||||
 121 AAGAAAAAATATCATGAAATCCATCCAGCAAAATATGCAATTTCTATCTCTTGGGCAAT 180
 |||||
 121 AAGAAAAAATATCATGAAATCCATCCAGCAAAATATGCAATTTCTATCTCTTGGGCAAT 180
 |||||
 181 CTTTACGGGGCTGGCTGCTCTGTCTCTTCAAGAGAGTCCCGTGGCAGCGGAGATGC 240
 |||||
 181 CTTTACGGGGCTGGCTGCTCTGTCTCTTCAAGAGAGTCCCGTGGCAGCGGAGATGC 240
 |||||
 241 CACCTTCCCAAGCTATGCAAACTGACGCTCCGGCAGCGGAGAGCGCCACCTCTAG 300
 |||||
 241 CACCTTCCCAAGCTATGCAAACTGACGCTCCGGCAGCGGAGAGCGCCACCTCTAG 300
 |||||
 301 GTGCACTATGCAACACCGGGTCAACCGGGTGGCTGGCTAAACCGGAGAGCAATCTCTA 360
 |||||
 301 GTGCACTATGCAACACCGGGTCAACCGGGTGGCTGGCTAAACCGGAGAGCAATCTCTA 360
 |||||
 361 TGTCTGGGAATGCAACAGTGGTCTGCTGATCCTCGGTGGTCTCTTCTGAGCAACACCCCAAC 420
 |||||
 361 TGTCTGGGAATGCAACAGTGGTCTGCTGATCCTCGGTGGTCTCTTCTGAGCAACACCCCAAC 420
 |||||
 421 GCAGTACAGATCGAGATCCAGAACTGATGTATGATGACAGGGGCCCTTACACCTGTCTC 480
 |||||
 421 GCAGTACAGATCGAGATCCAGAACTGATGTATGATGACAGGGGCCCTTACACCTGTCTC 480
 |||||
 481 GGTGACAGAGCAACACCCCAAGACCTTAGGTGTCACCTCTATTGTCAAGTATCTCC 540
 |||||
 481 GGTGACAGAGCAACACCCCAAGACCTTAGGTGTCACCTCTATTGTCAAGTATCTCC 540
 |||||
 541 CAAAATTTAGAGATTTCTTCAAGATATCTCCATTAATGAAGGAAACAATATTAGCTCTAC 600
 |||||
 541 CAAAATTTAGAGATTTCTTCAAGATATCTCCATTAATGAAGGAAACAATATTAGCTCTAC 600
 |||||
 601 CTCATAGCAACTGTAGTACAGAGCTACGTTACTTGGAGACACATCTCTCCCAAGC 660
 |||||
 601 CTCATAGCAACTGTGTAGACAGAGCTACGTTACTTGGAGACACATCTCTCCCAAGC 660
 |||||
 661 GGTGCTTTTGTGAGTGAAGACGAATATCTTGAATTTAGGAGCATCACCCGGAGAGCTC 720
 |||||
 661 GGTGCTTTTGTGAGTGAAGACGAATATCTTGAATTTAGGAGCATCACCCGGAGAGCTC 720
 |||||
 721 AGGGACTACGAGTGCAGTGCCTCCATCACTGCGCGCGCGCGGTGTCAGGAGAGTAAA 780
 |||||
 721 AGGGACTACGAGTGCAGTGCCTCCATCACTGCGCGCGCGCGGTGTCAGGAGAGTAAA 780
 |||||
 781 GGTCAACCGTGAATATCCACCATACATTTTCAAGAACCAAGGGTACAGGTGTCCCGTGG 840
 |||||
 781 GGTCAACCGTGAATATCCACCATACATTTTCAAGAACCAAGGGTACAGGTGTCCCGTGG 840
 |||||
 841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGTGTGA 900
 |||||
 841 ACAAAGGGGACACTGCAGTGTGAAGCTCAGAGTCCCTCAGCAGAAATTCAGTGTGA 900
 |||||
 901 CAAGGATGACAAAGACTGATTGAAGAAAGAAAGGGGTGAAGTGAAGTGAAGTGAAGTGA 960
 |||||
 901 CAAGGATGACAAAGACTGATTGAAGAAAGAAAGGGGTGAAGTGAAGTGAAGTGAAGTGA 960
 |||||
 961 CCTCTCAAAATCATCTTCTTCAATGTCTCTGAAATGATGGAATACACTTGGCT 1020
 |||||
 961 CCTCTCAAAATCATCTTCTTCAATGTCTCTGAAATGATGGAATACACTTGGCT 1020
 |||||
 1021 GGCTCTCAACAGCTGGGCCACCAATCCAGCATCATGCTATTGTGTCAGGCGCGCT 1080
 |||||
 1021 GGCTCTCAACAGCTGGGCCACCAATCCAGCATCATGCTATTGTGTCAGGCGCGCT 1080
 |||||
 1081 CAGCGAGGTGAGCAACCGGCACTGTCAGAGAGGGGAGGCTCGCTCGCTCTTCTTCT 1140
 |||||
 1081 CAGCGAGGTGAGCAACCGGCACTGTCAGAGAGGGGAGGCTCGCTCGCTCTTCTTCT 1140
 |||||

301 GTGCACTATTGACAAACGGGGTCAACCGGGTGGCTAAACCGGAGCAGCACCCTCTCTA 360
Db |
301 GTGCACTATTGACAAACGGGGTCAACCGGGTGGCTAAACCGGAGCAGCACCCTCTCTA 360
Qy |
361 TGTGGGAATGACAAAGTGGTGGATCCCTGGGTGCTCTCTGAGCAACACCCAAAC 420
Db |
361 TGTGGGAATGACAAAGTGGTGGATCCCTGGGTGCTCTCTGAGCAACACCCAAAC 420
Qy |
421 GCAGTACAGCATCGAGATCCAGAACGCTGGATGTGTATGACGAGGCGCTTACACCTGCTC 480
Db |
421 GCAGTACAGCATCGAGATCCAGAACGCTGGATGTGTATGACGAGGCGCTTACACCTGCTC 480
Qy |
481 GGTGAGACAGACAAACCAACCAAGACCTCTAGGTCACCTCATTTGTGCAAGTATCTCC 540
Db |
481 GGTGAGACAGACAAACCAACCAAGACCTCTAGGTCACCTCATTTGTGCAAGTATCTCC 540
Qy |
541 CAATATTTGAGAGATTTCTTCTGATATCTCCATTAATGAGGGAACAAATATTACCTCAC 600
Db |
541 CAATATTTGAGAGATTTCTTCTGATATCTCCATTAATGAGGGAACAAATATTACCTCAC 600
Qy |
601 CTGCATAGCAACTGTGAGACAGACCTACGTTTACTTTGGAGACACATCTCTCCCAAAGC 660
Db |
601 CTGCATAGCAACTGTGAGACAGACCTACGTTTACTTTGGAGACACATCTCTCCCAAAGC 660
Qy |
661 GGTGGCTTTGTGAGTGAAGCAATCTTGGAAATTCAGGGCATCACCGGAGCAGTC 720
Db |
661 GGTGGCTTTGTGAGTGAAGCAATCTTGGAAATTCAGGGCATCACCGGAGCAGTC 720
Qy |
721 AGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCCGCTGTGACGAGAGTAAA 780
Db |
721 AGGGACTACGAGTGCAGTGCCTCAATGACGTGGCGCGCCGCTGTGACGAGAGTAAA 780
Qy |
781 GGTCAACGTGAACTATCCACATATATTTCAGAGCCAGGGTACAGGTGTCCTCCGTTGG 840
Db |
781 GGTCAACGTGAACTATCCACATATATTTCAGAGCCAGGGTACAGGTGTCCTCCGTTGG 840
Qy |
841 ACAAAGGGGACACTGCGAGTGTGAAGCTCAGCAGTCCCTCAGCAGATTCACAGTGSTA 900
Db |
841 ACAAAGGGGACACTGCGAGTGTGAAGCTCAGCAGTCCCTCAGCAGATTCACAGTGSTA 900
Qy |
901 CAAGATGACAAAGACTGATTGAAGAAAGAGGGGTGAAGTGGAAACAGACCTTT 960
Db |
901 CAAGATGACAAAGACTGATTGAAGAAAGAGGGGTGAAGTGGAAACAGACCTTT 960
Qy |
961 CCTCTCAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGAACTACACTTCGGT 1020
Db |
961 CCTCTCAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGAACTACACTTCGGT 1020
Qy |
1021 GGCCTCCAAAGCTGGGCCAACCAATGCCAGCATCATGTTTGTCCAGGCGCGT 1080
Db |
1021 GGCCTCCAAAGCTGGGCCAACCAATGCCAGCATCATGTTTGTCCAGGCGCGT 1080
Qy |
1081 CAGCGAGTGAACAGCGCAGTCCGAGGAGGCGAGGCTGCTGCTGCTGCTCTTCT 1140
Db |
1081 CAGCGAGTGAACAGCGCAGTCCGAGGAGGCGAGGCTGCTGCTGCTGCTCTTCT 1140
Qy |
1141 GGTCTTGACCTGCTCTCAATTTTGTATGTGAGTGCACCTTCCCAACCGGAAAGCT 1200
Db |
1141 GGTCTTGACCTGCTCTCAATTTTGTATGTGAGTGCACCTTCCCAACCGGAAAGCT 1200
Qy |
1201 GCGGCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Db |
1201 GCGGCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Qy |
1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGAAC 1320
Db |
1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGAAC 1320
Qy |
1321 AAAGATATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGAAATTTGAAATTTG 1380
Db |
1321 AAAGATATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGAAATTTGAAATTTG 1380

1381 TTTAGTACAAATGGAGTTTCTTTTCCAAACGGGAAGAACACAGCACACCGGCTTGA 1440
Db |
1381 TTTAGTACAAATGGAGTTTCTTTTCCAAACGGGAAGAACACAGCACACCGGCTTGA 1440
Qy |
1441 CCCACTGCAAGCTGCATCGTGCACACTCTTTTGGTCCCAAGTGTGGCAAGGGCTCAGCCTC 1500
Db |
1441 CCCACTGCAAGCTGCATCGTGCACACTCTTTTGGTCCCAAGTGTGGCAAGGGCTCAGCCTC 1500
Qy |
1501 TCTGCCACAGAGTGGCCCGCCACGTCGAAACATCTCTGAGCTGGCCATCCAAATTCATCA 1560
Db |
1501 TCTGCCACAGAGTGGCCCGCCACGTCGAAACATCTCTGAGCTGGCCATCCAAATTCATCA 1560
Qy |
1561 GTCCATAGAGACAAACAGAAATGAGACCTTTCGGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
Db |
1561 GTCCATAGAGACAAACAGAAATGAGACCTTTCGGCCCAAGCGTGGCGCTCGGGCACTTTG 1620
Qy |
1621 GTAGACTGTGCCACCAACGCGCTGTGTGTGAACCTGTAAATTAAGAGCAAAAAA 1679
Db |
1621 GTAGACTGTGCCACCAACGCGCTGTGTGTGAACCTGTAAATTAAGAGCAAAAAA 1679

RESULT 160

ADD85310

ID ADD85310 standard; cDNA; 1679 bp.

XX

AC ADD85310;

XX

DT 29-JAN-2004 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO337 cDNA.

human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;
vulnary; aniahrthic; pericyte cell proliferation;
pericyte cell differentiation; chondrocyte cell proliferation;
chondrocyte cell differentiation; tumour necrosis factor alpha release;
(TNF)-alpha release; dermal fibroblast cell proliferation;
dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
colon tumour; breast tumour; prostate tumour; rectal tumour;
liver tumour; tissue typing; chromosome mapping; gene mapping;
gene therapy.

XX Homo sapiens.

XX

XX US2003100725-A1.

XX

XX 29-MAY-2003.

XX

XX 26-AUG-2002; 2002US-00227876.

XX

XX 15-SEP-2000; 2000US-0232887P.

XX

XX 01-JUN-2001; 2001WO-US017800.

XX

XX 29-JUN-2001; 2001WO-US021066.

XX

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2004-008975/01.

XX P-PSDB; ADD85311.

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

The invention describes an isolated PRO (secreted and transmembrane) polypeptide (I). PRO382, PRO1160, PRO1187 or PRO1329 polypeptide are useful for stimulating the proliferation of or gene expression in pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful for stimulating the proliferation or differentiation of chondrocyte

CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1063, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO1096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 XX
 SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
 Best Local Similarity 100.0%; Pred. No. 6.7e-05;
 Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGCTCTCAGCAAAAAGTGGATTAAATCTCTTCCACCAAGCTTGAGAGCAAC 60
 DB 1 GTTGTGCTCTCAGCAAAAAGTGGATTAAATCTCTTCCACCAAGCTTGAGAGCAAC 60
 QY 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 DB 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
 QY 121 AAGAAAGAAATCATGAAAGCAATCCAGCCAAAGAAATCATCTCTTTGGGCAAT 180
 DB 121 AAGAAAGAAATCATGAAAGCAATCCAGCCAAAGAAATCATCTCTTTGGGCAAT 180
 QY 181 CTTCCAGGGGTGGCTGCTCTGTCTCTTCCAGGAGTGGCCGTGGCAGCGGAGATGC 240
 DB 181 CTTCCAGGGGTGGCTGCTCTGTCTCTTCCAGGAGTGGCCGTGGCAGCGGAGATGC 240
 QY 241 CACCTTCCCAAGCTATGACAAACGTGACGGTCCGGCAGGGGGAGAGCGCCACCTTCAG 300
 DB 241 CACCTTCCCAAGCTATGACAAACGTGACGGTCCGGCAGGGGGAGAGCGCCACCTTCAG 300
 QY 301 GTGCACATATTGACAAACCGGGTACCCCGGGTGGCTGGCTAAACCGCAGCAACCTCTTA 360
 DB 301 GTGCACATATTGACAAACCGGGTACCCCGGGTGGCTGGCTAAACCGCAGCAACCTCTTA 360
 QY 361 TGCTGGGAATGACAAAGTGGTSCCTGGATCTCTCGGTGGTCTCTTGTGAGCAACCCAAAC 420
 DB 361 TGCTGGGAATGACAAAGTGGTSCCTGGATCTCTCGGTGGTCTCTTGTGAGCAACCCAAAC 420
 QY 421 GCAGTAGCATCGAGATCCAGACGTGGATGTGTATGAGAGGGCCCTTACACCTGCTC 480
 DB 421 GCAGTAGCATCGAGATCCAGACGTGGATGTGTATGAGAGGGCCCTTACACCTGCTC 480
 QY 481 GGTGACAGACACCAACCCAAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
 DB 481 GGTGACAGACACCAACCCAAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540

QY 541 CAAAATGTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
 DB 541 CAAAATGTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
 QY 601 CTGCATAGCAAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
 DB 601 CTGCATAGCAAACTGGTAGACAGAGCCTACGGTTACTTTGGAGACACATCTCTCCCAAGC 660
 QY 661 GGTGGCTTCTGTAGTGAAGACGAATACTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
 DB 661 GGTGGCTTCTGTAGTGAAGACGAATACTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
 QY 721 AGGGGACTACGAGTCAAGTCCCTCCAAATGACGTGGCCGCCCTCGTGTACGAGAGTAAA 780
 DB 721 AGGGGACTACGAGTCAAGTCCCTCCAAATGACGTGGCCGCCCTCGTGTACGAGAGTAAA 780
 QY 781 GGTACCGTGAACATATCCACCATATCTTCAAGAGCCAGGGTACAGGTGTCCTCGTGG 840
 DB 781 GGTACCGTGAACATATCCACCATATCTTCAAGAGCCAGGGTACAGGTGTCCTCGTGG 840
 QY 841 ACAAAGGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
 DB 841 ACAAAGGGGACACTGCGAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
 QY 901 CAGGATGACAAAGACATGATTGAAGAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
 DB 901 CAGGATGACAAAGACATGATTGAAGAGAAAGGGGTGAAGTGGAAACAGACCTTT 960
 QY 961 CTTCTCAAAATCATCTCTTCAATGTCTGTAACATGACTATGGAACTACCTTGGT 1020
 DB 961 CTTCTCAAAATCATCTCTTCAATGTCTGTAACATGACTATGGAACTACCTTGGT 1020
 QY 1021 GGCCTCCAAAGCTGGGCCACCAATGCCAGCATCATGCTATTGTGTCAGGGCCGT 1080
 DB 1021 GGCCTCCAAAGCTGGGCCACCAATGCCAGCATCATGCTATTGTGTCAGGGCCGT 1080
 QY 1081 CAGCGAGTGAAGCAACGCGCAGTCCAGGAGGCGAGCTGCGTCTGGCTGCTCTCTCT 1140
 DB 1081 CAGCGAGTGAAGCAACGCGCAGTCCAGGAGGCGAGCTGCGTCTGGCTGCTCTCTCT 1140
 QY 1141 GGTCTTGAACCTGCTTCAAAATTTTGTATGTAGTGCCTTCCCTCCACCCGGGAAAGCT 1200
 DB 1141 GGTCTTGAACCTGCTTCAAAATTTTGTATGTAGTGCCTTCCCTCCACCCGGGAAAGCT 1200
 QY 1201 GCGGCCACCCACCAACCAACAGCAACAGCAATGGCAACAGCAACCAATCAGATA 1260
 DB 1201 GCGGCCACCCACCAACCAACAGCAACAGCAATGGCAACAGCAACCAATCAGATA 1260
 QY 1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320
 DB 1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320
 QY 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGAAATTTGAAATTT 1380
 DB 1321 AAGAAATCTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGAAATTTGAAATTT 1380
 QY 1381 TTTAGGTACATAGGAGTTTCTTTTCCAAAGGGGAAAGAACACAGCACACCCGGCTTGG 1440
 DB 1381 TTTAGGTACATAGGAGTTTCTTTTCCAAAGGGGAAAGAACACACAGCACACCCGGCTTGG 1440
 QY 1441 CCCACTGCAAGCTGATGTGCAACCTCTTTGGTGCAGTGTGGCAGAGGCTCAGCCTC 1500
 DB 1441 CCCACTGCAAGCTGATGTGCAACCTCTTTGGTGCAGTGTGGCAGAGGCTCAGCCTC 1500
 QY 1501 TCTGCCACAGAGTGCCTCCACGTGGAAATCTTGGAGTGGCCATCCCAATTCATCA 1560
 DB 1501 TCTGCCACAGAGTGCCTCCACGTGGAAATCTTGGAGTGGCCATCCCAATTCATCA 1560
 QY 1561 GTCCATAGAGAGAAAGAAATGAGACCTTCGGGCCAAGCGTGGCGCTCGGGGCACTTTG 1620
 DB 1561 GTCCATAGAGAGAAAGAAATGAGACCTTCGGGCCAAGCGTGGCGCTCGGGGCACTTTG 1620
 QY 1621 GTAGACTGTGCCACCAACCGCGGTGTGTGTGAAACCTGTGAAATATAAAGAGCAAAAAA 1679

DB 1621 GTAGACTGTGCCACCACCGCGTGTGTGTGAACGTGAATATAAAGAGCAAAAAA 1679
|||||
RESULT 161
ADD73842
ID ADD73842 standard; cDNA; 1679 BP.
XX
AC ADD73842;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #63.
XX
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW arthritis; sports injury; cytostatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN US2003100710-A1.
XX
PD 29-MAY-2003.
XX
PF 09-AUG-2002; 2002US-00216164.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 15-SEP-2000; 2000US-0232887P.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
DR WPI; 2004-008960/01.
XX
PT P-PSDB; ADD73843.
XX
PT New secreted and transmembrane PRO polypeptide useful for preparing a
PT medicament for treating a condition that is responsive to the PRO
PT polypeptide or anti-PRO antibody, e.g. cancer.
XX
PS Claim 2; Fig 125; 309pp; English.
XX
CC The invention relates to human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. They are particularly useful for
CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC blood, for stimulating the proliferation or differentiation of
CC chondrocyte cells, for stimulating the proliferation of or gene
CC expression in pericyte cells or for stimulating the proliferation of
CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format

CC at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;
Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAAC 60
DB 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAAGCTTGAGAGCAAC 60
QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
QY 121 AAGAAAAAATCATGAAACCAATCCAGCCAAATATGCAATCTTATCTCTTGGCAAT 180
DB 121 AAGAAAAAATCATGAAACCAATCCAGCCAAATATGCAATCTTATCTCTTGGCAAT 180
QY 181 CTTTCAGGGGCTGGCTGCTCTGTGTCTCTTTCAGAGAGTGCCTGCGCAGCGGAGATGC 240
DB 181 CTTTCAGGGGCTGGCTGCTCTGTGTCTCTTTCAGAGAGTGCCTGCGCAGCGGAGATGC 240
QY 241 CACCTTCCCAAGCTATGGAACAACTGACGGTCCGGCAGGGGAGAGCCACCTCAG 300
DB 241 CACCTTCCCAAGCTATGGAACAACTGACGGTCCGGCAGGGGAGAGCCACCTCAG 300
QY 301 GTGCACCTATTGACAAACCGGCTCACCCGGGTGGCTTAAACCGCAGCACCCTCTTA 360
DB 301 GTGCACCTATTGACAAACCGGCTCACCCGGGTGGCTTAAACCGCAGCACCCTCTTA 360
QY 361 TGTGGGAATGACAAAGTGTGCTGATCTCTGCGTGGTCTTCTGAGCAACACCCAAAC 420
DB 361 TGTGGGAATGACAAAGTGTGCTGATCTCTGCGTGGTCTTCTGAGCAACACCCAAAC 420
QY 421 GCAGTCAGCATCGAGATCCAGAACTGATGTATGACAGGGGCCCTTACACCTGCTC 480
DB 421 GCAGTCAGCATCGAGATCCAGAACTGATGTATGACAGGGGCCCTTACACCTGCTC 480
QY 481 GGTGCGAGACAGCAACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGCGAGACAGCAACCCCAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
QY 541 CAAATTTGTAGATATTTCTCAGATATCTCCATTATGAAGGAAACAATATTAGCCTAC 600
DB 541 CAAATTTGTAGATATTTCTCAGATATCTCCATTATGAAGGAAACAATATTAGCCTAC 600
QY 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTGGAGACACATCTCTCCCAAGC 660
QY 661 GGTGGCTTTGTGAGTGAAGAGCAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
DB 661 GGTGGCTTTGTGAGTGAAGAGCAATCTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
QY 721 AGGGGACTACAGTGCAGTGCCTTCAATGACGTGGCGCGCCCGTGGTACGAGAGTAAA 780
DB 721 AGGGGACTACAGTGCAGTGCCTTCAATGACGTGGCGCGCCCGTGGTACGAGAGTAAA 780
QY 781 GGTACCGTGAATCTCCACCATACATTTTCAGAGCCAGGGGTACAGGTGTCCTCCGTTGG 840
DB 781 GGTACCGTGAATCTCCACCATACATTTTCAGAGCCAGGGGTACAGGTGTCCTCCGTTGG 840
QY 841 ACAAAAGGGGACACTGCAAGTGTGAAGCCTCAGCAGTCCCTCAGAGCAATTCAGTGGTA 900
DB 841 ACAAAAGGGGACACTGCAAGTGTGAAGCCTCAGCAGTCCCTCAGAGCAATTCAGTGGTA 900
QY 901 CAGAGATGACAAAGACTGATTGAAGAAAGAGGGGTGAAGTGAAGAAACAGACCTTT 960
DB 901 CAGAGATGACAAAGACTGATTGAAGAAAGAGGGGTGAAGTGAAGAAACAGACCTTT 960
QY 961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGGAACTACACTTGCCT 1020

Db 961 CCTCTCAAACTCATTTCTTCAATGCTCTGACATGACTATGGAACTACACTGGCT 1020
Qy 1021 GGCTTCAACAGCTGGGCGACACCAATGCGCATCATGCTATTTGGTCCAGGCGCGT 1080
Db 1021 GGCTTCAACAGCTGGGCGACACCAATGCGCATCATGCTATTTGGTCCAGGCGCGT 1080
Qy 1081 CAGCGAGGTGAGCAACCGGACGTCGAGGAGGCGAGGCTGCTGCTGCTGCTTCT 1140
Db 1081 CAGCGAGGTGAGCAACCGGACGTCGAGGAGGCGAGGCTGCTGCTGCTGCTTCT 1140
Qy 1141 GGTCTTGCACTCTCTCAATTTTGAATGATGATGCTGCTGCTGCTGCTGCTGCT 1200
Db 1141 GGTCTTGCACTCTCTCAATTTTGAATGATGATGCTGCTGCTGCTGCTGCTGCT 1200
Qy 1201 GCGCGCAC 1260
Db 1201 GCGCGCAC 1260
Qy 1261 TATACAAATGAATTAAGAGAAACACACACACACACACACACACACACACACAC 1320
Db 1261 TATACAAATGAATTAAGAGAAACACACACACACACACACACACACACACACAC 1320
Qy 1321 AAGGATACCTTTGGGGGAAAGAGTTTAAAGAGAAATGAAATTCGCTGCGAT 1380
Db 1321 AAGGATACCTTTGGGGGAAAGAGTTTAAAGAGAAATGAAATTCGCTGCGAT 1380
Qy 1381 TTTAGGTACATGAGAGTTTCTTTTCCCAACCGGAGAACACACACACACACAC 1440
Db 1381 TTTAGGTACATGAGAGTTTCTTTTCCCAACCGGAGAACACACACACACACAC 1440
Qy 1441 CCACATGCAAGCTGCAATGCGTGAACCTCTTTGTCAGTGGGCAAGGCTGAGCTTC 1500
Db 1441 CCACATGCAAGCTGCAATGCGTGAACCTCTTTGTCAGTGGGCAAGGCTGAGCTTC 1500
Qy 1501 TCTGCCACAGAGTGCCCGGACGAGCAATCTGAGCTGGGCAATCCCAAAATCAATCA 1560
Db 1501 TCTGCCACAGAGTGCCCGGACGAGCAATCTGAGCTGGGCAATCCCAAAATCAATCA 1560
Qy 1561 GTCCATAGACGCAACAGAAATGAGCTTCCGCGCCCAAGCGTGGCGCTGCGGCACTTTG 1620
Db 1561 GTCCATAGACGCAACAGAAATGAGCTTCCGCGCCCAAGCGTGGCGCTGCGGCACTTTG 1620
Qy 1621 GTAGCTGTGCCACACCGGCGTGTGTGTAACGTAATTAAGAGCAAAAAA 1679
Db 1621 GTAGCTGTGCCACACCGGCGTGTGTGTAACGTAATTAAGAGCAAAAAA 1679

RESULT 162
ADD74580
ID ADD74580 standard; cDNA; 1679 BP.
XX AC ADD74580;
XX DT
XX DE 29-JAN-2004 (first entry)
XX DE Human PRO polynucleotide #63.
XX KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
XX KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
XX KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
XX KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
XX KW arthritis; sports injury; cytostatic; antiarthritic.
XX OS Homo sapiens.
XX PN US2003100713-A1.
XX PD 29-MAY-2003.
XX PF 13-AUG-2002; 2002US-00219065.
XX PR 25-JUL-2000; 2000US-0220638P.

01-JUN-2001; 2001WO-US017800.
29-JUN-2001; 2001WO-US021066.
09-APR-2002; 2002US-00119480.
(GETH) GENENTECH INC.
Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PU,
Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
WPI; 2004-008963/01.
P-P5DB; ADD74581.
New secreted and transmembrane PRO polypeptide useful for preparing a
medicament for treating a condition that is responsive to the PRO
polypeptide or anti-PRO antibody, e.g. cancer.
Claim 2; Fig 125; 308pp; English.
The invention relates to human PRO polypeptides (secreted and
transmembrane polypeptides) and the PRO polynucleotides encoding them.
The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
diagnostics, biosensors or bioreactors. They are particularly useful for
detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
prostate tumour, rectal tumour or liver tumour) in a mammal, for
stimulating the release of tumour necrosis factor (TNF)-alpha from human
blood, for stimulating the proliferation or differentiation of
chondrocyte cells, for stimulating the proliferation of or gene
expression in pericyte cells or for stimulating the proliferation of
normal human dermal fibroblasts. The PRO nucleic acids are useful as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA, in preparing PRO polypeptides by recombinant
technology, in generating transgenic animals or knock-out animals which
may be used in the development and screening of therapeutically useful
reagents, in gene therapy, in chromosome identification, as chromosome
markers and in generating probes. The PRO polypeptides, or anti-PRO
antibodies, are useful for preparing a medicament for treating a
condition which is responsive to the PRO polypeptides or anti-PRO
antibodies, such as pericyte-associated tumours and bone and/or cartilage
disorders (e.g. arthritis, sports injuries), involving inducing the re-
differentiation of chondrocytes. The PRO polypeptides are useful as
molecular markers for protein electrophoresis, and in tissue typing. This
sequence represents a human PRO polynucleotide of the invention. Note:
The sequence data for this patent can also be obtained in electronic
format directly from USPTO at seqdata.uspto.gov/sequence.html.
Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGAGCAAC 60
Db 1 GTTGTGCTCTTCAGCAAAACAGTGGATTAAATCTCTTGCACAGCTTGAGAGCAAC 60
Qy 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 61 AATCTATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Qy 121 AAGAAAAAATCATGAAACCATCCAGCCAAATGCAATCTATCTCTTGGGAAT 180
Db 121 AAGAAAAAATCATGAAACCATCCAGCCAAATGCAATCTATCTCTTGGGAAT 180
Qy 181 CTTACGGGGCTGGCTGCTCTGTGCTCTTCCAGGAGTGCCCGTGGCAGCGAGATGC 240
Db 181 CTTACGGGGCTGGCTGCTCTGTGCTCTTCCAGGAGTGCCCGTGGCAGCGAGATGC 240
Qy 241 CACCTTCCCAAGCTATGGACAAAGTGAACGCTGCGGAGGGGAGAGCGCACCTTCAG 300
Db 241 CACCTTCCCAAGCTATGGACAAAGTGAACGCTGCGGAGGGGAGAGCGCACCTTCAG 300
Qy 301 GTGCACATTTGACAAACCGGGTCAACCGGCTGGCTGCTAAACCGCAGCACCTCCTTA 360

Db 301 GTGCACTATTGACAAACGGGTGTCACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTTA 360
Qy 361 TGCTGGGAATGACAAAGTGGTGCCTGGATCTCTCGGTGTCTTCTTGAGCAACACCCAAAC 420
Db 361 TGCTGGGAATGACAAAGTGGTGCCTGGATCTCTCGGTGTCTTCTTGAGCAACACCCAAAC 420
Qy 421 GCAGTACAGCATCGAGATCCAGAACGTCGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
Db 421 GCAGTACAGCATCGAGATCCAGAACGTCGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
Qy 481 GGTGACAGACAGAACACCAACCCAAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Db 481 GGTGACAGACAGAACACCAACCCAAAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCC 540
Qy 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAAATGAGGGGAAACAATATTAGCCTCAC 600
Db 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAAATGAGGGGAAACAATATTAGCCTCAC 600
Qy 601 CTGCATAGCAACTGTGTAGACAGAGCCCTACCGTTTACTTTGGAGACACATCTCTCCAAAGC 660
Db 601 CTGCATAGCAACTGTGTAGACAGAGCCCTACCGTTTACTTTGGAGACACATCTCTCCAAAGC 660
Qy 661 GGTGGCTTTGTGAGTGAAGACGAACTACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Db 661 GGTGGCTTTGTGAGTGAAGACGAACTACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
Qy 721 AGGGACTACAGTGCAGTCTCCATGACGTGGCCGCGCTGTGTGACGAGAGTAAA 780
Db 721 AGGGACTACAGTGCAGTCTCCATGACGTGGCCGCGCTGTGTGACGAGAGTAAA 780
Qy 781 GGTCACTGAACTATCCACCATATTTTGAAGACCAAGGTTACAGGTGTCCCGTGGG 840
Db 781 GGTCACTGAACTATCCACCATATTTTGAAGACCAAGGTTACAGGTGTCCCGTGGG 840
Qy 841 ACAAAGGGGACACTGACGTGTGAAGCTCAGCAGTCCCTCAGCAAGATTCAGTGGTA 900
Db 841 ACAAAGGGGACACTGACGTGTGAAGCTCAGCAGTCCCTCAGCAAGATTCAGTGGTA 900
Qy 901 CAAGCATCAAAAACACTGATTGAAGGAAAGAGGGGTGAAAGTGGAAACACAGACCTTT 960
Db 901 CAAGCATCAAAAACACTGATTGAAGGAAAGAGGGGTGAAAGTGGAAACACAGACCTTT 960
Qy 961 CCTCTCAAACTCATCTCTCTCAATGTCTCTGACATGACTATGGGAACACTACCTTCGT 1020
Db 961 CCTCTCAAACTCATCTCTCTCAATGTCTCTGACATGACTATGGGAACACTACCTTCGT 1020
Qy 1021 GGCCTTCAACAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGCGCCGT 1080
Db 1021 GGCCTTCAACAGCTGGGCCACCAATGCCAGCATCATGCTATTTGGTCCAGCGCCGT 1080
Qy 1081 CAGCGAGTGAACACGACGCTGAGGAGGGCAGGCTGCTGCTGCTGCTGCTCTTCT 1140
Db 1081 CAGCGAGTGAACACGACGCTGAGGAGGGCAGGCTGCTGCTGCTGCTGCTCTTCT 1140
Qy 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTGAGTGGCCACTTCCCAACCCGGGAAAGGCT 1200
Db 1141 GGTCTTGCACTGCTTCTCAAAATTTGATGTGAGTGGCCACTTCCCAACCCGGGAAAGGCT 1200
Qy 1201 GCCGCCACACACCAACCAACAGCAATGGCAATGGCAACCGACAGCAACCAATCAGATA 1260
Db 1201 GCCGCCACACACCAACCAACAGCAATGGCAATGGCAACCGACAGCAACCAATCAGATA 1260
Qy 1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
Db 1261 TATACAAATGAAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAAC 1320
Qy 1321 AAAGAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Db 1321 AAAGAATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTGCAGATA 1380
Qy 1381 TTTAGGTAATGAGTGTCTTTTCCCAACCGGAGAGACACAGCAGCACCCCGCTTGA 1440
Db 1381 TTTAGGTAATGAGTGTCTTTTCCCAACCGGAGAGACACAGCAGCACCCCGCTTGA 1440

RESULT 163

ADD77108

ID ADD77108 standard; cDNA; 1679 BP.

XX ADD77108;

XX DT 29-JAN-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO337 cDNA.

XX human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnery; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW Gene therapy.

XX Homo sapiens.

XX OS US2003100716-A1.

XX PD 29-MAY-2003.

XX PF 13-AUG-2002; 2002US-00219077.

XX PR 01-JUN-2001; 2001WO-US017800.

XX PR 29-JUN-2001; 2001WO-US021056.

XX PR 09-APR-2002; 2002US-00119480.

XX PA (GETH) GENENTECH INC.

XX PI Baker KD, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX DR WPI; 2004-008966/01.

XX DR P-PSDB; ADD77109.

XX PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, or for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
PT cancer.

XX PS Claim 2; SEQ ID NO 125; 308pp; English.

XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO329, PRO1372 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF).
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,

QY	601	CTGCATACCAACTGGTAGACCAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC	660
Db	601	CTGCATACCAACTGGTAGACCAGAGCCCTACGGTTACTTTGGAGACACATCTCTCCAAAGC	660
QY	661	GCTTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGCGCATCACCCGGGAGCAGTC	720
Db	661	GCTTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGCGCATCACCCGGGAGCAGTC	720
QY	721	AGGGAACTACGAGTGCAGTGCCTCCAAATGACGTGGCGCGCCCGTGTGTCGAGAGATAAA	780
Db	721	AGGGAACTACGAGTGCAGTGCCTCCAAATGACGTGGCGCGCCCGTGTGTCGAGAGATAAA	780
QY	781	GGTCCACGTGAACTATCCACCATACATTTACAAGCCAAAGGTTACAGGTGTCCCCCTGGG	840
Db	781	GGTCCACGTGAACTATCCACCATACATTTACAAGCCAAAGGTTACAGGTGTCCCCCTGGG	840
QY	841	ACAAAGGGGACACTGCAGTGTGAAGCCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
Db	841	ACAAAGGGGACACTGCAGTGTGAAGCCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA	900
QY	901	CAAGAGTGAACAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGGAAACACAGACCTTT	960
Db	901	CAAGAGTGAACAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGGAAACACAGACCTTT	960
QY	961	CTCTCAAAACTCATCTTCTTCCAAATGCTCTGAACATGACTATGGGAACTACACTTGCCT	1020
Db	961	CTCTCAAAACTCATCTTCTTCCAAATGCTCTGNAATGACTATGGGNACTACACTTGCCT	1020

1021 GGCCTCCACAAAGCTGGGCCACACCAATGCCAGCATCTGCTATTTTGGTCCAGCGCGGT 1080
 Db

QY		CACGAGGTGAATGCAAGCGGCTTTTGGCTGCTCCTCTCT	1140
Db	1081	CACGAGGTGAGCAATCGGCACGTCGAGGAGGCGAGCTTGCGTCTGGCTGCTCCTCTCT	1140
QY	1141	GGTCTTGCACTGCTTCTCAAATTTTTGATGTAGTGCACCTCCGCCACCCGGGAAAGGCT	1200
Db	1141	GGTCTTGCACTGCTTCTCAAATTTTTGATGTAGTGCACCTCCGCCACCCGGGAAAGGCT	1200
QY	1201	GCGCCACCAACCACCAACAACAGCAATGGCAACACCGACAGCAACCAATCAGATA	1260
Db	1201	GCGCCACCAACCACCAACAACAGCAATGGCAACACCGACAGCAACCAATCAGATA	1260
QY	1261	TATACAAATGAAATTAGAAGAAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC	1320
Db	1261	TATACAAATGAAATTTAGAAGAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC	1320
QY	1321	AAAGAATACTTTGGGGGAAAAAGAGTTTTAAAAAAGAAAATTTGAAAAATTGCTTCAGATA	1380
Db	1321	AAAGAATACTTTGGGGGAAAAAGAGTTTTAAAAAAGAAAATTTGAAAAATTGCTTCAGATA	1380
QY	1381	TTTAGTACAATGGAGTTTTCTTTCCCAAACGGGAGAACACAGCACACCCGGCTTGG	1440
Db	1381	TTTAGTACAATGGAGTTTTCTTTCCCAAACGGGAGAAACACAGCACACCCGGCTTGG	1440
QY	1441	CCCACGTCAAGCTGCATCGTGCAACTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC	1500
Db	1441	CCCACGTCAAGCTGCATCGTGCAACTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC	1500
QY	1501	TCTGCCCAACAGAGTGCCCCACGCTGGAAACATTTGGAGCTGGCCCATCCCAAATTCATCA	1560
Db	1501	TCTGCCCAACAGAGTGCCCCACGCTGGAAACATTTGGAGCTGGCCCATCCCAAATTCATCA	1560
QY	1561	GTCCATAGACACGAACGAATGAGACCTTCGGCCCCAAGCGTGGCGCTCGGGGCACTTTG	1620
Db	1561	GTCCATAGACACGAACGAATGAGACCTTCGGCCCCAAGCGTGGCGCTCGGGGCACTTTG	1620
QY	1621	GTAGACTGTGCCACCAACCGGCTGTGTGTGAAAACGTGAAATAAAAAGACAAAAAAA	1679
Db	1621	GTAGACTGTGCCACCAACCGGCTGTGTGTGAAAACGTGAAATAAAAAGACAAAAAAA	1679

RESULT 164

ADD85802

ID ADD85802 standard; CDNA; 1679 BP.

XX AC ADD85802;

XX DT 29-JAN-2004 (first entry)

XX DE Novel human secreted and transmembrane protein PRO337 cDNA.

XX human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.

XX OS Homo sapiens.

XX US 2003100720-A1.

XX PD 29-MAY-2003.

XX PF 14-AUG-2002; 2002US-00219471.

XX PR 18-NOV-1998; 98US-0108849P.

XX PR 01-SEP-1999; 99WO-US020111.

XX PR 01-JUN-2001; 2001WO-US017800.

XX PR 29-JUN-2001; 2001WO-US021066.

XX PR 09-APR-2002; 2002US-00119480.

XX PA (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2004-008970/01.

XX DR P-PSDB; ADD85803.

XX PT New secreted and transmembrane PRO polypeptide useful for preparing a

XX PT medicament for treating a condition that is responsive to the PRO

XX PS polypeptide or anti-PRO antibody, e.g. cancer.

XX PS Claim 2; SEQ ID NO 125; 308pp; English.

XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (1). PRO382, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO1154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of

CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (III) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.

XX SEQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query Match 100.0%; Score 1679; DB 1; Length 1679;

Best Local Similarity 100.0%; Fred. No. 6.7e-05;

Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGTCCTTCAGCAAAAACAGTGGATTTAAATCTCTTGCAACAGCTTGAGAGCAACAC 60

DB 1 GTTGTGTCCTTCAGCAAAAACAGTGGATTTAAATCTCTTGCAACAGCTTGAGAGCAACAC 60

QY 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

DB 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120

QY 121 AAGAAAAAATCATGAAAAACCATCCAGCAAAAATGCAAAATTCATCTCTTGGGCAAT 180

DB 121 AAGAAAAAATCATGAAAAACCATCCAGCAAAAATGCAAAATTCATCTCTTGGGCAAT 180

QY 181 CTTACGGGGCTGGCTGCTGTGTCTCTTCAAGAGAGTCCCGTGGCGAGGGAGATGC 240

DB 181 CTTACGGGGCTGGCTGCTGTGTCTCTTCAAGAGAGTCCCGTGGCGAGGGAGATGC 240

QY 241 CACCTTCCCCCAAGCTATGGACAACTGACGGTCCGGCAGGGGAGAGGCCACCCCTCAG 300

DB 241 CACCTTCCCCCAAGCTATGGACAACTGACGGTCCGGCAGGGGAGAGGCCACCCCTCAG 300

QY 301 GTCACATATTGACAAACCGGGTCAACCGGTGGCTGCTGCTTAAACCGGAGCACCATCTCTA 360

DB 301 GTCACATATTGACAAACCGGGTCAACCGGTGGCTGCTGCTTAAACCGGAGCACCATCTCTA 360

QY 361 TGTGGGAATGACAACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 420

DB 361 TGTGGGAATGACAACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 420

QY 421 GCAGTACAGCATCGAGATCCAGAACTGGATGTATGACAGGGGCCCTTACACCTGCTC 480

DB 421 GCAGTACAGCATCGAGATCCAGAACTGGATGTATGACAGGGGCCCTTACACCTGCTC 480

QY 481 GGTGACAGACAGCAACCCCAAGACCTTAGGGTCCACCTCATTTGTCAGAGTATCTCC 540

DB 481 GGTGACAGACAGCAACCCCAAGACCTTAGGGTCCACCTCATTTGTCAGAGTATCTCC 540

QY 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTTAATGAAGGAAACAATATTAGCCTCAC 600

DB 541 CAAAATTTAGAGATTTCTTCAGATATCTCCATTTAATGAAGGAAACAATATTAGCCTCAC 600

QY 601 CTCGATAGCACTGGTAGACAGGCTTACGTTACTTTGGAGACACATCTCTCCCAAGC 660

DB 601 CTCGATAGCACTGGTAGACAGGCTTACGTTACTTTGGAGACACATCTCTCCCAAGC 660

QY 661 GGTGGCTTTGTGAGTGAAGACGAATACATTTGAAATTCAGGGGCATCACCCTGGGAGCAGTC 720

DB 661 GGTGGCTTTGTGAGTGAAGACGAATACATTTGAAATTCAGGGGCATCACCCTGGGAGCAGTC 720

QY 721 AGGGGACTAGCAGTGCAGTGCCTCCAAATGACGTGGCGCGCGCTGGTACGAGAGTAAA 780

DB 721 AGGGGACTAGCAGTGCAGTGCCTCCAAATGACGTGGCGCGCGCTGGTACGAGAGTAAA 780

QY 781 GGTACCGTGAATCTATCCACCAATACATTTTCAAGAGCAAGGGGTACAGGTGTCCCGGTGG 840

DB 781 GGTACCGTGAATCTATCCACCAATACATTTTCAAGAGCAAGGGGTACAGGTGTCCCGGTGG 840

181 CTTTCAAGGGGCTGGCTGCTCTGTCTCTTTCRAAGAGTGGCCGTGGCAGCGGAGTGC 240
241 CACCTTCCCAAGAGCTATGGAACAAGTGAACGGTCCGGCAGGGGAGAGCGCCACCTTCAG 300
241 CACCTTCCCAAGAGCTATGGAACAAGTGAACGGTCCGGCAGGGGAGAGCGCCACCTTCAG 300
301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGGAGCAGCCATCTCTTA 360
301 GTGCACATATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGGAGCAGCCATCTCTTA 360
361 TGCTGGGAATGACAAAGTGGTGGCTGGATCTCTGGGTGGTCTCTGAGCAACACCCAAAC 420
361 TGCTGGGAATGACAAAGTGGTGGATCTCTGGGTGGTCTCTGAGCAACACCCAAAC 420
421 GCAGTACAGATCCAGATCCAGATCCAGATCCAGATCCAGATCCAGATCCAGATCCAGATCC 480
421 GCAGTACAGATCCAGATCCAGATCCAGATCCAGATCCAGATCCAGATCCAGATCCAGATCC 480
481 GGTGCAGACAGACAAACCAACCAAGACCTCTAGGGTCCACCTATTGTGCAAGTATCTCC 540
481 GGTGCAGACAGACAAACCAACCAAGACCTCTAGGGTCCACCTATTGTGCAAGTATCTCC 540
541 CAAATTTGTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
541 CAAATTTGTAGAGATTTCTTCCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
601 CTGCATAGCAACTGTAGACAGAGCCCTACGTTACTTTGGAGACACATCTCTCCCAAAGC 660
601 CTGCATAGCAACTGTAGACAGAGCCCTACGTTACTTTGGAGACACATCTCTCCCAAAGC 660
661 GGTGGCTTTGTAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
661 GGTGGCTTTGTAGTGAAGACGAATACTTGGAAATTCAGGGCATCACCGGGAGCAGTC 720
721 AGGGGACTACGAGTGCAGTGCCTCCAAATCAGTGGCGCGCCGCTGGTACGAGAGTAAA 780
721 AGGGGACTACGAGTGCAGTGCCTCCAAATCAGTGGCGCGCCGCTGGTACGAGAGTAAA 780
781 GGTCAAGTGAACATTCACATACATATTCAGAACGCAAGGTACAGGTGTCCTCCGCTGG 840
781 GGTCAAGTGAACATTCACATACATATTCAGAACGCAAGGTACAGGTGTCCTCCGCTGG 840
841 ACAAAGGGGACATCGCAGTGTGAAGCTCAGAGCTCCCTCAGCAGAAATTCAGTGGTA 900
841 ACAAAGGGGACATCGCAGTGTGAAGCTCAGAGCTCCCTCAGCAGAAATTCAGTGGTA 900
901 CAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGGAAACACAGACCTTT 960
901 CAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGGAAACACAGACCTTT 960
961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGAACACTACCTTCGCT 1020
961 CCTCTCAAACTCATCTTCTTCAATGCTCTGAACATGACTATGGAACACTACCTTCGCT 1020
1021 GGCCTCCAAAGCTGAGCAAGGCAAGTCCAGGAGGCGAGGCTGCTGCTGCTGCTCTTCT 1080
1021 GGCCTCCAAAGCTGAGCAAGGCAAGTCCAGGAGGCGAGGCTGCTGCTGCTGCTCTTCT 1080
1081 CAGCGAGTGAACAGGCAAGTCCAGGAGGCGAGGCTGCTGCTGCTGCTGCTCTTCT 1140
1081 CAGCGAGTGAACAGGCAAGTCCAGGAGGCGAGGCTGCTGCTGCTGCTGCTCTTCT 1140
1141 GGTCTTGACCTGCTCTCAATTTTGTATGAGTGCCACTTCCCAACCGGGAAAGGCT 1200
1141 GGTCTTGACCTGCTCTCAATTTTGTATGAGTGCCACTTCCCAACCGGGAAAGGCT 1200
1201 GCGGCACACCAACCAAC 1260
1201 GCGGCACACCAACCAACCAACACACACACACACACACACACACACACACACACACAC 1260
1261 TATACAAATGAATATGAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGAAC 1320

1261 TATACAAATGAATATGAGAAACACAGCCTCATGGACAGAAATTTGAGGGAGGGAAC 1320
1321 AAAGATATCTTTGGGGGAAAAGAGTTTAAAAAGAAATTTGAAATTTGCCCTTCAGATA 1380
1321 AAAGATATCTTTGGGGGAAAAGAGTTTAAAAAGAAATTTGAAATTTGCCCTTCAGATA 1380
1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAAAACGGGAAGAACACACAGCACACCGGCTTGA 1440
1381 TTTAGGTACAAATGGAGTTTCTTTTCCCAAAACGGGAAGAACACACAGCACACCGGCTTGA 1440
1441 CCACACTGCAAGTGCATGTCGCAACCTCTTTGGTCCAGTGTGGGCAAGGCTCAGCCTC 1500
1441 CCACACTGCAAGTGCATGTCGCAACCTCTTTGGTCCAGTGTGGGCAAGGCTCAGCCTC 1500
1501 TCTGCCACAGAGTGCCTCCACCTGGAACATTTCTGGAGCTGGCCATCCCAATTTCAATCA 1560
1501 TCTGCCACAGAGTGCCTCCACCTGGAACATTTCTGGAGCTGGCCATCCCAATTTCAATCA 1560
1561 GTCCATAGAGACGAACAGATAGACCTTCGCGCCCAAGCGTGGCGCTTCGCGGCACTTTG 1620
1561 GTCCATAGAGACGAACAGATAGACCTTCGCGCCCAAGCGTGGCGCTTCGCGGCACTTTG 1620
1621 GTAGACTGTGCCACCAACCGGCTGTGTGTGAAACCTGAAATATAAAGAGCAAAAAAAA 1679
1621 GTAGACTGTGCCACCAACCGGCTGTGTGTGAAACCTGAAATATAAAGAGCAAAAAAAA 1679

RESULT 166
ADD74826

ID ADD74826 standard; cDNA; 1679 BP.

XX ADD74826;

XX 29-JAN-2004 (first entry)

XX Human PRO polynucleotide #63.

XX Human; PRO; Gene; ss; secreted polypeptide; transmembrane polypeptide;
tumour; cancer; lung; colon; breast; prostate; rectum; liver;
tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
arthritis; sports injury; cytostatic; antiarthritic.

XX Homo sapiens.

XX US2003100724-A1.

XX 29-MAY-2003.

XX 26-AUG-2002; 2002US-00227874.

XX 01-MAR-2001; 2001WO-US006666.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX Grimaldi JC, Gurney AL, Smith V, Stephen JF, Watanabe CK, Wood WI;

XX WPI: 2004-008974/01.

XX P-PSDB; ADD74827.

XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
in gene therapy, or for preparing a medicament for treating a condition
that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
cancer.

XX Claim 2; Fig 125; 309pp; English.

XX The invention relates to human PRO polypeptides (secreted and
transmembrane polypeptides) and the PRO polynucleotides encoding them.

XX The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
diagnostics, biosensors or bioreactors. They are particularly useful for

detecting tumours (e.g. lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour) in a mammal, for stimulating the release of tumour necrosis factor (TNF)-alpha from human blood, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells or for stimulating the proliferation of normal human dermal fibroblasts. The PRO nucleic acids are useful as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, in preparing PRO polypeptides by recombinant technology, in generating transgenic animals or knock-out animals which may be used in the development and screening of therapeutically useful reagents, in gene therapy, in chromosome identification, as chromosome markers and in generating probes. The PRO polypeptides, or anti-PRO antibodies, are useful for preparing a medicament for treating a condition which is responsive to the PRO polypeptides or anti-PRO antibodies, such as pericyte-associated tumours and bone and/or cartilage disorders (e.g. arthritis, sports injuries), involving inducing the re-differentiation of chondrocytes. The PRO polypeptides are useful as molecular markers for protein electrophoresis, and in tissue typing. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent can also be obtained in electronic format directly from USPTO at seqdata.uspto.gov/sequence.html.

XX

SQ Sequence 1679 BP; 498 A; 432 C; 419 G; 330 T; 0 U; 0 Other;

Query March 100.0%; Score 1679; DB 1; Length 1679;
Best Local Similarity 100.0%; Pred. No. 6.7e-05;
Matches 1679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTCTTGCAACAGCTTGAGGCAACAC 60
DB 1 GTTGTGTCCTTCAGCAAAACAGTGGATTAAATCTCTCTTGCAACAGCTTGAGGCAACAC 60

QY 61 AATCTATCAGGAAGAAAGAAAGAAACCGAAGCTGCAAAAAGAAAGAAAGAG 120
DB 61 AATCTATCAGGAAGAAAGAAAGAAACCGAAGCTGCAAAAAGAAAGAAAGAG 120

QY 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAATTCCTCTTTGGGCAAT 180
DB 121 AAGAAAAAATCATGAAAAACCATCCAGCCAAAAATGCAATTCCTCTTTGGGCAAT 180

QY 181 CTTACGGGGCTGGCTCTGTGTCTCTTCCAAAGAGTGCCCGTGGCAGCGGAGATGC 240
DB 181 CTTACGGGGCTGGCTCTGTGTCTCTTCCAAAGAGTGCCCGTGGCAGCGGAGATGC 240

QY 241 CACCTTCCCAAGCTATGACAAAGTACGGTCCGGCAGGGGGAGCGCCACCTCTCAG 300
DB 241 CACCTTCCCAAGCTATGACAAAGTACGGTCCGGCAGGGGGAGCGCCACCTCTCAG 300

QY 301 GTGCATATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGACCAATCTCTTA 360
DB 301 GTGCATATTGACAAACCGGGTCAACCGGGTGGCTGGCTAAACCGCAGACCAATCTCTTA 360

QY 361 TGCTGGGAATGACAAGTGGTCCCTGGATCCTCGGTGGTCTCTTCTGAGCAACCCAAAC 420
DB 361 TGCTGGGAATGACAAGTGGTCCCTGGATCCTCGGTGGTCTCTTCTGAGCAACCCAAAC 420

QY 421 GCAGTACAGCATCAGATCCAGAACGTTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480
DB 421 GCAGTACAGCATCAGATCCAGAACGTTGGATGTGTATGACGAGGGCCCTTACACCTGCTC 480

QY 481 GGTGACAGACGACCAACCCAAAGACCTTAGGTCACCTCATTTGTGCAAGTATCTCC 540
DB 481 GGTGACAGACGACCAACCCAAAGACCTTAGGTCACCTCATTTGTGCAAGTATCTCC 540

QY 541 CAAAATTTGAGAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600
DB 541 CAAAATTTGAGAGATTTCTTTCAGATATCTCCATTAATGAAGGAAACAATATTAGCCTCAC 600

QY 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGAGACACATCTCTCCCAAGC 660
DB 601 CTGCATAGCAACTGGTAGACAGAGCCTACGGTTACTTTGAGACACATCTCTCCCAAGC 660

QY 661 GTTTGGCTTTGTGAGTGAGAGCAAGTAATCTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
DB 661 GTTTGGCTTTGTGAGTGAGAGCAAGTAATCTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720

QY 721 AGGGGACTTACGAGTGAGTGCTCCTCAATGACGTGGCGCGCCCGTGTACGGAGAGTAAA 780
DB 721 AGGGGACTTACGAGTGAGTGCTCCTCAATGACGTGGCGCGCCCGTGTACGGAGAGTAAA 780

QY 781 GGTCAACCGTGAACATATCCACATATCATTTTCAAGAACCAAGGGTACAGGTGTCCCGTGG 840
DB 781 GGTCAACCGTGAACATATCCACATATCATTTTCAAGAACCAAGGGTACAGGTGTCCCGTGG 840

QY 841 AAAAAAGGAGACTGCGAGTGGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGAGTGTA 900
DB 841 AAAAAAGGAGACTGCGAGTGGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGAGTGTA 900

QY 901 CAAGGATGACAAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGAAGAACAGACCTTT 960
DB 901 CAAGGATGACAAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAGTGAAGAACAGACCTTT 960

QY 961 CCTCTCAAACTCATCTTCTCAATGTCTCTGACATGACTATGGAACATACACTTTCGT 1020
DB 961 CCTCTCAAACTCATCTTCTCAATGTCTCTGACATGACTATGGAACATACACTTTCGT 1020

QY 1021 GGCCTTCAACAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080
DB 1021 GGCCTTCAACAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCGT 1080

QY 1081 CAGGAGGTGAGCAACCGCAGCTCGAGGAGGCGAGGTGGTCTGGCTGTGCTCTCTCTCT 1140
DB 1081 CAGGAGGTGAGCAACCGCAGCTCGAGGAGGCGAGGTGGTCTGGCTGTGCTCTCTCTCT 1140

QY 1141 GGTCTTGACCTGTCTCTCAAAATTTTGTATGTAGTGCCACTTCCCCACCCGGGAAAGCT 1200
DB 1141 GGTCTTGACCTGTCTCTCAAAATTTTGTATGTAGTGCCACTTCCCCACCCGGGAAAGCT 1200

QY 1201 GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
DB 1201 GCCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260

QY 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAA 1320
DB 1261 TATACAAATGAATTTAGAGAAACACAGCCTCATGGGACAGAAATTTGAGGAGGGGAA 1320

QY 1321 AAAGAATACTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCCTTGCAGATA 1380
DB 1321 AAAGAATACTTTGGGGGAAAGAGTTTAAAGAAAGAAATTTGAAATTTGCCTTGCAGATA 1380

QY 1381 TTTAGTACATGGAGTTTCTTTTCCAAACGGGAGAAACACAGCACCACCGGCTTGA 1440
DB 1381 TTTAGTACATGGAGTTTCTTTTCCAAACGGGAGAAACACAGCACCACCGGCTTGA 1440

QY 1441 CCCACTGCAAGCTGCATCGTGCACACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500
DB 1441 CCCACTGCAAGCTGCATCGTGCACACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC 1500

QY 1501 TCTGCCACAGAGTGCCCGCCACGTGGAAACATCTTGGAGCTGGCCATCCCAATTCATCA 1560
DB 1501 TCTGCCACAGAGTGCCCGCCACGTGGAAACATCTTGGAGCTGGCCATCCCAATTCATCA 1560

QY 1561 GTCCATAGAGACGAACAGATGAGACCTTCCGGCCCAAGCGTGGCGCTCGCGGACCTTG 1620
DB 1561 GTCCATAGAGACGAACAGATGAGACCTTCCGGCCCAAGCGTGGCGCTCGCGGACCTTG 1620

QY 1621 GTAGACTGTGCCACCAACCGCGGTGTGTGAAAAGTGAAGTAAAAAGAGCAAAAAAAA 1679
DB 1621 GTAGACTGTGCCACCAACCGCGGTGTGTGAAAAGTGAAGTAAAAAGAGCAAAAAAAA 1679

RESULT 167

ANZ47893

ID AAZ47893 standard; cDNA; 1693 BP.

XX

AC AAZ47893;
XX 10-MAR-2000 (first entry)
XX Human protein encoding cDNA SEQ ID NO:3.
XX Human; haematopoietic cell regulation; tissue generation; repair; reparation;
KW activin; inhibin; taxis; chemotaxis; blood coagulation; thrombus;
KW receptor; ligand; autoimmunity; infection-related immunodeficiency;
XX inflammatory disorder; neurological disease; ss.
XX Homo sapiens.
XX Key Location/Qualifiers
XX CDS 214..1164
XX /*tag= a
XX WO9958668-A1.
XX 18-NOV-1999.
XX 13-MAY-1999; 99WO-JP002485.
XX 14-MAY-1998; 98JP-00131815.
XX (ONON) ONO PHARM CO LTD.
XX Fukushima D, Shibayama S, Tada H;
XX WPI: 2000-062298/05.
XX P-PSDB; AAY57601.
XX New polypeptides of human origin having cell regulatory, tissue
XX generation, coagulant and other activities.
XX Claim 5; Page 42-45; 84pp; Japanese.
XX The present sequence encodes a specifically claimed novel human protein.
XX The novel human protein can be used in therapeutic drugs for the
XX prevention and treatment of a broad range of disorders including
XX autoimmune and infection-related immunodeficiency, inflammatory
XX disorders, and neurological diseases. The novel protein is expected of
XX having haematopoietic cell regulatory activity, tissue generation/
XX reparation activity, activin/inhibin activity, taxis/chemotaxis activity,
XX blood coagulation and thrombus activity, and receptor/ligand activity
SQ Sequence 1693 BP; 518 A; 432 C; 416 G; 327 T; 0 U; 0 Other;
Query Match 99.0%; Score 1661.9; DB 1; Length 1693;
Best Local Similarity 99.9%; Pred. No. 7.9e-05;
Matches 1673; Conservative 0; Mismatches 1; Indels 1; Gaps 1;
QY 6 GTCCTTCAGCAAAACAGTGGATTAAATCTCTCTGCAAGCTTGAGAGCAACAAATCT 65
DB 1 GTCCTTCAGCAAAACAGTGGATTAAATCTCTCTGCAAGCTTGAGAGCAACAAATCT 60
QY 66 ATCAGGAAAGAAAGAAAG-AAAAAACCCGAACTGACAAAAAGAAAGAAAGAAAGAA 124
DB 61 ATCAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAA 120
QY 125 AAAAAAATCATGAAACCATCCAGCCAAATGCAAAATTCATCTCTTGGGCAATCTTC 184
DB 121 AAAAAAATCATGAAACCATCCAGCCAAATGCAAAATTCATCTCTTGGGCAATCTTC 180
QY 185 ACGGGCTGGCTGCTGCTGCTCTCTTCAAGAGTGGCCGTCGCGAGGAGATGCCACC 244
DB 181 ACGGGCTGGCTGCTGCTGCTCTCTTCAAGAGTGGCCGTCGCGAGGAGATGCCACC 240
QY 245 TTCCCAAGAGTATGGAACAACTGACGTCGGCAGGGGAGAGCGCCACCTCAGGTGC 304
DB 241 TTCCCAAGAGTATGGAACAACTGACGTCGGCAGGGGAGAGCGCCACCTCAGGTGC 300
QY 305 ACTATTGACACCGGGTCAACCGGGTGGCTTAAACCGCAGCACCATCTCTATGCT 364

DB 301 ACTATTGACAAACGGGTCAACCGGGTGGCTGGCTAAACCGCAGCACCATCTCTATGCT 360
QY 365 GGAATGACAAAGTGGTGCCTGGATCTCGCGTGGTCTCTTCTGAGCAACACCAAGCGCAG 424
DB 361 GGAATGACAAAGTGGTGCCTGGATCTCGCGTGGTCTCTTCTGAGCAACACCAAGCGCAG 420
QY 425 TAGAGCATCGAGATCCAGAACGTGGATGTATGATGAGAGGGCCCTTACACCTGCTCGGTG 484
DB 421 TAGAGCATCGAGATCCAGAACGTGGATGTATGATGAGAGGGCCCTTACACCTGCTCGGTG 480
QY 485 CAGACAGACAAACCAACCAAGAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCCAAA 544
DB 481 CAGACAGACAAACCAACCAAGAGACCTCTAGGGTCCACCTCATTTGTGCAAGTATCTCCAAA 540
QY 545 ATTGTAGAGATTCTTTCAGATATCTCCATTAATGAAGGAAACAAATATTAGCTTCACCTGC 604
DB 541 ATTGTAGAGATTCTTTCAGATATCTCCATTAATGAAGGAAACAAATATTAGCTTCACCTGC 600
QY 605 ATAGCAACTGGTAGACAGAGCCTACGTTACTTTGGAGACACATCTCTCCCAAGCGGT 664
DB 601 ATAGCAACTGGTAGACAGAGCCTACGTTACTTTGGAGACACATCTCTCCCAAGCGGT 660
QY 665 GGCTTTGTGAGTGAAGACGAATATCTTTGGAATTTACGGGCATCACCGGGAGCAGTCAGGG 724
DB 661 GGCTTTGTGAGTGAAGACGAATATCTTTGGAATTTACGGGCATCACCGGGAGCAGTCAGGG 720
QY 725 GACTACAGTGCAGTGCCTCCCAATGACGTGGCGCCGCTGTGTACGGAGAGTAAAGGTC 784
DB 721 GACTACAGTGCAGTGCCTCCCAATGACGTGGCGCCGCTGTGTACGGAGAGTAAAGGTC 780
QY 785 ACCGTGAATATCCACCATACATTTTCAAGAACCAAGGTACAGGTGTCCCGTGGACAA 844
DB 781 ACCGTGAATATCCACCATACATTTTCAAGAACCAAGGTACAGGTGTCCCGTGGACAA 840
QY 845 AAGGGACACTGCAGTGTGAGCCTCAGCAGTCCCTCAGCAGATTTCCAGGTGTACAG 904
DB 841 AAGGGACACTGCAGTGTGAGCCTCAGCAGTCCCTCAGCAGATTTCCAGGTGTACAG 900
QY 905 GATGACAAAAGACTGATTGAAGGAAAGAAAGGGTGAAGTGAAGAAACAGACCTTTCTCT 964
DB 901 GATGACAAAAGACTGATTGAAGGAAAGAAAGGGTGAAGTGAAGAAACAGACCTTTCTCT 960
QY 965 TCAAACTCATCTCTTCAATGCTCTGAACTGAACTGAACTGAACTGAACTGAACTGAACTG 1024
DB 961 TCAAACTCATCTCTTCAATGCTCTGAACTGAACTGAACTGAACTGAACTGAACTGAACTG 1020
QY 1025 TCCAACAAGCTGGGCCACACCAATGCGCAGCATCATGCTATTTGGTCCAGGCGCGTCAGC 1084
DB 1021 TCCAACAAGCTGGGCCACACCAATGCGCAGCATCATGCTATTTGGTCCAGGCGCGTCAGC 1080
QY 1085 GAGTGAAGCAACGGCAGCTGAGAGGGGAGGCTGGCTGTGCTGCTGCTCTCTGCTC 1144
DB 1081 GAGTGAAGCAACGGCAGCTGAGAGGGGAGGCTGGCTGTGCTGCTGCTCTCTGCTC 1140
QY 1145 TTGCACCTGCTTCTCAAAATTTTGTGAGTGGCCACTTCCCGCAGCGGAAAGGCTGCCG 1204
DB 1141 TTGCACCTGCTTCTCAAAATTTTGTGAGTGGCCACTTCCCGCAGCGGAAAGGCTGCCG 1200
QY 1205 CACACCAACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1264
DB 1201 CACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
QY 1265 CAAATGAATTTAGAGAAACACACACCTCATGGACAGAAATTTGAGGGAGGGGAAACAAAG 1324
DB 1261 CAAATGAATTTAGAGAAACACACACCTCATGGACAGAAATTTGAGGGAGGGGAAACAAAG 1320
QY 1325 AATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTTGCGAGATATTTA 1384
DB 1321 AATCTTTGGGGGAAAGAGTTTAAAGAAATTTGAAATTTGCTTTGCGAGATATTTA 1380
QY 1385 GGTACAAAGTGGTTTCTTTTCCCAACCGGGAGGAAACACAGCACACCGCGCTTGACCCA 1444

Db 1381 GGTACATGAGTGTCTTTCCAAACGGGAAGAAACACAGCACACCCGGCTTGGACCCA 1440
QY 1445 CTGCAAGCTCATCGTGCACCTCTTTGGTGCCAGTGTGGCAAGGCTCAGCTCTCTG 1504
Db 1441 CTGCAAGCTCATCGTGCACCTCTTTGGTGCCAGTGTGGCAAGGCTCAGCTCTCTG 1500
QY 1505 CCACAGAGTGCCTCCACAGTGGAAACATTTCTGGAGCTGGCCATCCCAAAATTCATCACTCC 1564
Db 1501 CCACAGAGTGCCTCCACAGTGGAAACATTTCTGGAGCTGGCCATCCCAAAATTCATCACTCC 1560
QY 1565 ATAGAGCAGCAAGATGAGACCTTCGGCCCAAGCTGGCGCTGGCGCACTTTGGTAG 1624
Db 1561 ATAGAGCAGCAAGATGAGACCTTCGGCCCAAGCTGGCGCTGGCGCACTTTGGTAG 1620
QY 1625 ACTGTGCACACGGCGTGTGTGTGAACAGTGAATAAAGAGCAAAAAA 1679
Db 1621 ACTGTGCACACGGCGTGTGTGTGAACAGTGAATAAAGAGCAAAAAA 1675

RESULT 168
AAA88791
ID AAA88791 standard; cDNA; 2012 BP.
XX
AC AAA88791;
XX
DT 19-FEB-2001 (first entry)
XX
DE Human SECC cDNA Clone 11753149.0.37.
XX
KW SECC; human; diagnosis; gene therapy; cell adhesion; ss.
XX
OS Homo sapiens.

XX FH Key Location/Qualifiers
XX CDS 501..1535
FT FT /*tag= a
FT FT sig_peptide 501..599
FT FT /*tag= b
FT FT mat_peptide 600..1532
FT FT /*tag= c
XX
XX WO200061754-A2.
XX
XX 19-OCT-2000.
XX
XX 07-APR-2000; 2000WO-US009392.
XX
XX 09-APR-1999; 99US-0128514P.
XX 03-MAR-2000; 2000US-0186592P.
XX 06-APR-2000; 2000US-00544511.
XX
XX (CURA-) CURAGEN CORP.
XX
XX Fernandez E, Vernet C, Shinkets R;
XX
XX WPI; 2000-679487/66.
XX P-PSDB; AAB19722.
XX

PT SECC polypeptides and the nucleic acids that encode them, useful for
PT diagnosing, preventing and treating e.g. cancers, inflammation, arthritis
PT and immunological disorders.

XX Claim 14; Fig 3; 143pp; English.

XX The present sequence is that of SECC Clone 11753149.0.37, which resembles
CC rat neural cell adhesion molecule neurotrimin and human opioid binding
CC protein/cell adhesion molecule OBCAM. The clone was initially identified
CC in human fetal brain tissue. The invention provides novel SECC
CC polynucleotides (see AAB8789-804) and the secreted or membrane-
CC associated proteins encoded by them (see AAB19720-34). SECC
CC polynucleotides, polypeptides and antibodies can be used in the
CC detection, diagnosis and treatment (including gene therapy) of a broad
CC range of pathological states

XX SQ Sequence 2012 BP; 567 A; 503 C; 512 G; 430 T; 0 U; 0 Other;
Query Match 97.9%; Score 1643.4; DB 1; Length 2012;
Best Local Similarity 99.9%; Pred. No. 7.9e-05;
Matches 1644; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 GTTGTGTCCTTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAGCTTGGAGCAACAC 60
Db 368 GTTGTGTCCTTTCAGCAAAACAGTGGATTAAATCTCTTGCACAAGCTTGGAGCAACAC 427
QY 61 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 428 AATCTATCAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 487
QY 121 AAGAAAAAATCATGAAACCATCCAGCCAAAAATGCACAATTTCTATCTCTTGGCAAT 180
Db 488 AAGAAAAAATCATGAAACCATCCAGCCAAAAATGCACAATTTCTATCTCTTGGCAAT 547
QY 181 CTTCAAGGGGTGGCTGCTGTCTCTTCCAAAGAGTGCCTCGTGGCAGCGAGATGC 240
Db 548 CTTCAAGGGGTGGCTGCTGTCTCTTCCAAAGAGTGCCTCGTGGCAGCGAGATGC 607
QY 241 CACCTTCCCAAGCTATGGACAGTGCAGCGTCCGGCAGGGGAGAGCGCCACCTCAG 300
Db 608 CACCTTCCCAAGCTATGGACAGTGCAGCGTCCGGCAGGGGAGAGCGCCACCTCAG 667
QY 301 GTGCACATTATGACAAACCGGGTCAACCCGGGTGCCTGCTAAACCGCAGCACCATCTCTA 360
Db 668 GTGCACATTATGACAAACCGGGTCAACCCGGGTGCCTGCTAAACCGCAGCACCATCTCTA 727
QY 361 TGCTGGGAATCACAAGTGGTGCCTGGATCCTCGCGTGGTCTCTTGGAGCAACACCCAAAC 420
Db 728 TGCTGGGAATCACAAGTGGTGCCTGGATCCTCGCGTGGTCTCTTGGAGCAACACCCAAAC 787
QY 421 GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACGAGGGCCCTTACACGTCTC 480
Db 788 GCAGTACAGCATCGAGATCCAGAAACGTGGATGTGTATGACGAGGGCCCTTACACGTCTC 847
QY 481 GGTGCAGACAGAACCAACCCCAAGACCTCTAGGGTCCACTATTTGTGCAAGTATCTCC 540
Db 848 GGTGCAGACAGAACCAACCCCAAGACCTCTAGGGTCCACTATTTGTGCAAGTATCTCC 907
QY 541 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 600
Db 908 CAAATTTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC 967
QY 601 CTGCATAGCAACTGGTAGACCCAGAGCCTTACGGTTACTTTGGAGACACATCTCTCCAAAGC 660
Db 968 CTGCATAGCAACTGGTAGACCCAGAGCCTTACGGTTACTTTGGAGACACATCTCTCCAAAGC 1027
QY 661 GGTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATACCCGGGAGCAGTC 720
Db 1028 GGTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTCAGGGCATACCCGGGAGCAGTC 1087
QY 721 AGGGGACTACAGTGCAAGTGCTCCCAATGACGTGGCGCGCCCGTGGTACGGAGAGTAAA 780
Db 1088 AGGGGACTACAGTGCAAGTGCTCCCAATGACGTGGCGCGCCCGTGGTACGGAGAGTAAA 1147
QY 781 GGTACACGTGAACTATCCACCATACATTCAGAGCCCAAGGGTACAGGTGTCCCGTGGG 840
Db 1148 GGTACACGTGAACTATCCACCATACATTCAGAGCCCAAGGGTACAGGTGTCCCGTGGG 1207
QY 841 AAAAAAGGGGACACTGCAAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
Db 1208 AAAAAAGGGGACACTGCAAGTGTGAAGCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 1267
QY 901 CAAGGATGACAAAAGACTGATTGAAGAAAGAAAGGGGTGAAAGTGGAAACACACCTTT 960
Db 1268 CAAGGATGACAAAAGACTGATTGAAGAAAGAAAGGGGTGAAAGTGGAAACACACCTTT 1327
QY 961 CCTCTCAAAATCTATCTTCTCAATGCTCTGAAACATGACTATGGGAACATCACTTGGT 1020

Db 1328 CCTCTCAAACTCATCTCTTCAATGTCCTGAACATGACTATATGGAACTACACATTGCGT 1387
Qy 1021 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTGGTCCAGCGCGCT 1080
Db 1398 GGCCTCCAAAGCTGGGCCACACCAATGCCAGCATCATGCTATTGGTCCAGCGCGCT 1447
Qy 1081 CAGGAGGTGAGCAACGCGCAGTCGAGAGGGCAGGCTGCTGCTGCTGCTGCTCTTCT 1140
Db 1448 CAGGAGGTGAGCAACGCGCAGTCGAGAGGGCAGGCTGCTGCTGCTGCTGCTCTTCT 1507
Qy 1141 GGTCTTGACCTGCTTCTCAAAATTTGATGTGAGTGCACCTCCACCGCGGAAGGCT 1200
Db 1508 GGTCTTGACCTGCTTCTCAAAATTTGATGTGAGTGCACCTCCACCGCGGAAGGCT 1567
Qy 1201 GCGGCCACCAACACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
Db 1568 GCGGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1627
Qy 1261 TATACAAATGAATATAGAGAAACACACAGCCTCATGGGACGAGAAATTTGAGGGGGAAC 1320
Db 1628 TATACAAATGAATATAGAGAAACACACAGCCTCATGGGACGAGAAATTTGAGGGGGAAC 1687
Qy 1321 AAAGAATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAAAATTTGCTTGCAGATA 1380
Db 1688 AAAGAATCTTTGGGGGAAAGAGTTTAAAAAAGAAATTTGAAAAATTTGCTTGCAGATA 1747
Qy 1381 TTAGGTACATGGAGTTTCTTTCCCAACGGGAGACACACAGCACACCGGCTTGA 1440
Db 1748 TTAGGTACATGGAGTTTCTTTCCCAACGGGAGAAACACAGCACACCGGCTTGA 1807
Qy 1441 CCCACTGCAAGTGCATCGTCAACCTCTTTGGTCCAGTGTGGGCAAGGCTCAGCCTC 1500
Db 1808 CCCACTGCAAGTGCATCGTCAACCTCTTTGGTCCAGTGTGGGCAAGGCTCAGCCTC 1867
Qy 1501 TCTGCCACAGAGTCCCGCCACGATGGAACATCTGGAGCTGGCCATCCCAATTCATCA 1560
Db 1868 TCTGCCACAGAGTCCCGCCACGATGGAACATCTGGAGCTGGCCATCCCAATTCATCA 1927
Qy 1561 GTCCATAGACGACAGAAATGAGACCTTCGGGCCCAAGCGTGGCGCTGGGGCCTTTG 1620
Db 1928 GTCCATAGACGACAGAAATGAGACCTTCGGGCCCAAGCGTGGCGCTGGGGCCTTTG 1987
Qy 1621 GTAGACTGTGCCACACCGCGCTGTG 1645
Db 1988 GTAGACTGTGCCACACCGCGCTGTG 2012

RESULT 169
ADD18290
ID ADD18290 standard; DNA; 2012 BP.
XX
AC ADD18290;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human molecule (MOL) protein MOL11 DNA sequence.
XX
KW molecule protein; MOL protein; MOLX; MOLX agonist; MOLX antagonist;
KW cardiant; antidiabetic; antiatherosclerotic; gene therapy;
KW MOLX-associated disorder; cardiomyopathy; diabetes; atherosclerosis; ds;
KW human; MOL11.
OS Homo sapiens.
XX
PN WO2003003984-A2.
XX
PD 16-JAN-2003.
XX
PF 03-JUL-2002; 2002WO-US021268.
XX
PR 05-JUL-2001; 2001US-0303168P.
PR 05-JUL-2001; 2001US-0303241P.
PR 26-SEP-2001; 2001US-00965212.

PR 26-SEP-2001; 2001US-00966545.
PR 26-SEP-2001; 2001US-00966546.
PR 01-APR-2002; 2002US-0368996P.
PR 01-APR-2002; 2002US-0369065P.
PR 08-MAY-2002; 2002US-0378730P.
PR 30-MAY-2002; 2002US-0384327P.
PR 07-JUN-2002; 2002US-0386816P.
PR 17-JUN-2002; 2002US-00174372.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Fernandes ER, Vernet CAM, Shimkets RA, Anderson DM, Padigaru M;
PI Boldog FL, Li L, Shenoy SG, Casman SJ, Rastelli L, Alsobrook JP;
PI Burgess CE, Grosse WM, Gusev VI, Ji W, Repley DM, Liu X, Mezick AJ;
PI Patturajan M, Shen L, Spaderna SK, Spytek KA, Szekeres ES;
PI Taupier RJ, Tchernev VT, Zerhusen BD, Voss EZ;
XX
DR WPI; 2003-210304/20.
DR P-PSDB; ADD18291.
XX
XT New MOLX polypeptide, nucleic acid or MOLX-specific antibody, useful for
PT preparing a composition for treating or preventing a MOLX-associated
PT disorder, e.g., cardiomyopathy, diabetes or atherosclerosis.
XX
PS Claim 8; SEQ ID NO 139; 371pp; English.
XX
CC This invention relates to novel human nucleic acid sequences which encode
CC novel molecule (MOL) proteins numbered MOL1-23, referred to generally in
CC the specification as MOLX. Compounds which modulate the function of the
CC MOLX proteins of the invention, MOLX agonists or antagonists, may have
CC cardiant, antidiabetic or antiatherosclerotic activities. In addition,
CC the DNA and protein sequences disclosed may prove useful for gene
CC therapy. The protein, nucleic acid or antibody is useful for preparing a
CC composition for treating or preventing a MOLX-associated disorder, for
CC example cardiomyopathy, diabetes or atherosclerosis. The present sequence
CC is the DNA sequence encoding a MOL protein of the invention.
XX
SQ Sequence 2012 BP; 567 A; 503 C; 512 G; 430 T; 0 U; 0 Other;

Query Match 97.9%; Score 1643.4; DB 1; Length 2012;
Best Local Similarity 99.9%; Pred. No. 7.9e-05;
Matches 1644; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 GTTGTGTCCTTCAGCAAAACAGTGAATTAATCTCTTGCACAAAGTTGAGAGCAAC 60
Db 368 GTTGTGTCCTTCAGCAAAACAGTGAATTAATCTCTTGCACAAAGTTGAGAGCAAC 427
Qy 61 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 120
Db 428 AATCTATCAGGAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 487
Qy 121 AAGAAAAAATCATGAAACCATCCAGCCAAAAATGCAATTTCTATCTTTGGGCAAT 180
Db 488 AAGAAAAAATCATGAAACCATCCAGCCAAAAATGCAATTTCTATCTTTGGGCAAT 547
Qy 181 CTTACGGGGCTGGTCTCTCTTCCAGGAGTCCCGTCCGCGAGGAGATGC 240
Db 548 CTTACGGGGCTGGTCTCTCTTCCAGGAGTCCCGTCCGCGAGGAGATGC 607
Qy 241 CACCTTCCCCAAAGCTATGCAACAGTGCAGCGTCCGCGAGGGGAGAGCGCCACCTCAG 300
Db 608 CACCTTCCCCAAAGCTATGCAACAGTGCAGCGTCCGCGAGGGGAGAGCGCCACCTCAG 667
Qy 301 GTGCACTATTGACACCGGCTCACCGGGTGGCTTAAACCGCAGCAGCATCTCTA 360
Db 668 GTGCACTATTGACACCGGCTCACCGGGTGGCTTAAACCGCAGCAGCATCTCTCTA 727
Qy 361 TGCTGGGAATGACAAAGTGGTGGTCTGATCTCTCGCTGGTCTCTTCTGAGCAACACCAAC 420
Db 728 TGCTGGGAATGACAAAGTGGTGGTCTGATCTCTCGCTGGTCTCTTCTGAGCAACACCAAC 787
Qy 421 GCAGTACAGCATCGAGATCCAGAAAGTGGATGTATGAGAGGGCCCTTACACCTGCTC 480

XX Human Kruppel associated DNA binding protein 42 cDNA.
 DE
 XX
 KW Human; Kruppel associated DNA binding protein 42; gene; ss; cytostatic;
 KW virucide; immunomodulator; antiinflammatory; haemostatic; tumour; cancer;
 KW haemopathy; HIV infection; nervous system disease; developmental disease;
 KW hereditary disease; endocrine system disease; immune system disease;
 KW immunological disease; inflammation; human immunodeficiency virus.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT CDS 330..1475
 FT /*tag= a
 FT /product= "Human Kruppel associated DNA binding protein
 FT 42"
 XX
 FN WO200183541-A1.
 XX
 PD 08-NOV-2001.
 XX
 PF 28-APR-2001; 2001WO-CN000661.
 XX
 PF 29-APR-2000; 2000CN-00115515.
 XX
 PA (SHAN-) SHANGHAI BIOWINDOW GENE DEV INC.
 XX
 PI Mao Y, Xie Y;
 XX
 DR WPI: 2002-062108/08.
 DR P-PSDB; AAU79205.
 XX
 XX Human Kruppel-associated DNA-binding protein 42 and encoded
 PT polynucleotide, applicable in diagnosis and treatment of developmental
 PT disorders, cancer, hemopathy, HIV infection, immunological diseases and
 PT various inflammations.
 XX
 PS Claim 6; Page 30-31; 38pp; Chinese.
 XX
 CC The invention relates to the human Kruppel associated DNA binding protein
 CC 42 and the polynucleotide encoding it. The sequences of the invention are
 CC applicable in diagnosis and treatment of different kinds of tumour,
 CC haemopathy, HIV infection, nervous system disease, developmental disease,
 CC hereditary disease, endocrine system disease, immune system disease,
 CC immunological disease and various inflammations. This sequence represents
 CC cDNA encoding the human Kruppel associated DNA binding protein 42
 XX
 SQ Sequence 1873 BP; 563 A; 468 C; 471 G; 371 T; 0 U; 0 Other;
 Query Match 93.6%; Score 1571.3; DB 1; Length 1873;
 Best Local Similarity 93.1%; Pred. No. 0.00017;
 Matches 1674; Conservative 0; Mismatches 2; Indels 123; Gaps 4;
 QY 1 GTTGTGCTCTTTCAGCAAAACAGTGGATTAAATCTCTTGGCAAAAGCTTGAGAGCAAC 60
 DB 50 GTTGTGCTCTTTCAGCAAAACAGTGGATTAAATCTCTTGGCAAAAGCTTGAGAGCAAC 109
 QY 61 AATCTATCAGGAAG 120
 DB 110 AATCTATCAGGAAG 169
 QY 121 AAGAAAAAATCATGAAACCATCAGCCCAAAATGCAATTCATCTCTTGGGCAAT 180
 DB 170 AAGAAAAAATCATGAAACCATCAGCCCAAAATGCAATTCATCTCTTGGGCAAT 229
 QY 181 CTTTCAGGGGCTGGTGTCTGTGTCTCTTCCA- 213
 DB 230 CTTTCAGGGGCTGGTGTCTGTGTCTCTTCCAAGTAAAGTGACATTCATCTGCTCAT 289
 QY 214 ----- 213
 DB 290 CCCCAGGCAAGTGGATGTTTTTAAAGTGGAAAAAATAATCAACGGAAAAAGAACGG 349

214 -----AGGAGTGCCTGCGCAGCGAGATGC 240
 DB 350 GGAAGTGGGAAGAGGTGGAATGGAAGGGCAGCAGAGTGCCTGCGCAGCGAGATGC 409
 QY 241 CACCTTCCCAAGCTATGGAACAGTCAAGTTCGGGAGGGGAGAGCGGCCACCTTCAG 300
 DB 410 CACCTTCCCAAGCTATGGAACAGTCAAGTTCGGGAGGGGAGAGCGGCCACCTTCAG 469
 QY 301 GTGCACTATTGACAAACCGGCTCACCCGGTGGCTGTGCTTAAACCGCAGCAGCATCCTCTA 360
 DB 470 GTGCACTATTGACAAACCGGCTCACCCGGTGGCTGTGCTTAAACCGCAGCAGCATCCTCTA 529
 QY 361 TGTGTGGAATGACAAAGTGTGCTGATCTCGGTGCTGCTTCTTGTGAGAACACCAAC 420
 DB 530 TGTGTGGAATGACAAAGTGTGCTGATCTCGGTGCTGCTTCTTGTGAGAACACCAAC 589
 QY 421 GCAGTACAGCATCGAGATCCAGAACGTGTGATGATGACAGGGGCTTACACCTGTCTC 480
 DB 590 GCAGTACAGCATCGAGATCCAGAACGTGTGATGATGACAGGGGCTTACACCTGTCTC 649
 QY 481 GGTGACAGACAGAACCCCAAGACCTCTAGGTTCACCTCATTTGTGAAAGTATCTCC 540
 DB 650 GGTGACAGACAGAACCCCAAGACCTCTAGGTTCACCTCATTTGTGAAAGTATCTCC 709
 QY 541 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAAATATTAGCTCAC 600
 DB 710 CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAAATATTAGCTCAC 769
 QY 601 CTGCATAGCAACTGTGTAGACAGAGCTTACTTGGAGACACATCTCTCCAAAGC 660
 DB 770 CTGCATAGCAACTGTGTAGACAGAGCTTACTTGGAGACACATCTCTCCAAAGC 829
 QY 661 GGTGTGCTTTGTGAGTGAAGACGAACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 720
 DB 830 GGTGTGCTTTGTGAGTGAAGACGAACTTGGAAATTCAGGGCATCACCCGGGAGCAGTC 889
 QY 721 AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCGCGCGCTGGTACGAGAGTAAA 780
 DB 890 AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCGCGCGCTGGTACGAGAGTAAA 949
 QY 781 GGTCACTGTAATATCCACCATACATTTAGAGACAGAGGTGACAGGTGTCCTCCGTTGG 840
 DB 950 GGTCACTGTAATATCCACCATACATTTAGAGACAGAGGTGACAGGTGTCCTCCGTTGG 1009
 QY 841 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 900
 DB 1010 ACAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTA 1069
 QY 901 CAAGGATGACAAAGACTGATTTGAAGAGAGAGAGGGTGAAGTGAAGAGAGAGAGAGAG 960
 DB 1070 CAAGGATGACAAAGACTGATTTGAAGAGAGAGAGGGTGAAGTGAAGAGAGAGAGAGAG 1129
 QY 961 CCTCTCAAAACTCATCTTCTTCAATCTCTGTAACATGACTATGGGAACTACACTTTGCGT 1020
 DB 1130 CCTCTCAAAACTCATCTTCTTCAATCTCTGTAACATGACTATGGGAACTACACTTTGCGT 1189
 QY 1021 GGCCTCCAAAGCTGGGCGACACCAATGCGAGCATCATGCTATTTGGTCCAGGCGCGT 1080
 DB 1190 GGCCTCCAAAGCTGGGCGACACCAATGCGAGCATCATGCTATTTGGTCCAGGCGCGT 1249
 QY 1081 CAGGAGGTGAGCAACGGCAGCTGAGGAGGGGAGGCTGGCTCTGGCTGGCTCTTCT 1140
 DB 1250 CAGGAGGTGAGCAACGGCAGCTGAGGAGGGGAGGCTGGCTCTGGCTGGCTCTTCT 1309
 QY 1141 GGTCTTGCACTGCTCTCAAAATTTTGTAGTGTGCTTCCCAACCGGGAAGGCT 1200
 DB 1310 GGTCTTGCA-CTGCTTCTCAAAATTTTGTAGTGTGCTTCCCAACCGGGAAGGCT 1368
 QY 1201 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1260
 DB 1369 GCGCCACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCA 1427
 QY 1261 TATCAAAATGAAATTAGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1320

QY 934 AGGGGTGAAGTGGAAAAAGAGACCTTTCTCTCAAAAGTCATCTTCTCAATGTCTCTGA 993
DB 942 AGGGGTGAAGTGGAAAAAGAGACCTTTCTCTCAAAAGTCATCTTCTCAATGTCTCTGA 1001
QY 994 ACATGACTATGGAACTACACTTGGTGGCTTCCAAAGCTGGGCGACACCAATGCCAG 1053
DB 1002 ACATGACTATGGAACTACACTTGGTGGCTTCCAAAGCTGGGCGACACCAATGCCAG 1061
QY 1054 CATCATGCTATTGGTTCAGGGGCGCTCAGCGAGGTGAGCAACGGCAGCTCAGAGAGGC 1113
DB 1062 CATCATGCTATTGGTTCAGGGGCGCTCAGCGAGGTGAGCAACGGCAGCTCAGAGAGGC 1121
QY 1114 AGCTGCGTCTGGCTGCTGCTCTTCTGCTTGTGCTTGTGCTTGTGCTTGTGCTTGTGCT 1173
DB 1122 AGCTGCGTCTGGCTGCTGCTCTTCTGCTTGTGCTTGTGCTTGTGCTTGTGCTTGTGCT 1181
QY 1174 GTGCCACTTCCCAACCGGGAAGGCTGGCGCACCAACCAACCAACCAACCAACCAATG 1233
DB 1182 GTGCCACTTCCCAACCGGGAAGGCTGGCGCACCAACCAACCAACCAACCAACCAATG 1241
QY 1234 GCAACACGACAGCAACCAATCAGATATATACAAATGAAATAGAAAGAAACACAGCTCA 1293
DB 1242 GCAACACGACAGCAACCAATCAGATATATACAAATGAAATAGAAAGAAACACAGCTCA 1301
QY 1294 TGGGACAGAAATTTGAGGGAGGGAACAAAGAAATCTTTGGGGGAAGAGTTTAA 1353
DB 1302 TGGGACAGAAATTTGAGGGAGGGAACAAAGAAATCTTTGGGGGAAGAGTTTAA 1361
QY 1354 AAGAAATTTGAAATTTGCTTGCAGATATTAGGTACAAATGGAGTTTCTTTTCCCAACG 1413
DB 1362 AAGAAATTTGAAATTTGCTTGCAGATATTAGGTACAAATGGAGTTTCTTTTCCCAACG 1421
QY 1414 GGAAGACACACACACCGGCTTGGACCACTGCAAGCTGCAATGCTGCACTTTTGG 1473
DB 1422 GGAAGACACACACACCGGCTTGGACCACTGCAAGCTGCAATGCTGCACTTTTGG 1481
QY 1474 TGCCAGTGTGGCAAGGGCTCAGCTCTCTGCCCCACAGAGTCCCCCAGCTGGAACTTC 1533
DB 1482 TGCCAGTGTGGCAAGGGCTCAGCTCTCTGCCCCACAGAGTCCCCCAGCTGGAACTTC 1541
QY 1534 TGGAGCTGGCCATCCCAATTTCAATCAGTCCATAGAGAGCAACAGAAATGAGACCTTCGG 1593
DB 1542 TGGAGCTGGCCATCCCAATTTCAATCAGTCCATAGAGAGCAACAGAAATGAGACCTTCGG 1601
QY 1594 CCAAGCGTGGGGCTGCGGGCACTTTGGTGTAGACTGTGCCACCAACCGCGCTGTGTGAAA 1653
DB 1602 CCAAGCGTGGGGCTGCGGGCACTTTGGTGTAGACTGTGCCACCAACCGCGCTGTGTGAAA 1661
QY 1654 CGTGAATTAAGAGC 1670
DB 1662 CGTGAATTAAGAGC 1678

RESULT 174

ABT17390
ID ABT17390 standard; DNA; 1839 BP.

XX AC ABT17390;

XX DT 13-AUG-2003 (first entry)

XX DE Human IG gene related nucleic acid SEQ ID No 16.

XX XX Breast cancer; p53 pathway modulating agent; IG; colon cancer;
KW kidney cancer; lung cancer; ovary cancer; human; ds.

XX OS Homo sapiens.

XX PN WO200299040-A2.

XX XX 12-DEC-2002.

XX PD

03-JUN-2002; 2002WO-US017313.
05-JUN-2001; 2001US-0296076P.
10-OCT-2001; 2001US-0328605P.
22-OCT-2001; 2001US-0338733P.
15-FEB-2002; 2002US-0357253P.
15-FEB-2002; 2002US-0357600P.
(EXEL-) EXELIXIS INC.

Friedman L, Plowman GD, Belvin M, Francis-Lang H, Li D, Funke RP;
Lioubin MN;

WPI; 2003-148660/14.

Identifying a candidate p53 pathway modulators that are useful as targets
for therapeutics or for diagnosing cancers associated with defective p53
function, by providing an assay system having a purified IG polypeptide
or nucleic acid.

Example; Page 170-171; 248pp; English.

The invention relates to a novel method for identifying a candidate p53
pathway modulating agent. The method comprises providing an assay system
having a purified IG polypeptide or nucleic acid, or their functionally
active fragment or derivative. The method is useful for identifying
modulators of the p53 pathway, particularly for identifying agents for
treating disorders (e.g. breast cancer, colon cancer, kidney cancer, lung
cancer or cancer of the ovary) associated with defective p53 function.
The identified modulators are useful as targets for novel therapeutics.
The method is also useful for diagnosing disorders associated with
defective p53 function. The IG proteins or nucleic acids are useful as
modifiers of the p53 pathway, and as therapeutic targets for disorders
associated with defective p53 function. This polynucleotide sequence
represents a human nucleic acid relating to the human IG genes used in
the assay for identifying modulators of the p53 pathway of the invention

Sequence 1839 BP; 464 A; 506 C; 503 G; 366 T; 0 U; 0 Other;

Query Match 85.9%; Score 1442.8; DB 1; Length 1839;

Best Local Similarity 98.5%; Pred. No. 0.00056;

Matches 1464; Conservative 0; Mismatches 2; Indels 20; Gaps 1;

QY 214 AGGAGTCCCGTCCGAGCGGAGATGCCACCTTCCCAAGCTATGCAACCGTACGGT 273

DB 345 AGGAGTCCCGTCCGAGCGGAGATGCCACCTTCCCAAGCTATGCAACCGTACGGT 404

QY 274 CCAGCGGGGAGAGCGCCACCTCAGGTGCATTTGACAAACCGGTCACCGGCGTGC 333

DB 405 CCGGAGGGGAGAGCGCCACCTCAGGTGCATTTGACAAACCGGTCACCGGCGTGC 464

QY 334 CTGGCTAAACCGGAGCACCCTCTATGCTGGAAATGCAAGTGGTGGATCCTCG 393

DB 465 CTGGCTAAACCGGAGCACCCTCTATGCTGGAAATGCAAGTGGTGGATCCTCG 524

QY 394 CGTGGTCTTCTGAGCAACACCCAAACGAGTACGATCGAGTCCAGACGTGATCT 453

DB 525 CGTGGTCTTCTGAGCAACACCCAAACGAGTACGATCGAGTCCAGACGTGATCT 584

QY 454 GTATGACGAGGGCCCTTACACCTGCTCGGTGAGCAACCAACCCAAAGACCTCTAG 513

DB 585 GTATGACGAGGGCCCTTACACCTGCTCGGTGAGCAACCAACCCAAAGACCTCTAG 644

QY 514 GTGCCACCTCATTTGTGCAAGTATCTCCAAATTTAGAGATTTCTTCAGATATCTCCAT 573

DB 645 GTGCCACCTCATTTGTGCAAGTATCTCCAAATTTAGAGATTTCTTCAGATATCTCCAT 704

QY 574 TAATGAGGGAACAATATTAGCTCTACCTGATAGCAACTGGTAGACAGAGCTACGGT 633

DB 705 TAATGAGGGAACAATATTAGCTCTACCTGATAGCAACTGGTAGACAGAGCTACGGT 764

QY 634 TACTTGAGACACATCTCTCCCAAGGGTTGGCTTTGTGAGTGAAGAGCAATACTTGA 693

Db 765 TACTTGGAGACACATCTCTCCAAAGCGGTGGCTTTGTGAGTGAAGACGAATACTTGA 824
Qy 694 AATTTCAGGATACACCGGAGCAGTCAAGGGACTAGAGTGCAGTGCCTCCATGACGT 753
Db 825 AATTTCAGGATACACCGGAGCAGTCAAGGGACTAGAGTGCAGTGCCTCCATGACGT 884
Qy 754 GGCGCGCCCGTGTGTCAGGAGTAAAGGTCAACCGTGAATATCCACATACATTTTCA 813
Db 885 GGCGCGCCCGTGTGTCAGGAGTAAAGGTCAACCGTGAATATCCACATACATTTTCA 944
Qy 814 AGCCAAAGGTACAGTGTCCCGTGGGACAAAGGGGACACATGAGTGTGAAGCTCAGC 873
Db 945 AGCCAAAGGTACAGTGTCCCGTGGGACAAAGGGGACACATGAGTGTGAAGCTCAGC 1004
Qy 874 AGTCCCTCTCAGCAATTTCCAGTGGTACAAAGGTGACAAAGACTGATTCGAAGAAAGA 933
Db 1005 AGTCCCTCTCAGCAATTTCCAGTGGTACAAAGGTGACAAAGACTGATTCGAAGAAAGA 1064
Qy 934 AGGGGTGAAGTGAAGAACAGACCTTTCTCTCAAACTCATCTTTCAATGCTCTGA 993
Db 1065 AGGGGTGAAGTGAAGAACAGACCTTTCTCTCAAACTCATCTTTCAATGCTCTGA 1124
Qy 994 ACATGACTATGGGAATACACTTCGCTGGCTCCAAAGCTGGGCCACACCAATCCGAG 1053
Db 1125 ACATGACTATGGGAATACACTTCGCTGGCTCCAAAGCTGGGCCACACCAATCCGAG 1184
Qy 1054 CATCATGCTATTTGGTCCAGCGCCGTCAGCGAGTGAAGCAACCGCAGTGCAGAGGGC 1113
Db 1185 CATCATGCTATTTGGTCCAGCGCCGTCAGCGAGTGAAGCAACCGCAGTGCAGAGGGC 1244
Qy 1114 AGGCTGGCTGGCTGGCTCTCTCTGCTCTGCTGCTCTCTCTCTCTCTCTCTCTCTCT 1173
Db 1245 AGGCTGGCTGGCTGGCTCTCTCTGCTCTGCTGCTCTCTCTCTCTCTCTCTCTCTCT 1304
Qy 1174 GTGCACCTTCCCAACCGGGAAGGCTCGCCACCAACCAACCAACCAACCAACCAAG 1233
Db 1305 GTGCACCTTCCCAACCGGGAAGGCTCGCCACCAACCAACCAACCAACCAACCAAG 1364
Qy 1234 GCACACCGACAGCAACCAATCAGATATATACAAATGAAATAGAGAAACACAGCTCA 1293
Db 1365 GCACACCGACAGCAACCAATCAGATATATACAAATGAAATAGAGAAACACAGCTCA 1424
Qy 1294 TGGACAGAAATTTGAGGAGGGGAAACAAAGATATCTTTGGGGGAAAGAGTTTAA 1353
Db 1425 TGGACAGAAATTTGAGGAGGGGAAACAAAGATATCTTTGGGGGAAAGAGTTTAA 1484
Qy 1354 AAGAAATGAAATTTGCTTGCAGATATTTAGGTACAAATGAGATTTCTTTTCCCAAG 1413
Db 1485 AAGAAATGAAATTTGCTTGCAGATATTTAGGTACAAATGAGATTTCTTTTCCCAAG 1544
Qy 1414 GGAAGACACAGCACACCGGCTTGGACCCACCTGCAAGCTGCATCGTCAACCTCTTGG 1473
Db 1545 GGAAGACACAGCACACCGGCTTGGACCCACCTGCAAGCTGCATCGTCAACCTCTTGG 1604
Qy 1474 TGCAGTGTGGCAAGGGCTCAGCCTCTCTGCCCACAGAGTGCCTCCCAAGTGAACATTC 1533
Db 1605 TGCAGTGTGGCAAGGGCTCAGCCTCTCTGCCCACAGAGTGCCTCCCAAGTGAACATTC 1664
Qy 1534 TGGAGCTGGCCATCCCAATTCATCAGTCCATAGAGCAAGCAAGATGAGC----- 1586
Db 1665 TGGAGCTGGCCATCCCAATTCATCAGTCCATAGAGCAAGCAAGATGAGC----- 1724
Qy 1587 -----CTTCCGGCCCAAGCGTGGCGCTCGGGCACTTTGGTAGACTGTGCCA 1633
Db 1725 CCCAAGCGTGGCGCTTCCGGCCCAAGCGTGGCGCTCGGGCACTTTGGTAGACTGTGCCA 1784
Qy 1634 CCAGCGGTGTGTGTGAACGTGAATATAAAGAGCAAAAAA 1679
Db 1785 CCAGCGGTGTGTGTGAACGTGAATATAAAGAGCAAAAAA 1830

RESULT 175
ABX76448

ID XX ABX76448 standard; DNA; 1839 BP.
AC XX ABX76448;
DT XX 02-APR-2003 (first entry)
XX XX Lung cancer-associated polynucleotide #312.
DE XX Lung cancer-associated polynucleotide; gene; ds; cytostatic; emphysema;
KW antinflammatory; antiasthmatic; non-small cell lung cancer; atelectasis;
KW small cell lung cancer; benign lesion; precancerous lesion; bronchitis;
KW chronic obstructive pulmonary disease; hypersensitivity pneumonitis;
KW interstitial pulmonary fibrosis; fibrosis; asthma; bronchiectasis.
XX Unidentified.
OS XX WO200286443-A2.
XX PN 31-OCT-2002.
XX PD 18-APR-2002; 2002WO-US012476.
XX PF 18-APR-2001; 2001US-0284770P.
XX PR 10-MAY-2001; 2001US-0290492P.
XX PR 09-NOV-2001; 2001US-0339245P.
XX PR 13-NOV-2001; 2001US-0350666P.
XX PR 29-NOV-2001; 2001US-0334370P.
XX PR 12-APR-2002; 2002US-0372246P.
XX (EOSB-) EOS BIOTECHNOLOGY INC.
XX PA Aziz N, Murray R;
XX PI WPI; 2003-093161/08.
XX DR P-PSDB; ABUS6719.
XX PT Detecting a lung cancer-associated transcript in a cell from a patient
PT for treating lung cancer, by contacting a biological sample from the
PT patient with a polynucleotide that exhibits increased or decreased
PT expression in lung cancer.
XX Claim 22; Page 430-431; 453pp; English.
XX The invention relates to a method for detecting a lung cancer-associated
XX transcript in a cell from a patient, comprising contacting a biological
XX sample from the patient with a polynucleotide that selectively hybridizes
XX to a sequence that is at least 80 % identical to a gene that exhibits
XX increased or decreased expression in lung cancer samples. Lung cancer-
XX associated polynucleotides and polypeptides are used for identifying a
XX compound that modulates a lung cancer-associated polypeptide, for
XX inhibiting proliferation of a lung cancer-associated cell to treat lung
XX cancer in a patient and for treating a mammal having lung cancer by
XX administering a modulatory compound identified. The methods are useful
XX for treating lung cancer, such as small cell lung cancer, non-small cell
XX lung cancer or other benign or precancerous lesions, e.g. atelectasis,
XX emphysema, bronchitis, chronic obstructive pulmonary disease, fibrosis,
XX hypersensitivity pneumonitis, interstitial pulmonary fibrosis, asthma and
XX bronchiectasis. The genes, polynucleotides and polypeptides are useful
XX for diagnostic purposes and as targets for screening for therapeutic
XX compounds that modulate lung cancer, such as antibodies. Sequences
XX ABX76124-ABX76474 represent lung cancer-associated polynucleotides of the
XX invention
SQ Sequence 1839 BP; 464 A; 506 C; 503 G; 366 T; 0 U; 0 Other;

Query Match 85.9%; Score 1442.8; DB 1; Length 1839;
Best Local Similarity 98.5%; Pred. No. 0.00056;
Matches 1464; Conservative 0; Mismatches 2; Indels 20; Gaps 1;
Qy 214 AGGAGTGCCTGGCGCAGCGAGATGCCACCTTCCCAAGCTATGGCAACGTCAGCGT 273
Db 345 AGGAGTGCCTGGCGCAGCGAGATGCCACCTTCCCAAGCTATGGCAACGTCAGCGT 404

XX Fukushima D, Shibayama S, Tada H;
XX WPI; 2000-062298/05.
DR P-PSDB; AAY57601.
XX New polypeptides of human origin having cell regulatory, tissue
PT generation, coagulant and other activities.
XX
XX Claim 4; Page 41; 84pp; Japanese.
XX The present sequence encodes a specifically claimed novel human protein.
CC The novel human protein can be used in therapeutic drugs for the
CC prevention and treatment of a broad range of disorders including
CC autoimmune and infection-related immunodeficiency, inflammatory
CC disorders, and neurological diseases. The novel protein is expected of
CC having haematopoietic cell regulatory activity, tissue generation/
CC reparation activity, activin/inhibin activity, taxol/chemotaxis activity,
CC blood coagulation and thrombus activity, and receptor/ligand activity
XX
XX Sequence 1032 BP; 267 A; 281 C; 270 G; 214 T; 0 U; 0 Other;
Query Match 61.5%; Score 1032; DB 1; Length 1032;
Best Local Similarity 100.0%; Pred. No. 0.047;
Matches 1032; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 134 ATGAAAACCATCCAGCAAAATGCAATTTCTATCTTTGGCAATCTTCACGGGGCTG 193
Db 1 ATGAAAACCATCCAGCAAAATGCAATTTCTATCTTTGGCAATCTTCACGGGGCTG 60

QY 194 GTGTCTGTGTCTCTTCCAAAGAGTGCCTGTGCGCAGCGAGATGCCACCTTCCCCAAA 253
Db 61 GCTGTCTGTGTCTCTTCCAAAGAGTGCCTGTGCGCAGCGAGATGCCACCTTCCCCAAA 120

QY 254 GGTATGGACAAAGTGCAGCTCCGCGAGGGGAGAGCGCCACCTCAGGTGCACATTTGAC 313
Db 121 GGTATGGACAAAGTGCAGCTCCGCGAGGGGAGAGCGCCACCTCAGGTGCACATTTGAC 180

QY 314 AACCGGGTCAACCGGGTGCCTGGCTTAAACCGCAGCACCATCTCTATCTGGGAATGAC 373
Db 181 AACCGGGTCAACCGGGTGCCTGGCTTAAACCGCAGCACCATCTCTATCTGGGAATGAC 240

QY 374 AGTGTGTGCTGGATCTCGCTGTGCTCTTCTGAGCAGCACCACCGCAGTACAGCATC 433
Db 241 AGTGTGTGCTGGATCTCGCTGTGCTCTTCTGAGCAGCACCACCGCAGTACAGCATC 300

QY 434 GAGATCCAGAACGTGTGATGTATGACAGGGGCCCTTACACCTGTCTCGGTGCAGACAGAC 493
Db 301 GAGATCCAGAACGTGTGATGTATGACAGGGGCCCTTACACCTGTCTCGGTGCAGACAGAC 360

QY 494 AACCCCAAGACCTCTAGGTCCACCTCATTTGCAAGTATCTCCCAAAATTTAGAG 553
Db 361 AACCCCAAGACCTCTAGGTCCACCTCATTTGCAAGTATCTCCCAAAATTTAGAG 420

QY 554 ATTTCTTCAGATATCTCCATTAATGAAGGAACAATATTAGCTTCACCTGCATAGCAACT 613
Db 421 ATTTCTTCAGATATCTCCATTAATGAAGGAACAATATTAGCTTCACCTGCATAGCAACT 480

QY 614 GGTAGACAGAGCTACGGTTACTTTGGAGACACATCTCTTCCAAAGCGGTTGGCTTTGTG 673
Db 481 GGTAGACAGAGCTACGGTTACTTTGGAGACACATCTCTTCCAAAGCGGTTGGCTTTGTG 540

QY 674 AGTGAAGACGAATACTTTGGAATTTAGGGATCACCAGGAGCAGTACAGGGAGCTACGAG 733
Db 541 AGTGAAGACGAATACTTTGGAATTTAGGGATCACCAGGAGCAGTACAGGGAGCTACGAG 600

QY 734 TGCAGTGCCTCAATGACGTGCGCGGCGCGGTGGTACGAGAGTAAAGGTCAACCGTGAAC 793
Db 601 TGCAGTGCCTCAATGACGTGCGCGGCGCGGTGGTACGAGAGTAAAGGTCAACCGTGAAC 660

QY 794 TATCCACCATATTTCAAGCCAGGGTACAGGTGTCCTCGGTGGACAAAGGGGACA 853
Db 661 TATCCACCATATTTCAAGCCAGGGTACAGGTGTCCTCGGTGGACAAAGGGGACA 720

QY 854 CTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTACAAGGATGACAAA 913
Db 721 CTGCAGTGTGAAGCCTCAGCAGTCCCTCAGCAGAAATTCAGTGGTACAAGGATGACAAA 780

QY 914 AGACTGATTGAAGGAAGAAAGGGGTGAAGTGGAAAACAGACCTTTCTCTCAAAACTC 973
Db 781 AGACTGATTGAAGGAAGAAAGGGGTGAAGTGGAAAACAGACCTTTCTCTCAAAACTC 840

QY 974 ATCTTTCTCAATGTCTCTGAACAATGACTATGGGAACATACACTTTCGCTGGCCTCCAAACAAG 1033
Db 841 ATCTTTCTCAATGTCTCTGAACAATGACTATGGGAACATACACTTTCGCTGGCCTCCAAACAAG 900

QY 1034 CTGGGCCACACCAATGCCAGCATCTATTTGGTCCAGGGCCCTCAGCGAGGTGAGC 1093
Db 901 CTGGGCCACACCAATGCCAGCATCTATTTGGTCCAGGGCCCTCAGCGAGGTGAGC 960

QY 1094 AACGGCACGTCGAGGAGGGCAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1153
Db 961 AACGGCACGTCGAGGAGGGCAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1020

QY 1154 CTTCCTCAAAATTT 1165
Db 1021 CTTCCTCAAAATTT 1032

Search completed: June 4, 2004, 16:54:05
Job time : 290 secs